PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Powell, JE; Esteve, J; Mann, JR; Parker, L; Frappaz, D; Michaelis, J; Kerbl, R; Mutz, ID; Stiller, CA				Powell, JE; Esteve, J; Mann, JR; Parker, L; Frappaz, D; Michaelis, J; Kerbl, R; Mutz, ID; Stiller, CA		Sense	Neuroblastoma in Europe: differences in the pattern of disease in the UK	LANCET			English	Article							MORTALITY	Background Neuroblastoma is a major contributor to childhood cancer mortality, but its prognosis varies with age and stage of disease, and some tumours regress spontaneously. Urinary screening programmes or clinical examination may detect the disease before symptoms appear, but the benefit of early diagnosis is uncertain. We examined the incidence, pattern, and presentation of neuroblastoma in four European countries. Method Population-based incidence rates were derived for France, Austria, Germany, and the UK. Age, sex, and stage distribution were analysed by Mantel-Haenszel techniques and Poisson regression. The proportion of incidental diagnoses (cases without symptoms found at routine health checks or during investigation of other disorders) and mortality rates were also compared. Findings Between 1987 and 1991, 1672 cases of neuroblastoma were diagnosed in children under 15 years old (France, 624; Austria, 69;Germany, 493; UK, 486). Age-standardised annual incidence was significantly lower in the UK (10.1/million) than in France (12.5) and Germany (11.4). In the UK a deficit of low-stage disease in infants was accompanied by an excess of stage IV in older children. The UK had significantly fewer incidental diagnoses (8%) than Austria (27%) and Germany (34%). UK mortality rates were significantly higher than German or French rates. Interpretation In the UK, neuroblastoma diagnosis is delayed, possibly because of a less rigorous system of health checks for children. Although some overdiagnosis occurs in mainland Europe, our data suggest that in the UK some low-stage cases, undetected in infancy, may later present as advanced disease. This finding has implications for screening programmes and organisation of routine surveillance of infant health in the UK.	Univ Birmingham, Dept Epidemiol & Publ Hlth, Birmingham B15 2TT, W Midlands, England; Int Agcy Res Canc, F-69372 Lyon, France; Birmingham Childrens Hosp NHS Trust, Dept Oncol, Birmingham, W Midlands, England; Univ Newcastle Upon Tyne, Childrens Canc Unit, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; Ctr Leon Berard, F-69373 Lyon, France; Johannes Gutenberg Universitat Mainz, Inst Med Stat & Dokumentat, Mainz, Germany; Graz Univ, Dept Paediat, A-8010 Graz, Austria; Landeskrankenhauses, Kinderabstellung, Leoben, Austria; Childhood Canc Res Grp, Oxford, England	University of Birmingham; World Health Organization; International Agency for Research on Cancer (IARC); Newcastle University - UK; UNICANCER; Centre Leon Berard; Johannes Gutenberg University of Mainz; University of Graz; University of Oxford	Powell, JE (corresponding author), Univ Birmingham, Dept Epidemiol & Publ Hlth, Birmingham B15 2TT, W Midlands, England.			Stiller, Charles/0000-0002-3006-7869; PARKER, LOUISE/0000-0002-5188-8113				ABUHARB M, 1994, ARCH DIS CHILD, V71, P3, DOI 10.1136/adc.71.1.3; ARMATA J, 1994, ARCH DIS CHILD, V70, P253, DOI 10.1136/adc.70.3.253; BERNSTEIN ML, 1992, J CLIN ONCOL, V10, P323, DOI 10.1200/JCO.1992.10.2.323; BERTHOLD F, 1991, AM J PEDIAT HEMATOL, V13, P8; Bessho F, 1996, LANCET, V348, P1672, DOI 10.1016/S0140-6736(05)65814-X; CARLSEN NTL, 1991, AM J PAEDIAT HEMATOL, V14, P103; Craft AW, 1996, EUR J CANCER, V32A, P1540, DOI 10.1016/0959-8049(96)00152-9; Dezateux C, 1995, J Med Screen, V2, P200; ESTEVE J, 1995, BRIT J CANCER, V71, P1125, DOI 10.1038/bjc.1995.219; Esteve J., 1994, IARC SCI PUBLICATION, V128; Gao RN, 1997, CANCER CAUSE CONTROL, V8, P745, DOI 10.1023/A:1018483405637; KAATSCH P, 1995, EUR J CANCER, V31A, P993, DOI 10.1016/0959-8049(95)00091-7; LACOUR B, 1995, CANC ENFANT LORRAINE; Morgan M, 1989, Health Visit, V62, P244; Nishi M, 1997, INT J CANCER, V71, P552, DOI 10.1002/(SICI)1097-0215(19970516)71:4<552::AID-IJC8>3.0.CO;2-T; Parkin D. M, 1988, IARC SCI PUBLICATION, V87; SAWADA T, 1992, AM J PEDIAT HEMATOL, V14, P320; SCHWARTZ AD, 1974, J PEDIATR-US, V85, P760, DOI 10.1016/S0022-3476(74)80336-7; SMELLIE JM, 1994, BRIT MED J, V308, P1193, DOI 10.1136/bmj.308.6938.1193; STILLER CA, 1992, INT J CANCER, V52, P538, DOI 10.1002/ijc.2910520407; STILLER CA, 1993, EUR J CANCER, V29A, P1008, DOI 10.1016/S0959-8049(05)80213-8; Stiller CA, 1995, EUR J CANCER, V31A, P2028, DOI 10.1016/0959-8049(95)00428-9; Woods WG, 1996, LANCET, V348, P1682, DOI 10.1016/S0140-6736(96)06020-5; WOODS WG, 1992, PEDIATRICS, V89, P114	24	44	44	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	AUG 29	1998	352	9129					682	687		10.1016/S0140-6736(97)11239-9	http://dx.doi.org/10.1016/S0140-6736(97)11239-9			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	116MT	9728983				2022-12-28	WOS:000075729700011
J	Rigby, M; Roberts, R; Williams, J; Clark, J; Savill, A; Lervy, B; Mooney, G				Rigby, M; Roberts, R; Williams, J; Clark, J; Savill, A; Lervy, B; Mooney, G			Integrated record keeping as an essential aspect of a primary care led health service	BRITISH MEDICAL JOURNAL			English	Article									Univ Keele, Ctr Hlth Planning & Management, Keele ST5 5BG, Staffs, England; Morriston Hosp, Sch Postgrad Studies Med & Hlth Care, Swansea SA6 6NL, W Glam, Wales; Univ Wales, Sch Hlth Sci, Ctr Hlth Informat, Swansea SA2 8PP, W Glam, Wales	Keele University; Morriston Hospital; Swansea University; Swansea University	Rigby, M (corresponding author), Univ Keele, Ctr Hlth Planning & Management, Darwin Bldg, Keele ST5 5BG, Staffs, England.		Rigby, Michael J/B-9310-2009					*AUD COMM, 1997, COMP NOT STUD INF MA; BeuscartZephir MC, 1997, COMPUT METH PROG BIO, V54, P19, DOI 10.1016/S0169-2607(97)00030-8; BREWIN M, 1995, BR J OCCUP THER, V58, P519; *DEP HLTH, 1996, PRIM CAR FUT; Department of Health and Social Security, 1981, PRIM HLTH CAR TEAM R; DRAZEN EL, 1995, PATIENT CARE INFORMA; EDWARDS P, 1996, SHARED CARE MODEL CL; FOGARTY L, 1997, J INFORMATICS PRIMAR, P2; GILHOOLY MLM, 1991, J MED ETHICS, V17, P138, DOI 10.1136/jme.17.3.138; MILLBURN A, 1998, HOUSE COMMONS OFFICI; Pritchard P, 1995, SHARED CARE FUTURE I; Rigby M., 1998, BJHC&IM-British Journal of Healthcare Computing & Information Management, V15, P23; Rigby M, 1997, PERSONAL MEDICAL INFORMATION, P129; RIGBY M, 1997, INTEGRATED RECORD KE; RIGBY MJ, 1992, HLTH SUMMARY, V9, P5; RIGHY MJ, 1994, CASE BASED TELEMATIC, V14; *SCOTT HOM HLTH DE, 1996, PRIM CAR WAY AH; SCOTT NCH, 1995, J INTERPROFESSIONAL, V9, P95; *SECR STAT HLTH, 1996, NAT HLTH SERV SERV A; Swayne J., 1993, J INTERPROF CARE, V7, P29, DOI [10.3109/13561829309014956, DOI 10.3109/13561829309014956]; Tudor Hart J, 1994, FEASIBLE SOCIALISM N; Warner MM, 1997, REDESIGNING HLTH SER; Weed LL, 1969, MED RECORDS MED ED P; *WELSH OFF, 1996, PRIM CAR WAY FORW WA; *WELSH OFF SCOTT O, 1996, CHOIC OPP PRIM CAR F; Williams J G, 1993, Qual Health Care, V2, P73, DOI 10.1136/qshc.2.2.73; Williamson V, 1995, J INTERPROF CARE, V9, P101	27	16	16	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 29	1998	317	7158					579	582		10.1136/bmj.317.7158.579	http://dx.doi.org/10.1136/bmj.317.7158.579			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	117EK	9721116	Green Submitted, Bronze, Green Published			2022-12-28	WOS:000075767800020
J	Ward, HJ				Ward, HJ			Uric acid as an independent risk factor in the treatment of hypertension	LANCET			English	Editorial Material									Univ Calif Los Angeles, Div Nephrol & Hypertens, Los Angeles, CA 90059 USA; Drew Sch Med, Los Angeles, CA 90059 USA	University of California System; University of California Los Angeles	Ward, HJ (corresponding author), Univ Calif Los Angeles, Div Nephrol & Hypertens, Los Angeles, CA 90059 USA.							Alderman M.H., 1998, AM J HYPERTENS, V2, p16A; BARDENHEUER HJ, 1994, CARDIOVASC RES, V28, P656, DOI 10.1093/cvr/28.5.656; CAPPUCCIO FP, 1993, JAMA-J AM MED ASSOC, V270, P354, DOI 10.1001/jama.270.3.354; DESCHEERDER IK, 1991, AM J CARDIOL, V68, P392, DOI 10.1016/0002-9149(91)90838-C; FACCHINI F, 1991, JAMA-J AM MED ASSOC, V266, P3008, DOI 10.1001/jama.266.21.3008; JOHNSON WD, 1991, AM HEART J, V121, P20, DOI 10.1016/0002-8703(91)90950-M; Lacy F, 1998, J HYPERTENS, V16, P291, DOI 10.1097/00004872-199816030-00006; MESSERLI FH, 1980, ANN INTERN MED, V93, P817, DOI 10.7326/0003-4819-93-6-817; SELBY JV, 1990, AM J EPIDEMIOL, V131, P1017, DOI 10.1093/oxfordjournals.aje.a115593	9	122	137	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	AUG 29	1998	352	9129					670	671		10.1016/S0140-6736(05)60816-1	http://dx.doi.org/10.1016/S0140-6736(05)60816-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	116MT	9728978				2022-12-28	WOS:000075729700006
J	Epner, JEG; Jonas, HS; Seckinger, DL				Epner, JEG; Jonas, HS; Seckinger, DL			Late-term abortion	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							2ND-TRIMESTER ABORTIONS; GESTATIONAL-AGE; UNITED-STATES; MORTALITY; EVACUATION; MORBIDITY	Recent proposed federal legislation banning certain abortion procedures, particularly intact dilatation and extraction, would modify the US Criminal Code such that physicians performing these procedures would be liable for monetary and statutory damages. Clarification of medical procedures is important because some of the procedures used to induce abortion prior to viability are identical or similar to postviability procedures. This article reviews the scientific and medical information on late-term abortion and late-term abortion techniques and includes data on the prevalence of late-term abortion, abortion-related mortality and morbidity rates, and legal issues regarding fetal viability and the balance of maternal and fetal interests. According to enacted American Medical Association (AMA) policy, the use of appropriate medical terminology is critical in defining late-term abortion procedures, particularly intact dilatation and extraction, which is a variant of but distinct from dilatation and evacuation. The AMA recommends that the intact dilatation and extraction procedure not be used unless alternative procedures pose materially greater risk to the woman and that abortions not be performed in the third trimester except in cases of serious fetal anomalies incompatible with life. Major medical societies are urged to collaborate on clinical guidelines on late-term abortion techniques and circumstances that conform to standards of good medical practice. More research on the advantages and disadvantages of specific abortion procedures would help physicians make informed choices about specific abortion procedures. Expanded ongoing data surveillance systems estimating the prevalence of abortion are also needed.	Amer Med Assoc, Grp Sci Technol & Publ Hlth, Chicago, IL 60610 USA	American Medical Association	Jonas, HS (corresponding author), Amer Med Assoc, Grp Sci Technol & Publ Hlth, 515 N State St, Chicago, IL 60610 USA.							*A GUTTM I, 1996, FACTS BRIEF IND AB; *A GUTTM I, 1997, ISS BRIEF LIM US STA; *AM COLL OBST GYN, 1995, PER CAR THRESH VIAB; *AM MED ASS BOARD, 1997, 26 AM MED ASS BOARD; ATRASH HK, 1982, AM J OBSTET GYNECOL, V142, P269, DOI 10.1016/0002-9378(82)90729-3; ATRASH HK, 1990, CONT OB GYN, V35, P58; BINKIN NJ, 1986, CLIN OBSTET GYNAECOL, V13, P83; CATES W, 1982, JAMA-J AM MED ASSOC, V248, P559, DOI 10.1001/jama.248.5.559; CATES W, 1981, OBSTET GYNECOL, V58, P401; Cates WJ, 1981, ABORTION STERILIZATI, P155; *CDCP, 1980, AB SURV 1978; *CDCP, 1985, AB SURV 1981; COBLE YD, 1992, JAMA-J AM MED ASSOC, V268, P3231, DOI 10.1001/jama.1992.03490220075032; COPPER RL, 1993, AM J OBSTET GYNECOL, V168, P78, DOI 10.1016/S0002-9378(12)90889-3; CRIST T, 1983, N C MED J, V44, P549; CUNNINGHAM FC, 1997, WILLIAMS OBSTET, pCH7; CUNNINGHAM FG, 1997, WILLIAMS OBSTET, pCH34; FINNIS JM, 1978, ENCY BIOETHICS, P28; Golan A, 1989, Obstet Gynecol Surv, V44, P96, DOI 10.1097/00006254-198902000-00004; GRIMES D, 1997, TELINDES OPERATIVE G, pCH23; GRIMES DA, 1984, FAM PLANN PERSPECT, V16, P260, DOI 10.2307/2134915; GRIMES DA, 1985, J REPROD MED, V30, P505; HENSHAW SK, 1990, FAM PLANN PERSPECT, V22, P76, DOI 10.2307/2135512; HERN WM, 1984, OBSTET GYNECOL, V63, P26; HERN WM, 1990, ABORTION PRACTICE; HERN WM, 1988, GYNECOLOGY OBSTET; KALTREIDER NB, 1979, AM J OBSTET GYNECOL, V135, P235, DOI 10.1016/0002-9378(79)90351-X; Koonin L M, 1997, MMWR CDC Surveill Summ, V46, P37; LAWSON HW, 1994, AM J OBSTET GYNECOL, V171, P1365, DOI 10.1016/0002-9378(94)90162-7; Mohr James, 1978, ABORTION AM ORIGINS; *NAT CTR HLTH STAT, 1993, 42 US PHS NAT CTR HL; *NAT CTR HLTH STAT, 1991, VIT STAT US B, P2; POLICAR MJ, 1995, CLIN TRAINING CURRIC; RHOADS GG, 1989, NEW ENGL J MED, V320, P609, DOI 10.1056/NEJM198903093201001; SABBAGHA R, 1981, 2 TRIMESTER ABORTION, P57; SANTEE B, 1992, FAM PLANN PERSPECT, V24, P172, DOI 10.2307/2136020; SHULMAN LP, 1990, OBSTET GYNECOL, V75, P1037; SHULMAN LP, 1997, AM COLL OBSTET GYNEC, V22, P1; SLUPIK RI, 1996, AM MED ASS COMPLETE; SPITZ AM, 1983, AM J PUBLIC HEALTH, V73, P594, DOI 10.2105/AJPH.73.5.594; Tietze C, 1986, INDUCED ABORTION WOR; TORRES A, 1988, FAM PLANN PERSPECT, V20, P169, DOI 10.2307/2135792	42	20	19	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 26	1998	280	8					724	729		10.1001/jama.280.8.724	http://dx.doi.org/10.1001/jama.280.8.724			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	111PM	9728645				2022-12-28	WOS:000075446900035
J	Gottlieb, SS; McCarter, RJ; Vogel, RA				Gottlieb, SS; McCarter, RJ; Vogel, RA			Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							IDIOPATHIC DILATED CARDIOMYOPATHY; HEART-FAILURE; THROMBOLYTIC THERAPY; DIABETIC-PATIENTS; DISEASE; METOPROLOL; BLOCKERS; PROPRANOLOL; MORBIDITY; BLACKS	Background Long-term administration of beta-adrenergic blockers to patients after myocardial infarction improves survival. However, physicians are reluctant to administer beta-blockers to many patients, such as older patients and those with chronic pulmonary disease, left ventricular dysfunction, or non-Q-wave myocardial infarction. Methods The medical records of 201,752 patients with myocardial infarction were abstracted by the Cooperative Cardiovascular Project, which was sponsored by the Health Care Financing Administration. Using a Cox proportional-hazards model that accounted for multiple factors that might influence survival, we compared mortality among patients treated with beta-blockers with mortality among untreated patients during the two years after myocardial infarction. Results A total of 34 percent of the patients received beta-blockers. The percentage was lower among the very elderly, blacks, and patients with the lowest ejection fractions, heart failure, chronic obstructive pulmonary disease, elevated serum creatinine concentrations, or type 1 diabetes mellitus. Nevertheless, mortality was lower in every subgroup of patients treated with beta-blockade than in untreated patients. In patients with myocardial infarction and no other complications, treatment with beta-blockers was associated with a 40 percent reduction in mortality. Mortality was also reduced by 40 percent in patients with non-Q-wave infarction and those with chronic obstructive pulmonary disease. Blacks, patients 80 years old or older, and those with a left ventricular ejection fraction below 20 percent, serum creatinine concentration greater than 1.4 mg per deciliter (124 mu mol per liter), or diabetes mellitus had a lower percentage reduction in mortality. Given, however, the higher mortality rates in these subgroups, the absolute reduction in mortality was similar to or greater than that among patients with no specific risk factors. Conclusions After myocardial infarction, patients with conditions that are often considered contraindications to beta-blockade (such as heart failure, pulmonary disease, and older age) and those with nontransmural infarction benefit from beta-blocker therapy. (N Engl J Med 1998;339:489-97.) (C)1998, Massachusetts Medical Society.	Univ Maryland, Sch Med, Dept Med, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Dept Epidemiol, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore	Gottlieb, SS (corresponding author), Univ Maryland, Med Syst, Div Cardiol, 22 S Greene St, Baltimore, MD 21201 USA.							Anderson JL, 1996, ANN INTERN MED, V124, P335, DOI 10.7326/0003-4819-124-3-199602010-00009; [Anonymous], 1981, JAMA-J AM MED ASSOC, V246, P2073; Aronow WS, 1996, J AM GERIATR SOC, V44, P1075, DOI 10.1111/j.1532-5415.1996.tb02941.x; BECKER RC, 1994, CLIN CARDIOL, V17, P171, DOI 10.1002/clc.4960170406; BRAND DA, 1995, J AM COLL CARDIOL, V26, P1432, DOI 10.1016/0735-1097(95)00362-2; CHADDA K, 1986, CIRCULATION, V73, P503, DOI 10.1161/01.CIR.73.3.503; ELLERBECK EF, 1995, JAMA-J AM MED ASSOC, V273, P1509, DOI 10.1001/jama.273.19.1509; FOGARI R, 1990, CARDIOVASC DRUG THER, V4, P1145, DOI 10.1007/BF01856511; FRIEDMAN LM, 1982, JAMA-J AM MED ASSOC, V247, P1707; Giugliano D, 1997, ANN INTERN MED, V126, P955, DOI 10.7326/0003-4819-126-12-199706150-00004; GOLD MR, 1991, CHEST, V100, P1215, DOI 10.1378/chest.100.5.1215; GUNDERSEN T, 1983, DIABETES CARE, V6, P285, DOI 10.2337/diacare.6.3.285; GUNDERSEN T, 1982, CIRCULATION, V66, P1179, DOI 10.1161/01.CIR.66.6.1179; HAYWOOD LJ, 1984, AM HEART J, V108, P787; HJALMARSON A, 1981, LANCET, V2, P823; JOHNSON JA, 1995, J CARDIOVASC PHARM, V25, P90, DOI 10.1097/00005344-199501000-00015; KILLIP T, 1967, AM J CARDIOL, V20, P457, DOI 10.1016/0002-9149(67)90023-9; KJEKSHUS J, 1990, EUR HEART J, V11, P43, DOI 10.1093/oxfordjournals.eurheartj.a059591; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; LECHAT P, 1994, CIRCULATION, V90, P1765, DOI 10.1161/01.CIR.90.4.1765; MALMBERG K, 1989, EUR HEART J, V10, P423, DOI 10.1093/oxfordjournals.eurheartj.a059505; Marciniak TA, 1998, JAMA-J AM MED ASSOC, V279, P1351, DOI 10.1001/jama.279.17.1351; MATERSON BJ, 1993, NEW ENGL J MED, V328, P914, DOI 10.1056/NEJM199304013281303; MATERSON BJ, 1994, NEW ENGL J MED, V330, P1689, DOI 10.1056/NEJM199406093302316; Packer M, 1996, NEW ENGL J MED, V334, P1349, DOI 10.1056/NEJM199605233342101; PEDERSEN TR, 1981, NEW ENGL J MED, V304, P801; Prisant LM, 1996, J CLIN PHARMACOL, V36, P867, DOI 10.1002/j.1552-4604.1996.tb04752.x; ROBERTS R, 1991, CIRCULATION, V83, P422, DOI 10.1161/01.CIR.83.2.422; Ryan TJ, 1996, J AM COLL CARDIOL, V28, P1328; Soumeral SB, 1997, JAMA-J AM MED ASSOC, V277, P115, DOI 10.1001/jama.277.2.115; TATTERSFIELD A E, 1991, Cardiovascular Drugs and Therapy, V4, P1229, DOI 10.1007/BF00114225; VISKIN S, 1995, J AM COLL CARDIOL, V25, P1327, DOI 10.1016/0735-1097(94)00552-2; WAAGSTEIN F, 1993, LANCET, V342, P1441, DOI 10.1016/0140-6736(93)92930-R; WOODLEY SL, 1991, CIRCULATION, V84, P2426, DOI 10.1161/01.CIR.84.6.2426; WOOLCOCK AJ, 1991, AM REV RESPIR DIS, V143, P1438, DOI 10.1164/ajrccm/143.6.1438; YUSUF S, 1988, JAMA-J AM MED ASSOC, V260, P2088, DOI 10.1001/jama.260.14.2088; ZUANETTI G, 1993, J AM COLL CARDIOL, V22, P1788, DOI 10.1016/0735-1097(93)90758-S	37	692	739	0	16	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 20	1998	339	8					489	497		10.1056/NEJM199808203390801	http://dx.doi.org/10.1056/NEJM199808203390801			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	111PN	9709041				2022-12-28	WOS:000075447000001
J	Emanuel, LL				Emanuel, LL			Facing requests for physician-assisted suicide - Toward a practical and principled clinical skill set	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACTIVE EUTHANASIA; PATIENT REQUESTS; MEDICAL-CARE; RESUSCITATE; HYDRATION; NUTRITION; ATTITUDES; DECISIONS; ORDERS; STATE	Requests for physician-assisted suicide are not a new phenomenon, and many physicians are likely to face this challenging situation. This article proposes for professionals an 8-step approach to respond to requests for physician-assisted suicide. The approach seeks to identify and treat the root causes of the request and aims to present a plan for consistent application of a set of clinical skills. Justification for the steps requires only 2 noncontentious principles: the patient should be free of unwanted intervention, and the physician is obligated to provide suffering patients with comfort care. Care based on these 2 principles alone does not include physician-assisted suicide. The approach does, however, justify patient refusal of oral intake in specific circumstances. The approach could resolve a majority of requests for physician-assisted suicide and should be tested further for clinical efficacy.	Amer Med Assoc, Inst Eth, Chicago, IL 60610 USA	American Medical Association	Emanuel, LL (corresponding author), Amer Med Assoc, Inst Eth, 515 N State St, Chicago, IL 60610 USA.							Alpert HR, 1998, J GEN INTERN MED, V13, P175, DOI 10.1046/j.1525-1497.1998.00052.x; Back AL, 1996, JAMA-J AM MED ASSOC, V275, P919, DOI 10.1001/jama.275.12.919; Baron CH, 1996, HARVARD J LEGIS, V33, P1; BERNAT JL, 1993, ARCH INTERN MED, V153, P2723, DOI 10.1001/archinte.153.24.2723; BLOCH SD, 1994, ARCH INTERN MED, V154, P2039, DOI 10.1001/archinte.154.18.2039; Brody H, 1997, NEW ENGL J MED, V336, P652, DOI 10.1056/NEJM199702273360910; EDDY DM, 1994, JAMA-J AM MED ASSOC, V272, P179, DOI 10.1001/jama.272.3.179; Edelstein L., 1967, ANCIENT MED; Emanuel EJ, 1998, LANCET, V351, P21, DOI 10.1016/S0140-6736(98)90329-4; Emanuel EJ, 1996, LANCET, V347, P1805, DOI 10.1016/S0140-6736(96)91621-9; EMANUEL EJ, 1988, AM J MED, V84, P291, DOI 10.1016/0002-9343(88)90428-7; EMANUEL EJ, 1998, ANN M 1998 AM SOC CL; EMANUEL L, 1995, JAMA-J AM MED ASSOC, V274, P501, DOI 10.1001/jama.274.6.501; EMANUEL LL, 1991, NEW ENGL J MED, V324, P889, DOI 10.1056/NEJM199103283241305; Emanuel LL, 1995, HASTINGS CENT REP, V25, pS14, DOI 10.2307/3527851; EMANUEL LL, 1996, CONT INTERNAL MED, V8, P10; EMANUEL LL, 1998, REGULATING WE DIE; GILLIGAN T, 1995, CHEST, V108, P1407, DOI 10.1378/chest.108.5.1407; Glick SM, 1997, AM J MED, V102, P294, DOI 10.1016/S0002-9343(97)00016-8; Gloth F M 3rd, 1994, Md Med J, V43, P511; Gostin LO, 1997, JAMA-J AM MED ASSOC, V278, P1523, DOI 10.1001/jama.278.18.1523; Hirschfield RMA, 1997, JAMA-J AM MED ASSOC, V277, P333, DOI 10.1001/jama.277.4.333; KAMISAR Y, 1993, HASTINGS CENT REP, V23, P32, DOI 10.2307/3563366; Kamisar Y, 1998, MINN LAW REV, V82, P895; KNAUS WA, 1995, JAMA-J AM MED ASSOC, V274, P1591, DOI 10.1001/jama.1995.03530200027032; Koenig HG, 1996, ARCH INTERN MED, V156, P2240, DOI 10.1001/archinte.156.19.2240; KOUENHOVEN WB, 1960, JAMA-J AM MED ASSOC, V173, P1064; MCCANN RM, 1994, JAMA-J AM MED ASSOC, V272, P1263, DOI 10.1001/jama.272.16.1263; MILES SH, 1994, JAMA-J AM MED ASSOC, V271, P1786, DOI 10.1001/jama.271.22.1786; MILLER FG, 1994, NEW ENGL J MED, V331, P119, DOI 10.1056/NEJM199407143310211; MOORE FD, 1997, HARVARD ALUMNI M SEP, P3; Orentlicher D, 1997, NEW ENGL J MED, V337, P1236, DOI 10.1056/NEJM199710233371713; *PC STUD ETH PROBL, 1983, DEC FOR LIF SUST TRE; Quill TE, 1997, NEW ENGL J MED, V337, P1768, DOI 10.1056/NEJM199712113372413; Quill TE, 1997, JAMA-J AM MED ASSOC, V278, P2099, DOI 10.1001/jama.278.23.2099; RABKIN MT, 1976, NEW ENGL J MED, V295, P364, DOI 10.1056/NEJM197608122950705; Rousseau P, 1996, ARCH INTERN MED, V156, P1785, DOI 10.1001/archinte.156.16.1785; SAUNDERS CM, 1978, MANAGEMENT TERMINAL, P194; SOLOMON MZ, 1993, AM J PUBLIC HEALTH, V83, P14, DOI 10.2105/AJPH.83.1.14; STANLEY J, 1997, QUEST DIE DIGNITY; *SUPPORT PRINC INV, 1996, JAMA-J AM MED ASSOC, V275, P1232, DOI DOI 10.1001/JAMA.1995.03530200027032; Tulsky JA, 1996, ARCH INTERN MED, V156, P1285, DOI 10.1001/archinte.156.12.1285; van der Maas PJ, 1995, JAMA-J AM MED ASSOC, V273, P1411, DOI 10.1001/jama.273.18.1411; van der Maas PJ, 1991, LANCET, V338, P669, DOI 10.1016/0140-6736(91)91241-L; 1997, AM MED NEWS     0113, V40, P56; 1997, AM MED NEWS     0113, V40, P3	46	62	62	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 19	1998	280	7					643	647		10.1001/jama.280.7.643	http://dx.doi.org/10.1001/jama.280.7.643			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	110ME	9718058				2022-12-28	WOS:000075384300035
J	Gordon, S				Gordon, S			Letter to a patient's doctor	ANNALS OF INTERNAL MEDICINE			English	Editorial Material											Gordon, S (corresponding author), 11 Ely Rd, Arlington, MA 02476 USA.								0	0	0	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 15	1998	129	4					333	334		10.7326/0003-4819-129-4-199808150-00015	http://dx.doi.org/10.7326/0003-4819-129-4-199808150-00015			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	109NP	9729191				2022-12-28	WOS:000075329100013
J	Edwards, G				Edwards, G			If the drinks industry does not clean up its act, pariah status is inevitable	BRITISH MEDICAL JOURNAL			English	Article									Natl Addict Ctr, London SE5 8AF, England	University of London; King's College London	Edwards, G (corresponding author), Natl Addict Ctr, London SE5 8AF, England.							Babor TF, 1996, ADDICTION, V91, P5, DOI 10.1111/j.1360-0443.1996.tb03150.x; DOYLE L, 1994, INDEPENDENT     1204; Edwards G., 1994, ALCOHOL POLICY PUBLI; Jernigan D.H., 1997, THIRSTING MARKETS GL	4	13	13	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 1	1998	317	7154					336	336						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	110YQ	9729079				2022-12-28	WOS:000075409500033
J	Scolding, N; Franklin, R				Scolding, N; Franklin, R			Axon loss in multiple sclerosis.	LANCET			English	Editorial Material							RETINAL GANGLION-CELLS; DISABILITY; LESIONS; CULTURE; MRI		Univ Cambridge, Addenbrookes Hosp, Neurol Unit, Cambridge CB2 2QQ, England; MRC, Cambridge Ctr Brain Repair, London W1N 4AL, England; Univ Cambridge, Dept Vet Med, Cambridge CB2 1TN, England	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; University of Cambridge	Scolding, N (corresponding author), Univ Cambridge, Addenbrookes Hosp, Neurol Unit, Cambridge CB2 2QQ, England.			Franklin, Robin/0000-0001-6522-2104				BARNES D, 1991, BRAIN, V114, P1271, DOI 10.1093/brain/114.3.1271; Davie CA, 1995, BRAIN, V118, P1583, DOI 10.1093/brain/118.6.1583; DAVIE CA, 1994, BRAIN, V117, P49, DOI 10.1093/brain/117.1.49; DeStefano N, 1995, ANN NEUROL, V38, P901, DOI 10.1002/ana.410380610; Ferguson B, 1997, BRAIN, V120, P393, DOI 10.1093/brain/120.3.393; FRIESEN L, 1974, ARCH OPHTHALMOL-CHIC, V92, P91; Greenfield JG, 1936, BRAIN, V59, P445, DOI 10.1093/brain/59.4.445; LIPTON SA, 1986, P NATL ACAD SCI USA, V83, P9774, DOI 10.1073/pnas.83.24.9774; Losseff NA, 1996, BRAIN, V119, P701, DOI 10.1093/brain/119.3.701; MATTHEWS WB, 1979, J NEUROL SCI, V40, P11, DOI 10.1016/0022-510X(79)90004-2; MCDONALD W I, 1986, P112; MEYERFRANKE A, 1995, NEURON, V15, P805, DOI 10.1016/0896-6273(95)90172-8; RAINE CS, 1989, LAB INVEST, V60, P714; Sabel BA, 1997, NEUROSCIENTIST, V3, P366, DOI 10.1177/107385849700300609; Scolding N, 1997, CURR OPIN NEUROL, V10, P193, DOI 10.1097/00019052-199706000-00005; Trapp BD, 1998, NEW ENGL J MED, V338, P278, DOI 10.1056/NEJM199801293380502; Waxman SG, 1998, NEW ENGL J MED, V338, P323, DOI 10.1056/NEJM199801293380510	17	57	60	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	AUG 1	1998	352	9125					340	341		10.1016/S0140-6736(05)60463-1	http://dx.doi.org/10.1016/S0140-6736(05)60463-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	106BU	9717917				2022-12-28	WOS:000075110500005
J	Toon, PD				Toon, PD			Reforming the Russian health service - Otherwise it might be convenient	BRITISH MEDICAL JOURNAL			English	Article											Toon, PD (corresponding author), 137 Roding Rd, London E5 0DR, England.							Balint M., 1957, DOCTOR	1	4	4	2	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	SEP 12	1998	317	7160					741	742		10.1136/bmj.317.7160.741	http://dx.doi.org/10.1136/bmj.317.7160.741			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	121CT	9732348	Green Published			2022-12-28	WOS:000075995100027
J	Valden, M; Lai, X; Goodman, DW				Valden, M; Lai, X; Goodman, DW			Onset of catalytic activity of gold clusters on titania with the appearance of nonmetallic properties	SCIENCE			English	Article							CO OXIDATION; TIO2(110); SURFACE; TIO2; FILMS; ADSORPTION; OXYGEN; GROWTH; PD; AU	Cold clusters ranging in diameter from 1 to 6 nanometers have been prepared on single crystalline surfaces of titania in ultrahigh vacuum to investigate the unusual size dependence of the Low-temperature catalytic oxidation of carbon monoxide. Scanning tunneling microscopy/spectroscopy (STM/STS) and elevated pressure reaction kinetics measurements show that the structure sensitivity of this reaction on gold clusters supported on titania is related to a quantum size effect with respect to the thickness of the gold islands; islands with two Layers of gold are most effective for catalyzing the oxidation of carbon monoxide. These results suggest that supported clusters, in general, may have unusual catalytic properties as one dimension of the cluster becomes smaller than three atomic spacings.	Texas A&M Univ, Dept Chem, College Stn, TX 77842 USA	Texas A&M University System; Texas A&M University College Station	Valden, M (corresponding author), Texas A&M Univ, Dept Chem, College Stn, TX 77842 USA.		Valden, Mika/G-4241-2014	Valden, Mika/0000-0002-9693-9818				Bamwenda GR, 1997, CATAL LETT, V44, P83, DOI 10.1023/A:1018925008633; CAMPBELL RA, 1992, REV SCI INSTRUM, V63, P172, DOI 10.1063/1.1142951; CANNING NDS, 1984, SURF SCI, V141, P240, DOI 10.1016/0039-6028(84)90209-7; Goodman DW, 1996, J PHYS CHEM-US, V100, P13090, DOI 10.1021/jp953755e; HARUTA M, 1993, J CATAL, V144, P175, DOI 10.1006/jcat.1993.1322; Haruta M, 1997, CATAL TODAY, V36, P153, DOI 10.1016/S0920-5861(96)00208-8; HUBER H, 1977, INORG CHEM, V16, P975, DOI 10.1021/ic50171a001; Iizuka Y, 1997, CATAL TODAY, V36, P115, DOI 10.1016/S0920-5861(96)00204-0; LIN SD, 1993, CATAL LETT, V17, P245, DOI 10.1007/BF00766147; PAK S, UNPUB; PAN JM, 1992, J VAC SCI TECHNOL A, V10, P2470, DOI 10.1116/1.577986; PESTY F, 1995, SURF SCI, V339, P83, DOI 10.1016/0039-6028(95)00605-2; Rainer DR, 1997, J MOL CATAL A-CHEM, V119, P307, DOI 10.1016/S1381-1169(96)00494-3; STREET SC, 1997, CHEM PHYS SOLID SURF, V8, P375; Xu C, 1997, PHYS REV B, V56, P13464, DOI 10.1103/PhysRevB.56.13464; Xu C, 1997, J VAC SCI TECHNOL A, V15, P1261, DOI 10.1116/1.580604; Zhang L, 1997, PHYS REV B, V56, P10549, DOI 10.1103/PhysRevB.56.10549	17	3775	3846	24	1324	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 11	1998	281	5383					1647	1650		10.1126/science.281.5383.1647	http://dx.doi.org/10.1126/science.281.5383.1647			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	118TR	9733505				2022-12-28	WOS:000075856500038
J	de Ferranti, SD; Ioannidis, JPA; Lau, J; Anninger, WV; Barza, M				de Ferranti, SD; Ioannidis, JPA; Lau, J; Anninger, WV; Barza, M			Are amoxycillin and folate inhibitors as effective as other antibiotics for acute sinusitis? A meta-analysis	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ACUTE MAXILLARY SINUSITIS; RESPIRATORY-TRACT INFECTIONS; PLACEBO-CONTROLLED TRIAL; GENERAL-PRACTICE; DOUBLE-BLIND; CLINICAL-TRIALS; PENICILLIN-V; AMOXICILLIN; BRODIMOPRIM; CHILDREN	Objectives: To examine whether antibiotics are indicated in treating uncomplicated acute sinusitis and, if so, whether newer and more expensive antibiotics with broad spectra of antimicrobial activity are more effective than amoxycillin or folate inhibitors. Design: Meta-analysis of randomised trials. Setting: Outpatient clinics. Subjects: 2717 patients with acute sinusitis or acute exacerbation of chronic sinusitis from 27 trials. Interventions: Any antibiotic versus placebo; amoxycillin or folate inhibitors versus newer, more expensive antibiotics. Main outcome measurements: Clinical failures and cures. Results: Compared with placebo, antibiotics decreased the incidence of clinical failures by half (risk ratio 0.54 (95% confidence interval 0.37 to 0.79)). Risk of clinical failure among 1553 randomised patients was not meaningfully decreased with more expensive antibiotics as compared with amoxycillin (risk ratio 0.86 (0.62 to 1.19); risk difference 0.9 fewer failures per 100 patients (1.4 more failures to 3.1 fewer failures per 100 patients)). The results were similar for other antibiotics versus folate inhibitors (risk ratio 1.01 (0.52 to 1.97)), but data were sparse (n = 410) and of low quality. Conclusions: Amoxycillin and folate inhibitors are essentially as effective as more expensive antibiotics for the initial treatment of uncomplicated acute sinusitis. Small differences in efficacy may exist, but are unlikely to be clinically important.	Tufts Univ New England Med Ctr, Dept Med, Div Clin Care Res, Boston, MA 02111 USA; Tufts Univ New England Med Ctr, Dept Med, Div Geog Med & Infect Dis, Tupper Res Inst, Boston, MA 02111 USA	Tufts Medical Center; Tufts Medical Center	Lau, J (corresponding author), Tufts Univ New England Med Ctr, Dept Med, Div Clin Care Res, 750 Washington St, Boston, MA 02111 USA.	joseph.lau@es.nemc.org	Ioannidis, John P. A./G-9836-2011		AHRQ HHS [R01 HS07782] Funding Source: Medline; NIAID NIH HHS [T32 AI07389, T32 AI007389] Funding Source: Medline; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS007782] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007389] Funding Source: NIH RePORTER	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALVART R, 1992, J INT MED RES, V20, pA53; *AM SOC MICR, 1997, PROGR ABSTR INT C AN; *AM SOC MICR, 1996, PROGR ABSTR INT C AN; *AM SOC MICR, 1994, PROGR ABSTR INT C AN; *AM SOC MICR, 1995, PROGR ABSTR INT C AN; *AM SOC MICR, 1993, PROGR ABSTR INT C AN; Arason VA, 1996, BMJ-BRIT MED J, V313, P387; ARNDT J, 1994, J CHEMOTHERAPY, V6, P322; AXELSSON A, 1970, ACTA OTO-LARYNGOL, V70, P71, DOI 10.3109/00016487009181861; BOCKMEYER M, 1994, CLIN THER, V16, P653; BRODIE DP, 1989, J INT MED RES, V17, P547, DOI 10.1177/030006058901700608; Calhoun K H, 1993, Arch Fam Med, V2, P837, DOI 10.1001/archfami.2.8.837; CASIANO RR, 1991, AM J MED, V91, pS27, DOI 10.1016/0002-9343(91)90398-H; deBock GH, 1997, J CLIN EPIDEMIOL, V50, P881, DOI 10.1016/S0895-4356(97)00117-0; EDELSTEIN DR, 1993, LARYNGOSCOPE, V103, P33; EVANS FO, 1975, NEW ENGL J MED, V293, P735, DOI 10.1056/NEJM197510092931502; FALSER N, 1988, INFECTION, V16, pS51, DOI 10.1007/BF01650508; FELSTEAD SJ, 1991, J INT MED RES, V19, P363, DOI 10.1177/030006059101900502; Fleiss J L, 1993, Stat Methods Med Res, V2, P121, DOI 10.1177/096228029300200202; Gananca M, 1973, Curr Med Res Opin, V1, P362, DOI 10.1185/03007997309111694; GWALTNEY JM, 1995, MANDELL DOUGLAS BENN, P585; HAMORY BH, 1979, J INFECT DIS, V139, P197, DOI 10.1093/infdis/139.2.197; HANSEN JG, 1995, BRIT MED J, V311, P233, DOI 10.1136/bmj.311.6999.233; Haye R, 1996, EUR J CLIN MICROBIOL, V15, P849, DOI 10.1007/BF01691214; Huck W, 1993, Arch Fam Med, V2, P497, DOI 10.1001/archfami.2.5.497; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; JOHNSON DL, 1988, J PEDIATR-US, V113, P15, DOI 10.1016/S0022-3476(88)80522-5; Johnson S E, 1972, Curr Med Res Opin, V1, P37, DOI 10.1185/03007997209111143; KARMA P, 1991, J ANTIMICROB CHEMOTH, V27, P83, DOI 10.1093/jac/27.suppl_A.83; Laird N M, 1990, Int J Technol Assess Health Care, V6, P5; Lau J, 1997, ANN INTERN MED, V127, P820, DOI 10.7326/0003-4819-127-9-199711010-00008; Lindbaek M, 1996, Fam Med, V28, P183; Lindbaek M, 1996, BMJ-BRIT MED J, V313, P325, DOI 10.1136/bmj.313.7053.325; MANTEL N, 1959, J NATL CANCER I, V22, P719; MANZINI M, 1993, J CHEMOTHERAPY, V5, P521, DOI 10.1080/1120009X.1993.11741109; MATTHEWS BL, 1998, POSTGRAD MED     MAY, P41; MATTUCCI KF, 1986, ARCH OTOLARYNGOL, V112, P73; NISSINEN A, 1995, CLIN INFECT DIS, V21, P1193, DOI 10.1093/clinids/21.5.1193; NYFFENEGGER R, 1991, CLIN THER, V13, P589; OSMAN MF, 1983, P 13 INT C CHEM, P26; OTTE J, 1983, REV MED CHILE, V111, P1157; PODVINEC M, 1982, THER UMSCH, V39, P815; Rahlfs VW, 1996, CLIN DRUG INVEST, V11, P65, DOI 10.2165/00044011-199611020-00001; Rimmer D, 1998, POSTGRAD MED     MAY, P50; SALMI HA, 1986, DRUG EXP CLIN RES, V12, P349; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408; Seppala H, 1995, CLIN INFECT DIS, V21, P1378, DOI 10.1093/clinids/21.6.1378; SKELTON R, 1992, ARCH DIS CHILD, V67, P1478, DOI 10.1136/adc.67.12.1478; SODERSTROM M, 1991, SCAND J INFECT DIS, V23, P347, DOI 10.3109/00365549109024322; Stalman W, 1997, BRIT J GEN PRACT, V47, P794; vanBuchem FL, 1997, LANCET, V349, P683, DOI 10.1016/S0140-6736(96)07585-X; VONSYDOW C, 1995, SCAND J INFECT DIS, V27, P229; WALD ER, 1984, J PEDIATR-US, V104, P297, DOI 10.1016/S0022-3476(84)81018-5; WALD ER, 1986, PEDIATRICS, V77, P795; WALLACE RB, 1985, CURR MED RES OPIN, V9, P659, DOI 10.1185/03007998509109648; WILLIAMS JW, 1995, JAMA-J AM MED ASSOC, V273, P1015, DOI 10.1001/jama.273.13.1015	56	92	97	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 5	1998	317	7159					632	637		10.1136/bmj.317.7159.632	http://dx.doi.org/10.1136/bmj.317.7159.632			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	118GN	9727991	Bronze, Green Published, Green Submitted			2022-12-28	WOS:000075830200021
J	Eremets, MI; Shimizu, K; Kobayashi, TC; Amaya, K				Eremets, MI; Shimizu, K; Kobayashi, TC; Amaya, K			Metallic CsI at pressures of up to 220 gigapascals	SCIENCE			English	Article							DIAMOND-ANVIL CELL; X-RAY-DIFFRACTION; CESIUM IODIDE; OPTICAL-ABSORPTION; GPA; HYDROGEN; EQUATION; STATE; TRANSITIONS; MEGABARS	Direct electrical transport measurements in a diamond anvil cell provide evidence for the metallization of cesium iodide (Csl) at a pressure of 115 gigapascals, A drop in the temperature dependence of the resistance was found at pressures above 180 gigapascals, indicating that the Csl was superconductive. The superconductivity changed under the influence of a magnetic field to a Lower critical temperature ana disappeared above 0.3 tesla. The highest critical temperature at which superconductivity was observed was 2 kelvin, and the critical temperature decreased with increasing pressure.	Osaka Univ, Grad Sch Engn Sci, Dept Phys Sci, Toyonaka, Osaka 5608531, Japan; Osaka Univ, Res Ctr Mat Sci Extreme Condit, Toyonaka, Osaka 5608531, Japan; Japan Atom Energy Res Inst, Adv Sci Res Ctr, Tokai, Ibaraki 3191195, Japan	Osaka University; Osaka University; Japan Atomic Energy Agency	Amaya, K (corresponding author), Osaka Univ, Grad Sch Engn Sci, Dept Phys Sci, Toyonaka, Osaka 5608531, Japan.		KOBAYASHI, Tatsuo/B-1527-2011	Shimizu, Katsuya/0000-0003-0560-8325				AIDUN J, 1984, PHYS REV B, V29, P2611, DOI 10.1103/PhysRevB.29.2611; ASAUMI K, 1984, PHYS REV B, V29, P1118, DOI 10.1103/PhysRevB.29.1118; ASHCROFT NW, 1990, PHYS REV B, V41, P10963, DOI 10.1103/PhysRevB.41.10963; ASOKAMANI R, 1992, RECENT TRENDS HIGH P, P434; BLOCK S, 1976, PHYS TODAY, V29, P44, DOI 10.1063/1.3023899; EGGERT JH, 1991, PHYS REV B, V44, P7202, DOI 10.1103/PhysRevB.44.7202; EREMETS MI, 1996, HIGH PRESSURE SCI TE, P469; EREMETS MI, 1997, P ADR RES C SIMPL SY; EREMETS MI, 1996, HIGH PRESSURE EXPT M, P59; HUANG TL, 1984, PHYS REV B, V29, P112; KNITTLE E, 1984, SCIENCE, V223, P53, DOI 10.1126/science.223.4631.53; KNITTLE E, 1985, J PHYS CHEM SOLIDS, V46, P1179, DOI 10.1016/0022-3697(85)90147-7; KOMETANI S, 1997, J PHYS SOC JPN, V66, P818; MAKARENKO IN, 1984, PHYS REV B, V29, P6018, DOI 10.1103/PhysRevB.29.6018; MAO HK, 1994, REV MOD PHYS, V66, P671, DOI 10.1103/RevModPhys.66.671; MAO HK, 1978, SCIENCE, V200, P1145, DOI 10.1126/science.200.4346.1145; MAO HK, 1986, J GEOPHYS RES-SOLID, V91, P4673, DOI 10.1029/JB091iB05p04673; MAO HK, 1990, PHYS REV LETT, V64, P1749, DOI 10.1103/PhysRevLett.64.1749; MAO HK, 1989, SCIENCE, V246, P649, DOI 10.1126/science.246.4930.649; MAO HK, 1977, HIGH PRESSURE RES AP, P493; REICHLIN R, 1994, PHYS REV B, V49, P3725, DOI 10.1103/PhysRevB.49.3725; REICHLIN R, 1986, PHYS REV LETT, V56, P2858, DOI 10.1103/PhysRevLett.56.2858; Richardson CF, 1997, PHYS REV LETT, V78, P118, DOI 10.1103/PhysRevLett.78.118; Shimizu K, 1998, NATURE, V393, P767, DOI 10.1038/31656; SHIMIZU K, 1996, HIGH PRESSURE SCI TE, P498; SILVERA IF, 1985, REV SCI INSTRUM, V56, P121, DOI 10.1063/1.1138514; TAKEMURA K, UNPUB; VANSTRAATEN J, 1987, REV SCI INSTRUM, V58, P994, DOI 10.1063/1.1139588; Weir ST, 1996, PHYS REV LETT, V76, P1860, DOI 10.1103/PhysRevLett.76.1860; WILLIAMS Q, 1986, PHYS REV LETT, V56, P163, DOI 10.1103/PhysRevLett.56.163; WILLIAMS Q, 1987, PHYS REV LETT, V59, P1132, DOI 10.1103/PhysRevLett.59.1132	31	112	120	1	36	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 28	1998	281	5381					1333	1335		10.1126/science.281.5381.1333	http://dx.doi.org/10.1126/science.281.5381.1333			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	115LQ	9721094				2022-12-28	WOS:000075666800044
J	Celentano, DD; Vlahov, D; Cohn, S; Shadle, VM; Obasanjo, O; Moore, RD				Celentano, DD; Vlahov, D; Cohn, S; Shadle, VM; Obasanjo, O; Moore, RD			Self-reported antiretroviral therapy in injection drug users	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Context.-The US Public Health Service and the International AIDS Society-USA recently published recommendations for antiretroviral therapy (ART) for persons infected with human immunodeficiency virus (HIV); however, anecdotal evidence suggests that HIV-infected injection drug users (IDUs) may not be receiving optimal care as defined by the recommendations. Objective.-To assess ART use in HIV-infected IDUs. Design.-A cross-sectional survey of self-reported ART use between July 1996 and June 1997 in IDUs. Setting.-A community-based clinic affiliated with Johns Hopkins University, Baltimore, Md. Participants.-A total of 404 HIV-infected IDUs with CD4(+) cell counts less than 0.50 x 10(9)/L recruited into a longitudinal study in 1988 and 1989. Main Outcome Measure.-Self-reported ART use was assessed: no current therapy, monotherapy, or combination therapy with or without a protease inhibitor. Results.-One half (199/404 [49%]) of patients reported no recent ART. A total of 14% (58/404) had monotherapy, 23% (90/404) were receiving combination therapy without a protease inhibitor, and 14% (57/404) had triple-combination therapy with a protease inhibitor. A multivariate analysis of factors associated with ART showed that care continuity and recent HIV-related outpatient visit (odds ratio [OR], 4.30; 95% confidence interval [CI], 2.36-7.81 and OR, 2.84; 95% CI, 1.66-4.88, respectively), CD4(+) cell count of less than 0.20 x 10(9) (OR, 2.41,95% CI, 1.51-3.84), no current drug use and being in drug treatment (OR, 2.16; 95% CI, 1.34-3.47; OR, 2.12; 95% CI, 1.23-3.66, respectively), and unemployment (OR, 2.31;95% CI, 1.21-4.40) were associated with reporting ART use. In other analysis, less likely to receive protease inhibitors were current drug injectors (OR, 0.5; 95% CI, 0.3-1.0) and those recently incarcerated (OR, 0.2; 95% CI, 0.03-0.9), but patients with acquired immunodeficiency syndrome were more likely to receive protease inhibitors (OR, 2.0; 95% CI, 0.9-4.6). Protease inhibitor use doubled (P<.01) from July and December 1996 to January and June 1997 (7.7% and 14.8%, respectively). Conclusions.-Those IDUs infected with HIV who were not receiving ART tended to be active drug users without clinical disease who have less contact with health care providers. Although we do not have information on clinical judgment regarding treatment decisions or whether persons were prescribed therapy not taken, the proportion of subjects reporting receiving ART suggests that strategies for improving treatment in this population are indicated. Expanding simultaneous treatment services for HIV infection and substance abuse would enhance the response to these related epidemics.	Johns Hopkins Univ, Sch Hyg & Publ Hlth, Dept Epidemiol, Program Infect Dis, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University	Celentano, DD (corresponding author), Johns Hopkins Univ, Sch Hyg & Publ Hlth, Dept Epidemiol, Program Infect Dis, 615 N Wolfe St,E-7132, Baltimore, MD 21205 USA.	dcelenta@jhsph.edu			NATIONAL INSTITUTE ON DRUG ABUSE [R37DA004334, R01DA004334] Funding Source: NIH RePORTER; NIDA NIH HHS [DA04334] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		Bangsberg D, 1997, JAMA-J AM MED ASSOC, V278, P63, DOI 10.1001/jama.278.1.63; Carpenter CCJ, 1997, JAMA-J AM MED ASSOC, V277, P1962, DOI 10.1001/jama.277.24.1962; CRAMER JA, 1990, ARCH INTERN MED, V150, P1509, DOI 10.1001/archinte.150.7.1509; Deeks SG, 1997, JAMA-J AM MED ASSOC, V277, P145, DOI 10.1001/jama.277.2.145; DeGruttola V, 1997, J INFECT DIS, V175, P237, DOI 10.1093/infdis/175.2.237; *DEP HLTH HUM SERV, 1998, MMWR-MORBID MORTAL W, V47, P43; Flexner C, 1998, NEW ENGL J MED, V338, P1281, DOI 10.1056/NEJM199804303381808; Freeman RC, 1996, AIDS EDUC PREV, V8, P58; GULICK RM, 1996, 11 INT C AIDS JUL 7; HIRSCH M, 1997, 4 C RETR OPP INF JAN; HO DD, 1997, 4 C RETR OPP INF JAN; Kasl S V, 1975, J Human Stress, V1, P5; Mehta S, 1997, AIDS, V11, P1665, DOI 10.1097/00002030-199714000-00002; MOORE RD, 1994, NEW ENGL J MED, V20, P1412; SCHAUB AF, 1993, CLIN EXP HYPERTENS, V15, P1121, DOI 10.3109/10641969309037099; STRATHDEE SA, 1998, 5 C RETR OPP INF CHI; Vlahov D, 1991, NIDA Res Monogr, V109, P75; WONG JK, 1997, 4 C RETR OPP INF JAN	18	225	228	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 12	1998	280	6					544	546		10.1001/jama.280.6.544	http://dx.doi.org/10.1001/jama.280.6.544			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	108AY	9707145				2022-12-28	WOS:000075244900031
J	Stirling, CM; Boulton-Jones, JM; Simpson, K				Stirling, CM; Boulton-Jones, JM; Simpson, K			Progressive oedema in a 30-year-old	LANCET			English	Article							CAPILLARY LEAK SYNDROME		Glasgow Royal Infirm, Renal Unit, Glasgow G4 0SF, Lanark, Scotland	University of Glasgow	Stirling, CM (corresponding author), Glasgow Royal Infirm, Renal Unit, Glasgow G4 0SF, Lanark, Scotland.							CICARDI M, 1990, ANN INTERN MED, V113, P475, DOI 10.7326/0003-4819-113-6-475; CLARKSON B, 1960, AM J MED, V29, P193, DOI 10.1016/0002-9343(60)90018-8; JAAP AJ, 1993, DIABETOLOGIA, V36, P648, DOI 10.1007/BF00404075; TAN EM, 1982, ARTHRITIS RHEUM, V25, P1271, DOI 10.1002/art.1780251101; TEELUCKSINGH S, 1990, Q J MED, V75, P515	5	14	14	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	AUG 8	1998	352	9126					450	450		10.1016/S0140-6736(98)05348-3	http://dx.doi.org/10.1016/S0140-6736(98)05348-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	108EA	9708754				2022-12-28	WOS:000075252000013
J	Gardner, W; Rosenbaum, J				Gardner, W; Rosenbaum, J			Intellectual property - Database protection and access to information	SCIENCE			English	Editorial Material									Univ Pittsburgh, Sch Med, Dept Med, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA 15260 USA; Amer Assoc Advancement Sci, Joint Comm, Washington, DC 20005 USA; Amer Bar Assoc, Chicago, IL 60611 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Gardner, W (corresponding author), Univ Pittsburgh, Sch Med, Dept Med, Pittsburgh, PA 15260 USA.							TYSON LD, 1997, STATUTORY PROTECTION	1	10	10	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 7	1998	281	5378					786	787		10.1126/science.281.5378.786	http://dx.doi.org/10.1126/science.281.5378.786			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	108ZD	9714683				2022-12-28	WOS:000075295600033
J	Weiss, A; Schlessinger, J				Weiss, A; Schlessinger, J			Switching signals on or off by receptor dimerization	CELL			English	Review							TYROSINE-PHOSPHATASE; ACTIVATION; LIGAND; DOMAIN; CD45; BETA		Univ Calif San Francisco, Howard Hughes Med Inst, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Howard Hughes Med Inst, Dept Microbiol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Howard Hughes Med Inst, Dept Immunol, San Francisco, CA 94143 USA; NYU, Med Ctr, Dept Pharmacol, New York, NY 10016 USA; NYU, Med Ctr, Skirball Inst, New York, NY 10016 USA	Howard Hughes Medical Institute; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco; New York University; New York University	Weiss, A (corresponding author), Univ Calif San Francisco, Howard Hughes Med Inst, Dept Med, San Francisco, CA 94143 USA.							Bilwes AM, 1996, NATURE, V382, P555, DOI 10.1038/382555a0; Denu JM, 1996, CELL, V87, P361, DOI 10.1016/S0092-8674(00)81356-2; DESAI DM, 1993, CELL, V73, P541, DOI 10.1016/0092-8674(93)90141-C; DESAI DM, 1994, EMBO J, V13, P4002, DOI 10.1002/j.1460-2075.1994.tb06716.x; Fashena SJ, 1995, CURR BIOL, V5, P1367, DOI 10.1016/S0960-9822(95)00272-7; Hof P, 1998, CELL, V92, P441, DOI 10.1016/S0092-8674(00)80938-1; Hoffmann KMV, 1997, J BIOL CHEM, V272, P27505, DOI 10.1074/jbc.272.44.27505; Hubbard SR, 1998, J BIOL CHEM, V273, P11987, DOI 10.1074/jbc.273.20.11987; KISHIHARA K, 1993, CELL, V74, P143, DOI 10.1016/0092-8674(93)90302-7; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P21478; Lemmon MA, 1997, EMBO J, V16, P281, DOI 10.1093/emboj/16.2.281; LEMMON MA, 1994, TRENDS BIOCHEM SCI, V19, P459, DOI 10.1016/0968-0004(94)90130-9; Majeti R, 1998, SCIENCE, V279, P88, DOI 10.1126/science.279.5347.88; Neel BG, 1997, CURR OPIN CELL BIOL, V9, P193, DOI 10.1016/S0955-0674(97)80063-4; PELES E, 1995, CELL, V82, P251, DOI 10.1016/0092-8674(95)90312-7; Schlessinger J, 1997, CELL, V91, P869, DOI 10.1016/S0092-8674(00)80477-8; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; TROWBRIDGE IS, 1994, ANNU REV IMMUNOL, V12, P85, DOI 10.1146/annurev.iy.12.040194.000505; Wallace MJ, 1998, MOL CELL BIOL, V18, P2608, DOI 10.1128/MCB.18.5.2608; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0	20	321	330	0	7	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 7	1998	94	3					277	280		10.1016/S0092-8674(00)81469-5	http://dx.doi.org/10.1016/S0092-8674(00)81469-5			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	109EN	9708728	hybrid			2022-12-28	WOS:000075308400002
J	Manabe, T; Noda, Y; Mamiya, T; Katagiri, H; Houtani, T; Nishi, M; Noda, T; Takahashi, T; Sugimoto, T; Nabeshima, T; Takeshima, H				Manabe, T; Noda, Y; Mamiya, T; Katagiri, H; Houtani, T; Nishi, M; Noda, T; Takahashi, T; Sugimoto, T; Nabeshima, T; Takeshima, H			Facilitation of long-term potentiation and memory in mice lacking nociception receptors	NATURE			English	Article							HIPPOCAMPAL CA1 REGION; SYNAPTIC TRANSMISSION; CALCIUM CHANNELS; ORPHANIN-FQ; NEURONS; LTP; MODULATION; CELLS	The peptide nociceptin (also named orphanin FQ) acts in the brain to produce various pharmacological effects, including hyperalgesia and hypolocomotion(1,2). The nociceptin receptor uses guanine-nucleotide-binding proteins to mediate the inhibition of adenylyl cyclase, the activation of potassium channels and inhibition of calcium channels(3). It has been shown using knockout mice that the nociceptin receptor is not required for regulation of nociceptive responses or locomotion activity, but modulates the auditory function(4). Here we show that mice lacking the nociceptin receptor possess greater learning ability and have better memory than control mice. Histological analysis revealed the expression of both the nociceptin precursor and the nociceptin receptor in the hippocampus, thought to take part in aspects of learning and memory. Moreover, the receptor-deficient mice showed larger long-term potentiation in the hippocampal CAI region than control mice, without apparent changes in presynaptic or postsynaptic electrophysiological properties. These results show that the loss of the nociceptin receptor results in a gain-of-function mutation in both the memory process and the long-term potentiation mechanism in CA1, perhaps as a result of altered intracellular signal transduction systems in neurons.	Univ Tokyo, Fac Med, Dept Pharmacol, Bunkyo Ku, Tokyo 1138654, Japan; Univ Tokyo, Fac Med, Dept Neurophysiol, Bunkyo Ku, Tokyo 1138654, Japan; Nagoya Univ, Sch Med, Dept Neuropsychopharmacol, Nagoya, Aichi 4668560, Japan; Nagoya Univ, Sch Med, Hosp Pharm, Nagoya, Aichi 4668560, Japan; Kansai Med Univ, Dept Anat, Osaka 5708506, Japan; Inst Canc, Dept Cell Biol, Toshima Ku, Tokyo 1708455, Japan	University of Tokyo; University of Tokyo; Nagoya University; Nagoya University; Kansai Medical University	Takeshima, H (corresponding author), Univ Tokyo, Fac Med, Dept Pharmacol, Bunkyo Ku, Tokyo 1138654, Japan.		Noda, Tetsuo/B-1667-2016	Takeshima, Hiroshi/0000-0003-4525-3725				BAJOCCHI G, 1993, NAT GENET, V3, P229, DOI 10.1038/ng0393-229; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; Blitzer RD, 1995, NEURON, V15, P1403, DOI 10.1016/0896-6273(95)90018-7; FREY U, 1993, SCIENCE, V260, P1661, DOI 10.1126/science.8389057; Fukuda K, 1997, FEBS LETT, V412, P290, DOI 10.1016/S0014-5793(97)00815-6; Henderson G, 1997, TRENDS PHARMACOL SCI, V18, P293, DOI 10.1016/S0165-6147(97)90645-3; Houtani T, 1996, BIOCHEM BIOPH RES CO, V219, P714, DOI 10.1006/bbrc.1996.0300; HU GY, 1987, NATURE, V328, P426, DOI 10.1038/328426a0; Ikeda K, 1997, MOL BRAIN RES, V45, P117, DOI 10.1016/S0169-328X(96)00252-5; Knoflach F, 1996, J NEUROSCI, V16, P6657; Lou LG, 1997, BIOCHEM BIOPH RES CO, V240, P304, DOI 10.1006/bbrc.1997.7654; MADISON DV, 1982, NATURE, V299, P636, DOI 10.1038/299636a0; MALINOW R, 1989, SCIENCE, V245, P862, DOI 10.1126/science.2549638; Mamiya T, 1998, BRAIN RES, V783, P236, DOI 10.1016/S0006-8993(97)01406-6; MANABE T, 1993, J NEUROPHYSIOL, V70, P1451, DOI 10.1152/jn.1993.70.4.1451; MAYER ML, 1984, NATURE, V309, P261, DOI 10.1038/309261a0; MEUNIER JC, 1995, NATURE, V377, P532, DOI 10.1038/377532a0; MORRIS RGM, 1981, LEARN MOTIV, V12, P239, DOI 10.1016/0023-9690(81)90020-5; NABESHIMA T, 1993, METHODS NEUROSCIENCE, V14, P217; Nishi M, 1997, EMBO J, V16, P1858, DOI 10.1093/emboj/16.8.1858; NOWAK L, 1984, NATURE, V307, P462, DOI 10.1038/307462a0; REINSCHEID RK, 1995, SCIENCE, V270, P792, DOI 10.1126/science.270.5237.792; Sandin J, 1997, EUR J NEUROSCI, V9, P194, DOI 10.1111/j.1460-9568.1997.tb01367.x; TAKAHASHI T, 1993, NATURE, V366, P156, DOI 10.1038/366156a0; Thomas MJ, 1996, NEURON, V17, P475, DOI 10.1016/S0896-6273(00)80179-8; Tsien JZ, 1996, CELL, V87, P1327, DOI 10.1016/S0092-8674(00)81827-9; Yamada K, 1996, J PHARMACOL EXP THER, V276, P460; Yu TP, 1997, HIPPOCAMPUS, V7, P88, DOI 10.1002/(SICI)1098-1063(1997)7:1<88::AID-HIPO9>3.0.CO;2-3	28	282	319	0	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 6	1998	394	6693					577	581		10.1038/29073	http://dx.doi.org/10.1038/29073			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	107YN	9707118				2022-12-28	WOS:000075238700048
J	Gelijns, AC; Rosenberg, N; Moskowitz, AJ				Gelijns, AC; Rosenberg, N; Moskowitz, AJ			Capturing the unexpected benefits of medical research	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							CARE		Columbia Univ, New York, NY 10032 USA; Stanford Univ, Stanford, CA 94305 USA	Columbia University; Stanford University	Gelijns, AC (corresponding author), Columbia Univ, New York, NY 10032 USA.			Moskowitz, Alan/0000-0002-4412-9450				CAINE M, 1976, BRIT J UROL, V48, P255, DOI 10.1111/j.1464-410X.1976.tb03013.x; Crowley WF, 1996, ACAD MED, V71, P1154, DOI 10.1097/00001888-199611000-00013; FLECKENSTEIN A, 1969, ARCH EUR J PHYS, V307, pR26; GELIJNS AC, 1995, MED INN CR, V5, P67; HLATKY MA, 1984, STAT MED, V3, P375, DOI 10.1002/sim.4780030415; MARSHALL BJ, 1984, LANCET, V1, P1311; MARSHALL BJ, 1988, SCAND J GASTROENTERO, V23, P58, DOI 10.3109/00365528809099131; *MED EC, 1998, PHYS DESK REF, P3223; *NIH, 1997, REP PREP HLTH IND MA; SPETZ J, 1995, MED INN CR, V5, P41; *WILK GROUP, 1995, FORC RESH PERF CONTR, P275; WURTMAN RJ, 1995, NAT MED, V1, P1122, DOI 10.1038/nm1195-1122	13	67	70	0	7	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 3	1998	339	10					693	698		10.1056/NEJM199809033391010	http://dx.doi.org/10.1056/NEJM199809033391010			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	115WA	9725930				2022-12-28	WOS:000075688100010
J	Pestova, TV; Borukhov, SI; Hellen, CUT				Pestova, TV; Borukhov, SI; Hellen, CUT			Eukaryotic ribosomes require initiation factors 1 and 1A to locate initiation codons	NATURE			English	Article							MAMMALIAN PROTEIN-SYNTHESIS; AMINO-ACID-SEQUENCE; RABBIT RETICULOCYTES; BINDING PROTEIN; MESSENGER-RNA; TRANSLATION; MECHANISM; ENTRY; SUI1; PURIFICATION	The scanning model of translation initiation is a coherent description of how eukaryotic ribosomes reach the initiation codon after being recruited to the capped 5' end of messenger RNA. Five eukaryotic initiation factors (eIF 2, 3, 4A, 4B and 4F) with established functions have been assumed to be sufficient to mediate this process. Here we report that eIF1 and eIF1A are also both essential for translation initiation. In their absence, 43S ribosomal preinitiation complexes incubated with ATP, eIF4A, eIF4B and eIF4F bind exclusively to the cap-proximal region but are unable to reach the initiation codon. Individually, eIF1A enhances formation of this cap-proximal complex, and eIF1 weakly promotes formation of a 48S ribosomal compiler at the Initiation codon. These proteins act synergistically to mediate assembly of ribosomal initiation complexes at the Initiation codon and dissociate aberrant complexes from the mRNA.	SUNY Hlth Sci Ctr, Dept Microbiol & Immunol, Brooklyn, NY 11203 USA; Moscow MV Lomonosov State Univ, AN Belozersky Inst Physicochem Biol, Moscow 119899, Russia	State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; Lomonosov Moscow State University	Pestova, TV (corresponding author), SUNY Hlth Sci Ctr, Dept Microbiol & Immunol, 450 Clarkson Ave, Brooklyn, NY 11203 USA.	tpestova@netmail.hscbklyn.edu						ANTHONY DD, 1992, J BIOL CHEM, V267, P1554; BENNE R, 1978, J BIOL CHEM, V253, P3078; Chaudhuri J, 1997, J BIOL CHEM, V272, P7883, DOI 10.1074/jbc.272.12.7883; CHEN CY, 1995, SCIENCE, V268, P415, DOI 10.1126/science.7536344; Cui Y, 1998, MOL CELL BIOL, V18, P1506, DOI 10.1128/MCB.18.3.1506; DEVER TE, 1994, J BIOL CHEM, V269, P3212; EVSTAFIEVA AG, 1991, NUCLEIC ACIDS RES, V19, P665, DOI 10.1093/nar/19.3.665; FIELDS C, 1994, BIOCHEM BIOPH RES CO, V198, P288, DOI 10.1006/bbrc.1994.1040; HELLEN CUT, 1993, P NATL ACAD SCI USA, V90, P7642, DOI 10.1073/pnas.90.16.7642; JACKSON RJ, 1996, TRANSLATIONAL CONTRO, P71; KAMINSKI A, 1990, EMBO J, V9, P3753, DOI 10.1002/j.1460-2075.1990.tb07588.x; KASPERAITIS MAM, 1995, FEBS LETT, V365, P47, DOI 10.1016/0014-5793(95)00427-B; KEMPER WM, 1976, J BIOL CHEM, V251, P5551; KOZAK M, 1978, CELL, V15, P1109, DOI 10.1016/0092-8674(78)90039-9; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; Merrick WC., 1996, TRANSLATION CONTROL, P31; Pestova TV, 1998, GENE DEV, V12, P67, DOI 10.1101/gad.12.1.67; Pestova TV, 1996, MOL CELL BIOL, V16, P6870; Pestova TV, 1996, MOL CELL BIOL, V16, P6859, DOI 10.1128/mcb.16.12.6859; SCHREIER MH, 1977, J MOL BIOL, V116, P727, DOI 10.1016/0022-2836(77)90268-6; THOMAS A, 1980, EUR J BIOCHEM, V107, P39, DOI 10.1111/j.1432-1033.1980.tb04621.x; THOMAS A, 1980, FEBS LETT, V116, P67, DOI 10.1016/0014-5793(80)80530-8; TRACHSEL H, 1977, J MOL BIOL, V116, P755, DOI 10.1016/0022-2836(77)90269-8; WEI CL, 1995, J BIOL CHEM, V270, P5764, DOI 10.1074/jbc.270.11.5764; WEI CL, 1995, J BIOL CHEM, V270, P22788, DOI 10.1074/jbc.270.39.22788; YOON HJ, 1992, MOL CELL BIOL, V12, P248, DOI 10.1128/MCB.12.1.248	26	315	319	0	13	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 27	1998	394	6696					854	859		10.1038/29703	http://dx.doi.org/10.1038/29703			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	114LW	9732867				2022-12-28	WOS:000075611800037
J	Bado, A; Levasseur, S; Attoub, S; Kermorgant, S; Laigneau, JP; Bortoluzzi, MN; Moizo, L; Lehy, T; Guerre-Millo, M; Le Marchand-Brustel, Y; Lewin, MJM				Bado, A; Levasseur, S; Attoub, S; Kermorgant, S; Laigneau, JP; Bortoluzzi, MN; Moizo, L; Lehy, T; Guerre-Millo, M; Le Marchand-Brustel, Y; Lewin, MJM			The stomach is a source of leptin	NATURE			English	Article							OBESE GENE-PRODUCT; ADIPOSE-TISSUE; FOOD-INTAKE; CHOLECYSTOKININ; EXPRESSION; RATS; MICE; INHIBITION; INCREASE; ADIPOCYTES	The circulating peptide leptin, which is the product of the ob gene(1), provides feedback information on the size of fat stores to central Ob receptors(2,3) that control food intake and body-weight homeostasis(4-6). Leptin has so far been reported to be secreted only by adipocytes(1) and the placenta(7). Here we show that leptin messenger RNA and leptin protein are present in rat gastric epithelium, and that cells in the glands of the gastric fundic mucosa are immunoreactive for leptin, The physiological function of this previously unsuspected source of leptin is unknown. However, both feeding and administration of CCK-8 (the biologically active carboxy-terminal end of cholecystokinin) result in a rapid and large decrease in both leptin cell immunoreactivity and the leptin content of the fundic epithelium, with a concomitant increase in the concentration of leptin in the plasma. These results indicate that gastric leptin may be involved in early CCK-mediated effects activated by food intake, possibly including satiety.	Univ Paris 07, INSERM, U10, IFR2 Cellules Epitheliales,Hop Bichat, F-75018 Paris, France; Fac Med Nice, INSERM, U145, F-06107 Nice, France; Inst Biomed Cordeliers, INSERM, U465, F-75006 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite	Lewin, MJM (corresponding author), Univ Paris 07, INSERM, U10, IFR2 Cellules Epitheliales,Hop Bichat, 170 Blvd Ney, F-75018 Paris, France.	mjmlewin@bichat.inserm.fr	Guerre-Millo, Michele/G-7253-2017; Attoub, Samir/N-6852-2018; BADO, Andre/G-3408-2013; Kermorgant, Stephanie/AAB-4931-2020	Kermorgant, Stephanie/0000-0001-5921-479X; BADO, Andre/0000-0002-8007-1460				Ahima RS, 1996, NATURE, V382, P250, DOI 10.1038/382250a0; BADO A, 1994, YALE J BIOL MED, V67, P113; Barrachina MD, 1997, P NATL ACAD SCI USA, V94, P10455, DOI 10.1073/pnas.94.19.10455; Barzilai N, 1997, J CLIN INVEST, V100, P3105, DOI 10.1172/JCI119865; BUFFA R, 1976, GASTROENTEROLOGY, V70, P528; CAMPFIELD LA, 1995, SCIENCE, V269, P546, DOI 10.1126/science.7624778; DUGAIL I, 1988, BIOCHEM J, V254, P483, DOI 10.1042/bj2540483; GIBBS J, 1973, NATURE, V245, P323, DOI 10.1038/245323a0; HAINAULT I, 1991, J CLIN INVEST, V87, P1127, DOI 10.1172/JCI115077; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; Hardie LJ, 1996, BIOCHEM BIOPH RES CO, V223, P660, DOI 10.1006/bbrc.1996.0951; KOULISCHER D, 1982, REGUL PEPTIDES, V4, P127, DOI 10.1016/0167-0115(82)90080-5; Lee GH, 1996, NATURE, V379, P632, DOI 10.1038/379632a0; Levy R, 1997, BIOCHEM BIOPH RES CO, V237, P98, DOI 10.1006/bbrc.1997.7086; LIDDLE RA, 1984, GASTROENTEROLOGY, V87, P542; MACDOUGALD OA, 1995, P NATL ACAD SCI USA, V92, P9034, DOI 10.1073/pnas.92.20.9034; Mantzoros CS, 1996, DIABETES, V45, P909, DOI 10.2337/diabetes.45.7.909; Masuzaki H, 1997, NAT MED, V3, P1029, DOI 10.1038/nm0997-1029; Matson CA, 1997, PEPTIDES, V18, P1275, DOI 10.1016/S0196-9781(97)00138-1; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; Rose C, 1996, NATURE, V380, P403, DOI 10.1038/380403a0; SALADIN R, 1995, NATURE, V377, P527, DOI 10.1038/377527a0; SMITH GP, 1981, SCIENCE, V213, P1036, DOI 10.1126/science.7268408; Tanti JF, 1996, J BIOL CHEM, V271, P25227, DOI 10.1074/jbc.271.41.25227; Tartaglia LA, 1995, CELL, V83, P1263, DOI 10.1016/0092-8674(95)90151-5; Trayhurn P, 1996, BIOCHEM BIOPH RES CO, V228, P605, DOI 10.1006/bbrc.1996.1704; Wang YH, 1997, AM J PHYSIOL-REG I, V273, pR833, DOI 10.1152/ajpregu.1997.273.2.R833; Weigle DS, 1997, J CLIN ENDOCR METAB, V82, P561, DOI 10.1210/jc.82.2.561; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	29	940	983	0	45	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 20	1998	394	6695					790	793		10.1038/29547	http://dx.doi.org/10.1038/29547			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	112PR	9723619				2022-12-28	WOS:000075503600048
J	Stein, J				Stein, J			The Holy society	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material														Stein, Joel/0000-0001-5527-025X					0	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 19	1998	280	7					654	654		10.1001/jama.280.7.654	http://dx.doi.org/10.1001/jama.280.7.654			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	110ME	9718062				2022-12-28	WOS:000075384300039
J	Organ , CH; Porter, JM				Organ , CH; Porter, JM			General surgery	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MEDICAL-TREATMENT FACILITIES; DEPARTMENT-OF-DEFENSE; LAPAROSCOPIC CHOLECYSTECTOMY; EXTERNAL AUDIT		Univ Calif Davis E Bay, Dept Surg, Oakland, CA 94602 USA	University of California System; University of California Davis	Organ , CH (corresponding author), Univ Calif Davis E Bay, Dept Surg, 1411 E 31st St, Oakland, CA 94602 USA.							*CLIN OUTC SURG TH, 1996, DIS COLON RECTUM, V39, pS53; Ivatury RR, 1997, SURG CLIN N AM, V77, P783, DOI 10.1016/S0039-6109(05)70584-3; Mayberry JC, 1997, ARCH SURG-CHICAGO, V132, P957; *NCI, 1998, NCI HIGH PRIOR CLIN; Richards A, 1997, Ann R Coll Surg Engl, V79, P109; Richards A, 1997, ANN ROY COLL SURG, V79, P75; Rotondo MF, 1997, SURG CLIN N AM, V77, P761, DOI 10.1016/S0039-6109(05)70582-X; Silberg WM, 1997, JAMA-J AM MED ASSOC, V277, P1244, DOI 10.1001/jama.277.15.1244; Wang KK, 1997, MAYO CLIN PROC, V72, P66, DOI 10.4065/72.1.66; Watson DI, 1996, ANN SURG, V224, P198, DOI 10.1097/00000658-199608000-00013; WHERRY DC, 1994, ANN SURG, V220, P626, DOI 10.1097/00000658-199411000-00005; Wherry DC, 1996, ANN SURG, V224, P145, DOI 10.1097/00000658-199608000-00006	12	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 12	1998	280	6					495	496		10.1001/jama.280.6.495	http://dx.doi.org/10.1001/jama.280.6.495			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	108AY	9707126				2022-12-28	WOS:000075244900002
J	della Rovere, GQ; Bird, PA				della Rovere, GQ; Bird, PA			Sentinel-lymph-node biopsy in breast cancer	LANCET			English	Editorial Material									Royal Marsden NHS Trust, Sutton SM2 5PT, Surrey, England	Royal Marsden NHS Foundation Trust	della Rovere, GQ (corresponding author), Royal Marsden NHS Trust, Sutton SM2 5PT, Surrey, England.							Abati A, 1996, CANCER, V78, P1; Albertini JJ, 1996, JAMA-J AM MED ASSOC, V276, P1818, DOI 10.1001/jama.276.22.1818; CABANES PA, 1992, LANCET, V339, P1245, DOI 10.1016/0140-6736(92)91591-U; Cox CE, 1998, ANN SURG, V227, P645, DOI 10.1097/00000658-199805000-00005; GIULIANO AE, 1994, ANN SURG, V220, P391, DOI 10.1097/00000658-199409000-00015; HADDAD FF, 1997, REF GYNECOL OBSTET, V5, P2; MORTON DL, 1992, ARCH SURG-CHICAGO, V127, P392; O'Hea BJ, 1998, J AM COLL SURGEONS, V186, P423, DOI 10.1016/S1072-7515(98)00060-X; Rodier JF, 1997, ONCOL REP, V4, P281; ROSEN PP, 1983, ANN SURG, V197, P276, DOI 10.1097/00000658-198303000-00006; Roumen RMH, 1997, EUR J SURG ONCOL, V23, P495, DOI 10.1016/S0748-7983(97)92885-7; VERONESI U, 1990, EUR J SURG ONCOL, V16, P127; Veronesi U, 1997, LANCET, V349, P1864, DOI 10.1016/S0140-6736(97)01004-0	13	14	14	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	AUG 8	1998	352	9126					421	422		10.1016/S0140-6736(05)79184-4	http://dx.doi.org/10.1016/S0140-6736(05)79184-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	108EA	9708748				2022-12-28	WOS:000075252000007
J	Weissman, NJ; Tighe, JF; Gottdiener, JS; Gwynne, JT				Weissman, NJ; Tighe, JF; Gottdiener, JS; Gwynne, JT		Sustained Release Dexfenfluramine Study Grp	An assessment of heart-valve abnormalities in obese patients taking dexfenfluramine, sustained-release dexfenfluramine, or placebo	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MITRAL REGURGITATION; DOPPLER; PREVALENCE	Background. The appetite-suppressant drug fenfluramine, usually given in combination with phentermine, has been reported to be associated with cardiac valvular regurgitation. Concern has been raised that the d-enantiomer of fenfluramine, dexfenfluramine, may also cause this problem. We were able to study the question by modifying an ongoing trial comparing sustained-release dexfenfluramine with regular dexfenfluramine and placebo. Methods We modified our randomized, double-blind, placebo-controlled study of dexfenfluramine to include echocardiographic examinations of 1072 overweight patients within a median of one month after the discontinuation of treatment. The patients (approximately 80 percent of whom were women) had been randomly assigned to receive dexfenfluramine (366 patients), investigational sustained-release dexfenfluramine (352 patients), or placebo (354 patients). The average duration of treatment was 71 to 72 days in each of the three groups. Echocardiograms were assessed in a blinded fashion. Results. When all degrees of valvular regurgitation were considered and when the two dexfenfluramine groups were combined, there was a higher prevalence of any degree of aortic regurgitation (17.0 percent vs. 11.8 percent, P = 0.03) and any degree of mitral regurgitation (61.4 percent vs. 54.4 percent, P = 0.01) in the active-treatment groups than in the placebo group. These differences were primarily due to a higher prevalence of physiologic, trace, or mild regurgitation. Analyses that used the criteria of the Food and Drug Administration for aortic regurgitation of mild or greater severity and mitral regurgitation of moderate or greater severity found no significant difference among the groups (P = 0.14 to 0.75). These analyses showed that aortic regurgitation of mild or greater severity occurred in 5.0 percent of the patients in the dexfenfluramine group, 5.8 percent of those in the sustained-release dexfenfluramine group, The pa 5.4 percent of those in the two active-treatment groups combined, and 3.6 percent of those in the placebo group. Mitral regurgitation of moderate or greater severity occurred in 1.7, 1.8, 1.8, and 1.2 percent, respectively. Aortic regurgitation of mild or greater severity, mitral regurgitation of moderate or greater severity, or both occurred in 6.5 percent, 7.3 percent, 6.9 percent, and 4.5 percent, respectively. Conclusions. We found a small increase in the prevalence of aortic and mitral regurgitation in patients treated with dexfenfluramine, and the degree of regurgitation was in most cases classified as physiologic, trace, or mild. However, the duration of therapy was short, and whether therapy of longer duration would yield the same or different results is not known. (N Engl J Med 1998;339:725-32.) (C) 1998, Massachusetts Medical Society.	Georgetown Univ, Med Ctr, Div Cardiol, Washington, DC 20007 USA; Georgetown Univ, Med Ctr, Cardiovasc Inst, Washington, DC 20007 USA; Wyeth Ayerst Res, Dept Clin Res, Philadelphia, PA USA	Georgetown University; Georgetown University; Pfizer	Weissman, NJ (corresponding author), Georgetown Univ, Med Ctr, Div Cardiol, 3800 Reservoir Rd NW, Washington, DC 20007 USA.							Cannistra LB, 1997, NEW ENGL J MED, V337, P636, DOI 10.1056/NEJM199708283370912; Centers for Disease Control (CDC), 1997, MMWR-MORBID MORTAL W, V46, P1061; CHOONG CY, 1989, AM HEART J, V117, P636, DOI 10.1016/0002-8703(89)90739-4; Connolly HM, 1997, NEW ENGL J MED, V337, P581, DOI 10.1056/NEJM199708283370901; Davis R, 1996, DRUGS, V52, P696, DOI 10.2165/00003495-199652050-00007; HELMCKE F, 1987, CIRCULATION, V75, P175, DOI 10.1161/01.CIR.75.1.175; JOBIC Y, 1993, BRIT HEART J, V69, P109; KISSEBAH AH, 1989, MED CLIN N AM, V73, P111, DOI 10.1016/S0025-7125(16)30695-2; Klein A L, 1990, J Am Soc Echocardiogr, V3, P54; Kurz X, 1997, NEW ENGL J MED, V337, P1772; PERRY GJ, 1987, J AM COLL CARDIOL, V9, P952, DOI 10.1016/S0735-1097(87)80254-1; RANGANATHAN N, 1970, CIRCULATION, V41, P459, DOI 10.1161/01.CIR.41.3.459; Rasmussen S, 1997, NEW ENGL J MED, V337, P1773; REID CL, 1994, CIRCULATION, V90, P282; SINGH JP, 1997, CIRCULATION S1, V96, P541; Stevens J, 1998, NEW ENGL J MED, V338, P1, DOI 10.1056/NEJM199801013380101; WEINTRAUB M, 1992, CLIN PHARMACOL THER, V51, P619, DOI 10.1038/clpt.1992.74; Wong J, 1998, CLEV CLIN J MED, V65, P35, DOI 10.3949/ccjm.65.1.35; YOCK PG, 1984, CIRCULATION, V70, P657, DOI 10.1161/01.CIR.70.4.657	19	179	183	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 10	1998	339	11					725	732		10.1056/NEJM199809103391103	http://dx.doi.org/10.1056/NEJM199809103391103			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	116RF	9731088				2022-12-28	WOS:000075737800003
J	Cooper, RA; Henderson, T; Dietrich, CL				Cooper, RA; Henderson, T; Dietrich, CL			Roles of nonphysician clinicians as autonomous providers of patient care	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PHYSICIAN WORKFORCE; EDUCATION; MEDICINE; REFORM	Studies were undertaken to assess the practice prerogatives of nonphysician clinicians (NPCs) in 10 disciplines that, collectively, are the major nonphysician contributors to the delivery of medical and surgical services. These disciplines include nurse practitioners, physician assistants, nurse-midwives, chiropractors, acupuncturists, naturopaths, optometrists, podiatrists, nurse anesthetists, and clinical nurse specialists. Marked differences were found in the practice prerogatives that states granted NPCs in the various disciplines. For most disciplines, the magnitude of their prerogatives correlated with the numbers of NPCs practicing in each state. At their maximal levels, state practice prerogatives authorized a high degree of autonomy and a broad range of authority to provide discrete levels of uncomplicated primary and specialty care. The recent growth in these prerogatives is fostering new opportunities for NPCs; however, it also is creating a pluralism that has the potential to further fragment the US health care system. It is time for regulatory integration and professional collaboration so that a health care workforce that includes a diversity of disciplines can be assured of providing a coherent set of patient care services in the future.	Med Coll Wisconsin, Hlth Policy Inst, Milwaukee, WI 53226 USA; Natl Conf State Legislatures, Washington, DC USA	Medical College of Wisconsin	Cooper, RA (corresponding author), Med Coll Wisconsin, Hlth Policy Inst, 8701 Watertown Plank Rd, Milwaukee, WI 53226 USA.							AIKEN LH, 1994, INQUIRY-J HEALTH CAR, V31, P318; *ALL STAT LIC DIV, 1997, STAT NAT LIC SUMM; *AM AC PHYS ASS, 1997, INF UPD PROJ NUMB PH; *AM AC PHYS ASS, 1997, STAT LAWS PHYS ASS; *AM AC PHYS ASS, 1997, 3 PART REIMB PHYS AS; *AM AC PHYS ASS, 1996, PHYS ASS STAT CRED; *AM ASS NURS AN, 1996, SCOP STAND NURS AN P; *AM CHIR ASS, 1994, CHIR STAT ART; *AM COLL NURS MIDW, 1995, NURS MIDW TOD HDB ST; *AM COLLNURS MIDW, 1997, 3 PART REIMB CERT NU; *AM OPT ASS, 1997, LIC REQ OPT; *AM OPT ASS, 1997, STAT STAT BOARD RUL; *AM OPT ASS, 1997, PHARM AG NAM TYP STA; *AM POD MED ASS, 1997, LIC REQ QUAL; *AM POD MED ASS, 1997, INS REL REIMB NOND P; *AM POD MED ASS, 1997, SCOP PRACT PROV; BERLIN LE, 1997, ENROLLMENT GRADUATIO; Bullock M L, 1997, J Altern Complement Med, V3, P31, DOI 10.1089/acm.1997.3.31; COHEN JJ, 1994, JAMA-J AM MED ASSOC, V272, P712, DOI 10.1001/jama.272.9.712; COOPER RA, 1994, JAMA-J AM MED ASSOC, V272, P680, DOI 10.1001/jama.272.9.680; Cooper RA, 1996, HEALTH AFFAIR, V15, P226, DOI 10.1377/hlthaff.15.3.226; COOPER RA, 1995, JAMA-J AM MED ASSOC, V274, P1534, DOI 10.1001/jama.274.19.1534; Cooper RA, 1998, JAMA-J AM MED ASSOC, V280, P788, DOI 10.1001/jama.280.9.788; *COUNC GRAD MED ED, 1994, REC IMPR ACC HLTH CA; *COUNC STAT GOV, 1994, BOOK STAT 1994 1995, V30; DIAL TH, 1995, HLTH AFF MILLWOOD, V14, P169; Ellis GL, 1997, AM J EMERG MED, V15, P229, DOI 10.1016/S0735-6757(97)90002-4; ERGIL KV, 1997, NIH CONS DEV C AC BE, P31; *FED CHIR LIC BOAR, 1994, OFF DIR CHIR LIC PRA; FINOCCHIO LJ, 1995, HLTH CARE WORKFORCE; Flexner A., 1910, FLEXNER REPORT; Frampton J, 1994, HMO Pract, V8, P165; HENDERSON T, 1995, SCOPE PRACTICE REIMB; HENDERSON T, 1994, REMOVING PRACTICE BA; *HLTH POL TRACK SE, NAT C STAT LEG ISS B; HOOKER RS, 1997, J AM ACAD PHYS ASSIS, V10, P81; JONES PE, 1994, JAMA-J AM MED ASSOC, V271, P1266, DOI 10.1001/jama.271.16.1266; *LIB C, STAT LOC GOV LIB C I; LOMAS J, 1985, CAN J PUBLIC HEALTH, V76, P119; *MED GROUP MAN ASS, 1996, COST SURV 199L REP B; MITCHELL B, 1997, ACUPUNCUTRE ORIENTAL; MITCHELL B, 1993, STATE ACUPUNCTURE LA; MITCHELL B, 1998, ACUPUNCTURE ORIENTAL; MOSES E, 1997, REGISTERED NURSE POP; MUNDINGER MO, 1994, NEW ENGL J MED, V330, P211, DOI 10.1056/NEJM199401203300314; *NIH, 1997, CONS DEV C STAT AC; OSTERWEIS M, 1996, US HLTH WORKFORCE PO; OSTERWEIS M, 1993, ROLES PHYSICIAN ASSI; Pearson L J, 1997, Nurse Pract, V22, P18; *PHYS PAYM REV COM, 1994, ANN REP C 1994, P205; SAFRIET BJ, 1994, INQUIRY-J HEALTH CAR, V31, P310; SAGE WM, 1997, REGULATION HEALTHCAR, P71; SEKSCESKI ES, 1994, NEW ENGL J MED, V1, P1266; SHARP N, 1997, NURSE PRACT, V22, P105; SIMON A, 1996, 12 ASS PHYS ASS PROG; SMITHPETERS L, 1994, DIRECTORY PROFESSION; WOZNIAK GD, 1995, SOCIOECONOMIC CHARAC, P15	57	121	121	2	11	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 2	1998	280	9					795	802		10.1001/jama.280.9.795	http://dx.doi.org/10.1001/jama.280.9.795			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	114LA	9729991				2022-12-28	WOS:000075609900008
J	Simini, B				Simini, B			Unexpected endotracheal extubations	LANCET			English	Editorial Material									Osped Lucca, Dept Anaesthesia, I-55100 Lucca, Italy		Simini, B (corresponding author), Osped Lucca, Dept Anaesthesia, I-55100 Lucca, Italy.							Boulain T, 1998, AM J RESP CRIT CARE, V157, P1131, DOI 10.1164/ajrccm.157.4.9702083; Brandt CJ, 1997, LANCET, V349, P253, DOI 10.1016/S0140-6736(05)64863-5; ESTEBAN A, 1995, NEW ENGL J MED, V332, P345, DOI 10.1056/NEJM199502093320601	3	3	3	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	AUG 29	1998	352	9129					671	672		10.1016/S0140-6736(05)60817-3	http://dx.doi.org/10.1016/S0140-6736(05)60817-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	116MT	9728979				2022-12-28	WOS:000075729700007
J	Grimes, DA				Grimes, DA			The continuing need for late abortions	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							UNITED-STATES; PREGNANCY; TERMINATION; TRIMESTER; MORTALITY; WOMEN		San Francisco Gen Hosp, Dept Obstet Gynecol & Reprod Sci, San Francisco, CA 94110 USA	San Francisco General Hospital Medical Center	Grimes, DA (corresponding author), San Francisco Gen Hosp, Dept Obstet Gynecol & Reprod Sci, Ward 6D14, San Francisco, CA 94110 USA.							BOWERS CH, 1989, J REPROD MED, V34, P880; BURR WA, 1980, JAMA-J AM MED ASSOC, V244, P44; CAMPBELL AV, 1985, ABORTION MED PROGR S, P228; CARVEL J, 1987, LANCET, V2, P978; CATES W, 1982, JAMA-J AM MED ASSOC, V248, P559, DOI 10.1001/jama.248.5.559; CHERVENAK FA, 1984, NEW ENGL J MED, V310, P501, DOI 10.1056/NEJM198402233100806; COOK RJ, 1985, ABORTION MED PROGR S, P211; DAGG PKB, 1991, AM J PSYCHIAT, V148, P578; Farmakides G, 1988, J Perinatol, V8, P101; Gleicher N, 1979, Obstet Gynecol Surv, V34, P721, DOI 10.1097/00006254-197910000-00001; GUILBERT E, 1994, CAN J PUBLIC HEALTH, V85, P402; HENSHAW SK, 1995, FAM PLANN PERSPECT, V27, P54, DOI 10.2307/2135905; HEWITT J, 1988, LANCET, V1, P186; Holmes MM, 1996, AM J OBSTET GYNECOL, V175, P320, DOI 10.1016/S0002-9378(96)70141-2; JACOT FRM, 1993, AM J OBSTET GYNECOL, V168, P633, DOI 10.1016/0002-9378(93)90509-H; JONES DG, 1989, J MED ETHICS, V15, P173, DOI 10.1136/jme.15.4.173; Koonin Lisa M., 1996, Morbidity and Mortality Weekly Report, V45, P1; KRAUSS T, 1994, GEBURTSH FRAUENHEILK, V54, P623, DOI 10.1055/s-2007-1022353; LAWSON HW, 1994, AM J OBSTET GYNECOL, V171, P1365, DOI 10.1016/0002-9378(94)90162-7; MACKLIN R, 1995, MODERN METHODS INDUC, P170; MCCULLOUGH LB, 1994, ETHICS OBSTET GYNECO, P166; RICH F, 1997, NY TIMES        0309, P15; ROSENFIELD A, 1994, NEW ENGL J MED, V331, P324, DOI 10.1056/NEJM199408043310511; SPITZ AM, 1983, AM J PUBLIC HEALTH, V73, P594, DOI 10.2105/AJPH.73.5.594; TIMOTHY J, 1986, BRIT J OBSTET GYNAEC, V93, P343	26	22	22	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 26	1998	280	8					747	750		10.1001/jama.280.8.747	http://dx.doi.org/10.1001/jama.280.8.747			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	111PM	9728652				2022-12-28	WOS:000075446900042
J	Jones, EM; MacGowan, AP				Jones, EM; MacGowan, AP			Back to basics in management of Clostridium difficile infections	LANCET			English	Editorial Material							DIARRHEA		Southmead Gen Hosp, Dept Med Microbiol, Bristol BS10 5NB, Avon, England	Southmead Hospital	MacGowan, AP (corresponding author), Southmead Gen Hosp, Dept Med Microbiol, Bristol BS10 5NB, Avon, England.		MacGowan, Alasdair/AAM-1582-2020	MacGowan, Alasdair/0000-0002-6720-5268				CARTMILL TDI, 1994, J HOSP INFECT, V27, P1, DOI 10.1016/0195-6701(94)90063-9; Climo MW, 1998, ANN INTERN MED, V128, P989, DOI 10.7326/0003-4819-128-12_Part_1-199806150-00005; *DEP HLTH PUBL HLT, 1994, PREV MAN CLOSTR DIFF; IMPALLOMENI M, 1995, BRIT MED J, V311, P1345, DOI 10.1136/bmj.311.7016.1345; Jones EM, 1997, LANCET, V349, P1176, DOI 10.1016/S0140-6736(05)63056-5; McNulty C, 1997, J ANTIMICROB CHEMOTH, V40, P707, DOI 10.1093/jac/40.5.707; Wilcox MH, 1998, J HOSP INFECT, V38, P93, DOI 10.1016/S0195-6701(98)90062-7; Wilcox MH, 1996, J HOSP INFECT, V34, P23, DOI 10.1016/S0195-6701(96)90122-X	8	11	11	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	AUG 15	1998	352	9127					505	506		10.1016/S0140-6736(05)79246-1	http://dx.doi.org/10.1016/S0140-6736(05)79246-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	111KC	9716052				2022-12-28	WOS:000075435300006
J	Pusztal, L; Hortobagyi, GN				Pusztal, L; Hortobagyi, GN			Discouraging news for high-dose chemotherapy in high-risk breast cancer	LANCET			English	Editorial Material									Univ Texas, Md Anderson Canc Ctr, Dept Breast Med Oncol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Hortobagyi, GN (corresponding author), Univ Texas, Md Anderson Canc Ctr, Dept Breast Med Oncol, Houston, TX 77030 USA.							BEHRENS BC, 1987, CANCER RES, V47, P414; Clarke M, 1998, LANCET, V351, P1451; Gradishar WJ, 1996, ANN INTERN MED, V125, P599, DOI 10.7326/0003-4819-125-7-199610010-00010; HORTOBAGYI G, 1998, P ASCO, V17; PETERS WP, 1995, P ASCO, V14; Pusztai L, 1998, DRUG RESIST UPDATE, V1, P62, DOI 10.1016/S1368-7646(98)80216-1; SCHABEL FM, 1984, CANCER, V54, P1160, DOI 10.1002/1097-0142(19840915)54:1+<1160::AID-CNCR2820541312>3.0.CO;2-P	7	7	7	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 15	1998	352	9127					501	502		10.1016/S0140-6736(05)79310-7	http://dx.doi.org/10.1016/S0140-6736(05)79310-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	111KC	9716049				2022-12-28	WOS:000075435300003
J	Harvey, RP				Harvey, RP			Links in the left/right axial pathway	CELL			English	Review							LEFT-RIGHT ASYMMETRY		Victor Chang Cardiac Res Inst, Dev Biol Unit, Darlinghurst, NSW 2010, Australia; Univ New S Wales, Kensington, NSW 2033, Australia	Victor Chang Cardiac Research Institute; University of New South Wales Sydney	Harvey, RP (corresponding author), Victor Chang Cardiac Res Inst, Dev Biol Unit, Darlinghurst, NSW 2010, Australia.			Harvey, Richard/0000-0002-9950-9792				BROWN NA, 1990, DEVELOPMENT, V109, P1; Gebbia M, 1997, NAT GENET, V17, P305, DOI 10.1038/ng1197-305; Hyatt BA, 1998, CELL, V93, P37, DOI 10.1016/S0092-8674(00)81144-7; Isaac A, 1997, SCIENCE, V275, P1301, DOI 10.1126/science.275.5304.1301; Jefferies RPS, 1996, ACTA ZOOL-STOCKHOLM, V77, P101, DOI 10.1111/j.1463-6395.1996.tb01256.x; Levin M, 1997, BIOESSAYS, V19, P287, DOI 10.1002/bies.950190406; Levin M, 1997, DEV BIOL, V189, P57, DOI 10.1006/dbio.1997.8662; LEVIN M, 1995, CELL, V82, P803, DOI 10.1016/0092-8674(95)90477-8; Logan M, 1998, CELL, V94, P307, DOI 10.1016/S0092-8674(00)81474-9; Meno C, 1998, CELL, V94, P287, DOI 10.1016/S0092-8674(00)81472-5; Nascone N, 1997, DEV BIOL, V189, P68, DOI 10.1006/dbio.1997.8635; Pagan-Westphal SM, 1998, CELL, V93, P25, DOI 10.1016/S0092-8674(00)81143-5; Piedra ME, 1998, CELL, V94, P319, DOI 10.1016/S0092-8674(00)81475-0; Psychoyos D, 1996, DEVELOPMENT, V122, P3263; Wood WB, 1998, SEMIN CELL DEV BIOL, V9, P53, DOI 10.1006/scdb.1997.0189; Yoshioka H, 1998, CELL, V94, P299, DOI 10.1016/S0092-8674(00)81473-7; Yost HJ, 1998, SEMIN CELL DEV BIOL, V9, P61, DOI 10.1006/scdb.1997.0191	17	116	117	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	AUG 7	1998	94	3					273	276		10.1016/S0092-8674(00)81468-3	http://dx.doi.org/10.1016/S0092-8674(00)81468-3			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	109EN	9708727	Bronze			2022-12-28	WOS:000075308400001
J	Schimmel, P; Alexander, R				Schimmel, P; Alexander, R			Protein synthesis - All you need is RNA	SCIENCE			English	Editorial Material							LARGE RIBOSOMAL-SUBUNIT; ESCHERICHIA-COLI; PEPTIDYL TRANSFERASE; TERTIARY STRUCTURE; CROSS-LINKS; SECONDARY; MODEL		Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA	Scripps Research Institute	Schimmel, P (corresponding author), Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA.							FRANCESCHI FJ, 1990, J BIOL CHEM, V265, P16676; FRANCKLYN C, 1992, SCIENCE, V255, P1121, DOI 10.1126/science.1546312; FRUGIER M, 1994, EMBO J, V13, P2219; GRIFFITH L, UNPUB; MAIZELS N, 1994, P NATL ACAD SCI USA, V91, P6729, DOI 10.1073/pnas.91.15.6729; MITCHELL P, 1990, NUCLEIC ACIDS RES, V18, P4325, DOI 10.1093/nar/18.15.4325; Nierhaus K., 1990, RIBOSOMES PROTEIN SY, P161; Nitta I, 1998, RNA, V4, P257; Nitta I, 1998, SCIENCE, V281, P666, DOI 10.1126/science.281.5377.666; Noller H.F., 1993, RNA WORLD, P137; NOLLER HF, 1981, NUCLEIC ACIDS RES, V9, P6167, DOI 10.1093/nar/9.22.6167; NOLLER HF, 1992, SCIENCE, V256, P1416, DOI 10.1126/science.1604315; Rich A., 1962, HORIZONS BIOCH, P103; SAMAHA RR, 1995, NATURE, V377, P309, DOI 10.1038/377309a0; SCHIMMEL P, 1993, P NATL ACAD SCI USA, V90, P8763, DOI 10.1073/pnas.90.19.8763; STIEGE W, 1983, NUCLEIC ACIDS RES, V11, P1687, DOI 10.1093/nar/11.6.1687; Zhang BL, 1997, NATURE, V390, P96, DOI 10.1038/36375	17	9	9	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 31	1998	281	5377					658	659		10.1126/science.281.5377.658	http://dx.doi.org/10.1126/science.281.5377.658			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	106AQ	9714675				2022-12-28	WOS:000075107900029
J	Chawla, S; Hardingham, GE; Quinn, DR; Bading, H				Chawla, S; Hardingham, GE; Quinn, DR; Bading, H			CBP: A signal-regulated transcriptional coactivator controlled by nuclear calcium and CaM kinase IV	SCIENCE			English	Article							DEPENDENT PROTEIN-KINASE; C-FOS PROMOTER; GENE-EXPRESSION; CYTOPLASMIC CALCIUM; COMPLEX-FORMATION; MAP KINASE; ACTIVATION; CREB; PHOSPHORYLATION; GROWTH	Recruitment of the coactivator, CREB binding protein (CBP), by signal-regulated transcription factors, such as CREB [adenosine 3',5'-monophosphate (cAMP) response element binding protein]. is critical for stimulation of gene expression. The mouse pituitary cell line AtT20 was used to show that the CBP recruitment step (CREB phosphorylation on serine-133) can be uncoupled from CREB/CBP-activated transcription. CBP was found to contain a signal-regulated transcriptional activation domain that is controlled by nuclear calcium and calcium/calmodulin-dependent (CaM) protein kinase IV and by cAMP, Cytoplasmic calcium signals that stimulate the Ras mitogen-activated protein kinase signaling cascade or expression of the activated form of Ras provided the CBP recruitment signal but did not increase CBP activity and failed to activate CREB- and CBP-mediated transcription. These results identify CBP as a signal-regulated transcriptional coactivator and define a regulatory role for nuclear calcium and cAMP in CBP-dependent gene expression.	MRC, Mol Biol Lab, Cambridge CB2 2QH, England	MRC Laboratory Molecular Biology	Bading, H (corresponding author), MRC, Mol Biol Lab, Hills Rd, Cambridge CB2 2QH, England.			Hardingham, Giles/0000-0002-7629-5314				Anderson KA, 1997, MOL ENDOCRINOL, V11, P725, DOI 10.1210/me.11.6.725; ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; Bading H, 1997, BIOCHEM BIOPH RES CO, V236, P541, DOI 10.1006/bbrc.1997.7037; BADING H, 1993, SCIENCE, V260, P181, DOI 10.1126/science.8097060; BADING H, 1991, SCIENCE, V253, P912, DOI 10.1126/science.1715095; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; BANNISTER AJ, 1995, EMBO J, V14, P4758, DOI 10.1002/j.1460-2075.1995.tb00157.x; Bhattacharya S, 1996, NATURE, V383, P344, DOI 10.1038/383344a0; Bito H, 1997, CURR OPIN NEUROBIOL, V7, P419, DOI 10.1016/S0959-4388(97)80072-4; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; CHAWLA SK, UNPUB; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; GHOSH A, 1995, SCIENCE, V268, P239, DOI 10.1126/science.7716515; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GINTY DD, 1993, SCIENCE, V260, P238, DOI 10.1126/science.8097062; GINTY DD, 1994, CELL, V77, P713, DOI 10.1016/0092-8674(94)90055-8; Goldman PS, 1997, RECENT PROG HORM RES, V52, P103; Hardingham GE, 1997, NATURE, V385, P260, DOI 10.1038/385260a0; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Janknecht R, 1996, ONCOGENE, V12, P1961; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; Janknecht R, 1996, CURR BIOL, V6, P951, DOI 10.1016/S0960-9822(02)00636-X; JENSEN KF, 1991, P NATL ACAD SCI USA, V88, P2850, DOI 10.1073/pnas.88.7.2850; Johnson CM, 1997, J NEUROSCI, V17, P6189; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kee BL, 1996, J BIOL CHEM, V271, P2373, DOI 10.1074/jbc.271.5.2373; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MORGAN JI, 1991, ANNU REV NEUROSCI, V14, P421, DOI 10.1146/annurev.ne.14.030191.002225; Nakajima T, 1997, GENE DEV, V11, P738, DOI 10.1101/gad.11.6.738; Nakajima T, 1996, CELL, V86, P465, DOI 10.1016/S0092-8674(00)80119-1; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Parker D, 1996, MOL CELL BIOL, V16, P694; ROSEN LB, 1994, NEURON, V12, P1207, DOI 10.1016/0896-6273(94)90438-3; Rusanescu G, 1995, NEURON, V15, P1415, DOI 10.1016/0896-6273(95)90019-5; SHENG M, 1988, MOL CELL BIOL, V8, P2787, DOI 10.1128/MCB.8.7.2787; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; SUN PQ, 1994, GENE DEV, V8, P2527, DOI 10.1101/gad.8.21.2527; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Yuan WC, 1996, J BIOL CHEM, V271, P9009, DOI 10.1074/jbc.271.15.9009	43	372	375	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 4	1998	281	5382					1505	1509		10.1126/science.281.5382.1505	http://dx.doi.org/10.1126/science.281.5382.1505			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	116RJ	9727976				2022-12-28	WOS:000075738100040
J	Ashkenazi, A; Dixit, VM				Ashkenazi, A; Dixit, VM			Death receptors: Signaling and modulation	SCIENCE			English	Review							NF-KAPPA-B; INDUCED CELL-DEATH; DOMAIN-CONTAINING RECEPTOR; TRAIL-INDUCED APOPTOSIS; TNF RECEPTOR; ADAPTER MOLECULE; ELEGANS CED-4; NMR STRUCTURE; ACTIVATION; PROTEIN	Apoptosis is a cell suicide mechanism that enables metazoans to control cell number in tissues and to eliminate individual cells that threaten the animal's survival. Certain cells have unique sensors, termed death receptors, on their surface. Death receptors detect the presence of extracellular death signals and, in response, they rapidly ignite the cell's intrinsic apoptosis machinery.	Genentech Inc, Dept Mol Oncol, S San Francisco, CA 94080 USA	Roche Holding; Genentech	Ashkenazi, A (corresponding author), Genentech Inc, Dept Mol Oncol, 1 DNA Way, S San Francisco, CA 94080 USA.	aa@gene.com; dixit@gene.com	dixit, vishva m/A-4496-2012; Ashkenazi, Avi/ABG-2712-2020	dixit, vishva m/0000-0001-6983-0326; Ashkenazi, Avi/0000-0002-6890-4589				Ahmad M, 1997, CANCER RES, V57, P615; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Boise LH, 1996, SCIENCE, V274, P67, DOI 10.1126/science.274.5284.67; BOLDIN MP, 1995, J BIOL CHEM, V270, P387, DOI 10.1074/jbc.270.1.387; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Brojatsch J, 1996, CELL, V87, P845, DOI 10.1016/S0092-8674(00)81992-3; Chaudhary PM, 1997, IMMUNITY, V7, P821, DOI 10.1016/S1074-7613(00)80400-8; Chicheportiche Y, 1997, J BIOL CHEM, V272, P32401, DOI 10.1074/jbc.272.51.32401; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chinnaiyan AM, 1996, SCIENCE, V274, P990, DOI 10.1126/science.274.5289.990; Chinnaiyan AM, 1997, SCIENCE, V275, P1122, DOI 10.1126/science.275.5303.1122; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; CHINNAIYANA M, 1997, NATURE, V388, P728; Degli-Esposti MA, 1997, IMMUNITY, V7, P813, DOI 10.1016/S1074-7613(00)80399-4; DegliEsposti MA, 1997, J EXP MED, V186, P1165, DOI 10.1084/jem.186.7.1165; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Duan H, 1997, NATURE, V385, P86, DOI 10.1038/385086a0; Emery JG, 1998, J BIOL CHEM, V273, P14363, DOI 10.1074/jbc.273.23.14363; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; GOLSTEIN P, 1997, CURR BIOL, V7, P750; Goltsev YV, 1997, J BIOL CHEM, V272, P19641, DOI 10.1074/jbc.272.32.19641; Hahne M, 1996, SCIENCE, V274, P1363, DOI 10.1126/science.274.5291.1363; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; Hofmann K, 1997, TRENDS BIOCHEM SCI, V22, P155, DOI 10.1016/S0968-0004(97)01043-8; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Hu SM, 1997, J BIOL CHEM, V272, P17255, DOI 10.1074/jbc.272.28.17255; Huang BH, 1996, NATURE, V384, P638, DOI 10.1038/384638a0; JERAMIAS I, 1998, IN PRESS EUR J IMMUN, V28, P143; Kelliher MA, 1998, IMMUNITY, V8, P297, DOI 10.1016/S1074-7613(00)80535-X; Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092-8674(00)81569-X; Lee SY, 1997, IMMUNITY, V7, P703, DOI 10.1016/S1074-7613(00)80390-8; Liepinsh E, 1997, EMBO J, V16, P4999, DOI 10.1093/emboj/16.16.4999; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Mariani SM, 1998, EUR J IMMUNOL, V28, P973, DOI 10.1002/(SICI)1521-4141(199803)28:03<973::AID-IMMU973>3.0.CO;2-T; Mariani SM, 1997, J CELL BIOL, V137, P221, DOI 10.1083/jcb.137.1.221; Marsters SA, 1996, CURR BIOL, V6, P750, DOI 10.1016/S0960-9822(09)00456-4; Marsters SA, 1997, CURR BIOL, V7, P1003, DOI 10.1016/S0960-9822(06)00422-2; Marsters SA, 1998, CURR BIOL, V8, P525, DOI 10.1016/S0960-9822(98)70204-0; MARTINEZLORENZO MJ, IN PRESS EUR J IMMUN; MCFARLANE M, 1997, J BIOL CHEM, V272, P25417; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Mongkolsapaya J, 1998, J IMMUNOL, V160, P3; Muzio M, 1998, J BIOL CHEM, V273, P2926, DOI 10.1074/jbc.273.5.2926; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Newton K, 1998, EMBO J, V17, P706, DOI 10.1093/emboj/17.3.706; Pan GH, 1997, SCIENCE, V277, P815, DOI 10.1126/science.277.5327.815; Pan GH, 1998, FEBS LETT, V424, P41, DOI 10.1016/S0014-5793(98)00135-5; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Rothe M, 1995, CELL, V83, P1243, DOI 10.1016/0092-8674(95)90149-3; Roulston A, 1998, J BIOL CHEM, V273, P10232, DOI 10.1074/jbc.273.17.10232; SALVESEN GS, 1997, CELL, V76, P665; Schneider P, 1997, FEBS LETT, V416, P329, DOI 10.1016/S0014-5793(97)01231-3; Screaton GR, 1997, CURR BIOL, V7, P693, DOI 10.1016/S0960-9822(06)00297-1; Seshagiri S, 1997, CURR BIOL, V7, P455, DOI 10.1016/S0960-9822(06)00216-8; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; Shu HB, 1997, IMMUNITY, V6, P751, DOI 10.1016/S1074-7613(00)80450-1; Shu HB, 1996, P NATL ACAD SCI USA, V93, P13973, DOI 10.1073/pnas.93.24.13973; Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092-8674(00)80209-3; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; Song HY, 1997, P NATL ACAD SCI USA, V94, P9792, DOI 10.1073/pnas.94.18.9792; Spector MS, 1997, NATURE, V385, P653, DOI 10.1038/385653a0; Srinivasula SM, 1997, J BIOL CHEM, V272, P18542, DOI 10.1074/jbc.272.30.18542; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; TARTAGLIA LA, 1992, IMMUNOL TODAY, V13, P151, DOI 10.1016/0167-5699(92)90116-O; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; THORNE M, 1997, NATURE, V386, P517; Ting AT, 1996, EMBO J, V15, P6189, DOI 10.1002/j.1460-2075.1996.tb01007.x; VANANTWERP DJ, 1996, SCIENCE, V274, P784; Walczak H, 1997, EMBO J, V16, P5386, DOI 10.1093/emboj/16.17.5386; Wallach D, 1997, NATURE, V388, P123, DOI 10.1038/40516; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Wu DY, 1997, SCIENCE, V275, P1126, DOI 10.1126/science.275.5303.1126; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141; Yang E, 1996, BLOOD, V88, P386, DOI 10.1182/blood.V88.2.386.bloodjournal882386; Yang XL, 1997, CELL, V89, P1067, DOI 10.1016/S0092-8674(00)80294-9; Yeh WC, 1998, SCIENCE, V279, P1954, DOI 10.1126/science.279.5358.1954; Yeh WC, 1997, IMMUNITY, V7, P715, DOI 10.1016/S1074-7613(00)80391-X; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; Zhang JK, 1998, NATURE, V392, P296, DOI 10.1038/32681; Zornig M, 1998, CURR BIOL, V8, P467, DOI 10.1016/S0960-9822(98)70182-4; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	89	4869	5174	6	390	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 28	1998	281	5381					1305	1308		10.1126/science.281.5381.1305	http://dx.doi.org/10.1126/science.281.5381.1305			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	115LQ	9721089				2022-12-28	WOS:000075666800038
J	Green, DR; Reed, JC				Green, DR; Reed, JC			Mitochondria and apoptosis	SCIENCE			English	Review							PROGRAMMED CELL-DEATH; PERMEABILITY TRANSITION; CYTOCHROME-C; BCL-2 ONCOPROTEIN; ION-CHANNEL; INHIBITION; MEMBRANE; BCL-X(L); PROTEASES; NECROSIS	A variety of key events in apoptosis focus on mitochondria, including the release of caspase activators (such as cytochrome c), changes in electron transport, loss of mitochondrial transmembrane potential, altered cellular oxidation-reduction, and participation of pro- and antiapoptotic Bcl-2 family proteins. The different signals that converge on mitochondria to trigger or inhibit these events and their downstream effects delineate several major pathways in physiological cell death.	La Jolla Inst Allergy & Immunol, San Diego, CA 92121 USA; Burnham Inst, La Jolla, CA 92037 USA	La Jolla Institute for Immunology; Sanford Burnham Prebys Medical Discovery Institute	Green, DR (corresponding author), La Jolla Inst Allergy & Immunol, 10355 Sci Ctr Dr, San Diego, CA 92121 USA.		Green, Douglas R/N-8083-2018	Green, Douglas R/0000-0002-7332-1417				Adachi S, 1997, J BIOL CHEM, V272, P21878, DOI 10.1074/jbc.272.35.21878; Amarante-Mendes GP, 1998, CELL DEATH DIFFER, V5, P298, DOI 10.1038/sj.cdd.4400354; Antonsson B, 1997, SCIENCE, V277, P370, DOI 10.1126/science.277.5324.370; BAFFY G, 1993, J BIOL CHEM, V268, P6511; BERNARDI P, 1994, J BIOENERG BIOMEMBR, V26, P509, DOI 10.1007/BF00762735; BLACKSTONE NW, 1995, EVOLUTION, V49, P785, DOI 10.1111/j.1558-5646.1995.tb02315.x; Bossy-Wetzel E, 1998, EMBO J, V17, P37, DOI 10.1093/emboj/17.1.37; Bredesen DE, 1995, ANN NEUROL, V38, P839, DOI 10.1002/ana.410380604; Brunet CL, 1998, CELL DEATH DIFFER, V5, P107, DOI 10.1038/sj.cdd.4400334; Degli Esposti M, 1998, FEBS LETT, V430, P338, DOI 10.1016/S0014-5793(98)00688-7; Eguchi Y, 1997, CANCER RES, V57, P1835; Frade JM, 1997, BIOESSAYS, V19, P827, DOI 10.1002/bies.950190913; GarciaRuiz C, 1997, J BIOL CHEM, V272, P11369; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; Hirsch T, 1997, ONCOGENE, V15, P1573, DOI 10.1038/sj.onc.1201324; HURT KJ, 1995, J NEUROCHEM, V65, P2432; Ichas F, 1997, CELL, V89, P1145, DOI 10.1016/S0092-8674(00)80301-3; JACOBSON MD, 1995, NATURE, V374, P814, DOI 10.1038/374814a0; JACOBSON MD, 1993, NATURE, V361, P365, DOI 10.1038/361365a0; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; KRAJEWSKI S, 1993, CANCER RES, V53, P4701; Kroemer G, 1997, CELL DEATH DIFFER, V4, P443, DOI 10.1038/sj.cdd.4400266; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; Kuwana T, 1998, J BIOL CHEM, V273, P16589, DOI 10.1074/jbc.273.26.16589; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Mancini M, 1998, J CELL BIOL, V140, P1485, DOI 10.1083/jcb.140.6.1485; MANNELLA CA, 1992, J BIOENERG BIOMEMBR, V24, P7, DOI 10.1007/BF00769525; Marchetti P, 1996, J EXP MED, V184, P1155, DOI 10.1084/jem.184.3.1155; Margulis L, 1996, P NATL ACAD SCI USA, V93, P1071, DOI 10.1073/pnas.93.3.1071; Marzo I, 1998, J EXP MED, V187, P1261, DOI 10.1084/jem.187.8.1261; Matsuyama S, 1998, MOL CELL, V1, P327, DOI 10.1016/S1097-2765(00)80033-7; McCarthy NJ, 1997, J CELL BIOL, V136, P215, DOI 10.1083/jcb.136.1.215; Metivier D, 1998, IMMUNOL LETT, V61, P157, DOI 10.1016/S0165-2478(98)00013-3; Minn AJ, 1997, NATURE, V385, P353, DOI 10.1038/385353a0; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; NEWMEYER DD, 1994, CELL, V79, P353, DOI 10.1016/0092-8674(94)90203-8; Petit PX, 1996, FEBS LETT, V396, P7, DOI 10.1016/0014-5793(96)00988-X; Qian T., 1997, CELL VISION, V4, P166; Schendel SL, 1997, P NATL ACAD SCI USA, V94, P5113, DOI 10.1073/pnas.94.10.5113; Schlesinger PH, 1997, P NATL ACAD SCI USA, V94, P11357, DOI 10.1073/pnas.94.21.11357; SCIAFE JF, 1966, CAN J BIOCHEM, V44, P433; Shimizu S, 1996, ONCOGENE, V13, P21; Shimizu S, 1996, CANCER RES, V56, P2161; Shimizu S, 1998, P NATL ACAD SCI USA, V95, P1455, DOI 10.1073/pnas.95.4.1455; SHIMIZU S, 1995, NATURE, V374, P811, DOI 10.1038/374811a0; Susin SA, 1997, J EXP MED, V186, P25, DOI 10.1084/jem.186.1.25; Susin SA, 1996, J EXP MED, V184, P1331, DOI 10.1084/jem.184.4.1331; VanderHeiden MG, 1997, CELL, V91, P627, DOI 10.1016/S0092-8674(00)80450-X; Wyllie A H, 1980, Int Rev Cytol, V68, P251; Xiang JL, 1996, P NATL ACAD SCI USA, V93, P14559, DOI 10.1073/pnas.93.25.14559; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Zamzami N, 1996, J EXP MED, V183, P1533, DOI 10.1084/jem.183.4.1533; Zamzami N, 1996, FEBS LETT, V384, P53, DOI 10.1016/0014-5793(96)00280-3	56	7849	8347	34	1718	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 28	1998	281	5381					1309	1312		10.1126/science.281.5381.1309	http://dx.doi.org/10.1126/science.281.5381.1309			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	115LQ	9721092				2022-12-28	WOS:000075666800039
J	Pui, CH; Evans, WE				Pui, CH; Evans, WE			Acute lymphoblastic leukemia	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							CHILDRENS-CANCER-GROUP; ACUTE LYMPHOCYTIC-LEUKEMIA; BONE-MARROW TRANSPLANTATION; COLONY-STIMULATING FACTOR; PHASE-III TRIAL; PEDIATRIC-ONCOLOGY-GROUP; HIGH-DOSE METHOTREXATE; ACUTE MYELOID-LEUKEMIA; PROGNOSTIC-SIGNIFICANCE; INDUCTION CHEMOTHERAPY		St Jude Childrens Res Hosp, Memphis, TN 38105 USA; Univ Tennessee, Coll Med, Memphis, TN USA; Univ Tennessee, Coll Pharm, Memphis, TN USA	St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center	Pui, CH (corresponding author), St Jude Childrens Res Hosp, 332 N Lauderdale St, Memphis, TN 38105 USA.				NATIONAL CANCER INSTITUTE [R01CA078224, P01CA020180, R37CA036401] Funding Source: NIH RePORTER; NCI NIH HHS [R37 CA36401, R01 CA-78224, P01 CA-20180] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Appelbaum FR, 1997, SEMIN ONCOL, V24, P114; BALIS FM, 1987, J CLIN ONCOL, V5, P202, DOI 10.1200/JCO.1987.5.2.202; BARRETT AJ, 1994, NEW ENGL J MED, V331, P1253, DOI 10.1056/NEJM199411103311902; Behm FG, 1996, BLOOD, V87, P2870, DOI 10.1182/blood.V87.7.2870.bloodjournal8772870; Borkhardt A, 1997, BLOOD, V90, P571, DOI 10.1182/blood.V90.2.571.571_571_577; BOSTROM B, 1998, P AN M AM SOC CLIN, V17, pA527; Braun SE, 1997, MOL MED TODAY, V3, P39, DOI 10.1016/S1357-4310(96)10052-6; BUNIN NJ, 1985, J CLIN ONCOL, V3, P1590, DOI 10.1200/JCO.1985.3.12.1590; CAMPANA D, 1995, BLOOD, V85, P1416, DOI 10.1182/blood.V85.6.1416.bloodjournal8561416; CASSILETH PA, 1992, LEUKEMIA, V6, P178; Cave H, 1998, NEW ENGL J MED, V339, P591, DOI 10.1056/NEJM199808273390904; Charrin C, 1996, BLOOD, V87, P3135; Chessells JM, 1997, BRIT J HAEMATOL, V98, P945, DOI 10.1046/j.1365-2141.1997.3113127.x; Chessells JM, 1998, LEUKEMIA, V12, P463, DOI 10.1038/sj.leu.2400959; CHESSELLS JM, 1995, LANCET, V345, P143, DOI 10.1016/S0140-6736(95)90164-7; Childhood A, 1996, LANCET, V347, P1783, DOI DOI 10.1016/S0140-6736(96)91615-3; Conter V, 1997, J CLIN ONCOL, V15, P2786, DOI 10.1200/JCO.1997.15.8.2786; COPELAN EA, 1995, BLOOD, V85, P1151, DOI 10.1182/blood.V85.5.1151.bloodjournal8551151; CORTES J, 1995, BLOOD, V86, P2091, DOI 10.1182/blood.V86.6.2091.bloodjournal8662091; CORTES JE, 1995, CANCER-AM CANCER SOC, V76, P2393, DOI 10.1002/1097-0142(19951215)76:12<2393::AID-CNCR2820761203>3.0.CO;2-P; Coustan-Smith E, 1998, LANCET, V351, P550, DOI 10.1016/S0140-6736(97)10295-1; CUTTNER J, 1991, LEUKEMIA, V5, P425; Dinarello CA, 1997, SEMIN ONCOL, V24, P288; Evans WE, 1998, NEW ENGL J MED, V338, P499, DOI 10.1056/NEJM199802193380803; EVANS WE, 1991, J PEDIATR-US, V119, P985, DOI 10.1016/S0022-3476(05)83063-X; EVANS WE, 1986, NEW ENGL J MED, V314, P471, DOI 10.1056/NEJM198602203140803; FIERE D, 1993, J CLIN ONCOL, V11, P1990, DOI 10.1200/JCO.1993.11.10.1990; GAJJAR A, 1995, BLOOD, V86, P1292, DOI 10.1182/blood.V86.4.1292.bloodjournal8641292; Galpin AJ, 1997, MOL PHARMACOL, V52, P155, DOI 10.1124/mol.52.1.155; Gaynon PS, 1997, CANCER-AM CANCER SOC, V80, P1717, DOI 10.1002/(SICI)1097-0142(19971101)80:9<1717::AID-CNCR4>3.0.CO;2-B; GAYNON PS, 1993, J CLIN ONCOL, V11, P2234, DOI 10.1200/JCO.1993.11.11.2234; Geissler K, 1997, BLOOD, V90, P590, DOI 10.1182/blood.V90.2.590.590_590_596; Gluckman E, 1997, NEW ENGL J MED, V337, P373, DOI 10.1056/NEJM199708073370602; Gottesfeld JM, 1997, NATURE, V387, P202, DOI 10.1038/387202a0; Hart I, 1997, NATURE, V388, P626, DOI 10.1038/41662; HAWKINS MM, 1995, BRIT J CANCER, V71, P1335, DOI 10.1038/bjc.1995.259; HOELZER D, 1992, LEUKEMIA, V6, P175; Hoelzer D, 1996, BLOOD, V87, P495, DOI 10.1182/blood.V87.2.495.bloodjournal872495; Hongeng S, 1997, LANCET, V350, P767, DOI 10.1016/S0140-6736(97)03098-5; HUGHES WT, 1987, NEW ENGL J MED, V316, P1627, DOI 10.1056/NEJM198706253162604; Hunger SP, 1998, BLOOD, V91, P1021; Kaspers GJL, 1997, BLOOD, V90, P2723, DOI 10.1182/blood.V90.7.2723.2723_2723_2729; Kenney LB, 1996, CANCER, V78, P169, DOI 10.1002/(SICI)1097-0142(19960701)78:1<169::AID-CNCR23>3.3.CO;2-S; Kishimoto T, 1997, BLOOD, V89, P3502, DOI 10.1182/blood.V89.10.3502.3502_3502_3502; Kumagai MA, 1996, J CLIN INVEST, V97, P755, DOI 10.1172/JCI118474; Kurtzberg J., 1996, Blood, V88, p669A; Laport GF, 1997, SEMIN ONCOL, V24, P70; LARSON RA, 1995, BLOOD, V85, P2025, DOI 10.1182/blood.V85.8.2025.bloodjournal8582025; LENNARD L, 1990, LANCET, V336, P225, DOI 10.1016/0140-6736(90)91745-V; LIPSHULTZ SE, 1995, NEW ENGL J MED, V332, P1738, DOI 10.1056/NEJM199506293322602; Look AT, 1997, SCIENCE, V278, P1059, DOI 10.1126/science.278.5340.1059; MAHMOUD HH, 1993, NEW ENGL J MED, V329, P314, DOI 10.1056/NEJM199307293290504; Mahoney DH, 1998, J CLIN ONCOL, V16, P1712, DOI 10.1200/JCO.1998.16.5.1712; Mahoney DH, 1998, J CLIN ONCOL, V16, P246, DOI 10.1200/JCO.1998.16.1.246; Masson E, 1996, LEUKEMIA, V10, P56; NACHMAN J, 1993, CANCER, V71, P3377, DOI 10.1002/1097-0142(19930515)71:10+<3377::AID-CNCR2820711741>3.0.CO;2-8; Nachman J, 1998, J CLIN ONCOL, V16, P920, DOI 10.1200/JCO.1998.16.3.920; Nachman JB, 1998, NEW ENGL J MED, V338, P1663, DOI 10.1056/NEJM199806043382304; NELSON SC, 1993, AM J PEDIAT HEMATOL, V15, P351; NIEMEYER CM, 1991, BLOOD, V78, P2514, DOI 10.1182/blood.V78.10.2514.2514; Otten J., 1996, Blood, V88, p669A; OTTMANN OG, 1995, BLOOD, V86, P444, DOI 10.1182/blood.V86.2.444.bloodjournal862444; Parker SL, 1997, CA-CANCER J CLIN, V47, P5, DOI 10.3322/canjclin.47.1.5; Parker SL, 1997, CA-CANCER J CLIN, V47, P68; Patte C, 1998, EUR J CANCER, V34, P359, DOI 10.1016/S0959-8049(97)10142-3; PerezAtayde AR, 1997, AM J PATHOL, V150, P815; PUI CH, 1993, BLOOD, V82, P343; PUI CH, 1991, BLOOD, V78, P1327, DOI 10.1182/blood.V78.5.1327.1327; PUI CH, 1995, JAMA-J AM MED ASSOC, V273, P633, DOI 10.1001/jama.273.8.633; Pui CH, 1997, LEUKEMIA, V11, P1813, DOI 10.1038/sj.leu.2400850; Pui CH, 1997, PEDIATR CLIN N AM, V44, P831, DOI 10.1016/S0031-3955(05)70532-0; PUI CH, 1990, BLOOD, V75, P1170; Pui CH, 1995, LEUKEMIA, V9, P1990; PUI CH, 1994, J PEDIATR-US, V124, P491, DOI 10.1016/S0022-3476(05)83125-7; PUI CH, 1995, LEUKEMIA, V9, P762; PUI CH, 1991, BLOOD, V77, P440; PUI CH, 1995, NEW ENGL J MED, V332, P1618, DOI 10.1056/NEJM199506153322407; Pui CH, 1997, NEW ENGL J MED, V336, P1781, DOI 10.1056/NEJM199706193362503; PUI CH, 1991, NEW ENGL J MED, V325, P1682, DOI 10.1056/NEJM199112123252402; Pui CH, 1998, BLOOD, V92, P411, DOI 10.1182/blood.V92.2.411.414k34_411_415; REITER A, 1994, BLOOD, V84, P3122, DOI 10.1182/blood.V84.9.3122.3122; REITER A, 1992, BLOOD, V80, P2471; Ribeiro RC, 1997, LEUKEMIA, V11, P1493, DOI 10.1038/sj.leu.2400749; RIVERA GK, 1991, LANCET, V337, P61, DOI 10.1016/0140-6736(91)90733-6; ROHATINER AZS, 1990, BRIT J CANCER, V62, P454, DOI 10.1038/bjc.1990.317; RUBNITZ JE, 1994, BLOOD, V84, P570; Rubnitz JE, 1997, J CLIN ONCOL, V15, P1150, DOI 10.1200/JCO.1997.15.3.1150; SackmannMuriel F, 1996, INT J PEDIAT HEM ONC, V3, P439; Sankila R, 1998, NEW ENGL J MED, V338, P1339, DOI 10.1056/NEJM199805073381902; Schmiegelow K, 1997, J PEDIAT HEMATOL ONC, V19, P102, DOI 10.1097/00043426-199703000-00002; SCHORIN MA, 1994, J CLIN ONCOL, V12, P740, DOI 10.1200/JCO.1994.12.4.740; SCHRAPPE M, IN PRESS BLOOD; SEBBAN C, 1994, J CLIN ONCOL, V12, P2580, DOI 10.1200/JCO.1994.12.12.2580; Sierra J, 1997, BLOOD, V90, P1410, DOI 10.1182/blood.V90.4.1410.1410_1410_1414; Smith M, 1996, J CLIN ONCOL, V14, P18, DOI 10.1200/JCO.1996.14.1.18; SOUSSAIN C, 1995, BLOOD, V85, P664, DOI 10.1182/blood.V85.3.664.bloodjournal853664; SYNOLD TW, 1994, J CLIN INVEST, V94, P1996, DOI 10.1172/JCI117552; TUBERGEN DG, 1993, J CLIN ONCOL, V11, P527, DOI 10.1200/JCO.1993.11.3.527; Uckun FM, 1996, BLOOD, V88, P1135, DOI 10.1182/blood.V88.4.1135.bloodjournal8841135; Uckun FM, 1997, BLOOD, V90, P28; UDERZO C, 1995, J CLIN ONCOL, V13, P352, DOI 10.1200/JCO.1995.13.2.352; Veerman AJP, 1996, J CLIN ONCOL, V14, P911, DOI 10.1200/JCO.1996.14.3.911; WABER DP, 1995, J CLIN ONCOL, V13, P2490, DOI 10.1200/JCO.1995.13.10.2490; WHITEHEAD VM, 1992, BLOOD, V80, P1316; WINICK NJ, 1992, J NATL CANCER I, V84, P252, DOI 10.1093/jnci/84.4.252; Yates CR, 1997, ANN INTERN MED, V126, P608, DOI 10.7326/0003-4819-126-8-199704150-00003; 1996, BLOOD, V88, P2818	107	702	734	0	38	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 27	1998	339	9					605	615		10.1056/NEJM199808273390907	http://dx.doi.org/10.1056/NEJM199808273390907			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	113LR	9718381				2022-12-28	WOS:000075552900007
J	Templeton, A; Morris, JK				Templeton, A; Morris, JK			Reducing the risk of multiple births by transfer of two embryos after in vitro fertilization	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							GESTATION; IVF; PREGNANCIES; NUMBER; WOMEN	Background In vitro fertilization is associated with a high risk of multiple births, which is a direct consequence of the number of embryos transferred. However, other factors that contribute to the risk are not well defined. Methods Using the data base established by the Human Fertilisation and Embryology Authority in the United Kingdom, we studied the factors associated with an increased risk of multiple births in 44,236 cycles in 25,240 women. The factors included the woman's age, the cause and duration of infertility, previous attempts at in vitro fertilization, previous live births, number of eggs fertilized, and number of embryos transferred. Results Older age, tubal infertility, longer duration of infertility, and a higher number of previous attempts at in vitro fertilization were all associated with a significantly decreased chance of a birth and of multiple births. Previous live birth was associated with an increased chance of a birth but not of multiple births. The higher the number of eggs fertilized, the higher the likelihood of a live birth. When more than four eggs were fertilized, there was no increase in the birth rate for women receiving three transferred embryos as compared with those receiving two, but there was a considerable increase in the rate of multiple births when three were transferred (odds ratio, 1.6; 95 percent confidence interval, 1.5 to 1.8). Conclusions Among women undergoing in vitro fertilization, the chances of a live birth are related to the number of eggs fertilized, presumably because of the greater selection of embryos for transfer. When more than four eggs are fertilized and available for transfer, the woman's chance of a birth is not diminished by transferring only two embryos. Transferring more embryos increases the risk of multiple births. (N Engl J Med 1998;339:573-7.) (C) 1998, Massachusetts Medical Society.	Human Fertilisat & Embryol Author, London, England; Wolfson Inst Prevent Med, Dept Environm & Prevent Med, London, England	University of London; Queen Mary University London	Templeton, A (corresponding author), Aberdeen Matern Hosp, Dept Obstet & Gynaecol, Cornhill Rd, Aberdeen AB25 2ZD, Scotland.		Morris, Joan/AAT-9211-2020	Morris, Joan/0000-0002-7164-612X				[Anonymous], 1995, FERTIL STERIL, V64, P13; AZEM F, 1995, FERTIL STERIL, V63, P1043, DOI 10.1016/S0015-0282(16)57545-1; Baldwin VJ., 1994, PATHOLOGY MULTIPLE P; Bronson R, 1997, HUM REPROD, V12, P1605, DOI 10.1093/humrep/12.8.1605; CALLAHAN TL, 1994, NEW ENGL J MED, V331, P244, DOI 10.1056/NEJM199407283310407; COHEN J, 1991, HUM REPROD, V6, P613, DOI 10.1093/oxfordjournals.humrep.a137393; CRAFT I, 1991, BRIT MED J, V303, P185, DOI 10.1136/bmj.303.6795.185; EASTON DF, 1991, STAT MED, V10, P1025, DOI 10.1002/sim.4780100703; Faber K, 1997, HUM REPROD, V12, P1614; *HUM FERT EMBR AUT, 1997, 6 HUM FERT EMBR AUTH; JONES HW, 1995, FERTIL STERIL, V63, P701, DOI 10.1016/S0015-0282(16)57468-8; LOGEROTLEBRUN H, 1995, FERTIL STERIL, V64, P746; MCLAREN A, 1985, P 12 STUD GROUP ROYA, P13; Roest J, 1997, FERTIL STERIL, V67, P290, DOI 10.1016/S0015-0282(97)81913-9; ROYSTON P, 1994, J R STAT SOC C-APPL, V43, P429, DOI 10.2307/2986270; Senoz S, 1997, J ASSIST REPROD GEN, V14, P192, DOI 10.1007/BF02766109; STAESSEN C, 1993, HUM REPROD, V8, P1650, DOI 10.1093/oxfordjournals.humrep.a137907; TASDEMIR M, 1995, HUM REPROD, V10, P2155; Templeton A, 1996, LANCET, V348, P1402, DOI 10.1016/S0140-6736(96)05291-9; Walters DE, 1996, HUM REPROD, V11, P10; Widra EA, 1996, FERTIL STERIL, V65, P103, DOI 10.1016/S0015-0282(16)58035-2	21	291	295	0	8	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 27	1998	339	9					573	577		10.1056/NEJM199808273390901	http://dx.doi.org/10.1056/NEJM199808273390901			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	113LR	9718375				2022-12-28	WOS:000075552900001
J	Davidson, PW; Myers, GJ; Cox, C; Axtell, C; Shamlaye, C; Sloane-Reeves, J; Cernichiari, E; Needham, L; Choi, A; Wang, YN; Berlin, M; Clarkson, TW				Davidson, PW; Myers, GJ; Cox, C; Axtell, C; Shamlaye, C; Sloane-Reeves, J; Cernichiari, E; Needham, L; Choi, A; Wang, YN; Berlin, M; Clarkson, TW			Effects of prenatal and postnatal methylmercury exposure from fish consumption on neurodevelopment - Outcomes at 66 months of age in the Seychelles Child Development Study	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							IN-UTERO EXPOSURE; POLYCHLORINATED-BIPHENYLS; MERCURY; DIET; HAIR; LEAD	Context.-Human neurodevelopmental consequences of exposure to methylmercury (MeHg) from eating fish remain a question of public health concern. Objective.-To study the association between MeHg exposure and the developmental outcomes of children in the Republic of Seychelles at 66 months of age. Design.-A prospective longitudinal cohort study. Participants.-A total of 711 of 779 cohort mother-child pairs initially enrolled in the Seychelles Child Development Study in 1989. Setting.-The Republic of Seychelles, an archipelago in the Indian Ocean where 85% of the population consumes ocean fish daily. Main Outcome Measures.-Prenatal and postnatal MeHg exposure and 6 age-appropriate neurodevelopmental tests: the McCarthy Scales of Children's Abilities, the Preschool Language Scale, the Woodcock-Johnson Applied Problems and Letter and Word Recognition Tests of Achievement, the Bender Gestalt test, and the Child Behavior Checklist. Results.-The mean maternal hair total mercury level was 6.8 ppm and the mean child hair total mercury level at age 66 months was 6.5 ppm. No adverse outcomes at 66 months were associated with either prenatal or postnatal MeHg exposure. Conclusion,-In the population studied, consumption of a diet high in ocean fish appears to pose no threat to developmental outcomes through 66 months of age.	Univ Rochester, Sch Med & Dent, Strong Ctr Dev Disabil, Rochester, NY 14642 USA; Republ Seychelles Minist Hlth, Victoria, Mahe, Seychelles; Ctr Dis Control & Prevent, Atlanta, GA USA; Univ Lund, Lund, Sweden	University of Rochester; Centers for Disease Control & Prevention - USA; Lund University	Davidson, PW (corresponding author), Univ Rochester, Sch Med & Dent, Strong Ctr Dev Disabil, Box 671,601 Elmwood Ave, Rochester, NY 14642 USA.	pdavidson@cc.urmc.rochester.edu	Myers, Gary J/I-4901-2013; Needham, Larry/E-4930-2011	Myers, Gary J/0000-0003-4317-015X; Wang, Yining/0000-0003-2763-1008	NIEHS NIH HHS [ES-01247, ES-07271, ES-05497] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES001247] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		*AG TOX SUBST DIS, 1997, TOX PROF POL BIOPH U; AIREY D, 1983, SCI TOTAL ENVIRON, V31, P157, DOI 10.1016/0048-9697(83)90067-0; AMLER RW, 1996, PEDIAT ENV NEUROBEHA; [Anonymous], 1958, STANDARD PROGR MATRI; [Anonymous], 1991, MANUAL CHILD BEHAV C; BELLINGER D, 1987, NEW ENGL J MED, V316, P1037, DOI 10.1056/NEJM198704233161701; BENDERSKY M, 1994, DEV PSYCHOL, V30, P484, DOI 10.1037/0012-1649.30.4.484; BENDERSKY M, 1995, J DEV BEHAV PEDIATR, V16, P89; BLOOM NS, 1992, CAN J FISH AQUAT SCI, V49, P1010, DOI 10.1139/f92-113; BOVET P, 1997, SEYCHELLES MED DENT, V1, P8; BROCK JW, 1996, J ANAL TOXICOL, V20, P1; Caldwell B., 1984, HOME OBSERVATION MEA; Cernichiari E, 1995, NEUROTOXICOLOGY, V16, P705; Cernichiari E, 1995, NEUROTOXICOLOGY, V16, P613; Cook RD, 1982, RESIDUALS INFLUENCE; Cox C, 1995, NEUROTOXICOLOGY, V16, P727; Cox C, 1989, ENV RES, V31, P640; Davidson PW, 1995, NEUROTOXICOLOGY, V16, P665; Davidson PW, 1995, NEUROTOXICOLOGY, V16, P677; Egeland GM, 1997, SCIENCE, V278, P1904, DOI 10.1126/science.278.5345.1904; GRANDJEAN P, 1992, ARCH ENVIRON HEALTH, V47, P185, DOI 10.1080/00039896.1992.9938348; GRANDJEAN P, 1995, NEUROTOXICOLOGY, V16, P32; HUISMAN M, 1995, EARLY HUM DEV, V41, P111, DOI 10.1016/0378-3782(94)01611-R; IPCS, 1990, ENV HLTH CRIT 101 ME; Jacobson JL, 1996, NEW ENGL J MED, V335, P783, DOI 10.1056/NEJM199609123351104; Kjellstrom T, 1989, 3642 NAT SWED ENV PR; Kjellstrom T, 1986, 3080 NAT SWED ENV BO; KOPPITZ EM, 1963, BENDER GESTALT TEST; LUCAS A, 1992, LANCET, V339, P261, DOI 10.1016/0140-6736(92)91329-7; MARSH DO, 1980, ANN NEUROL, V7, P348, DOI 10.1002/ana.410070412; Marsh DO, 1995, NEUROTOXICOLOGY, V16, P583; MATSUMOTO H, 1965, J NEUROPATH EXP NEUR, V24, P563, DOI 10.1097/00005072-196510000-00002; McCarthy D, 1972, MCCARTHY SCALES CHIL; MCKEOWNEYSSEN GE, 1983, AM J EPIDEMIOL, V118, P470, DOI 10.1093/oxfordjournals.aje.a113652; Myers GJ, 1995, NEUROTOXICOLOGY, V16, P639; Myers GJ, 1995, NEUROTOXICOLOGY, V16, P653; Needleman HL, 1996, JAMA-J AM MED ASSOC, V275, P363, DOI 10.1001/jama.275.5.363; RANDJEAN P, 1997, NEUROTOXICOL TERATOL, V19, P417; Sanderson K, 1996, SCI TOTAL ENVIRON, V186, P1, DOI 10.1016/S0048-9697(96)90032-7; Shamlaye CF, 1995, NEUROTOXICOLOGY, V16, P597; Smith JC, 1997, ARCH ENVIRON HEALTH, V52, P476, DOI 10.1080/00039899709602227; Swedish Expert Group, 1971, NORD HYG TIDSKR, V4, P1; Takeuchi T., 1968, MINAMATA DISEASE, P141; Weihe P, 1996, SCI TOTAL ENVIRON, V186, P141, DOI 10.1016/0048-9697(96)05094-2; *WHO, 1972, TECHN REP SER WHO, V505; WOODCOCK R, 1989, WOODCOCKJOHNSON TEST; Zimmerman IL., 1979, PRESCHOOL LANGUAGE S	47	495	508	5	60	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 26	1998	280	8					701	707		10.1001/jama.280.8.701	http://dx.doi.org/10.1001/jama.280.8.701			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	111PM	9728641	Bronze			2022-12-28	WOS:000075446900031
J	Drife, JO				Drife, JO			Soundings - NPD blues	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 22	1998	317	7157					546	546						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	115AM	9712624				2022-12-28	WOS:000075641400066
J	Garner, P; Kale, R; Dickson, R; Dans, T; Salinas, R				Garner, P; Kale, R; Dickson, R; Dans, T; Salinas, R			Getting research findings into practice - Implementing research findings in developing countries	BRITISH MEDICAL JOURNAL			English	Article							RANDOMIZED CONTROLLED TRIAL; NETWORK; IMPACT		Univ Liverpool, Liverpool Sch Trop Med, Int Hlth Div, Liverpool L3 5QA, Merseyside, England; Univ Philippines, Coll Med, Manila 1000, Philippines; Univ Chile, Dept Ciencias Neurol, Santiago, Chile	Liverpool School of Tropical Medicine; University of Liverpool; University of the Philippines System; University of the Philippines Manila; Universidad de Chile	Garner, P (corresponding author), Univ Liverpool, Liverpool Sch Trop Med, Int Hlth Div, Liverpool L3 5QA, Merseyside, England.	pgarner@liv.ac.uk	Garner, Paul/HII-5856-2022	Garner, Paul/0000-0002-0607-6941				BEATON GH, 1993, 13 ADM COMM COORD SU; Bero LA, 1998, BMJ-BRIT MED J, V317, P465; BHUTTA TI, 1995, NEWSLETTER, V4, P3; BIDDULPH J, 1989, TROP DOCT, V19, P126, DOI 10.1177/004947558901900311; DULEY L, 1995, LANCET, V345, P1455; *EFF NETW EUR UN, 1996, STAT INT 3 PROJ INT; Garner P, 1997, BRIT MED J, V315, P760; GARNER P, 1996, LANCET, V347, P113; Glanville J, 1998, BRIT MED J, V317, P200, DOI 10.1136/bmj.317.7152.200; GORE SM, 1992, BMJ-BRIT MED J, V304, P287, DOI 10.1136/bmj.304.6822.287; GROSSKURTH H, 1995, LANCET, V346, P530, DOI 10.1016/S0140-6736(95)91380-7; GULMEZOGLU AM, 1998, INFECT DIS MODULE CO; HALSTEAD SB, 1991, J CLIN EPIDEMIOL, V44, P579, DOI 10.1016/0895-4356(91)90222-U; HORNABROOK RW, 1977, MONOGRAPH SERIES, V5; MARTINEZ J, 1994, LANCET, V344, P956, DOI 10.1016/S0140-6736(94)92310-8; *MULT TASK FORC DE, 1997, PHILIPPINES J INTERN, V35, P67; *MULT TASK FORC GU, 1996, PHILIPPINES J CARDIO, V24, P147; Munjanja SP, 1996, LANCET, V348, P364, DOI 10.1016/S0140-6736(96)01250-0; Olliaro P, 1996, LANCET, V348, P1196, DOI 10.1016/S0140-6736(96)06217-4; *OV DEV ADM NAT AU, 1995, HLTH POP OV AID REP; ROSS DA, 1993, LANCET, V342, P750; ROSSDEGNAN D, 1992, SOC SCI MED, V35, P1329, DOI 10.1016/0277-9536(92)90037-Q; SHANN F, 1984, B WORLD HEALTH ORGAN, V62, P749; UPLEKAR MW, 1993, TUBERCLE LUNG DIS, V74, P332, DOI 10.1016/0962-8479(93)90108-A; WELSCH R, 1982, THESIS U WASHINGTON; *WHO, 1997, INT REP BIENN 1996 1; *WORLD BANK, 1993, WORLD DEV REP 1993 I	27	69	70	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 22	1998	317	7157					531	535						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	115AM	9712608				2022-12-28	WOS:000075641400030
J	Jensen, TK; Hjollund, NHI; Henriksen, TB; Scheike, T; Kolstad, H; Giwercman, A; Ernst, E; Bonde, JP; Skakkebaek, NF; Olsen, J				Jensen, TK; Hjollund, NHI; Henriksen, TB; Scheike, T; Kolstad, H; Giwercman, A; Ernst, E; Bonde, JP; Skakkebaek, NF; Olsen, J			Does moderate alcohol consumption affect fertility? Follow up study among couples planning first pregnancy	BRITISH MEDICAL JOURNAL			English	Article							CIGARETTE-SMOKING; CAFFEINE CONSUMPTION; DELAYED CONCEPTION; COFFEE-DRINKING; RISK-FACTORS; WOMEN; INFERTILITY; ETHANOL; FECUNDABILITY; SUBFECUNDITY	Objective: To examine the effect of alcohol consumption on the probability of conception. Design: A follow up study over six menstrual cycles or until a clinically recognised pregnancy occurred after discontinuation of contraception. Subjects: 430 Danish couples aged 20-35 years trying to conceive for the first time. Main outcome measures: Clinically recognised pregnancy. Fecundability odds ratio: odds of conception among exposed couples divided by odds among those not exposed. Results: In the six cycles of follow up 64% (179) of women with a weekly alcohol intake of less than five drinks and 55% (75) of women with a higher intake conceived. After adjustment for cycle number, smoking in either partner or smoking exposure in utero, centre of enrolment, diseases in female reproductive organs, woman's body mass index, sperm concentration, and duration of menstrual cycle, the odds ratio decreased with increasing alcohol intake from 0.61 (95% confidence interval 0.40 to 0.93) among women consuming 1-5 drinks a week to 0.34 (0.22 to 0.52) among women consuming more than 10 drinks a week (P = 0.03 for trend) compared with women with no alcohol intake. Among men no dose-response association was found after control for confounders including women's alcohol intake. Conclusion: A woman's alcohol intake is associated with decreased fecundability even among women with a weekly alcohol intake corresponding to five or fewer drinks. This finding needs further corroboration, but it seems reasonable to encourage women to avoid intake of alcohol when they are trying to become pregnant.	Natl Univ Hosp, Rigshosp, Dept Growth & Reprod, DK-2100 Copenhagen, Denmark; Aarhus Univ Hosp, Dept Occupat Med, DK-8000 Aarhus C, Denmark; Aarhus Univ Hosp, Perinatal Epidemiol Res Unit, Dept Obstet & Gynaecol, Aarhus, Denmark; Univ Copenhagen, Dept Biostat, DK-2200 Copenhagen N, Denmark; Aarhus Univ, Danish Epidemiol Sci Ctr, DK-8000 Aarhus C, Denmark	Rigshospitalet; University of Copenhagen; Aarhus University; Aarhus University; University of Copenhagen; Aarhus University	Jensen, TK (corresponding author), Natl Univ Hosp, Rigshosp, Dept Growth & Reprod, Sect GR 5064,9 Blegdamsvej, DK-2100 Copenhagen, Denmark.	tkjensen@winsloew.ou.dk		Jensen, Tina Kold/0000-0003-2311-5778; Hjollund, Niels Henrik I/0000-0002-6697-6597				Ahlborg G, 1996, INT J EPIDEMIOL, V25, P783, DOI 10.1093/ije/25.4.783; ALDERETE E, 1995, EPIDEMIOLOGY, V6, P403, DOI 10.1097/00001648-199507000-00013; BAHAMONDES L, 1994, FERTIL STERIL, V61, P478; BAIRD DD, 1985, JAMA-J AM MED ASSOC, V253, P2979, DOI 10.1001/jama.253.20.2979; BECKER U, 1989, DRUG ALCOHOL DEPEN, V24, P75, DOI 10.1016/0376-8716(89)90012-4; BECKER U, 1993, DAN MED BULL, V40, P447; Bonde JPE, 1998, REPROD TOXICOL, V12, P19, DOI 10.1016/S0890-6238(97)00096-8; BUNKER ML, 1979, J AM DIET ASSOC, V74, P28; COLDITZ GA, 1991, AM J CLIN NUTR, V54, P49, DOI 10.1093/ajcn/54.1.49; Curtis KM, 1997, AM J EPIDEMIOL, V146, P32, DOI 10.1093/oxfordjournals.aje.a009189; DEMOUZON J, 1988, INT J EPIDEMIOL, V17, P378, DOI 10.1093/ije/17.2.378; DUNPHY BC, 1991, ANDROLOGIA, V23, P219; FLORACK EIM, 1994, PREV MED, V23, P175, DOI 10.1006/pmed.1994.1024; GAVALER JS, 1980, ALCOHOL CLIN EXP RES, V4, P271, DOI 10.1111/j.1530-0277.1980.tb04813.x; GRODSTEIN F, 1994, AM J PUBLIC HEALTH, V84, P1429, DOI 10.2105/AJPH.84.9.1429; GRONBAEK M, 1995, BRIT MED J, V310, P1165, DOI 10.1136/bmj.310.6988.1165; Hadi H A, 1987, Obstet Gynecol Surv, V42, P69; HARLAP S, 1980, LANCET, V2, P173, DOI 10.1016/S0140-6736(80)90061-6; HOWE G, 1985, BRIT MED J, V290, P1697, DOI 10.1136/bmj.290.6483.1697; Joesoef M R, 1993, Ann Epidemiol, V3, P592, DOI 10.1016/1047-2797(93)90080-N; JOFFE M, 1994, AM J EPIDEMIOL, V140, P921, DOI 10.1093/oxfordjournals.aje.a117180; LEACH RE, 1993, TERATOLOGY, V47, P57, DOI 10.1002/tera.1420470110; MELLO NK, 1983, SCIENCE, V221, P677, DOI 10.1126/science.6867739; OLDEREID NB, 1992, INT J FERTIL, V37, P343; OLSEN J, 1991, AM J EPIDEMIOL, V133, P734, DOI 10.1093/oxfordjournals.aje.a115948; Olsen J, 1996, FERTIL STERIL, V66, P95, DOI 10.1016/S0015-0282(16)58393-9; Olsen J, 1997, ALCOHOL CLIN EXP RES, V21, P206, DOI 10.1111/j.1530-0277.1997.tb03751.x; OLSEN J, 1983, INT J EPIDEMIOL, V12, P179, DOI 10.1093/ije/12.2.179; PARAZZINI F, 1993, ARCH ANDROLOGY, V31, P105; SALLMEN M, 1995, AM J IND MED, V27, P699, DOI 10.1002/ajim.4700270506; Schmidt L, 1995, BRIT J OBSTET GYNAEC, V102, P978, DOI 10.1111/j.1471-0528.1995.tb10905.x; SHARMA SC, 1970, INDIAN J MED RES, V58, P501; Stanton CK, 1995, AM J EPIDEMIOL, V142, P1322, DOI 10.1093/oxfordjournals.aje.a117600; VALIMAKI MJ, 1995, ACTA OBSTET GYN SCAN, V74, P462, DOI 10.3109/00016349509024410; WILCOX A, 1988, LANCET, V2, P1453; WILLIAMSON DF, 1987, AM J PUBLIC HEALTH, V77, P1324, DOI 10.2105/AJPH.77.10.1324; WILSNACK SC, 1984, ALCOHOL CLIN EXP RES, V8, P451, DOI 10.1111/j.1530-0277.1984.tb05700.x; ZAADSTRA BM, 1994, FERTIL STERIL, V62, P948	39	128	130	0	8	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 22	1998	317	7157					505	510						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	115AM	9712595	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000075641400018
J	Chan, YM; Jan, YN				Chan, YM; Jan, YN			Roles for proteolysis and trafficking in notch maturation and signal transduction	CELL			English	Review							RECEPTOR; MEMBRANE		Univ Calif San Francisco, Howard Hughes Med Inst, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Physiol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Biochem, San Francisco, CA 94143 USA	Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Chan, YM (corresponding author), Univ Calif San Francisco, Howard Hughes Med Inst, San Francisco, CA 94143 USA.			Jan, Yuh Nung/0000-0003-1367-6299				ARTAVANISTSAKONAS S, 1995, SCIENCE, V268, P225, DOI 10.1126/science.7716513; Blaumueller CM, 1997, CELL, V90, P281, DOI 10.1016/S0092-8674(00)80336-0; Bray S, 1998, CELL, V93, P499, DOI 10.1016/S0092-8674(00)81180-0; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; FORTINI ME, 1994, CELL, V79, P273, DOI 10.1016/0092-8674(94)90196-1; Kim TW, 1997, CURR OPIN NEUROBIOL, V7, P683, DOI 10.1016/S0959-4388(97)80089-X; Kimble J, 1997, ANNU REV CELL DEV BI, V13, P333, DOI 10.1146/annurev.cellbio.13.1.333; Kopan R, 1996, P NATL ACAD SCI USA, V93, P1683, DOI 10.1073/pnas.93.4.1683; Lecourtois M, 1998, CURR BIOL, V8, P771, DOI 10.1016/S0960-9822(98)70300-8; LEVITAN D, 1998, IN PRESS DEVELOPMENT; LIEBER T, 1993, GENE DEV, V7, P1949, DOI 10.1101/gad.7.10.1949; Logeat F, 1998, P NATL ACAD SCI USA, V95, P8108, DOI 10.1073/pnas.95.14.8108; Pan DJ, 1997, CELL, V90, P271, DOI 10.1016/S0092-8674(00)80335-9; Rawson RB, 1997, MOL CELL, V1, P47, DOI 10.1016/S1097-2765(00)80006-4; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; SELKOE DJ, 1994, ANNU REV CELL BIOL, V10, P373, DOI 10.1146/annurev.cb.10.110194.002105; Struhl G, 1998, CELL, V93, P649, DOI 10.1016/S0092-8674(00)81193-9; STRUHL G, 1993, CELL, V74, P331, DOI 10.1016/0092-8674(93)90424-O	19	87	92	1	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	AUG 21	1998	94	4					423	426		10.1016/S0092-8674(00)81583-4	http://dx.doi.org/10.1016/S0092-8674(00)81583-4			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	113GB	9727485	Bronze			2022-12-28	WOS:000075541100004
J	Hupe, JM; James, AC; Payne, BR; Lomber, SG; Girard, P; Bullier, J				Hupe, JM; James, AC; Payne, BR; Lomber, SG; Girard, P; Bullier, J			Cortical feedback improves discrimination between figure and background by V1, V2 and V3 neurons	NATURE			English	Article							MACAQUE MONKEY; VISUAL-CORTEX; CORTICOCORTICAL CONNECTIONS; AFFERENT CONNECTIVITY; RECEPTIVE-FIELD; AREAS V1; STRIATE; CAT; ORGANIZATION; SYSTEM	A single visual stimulus activates neurons in many different cortical areas. A major challenge in cortical physiology is to understand how the neural activity in these numerous active zones leads to a unified percept of the visual sct ne. The anatomical basis for these interactions is the dense network of connections that link the visual areas. Within this network, feedforward connections transmit signals from lower-order areas such as V1 or V2 to higher-order areas. In addition, there is a dense web of feedback connections which, despite their anatomical prominence(1,4), remain functionally mysterious(5-8). Here we show, using reversible inactivation of a higher-order area (monkey area V5/MT), that feedback connections serve to amplify and focus activity of neurons in lower-order areas, and that they are important in the differentiation of figure from ground, particularly in the case of stimuli of low visibility. More specifically, we show that feedback connections facilitate responses to objects moving within the classical receptive field; enhance suppression evoked by background stimuli in the surrounding region; and have the strongest effects for stimuli of low salience.	INSERM, F-69675 Bron, France	Institut National de la Sante et de la Recherche Medicale (Inserm)	Bullier, J (corresponding author), INSERM, 18 Ave Doyen Lepine, F-69675 Bron, France.	bullier@lyon151.inserm.fr	Girard, Pascal/C-6427-2009; James, Andrew C/C-9307-2009; Lomber, Stephen/B-6820-2015	James, Andrew C/0000-0002-2447-8549; Lomber, Stephen/0000-0002-3001-7909				ALONSO JM, 1993, EXP BRAIN RES, V93, P363; BENITA M, 1972, BRAIN RES, V36, P133, DOI 10.1016/0006-8993(72)90771-8; Brook V, 1983, REV PHYSL BIOCH PHAR, V95, P1; BULLIER J, 1994, PRIMARY VISUAL CORTE, V10, P301; DEYOE EA, 1990, VISUAL NEUROSCI, V5, P67, DOI 10.1017/S0952523800000080; Efron B., 1994, MONOGRAPHS STAT APPL; Felleman DJ, 1997, J COMP NEUROL, V379, P21, DOI 10.1002/(SICI)1096-9861(19970303)379:1<21::AID-CNE3>3.0.CO;2-K; GIRARD P, 1992, J NEUROPHYSIOL, V67, P1; Johnson RR, 1996, J COMP NEUROL, V368, P383, DOI 10.1002/(SICI)1096-9861(19960506)368:3<383::AID-CNE5>3.0.CO;2-1; KENNEDY H, 1985, J NEUROSCI, V5, P2815; Levitt JB, 1997, NATURE, V387, P73, DOI 10.1038/387073a0; LI CY, 1994, VISION RES, V34, P2337, DOI 10.1016/0042-6989(94)90280-1; Lomber SG, 1996, P NATL ACAD SCI USA, V93, P1654, DOI 10.1073/pnas.93.4.1654; MIGNARD M, 1991, SCIENCE, V251, P1249, DOI 10.1126/science.1848727; NELSON JI, 1978, BRAIN RES, V139, P359, DOI 10.1016/0006-8993(78)90937-X; NEWSOME WT, 1988, J NEUROSCI, V8, P220; NOWAK LG, 1995, VISUAL NEUROSCI, V12, P371, DOI 10.1017/S095252380000804X; PASTERNAK T, 1994, CEREB CORTEX, V4, P247, DOI 10.1093/cercor/4.3.247; PERKEL DJ, 1986, J COMP NEUROL, V253, P374, DOI 10.1002/cne.902530307; Polyak S., 1957, VERTEBRATE VISUAL SY; RODMAN HR, 1989, J NEUROSCI, V9, P2033; SALIN PA, 1995, PHYSIOL REV, V75, P107, DOI 10.1152/physrev.1995.75.1.107; SALIN PA, 1992, J COMP NEUROL, V320, P415, DOI 10.1002/cne.903200402; SANDELL JH, 1982, J NEUROPHYSIOL, V48, P38, DOI 10.1152/jn.1982.48.1.38; SHIPP S, 1989, EUR J NEUROSCI, V1, P333, DOI 10.1111/j.1460-9568.1989.tb00799.x; SHIPP S, 1989, EUR J NEUROSCI, V1, P308; Vanduffel W, 1997, P NATL ACAD SCI USA, V94, P7617, DOI 10.1073/pnas.94.14.7617	27	620	623	0	35	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 20	1998	394	6695					784	787		10.1038/29537	http://dx.doi.org/10.1038/29537			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	112PR	9723617				2022-12-28	WOS:000075503600046
J	Rogaeva, E; Premkumar, S; Song, YQ; Sorbi, S; Brindle, N; Paterson, A; Duara, R; Levesque, G; Yu, G; Nishimura, M; Ikeda, M; O'Toole, C; Kawarai, T; Jorge, R; Vilarino, D; Bruni, AC; Farrer, LA; St George-Hyslop, PH				Rogaeva, E; Premkumar, S; Song, YQ; Sorbi, S; Brindle, N; Paterson, A; Duara, R; Levesque, G; Yu, G; Nishimura, M; Ikeda, M; O'Toole, C; Kawarai, T; Jorge, R; Vilarino, D; Bruni, AC; Farrer, LA; St George-Hyslop, PH			Evidence for an Alzheimer disease susceptibility locus on chromosome 12 and for further locus heterogeneity	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							AMYLOID PRECURSOR PROTEIN; EARLY-ONSET ALZHEIMERS; APOLIPOPROTEIN-E; CLINICAL-DIAGNOSIS; MISSENSE MUTATIONS; TYPE-4 ALLELE; GENE; LINKAGE; PRESENILIN-1; EPSILON-4	Context. - Alzheimer disease (AD) susceptibility genes have been identified on chromosomes 1, 14, 19, and 21, and a recent study has suggested a locus on chromosome 12. Objective. - To confirm or refute the existence of a familiar AD susceptibility locus on chromosome 12 in an independent sample of familial AD cases. Design.-Retrospective cohort study. DNA data for 6 chromosome 12 genetic markers were evaluated using parametric lod score and nonparametric linkage methods and linkage heterogeneity tests. The latter include the admixture test of homogeneity in the total group of families and the predivided sample test in families stratified by the presence or absence of an apolipoprotein E (APOE) epsilon 4 allele among affected members. Parametric analyses were repeated assuming autosomal dominant inheritance of AD and either age- and sex-dependent penetrance or zero penetrance for the analysis of unaffected relatives. Setting. - Clinical populations in the continental United States, Canada, Argentina, and Italy. Patients.-Fifty-three white families composed of multiple members affected with AD, from whom DNA samples were obtained from 173 patients with AD whose conditions were diagnosed using established criteria and from 146 nondemented relatives. Main Outcome Measure. - Presence of an APOE epsilon 4 allele among affected family members. Results. - Using parametric methods, no evidence for linkage to the region spanned by the chromosome 12 markers could be detected if familial AD is assumed to arise from the same genetic locus in all 53 families. However, significant evidence for linkage was detected in the presence of locus heterogeneity using the admixture test (odds ratio, 15, 135:1). The estimated proportion of linked families within the 53 families examined varied between 0.40 and 0.65, depending on the genetic model assumed and APOE status. The precise location of the AD gene could not be determined, but includes the entire region suggested previously. Nonparametric linkage analysis confirmed linkage to chromosome 12 with the strongest evidence at D12S96 (P < .001). Conclusions. - Our data provide independent confirmation of the existence of an AD susceptibility locus on chromosome 12 and suggest the existence of AD susceptibility genes on other chromosomes. Screening a larger set of families with additional chromosome markers will be necessary for identifying the chromosome 12 AD gene.	Univ Toronto, Dept Med, Div Neurol, Ctr Res Neurodegenerat Dis, Toronto, ON M5S 3H2, Canada; Univ Toronto, Clarke Inst Psychiat, Neurogenet Lab, Toronto, ON M5S 3H2, Canada; Toronto Hosp, Dept Med, Div Neurol, Toronto, ON M5T 2S8, Canada; Boston Univ, Sch Med, Genet Program, Boston, MA 02118 USA; Mt Sinai Med Ctr, Dept Neurol, Miami Beach, FL 33140 USA; Univ Florence, Dept Neurol & Psychiat, Firenze, Italy; Univ Buenos Aires, Hosp Clin, Dept Neurol, Buenos Aires, DF, Argentina; Ctr Reg Neurogenet ASL 6, Lamezia Terme, Italy	University of Toronto; University of Toronto; University Toronto Affiliates; Centre for Addiction & Mental Health - Canada; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Boston University; Mount Sinai Medical Center; University of Florence; University of Buenos Aires	St George-Hyslop, PH (corresponding author), Univ Toronto, Dept Med, Div Neurol, Ctr Res Neurodegenerat Dis, Room 118,Tanz Neurosci Bldg,6 Queens Pk Crescent, Toronto, ON M5S 3H2, Canada.		Paterson, Andrew D/A-4088-2011; Song, You-qiang/C-4401-2009; Song, You-Qiang/E-5207-2011; Farrer, Lindsay/AAS-1035-2020; Kawarai, Toshitaka/C-2822-2013; Bruni, Amalia/K-5038-2016	Paterson, Andrew D/0000-0002-9169-118X; Kawarai, Toshitaka/0000-0003-4547-8131; Farrer, Lindsay/0000-0001-5533-4225; sorbi, sandro/0000-0002-0380-6670; Bruni, Amalia/0000-0003-3471-3343; St George-Hyslop, Peter/0000-0003-0796-7209; Song, You-Qiang/0000-0001-9407-2256	NATIONAL INSTITUTE ON AGING [R01AG009029, T32AG000115] Funding Source: NIH RePORTER; CIHR [37920] Funding Source: Medline; NIA NIH HHS [AG09029, T32-AG00115] Funding Source: Medline; Telethon [E.0352] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); CIHR(Canadian Institutes of Health Research (CIHR)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); Telethon(Fondazione Telethon)		Borchelt DR, 1996, NEURON, V17, P1005, DOI 10.1016/S0896-6273(00)80230-5; CHARTIERHARLIN MC, 1994, HUM MOL GENET, V3, P569, DOI 10.1093/hmg/3.4.569; Citron M, 1997, NAT MED, V3, P67, DOI 10.1038/nm0197-67; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; CLERGETDARPOUX F, 1986, BIOMETRICS, V42, P393, DOI 10.2307/2531059; CORDER EH, 1994, NAT GENET, V7, P180, DOI 10.1038/ng0694-180; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; Duff K, 1996, NATURE, V383, P710, DOI 10.1038/383710a0; Fagan AM, 1996, J BIOL CHEM, V271, P30121, DOI 10.1074/jbc.271.47.30121; Farrer LA, 1997, JAMA-J AM MED ASSOC, V278, P1349, DOI 10.1001/jama.1997.03550160069041; FARRER LA, 1990, NEUROLOGY, V40, P395, DOI 10.1212/WNL.40.3_Part_1.395; FARRER LA, 1993, GENET EPIDEMIOL, V10, P425, DOI 10.1002/gepi.1370100616; GEARING M, 1995, NEUROLOGY, V45, P461, DOI 10.1212/WNL.45.3.461; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; HAASS C, 1994, J BIOL CHEM, V269, P17741; HODGE SE, 1983, AM J HUM GENET, V35, P1139; Kang DE, 1997, NEUROLOGY, V49, P56, DOI 10.1212/WNL.49.1.56; KARLINSKY H, 1992, NEUROLOGY, V42, P1445, DOI 10.1212/WNL.42.8.1445; KATZMAN R, 1986, NEW ENGL J MED, V314, P964, DOI 10.1056/NEJM198604103141506; KHACHATURIAN ZS, 1985, ARCH NEUROL-CHICAGO, V42, P1097, DOI 10.1001/archneur.1985.04060100083029; Knauer MF, 1996, BRAIN RES, V740, P6, DOI 10.1016/S0006-8993(96)00711-1; KOUNNAS MZ, 1995, CELL, V82, P331, DOI 10.1016/0092-8674(95)90320-8; Kruglyak L, 1996, AM J HUM GENET, V58, P1347; LANDER E, 1995, NAT GENET, V11, P241, DOI 10.1038/ng1195-241; Lendon CL, 1997, NEUROSCI LETT, V222, P187, DOI 10.1016/S0304-3940(97)13381-X; LEVYLAHAD E, 1995, SCIENCE, V269, P973, DOI 10.1126/science.7638622; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; MULLAN M, 1992, NAT GENET, V1, P345, DOI 10.1038/ng0892-345; OKUIZUMI K, 1994, NAT GENET, V7, P10, DOI 10.1038/ng0594-10b; Ott J., 1991, ANAL HUMAN GENETIC L; PericakVance MA, 1997, JAMA-J AM MED ASSOC, V278, P1237, DOI 10.1001/jama.278.15.1237; RISCH N, 1991, MULTIPOINT MAPPING L, V6, P183; ROGAEV EI, 1995, NATURE, V376, P775, DOI 10.1038/376775a0; Roses A. D., 1995, American Journal of Human Genetics, V57, pA202; SAUNDERS AM, 1993, NEUROLOGY, V43, P1467, DOI 10.1212/WNL.43.8.1467; SCOTT WK, IN PRESS NEUROGENETI; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; SMITH CAB, 1963, ANN HUM GENET, V27, P175, DOI 10.1111/j.1469-1809.1963.tb00210.x; STGEORGEHYSLOP P, 1992, NAT GENET, V2, P330, DOI 10.1038/ng1292-330; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; SUSUKI N, 1994, SCIENCE, V264, P1336; TEWILLIGER JD, 1994, HDB HUMAN GENETIC LI; VANDUIJN CM, 1994, NAT GENET, V7, P74, DOI 10.1038/ng0594-74; WavrantDeVrieze F, 1997, NEUROSCI LETT, V227, P68, DOI 10.1016/S0304-3940(97)00304-2	44	140	145	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 19	1998	280	7					614	618		10.1001/jama.280.7.614	http://dx.doi.org/10.1001/jama.280.7.614			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	110ME	9718052	Bronze			2022-12-28	WOS:000075384300029
J	Price, SR; Evens, PR; Nagai, K				Price, SR; Evens, PR; Nagai, K			Crystal structure of the spliceosomal U2B ''-U2A ' protein complex bound to a fragment of U2 small nuclear RNA	NATURE			English	Article							LEUCINE-RICH REPEATS; BINDING DOMAIN; U1A PROTEIN; PREMESSENGER RNA; A-PROTEIN; RIBONUCLEOPROTEIN; RECOGNITION; SEQUENCE; IDENTIFICATION; MOTIF	We have determined the crystal structure at 2.4 Angstrom resolution of a ternary complex between the spliceosomal U2B "/U2A' protein complex and hairpin-loop IV of U2 small nuclear RNA. Unlike its close homologue the U1A protein, U2B " binds to its cognate RNA only in the presence of U2A', which contains leucine-rich repeats in its sequence. The concave surface of a parallel p-sheet within the leucine-rich-repeat region of U2A' Interacts with the ribonucleoprotein domain of U2B " on the surface opposite its RNA-binding surface. The basic carboxy-terminal region of U2A' interacts with the RNA stem. the crystal structure reveals how protein-protein interaction regulates RNA-binding specificity, and how replacing only a few key residues allows the U2B " and U1B proteins to discriminate between their cognate RNA hairpins by forming alternative networks of interactions.	MRC, Mol Biol Lab, Cambridge CB2 2QH, England	MRC Laboratory Molecular Biology	Nagai, K (corresponding author), MRC, Mol Biol Lab, Hills Rd, Cambridge CB2 2QH, England.	kn@mrc-lmb.cam.ac		Price, Stephen/0000-0001-7804-9849				Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; Allain FHT, 1997, EMBO J, V16, P5764, DOI 10.1093/emboj/16.18.5764; Avis JM, 1996, J MOL BIOL, V257, P398, DOI 10.1006/jmbi.1996.0171; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BENTLEY RC, 1991, MOL CELL BIOL, V11, P1829, DOI 10.1128/MCB.11.4.1829; BIRNEY E, 1993, NUCLEIC ACIDS RES, V21, P5803, DOI 10.1093/nar/21.25.5803; Biswas R, 1997, J MOL BIOL, V267, P1149, DOI 10.1006/jmbi.1997.0936; BOELENS W, 1991, NUCLEIC ACIDS RES, V19, P455, DOI 10.1093/nar/19.3.455; BOELENS WC, 1993, CELL, V72, P881, DOI 10.1016/0092-8674(93)90577-D; Buchanan SGS, 1996, PROG BIOPHYS MOL BIO, V65, P1, DOI 10.1016/S0079-6107(96)00003-X; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; FRESCO LD, 1991, MOL CELL BIOL, V11, P1578, DOI 10.1128/MCB.11.3.1578; HABETS WJ, 1987, P NATL ACAD SCI USA, V84, P2421, DOI 10.1073/pnas.84.8.2421; HALL KB, 1994, BIOCHEMISTRY-US, V33, P10076, DOI 10.1021/bi00199a035; HARPER DS, 1992, NUCLEIC ACIDS RES, V20, P3645, DOI 10.1093/nar/20.14.3645; JESSEN TH, 1991, EMBO J, V10, P3447, DOI 10.1002/j.1460-2075.1991.tb04909.x; JONES TA, 1994, MANUAL; Jovine L, 1996, STRUCTURE, V4, P621, DOI 10.1016/S0969-2126(96)00066-4; KAJAVA AV, 1995, STRUCTURE, V3, P867, DOI 10.1016/S0969-2126(01)00222-2; KOBE B, 1995, NATURE, V374, P183, DOI 10.1038/374183a0; KOBE B, 1993, NATURE, V366, P751, DOI 10.1038/366751a0; KOBE B, 1995, CURR OPIN STRUC BIOL, V5, P409, DOI 10.1016/0959-440X(95)80105-7; LAIRDOFFRINGA IA, 1995, P NATL ACAD SCI USA, V92, P11859, DOI 10.1073/pnas.92.25.11859; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; MATTAJ IW, 1993, CELL, V73, P837, DOI 10.1016/0092-8674(93)90265-R; NAGAI K, 1995, TRENDS BIOCHEM SCI, V20, P235, DOI 10.1016/S0968-0004(00)89024-6; Nagai K, 1996, CURR OPIN STRUC BIOL, V6, P53, DOI 10.1016/S0959-440X(96)80095-9; NAGAI K, 1990, NATURE, V348, P515, DOI 10.1038/348515a0; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; OUBRIDGE C, 1995, J MOL BIOL, V249, P409, DOI 10.1006/jmbi.1995.0306; OUBRIDGE C, 1994, NATURE, V372, P432, DOI 10.1038/372432a0; Patikoglou G, 1997, ANNU REV BIOPH BIOM, V26, P289, DOI 10.1146/annurev.biophys.26.1.289; PolycarpouSchwarz M, 1996, RNA, V2, P11; Price Sr, 1998, PRACT APPROACH SER, V192, P37; Saenger W., 1984, PRINCIPLES NUCL ACID; SCHERLY D, 1989, EMBO J, V8, P4163, DOI 10.1002/j.1460-2075.1989.tb08601.x; SCHERLY D, 1991, J MOL BIOL, V219, P577, DOI 10.1016/0022-2836(91)90651-L; SCHERLY D, 1990, NATURE, V345, P502, DOI 10.1038/345502a0; SCHERLY D, 1990, EMBO J, V9, P3675, DOI 10.1002/j.1460-2075.1990.tb07579.x; SCHWABE JWR, 1993, CELL, V75, P567, DOI 10.1016/0092-8674(93)90390-C; Shamoo Y, 1997, NAT STRUCT BIOL, V4, P215, DOI 10.1038/nsb0397-215; SILLEKENS PTG, 1989, NUCLEIC ACIDS RES, V17, P1893, DOI 10.1093/nar/17.5.1893; SILLEKENS PTG, 1987, EMBO J, V6, P3841, DOI 10.1002/j.1460-2075.1987.tb02721.x; TSAI DE, 1991, NUCLEIC ACIDS RES, V19, P4931, DOI 10.1093/nar/19.18.4931; Uhlenbeck OC, 1997, CELL, V90, P833, DOI 10.1016/S0092-8674(00)80348-7; VANGELDER CWG, 1993, EMBO J, V12, P5191, DOI 10.1002/j.1460-2075.1993.tb06214.x; Williams DJ, 1996, J MOL BIOL, V257, P265; Xu RM, 1997, STRUCTURE, V5, P559, DOI 10.1016/S0969-2126(97)00211-6	50	308	315	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 13	1998	394	6694					645	650		10.1038/29234	http://dx.doi.org/10.1038/29234			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	110MD	9716128				2022-12-28	WOS:000075384200033
J	St Louis, ME; Wasserheit, JN				St Louis, ME; Wasserheit, JN			Epidemiology - Elimination of syphilis in the United States	SCIENCE			English	Editorial Material									Ctr Dis Control & Prevent, Natl Ctr HIV STD & TB Prevent, Atlanta, GA 30333 USA	Centers for Disease Control & Prevention - USA	St Louis, ME (corresponding author), Ctr Dis Control & Prevent, Natl Ctr HIV STD & TB Prevent, Mailstop E-02, Atlanta, GA 30333 USA.	mes2@cdc.gov; jzw6@cdc.gov						Berkelman RL, 1996, JAMA-J AM MED ASSOC, V275, P315, DOI 10.1001/jama.275.4.315; DOWDLE WR, 1988, ERADICATION INFECT D; Fraser CM, 1998, SCIENCE, V281, P375, DOI 10.1126/science.281.5375.375; GORDON SM, 1994, NEW ENGL J MED, V331, P1469, DOI 10.1056/NEJM199412013312201; Hook EW, 1996, SEX TRANSM DIS, V23, P5, DOI 10.1097/00007435-199601000-00004; Institute of Medicine, 1997, HIDD EP CONFR SEX TR; Jones JH, 1981, BAD BLOOD TUSKEGEE S; PARRA T, 1937, SHADOW LAND; PILLAY A, IN PRESS SCIENCE; VALDISERRI RO, 1995, J COMMUN HEALTH, V20, P87, DOI 10.1007/BF02260331; Wortley PM, 1997, JAMA-J AM MED ASSOC, V278, P911, DOI 10.1001/jama.278.11.911	11	71	71	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 17	1998	281	5375					353	354		10.1126/science.281.5375.353	http://dx.doi.org/10.1126/science.281.5375.353			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	102HR	9705711				2022-12-28	WOS:000074918800028
J	Elwyn, G; Smail, SA; Edwards, AGK				Elwyn, G; Smail, SA; Edwards, AGK			Is general practice in need of a career structure?	BRITISH MEDICAL JOURNAL			English	Article									Univ Wales Coll Med, Dept Postgrad Educ Gen Practice, Cardiff CF4 4XN, S Glam, Wales; Univ Wales Coll Med, Dept Gen Practice, Cardiff CF4 4XN, S Glam, Wales	Cardiff University; Cardiff University	Elwyn, G (corresponding author), Univ Wales Coll Med, Dept Postgrad Educ Gen Practice, Cardiff CF4 4XN, S Glam, Wales.		Elwyn, Glyn/B-4798-2009; Elwyn, G./L-4292-2015	Elwyn, Glyn/0000-0002-0917-6286; 				Allen I., 1994, DOCTORS THEIR CAREER; Bain J, 1996, BRIT J GEN PRACT, V46, P328; BOSNOR R, 1998, BR J GEN PRACT, V48, P915; Carlisle R, 1996, BRIT MED J, V313, P468; *DEP HLTH, 1996, GUID SPEC REG TRAIN; Elwyn GJ, 1998, BMJ-BRIT MED J, V316, P1619, DOI 10.1136/bmj.316.7145.1619; HASLER J, 1997, VOCATIONAL TRAINING; *MED PRACT COMM, 1997, SURV GEN PRACT RECR; MURPHY A, 1995, ED GEN PRACTICE, V6, P19; *NAT ASS HLTH AUTH, 1994, PART LEARN DEV POSTG; PAICE E, 1997, BRIT MED J, V314, P710; Petchey R, 1997, FAM PRACT, V14, P194, DOI 10.1093/fampra/14.3.194; RHODES M, 1997, ED GEN PRACTICE, V8, P1; Savage R, 1997, ED GEN PRACTICE, V8, P280; SMAIL SA, 1996, PRESENT STATE FUTURE; STANTON F, 1997, EFFECTIVENESS CONTIN; Taylor DH, 1997, BRIT MED J, V314, P1806, DOI 10.1136/bmj.314.7097.1806; TEGNER H, 1997, ED GEN PRACTICE, V8, P95; WALL D, 1997, ED NEEDS GEN PRACTIT; [No title captured]	20	20	20	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	SEP 12	1998	317	7160					730	733		10.1136/bmj.317.7160.730	http://dx.doi.org/10.1136/bmj.317.7160.730			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	121CT	9732343	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000075995100024
J	Xu, XHN; Yeung, ES				Xu, XHN; Yeung, ES			Long-range electrostatic trapping of single-protein molecules at a liquid-solid interface	SCIENCE			English	Article							CONFOCAL FLUORESCENCE MICROSCOPY; ZONE ELECTROPHORESIS; INDIVIDUAL MOLECULES; ENZYME; FRAGMENTS; DIFFUSION; FLOW	The motion of single, dye-labeled protein molecules was monitored at various pH and ionic strengths within the 180-nanometer-thick evanescent-field layer at a fused-silica surface. Below the isoelectric point, molecules partitioning into the excitation region increased in number but maintained a random spatial distribution, implying that surface charge can influence the charged protein at. distances beyond that of the electrical double-layer thickness. The residence times of the molecules in the interfacial layer also increased below the isoelectric point. However, immobilization on the solid surface for extended periods was not observed. Histograms of residence times exhibit nearly identical asymmetry as the corresponding elution peaks in capillary electrophoresis. These results are a direct verification of the statistical theory of chromatography at the single-molecule level, with the caveat that Long-range trapping rather than adsorption is the dominant mechanism.	Iowa State Univ, US DOE, Ames Lab, Ames, IA 50011 USA; Iowa State Univ, Dept Chem, Ames, IA 50011 USA	Iowa State University; United States Department of Energy (DOE); Ames National Laboratory; Iowa State University	Yeung, ES (corresponding author), Iowa State Univ, US DOE, Ames Lab, Ames, IA 50011 USA.							BARD AJ, 1980, ELECTROCHEMICAL METH, P488; Behrens SH, 1998, LANGMUIR, V14, P1951, DOI 10.1021/la971237k; BOCKRIS JO, 1970, MODERN ELECTROCHEMIS, V2, P826; Craig DB, 1996, J AM CHEM SOC, V118, P5245, DOI 10.1021/ja9540839; Derjaguin B. V., 1941, ACTA PHYSICOCHIM URS, V14, P633, DOI DOI 10.1016/0079-6816(93)90013-L; Dickson RM, 1996, SCIENCE, V274, P966, DOI 10.1126/science.274.5289.966; EIGEN M, 1994, P NATL ACAD SCI USA, V91, P5740, DOI 10.1073/pnas.91.13.5740; FUNATSU T, 1995, NATURE, V374, P555, DOI 10.1038/374555a0; GUTIERREZ C, 1990, SPECTROSCOPIC DIFFRA, P1; Iki N, 1996, ANAL CHEM, V68, P4321, DOI 10.1021/ac9605814; LAMBERT WJ, 1990, ANAL CHEM, V62, P1585, DOI 10.1021/ac00214a009; Larsen AE, 1997, NATURE, V385, P230, DOI 10.1038/385230a0; LIPKOWSKI J, 1993, STRUCTURE ELECTRIFIE, P201; Lyon WA, 1997, ANAL CHEM, V69, P3400, DOI 10.1021/ac9700742; MARTIN M, 1984, ANAL CHEM, V56, P614, DOI 10.1021/ac00268a006; MIKKERS FEP, 1979, J CHROMATOGR, V169, P11, DOI 10.1016/0021-9673(75)85029-1; NIE SM, 1994, SCIENCE, V266, P1018, DOI 10.1126/science.7973650; NIE SM, 1995, ANAL CHEM, V67, P2849, DOI 10.1021/ac00113a019; PETTY JT, 1995, ANAL CHEM, V67, P1755, DOI 10.1021/ac00106a017; REIJENGA JC, 1983, J CHROMATOGR, V260, P241, DOI 10.1016/0021-9673(83)80034-X; RICE CL, 1965, J PHYS CHEM-US, V69, P4017, DOI 10.1021/j100895a062; ROERAADE J, 1996, 8 INT S HIGH PERF CA; Schmidt T, 1996, P NATL ACAD SCI USA, V93, P2926, DOI 10.1073/pnas.93.7.2926; Skoog D.A, 1992, PRINCIPLES INSTRUMEN, P579; STEVENS TS, 1983, ANAL CHEM, V55, P1365, DOI 10.1021/ac00259a040; Tan WH, 1997, ANAL CHEM, V69, P4242, DOI 10.1021/ac970631k; VERVWEY EJW, 1948, THEORY STABILITY LYO; Xu XH, 1997, SCIENCE, V275, P1106, DOI 10.1126/science.275.5303.1106; XUE QF, 1995, NATURE, V373, P681, DOI 10.1038/373681a0	29	158	172	2	59	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 11	1998	281	5383					1650	1653		10.1126/science.281.5383.1650	http://dx.doi.org/10.1126/science.281.5383.1650			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	118TR	9733506				2022-12-28	WOS:000075856500039
J	Khan, MA; Herzog, CA; St Peter, JV; Hartley, GG; Madlon-Kay, R; Dick, CD; Asinger, RW; Vessey, JT				Khan, MA; Herzog, CA; St Peter, JV; Hartley, GG; Madlon-Kay, R; Dick, CD; Asinger, RW; Vessey, JT			The prevalence of cardiac valvular insufficiency assessed by transthoracic echocardiography in obese patients treated with appetite-suppressant drugs	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							TERM WEIGHT CONTROL; FENFLURAMINE PLUS PHENTERMINE; CARCINOID HEART-DISEASE; DOPPLER-ECHOCARDIOGRAPHY; TRICUSPID REGURGITATION; BEHAVIOR-MODIFICATION; MITRAL REGURGITATION; AORTIC REGURGITATION; CALORIC RESTRICTION; OPEN-LABEL	Background. After case reports of cardiac-valve abnormalities related to the use of appetite suppressants were published, we undertook a study to determine the prevalence of the problem using transthoracic echocardiography. Methods. We examined patients who had taken dexfenfluramine alone, dexfenfluramine and phentermine, or fenfluramine and phentermine for various periods. We enrolled obese patients who had taken or were taking these agents during open-label trials from January 1994 through August 1997. We also recruited subjects who had not taken appetite suppressants and who were matched to the patients for sex, height, and pretreatment age and body-mass index. The presence of cardiac-valve abnormalities, defined by the Food and Drug Administration and Centers for Disease Control and Prevention as at least mild aortic-valve or moderate mitral-valve insufficiency, was determined independently by at least two cardiologists. Multivariate logistic-regression analysis was used to identify factors associated with cardiac-valve abnormalities. Results. Echocardiograms were available for 257 patients and 239 control subjects. The association between the use of any appetite suppressant and cardiac-valve abnormalities was analyzed in a final matched group of 233 pairs of patients and controls. A total of 1.3 percent of the controls (3 of 233) and 22.7 percent of the patients (53 of 233) met the case definition for cardiac-valve abnormalities (odds ratio, 22.6; 95 percent confidence interval, 7.1 to 114.2; P < 0.001). The odds ratio for such cardiac-valve abnormalities was 12.7 (95 percent confidence interval, 2.9 to 56.4) with the use of dexfenfluramine alone, 24.5 (5.9 to 102.2) with the use of dexfenfluramine and phentermine, and 26.3 (7.9 to 87.1) with the use of fenfluramine and phentermine. Conclusions. Obese patients who took fenfluramine and phentermine, dexfenfluramine alone, or dexfenfluramine and phentermine had a significantly higher prevalence of cardiac valvular insufficiency than a matched group of control subjects. (N Engl J Med 1998;339:713-8.) (C) 1998, Massachusetts Medical Society.	Hennepin Cty Med Ctr, Dept Med, Div Endocrinol, Minneapolis, MN 55415 USA; Hennepin Cty Med Ctr, Dept Med, Div Cardiol, Minneapolis, MN 55415 USA; Hennepin Cty Med Ctr, Dept Med, Div Internal Med, Minneapolis, MN 55415 USA; Hlth Syst Minnesota, Minneapolis, MN USA; Minnesota Heart Clin, Minneapolis, MN USA; Univ Minnesota, Sch Publ Hlth, Div Epidemiol, Minneapolis, MN 55455 USA; Minnesota Obes Ctr, Minneapolis, MN USA	Hennepin County Medical Center; Hennepin County Medical Center; Hennepin County Medical Center; University of Minnesota System; University of Minnesota Twin Cities	Khan, MA (corresponding author), Hennepin Cty Med Ctr, Dept Med, Div Endocrinol, 701 Pk Ave,865B, Minneapolis, MN 55415 USA.		StPeter, John/N-1140-2019	St. Peter, John/0000-0003-4359-7524	NIDDK NIH HHS [3P30-DK50456-03S1] Funding Source: Medline; SAMHSA HHS [MOA-5960] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK050456] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); SAMHSA HHS; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AKASAKA T, 1987, CIRCULATION, V76, P262, DOI 10.1161/01.CIR.76.2.262; BARGIGGIA GS, 1991, CIRCULATION, V84, P1481, DOI 10.1161/01.CIR.84.4.1481; BERGER M, 1985, J AM COLL CARDIOL, V6, P359, DOI 10.1016/S0735-1097(85)80172-8; Connolly HM, 1997, NEW ENGL J MED, V337, P581, DOI 10.1056/NEJM199708283370901; Connolly HM, 1997, NEW ENGL J MED, V337, P1783; CURRIE PJ, 1985, J AM COLL CARDIOL, V6, P750, DOI 10.1016/S0735-1097(85)80477-0; DOLAN MS, 1995, AM HEART J, V129, P1014, DOI 10.1016/0002-8703(95)90125-6; ENRIQUEZSARANO M, 1994, J AM COLL CARDIOL, V23, P443, DOI 10.1016/0735-1097(94)90432-4; GRAY GW, 1995, AVIAT SPACE ENVIR MD, V66, P32; HARTLEY GG, 1997, OBES RES S1, V5, pS58; KHAN MA, 1997, OBES RES S1, V5, pS22; Kushner R, 1997, ARCH INTERN MED, V157, P602, DOI 10.1001/archinte.157.6.602; PELLIKKA PA, 1993, CIRCULATION, V87, P1188, DOI 10.1161/01.CIR.87.4.1188; PERRY GJ, 1987, J AM COLL CARDIOL, V9, P952, DOI 10.1016/S0735-1097(87)80254-1; REID CL, 1994, CIRCULATION, V90, P282; ROBIOLIO PA, 1995, CIRCULATION, V92, P790, DOI 10.1161/01.CIR.92.4.790; STRYDOM AJC, 1992, CLIN CHEM, V38, P323; TRIBOUILLOY C, 1991, EUR HEART J, V12, P352, DOI 10.1093/oxfordjournals.eurheartj.a059901; *US DEP HHS, 1997, MMWR-MORBID MORTAL W, V46, P1061; WEINTRAUB M, 1992, CLIN PHARMACOL THER, V51, P615, DOI 10.1038/clpt.1992.73; WEINTRAUB M, 1992, CLIN PHARMACOL THER, V51, P581, DOI 10.1038/clpt.1992.68; WEINTRAUB M, 1992, CLIN PHARMACOL THER, V51, P586, DOI 10.1038/clpt.1992.69; WEINTRAUB M, 1992, CLIN PHARMACOL THER, V51, P642, DOI 10.1038/clpt.1992.76; WEINTRAUB M, 1992, CLIN PHARMACOL THER, V51, P608, DOI 10.1038/clpt.1992.72; WEINTRAUB M, 1992, CLIN PHARMACOL THER, V51, P634, DOI 10.1038/clpt.1992.75; WEINTRAUB M, 1992, CLIN PHARMACOL THER, V51, P619, DOI 10.1038/clpt.1992.74; WEINTRAUB M, 1992, CLIN PHARMACOL THER, V51, P595, DOI 10.1038/clpt.1992.70; WEINTRAUB M, 1992, CLIN PHARMACOL THER, V51, P602, DOI 10.1038/clpt.1992.71; YOCK PG, 1984, CIRCULATION, V70, P657, DOI 10.1161/01.CIR.70.4.657	29	189	189	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 10	1998	339	11					713	718		10.1056/NEJM199809103391101	http://dx.doi.org/10.1056/NEJM199809103391101			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	116RF	9731086				2022-12-28	WOS:000075737800001
J	Aronson, J				Aronson, J			When I use a word ... Grapes	BRITISH MEDICAL JOURNAL			English	Article																			0	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	SEP 5	1998	317	7159					688	688		10.1136/bmj.317.7159.688	http://dx.doi.org/10.1136/bmj.317.7159.688			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	118GN	9728018	Green Published			2022-12-28	WOS:000075830200078
J	Horowitz, HW				Horowitz, HW			Hey! I'm a teacher too	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 2	1998	280	9					765	765		10.1001/jama.280.9.765	http://dx.doi.org/10.1001/jama.280.9.765			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	114LA	9729985				2022-12-28	WOS:000075609900001
J	Kaufman, JS; Reda, DJ; Fye, CL; Goldfarb, DS; Henderson, WG; Kleinman, JG; Vaamonde, CA				Kaufman, JS; Reda, DJ; Fye, CL; Goldfarb, DS; Henderson, WG; Kleinman, JG; Vaamonde, CA		Dept Vet Affairs Cooperative Study Grp Erythrop	Subcutaneous compared with intravenous epoetin in patients receiving hemodialysis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RECOMBINANT-HUMAN-ERYTHROPOIETIN; STAGE RENAL-DISEASE; MAINTENANCE HEMODIALYSIS; ANEMIC PATIENTS; PHARMACOKINETICS; CROSSOVER; PAIN; PHARMACODYNAMICS; INJECTION; DIALYSIS	Background Several studies have suggested that if recombinant human erythropoietin (epoetin) is administered subcutaneously rather than intravenously, a lower dose may be sufficient to maintain the hematocrit at a given level. Methods In a randomized, unblinded trial conducted at 24 hemodialysis units at Veterans Affairs medical centers, we assigned 208 patients who were receiving long-term hemodialysis and epoetin therapy to treatment with either subcutaneous or intravenous epoetin. The dose was initially reduced until the hematocrit was below 30 percent and then was gradually increased to a level that would maintain the hematocrit in the range of 30 to 33 percent for 26 weeks. We compared the average doses in the 26-week maintenance phase and the discomfort associated with the two routes of administration. Results For the 107 patients treated by the subcutaneous route, the average weekly dose of epoetin during the maintenance phase was 32 percent less than that for the 101 patients treated by the intravenous route (mean [+/- SD], 95.1 +/- 75.0 vs. 140.3 +/- 88.5 U per kilogram of body weight per week; P<0.001). Only one patient in the subcutaneous-therapy group withdrew from the study because of pain at the injection site, and 86 percent rated the pain associated with subcutaneous administration as ranging from absent to mild. Conclusions In patients receiving hemodialysis, subcutaneous administration of epoetin can maintain the hematocrit in a desired target range, with an average weekly dose of epoetin that is lower than with intravenous administration. (N Engl J Med 1998; 339:578-83.) (C) 1998, Massachusetts Medical Society.	Boston Vet Affairs Med Ctr, Boston, MA 02130 USA; Boston Univ, Sch Med, Dept Med, Boston, MA 02118 USA; Vet Affairs Cooperat Studies Program, Coordinating Ctr, Hines, IL USA; Vet Affairs Cooperat Studies Program, Clin Res Pharm Coordinating Ctr, Albuquerque, NM USA; New York Vet Affairs Med Ctr, New York, NY USA; NYU, Sch Med, Dept Med, New York, NY USA; Milwaukee Vet Affairs Med Ctr, Milwaukee, WI USA; Med Coll Wisconsin, Dept Med, Milwaukee, WI 53226 USA; Miami Vet Affairs Med Ctr, Miami, FL USA; Univ Miami, Sch Med, Dept Med, Miami, FL USA	Boston University; New York University; Medical College of Wisconsin; University of Miami	Kaufman, JS (corresponding author), Boston Vet Affairs Med Ctr, 150 S Huntington Ave, Boston, MA 02130 USA.			, Domenic/0000-0003-1831-4270; Goldfarb, David/0000-0002-9215-1273				ALBITAR S, 1995, NEPHROL DIAL TRANSPL, V10, P40, DOI 10.1093/ndt/10.supp6.40; [Anonymous], 1997, Am J Kidney Dis, V30, pS192; BARCLAY PG, 1993, CLIN NEPHROL, V40, P277; BESARAB A, 1992, J AM SOC NEPHROL, V2, P1405; BROCKMOLLER J, 1992, BRIT J CLIN PHARMACO, V34, P499; CANAUD B, 1995, DIALYSIS TRANSPLANT, V24, P306; EIDEMAK I, 1992, NEPHROL DIAL TRANSPL, V7, P526; ESCHBACH JW, 1989, ANN INTERN MED, V111, P992, DOI 10.7326/0003-4819-111-12-992; FRENKEN LAM, 1991, BRIT MED J, V303, P288, DOI 10.1136/bmj.303.6797.288; GRANOLLERAS C, 1991, CLIN NEPHROL, V36, P294; HALSTENSON CE, 1991, CLIN PHARMACOL THER, V50, P702, DOI 10.1038/clpt.1991.210; Ifudu O, 1996, NEW ENGL J MED, V334, P420, DOI 10.1056/NEJM199602153340702; Jensen JD, 1996, EUR J CLIN PHARMACOL, V50, P171, DOI 10.1007/s002280050088; KOOISTRA MP, 1991, BRIT J HAEMATOL, V79, P634, DOI 10.1111/j.1365-2141.1991.tb08093.x; MACDOUGALL IC, 1989, BRIT MED J, V299, P157, DOI 10.1136/bmj.299.6692.157; MCMAHON FG, 1990, BLOOD, V76, P1718; MUIRHEAD N, 1992, AM J NEPHROL, V12, P303, DOI 10.1159/000168464; PAGANINI EP, 1995, AM J KIDNEY DIS, V26, P331, DOI 10.1016/0272-6386(95)90654-1; Parker KP, 1997, J AM SOC NEPHROL, V8, P288; RAO DS, 1993, NEW ENGL J MED, V328, P171, DOI 10.1056/NEJM199301213280304; SALMONSON T, 1990, BRIT J CLIN PHARMACO, V29, P709, DOI 10.1111/j.1365-2125.1990.tb03692.x; SCHALLER R, 1994, ARTIF ORGANS, V18, P552, DOI 10.1111/j.1525-1594.1994.tb03378.x; STEFFENSEN G, 1992, BLOOD PURIFICAT, V10, P241, DOI 10.1159/000170054; STOCKENHUBER F, 1991, NEPHRON, V59, P399, DOI 10.1159/000186598; TAYLOR JE, 1994, CLIN NEPHROL, V41, P297; TOMSON CRV, 1992, NEPHROL DIAL TRANSPL, V7, P129, DOI 10.1093/oxfordjournals.ndt.a092082; Valderrabano F, 1996, KIDNEY INT, V50, P1373, DOI 10.1038/ki.1996.452; VEYS N, 1992, AM J NEPHROL, V12, P68, DOI 10.1159/000168420; Virot JS, 1996, AM J KIDNEY DIS, V28, P400, DOI 10.1016/S0272-6386(96)90498-9; Woolson RF, 1987, STAT METHODS ANAL BI; ZEHNDER C, 1991, NEPHRON, V57, P485, DOI 10.1159/000186357	31	223	231	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 27	1998	339	9					578	583		10.1056/NEJM199808273390902	http://dx.doi.org/10.1056/NEJM199808273390902			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	113LR	9718376	Bronze			2022-12-28	WOS:000075552900002
J	Aronson, J				Aronson, J			The venereal game	BRITISH MEDICAL JOURNAL			English	Article																			0	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 22	1998	317	7157					535	535						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	115AM	9712610				2022-12-28	WOS:000075641400031
J	Shimm, DS				Shimm, DS			Chained smoker	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									Univ Arizona, Hlth Sci Ctr, Dept Radiat Oncol, Tucson, AZ 85724 USA	University of Arizona; University of Arizona Health Sciences	Shimm, DS (corresponding author), Univ Arizona, Hlth Sci Ctr, Dept Radiat Oncol, 1501 N Campbell Ave, Tucson, AZ 85724 USA.								0	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 15	1998	129	4					331	332		10.7326/0003-4819-129-4-199808150-00013	http://dx.doi.org/10.7326/0003-4819-129-4-199808150-00013			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	109NP	9729190				2022-12-28	WOS:000075329100012
J	Topham, MK; Bunting, M; Zimmerman, GA; McIntyre, TM; Blackshear, PJ; Prescott, SM				Topham, MK; Bunting, M; Zimmerman, GA; McIntyre, TM; Blackshear, PJ; Prescott, SM			Protein kinase C regulates the nuclear localization of diacylglycerol kinase-zeta	NATURE			English	Article							MOLECULAR-CLONING; SUBSTRATE MARCKS; CELL-CYCLE; MEMBRANE; FAMILY; PHOSPHORYLATION; EXPRESSION; LOCATION; ISOZYME; DOMAIN	Diacylglycerol kinases (DGKs) terminate signalling from diacylglycerol by converting it to phosphatidic acid(1-8) Diacylglycerol regulates cell growth and differentiation, and its transient accumulation in the nucleus may be particularly important in this regulation(9,10) Here we show that a fraction of DGK-zeta is found in the nucleus, where it regulates the amount of nuclear diacylglycerol. Reducing nuclear diacylglycerol levels by conditional expression of DGK-zeta attenuates cell growth. The nuclear-localization signal of DGK-zeta is located in a region that is homologous to the phosphorylation-site domain of the MARCKS protein. This is, to our knowledge, the first evidence that this domain, which is a major target for protein kinase C, can localize a protein to the nucleus. Two isoforms of protein kinase C, but not others, regulate the localization of DGK-zeta. Our results define a cycle in which diacylglycerol activates protein kinase C, which then regulates the metabolism of diacylglycerol by alternating the intracellular location of DGK-zeta. This maybe a general mechanism to control mitogenic signals that depend on nuclear diacylglycerol.	Univ Utah, Huntman Canc Inst, Salt Lake City, UT 84112 USA; Univ Utah, Eccles Program Human Mol Biol & Genet, Salt Lake City, UT 84112 USA; Univ Utah, Dept Internal Med, Salt Lake City, UT 84112 USA; Natl Inst Environm Hlth, Res Triangle Pk, NC 27709 USA	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Prescott, SM (corresponding author), Univ Utah, Huntman Canc Inst, Salt Lake City, UT 84112 USA.		Blackshear, Perry J./C-6206-2019	Blackshear, Perry J./0000-0002-9561-8529				ADEREM A, 1992, CELL, V71, P713, DOI 10.1016/0092-8674(92)90546-O; BANFIC H, 1993, BIOCHEM J, V290, P633, DOI 10.1042/bj2900633; BLACKSHEAR PJ, 1993, J BIOL CHEM, V268, P1501; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Bunting M, 1996, J BIOL CHEM, V271, P10230, DOI 10.1074/jbc.271.17.10230; Ding L, 1997, P NATL ACAD SCI USA, V94, P5519, DOI 10.1073/pnas.94.11.5519; DIVECHA N, 1993, BIOCHEM J, V289, P617, DOI 10.1042/bj2890617; DIVECHA N, 1991, EMBO J, V10, P3207, DOI 10.1002/j.1460-2075.1991.tb04883.x; DIVECHA N, 1993, CELL, V74, P405, DOI 10.1016/0092-8674(93)80041-C; GOTO K, 1993, P NATL ACAD SCI USA, V90, P7598, DOI 10.1073/pnas.90.16.7598; GRAFF JM, 1991, J BIOL CHEM, V266, P14390; HALSEY DL, 1987, J BIOL CHEM, V262, P2234; HERGET T, 1995, EUR J BIOCHEM, V233, P448, DOI 10.1111/j.1432-1033.1995.448_2.x; Houssa B, 1997, J BIOL CHEM, V272, P10422; Jackowski S, 1996, J BIOL CHEM, V271, P20219, DOI 10.1074/jbc.271.34.20219; KAI M, 1994, J BIOL CHEM, V269, P18492; KLAUCK TM, 1996, J BIOL CHEM, V271, P19871; LEACH KL, 1992, J BIOL CHEM, V267, P21816; OLSON EN, 1993, CELL GROWTH DIFFER, V4, P699; PAYRASTRE B, 1992, J BIOL CHEM, V267, P5078; SAKANE F, 1990, NATURE, V344, P345, DOI 10.1038/344345a0; Sakane F, 1996, J BIOL CHEM, V271, P8394, DOI 10.1074/jbc.271.14.8394; Sun B, 1997, J BIOL CHEM, V272, P26313, DOI 10.1074/jbc.272.42.26313; Swierczynski SL, 1996, J BIOL CHEM, V271, P23424, DOI 10.1074/jbc.271.38.23424; Tang W, 1996, J BIOL CHEM, V271, P10237, DOI 10.1074/jbc.271.17.10237; VERGHESE GM, 1994, J BIOL CHEM, V269, P9361; WHATLEY RE, 1993, J BIOL CHEM, V268, P16130; XIAO HG, 1994, J NEUROSURG, V81, P734, DOI 10.3171/jns.1994.81.5.0734; YORK JD, 1994, J BIOL CHEM, V269, P7847	29	245	250	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 13	1998	394	6694					697	700		10.1038/29337	http://dx.doi.org/10.1038/29337			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	110MD	9716136				2022-12-28	WOS:000075384200049
J	Garbe, E; Suissa, S; LeLorier, J				Garbe, E; Suissa, S; LeLorier, J			Association of inhaled corticosteroid use with cataract extraction in elderly patients	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							POSTERIOR SUBCAPSULAR CATARACTS; ASPIRIN-LIKE ANALGESICS; AGE-RELATED CATARACTS; RISK-FACTORS; STEROID AEROSOLS; ASTHMA; THERAPY; BECLOMETHASONE; GLUCOCORTICOIDS; EPIDEMIOLOGY	Context.-The use of systemic corticosteroids is a known risk factor for the development of cataracts. Objective.-To determine whether treatment with inhaled corticosteroids is associated with cataract extraction in the elderly. Design.-Case-control study. Setting.-Quebec universal health insurance program for all elderly (provincial health insurance plan database [RAMQ database]). Patients.-RAMQ enrollees 70 years and older. The 3677 cases were patients with a cataract extraction between 1992 and 1994. The 21 868 controls were randomly selected from patients who did not have a diagnosis of cataract and matched to cases on the index date of the case. Main Outcome Measures.-Odds ratio of cataract extraction in patients with prolonged cumulative exposure to inhaled corticosteroids compared with nonusers. Results.-Excluding patients with systemic steroid treatment and after adjusting for age, sex, diabetes, systemic hypertension, glaucoma, ophthalmic steroids, and the number of physician claims for services, use of inhaled corticosteroids for more than 3 years was associated with undergoing cataract extraction (odds ratio [OR], 3.06; 95% confidence interval [CI], 1.53-6.13). For high average daily doses of beclomethasone or budesonide (>1 mg), the OR was elevated after more than 2 years of treatment (OR, 3.40; 95% CI, 1.49-7.76), whereas for low to medium doses (less than or equal to 1 mg) of these drugs, the OR was 1.63 (95% CI, 0.85-3.13) after 2 years. Conclusion.-Prolonged administration of high doses of inhaled corticosteroids increases the likelihood of undergoing cataract extraction in elderly patients. Further studies are needed to investigate the risk of developing cataracts for low to medium doses over longer periods.	Potsdam Inst Pharmacoepidemiol & Technol Assessme, D-14482 Potsdam, Germany; Royal Victoria Hosp, Div Clin Epidemiol, Montreal, PQ H3A 1A1, Canada; McGill Univ, Dept Epidemiol & Biostat, Montreal, PQ, Canada; Univ Montreal, Hotel Dieu, Ctr Rech, Montreal, PQ, Canada	McGill University; Royal Victoria Hospital; McGill University; Laval University; Universite de Montreal	Garbe, E (corresponding author), Potsdam Inst Pharmacoepidemiol & Technol Assessme, Otto Erich Str 7, D-14482 Potsdam, Germany.	106700.3205@compuserve.com						ABUEKTEISH F, 1995, THORAX, V50, P674, DOI 10.1136/thx.50.6.674; ALLEN MB, 1989, BRIT MED J, V299, P432, DOI 10.1136/bmj.299.6696.432; [Anonymous], 1990, BRIT MED J, V301, P651; [Anonymous], 1993, BRIT MED J, V306, P776; BARNES NC, 1993, RESP MED, V87, P27, DOI 10.1016/S0954-6111(05)80254-9; BARNES PJ, 1995, NEW ENGL J MED, V332, P868, DOI 10.1056/NEJM199503303321307; BLACK RL, 1960, JAMA-J AM MED ASSOC, V174, P166, DOI 10.1001/jama.1960.63030020005014; BOCHOW TW, 1989, ARCH OPHTHALMOL-CHIC, V107, P369, DOI 10.1001/archopht.1989.01070010379027; Bonomi L, 1989, Dev Ophthalmol, V17, P196; Cumming RG, 1997, NEW ENGL J MED, V337, P1555; Cumming RG, 1997, NEW ENGL J MED, V337, P8, DOI 10.1056/NEJM199707033370102; DOLEZAL JM, 1989, AM J EPIDEMIOL, V129, P559, DOI 10.1093/oxfordjournals.aje.a115168; FORERO R, 1992, J ADOLESCENT HEALTH, V13, P707, DOI 10.1016/1054-139X(92)90068-M; FRAUNFELDER FT, 1990, AM J OPHTHALMOL, V109, P489, DOI 10.1016/S0002-9394(14)74627-6; Garbe E, 1997, NEW ENGL J MED, V337, P1555; HANANIA NA, 1995, AM J MED, V98, P196, DOI 10.1016/S0002-9343(99)80404-5; HARDING JJ, 1993, BRIT J OPHTHALMOL, V77, P2, DOI 10.1136/bjo.77.1.2; HARDING JJ, 1988, BRIT J OPHTHALMOL, V72, P809, DOI 10.1136/bjo.72.11.809; Hodge WG, 1995, EPIDEMIOL REV, V17, P336, DOI 10.1093/oxfordjournals.epirev.a036197; ISAAC NE, 1991, ARCH OPHTHALMOL-CHIC, V109, P256, DOI 10.1001/archopht.1991.01080020102053; JICK H, 1984, AM J OPHTHALMOL, V98, P355, DOI 10.1016/0002-9394(84)90328-3; KARIM AKA, 1989, BRIT MED J, V299, P918, DOI 10.1136/bmj.299.6704.918; KEWLEY GD, 1980, AUST PAEDIATR J, V16, P117; KLEIN BEK, 1995, AM J OPHTHALMOL, V119, P640, DOI 10.1016/S0002-9394(14)70223-5; KLEINBAUM DG, 1982, EPIDEMIOLOGIC RES; LESKE MC, 1983, AM J EPIDEMIOL, V118, P152, DOI 10.1093/oxfordjournals.aje.a113625; Livingston P M, 1995, Ophthalmic Epidemiol, V2, P151, DOI 10.3109/09286589509057097; MOHAN M, 1989, ARCH OPHTHALMOL-CHIC, V107, P670, DOI 10.1001/archopht.1989.01070010688028; MUNOZ B, 1993, ARCH OPHTHALMOL-CHIC, V111, P110, DOI 10.1001/archopht.1993.01090010114036; NASSIF E, 1987, J ALLERGY CLIN IMMUN, V80, P518, DOI 10.1016/0091-6749(87)90002-9; REED CE, 1990, AM REV RESPIR DIS, V141, pS82; RENFRO L, 1992, DERMATOL CLIN, V10, P505; *SAS I INC, 1992, P229 SAS I INC, P435; SIMONS FER, 1993, LANCET, V342, P776, DOI 10.1016/0140-6736(93)91541-S; TAMBLYN R, 1995, J CLIN EPIDEMIOL, V48, P999, DOI 10.1016/0895-4356(94)00234-H; TINKELMAN DG, 1993, PEDIATRICS, V92, P64; TOOGOOD JH, 1993, J ALLERGY CLIN IMMUN, V91, P571, DOI 10.1016/0091-6749(93)90263-F; TROISI RJ, 1995, CHEST, V108, P1557, DOI 10.1378/chest.108.6.1557; URBAN RC, 1986, SURV OPHTHALMOL, V31, P102, DOI 10.1016/0039-6257(86)90077-9; VANHEYNINGEN R, 1986, LANCET, V1, P1111; WALKER A M, 1988, Journal of Clinical Research and Drug Development, V2, P227; WEST SK, 1995, SURV OPHTHALMOL, V39, P323; World Health Organization, 1977, INT CLASS DIS 9 REVI	43	144	148	0	9	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 12	1998	280	6					539	543		10.1001/jama.280.6.539	http://dx.doi.org/10.1001/jama.280.6.539			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	108AY	9707144				2022-12-28	WOS:000075244900030
J	Rundall, P				Rundall, P			How much research in infant feeding comes from unethical marketing?	BRITISH MEDICAL JOURNAL			English	Article									Baby Milk Act, Cambridge CB2 3AX, England		Rundall, P (corresponding author), Baby Milk Act, 23 St Andrews, Cambridge CB2 3AX, England.							Mehdi T, 1998, FEEDING FIASCO PUSHI; SOKOL E, 1998, BREAKING RULES STRET; Taylor A, 1998, BMJ-BRIT MED J, V316, P1117, DOI 10.1136/bmj.316.7138.1117	3	7	7	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 1	1998	317	7154					338	339						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	110YQ	9729081				2022-12-28	WOS:000075409500035
J	Ronaghi, M; Uhlen, M; Nyren, P				Ronaghi, M; Uhlen, M; Nyren, P			A sequencing method based on real-time pyrophosphate	SCIENCE			English	Article							DNA		Royal Inst Technol, Dept Biochem & Biotechnol, SE-10044 Stockholm, Sweden	Royal Institute of Technology	Nyren, P (corresponding author), Royal Inst Technol, Dept Biochem & Biotechnol, SE-10044 Stockholm, Sweden.		Uhlen, Mathias/AAV-8746-2021; Uhlen, Mathias/B-3262-2016	Uhlen, Mathias/0000-0002-4858-8056				Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; DOREMUS HD, 1988, PLANT PHYSIOL, V87, P36, DOI 10.1104/pp.87.1.36; DRMANAC R, 1989, GENOMICS, V4, P114; EKSTROM B, UNPUB; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; FRASER CM, 1995, SCIENCE, V270, P397, DOI 10.1126/science.270.5235.397; HOLMBERG A, UNPUB; HULTMAN T, 1989, NUCLEIC ACIDS RES, V17, P4937, DOI 10.1093/nar/17.13.4937; HYMAN ED, 1988, ANAL BIOCHEM, V174, P423, DOI 10.1016/0003-2697(88)90041-3; Jones DH, 1997, BIOTECHNIQUES, V22, P938, DOI 10.2144/97225rr01; Koster H, 1996, NAT BIOTECHNOL, V14, P1123, DOI 10.1038/nbt0996-1123; METZKER ML, 1994, NUCLEIC ACIDS RES, V22, P4259, DOI 10.1093/nar/22.20.4259; Mewes HW, 1997, NATURE, V387, P7, DOI 10.1038/387s007; NYREN P, 1985, ANAL BIOCHEM, V151, P504, DOI 10.1016/0003-2697(85)90211-8; Ronaghi M, 1996, ANAL BIOCHEM, V242, P84, DOI 10.1006/abio.1996.0432; ROSENTHAL A, 1989, Patent No. 761107; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Tomb JF, 1997, NATURE, V388, P539, DOI 10.1038/41483; VELCULESCU VE, 1995, SCIENCE, V270, P484, DOI 10.1126/science.270.5235.484	19	1102	1637	10	182	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 17	1998	281	5375					363	+		10.1126/science.281.5375.363	http://dx.doi.org/10.1126/science.281.5375.363			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	102HR	9705713				2022-12-28	WOS:000074918800035
J	Farrell, L				Farrell, L			The value of life	BRITISH MEDICAL JOURNAL			English	Editorial Material																		Joyce James, ULYSSES	1	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	SEP 12	1998	317	7160					756	756		10.1136/bmj.317.7160.756	http://dx.doi.org/10.1136/bmj.317.7160.756			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	121CT	9732358	Green Published			2022-12-28	WOS:000075995100061
J	Albota, M; Beljonne, D; Bredas, JL; Ehrlich, JE; Fu, JY; Heikal, AA; Hess, SE; Kogej, T; Levin, MD; Marder, SR; McCord-Maughon, D; Perry, JW; Rockel, H; Rumi, M; Subramaniam, C; Webb, WW; Wu, XL; Xu, C				Albota, M; Beljonne, D; Bredas, JL; Ehrlich, JE; Fu, JY; Heikal, AA; Hess, SE; Kogej, T; Levin, MD; Marder, SR; McCord-Maughon, D; Perry, JW; Rockel, H; Rumi, M; Subramaniam, C; Webb, WW; Wu, XL; Xu, C			Design of organic molecules with large two-photon absorption cross sections	SCIENCE			English	Article							2-PHOTON; MICROSCOPY; EXCITATION; SPECTROSCOPY; NM	A strategy for the design of molecules with Large two-photon absorption cross sections, delta, was developed, on the basis of the concept that symmetric charge transfer, from the ends of a conjugated system to the middle, or vice versa, upon excitation is correlated to enhanced values of delta. Synthesized bis(styryl)benzene derivatives with donor-pi-donor, donor-acceptor-donor, and acceptor-donor-acceptor structural motifs exhibit exceptionally Large values of delta, up to about 400 times that of trans-stilbene. Quantum chemical calculations performed on these molecules indicate that substantial symmetric charge redistribution occurs upon excitation and provide delta values in good agreement with experimental values. The combination of Large delta and high fluorescence quantum yield or triplet yield exhibited by molecules developed here offers potential for unprecedented brightness in two-photon fluorescent imaging or enhanced photosensitivity in two-photon sensitization, respectively.	Univ Mons, Ctr Res Mol Elect & Photon, B-7000 Mons, Belgium; Cornell Univ, Sch Appl & Engn Phys, Ithaca, NY 14853 USA; CALTECH, Jet Prop Lab, Pasadena, CA 91109 USA; CALTECH, Beckman Inst, Mol Mat Resource Ctr, Pasadena, CA 91125 USA; Univ Arizona, Dept Chem, Tucson, AZ 85721 USA; Penn State Univ, Dept Chem, Hazleton, PA 18201 USA	University of Mons; Cornell University; California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL); California Institute of Technology; University of Arizona; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University	Bredas, JL (corresponding author), Univ Mons, Ctr Res Mol Elect & Photon, Pl Parc 20, B-7000 Mons, Belgium.		Webb, Watt W./B-5905-2011; Bredas, Jean-Luc E/A-3431-2008; Rumi, Mariacristina/C-9474-2009; Marder, Seth/GRR-9990-2022; Perry, Joseph W/B-7191-2011; Xu, Chris/F-2703-2010	Bredas, Jean-Luc E/0000-0001-7278-4471; Rumi, Mariacristina/0000-0002-4597-9617; Perry, Joseph W/0000-0003-1101-7337; Xu, Chris/0000-0002-3493-6427				ANDERSON RJM, 1979, J CHEM PHYS, V70, P4310, DOI 10.1063/1.438005; BIRGE RR, 1986, ACCOUNTS CHEM RES, V19, P138, DOI 10.1021/ar00125a003; BUENKER RJ, 1974, THEOR CHIM ACTA, V35, P33, DOI 10.1007/BF02394557; CUMPSTON BH, UNPUB; DENK W, 1994, P NATL ACAD SCI USA, V91, P6629, DOI 10.1073/pnas.91.14.6629; DENK W, 1990, SCIENCE, V248, P73, DOI 10.1126/science.2321027; Denk W, 1997, NEURON, V18, P351, DOI 10.1016/S0896-6273(00)81237-4; DEWAR MJS, 1985, J AM CHEM SOC, V107, P3902, DOI 10.1021/ja00299a024; DICK B, 1987, NONLINEAR OPTICAL PR, V2, P167; Ehrlich JE, 1997, OPT LETT, V22, P1843, DOI 10.1364/OL.22.001843; KENNEDY SM, 1986, ANAL CHEM, V58, P2643, DOI 10.1021/ac00126a014; Kohler RH, 1997, SCIENCE, V276, P2039, DOI 10.1126/science.276.5321.2039; LIPSON M, UNPUB; ORR BJ, 1971, MOL PHYS, V20, P513, DOI 10.1080/00268977100100481; PARTHENOPOULOS DA, 1989, SCIENCE, V245, P843, DOI 10.1126/science.245.4920.843; RIDLEY J, 1973, THEOR CHIM ACTA, V32, P111, DOI 10.1007/BF00528484; SAID AA, 1994, CHEM PHYS LETT, V228, P646, DOI 10.1016/0009-2614(94)00999-6; WILLIAMS RM, 1994, FASEB J, V8, P804, DOI 10.1096/fasebj.8.11.8070629; Xu C, 1996, P NATL ACAD SCI USA, V93, P10763, DOI 10.1073/pnas.93.20.10763; Xu C, 1996, J OPT SOC AM B, V13, P481, DOI 10.1364/JOSAB.13.000481	20	2099	2173	17	763	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 11	1998	281	5383					1653	1656		10.1126/science.281.5383.1653	http://dx.doi.org/10.1126/science.281.5383.1653			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Index Chemicus (IC)	Science & Technology - Other Topics	118TR	9733507				2022-12-28	WOS:000075856500040
J	Kaushansky, K				Kaushansky, K			Thrombopoietin	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							HUMAN MEGAKARYOCYTE GROWTH; C-MPL LIGAND; STEM-CELL FACTOR; BONE-MARROW TRANSPLANTATION; COLONY-STIMULATING FACTOR; CHEMOTHERAPY-INDUCED THROMBOCYTOPENIA; RECOMBINANT HUMAN THROMBOPOIETIN; PLATELET PRODUCTION; IN-VITRO; NONHUMAN-PRIMATES		Univ Washington, Div Hematol, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Kaushansky, K (corresponding author), Univ Washington, Div Hematol, Box 357710, Seattle, WA 98195 USA.							Akahori H, 1996, BRIT J HAEMATOL, V94, P722, DOI 10.1046/j.1365-2141.1996.d01-1842.x; Alexander WS, 1996, BLOOD, V87, P2162, DOI 10.1182/blood.V87.6.2162.bloodjournal8762162; BARTLEY TD, 1994, CELL, V77, P1117, DOI 10.1016/0092-8674(94)90450-2; Basser RL, 1996, LANCET, V348, P1279, DOI 10.1016/S0140-6736(96)04471-6; Basser RL, 1997, BLOOD, V89, P3118; BASSER RL, 1997, BLOOD, V90, P2513; Beveridge R., 1997, Blood, V90, p580A; BODINE DM, 1993, BLOOD, V82, P445; Bolwell B., 1997, Blood, V90, p171A; BRIDDELL RA, 1991, BLOOD, V78, P2854; BROUDY VC, 1995, BLOOD, V85, P1719, DOI 10.1182/blood.V85.7.1719.bloodjournal8571719; CHEN JC, 1995, BLOOD, V86, P4054, DOI 10.1182/blood.V86.11.4054.bloodjournal86114054; CHOI ES, 1995, BLOOD, V85, P402; Collins Mark, 1997, Blood, V90, p172A; Cramer EM, 1997, BLOOD, V89, P2336, DOI 10.1182/blood.V89.7.2336; Cwirla SE, 1997, SCIENCE, V276, P1696, DOI 10.1126/science.276.5319.1696; DEBILI N, 1993, BLOOD, V82, P84, DOI 10.1182/blood.V82.1.84.bloodjournal82184; DESAUVAGE FJ, 1994, NATURE, V369, P533, DOI 10.1038/369533a0; deSauvage FJ, 1996, J EXP MED, V183, P651, DOI 10.1084/jem.183.2.651; Du XX, 1997, BLOOD, V89, P3897, DOI 10.1182/blood.V89.11.3897; EBBE S, 1973, BLOOD, V42, P865, DOI 10.1182/blood.V42.6.865.865; Fanucchi M, 1997, NEW ENGL J MED, V336, P404, DOI 10.1056/NEJM199702063360603; FIBBE WE, 1995, BLOOD, V86, P3308, DOI 10.1182/blood.V86.9.3308.bloodjournal8693308; Fielder PJ, 1996, BLOOD, V87, P2154, DOI 10.1182/blood.V87.6.2154.bloodjournal8762154; Geissler K., 1997, Blood, V90, p98A; Glaspy J., 1997, Blood, V90, p580A; GORDON MS, 1992, BLOOD, V80, P302; Grossmann A, 1996, BLOOD, V88, P3363, DOI 10.1182/blood.V88.9.3363.bloodjournal8893363; Grossmann A, 1996, EXP HEMATOL, V24, P1238; GURNEY AL, 1994, SCIENCE, V265, P1445, DOI 10.1126/science.8073287; Harker LA, 1996, BLOOD, V88, P511, DOI 10.1182/blood.V88.2.511.bloodjournal882511; Harker LA, 1996, BLOOD, V87, P1833, DOI 10.1182/blood.V87.5.1833.bloodjournal8751833; Harker LA, 1997, BLOOD, V89, P155, DOI 10.1182/blood.V89.1.155.155_155_165; HEDDLE NM, 1994, NEW ENGL J MED, V331, P625, DOI 10.1056/NEJM199409083311001; HILL RJ, 1989, BLOOD CELLS, V15, P141; HOKOM MM, 1995, BLOOD, V86, P4486, DOI 10.1182/blood.V86.12.4486.bloodjournal86124486; Kabaya K, 1996, BONE MARROW TRANSPL, V18, P1035; Kabaya K, 1997, BONE MARROW TRANSPL, V20, P619, DOI 10.1038/sj.bmt.1700840; Kaushansky K, 1997, ANNU REV MED, V48, P1; KAUSHANSKY K, 1994, NATURE, V369, P568, DOI 10.1038/369568a0; Kaushansky K, 1996, HEMATOL ONCOL CLIN N, V10, P431, DOI 10.1016/S0889-8588(05)70346-4; KAUSHANSKY K, 1995, J CLIN INVEST, V96, P1683, DOI 10.1172/JCI118210; Kaushansky K, 1996, EXP HEMATOL, V24, P265; KELEMEN E., 1958, ACTA HAEMATOL, V20, P350; Ku H, 1996, BLOOD, V87, P4544, DOI 10.1182/blood.V87.11.4544.bloodjournal87114544; Kuter D., 1997, Blood, V90, p579A; KUTER DJ, 1995, BLOOD, V85, P2720, DOI 10.1182/blood.V85.10.2720.bloodjournal85102720; LEARY AG, 1992, P NATL ACAD SCI USA, V89, P4013, DOI 10.1073/pnas.89.9.4013; LOK S, 1994, NATURE, V369, P565, DOI 10.1038/369565a0; MCCARTY JM, 1995, BLOOD, V86, P3668, DOI 10.1182/blood.V86.10.3668.bloodjournal86103668; METCALF D, 1994, NATURE, V369, P519, DOI 10.1038/369519a0; METCALF D, 1993, BLOOD, V82, P3515; Molineux G, 1996, BLOOD, V88, P1509, DOI 10.1182/blood.V88.4.1509.bloodjournal8841509; Molineux G, 1996, BLOOD, V88, P366; MUTA K, 1994, J CLIN INVEST, V94, P34, DOI 10.1172/JCI117327; Nash R., 1997, Blood, V90, p262A; Neelis KJ, 1997, BLOOD, V90, P58; Neelis KJ, 1997, EXP HEMATOL, V25, P1094; NICHOL JL, 1995, J CLIN INVEST, V95, P2973, DOI 10.1172/JCI118005; OMalley CJ, 1996, BLOOD, V88, P3288, DOI 10.1182/blood.V88.9.3288.bloodjournal8893288; ORLIC D, 1994, BLOOD, V84, P3991, DOI 10.1182/blood.V84.12.3991.bloodjournal84123991; Osler William, 1892, PRINCIPLES PRACTICE, P320; Shibuya K, 1998, BLOOD, V91, P37, DOI 10.1182/blood.V91.1.37.37_37_45; Sitnicka E, 1996, BLOOD, V87, P4998, DOI 10.1182/blood.V87.12.4998.bloodjournal87124998; SNIECINSKI I, 1988, BLOOD, V71, P1402; SOHMA Y, 1994, FEBS LETT, V353, P57, DOI 10.1016/0014-5793(94)01008-0; Tepler I, 1996, BLOOD, V87, P3607; TERAMURA M, 1992, BLOOD, V79, P327; Turzanski J, 1997, BRIT J HAEMATOL, V96, P46, DOI 10.1046/j.1365-2141.1997.d01-2000.x; Ulich TR, 1996, BLOOD, V87, P5006, DOI 10.1182/blood.V87.12.5006.bloodjournal87125006; Vadhan-Raj S., 1997, Blood, V90, p580A; VadhanRaj S, 1997, ANN INTERN MED, V126, P673, DOI 10.7326/0003-4819-126-9-199705010-00001; VIGON I, 1992, P NATL ACAD SCI USA, V89, P5640, DOI 10.1073/pnas.89.12.5640; WALLACE EL, 1995, TRANSFUSION, V35, P802, DOI 10.1046/j.1537-2995.1995.351096026360.x; WILLIAMS N, 1982, J CELL PHYSIOL, V110, P101, DOI 10.1002/jcp.1041100116	75	291	320	0	12	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 10	1998	339	11					746	754		10.1056/NEJM199809103391107	http://dx.doi.org/10.1056/NEJM199809103391107			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	116RF	9731092				2022-12-28	WOS:000075737800007
J	He, TC; Sparks, AB; Rago, C; Hermeking, H; Zawel, L; da Costa, LT; Morin, PJ; Vogelstein, B; Kinzler, KW				He, TC; Sparks, AB; Rago, C; Hermeking, H; Zawel, L; da Costa, LT; Morin, PJ; Vogelstein, B; Kinzler, KW			Identification of c-MYC as a target of the APC pathway	SCIENCE			English	Article							TUMOR-SUPPRESSOR PROTEIN; HUMAN-COLON-CARCINOMA; LEUKEMIA-CELL-LINE; BETA-CATENIN; COLORECTAL-CANCER; TRANSCRIPTION FACTOR; BURKITT-LYMPHOMA; GENE-EXPRESSION; ONC GENE; AMPLIFICATION	The adenomatous polyposis coil gene (APC) is a tumor suppressor gene that is inactivated in most colorectal cancers. Mutations of APC cause aberrant accumulation of beta-catenin, which then binds T cell factor-4 (Tcf-4), causing increased transcriptional activation of unknown genes. Here, the c-MYC oncogene is identified as a target gene in this signaling pathway. Expression of c-MYC was shown to be repressed by wild-type APC and activated by beta-catenin, and these effects were mediated through Tcf-4 binding sites in the c-MYC promoter. These results provide a molecular framework for understanding the previously enigmatic overexpression of c-MYC in colorectal cancers.	Johns Hopkins Oncol Ctr, Baltimore, MD 21231 USA; Howard Hughes Med Inst, Baltimore, MD 21231 USA; Johns Hopkins Univ, Sch Med, Program Human Genet, Baltimore, MD 21205 USA; NIA, Baltimore, MD 21224 USA	Johns Hopkins University; Johns Hopkins Medicine; Howard Hughes Medical Institute; Johns Hopkins University; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	Kinzler, KW (corresponding author), Johns Hopkins Oncol Ctr, 424 N Bond St, Baltimore, MD 21231 USA.				NCI NIH HHS [CA62924, CA57345] Funding Source: Medline; NIGMS NIH HHS [GM07309] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA062924, R01CA057345, R37CA057345] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alevizopoulos K, 1997, EMBO J, V16, P5322, DOI 10.1093/emboj/16.17.5322; Amati B, 1998, FRONT BIOSCI, V3, pd250, DOI [10.2741/a239, DOI 10.2741/A239]; BRODEUR GM, 1998, GENETIC BASIS HUMAN, V1, P161; COLLINS S, 1982, NATURE, V298, P679, DOI 10.1038/298679a0; DALLAFAVERA R, 1982, P NATL ACAD SCI-BIOL, V79, P7824, DOI 10.1073/pnas.79.24.7824; DALLAFAVERA R, 1982, NATURE, V299, P61; ERISMAN MD, 1988, ONCOGENE, V2, P367; ERISMAN MD, 1985, MOL CELL BIOL, V5, P1969, DOI 10.1128/MCB.5.8.1969; FINLEY GG, 1989, ONCOGENE, V4, P963; GIESE K, 1991, GENE DEV, V5, P2567, DOI 10.1101/gad.5.12b.2567; GOYETTE MC, 1992, MOL CELL BIOL, V12, P1387, DOI 10.1128/MCB.12.3.1387; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; IMASEKI H, 1989, CANCER, V64, P704, DOI 10.1002/1097-0142(19890801)64:3<704::AID-CNCR2820640323>3.0.CO;2-S; JEN J, 1994, CANCER RES, V54, P6353; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KATO GJ, 1992, FASEB J, V6, P3065, DOI 10.1096/fasebj.6.12.1521738; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Korinek V, 1998, NAT GENET, V19, P379, DOI 10.1038/1270; LEDER P, 1983, SCIENCE, V222, P765, DOI 10.1126/science.6356357; LITTLE CD, 1983, NATURE, V306, P194, DOI 10.1038/306194a0; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; Morin PJ, 1996, P NATL ACAD SCI USA, V93, P7950, DOI 10.1073/pnas.93.15.7950; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; MUNEMITSU S, 1995, P NATL ACAD SCI USA, V92, P3046, DOI 10.1073/pnas.92.7.3046; Ohhara M, 1996, BIOCHEM BIOPH RES CO, V226, P791, DOI 10.1006/bbrc.1996.1430; RODRIGUEZALFAGEME C, 1992, P NATL ACAD SCI USA, V89, P1482, DOI 10.1073/pnas.89.4.1482; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; Sellers WR, 1997, J CLIN ONCOL, V15, P3301, DOI 10.1200/JCO.1997.15.11.3301; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SIKORA K, 1987, CANCER-AM CANCER SOC, V59, P1289, DOI 10.1002/1097-0142(19870401)59:7<1289::AID-CNCR2820590710>3.0.CO;2-O; SMITH DR, 1993, BRIT J CANCER, V68, P407, DOI 10.1038/bjc.1993.350; SMITH KJ, 1994, CANCER RES, V54, P3672; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; TAUB R, 1982, P NATL ACAD SCI-BIOL, V79, P7837, DOI 10.1073/pnas.79.24.7837; VANDEWETERING M, 1991, EMBO J, V10, P123, DOI 10.1002/j.1460-2075.1991.tb07928.x; VELCULESCU VE, 1995, SCIENCE, V270, P484, DOI 10.1126/science.270.5235.484; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1	40	3953	4119	6	233	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 4	1998	281	5382					1509	1512		10.1126/science.281.5382.1509	http://dx.doi.org/10.1126/science.281.5382.1509			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	116RJ	9727977				2022-12-28	WOS:000075738100041
J	Kunin, WE				Kunin, WE			Extrapolating species abundance across spatial scales	SCIENCE			English	Article							FRACTAL ANALYSIS; RANGES	The analysis, measurement, and management of species abundance is central to ecology and conservation biology, but it has proved difficult to find a single index that adequately reflects the commonness or rarity of species across a range of spatial scales. Here, a scale-independent measure of species abundance is developed, using presence-absence maps at varying spatial resolutions. By extrapolating such "scale-area" curves, species abundance can be estimated accurately even at scales finer than those used to parameterize the model, a task that had previously been deemed impossible in principle.	Univ Leeds, Sch Biol, Ctr Biodivers & Conservat, Leeds LS2 9JT, W Yorkshire, England	University of Leeds	Kunin, WE (corresponding author), Univ Leeds, Sch Biol, Ctr Biodivers & Conservat, Leeds LS2 9JT, W Yorkshire, England.	w.e.kunin@leeds.ac.uk						CRACKLES E, 1990, FLORA E RIDING YORKS; Fiedler P. L., 1992, Conservation biology: the theory and practice of nature conservation, preservation, and management., P23; Gaston K.J., 1994, RARITY, P1; Gaston KJ, 1997, J ANIM ECOL, V66, P579, DOI 10.2307/5951; GAUTESTAD AO, 1994, OIKOS, V69, P154, DOI 10.2307/3545296; Hastings HM, 1993, FRACTALS USERS GUIDE; Jalas J, 1988, ATLAS FLORAE EUROPEA; LOEHLE C, 1990, LANDSCAPE ECOL, V5, P39, DOI 10.1007/BF00153802; Maurer B. A, 1994, GEOGRAPHICAL POPULAT; PALMER MW, 1992, AM NAT, V139, P375, DOI 10.1086/285332; PEITGEN H, 1992, CHAOS FRACTALS NEW F; Perring F.H., 1976, ATLAS BRIT FLORA; Rabinowitz D., 1981, BIOL ASPECTS RARE PL, P205, DOI DOI 10.1177/004728702237415; Richards AJ., 1994, SCARCE PLANTS BRITAI, P152; SUGIHARA G, 1990, TRENDS ECOL EVOL, V5, P79, DOI 10.1016/0169-5347(90)90235-6; VIRKKALA R, 1993, OIKOS, V67, P218, DOI 10.2307/3545466; Williamson M.H., 1991, P69; [No title captured]	18	225	246	1	65	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 4	1998	281	5382					1513	1515		10.1126/science.281.5382.1513	http://dx.doi.org/10.1126/science.281.5382.1513			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	116RJ	9727978				2022-12-28	WOS:000075738100042
J	Sibai, BM; Lindheimer, M; Hauth, J; Caritis, S; VanDorsten, P; Klebanoff, M; MacPherson, C; Landon, M; Miodovnik, M; Paul, R; Meis, P; Dombrowski, M				Sibai, BM; Lindheimer, M; Hauth, J; Caritis, S; VanDorsten, P; Klebanoff, M; MacPherson, C; Landon, M; Miodovnik, M; Paul, R; Meis, P; Dombrowski, M		Natl Inst Hlth Human Dev Network Maternal Fetal	Risk factors for preeclampsia, abruptio placentae, and adverse neonatal outcomes among women with chronic hypertension	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Proceedings Paper	18th Annual Meeting of the Society-of-Perinatal-Obstetricians	FEB 02-07, 1998	MIAMI, FL	Soc Perinatal Obstetricians			LOW-DOSE ASPIRIN; PREGNANT-WOMEN; PROGNOSIS; TRIMESTER; THERAPY; TERM	Background Women with chronic hypertension who become pregnant have an increased risk of preeclampsia and adverse neonatal outcomes. However, within this group, the risk factors for these adverse events are not known. Methods We analyzed data on outcomes for 763 women with chronic hypertension enrolled in a multicenter trial of low-dose aspirin for the prevention of preeclampsia. Preeclampsia was defined as new-onset proteinuria (urinary protein excretion, greater than or equal to 300 mg per 24 hours) in the 682 women without proteinuria at base line. it was defined according to strict clinical criteria in the 81 women who had proteinuria at base line. The end points were maternal and neonatal outcomes. Results Among the 763 women, 193 (25 percent) had preeclampsia. The frequency of preeclampsia was not affected by the presence of proteinuria at base line (27 percent among women with proteinuria, vs. 25 percent among those without it), but it was greater in women who had had hypertension for at least four years (31 percent vs. 22 percent; odds ratio, 1.6; 95 percent confidence interval, 1.1 to 2.2) and in those with preeclampsia during a previous pregnancy (32 percent vs. 23 percent; odds ratio, 1.6; 95 percent confidence interval, 1.1 to 2.3). Women with proteinuria at base line were significantly more likely to deliver their babies at less than 35 weeks of gestation (36 percent vs. 16 percent; odds ratio, 3.1; 95 percent confidence interval, 1.8 to 5.3) and to have infants that were small for gestational age (23 percent vs. 10 percent; odds ratio, 2.8; 95 percent confidence interval, 1.6 to 5.0). Conclusions In women with chronic hypertension, the presence of proteinuria early in pregnancy is associated with adverse neonatal outcomes independently of the development of preeclampsia. (N Engl J Med 1998;339:667-71.) (C)1998, Massachusetts Medical Society.	Univ Tennessee, Dept Obstet & Gynecol, Memphis, TN 38103 USA; Univ Chicago, Dept Obstet & Gynecol, Chicago, IL 60637 USA; Univ Alabama Birmingham, Dept Obstet & Gynecol, Birmingham, AL 35294 USA; Med Univ S Carolina, Dept Obstet & Gynecol, Charleston, SC 29425 USA; NICHHD, Dept Epidemiol, Bethesda, MD 20892 USA; George Washington Univ, Ctr Biostat, Washington, DC USA; Ohio State Univ, Columbus, OH 43210 USA; Univ Cincinnati, Coll Med, Cincinnati, OH USA; Univ So Calif, Los Angeles, CA USA; Wake Forest Univ, Bowman Gray Sch Med, Winston Salem, NC USA; Hutzel Hosp, Detroit, MI 48201 USA; Univ Oklahoma, Oklahoma City, OK USA; Univ Pittsburgh, Pittsburgh, PA USA; NICHHD, Pregnancy & Perinatol Branch, Bethesda, MD 20892 USA	University of Tennessee System; University of Tennessee Health Science Center; University of Chicago; University of Alabama System; University of Alabama Birmingham; Medical University of South Carolina; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); George Washington University; University System of Ohio; Ohio State University; University System of Ohio; University of Cincinnati; University of Southern California; Wake Forest University; Wake Forest Baptist Medical Center; University of Oklahoma System; University of Oklahoma Health Sciences Center; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Sibai, BM (corresponding author), Univ Tennessee, Dept Obstet, 853 Jefferson Ave,Suite E102, Memphis, TN 38103 USA.			caritis, steve/0000-0002-2169-0712	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [U10HD021410] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [U01HD021410, U10HD021414, U01HD021414, U01HD019897] Funding Source: NIH RePORTER; NICHD NIH HHS [HD19897, HD21414, HD21410] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		[Anonymous], 1990, AM J OBSTET GYNECOL, V163, P1691; Barton JR, 1997, AM J OBSTET GYNECOL, V176, P1236, DOI 10.1016/S0002-9378(97)70340-5; BRENNER WE, 1976, AM J OBSTET GYNECOL, V126, P555, DOI 10.1016/0002-9378(76)90748-1; Caritis S, 1998, NEW ENGL J MED, V338, P701, DOI 10.1056/NEJM199803123381101; FERRAZZANI S, 1990, AM J OBSTET GYNECOL, V162, P366, DOI 10.1016/0002-9378(90)90387-M; Gallery EDM, 1997, HYPERTENS PREGNANCY, V16, P229, DOI 10.3109/10641959709031640; Jungers P, 1997, KIDNEY INT, V52, P871, DOI 10.1038/ki.1997.408; Jungers P, 1986, Adv Nephrol Necker Hosp, V15, P103; LIN CC, 1982, AM J OBSTET GYNECOL, V142, P255, DOI 10.1016/0002-9378(82)90727-X; McCowan LME, 1996, BRIT J OBSTET GYNAEC, V103, P123, DOI 10.1111/j.1471-0528.1996.tb09662.x; REY E, 1994, AM J OBSTET GYNECOL, V171, P410, DOI 10.1016/0002-9378(94)90276-3; SIBAI BM, 1986, OBSTET GYNECOL, V67, P517; SIBAI BM, 1991, OBSTET GYNECOL, V78, P451; SIBAI BM, 1991, AM J OBSTET GYNECOL, V165, P1408; Sibai BM, 1996, NEW ENGL J MED, V335, P257, DOI 10.1056/NEJM199607253350407; VIINIKKA L, 1993, BRIT J OBSTET GYNAEC, V100, P809, DOI 10.1111/j.1471-0528.1993.tb14304.x	16	281	294	0	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 3	1998	339	10					667	671		10.1056/NEJM199809033391004	http://dx.doi.org/10.1056/NEJM199809033391004			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	115WA	9725924	Bronze			2022-12-28	WOS:000075688100004
J	Tozzi, AE; degli Atti, MLC; Salmaso, S; Anemona, A				Tozzi, AE; degli Atti, MLC; Salmaso, S; Anemona, A			Repeat whole cell vaccinations should be avoided after hypotonic-hyporesponsive episodes	BRITISH MEDICAL JOURNAL			English	Letter									Ist Super Sanita, Epidemiol & Biostat Lab, I-00161 Rome, Italy	Istituto Superiore di Sanita (ISS)	Tozzi, AE (corresponding author), Ist Super Sanita, Epidemiol & Biostat Lab, Viale Regina Elena 299, I-00161 Rome, Italy.		Tozzi, Alberto Eugenio/F-9494-2012; degli Atti, Marta Ciofi/K-4650-2018	Tozzi, Alberto Eugenio/0000-0002-6884-984X; degli Atti, Marta Ciofi/0000-0001-6492-4497				Greco D, 1996, NEW ENGL J MED, V334, P341, DOI 10.1056/NEJM199602083340601; Vermeer-de Bondt PE, 1998, BRIT MED J, V316, P902, DOI 10.1136/bmj.316.7135.902	2	6	6	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 29	1998	317	7158					604	604		10.1136/bmj.317.7158.604a	http://dx.doi.org/10.1136/bmj.317.7158.604a			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	117EK	9721136	Green Published			2022-12-28	WOS:000075767800044
J	Willatts, P; Forsyth, JS; DiModugno, MK; Varma, S; Colvin, M				Willatts, P; Forsyth, JS; DiModugno, MK; Varma, S; Colvin, M			Effect of long-chain polyunsaturated fatty acids in infant formula on problem solving at 10 months of age	LANCET			English	Article; Proceedings Paper	Meeting of the American-Oil-Chemists-Society on PUFA in Infant Nutrition	NOV 07-09, 1996	BARCELONA, SPAIN	Amer Oil Chemists Soc			VISUAL-ATTENTION; RANDOMIZED TRIAL; LINOLENIC ACID; LATER IQ; BEHAVIOR; MONKEYS; MEMORY	Background Long-chain polyunsaturated fatty acids (LCPUFA) are important for normal visual and brain development. Although present in human milk, LCPUFA have until recently been absent from artificial formulas, and infants may have limited ability to synthesise LCPUFA. To determine the clinical significance of this relative deficiency of LCPUFA, we undertook a randomised trial of the relation between LCPUFA supplementation and infant cognitive behaviour. Methods 44 term infants had been randomised to a formula supplemented with LCPUFA (21) or not supplemented with LCPUFA (23), which they had taken from birth to age 4 months. Infant cognitive behaviour was assessed at 10 months of age by a means-end problem-solving test-the intentional execution of a sequence of steps to achieve a goal. The problem required three intermediate steps to achieve the final goal, uncovering and retrieving a hidden toy. Findings Infants who received LCPUFA-supplemented formula had significantly more intentional solutions than infants who received the no-LCPUFA formula (median 2.0 vs 0, p=0.021). Intention scores (median 14.0 vs 11.5 [maximum 18]) were also increased in this group (p=0.035). Interpretation These findings suggest that term infants may benefit from LCPUFA supplementation, and that the effects persist beyond the period of supplementation. Since higher problem-solving scores in infancy are related to higher childhood IQ scores, supplementation with LCPUFA may be important for the development of childhood intelligence.	Univ Dundee, Dept Psychol, Dundee DD1 4HN, Scotland; Univ Dundee, Dept Child Hlth, Dundee DD1 4HN, Scotland	University of Dundee; University of Dundee	Willatts, P (corresponding author), Univ Dundee, Dept Psychol, Dundee DD1 4HN, Scotland.							AGOSTONI C, 1995, PEDIATR RES, V38, P262, DOI 10.1203/00006450-199508000-00021; AGOSTONI C, 1996, RECENT DEV INFANT NU, P212; Bayley N., 1993, BAYLEY SCALES INFANT, Vsecond; CARLSON SE, 1986, AM J CLIN NUTR, V44, P798, DOI 10.1093/ajcn/44.6.798; Carlson SE, 1996, LIPIDS, V31, P85, DOI 10.1007/BF02522416; CLARK KJ, 1992, J PEDIATR-US, V120, pS151, DOI 10.1016/S0022-3476(05)81250-8; Colombo J., 1990, INDIVIDUAL DIFFERENC, P193, DOI [10.2307/1130804, DOI 10.2307/1130804]; CRAWFORD MA, 1971, LIPIDS MALNUTRITION, P267; DIAMOND A, 1998, MONOGR SOC RES CHILD, V62; DIAMOND A, 1990, ANN NY ACAD SCI, V608, P267; FARQUHARSON J, 1995, ARCH DIS CHILD, V72, P198, DOI 10.1136/adc.72.3.198; HOOD BM, 1993, INFANT BEHAV DEV, V16, P405, DOI 10.1016/0163-6383(93)80001-O; JACKSON KA, 1989, AM J CLIN NUTR, V50, P980, DOI 10.1093/ajcn/50.5.980; JACOBSON SW, 1992, CHILD DEV, V63, P711; Johnson Mark H., 1995, P735; JOHNSON MH, 1991, J COGNITIVE NEUROSCI, V3, P335, DOI 10.1162/jocn.1991.3.4.335; LAMPTEY MS, 1976, J NUTR, V106, P86, DOI 10.1093/jn/106.1.86; LAMPTEY MS, 1978, J NUTR, V108, P358, DOI 10.1093/jn/108.3.358; MAKRIDES M, 1993, PEDIATR RES, V33, P425; MAKRIDES M, 1995, LANCET, V345, P1463, DOI 10.1016/S0140-6736(95)91035-2; MARTINEZ M, 1992, J PEDIATR-US, V120, pS129, DOI 10.1016/S0022-3476(05)81247-8; MCCALL RB, 1979, HDB INFANT DEV, P707; Reisbick S, 1997, DEV PSYCHOL, V33, P387; Rose SA, 1997, CHILD DEV, V68, P630; SLATER A, 1995, J CHILD PSYCHOL PSYC, V36, P69, DOI 10.1111/j.1469-7610.1995.tb01656.x; Werkman SH, 1996, LIPIDS, V31, P91, DOI 10.1007/BF02522417; Willatts P, 1996, ROY SOC MED INT CONG, P57; WILLATTS P, 1984, DEV PSYCHOL, V20, P389, DOI 10.1037/0012-1649.20.3.389; WILLATTS P, 1984, INFANT BEHAV DEV, V7, P125, DOI 10.1016/S0163-6383(84)80053-3; WILLATTS P, 1989, INFANT DEV, P143; Willatts P., 1997, INFANT DEV RECENT AD, P109; [No title captured]	32	316	355	0	35	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 29	1998	352	9129					688	691		10.1016/S0140-6736(97)11374-5	http://dx.doi.org/10.1016/S0140-6736(97)11374-5			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	116MT	9728984				2022-12-28	WOS:000075729700012
J	Smith, DE; Chu, S				Smith, DE; Chu, S			Response of flexible polymers to a sudden elongational flow	SCIENCE			English	Article							COIL-STRETCH TRANSITIONS; STRONG EXTENSIONAL FLOW; DNA-MOLECULES; MACROMOLECULAR DYNAMICS; BIREFRINGENCE; MODEL; CHAIN; RELAXATION; VISCOSITY; RHEOLOGY	Individual polymers at thermal equilibrium were exposed to an elongational flow producing a high strain rate; and their dynamics were recorded with video fluorescence microscopy. The flow was turned on suddenly so that the entire evolution of molecular conformation could be observed without initial perturbations. The rate of stretching of individual molecules is highly variable and depends on the molecular conformation that develops during stretching. This variability is due to a dependence of the dynamics on the initial, random equilibrium conformation of the polymer coil. The increasing appearance at high strain rates of slowly unraveling hairpin folds is an example of nonergodic dynamics, which can occur when a statistical mechanical system is subjected to nonadiabatic, or "sudden," external forces.	Stanford Univ, Dept Phys, Stanford, CA 94305 USA; Stanford Univ, Dept Appl Phys, Stanford, CA 94305 USA	Stanford University; Stanford University	Chu, S (corresponding author), Stanford Univ, Dept Phys, Varian Bldg, Stanford, CA 94305 USA.	schu@leland.stanford.edu	Smith, Douglas E/A-3131-2017	Smith, Douglas E/0000-0002-8206-3632				ACIERNO D, 1974, J POLYM SCI POL PHYS, V12, P2177, DOI 10.1002/pol.1974.180121101; [Anonymous], 1987, DYNAMICS POLYM LIQUI; [Anonymous], 1980, VISCOELASTIC PROPERT; ATKINS EDT, 1992, BIOPOLYMERS, V32, P911, DOI 10.1002/bip.360320803; Carrington SP, 1996, J NON-NEWTON FLUID, V67, P269, DOI 10.1016/S0377-0257(96)01455-3; Carrington SP, 1997, POLYMER, V38, P4595, DOI 10.1016/S0032-3861(96)01080-4; Carrington SP, 1997, POLYMER, V38, P4151, DOI 10.1016/S0032-3861(96)00999-8; CATHEY CA, 1990, J NON-NEWTON FLUID, V34, P63, DOI 10.1016/0377-0257(90)80012-O; CHAVEZ AE, 1991, J STAT PHYS, V62, P1255, DOI 10.1007/BF01128186; deGennes PG, 1997, SCIENCE, V276, P1999, DOI 10.1126/science.276.5321.1999; Diau EWG, 1998, SCIENCE, V279, P847, DOI 10.1126/science.279.5352.847; DUNLAP PN, 1987, J NON-NEWTON FLUID, V23, P5, DOI 10.1016/0377-0257(87)80009-5; FAN XJ, 1985, J NON-NEWTON FLUID, V18, P255, DOI 10.1016/0377-0257(85)87002-6; Flory P. J., 1969, STAT MECH CHAIN MOL, V8, P699, DOI [10.1002/bip.1969.360080514, DOI 10.1002/BIP.1969.360080514]; FULLER GG, 1980, RHEOL ACTA, V19, P580, DOI 10.1007/BF01517512; HENYEY FS, 1985, J CHEM PHYS, V82, P4362, DOI 10.1063/1.448828; HINCH E, 1994, J NONNEWTONIAN FLUID, V34, P181; HINCH EJ, 1994, J NON-NEWTON FLUID, V54, P209, DOI 10.1016/0377-0257(94)80023-5; HINCH EJ, 1974, P S POL LUBR BREST F; Hunkeler D, 1996, POLYMER, V37, P4257, DOI 10.1016/0032-3861(96)00290-X; Hunkeler D, 1996, POLYMER, V37, P4271, DOI 10.1016/0032-3861(96)00187-5; JAMES DF, 1995, J RHEOL, V39, P713, DOI 10.1122/1.550653; KELLER A, 1985, COLLOID POLYM SCI, V263, P181, DOI 10.1007/BF01415506; Keunings R, 1997, J NON-NEWTON FLUID, V68, P85, DOI 10.1016/S0377-0257(96)01497-8; KING DH, 1983, J CHEM PHYS, V78, P4749, DOI 10.1063/1.445274; KOBE JM, 1993, J RHEOL, V37, P947, DOI 10.1122/1.550405; Kuhn W, 1934, KOLLOID Z, V68, P2, DOI 10.1007/BF01451681; Larson R. G., 1988, CONSTITUTIVE EQUATIO; LARSON RG, 1989, MACROMOLECULES, V22, P3004, DOI 10.1021/ma00197a022; Larson RG, 1997, PHYS REV E, V55, P1794, DOI 10.1103/PhysRevE.55.1794; LARSON RG, 1990, RHEOL ACTA, V29, P371, DOI 10.1007/BF01376787; LARSON RG, UNPUB; LIU TW, 1989, J CHEM PHYS, V90, P5826, DOI 10.1063/1.456389; LUMLEY JL, 1977, PHYS FLUIDS, V20, pS64, DOI 10.1063/1.861760; MENASVETA MJ, 1991, MACROMOLECULES, V24, P3427, DOI 10.1021/ma00011a060; MULLER AJ, 1988, J NON-NEWTON FLUID, V30, P99, DOI 10.1016/0377-0257(88)85018-3; NARH KA, 1992, J POLYM SCI POL PHYS, V30, P335, DOI 10.1002/polb.1992.090300403; Ng SL, 1996, J NON-NEWTON FLUID, V65, P291, DOI 10.1016/0377-0257(96)01463-2; NGUYEN TQ, 1995, MACROMOLECULES, V28, P4851, DOI 10.1021/ma00118a010; ODELL JA, 1994, BIOPOLYMERS, V34, P1483, DOI 10.1002/bip.360341106; ONUCHIC JN, 1997, ANNU REV PHYS CHEM, V48, P539; Orr NV, 1996, J NON-NEWTON FLUID, V67, P77, DOI 10.1016/S0377-0257(96)01487-5; Perkins TT, 1997, SCIENCE, V276, P2016, DOI 10.1126/science.276.5321.2016; PERKINS TT, 1994, SCIENCE, V264, P822, DOI 10.1126/science.8171336; PERKINS TT, 1995, SCIENCE, V268, P83, DOI 10.1126/science.7701345; RABIN Y, 1986, J CHEM PHYS, V85, P4696, DOI 10.1063/1.451744; RABIN Y, 1988, J CHEM PHYS, V88, P4014, DOI 10.1063/1.453853; Rallison JM, 1997, J NON-NEWTON FLUID, V68, P61, DOI 10.1016/S0377-0257(96)01492-9; REESE HR, 1990, J CHEM PHYS, V92, P2650, DOI 10.1063/1.457960; RYSKIN G, 1987, J FLUID MECH, V178, P423, DOI 10.1017/S0022112087001290; Sasaki N, 1996, J APPL POLYM SCI, V59, P1389, DOI 10.1002/(SICI)1097-4628(19960228)59:9<1389::AID-APP6>3.0.CO;2-7; SMITH DE, 1995, PHYS REV LETT, V75, P4146, DOI 10.1103/PhysRevLett.75.4146; Smith DE, 1996, MACROMOLECULES, V29, P1372, DOI 10.1021/ma951455p; SMITH KA, 1975, C INT CNRS PARIS, V233, P341; SMITH SB, 1992, SCIENCE, V258, P1122, DOI 10.1126/science.1439819; SMITH SB, 1989, SCIENCE, V243, P203, DOI 10.1126/science.2911733; Spiegelberg SH, 1996, J NON-NEWTON FLUID, V67, P49, DOI 10.1016/S0377-0257(96)01475-9; TIRTAATMADJA V, 1993, J RHEOL, V37, P1081, DOI 10.1122/1.550372; WEDGEWOOD LE, 1991, J NON-NEWTON FLUID, V40, P119, DOI 10.1016/0377-0257(91)87029-W; WIEST JM, 1989, J CHEM PHYS, V90, P587, DOI 10.1063/1.456457; WINKLER RG, 1989, EUROPHYS LETT, V8, P493, DOI 10.1209/0295-5075/8/6/001	64	357	366	3	99	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 28	1998	281	5381					1335	1340		10.1126/science.281.5381.1335	http://dx.doi.org/10.1126/science.281.5381.1335			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	115LQ	9721095				2022-12-28	WOS:000075666800045
J	Luo, X; Budihardjo, I; Zou, H; Slaughter, C; Wang, XD				Luo, X; Budihardjo, I; Zou, H; Slaughter, C; Wang, XD			Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors	CELL			English	Article							INDUCED APOPTOSIS; FREE SYSTEM; INTERLEUKIN-1-BETA-CONVERTING ENZYME; BCL-X(L); PROTEOLYSIS; CASPASES; PATHWAYS; MEMBRANE; COMPLEX; CPP32	We report here the purification of a cytosolic protein that induces cytochrome c release from mitochondria in response to caspase-8, the apical caspase activated by cell surface death receptors such as Fas and TNF. Peptide mass fingerprinting identified this protein as Bid, a BH3 domain-containing protein known to interact with both Bcl2 and Bar. Caspase-8 cleaves Bid, and the COOH-terminal part translocates to mitochondria where it triggers cytochrome c release. Immunodepletion of Bid from cell extracts eliminated the cytochrome c releasing activity. The cytochrome c releasing activity of Bid was antagonized by Bcl2. A mutation at the BH3 domain diminished its cytochrome c releasing activity. Bid, therefore, relays an apoptotic signal from the cell surface to mitochondria.	Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75235 USA	Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Wang, XD (corresponding author), Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75235 USA.			Wang, Xiaodong/0000-0001-9885-356X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057158] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01GM-57158] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Boise LH, 1997, P NATL ACAD SCI USA, V94, P3759, DOI 10.1073/pnas.94.8.3759; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Conradt B, 1998, CELL, V93, P519, DOI 10.1016/S0092-8674(00)81182-4; Cosulich SC, 1997, CURR BIOL, V7, P913, DOI 10.1016/S0960-9822(06)00410-6; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; Ellerby HM, 1997, J NEUROSCI, V17, P6165; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Faleiro L, 1997, EMBO J, V16, P2271, DOI 10.1093/emboj/16.9.2271; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; Jensen ON, 1996, RAPID COMMUN MASS SP, V10, P1371, DOI 10.1002/(SICI)1097-0231(199608)10:11<1371::AID-RCM682>3.0.CO;2-5; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kothakota S, 1997, SCIENCE, V278, P294, DOI 10.1126/science.278.5336.294; Krippner A, 1996, J BIOL CHEM, V271, P21629, DOI 10.1074/jbc.271.35.21629; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; Kuwana T, 1998, J BIOL CHEM, V273, P16589, DOI 10.1074/jbc.273.26.16589; LAZEBNIK YA, 1995, P NATL ACAD SCI USA, V92, P9042, DOI 10.1073/pnas.92.20.9042; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Liu XS, 1996, J BIOL CHEM, V271, P13371, DOI 10.1074/jbc.271.23.13371; Liu XS, 1998, P NATL ACAD SCI USA, V95, P8461, DOI 10.1073/pnas.95.15.8461; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; MARTIN SJ, 1995, J BIOL CHEM, V270, P6425, DOI 10.1074/jbc.270.12.6425; Medema JP, 1998, J BIOL CHEM, V273, P3388, DOI 10.1074/jbc.273.6.3388; MINN AJ, 1997, NATURE, V381, P335; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Muzio M, 1997, J BIOL CHEM, V272, P2952, DOI 10.1074/jbc.272.5.2952; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Pastorino JG, 1998, J BIOL CHEM, V273, P7770, DOI 10.1074/jbc.273.13.7770; Reed JC, 1997, CELL, V91, P559, DOI 10.1016/S0092-8674(00)80442-0; Rosse T, 1998, NATURE, V391, P496, DOI 10.1038/35160; Rudel T, 1997, SCIENCE, V276, P1571, DOI 10.1126/science.276.5318.1571; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Sambrook J., 2002, MOL CLONING LAB MANU; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Srinivasan A, 1998, J BIOL CHEM, V273, P4523, DOI 10.1074/jbc.273.8.4523; Srinivasula SM, 1996, P NATL ACAD SCI USA, V93, P14486, DOI 10.1073/pnas.93.25.14486; Strasser A, 1995, EMBO J, V14, P6136, DOI 10.1002/j.1460-2075.1995.tb00304.x; Susin SA, 1997, J EXP MED, V186, P25, DOI 10.1084/jem.186.1.25; TEWARI M, 1995, J BIOL CHEM, V270, P3255, DOI 10.1074/jbc.270.7.3255; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; VanderHeiden MG, 1997, CELL, V91, P627, DOI 10.1016/S0092-8674(00)80450-X; Wang K, 1996, GENE DEV, V10, P2859, DOI 10.1101/gad.10.22.2859; WILLIAMS KR, 1995, TECH PROT CHEM, V6, P143, DOI 10.1016/S1080-8914(06)80020-7; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	52	2954	3073	5	168	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	AUG 21	1998	94	4					481	490		10.1016/S0092-8674(00)81589-5	http://dx.doi.org/10.1016/S0092-8674(00)81589-5			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	113GB	9727491	Bronze			2022-12-28	WOS:000075541100010
J	Agrawal, A; Eastman, QM; Schatz, DG				Agrawal, A; Eastman, QM; Schatz, DG			Transposition mediated by RAG1 and RAG2 and its implications for the evolution of the immune system	NATURE			English	Article							V(D)J RECOMBINATION; RETROVIRAL INTEGRATION; CATALYTIC DOMAIN; DNA; GENES; RESOLUTION; INITIATION; 12/23-RULE; MECHANISM; SEQUENCES	Immunoglobulin and T-cell-receptor genes are assembled from component gene segments in developing lymphocytes by a site-specific recombination reaction, V(D)J recombination, The proteins encoded by the recombination-activating genes, RAG1 and RAG2, are essential in this reaction, mediating sequence-specific DNA recognition of well-defined recombination signals and DNA cleavage next to these signals. Here we show that RAG1 and RAG2 together form a transposase capable of excising a piece of DNA containing recombination signals from a donor site and inserting it into a target DNA molecule. The products formed contain a short duplication of target DNA Immediately flanking the transposed fragment, a structure like that created by retroviral integration and all known transposition reactions. The results support the theory that RAG1 and RAG2 were once components of a transposable element, and that the split nature of Immunoglobulin and T-cell-receptor genes derives from germline insertion of this element into an ancestral receptor gene soon after the evolutionary divergence of jawed and jawless vertebrates.	Yale Univ, Sch Med, Howard Hughes Med Inst, Immunobiol Sect, New Haven, CT 06510 USA; Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06510 USA; Yale Univ, Sch Med, Dept Biochem & Mol Biophys, New Haven, CT 06510 USA	Howard Hughes Medical Institute; Yale University; Yale University; Yale University	Schatz, DG (corresponding author), Yale Univ, Sch Med, Howard Hughes Med Inst, Immunobiol Sect, 333 Cedar St, New Haven, CT 06510 USA.	david.schatz@yale.edu	Schatz, David/A-6748-2013	Schatz, David/0000-0002-5669-1176				Agrawal A, 1997, CELL, V89, P43, DOI 10.1016/S0092-8674(00)80181-6; BENJAMIN HW, 1989, CELL, V59, P373, DOI 10.1016/0092-8674(89)90298-5; Berg DE, 1989, MOBILE DNA; BROWN PO, 1989, P NATL ACAD SCI USA, V86, P2525, DOI 10.1073/pnas.86.8.2525; BUJACZ G, 1995, J MOL BIOL, V253, P333, DOI 10.1006/jmbi.1995.0556; Chalmers R, 1998, CELL, V93, P897, DOI 10.1016/S0092-8674(00)81449-X; Chu G, 1997, J BIOL CHEM, V272, P24097, DOI 10.1074/jbc.272.39.24097; CRAIG NL, 1995, SCIENCE, V270, P253, DOI 10.1126/science.270.5234.253; Craig NL, 1997, ANNU REV BIOCHEM, V66, P437, DOI 10.1146/annurev.biochem.66.1.437; DYDA F, 1994, SCIENCE, V266, P1981, DOI 10.1126/science.7801124; Eastman QM, 1996, NATURE, V380, P85, DOI 10.1038/380085a0; FUJIWARA T, 1988, CELL, V54, P497, DOI 10.1016/0092-8674(88)90071-2; Gellert M, 1997, ADV IMMUNOL, V64, P39, DOI 10.1016/S0065-2776(08)60886-X; Grawunder U, 1998, CURR OPIN IMMUNOL, V10, P172, DOI 10.1016/S0952-7915(98)80246-X; Hiom K, 1998, MOL CELL, V1, P1011, DOI 10.1016/S1097-2765(00)80101-X; HSIEH CL, 1991, MOL CELL BIOL, V11, P3972, DOI 10.1128/MCB.11.8.3972; ISBERG RR, 1985, J MOL BIOL, V182, P69, DOI 10.1016/0022-2836(85)90028-2; Kleckner N, 1996, CURR TOP MICROBIOL, V204, P49; LEE YMH, 1990, J VIROL, V64, P5958, DOI 10.1128/JVI.64.12.5958-5965.1990; Lewis SM, 1997, CELL, V88, P159, DOI 10.1016/S0092-8674(00)81833-4; LEWIS SM, 1991, EMBO J, V10, P3631, DOI 10.1002/j.1460-2075.1991.tb04929.x; LEWIS SM, 1994, ADV IMMUNOL, V56, P27, DOI 10.1016/S0065-2776(08)60450-2; LITMAN GW, 1993, MOL BIOL EVOL, V10, P60; MCBLANE JF, 1995, CELL, V83, P387, DOI 10.1016/0092-8674(95)90116-7; Melek M, 1998, SCIENCE, V280, P301, DOI 10.1126/science.280.5361.301; MIZUUCHI K, 1992, J BIOL CHEM, V267, P21273; MIZUUCHI K, 1992, ANNU REV BIOCHEM, V61, P1011; OETTINGER MA, 1990, SCIENCE, V248, P1517, DOI 10.1126/science.2360047; Rast JP, 1997, IMMUNITY, V6, P1, DOI 10.1016/S1074-7613(00)80237-X; RICE P, 1995, CELL, V82, P209, DOI 10.1016/0092-8674(95)90308-9; Sakai J, 1997, CELL, V89, P205, DOI 10.1016/S0092-8674(00)80200-7; SAKANO H, 1979, NATURE, V280, P288, DOI 10.1038/280288a0; Sawchuk DJ, 1997, J EXP MED, V185, P2025, DOI 10.1084/jem.185.11.2025; SCHATZ DG, 1989, CELL, V59, P1035, DOI 10.1016/0092-8674(89)90760-5; SHOEMAKER C, 1981, J VIROL, V40, P164, DOI 10.1128/JVI.40.1.164-172.1981; Spanopoulou E, 1996, CELL, V87, P263, DOI 10.1016/S0092-8674(00)81344-6; THOMPSON CB, 1995, IMMUNITY, V3, P531, DOI 10.1016/1074-7613(95)90124-8; TONEGAWA S, 1983, NATURE, V302, P575, DOI 10.1038/302575a0; vanGent DC, 1997, EMBO J, V16, P2665, DOI 10.1093/emboj/16.10.2665; vanGent DC, 1996, CELL, V85, P107, DOI 10.1016/S0092-8674(00)81086-7; vanGent DC, 1996, SCIENCE, V271, P1592, DOI 10.1126/science.271.5255.1592; WEAVER DT, 1995, TRENDS GENET, V11, P388, DOI 10.1016/S0168-9525(00)89121-0; WEINERT TA, 1984, COLD SPRING HARB SYM, V49, P251, DOI 10.1101/SQB.1984.049.01.029; ZWILLING S, 1995, EMBO J, V14, P1198, DOI 10.1002/j.1460-2075.1995.tb07103.x	44	568	584	2	43	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 20	1998	394	6695					744	751		10.1038/29457	http://dx.doi.org/10.1038/29457			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	112PR	9723614				2022-12-28	WOS:000075503600035
J	Chen, H; Fre, S; Slepnev, VI; Capua, MR; Takei, K; Butler, MH; Di Fiore, PP; De Camilli, P				Chen, H; Fre, S; Slepnev, VI; Capua, MR; Takei, K; Butler, MH; Di Fiore, PP; De Camilli, P			Epsin is an EH-domain-binding protein implicated in clathrin-mediated endocytosis	NATURE			English	Article							NERVE-TERMINALS; ALPHA-ADAPTIN; VESICLES; DYNAMIN; EPS15	During endocytosis, clathrin and the clathrin adaptor protein AP-2 (ref, 1), assisted by a variety of accessory factors, help to generate an invaginated bud at the cell membrane(2,3). One of these factors is Eps15, a clathrin-coat-associated protein that binds the alpha-adaptin subunit of AP-2 (refs 4-8). Here we investigate the function of Eps15 by characterizing an important binding partner for its region containing EH domains(9); this protein, epsin, is closely related to the Xenopus mitotic phosphoprotein MP90 (ref. 10) and has a ubiquitous tissue distribution. It is concentrated together with Eps15 in presynaptic nerve terminals, which are sites specialized for the clathrin-mediated endocytosis of synaptic vesicles. The central region of epsin binds AP-2 and its carboxyterminal region binds Eps15. Epsin is associated with clathrin coats in situ, can be co-precipitated with AP-2 and Eps15 from brain extracts, but does not co-purify with clathrin coat components in a clathrin-coated vesicle fraction. When epsin function is disrupted, clathrin-mediated endocytosis is blocked. We propose that epsin may participate, together with Eps15, in the molecular rearrangement of the clathrin coats that are required for coated-pit imagination and vesicle fission.	Yale Univ, Sch Med, Howard Hughes Med Inst, New Haven, CT 06510 USA; Yale Univ, Sch Med, Dept Cell Biol, New Haven, CT 06510 USA; European Inst Oncol, Dept Expt Oncol, I-20141 Milan, Italy; Univ Bari, Ist Microbiol, I-70124 Bari, Italy	Howard Hughes Medical Institute; Yale University; Yale University; IRCCS European Institute of Oncology (IEO); Universita degli Studi di Bari Aldo Moro	De Camilli, P (corresponding author), Yale Univ, Sch Med, Howard Hughes Med Inst, 295 Congress Ave, New Haven, CT 06510 USA.		Fre, Silvia/C-7540-2017; Di Fiore, Pier Paolo/K-2130-2012	Fre, Silvia/0000-0002-7209-7636; Di Fiore, Pier Paolo/0000-0002-2252-0950; Takei, Kohji/0000-0002-6555-9425				Bauerfeind R, 1997, J BIOL CHEM, V272, P30984, DOI 10.1074/jbc.272.49.30984; Benmerah A, 1996, J BIOL CHEM, V271, P12111, DOI 10.1074/jbc.271.20.12111; Benmerah A, 1998, J CELL BIOL, V140, P1055, DOI 10.1083/jcb.140.5.1055; CAMERON PL, 1991, J CELL BIOL, V115, P151, DOI 10.1083/jcb.115.1.151; Carbone R, 1997, CANCER RES, V57, P5498; Coda L, 1998, J BIOL CHEM, V273, P3003, DOI 10.1074/jbc.273.5.3003; Cremona O, 1997, CURR OPIN NEUROBIOL, V7, P323, DOI 10.1016/S0959-4388(97)80059-1; Cupers P, 1998, J BIOL CHEM, V273, P1847, DOI 10.1074/jbc.273.4.1847; Cupers P, 1997, J BIOL CHEM, V272, P33430, DOI 10.1074/jbc.272.52.33430; David C, 1996, P NATL ACAD SCI USA, V93, P331, DOI 10.1073/pnas.93.1.331; Dreyling MH, 1996, P NATL ACAD SCI USA, V93, P4804, DOI 10.1073/pnas.93.10.4804; Haffner C, 1997, FEBS LETT, V419, P175, DOI 10.1016/S0014-5793(97)01451-8; HUTTNER WB, 1983, J CELL BIOL, V96, P1374, DOI 10.1083/jcb.96.5.1374; Iannolo G, 1997, CANCER RES, V57, P240; Kirchhausen T, 1997, CURR OPIN CELL BIOL, V9, P488, DOI 10.1016/S0955-0674(97)80024-5; MAYCOX PR, 1992, J CELL BIOL, V118, P1379, DOI 10.1083/jcb.118.6.1379; McPherson PS, 1996, NATURE, V379, P353, DOI 10.1038/379353a0; NAVONE F, 1986, J CELL BIOL, V103, P2511, DOI 10.1083/jcb.103.6.2511; Ringstad N, 1997, P NATL ACAD SCI USA, V94, P8569, DOI 10.1073/pnas.94.16.8569; ROBINSON MS, 1994, CURR OPIN CELL BIOL, V6, P538, DOI 10.1016/0955-0674(94)90074-4; ROOS J, IN PRESS J BIOL CHEM; Salcini AE, 1997, GENE DEV, V11, P2239, DOI 10.1101/gad.11.17.2239; Srinivasan S, 1997, EUR J CELL BIOL, V74, P350; Stukenberg PT, 1997, CURR BIOL, V7, P338, DOI 10.1016/S0960-9822(06)00157-6; TAKEI K, 1995, NATURE, V374, P186, DOI 10.1038/374186a0; Tebar F, 1996, J BIOL CHEM, V271, P28727, DOI 10.1074/jbc.271.46.28727; WANG LH, 1995, J BIOL CHEM, V270, P10079, DOI 10.1074/jbc.270.17.10079; Wendland B, 1998, J CELL BIOL, V141, P71, DOI 10.1083/jcb.141.1.71; WONG WT, 1995, P NATL ACAD SCI USA, V92, P9530, DOI 10.1073/pnas.92.21.9530; ZHOU SB, 1992, J NEUROSCI, V12, P2144	30	463	476	0	19	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 20	1998	394	6695					793	797		10.1038/29555	http://dx.doi.org/10.1038/29555			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	112PR	9723620				2022-12-28	WOS:000075503600049
J	Varma, R; Mayor, S				Varma, R; Mayor, S			GPI-anchored proteins are organized in submicron domains at the cell surface	NATURE			English	Article							DETERGENT INSOLUBILITY; ALKALINE-PHOSPHATASE; CROSS-LINKING; MDCK CELLS; CHOLESTEROL; CAVEOLAE; TRANSPORT; MEMBRANES; RECEPTOR; FOLATE	Lateral heterogeneities in the classical fluid-mosaic model of cell membranes are now envisaged as domains or 'rafts' that are enriched in (glyco)sphingolipids, cholesterol, specific membrane proteins and glycosylphosphatidylinositol (GPI)-anchored proteins(1). These rafts dictate the sorting of associated proteins and/or provide sites for assembling cytoplasmic signalling molecules(2). However, there is no direct evidence that rafts exist in living cells(3,4). We have now measured the extent of energy transfer between isoforms of the folate receptor bound to a fluorescent analogue of folic acid, in terms of the dependence of fluorescence polarization on fluorophore densities in membranes(5). We find that the extent of energy transfer for the GPI-anchored folate-receptor isoform is density-independent, which is characteristic of organization in sub-pixel-sized domains at the surface of living cells; however, the extent of energy transfer for the transmembrane-anchored folate-receptor isoform was density-dependent, which is consistent with a random distribution. These domains are likely to be less than 70 nm in diameter and are disrupted by removal of cellular cholesterol. These results indicate that lipid-linked proteins are organized in cholesterol-dependent submicron-sized domains. Our methodology offers a new way of monitoring nanometre-scale association between molecules in living cells.	Natl Ctr Biol Sci, TIFR Ctr, Bangalore 560012, Karnataka, India	Tata Institute of Fundamental Research (TIFR); National Centre for Biological Sciences (NCBS)	Mayor, S (corresponding author), Natl Ctr Biol Sci, TIFR Ctr, IISc Campus,POB 1234, Bangalore 560012, Karnataka, India.		Varma, Rajat/I-1209-2012	Varma, Rajat/0000-0001-5131-0402				BROWN D, 1993, CURR OPIN IMMUNOL, V5, P349, DOI 10.1016/0952-7915(93)90052-T; Brown RE, 1998, J CELL SCI, V111, P1; CERNEUS DP, 1993, J BIOL CHEM, V268, P3150; CHANG WJ, 1992, J CELL BIOL, V118, P63, DOI 10.1083/jcb.118.1.63; Edidin M, 1997, CURR OPIN STRUC BIOL, V7, P528, DOI 10.1016/S0959-440X(97)80117-0; Friedrichson T, 1998, NATURE, V394, P802, DOI 10.1038/29570; Fujimoto T, 1996, J HISTOCHEM CYTOCHEM, V44, P929, DOI 10.1177/44.8.8756764; Griffiths G., 1993, FINE STRUCTURE IMMUN, P1; HANADA K, 1995, J BIOL CHEM, V270, P6254, DOI 10.1074/jbc.270.11.6254; HANNAN LA, 1993, J CELL BIOL, V120, P353, DOI 10.1083/jcb.120.2.353; Harder T, 1997, CURR OPIN CELL BIOL, V9, P534, DOI 10.1016/S0955-0674(97)80030-0; JACOBSON K, 1995, SCIENCE, V268, P1441, DOI 10.1126/science.7770769; Kenworthy AK, 1998, BIOPHYS J, V74, pA8; KURZCHALIA T, 1995, TRENDS CELL BIOL, V5, P187, DOI 10.1016/S0962-8924(00)88990-4; Matko J, 1997, METHOD ENZYMOL, V278, P444; MATTER K, 1992, CELL, V71, P741, DOI 10.1016/0092-8674(92)90551-M; MAYOR S, 1994, SCIENCE, V264, P1948, DOI 10.1126/science.7516582; MAYOR S, 1995, MOL BIOL CELL, V6, P929, DOI 10.1091/mbc.6.7.929; MAYOR S, IN PRESS EMBO J; MCCONVILLE MJ, 1993, BIOCHEM J, V294, P305, DOI 10.1042/bj2940305; PARTON RG, 1994, J CELL BIOL, V127, P1199, DOI 10.1083/jcb.127.5.1199; RITTER TE, 1995, P NATL ACAD SCI USA, V92, P3824, DOI 10.1073/pnas.92.9.3824; RUNNELS LW, 1995, BIOPHYS J, V69, P1569, DOI 10.1016/S0006-3495(95)80030-5; Sheets ED, 1997, BIOCHEMISTRY-US, V36, P12449, DOI 10.1021/bi9710939; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Simson R, 1998, BIOPHYS J, V74, P297, DOI 10.1016/S0006-3495(98)77787-2; Stulnig TM, 1997, J BIOL CHEM, V272, P19242, DOI 10.1074/jbc.272.31.19242; TARABOULOS A, 1995, J CELL BIOL, V129, P121, DOI 10.1083/jcb.129.1.121; WEBER G, 1954, T FARADAY SOC, V50, P552, DOI 10.1039/tf9545000552; Weimbs T, 1997, TRENDS CELL BIOL, V7, P393, DOI 10.1016/S0962-8924(97)01130-6; Yancey PG, 1996, J BIOL CHEM, V271, P16026, DOI 10.1074/jbc.271.27.16026	31	976	1005	0	92	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 20	1998	394	6695					798	801		10.1038/29563	http://dx.doi.org/10.1038/29563			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	112PR	9723621				2022-12-28	WOS:000075503600050
J	Qiu, YL; Cho, YR; Cox, JC; Palmer, JD				Qiu, YL; Cho, YR; Cox, JC; Palmer, JD			The gain of three mitochondrial introns identifies liverworts as the earliest land plants	NATURE			English	Article							PHYLOGENETIC-RELATIONSHIPS; RBCL SEQUENCES; BRYOPHYTES	The first evidence for the emergence of land plants (embryophytes) consists of mid-Ordovician spore tetrads (similar to 476 Myr old)(1,2). The identity of the early plants that produced these spores is unclear; they are sometimes claimed to be liverworts(3,4), but there are no associated megafossils, and similar spores can be produced by a diversity of plants(2), Indeed, the earliest unequivocal megafossils of land plants consist of early vascular plants and various plants of uncertain affinity(1). Different phylogenetic analyses have identified liverworts, hornworts and bryophytes as each being the first lineage of land plants(1,2,5-13); the consensus of these conflicting topologies yields an unresolved polychotomy at the base of land plants. Here we survey 352 diverse land plants and find that three mitochondrial group II introns are present, with occasional losses, in mosses, hornworts and all major lineages of vascular plants, but are entirely absent from Liverworts, green algae and all other eukaryotes. These results indicate that liverworts are the earliest land plants, with the three introns having been acquired in a common ancestor of all other land plants, and have important implications concerning the early stages of plant evolution.	Indiana Univ, Dept Biol, Bloomington, IN 47405 USA	Indiana University System; Indiana University Bloomington	Palmer, JD (corresponding author), Univ Zurich, Inst Syst Bot, Zollikerstr 107, CH-8008 Zurich, Switzerland.		Palmer, Jeffrey/P-6747-2014	Palmer, Jeffrey/0000-0002-4626-2220				Capesius I, 1997, PLANT SYST EVOL, V207, P87, DOI 10.1007/BF00985210; Chaw SM, 1997, MOL BIOL EVOL, V14, P56, DOI 10.1093/oxfordjournals.molbev.a025702; Doyle J. J., 1987, PHYTOCHEMISTRY B, V19, P11, DOI DOI 10.2307/4119796; DOYLE JA, 1986, BOT REV, V52, P321, DOI 10.1007/BF02861082; EDWARDS D, 1995, NATURE, V374, P635, DOI 10.1038/374635a0; GARBARY DJ, 1993, PLANT SYST EVOL, V188, P237; Graham L, 1993, ORIGIN LAND PLANTS; GRAY J, 1993, PALAEOGEOGR PALAEOCL, V104, P153, DOI 10.1016/0031-0182(93)90127-5; Hedderson TA, 1996, PLANT SYST EVOL, V200, P213, DOI 10.1007/BF00984936; Kenrick P, 1997, NATURE, V389, P33, DOI 10.1038/37918; Kenrick P., 1997, ORIGIN EARLY DIVERSI; Lewis LA, 1997, MOL PHYLOGENET EVOL, V7, P377, DOI 10.1006/mpev.1996.0395; Malek O, 1996, EMBO J, V15, P1403, DOI 10.1002/j.1460-2075.1996.tb00482.x; MANHART JR, 1994, MOL PHYLOGENET EVOL, V3, P114, DOI 10.1006/mpev.1994.1014; Nugent Jacqueline M., 1993, P163; ODA K, 1992, J MOL BIOL, V223, P1, DOI 10.1016/0022-2836(92)90708-R; PALMER JD, 1988, J MOL EVOL, V28, P87, DOI 10.1007/BF02143500; Pryer KM, 1995, AM FERN J, V85, P205, DOI 10.2307/1547810; Samigullin TH, 1998, FEBS LETT, V422, P47, DOI 10.1016/S0014-5793(97)01600-1; SLUIMAN HJ, 1985, PLANT SYST EVOL, V149, P217, DOI 10.1007/BF00983308; TAYLOR WA, 1995, NATURE, V373, P391, DOI 10.1038/373391b0; WOLFE KH, 1987, P NATL ACAD SCI USA, V84, P9054, DOI 10.1073/pnas.84.24.9054	22	260	272	1	46	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 13	1998	394	6694					671	674		10.1038/29286	http://dx.doi.org/10.1038/29286			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	110MD	9716129				2022-12-28	WOS:000075384200041
J	Marcus, SL; Chao, Y; Dickey, JO; Gegout, P				Marcus, SL; Chao, Y; Dickey, JO; Gegout, P			Detection and modeling of nontidal oceanic effects on Earth's rotation rate	SCIENCE			English	Article							GENERAL-CIRCULATION MODEL; ATMOSPHERIC ANGULAR-MOMENTUM; ISOPYCNIC COORDINATE MODEL; SEA-LEVEL; BUDGET	Subdecadal changes in Earth's rotation rate, and hence in the Length of day (LOD), are largely controlled by variations in atmospheric angular momentum. Results from two oceanic general circulation models (OGCMs), forced by observed wind stress and heat flux for the years 1992 through 1994 show that ocean current and mass distribution changes also induce detectable LOD variations. The close similarity of axial oceanic angular momentum (OAM) results from two independent OGCMs, and their coherence with LOD, demonstrate that global ocean models can successfully capture the large-scale circulation changes that drive OAM variability on seasonal and shorter time scales.	CALTECH, Jet Prop Lab, Pasadena, CA 91109 USA	California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL)	Marcus, SL (corresponding author), CALTECH, Jet Prop Lab, 4800 Oak Grove Dr, Pasadena, CA 91109 USA.			Marcus, Steven/0000-0002-5763-6961				BARNES RTH, 1983, P ROY SOC LOND A MAT, V387, P31, DOI 10.1098/rspa.1983.0050; BLECK R, 1989, J PHYS OCEANOGR, V19, P1417, DOI 10.1175/1520-0485(1989)019<1417:MLTIIA>2.0.CO;2; BLECK R, 1992, J PHYS OCEANOGR, V22, P1486, DOI 10.1175/1520-0485(1992)022<1486:SDTTIA>2.0.CO;2; Bryan FO, 1997, DYNAM ATMOS OCEANS, V25, P191, DOI 10.1016/S0377-0265(96)00477-0; Bryan K., 1997, Journal of Computational Physics, V135, P154, DOI [10.1016/0021-9991(69)90004-7, 10.1006/jcph.1997.5699]; Chao Y, 1995, J GEOPHYS RES-OCEANS, V100, P24965, DOI 10.1029/95JC02260; DESAI SD, 1996, THESIS U COLORADO; DICKEY JO, 1992, SCIENCE, V255, P321, DOI 10.1126/science.255.5042.321; Fu LL, 1997, GEOPHYS RES LETT, V24, P1783, DOI 10.1029/97GL01532; GREATBATCH RJ, 1994, J GEOPHYS RES-OCEANS, V99, P12767, DOI 10.1029/94JC00847; Gross RS, 1996, GEOPHYS RES LETT, V23, P3373, DOI 10.1029/96GL03260; GROSS RS, 1997, 1996 IERS ANN REP, P1129; HELLERMAN S, 1983, J PHYS OCEANOGR, V13, P1093, DOI 10.1175/1520-0485(1983)013<1093:NMWSOT>2.0.CO;2; HIDE R, 1991, SCIENCE, V253, P629, DOI 10.1126/science.253.5020.629; HIDE R, 1993, GEOPH MONOG SERIES, V72, P109; HU D, IN PRESS MON WEATHER; Hu DM, 1997, J PHYS OCEANOGR, V27, P96, DOI 10.1175/1520-0485(1997)027<0096:GSWMMC>2.0.CO;2; KRAUS EB, 1967, TELLUS, V19, P98; Levitus S., 1982, 13 NOAA; McWilliams JC, 1996, ANNU REV FLUID MECH, V28, P215, DOI 10.1146/annurev.fl.28.010196.001243; PACANOWSKI R, 1991, MODULAR OCEAN MODEL; PACANOWSKI RC, 1981, J PHYS OCEANOGR, V11, P1443, DOI 10.1175/1520-0485(1981)011<1443:POVMIN>2.0.CO;2; PONTE RM, 1994, J PHYS OCEANOGR, V24, P1966, DOI 10.1175/1520-0485(1994)024<1966:OAMATI>2.0.CO;2; PONTE RM, 1990, J GEOPHYS RES-OCEANS, V95, P11369, DOI 10.1029/JC095iC07p11369; ROSEN RD, 1991, GEOPHYS RES LETT, V18, P1925, DOI 10.1029/91GL02312; SALSTEIN DA, 1993, B AM METEOROL SOC, V74, P67, DOI 10.1175/1520-0477(1993)074<0067:TSBFAA>2.0.CO;2; SALSTEIN DA, 1997, 7 C CLIM VAR AM MET, P344; SWINBANK R, 1994, MON WEATHER REV, V122, P686, DOI 10.1175/1520-0493(1994)122<0686:ASTDAS>2.0.CO;2	28	73	77	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 11	1998	281	5383					1656	1659		10.1126/science.281.5383.1656	http://dx.doi.org/10.1126/science.281.5383.1656			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	118TR	9733508				2022-12-28	WOS:000075856500041
J	Belongia, EA; Schwartz, B				Belongia, EA; Schwartz, B			Strategies for promoting judicious use of antibiotics by doctors and patients	BRITISH MEDICAL JOURNAL			English	Article							PENICILLIN-RESISTANT PNEUMOCOCCI; RESPIRATORY-TRACT INFECTIONS; RISK-FACTORS; EDUCATIONAL OUTREACH; CONTROLLED TRIAL; GENERAL-PRACTICE; EXPECTATIONS; CHILDREN; CARE; PRACTITIONERS		Resp Dis Branch, Atlanta, GA 30333 USA; Marshfield Clin, Epidemiol Res Ctr, Marshfield, WI USA	Marshfield Clinic	Schwartz, B (corresponding author), Resp Dis Branch, 1600 Clifton Rd,MS E-61, Atlanta, GA 30333 USA.	Schwartz.bxsl@cdc.gov		Belongia, Edward/0000-0001-7478-0415				Arason VA, 1996, BMJ-BRIT MED J, V313, P387; AVORN J, 1983, NEW ENGL J MED, V308, P1457, DOI 10.1056/NEJM198306163082406; Bisno AL, 1997, CLIN INFECT DIS, V25, P574, DOI 10.1086/513768; Chan CSY, 1996, FAM PRACT, V13, P229, DOI 10.1093/fampra/13.3.229; ClavoSanchez AJ, 1997, CLIN INFECT DIS, V24, P1052, DOI 10.1086/513628; DAVIS DA, 1995, JAMA-J AM MED ASSOC, V274, P700; DESANTIS G, 1994, MED J AUSTRALIA, V160, P502; Dowell SF, 1997, AM FAM PHYSICIAN, V55, P1647; Dowell SF, 1998, PEDIATRICS, V101, P163; EKEDAHL A, 1995, EUR J CLIN PHARMACOL, V47, P381; Evans RS, 1998, NEW ENGL J MED, V338, P232, DOI 10.1056/NEJM199801223380406; Fairchok MP, 1996, CLIN INFECT DIS, V22, P966, DOI 10.1093/clinids/22.6.966; Gonzales R, 1997, JAMA-J AM MED ASSOC, V278, P901, DOI 10.1001/jama.278.11.901; GRIMSHAW JM, 1993, LANCET, V342, P317; Guillemot D, 1998, JAMA-J AM MED ASSOC, V279, P365, DOI 10.1001/jama.279.5.365; Hamm RM, 1996, J FAM PRACTICE, V43, P56; KAFKA F, 1952, COUNTRY DOCTOR SELEC; Macfarlane J, 1997, BMJ-BRIT MED J, V315, P1211, DOI 10.1136/bmj.315.7117.1211; Mainous AG, 1997, J FAM PRACTICE, V45, P75; Mainous AG, 1997, LANCET, V350, P1077, DOI 10.1016/S0140-6736(05)70457-8; McIsaac WJ, 1997, FAM PRACT, V14, P34, DOI 10.1093/fampra/14.1.34; Nyquist AC, 1998, JAMA-J AM MED ASSOC, V279, P875, DOI 10.1001/jama.279.11.875; *OT MED GUID PAN, 1994, 940622 AG HLTH CARE; PALLARES R, 1987, NEW ENGL J MED, V317, P18, DOI 10.1056/NEJM198707023170104; RADETSKY MS, 1981, LANCET, V2, P771; SCHAFFNER W, 1983, JAMA-J AM MED ASSOC, V250, P1728, DOI 10.1001/jama.250.13.1728; Schoenbaum S C, 1993, HMO Pract, V7, P5; Schwartz B, 1997, JAMA-J AM MED ASSOC, V278, P944, DOI 10.1001/jama.278.11.944; SCHWARTZ B, 1998, INT C EM INF DIS ATL, P66; Schwartz RH, 1997, PEDIATR INFECT DIS J, V16, P185, DOI 10.1097/00006454-199702000-00004; Seppala H, 1997, NEW ENGL J MED, V337, P441, DOI 10.1056/NEJM199708143370701; SOUMERAI SB, 1989, MILBANK Q, V67, P268, DOI 10.2307/3350142; SOUMERAI SB, 1990, JAMA-J AM MED ASSOC, V263, P549, DOI 10.1001/jama.263.4.549; Stephenson J, 1996, JAMA-J AM MED ASSOC, V275, P175, DOI 10.1001/jama.275.3.175; TAN TQ, 1993, PEDIATRICS, V92, P761; Trepka MJ, 1998, INT C EM INF DIS ATL, P68	36	103	110	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	SEP 5	1998	317	7159					668	671		10.1136/bmj.317.7159.668	http://dx.doi.org/10.1136/bmj.317.7159.668			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	118GN	9728003	Green Published			2022-12-28	WOS:000075830200033
J	Johnston, AM				Johnston, AM			Use of antimicrobial drugs in veterinary practice	BRITISH MEDICAL JOURNAL			English	Article							ANIMALS		Univ London Royal Coll Vet Surg, Dept Farm Anim & Equine Med & Surg, Hatfield AL9 7TA, Herts, England	University of London; University of London Royal Veterinary College	Johnston, AM (corresponding author), Univ London Royal Coll Vet Surg, Dept Farm Anim & Equine Med & Surg, Hatfield AL9 7TA, Herts, England.							BROWN SA, 1996, J VET PHARMACOL THER, V1, P1; Cars O, 1997, DRUGS, V54, P4, DOI 10.2165/00003495-199700546-00004; Fleming A, 1929, BRIT J EXP PATHOL, V10, P226; FOLEY EG, 1946, J FOOD TECHNOL, V8, P129; *JOINT COMM US ANT, 1968, REP; SCHRODER J, 1989, J S AFR VET ASSOC, V60, P122; VANCUTSEM PM, 1990, CORNELL VET, V80, P173; WALTON JR, 1983, ZBL VET MED A, V30, P81; WALTON JR, 1980, IN PRACTICE      NOV, P29	9	25	28	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	SEP 5	1998	317	7159					665	667		10.1136/bmj.317.7159.665	http://dx.doi.org/10.1136/bmj.317.7159.665			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	118GN	9728002	Green Published			2022-12-28	WOS:000075830200032
J	Wise, R				Wise, R			Science, medicine, and the future - The development of new antimicrobial agents	BRITISH MEDICAL JOURNAL			English	Review							IN-VITRO ACTIVITY		City Hosp Trust, Dept Med Microbiol, Birmingham B18 7QH, W Midlands, England		Wise, R (corresponding author), City Hosp Trust, Dept Med Microbiol, Birmingham B18 7QH, W Midlands, England.							CHILD J, 1995, J ANTIMICROB CHEMOTH, V35, P869, DOI 10.1093/jac/35.6.869; COMICAN MG, 1997, ANTIMICROB AGENT CHE, V41, P204; DIMODUGNO E, 1994, ANTIMICROB AGENTS CH, V38, P2362, DOI 10.1128/AAC.38.10.2362; Hartman G, 1998, LANCET, V351, P848, DOI 10.1016/S0140-6736(05)70282-8; *HOUS LORDS SEL CO, 1998, 7 HOUS LORDS SEL COM; Knowles DJC, 1997, TRENDS MICROBIOL, V5, P379, DOI 10.1016/S0966-842X(97)01128-1; LEE VJ, 1998, CLEAR, V1, P39; Wainwright M, 1998, J ANTIMICROB CHEMOTH, V42, P13, DOI 10.1093/jac/42.1.13; WERNER G, IN PRESS EUR J CLIN; ZASLOFF M, 1987, P NATL ACAD SCI USA, V84, P5449, DOI 10.1073/pnas.84.15.5449	10	3	4	1	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	SEP 5	1998	317	7159					643	644		10.1136/bmj.317.7159.643	http://dx.doi.org/10.1136/bmj.317.7159.643			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	118GN	9727993	Green Published			2022-12-28	WOS:000075830200023
J	Lawrence, DJ; Feldman, WC; Barraclough, BL; Binder, AB; Elphic, RC; Maurice, S; Thomsen, DR				Lawrence, DJ; Feldman, WC; Barraclough, BL; Binder, AB; Elphic, RC; Maurice, S; Thomsen, DR			Global elemental maps of the moon: The Lunar Prospector gamma-ray spectrometer	SCIENCE			English	Article							ACTIVATION	Lunar Prospector gamma-ray spectrometer spectra along with counting rate maps of thorium, potassium, and iron delineate Large compositional variations over the lunar surface. Thorium and potassium are highly concentrated in and around the nearside western maria and Less so in the South Pole-Aitken basin. Counting rate maps of iron gamma-rays show a surface iron distribution that is in general agreement with other measurements from Clementine and the Lunar Prospector neutron detectors.	Univ Calif Los Alamos Natl Lab, Los Alamos, NM 87545 USA; Lunar Res Inst, Gilroy, CA 95020 USA; Observ Midi Pyrenees, F-31400 Toulouse, France	United States Department of Energy (DOE); Los Alamos National Laboratory; Universite de Toulouse; Universite Toulouse III - Paul Sabatier	Lawrence, DJ (corresponding author), Univ Calif Los Alamos Natl Lab, Mail Stop D466, Los Alamos, NM 87545 USA.		Lawrence, David J/E-7463-2015	Lawrence, David J/0000-0002-7696-6667				FELDMAN WC, 1996, LUNAR PLANET SCI, V27, P355; HASKIN L, 1991, LUNAR SOURCEBOOK USE, P357; LUCEY PG, 1995, J GEOPHYS RES, V266, P1855; METZGER AE, 1993, REMOTE GEOCHEMICAL A, P341; *NAS LUN EXPL SCI, 1992, JSC25920 NASA LUN EX; Reedy R.C., 1978, P LUN PLAN SCI 9, P2961; Schultz P.H., 1979, P LUNAR PLANET SCI C, P2899; SCHULTZ PH, 1983, NATURE, V302, P233, DOI 10.1038/302233a0; Smith DE, 1997, J GEOPHYS RES-PLANET, V102, P1591, DOI 10.1029/96JE02940; Truscott PR, 1996, IEEE T NUCL SCI, V43, P1510, DOI 10.1109/23.507094; TRUSCOTT PR, 1995, IEEE T NUCL SCI, V42, P946, DOI 10.1109/23.467766; [No title captured]	12	226	241	4	30	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 4	1998	281	5382					1484	1489		10.1126/science.281.5382.1484	http://dx.doi.org/10.1126/science.281.5382.1484			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	116RJ	9727970				2022-12-28	WOS:000075738100034
J	Beran, RL; Lawson, GE				Beran, RL; Lawson, GE			Medical student financial assistance, 1996-1997	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Loans account for the major portion of financial aid available to medical students. In the academic year 1996-1997, 80.1% of all available financial aid came from loans, and medical students borrowed more than $1.11 billion. Of the 1997 medical school graduating class, 83.2% had educational debt, 46% of whom had mean educational debt levels higher than $75 000.	Assoc Amer Med Coll, Div Student Affairs & Educ Serv, Washington, DC 20037 USA; Assoc Amer Med Coll, Sect Inst & Fac Studies, Washington, DC 20037 USA	Association of American Medical Colleges; Association of American Medical Colleges	Beran, RL (corresponding author), Assoc Amer Med Coll, Div Student Affairs & Educ Serv, 2450 N St NW, Washington, DC 20037 USA.								0	20	20	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 2	1998	280	9					819	820		10.1001/jama.280.9.819	http://dx.doi.org/10.1001/jama.280.9.819			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	114LA	9729995				2022-12-28	WOS:000075609900012
J	Gaine, SP; Rubin, LJ				Gaine, SP; Rubin, LJ			Primary pulmonary hypertension	LANCET			English	Article							HEART-LUNG TRANSPLANTATION; INTRAVENOUS EPOPROSTENOL PROSTACYCLIN; INHALED NITRIC-OXIDE; SLEEP-APNEA SYNDROME; ATRIAL SEPTOSTOMY; SURVIVAL; REGISTRY; INFUSION; ENDOTHELIN-1; ARTERIOPATHY	Primary pulmonary hypertension (PPH) is a progressive disease characterised by raised pulmonary vascular resistance, which results in diminished right-heart function due to increased right ventricular afterload. PPH occurs most commonly in young and middle-aged women; mean survival from onset of symptoms is 2-3 years. The aetiology of PPH is unknown, although familia! disease accounts for roughly 10% of cases, which suggests a genetic predisposition. Current theories on pathogenesss focus on abnormalities in interaction between endothelial and smooth-muscle cells. Endothelial-cell injury may result in an imbalance in endothelium-derived mediators, favouring vasoconstriction. Defects in ion-channel activity in smooth-muscle cells in the pulmonary artery may contribute to vasoconstriction and vascular proliferation. Diagnostic testing primarily excludes secondary causes. Catheterisation is necessary to assess haemodynamics and to evaluate vasoreactivity during acute drug challenge. Decrease in pulmonary vascular resistance in response to acute vasodilator challenge occurs in about 30% of patients, and predicts a good response to chronic therapy with oral calcium-channel blockers. For patients unresponsive during acute testing, continuous intravenous epoprostenol (prostacyclin, PGI(2)) improves haemodynamics and exercise tolerance, and prolongs survival in severe PPH (NYHA functional class III-IV). Thoracic transplantation is reserved for patients who fail medical therapy. We review the progress made in diagnosis and treatment of PPH over the past 20 years.	Univ Maryland, Sch Med, Div Pulm & Crit Care Med, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore	Gaine, SP (corresponding author), Univ Maryland, Sch Med, Div Pulm & Crit Care Med, 10 S Pine St,Room 800, Baltimore, MD 21201 USA.			Gaine, Sean/0000-0002-5941-684X				Abenhaim L, 1996, NEW ENGL J MED, V335, P609, DOI 10.1056/NEJM199608293350901; Anderson G, 1973, Clin Radiol, V24, P113, DOI 10.1016/S0009-9260(73)80129-1; BANDO K, 1994, J THORAC CARDIOV SUR, V108, P1056, DOI 10.1016/S0022-5223(94)70148-2; Barst RJ, 1996, NEW ENGL J MED, V334, P296, DOI 10.1056/NEJM199602013340504; BARST RJ, 1994, ANN INTERN MED, V121, P409, DOI 10.7326/0003-4819-121-6-199409150-00003; BJORNSSON J, 1985, MAYO CLIN PROC, V60, P16, DOI 10.1016/S0025-6196(12)65277-X; BRENOT F, 1994, CHEST, V105, pS33, DOI 10.1378/chest.105.2_Supplement.33S; CHRISTMAN BW, 1992, NEW ENGL J MED, V327, P70, DOI 10.1056/NEJM199207093270202; Connolly HM, 1997, NEW ENGL J MED, V337, P581, DOI 10.1056/NEJM199708283370901; DALONZO GE, 1991, ANN INTERN MED, V115, P343, DOI 10.7326/0003-4819-115-5-343; DALONZO GE, 1987, CHEST, V92, P57, DOI 10.1378/chest.92.1.57; DALONZO GE, 1984, CHEST, V85, P457, DOI 10.1378/chest.85.4.457; DRESDALE DT, 1951, AM J MED, V11, P686, DOI 10.1016/0002-9343(51)90020-4; FISHMAN AP, 1974, CIRC RES, V35, P657, DOI 10.1161/01.RES.35.5.657; FUSTER V, 1984, CIRCULATION, V70, P580, DOI 10.1161/01.CIR.70.4.580; Gaine SP, 1998, AM J MED SCI, V315, P179, DOI 10.1097/00000441-199803000-00006; GIAID A, 1993, NEW ENGL J MED, V328, P1732, DOI 10.1056/NEJM199306173282402; GIAID A, 1995, NEW ENGL J MED, V333, P214, DOI 10.1056/NEJM199507273330403; GLANVILLE AR, 1987, CHEST, V91, P675, DOI 10.1378/chest.91.5.675; GRIFFITH BP, 1993, ANN SURG, V218, P310, DOI 10.1097/00000658-199309000-00010; GURTNER HP, 1985, COR VASA, V27, P160; Hatano S, 1975, PRIMARY PULMONARY HY, P1; HAUSKNECHT MJ, 1990, AM J CARDIOL, V65, P1045, DOI 10.1016/0002-9149(90)91016-Y; HEATH D, 1958, CIRCULATION, V18, P533, DOI 10.1161/01.CIR.18.4.533; HERVE P, 1995, AM J MED, V99, P249, DOI 10.1016/S0002-9343(99)80156-9; HIGENBOTTAM T, 1984, LANCET, V1, P1046; HIGENBOTTAM TW, 1993, BRIT HEART J, V70, P366; Hinderliter AL, 1997, CIRCULATION, V95, P1479; *INT PRIM PULM HYP, 1994, CHEST, V105, pS37; ISERN RA, 1992, AM J MED, V93, P307, DOI 10.1016/0002-9343(92)90238-7; KERSTEIN D, 1995, CIRCULATION, V91, P2028, DOI 10.1161/01.CIR.91.7.2028; Kessler R, 1996, EUR RESPIR J, V9, P787, DOI 10.1183/09031936.96.09040787; Kuo PC, 1997, TRANSPLANTATION, V63, P604, DOI 10.1097/00007890-199702270-00020; LANGLEBEN D, 1994, CHEST, V105, pS13, DOI 10.1378/chest.105.2_Supplement.13S; LOUIE EK, 1986, J AM COLL CARDIOL, V8, P1298, DOI 10.1016/S0735-1097(86)80300-X; Loyd JE, 1997, CHEST, V111, pS82, DOI 10.1378/chest.111.6_Supplement.82S; LOYD JE, 1995, AM J RESP CRIT CARE, V152, P93, DOI 10.1164/ajrccm.152.1.7599869; LOYD JE, 1984, AM REV RESPIR DIS, V129, P194; MCDONNELL PJ, 1983, AM REV RESPIR DIS, V127, P437, DOI 10.1164/arrd.1983.127.4.437; METTE SA, 1992, AM REV RESPIR DIS, V145, P1196, DOI 10.1164/ajrccm/145.5.1196; MOSER KM, 1988, WESTERN J MED, V148, P167; Nichols WC, 1997, NAT GENET, V15, P277, DOI 10.1038/ng0397-277; OAKLEY C, 1968, LANCET, V1, P890; OAKLEY CW, 1994, CHEST, V105, pS29, DOI 10.1378/chest.105.2_Supplement.29S; Olschewski H, 1996, ANN INTERN MED, V124, P820, DOI 10.7326/0003-4819-124-9-199605010-00006; PALEVSKY HI, 1989, CIRCULATION, V80, P1207, DOI 10.1161/01.CIR.80.5.1207; PASQUE MK, 1992, J THORAC CARDIOV SUR, V103, P475; PEPKEZABA J, 1991, LANCET, V338, P1173, DOI 10.1016/0140-6736(91)92033-X; PIETRA GG, 1989, CIRCULATION, V80, P1198, DOI 10.1161/01.CIR.80.5.1198; REITZ BA, 1982, NEW ENGL J MED, V306, P557, DOI 10.1056/NEJM198203113061001; RICH S, 1986, J AM COLL CARDIOL, V8, P1307, DOI 10.1016/S0735-1097(86)80301-1; RICH S, 1987, ANN INTERN MED, V107, P216, DOI 10.7326/0003-4819-107-2-216; RICH S, 1992, NEW ENGL J MED, V327, P76, DOI 10.1056/NEJM199207093270203; Romberg E., 1891, DTSCH ARCH KLIN MED, V48, P197; RUBIN L, 1987, CHEST, V104, P236; RUBIN LJ, 1990, ANN INTERN MED, V112, P485, DOI 10.7326/0003-4819-112-7-485; RUBIN LJ, 1982, CIRCULATION, V66, P334, DOI 10.1161/01.CIR.66.2.334; RUBIN LJ, 1997, PRIMARY PULMONARY HY, P271; SCHAIBERGER PH, 1993, CHEST, V104, P614, DOI 10.1378/chest.104.2.614; Shapiro SM, 1997, J AM COLL CARDIOL, V30, P343, DOI 10.1016/S0735-1097(97)00187-3; SNELL GI, 1995, AM J RESP CRIT CARE, V151, P1263; STEWART DJ, 1991, ANN INTERN MED, V114, P464, DOI 10.7326/0003-4819-114-6-464; TUDER RM, 1994, SEM RESP CRIT CARE M, V15, P207, DOI 10.1055/s-2007-1006364; VOELKEL NF, 1997, PRIMARY PULMONARY HY, P83; WAGENVOORT CA, 1970, CIRCULATION, V42, P1163, DOI 10.1161/01.CIR.42.6.1163; WAGENVOORT CA, 1993, CHEST, V103, P844, DOI 10.1378/chest.103.3.844; WEIR EK, 1989, AM REV RESPIR DIS, V140, P1623, DOI 10.1164/ajrccm/140.6.1623; WEITZENBLUM E, 1988, AM REV RESPIR DIS, V138, P345, DOI 10.1164/ajrccm/138.2.345; WOOD P, 1958, BRIT HEART J, V20, P557; Yuan XJ, 1998, LANCET, V351, P726, DOI 10.1016/S0140-6736(05)78495-6	70	391	424	0	11	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 29	1998	352	9129					719	725		10.1016/S0140-6736(98)02111-4	http://dx.doi.org/10.1016/S0140-6736(98)02111-4			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	116MT	9729004				2022-12-28	WOS:000075729700046
J	Roberts, I; Po, ALW; Chalmers, L				Roberts, I; Po, ALW; Chalmers, L			Intellectual property, drug licensing, freedom of information, and public health	LANCET			English	Article									Inst Child Hlth, Dept Epidemiol & Publ Hlth, Child Hlth Monitoring Unit, London WC1N 1EH, England; Univ Nottingham, Sch Pharm, Ctr Evidence Based Pharmacotherapy, Nottingham NG7 2RD, England; UK Cohrane Ctr, NHS R&D Programme, Oxford, England	University of London; University College London; University of Nottingham	Roberts, I (corresponding author), Inst Child Hlth, Dept Epidemiol & Publ Hlth, Child Hlth Monitoring Unit, 30 Guilford St, London WC1N 1EH, England.							*ASS BRIT PHARM IN, 1998, ABPI COMP DAT SHEETS; *BIO PROD LAB, ALB CLIN PAP; Blunt J, 1998, BMJ-BRIT MED J, V316, P58, DOI 10.1136/bmj.316.7124.58; BOSELEY S, 1998, GUARDIAN        0218, P2; BROWN RO, 1988, CRIT CARE MED, V16, P1177, DOI 10.1097/00003246-198812000-00002; *CEM CMO, 1998, CEMCMO9811; *COCHR INJ GROUP A, 1998, COCHR LIB; Dent THS, 1997, BMJ-BRIT MED J, V315, P1248, DOI 10.1136/bmj.315.7118.1248; HEMMINKI E, 1980, BRIT MED J, V280, P833, DOI 10.1136/bmj.280.6217.833; HORROBIN DF, 1995, BRIT MED J, V311, P688, DOI 10.1136/bmj.311.7006.688a; *INS DEP DIAB TRUS, 1998, PAT MAN; Mitchell P, 1998, LANCET, V352, P377, DOI 10.1016/S0140-6736(05)60480-1; MONTAGNE M, 1996, CLIN RES PHARM DEV, P62; *OFF SCI TECHN, 1997, US SCI ADV POL MAK; Ollila E, 1996, Int J Risk Saf Med, V9, P161, DOI 10.3233/JRS-1996-9306; ONeill RT, 1996, CLIN RES REGUL AFF, V13, P23, DOI 10.3109/10601339609019626; Peters T., 1996, ALL ALBUMIN BIOCH GE; 1997, CM3818	18	19	19	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	AUG 29	1998	352	9129					726	729		10.1016/S0140-6736(98)07600-4	http://dx.doi.org/10.1016/S0140-6736(98)07600-4			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	116MT	9729005				2022-12-28	WOS:000075729700047
J	Moldowan, JM; Talyzina, NM				Moldowan, JM; Talyzina, NM			Biogeochemical evidence for dinoflagellate ancestors in the Early Cambrian	SCIENCE			English	Article							4-METHYL STEROLS; STERANE	Dinoflagellates are single-celled organisms that reflect the ecological conditions in modern oceans and Lakes. Ultrastructural data and molecular phylogeny suggest that they originated in the Neoproterozoic, yet dinoflagellate ancestors are classified only to the Middle Triassic (similar to 240 million years ago). Examination of dinoflagellate-specific biological markers (dinosteranes and 4 alpha-methyl-24-ethylcholestane) in concentrated microfossils with known morphology identified ancient dinoflagellate ancestors from the Early Cambrian (similar to 520 million years ago).	Stanford Univ, Dept Geol & Environm Sci, Stanford, CA 94305 USA; Uppsala Univ, Dept Earth Sci Hist Geol & Paleontol, S-75236 Uppsala, Sweden	Stanford University; Uppsala University	Moldowan, JM (corresponding author), Stanford Univ, Dept Geol & Environm Sci, Stanford, CA 94305 USA.							ANDERSON DM, 1985, LIMNOL OCEANOGR, V30, P1000, DOI 10.4319/lo.1985.30.5.1000; Dale B, 1996, PALYNOLOGY PRINCIPLE, P1249; FENSOME RA, 1993, 7 MICROPALEONTOL SPE; Goodman D.K., 1987, Botanical Monographs (Oxford), V21, P649; GUYOHLSON D, 1992, PHYCOLOGIA, V31, P523, DOI 10.2216/i0031-8884-31-6-523.1; Hayes J. M., 1983, EARTHS EARLIEST BIOS, P93; HELBY R, 1987, ASS AUSTRALASIAN PAL, V4, P1; Knoll A.H., 1996, PALYNOLOGY PRINCIPLE, V1, P51; Lipps Jere H., 1993, P1; Margulis L., 1982, 5 KINGDOMS ILLUSTRAT; MARTIN F, 1973, NEUSSER JB GEOL PALA, P44; Mendelson Carl V., 1993, P77; MENS K, 1987, VALGUS TALLIN, P14; Moldowan JM, 1996, GEOLOGY, V24, P159; MOLDOWAN JM, IN PRESS ECOLOGY CAM; Peters K. E., 1993, BIOMARKER GUIDE INTE; PRATT LM, 1991, GEOCHIM COSMOCHIM AC, V55, P911, DOI 10.1016/0016-7037(91)90351-5; SUMMONS RE, 1990, AM J SCI, V290A, P212; Talyzina NM, 1998, REV PALAEOBOT PALYNO, V100, P99, DOI 10.1016/S0034-6667(97)00059-6; Tappan H, 1980, PALEOBIOLOGY PLANT P; VOLKMAN JK, 1990, ORG GEOCHEM, V15, P489, DOI 10.1016/0146-6380(90)90094-G; VOLKMAN JK, 1993, ORG GEOCHEM, V20, P7, DOI 10.1016/0146-6380(93)90076-N; WALL D, 1968, Micropaleontology (New York), V14, P265, DOI 10.2307/1484690; WARBURTON GA, 1983, ANAL CHEM, V55, P123, DOI 10.1021/ac00252a032; Withers N., 1987, Botanical Monographs (Oxford), V21, P316	25	163	197	1	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 21	1998	281	5380					1168	1170		10.1126/science.281.5380.1168	http://dx.doi.org/10.1126/science.281.5380.1168			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	113CE	9712575				2022-12-28	WOS:000075531200045
J	Munn, DH; Zhou, M; Attwood, JT; Bondarev, I; Conway, SJ; Marshall, B; Brown, C; Mellor, AL				Munn, DH; Zhou, M; Attwood, JT; Bondarev, I; Conway, SJ; Marshall, B; Brown, C; Mellor, AL			Prevention of allogeneic fetal rejection by tryptophan catabolism	SCIENCE			English	Article							COLONY-STIMULATING FACTOR; INDOLEAMINE 2,3-DIOXYGENASE; DIFFERENTIATION; PREGNANCY	In 1953 Medawar pointed out that survival of the genetically disparate (allogeneic) mammalian conceptus contradicts the Laws of tissue transplantation. Rapid T cell-induced rejection of all allogeneic concepti occurred when pregnant mice were treated with a pharmacologic inhibitor of indoleamine 2,3-dioxygenase (IDO), a tryptophan-catabolizing enzyme expressed by trophoblasts and macrophages. Thus, by catabolizing tryptophan, the mammalian conceptus suppresses T cell activity and defends itself against rejection.	Med Coll Georgia, Inst Mol Med & Genet, Program Mol Immunol, Augusta, GA 30912 USA; Med Coll Georgia, Inst Mol Med & Genet, Program Dev Biol, Augusta, GA 30912 USA; Med Coll Georgia, Dept Pediat, Augusta, GA 30912 USA; Univ Georgia, Dept Pathol, Athens, GA 30602 USA	University System of Georgia; Augusta University; University System of Georgia; Augusta University; University System of Georgia; Augusta University; University System of Georgia; University of Georgia	Mellor, AL (corresponding author), Med Coll Georgia, Inst Mol Med & Genet, Program Mol Immunol, 1120 15th St, Augusta, GA 30912 USA.	mellor@immag.mcg.edu		Munn, David/0000-0002-7711-2858				Bonney EA, 1997, J IMMUNOL, V158, P40; CADY SG, 1991, ARCH BIOCHEM BIOPHYS, V291, P326, DOI 10.1016/0003-9861(91)90142-6; HABARAOHKUBO A, 1991, GENE, V105, P221, DOI 10.1016/0378-1119(91)90154-4; KAMIMURA S, 1991, ACTA MED OKAYAMA, V45, P135; MEDAWAR PB, 1953, SYM SOC EXP BIOL, V7, P320; MUNN DH, 1993, CANCER RES, V53, P2603; Munn DH, 1996, J IMMUNOL, V156, P523; MUNN DH, UNPUB; MUNN DH, UNPUB HUMAN MACROPHA; POLLARD WJ, 1997, MOL REPROD DEV, V46, P54; Schrocksnadel H, 1996, OBSTET GYNECOL, V88, P47, DOI 10.1016/0029-7844(96)00084-1; SPANOPOULOU E, 1994, GENE DEV, V8, P1030, DOI 10.1101/gad.8.9.1030; TAFURI A, 1995, SCIENCE, V270, P630, DOI 10.1126/science.270.5236.630; Tarazona R, 1996, INT IMMUNOL, V8, P351, DOI 10.1093/intimm/8.3.351; ZHOU M, IN PRESS J REPROD IM; ZHOU M, UNPUB	16	1990	2130	2	119	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 21	1998	281	5380					1191	1193		10.1126/science.281.5380.1191	http://dx.doi.org/10.1126/science.281.5380.1191			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	113CE	9712583				2022-12-28	WOS:000075531200053
J	Breman, JG; Henderson, DA				Breman, JG; Henderson, DA			Poxvirus dilemmas - Monkeypox, smallpox, and biologic terrorism	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							VIRUS STOCKS; GENOME; SEQUENCE; STRAIN; DNA		NIH, Bethesda, MD 20892 USA; Johns Hopkins Univ, Sch Hyg & Publ Hlth, Baltimore, MD 21205 USA	National Institutes of Health (NIH) - USA; Johns Hopkins University	Breman, JG (corresponding author), NIH, Bldg 10, Bethesda, MD 20892 USA.							[Anonymous], 1997, MMWR-MORBID MORTAL W, V46, P1; Betts RK, 1998, FOREIGN AFF, V77, P26, DOI 10.2307/20048360; BREMAN JG, 1980, B WORLD HEALTH ORGAN, V58, P165; BREMAN JG, 1980, NEW ENGL J MED, V303, P1263, DOI 10.1056/NEJM198011273032204; COHEN J, 1996, 6 PLEN M A49 VR 6 GE; FENNER F, 1988, HIST INT PUBLIC HLTH, V6; FINE PEM, 1988, INT J EPIDEMIOL, V17, P643, DOI 10.1093/ije/17.3.643; FOSTER SO, 1970, J NIGERIAN MED ASSOC, V7, P41; Franz DR, 1997, JAMA-J AM MED ASSOC, V278, P399, DOI 10.1001/jama.278.5.399; GARRETT L, 1997, NEWSDAY         0810, P1; HENDERSON DA, IN PRESS EMERG INFEC; Heymann DL, 1998, BRIT MED BULL, V54, P693, DOI 10.1093/oxfordjournals.bmb.a011720; JEZEK Z, 1987, AM J EPIDEMIOL, V126, P1082, DOI 10.1093/oxfordjournals.aje.a114747; JEZEK Z, 1988, B WORLD HEALTH ORGAN, V66, P465; Jezek Z, 1988, HUMAN MONKEYPOX, V17; JOKLIK WK, 1993, SCIENCE, V262, P1225, DOI 10.1126/science.8235652; Joklik WK, 1996, SCIENTIST, V10, P11; Kadlec RP, 1997, JAMA-J AM MED ASSOC, V278, P351, DOI 10.1001/jama.278.5.351; KUPPERMAN RH, 1993, BIOL WEAPONS WEAPONS, P35; LADNYJ ID, 1972, B WORLD HEALTH ORGAN, V46, P593; LANE JM, 1969, NEW ENGL J MED, V281, P1201, DOI 10.1056/NEJM196911272812201; MAHY BWJ, 1993, SCIENCE, V262, P1223, DOI 10.1126/science.8235651; MAHY BWJ, 1993, REV MED VIROL, V3, P131, DOI 10.1002/rmv.1980030302; MAHY BWJ, 1991, ASM NEWS, V57, P577; Massung RF, 1996, VIROLOGY, V221, P291, DOI 10.1006/viro.1996.0378; MASSUNG RF, 1993, NATURE, V366, P748, DOI 10.1038/366748a0; MASSUNG RF, 1994, VIROLOGY, V201, P215, DOI 10.1006/viro.1994.1288; Moss B, 1996, P NATL ACAD SCI USA, V93, P11341, DOI 10.1073/pnas.93.21.11341; Mukinda VBK, 1997, LANCET, V349, P1449, DOI 10.1016/S0140-6736(05)63725-7; Preston R., 1998, NEW YORKER, P52; RAO AR, 1968, INDIAN J MED RES, V56, P1826; ROIZMAN B, 1994, INFECT AGENT DIS, V3, P215; Senkevich TG, 1996, SCIENCE, V273, P813, DOI 10.1126/science.273.5276.813; SHCHELKUNOV SN, 1995, VIRUS RES, V36, P107, DOI 10.1016/0168-1702(94)00113-Q; Simon JD, 1997, JAMA-J AM MED ASSOC, V278, P428, DOI 10.1001/jama.278.5.428; Simon JD., 1989, TERRORISTS POTENTIAL; SUTTER G, 1995, DEV BIOL STAND, V84, P195; *WHO, 1997, WKLY EPIDEMIOL REC, V72, P369; *WHO, 1980, HLTH INT PUBL HLTH, V4; Zilinskas RA, 1997, JAMA-J AM MED ASSOC, V278, P418, DOI 10.1001/jama.278.5.418; 1997, MMWR MORB MORTAL WKL, V46, P304	41	128	133	0	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 20	1998	339	8					556	559		10.1056/NEJM199808203390811	http://dx.doi.org/10.1056/NEJM199808203390811			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	111PN	9709051				2022-12-28	WOS:000075447000011
J	Roddy, RE; Zekeng, L; Ryan, KA; Tamoufe, U; Weir, SS; Wong, EL				Roddy, RE; Zekeng, L; Ryan, KA; Tamoufe, U; Weir, SS; Wong, EL			A controlled trial of nonoxynol 9 film to reduce male-to-female transmission of sexually transmitted diseases	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HUMAN IMMUNODEFICIENCY VIRUS; CHLAMYDIA-TRACHOMATIS; NEISSERIA-GONORRHOEAE; CONTRACEPTIVE SPONGE; CHEMICAL BARRIERS; HIV-INFECTION; IN-VITRO; INVITRO; INACTIVATION; CONDOMS	Background Nonoxynol 9 is a proved spermicide, but whether it is also a microbicide is uncertain. A truly effective vaginal microbicide would reduce the susceptibility of women to sexually transmitted diseases, including infection with the human immunodeficiency virus (HIV). Methods We enrolled 1292 HIV-negative female sex workers in Cameroon in a double-blind, placebo-controlled study in which the participants were randomly assigned to use either a film containing 70 mg of nonoxynol 9 or a placebo film, inserted into the vagina before intercourse. All of the women were provided with latex condoms and were instructed to have their male sexual partners use them. At monthly follow-up visits, we examined the women with a colposcope for genital lesions, tested endocervical specimens for gonorrhea and chlamydia infection with DNA probes, tested for HIV infection, and treated the women for curable sexually transmitted diseases. Results The rates of HIV infection (cases per 100 woman-years) were 6.7 in the nonoxynol 9 group and 6.6 in the placebo group (rate ratio, 1.0; 95 per cent confidence interval, 0.7 to 1.5). The rates of genital lesions were 42.2 cases per 100 woman-years in the nonoxynol 9 group and 33.5 in the placebo group (rate ratio, 1.3; 95 percent confidence interval, 1.0 to 1.6). The rates of gonorrhea were 33.3 and 31.1 cases per 100 woman-years in the nonoxynol 9 and placebo groups, respectively (rate ratio, 1.1; 95 percent confidence interval, 0.8 to 1.4). The corresponding rates of chlamydia infection in the nonoxynol 9 group and the placebo group were 20.6 and 22.2 cases per 100 woman-years (rate ratio, 0.9; 95 percent confidence interval, 0.7 to 1.3). The women reported that condoms were used during 90 percent of sexual acts. Conclusions The use of a nonoxynol 9 vaginal film did not reduce the rate of new HIV, gonorrhea, or chlamydia infection in this group of sex workers who used condoms and received treatment for sexually transmitted diseases. (N Engl J Med 1998;339: 504-10.) (C)1998, Massachusetts Medical Society.	Family Hlth Int, Epidemiol Unit, Durham, NC 27709 USA; Family Hlth Int, Div Biostat, Durham, NC 27709 USA; Minist Publ Hlth, Yaounde, Cameroon		Roddy, RE (corresponding author), Family Hlth Int, Epidemiol Unit, POB 13950, Durham, NC 27709 USA.		Wong, Eliza Lai-Yi/ABI-2092-2020; Weir, Sharon/A-8205-2009	Weir, Sharon/0000-0001-6014-1460	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI034714] Funding Source: NIH RePORTER; NIAID NIH HHS [AI34714] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ASCULAI SS, 1978, ANTIMICROB AGENTS CH, V13, P686, DOI 10.1128/AAC.13.4.686; BARBONE F, 1990, AM J OBSTET GYNECOL, V163, P510, DOI 10.1016/0002-9378(90)91186-G; BENES S, 1985, ANTIMICROB AGENTS CH, V27, P724, DOI 10.1128/AAC.27.5.724; BOLCH OH, 1973, AM J OBSTET GYNECOL, V115, P1145, DOI 10.1016/0002-9378(73)90566-8; HICKS DR, 1985, LANCET, V2, P1422; Hira SK, 1997, INT J STD AIDS, V8, P243, DOI 10.1258/0956462971919994; JONES BM, 1991, GENITOURIN MED, V67, P268; JUDSON FN, 1989, SEX TRANSM DIS, V16, P51, DOI 10.1097/00007435-198904000-00001; KELLY JP, 1985, ANTIMICROB AGENTS CH, V27, P760, DOI 10.1128/AAC.27.5.760; KREISS J, 1992, JAMA-J AM MED ASSOC, V268, P477, DOI 10.1001/jama.268.4.477; LAN KKG, 1983, BIOMETRIKA, V70, P659, DOI 10.2307/2336502; LOUV WC, 1988, J INFECT DIS, V158, P518, DOI 10.1093/infdis/158.3.518; MALKOVSKY M, 1988, LANCET, V1, P645; Mauck CK, 1997, CONTRACEPTION, V56, P103, DOI 10.1016/S0010-7824(97)00100-5; MILLER CJ, 1992, FERTIL STERIL, V57, P1126; MOENCH TR, 1993, AIDS, V7, P797, DOI 10.1097/00002030-199306000-00006; NIRUTHISARD S, 1992, LANCET, V339, P1371, DOI 10.1016/0140-6736(92)91195-E; *NY STAT DEP HLTH, 1994, WOM ONL WHAT WOM CAN; POLSKY B, 1988, LANCET, V1, P1456; RIETMEIJER CAM, 1988, JAMA-J AM MED ASSOC, V259, P1851, DOI 10.1001/jama.259.12.1851; Roddy RE, 1998, SEX TRANSM DIS, V25, P151, DOI 10.1097/00007435-199803000-00008; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408; SINGH B, 1972, BRIT J VENER DIS, V48, P57; SINGH B, 1976, AM J OBSTET GYNECOL, V126, P422, DOI 10.1016/0002-9378(76)90630-X; Turner CF, 1997, SEX TRANSM DIS, V24, P522, DOI 10.1097/00007435-199710000-00005; ZEKENG L, 1993, AIDS, V7, P725, DOI 10.1097/00002030-199305000-00018	26	315	332	0	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 20	1998	339	8					504	510		10.1056/NEJM199808203390803	http://dx.doi.org/10.1056/NEJM199808203390803			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	111PN	9709043	Bronze			2022-12-28	WOS:000075447000003
J	Mullan, F				Mullan, F			Linda Headrick, MD - Seeking a common language in primary care	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Biographical-Item									Hlth Affairs, Bethesda, MD 20814 USA; George Washington Univ, Sch Med & Hlth Sci, Washington, DC 20052 USA	George Washington University	Mullan, F (corresponding author), Hlth Affairs, 7500 Old Georgetown Rd,Suite 600, Bethesda, MD 20814 USA.								0	0	0	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 19	1998	280	7					655	658		10.1001/jama.280.7.655	http://dx.doi.org/10.1001/jama.280.7.655			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	110ME	9718063				2022-12-28	WOS:000075384300040
J	Emanuel, EJ; Daniels, ER; Fairclough, DL; Clarridge, BR				Emanuel, EJ; Daniels, ER; Fairclough, DL; Clarridge, BR			The practice of euthanasia and physician-assisted suicide in the United States - Adherence to proposed safeguards and effects on physicians	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							ACTIVE EUTHANASIA; WASHINGTON-STATE; CANCER-PATIENTS; ATTITUDES; NETHERLANDS; LIFE; END; EXPERIENCES; PREVALENCE; DECISIONS	Context.-Despite intense debates about legalization, there are few data examining the details of actual euthanasia and physician-assisted suicide (PAS) cases in the United States. Objective.-To determine whether the practices of euthanasia and PAS are consistent with proposed safeguards and the effect on physicians of having performed euthanasia or PAS. Design.-Structured in-depth telephone interviews. Setting and Participants.-Randomly selected oncologists;in the United States. Outcome Measures.-Adherence to primary and secondary safeguards for the practice of euthanasia and PAS; regret, comfort, and fear of prosecution from performing euthanasia or PAS. Results.-A total of 355 oncologists (72.6% response rate) were interviewed on euthanasia and PAS. On 2 screening questions, 56 oncologists (15.8%) reported participating in euthanasia or PAS; 53 oncologists (94.6% response rate) participated in in-depth interviews. Thirty-eight of 53 oncologists described clearly defined cases of euthanasia or PAS. Twenty-three patients (60.5%) both initiated and repeated their request for euthanasia or PAS, but 6 patients (15.8%) did not participate in the decision for euthanasia or PAS. Thirty-seven patients (97.4%) were experiencing unremitting pain or such poor physical functioning they could not perform self-care. Physicians sought consultation in 15 cases (39.5%), Overall, oncologists adhered to all 3 main safeguards in 13 cases (34.2%), (1) having the patient initiate and repeat the request for euthanasia or PAS, (2) ensuring the patient was experiencing extreme physical pain or suffering, and (3) consulting with a colleague. Those who adhered to the safeguards had known their patients longer and tended to be more religious. In 28 cases (73.7%), the family supported the decision. In all cases of pain, patients were receiving narcotic analgesia. Fifteen patients (39.5%) were enrolled in a hospice, While 19 oncologists (52.6%) received comfort from having helped a patient with euthanasia or PAS, 9 (23.7%) regretted having performed euthanasia or PAS, and 15(39.5%) feared prosecution. Conclusions.-Intractable pain or poor physical functioning seem to be nearly absolute requirements for physicians to perform euthanasia or PAS. Only one third of cases are performed consistently with proposed safeguards. For some patients, end-of-life care that includes opioid analgesia and hospice care does not obviate their desire for euthanasia or PAS. While the majority of physicians seem comforted by their actions, some experience adverse consequences from having performed euthanasia or PAS.	Dana Farber Canc Inst, Div Canc Prevent & Control, Ctr Outcomes & Policy Res, Boston, MA 02115 USA; Amer Med Ctr, Ctr Canc Res, Ctr Res Methodol & Biometr, Denver, CO USA; Univ Massachusetts, Survey Res Ctr, Boston, MA 02125 USA	Harvard University; Dana-Farber Cancer Institute; University of Massachusetts System; University of Massachusetts Boston	Emanuel, EJ (corresponding author), Dana Farber Canc Inst, Div Canc Prevent & Control, Ctr Outcomes & Policy Res, 44 Biney St, Boston, MA 02115 USA.							ALLEBECK P, 1989, J CLIN EPIDEMIOL, V42, P611, DOI 10.1016/0895-4356(89)90003-6; Back AL, 1996, JAMA-J AM MED ASSOC, V275, P919, DOI 10.1001/jama.275.12.919; Baron CH, 1996, HARVARD J LEGIS, V33, P1; Breitbart W, 1996, AM J PSYCHIAT, V153, P238; BROCK DW, 1992, HASTINGS CENT REP, V22, P10, DOI 10.2307/3562560; BRODY H, 1993, J FAM PRACTICE, V37, P123; Callahan Daniel, 1996, Univ Richmond Law Rev, V30, P1; COHEN JS, 1994, NEW ENGL J MED, V331, P89, DOI 10.1056/NEJM199407143310206; DEROGATIS LR, 1983, JAMA-J AM MED ASSOC, V249, P751, DOI 10.1001/jama.249.6.751; DEWACHTER MAM, 1989, JAMA-J AM MED ASSOC, V262, P3316, DOI 10.1001/jama.262.23.3316; EDDY DM, 1994, JAMA-J AM MED ASSOC, V272, P179, DOI 10.1001/jama.272.3.179; EMANUEL EJ, 1994, ARCH INTERN MED, V154, P1890, DOI 10.1001/archinte.154.17.1890; Emanuel EJ, 1996, LANCET, V347, P1805, DOI 10.1016/S0140-6736(96)91621-9; Emanuel EJ, 1996, ARCH INTERN MED, V156, P825, DOI 10.1001/archinte.156.8.825; Emanuel Ezekiel, 1997, Atl Mon, V279, P73; Folker AP, 1996, BIOETHICS, V10, P233, DOI 10.1111/j.1467-8519.1996.tb00122.x; FRIED TR, 1993, ARCH INTERN MED, V153, P722, DOI 10.1001/archinte.153.6.722; GEVERS JKM, 1992, J MED ETHICS, V18, P138, DOI 10.1136/jme.18.3.138; KINSELLA TD, 1993, CAN MED ASSOC J, V148, P1921; Lee MA, 1996, NEW ENGL J MED, V334, P310, DOI 10.1056/NEJM199602013340507; MANDERMAAS PJ, 1991, LANCET, V388, P669; Meier DE, 1998, NEW ENGL J MED, V338, P1193, DOI 10.1056/NEJM199804233381706; MILLER FG, 1994, NEW ENGL J MED, V331, P119, DOI 10.1056/NEJM199407143310211; PIJNENBORG L, 1994, BMJ-BRIT MED J, V309, P1209, DOI 10.1136/bmj.309.6963.1209; PORTENOY RK, 1994, QUAL LIFE RES, V3, P183, DOI 10.1007/BF00435383; QUILL TE, 1992, NEW ENGL J MED, V327, P1380, DOI 10.1056/NEJM199211053271911; QUILL TE, 1998, DEATH DIGNITY MAKING; Ryan CJ, 1996, NEW ENGL J MED, V334, P326, DOI 10.1056/NEJM199602013340512; SHAPIRO RS, 1994, ARCH INTERN MED, V154, P575, DOI 10.1001/archinte.154.5.575; Slome LR, 1997, NEW ENGL J MED, V336, P417, DOI 10.1056/NEJM199702063360606; STEVENS CA, 1994, J MED ETHICS, V20, P41, DOI 10.1136/jme.20.1.41; van der Maas PJ, 1996, NEW ENGL J MED, V335, P1699, DOI 10.1056/NEJM199611283352227; WARD BJ, 1994, BRIT MED J, V308, P1332, DOI 10.1136/bmj.308.6940.1332	33	100	101	0	18	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 12	1998	280	6					507	513		10.1001/jama.280.6.507	http://dx.doi.org/10.1001/jama.280.6.507			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	108AY	9707132				2022-12-28	WOS:000075244900013
J	Bingham, CM; Higgins, G; Coleman, R; Van Der Weyden, MB				Bingham, CM; Higgins, G; Coleman, R; Van Der Weyden, MB			The Medical Journal of Australia Internet peer-review study	LANCET			English	Article								Background Peer review of medical papers is a confidential consultancy between the reviewer and the journal editor, and has been criticised for its potential bias and inadequacy. We explored the potential of the internet for open peer review to see whether this approach improved the quality and outcome df peer review. Methods Research and review articles that had been accepted for publication in The Medical Journal of Australia (MJA) were published together with the reviewers' reports on the worldwide web, with the consent of authors and referees. Selected readers' e-mailed comments were electronically published as additional commentary; authors could reply or revise their paper in response to readers' comments. Articles were edited and published in print after this open review. Findings 60 (81%) of 74 authors agreed to take part in the study, together with 150 (92%) of 162 reviewers. There was no significant difference in the performance of commissioned reviewers before and during the study. Four articles were not included because of insufficient time before print publication. Of the remaining 56 papers, 28 received 52 comments from 42 readers (2% of readers submitted comments). Most readers' comments were short and specific, and seven articles were changed by the authors in response. Interpretation Open peer review is acceptable to most authors and reviewers. Postpublication review by readers on the internet is no substitute for commissioned prepublication review, but can provide editors with valuable input from individuals who would not otherwise be consulted. Readers also gain insight into the processes of peer review and publication.	Med Journal Australia, N Sydney, NSW 2059, Australia; Univ Sydney Lib, Sydney, NSW, Australia	University of Sydney	Bingham, CM (corresponding author), Med Journal Australia, Private Bag 901, N Sydney, NSW 2059, Australia.		higgins, gail/J-1994-2012					BROAD WJ, 1980, SCIENCE, V210, P38, DOI 10.1126/science.210.4465.38; FEURER ID, 1994, JAMA-J AM MED ASSOC, V272, P98, DOI 10.1001/jama.272.2.98; GODLEE F, 1997, INT C BIOM PEER REV; HORROBIN DF, 1990, JAMA-J AM MED ASSOC, V263, P1438, DOI 10.1001/jama.263.10.1438; KASSIRER JP, 1994, JAMA-J AM MED ASSOC, V272, P96, DOI 10.1001/jama.272.2.96; KASSIRER JP, 1995, NEW ENGL J MED, V332, P1709, DOI 10.1056/NEJM199506223322509; LAPORTE RE, 1995, BRIT MED J, V310, P1387, DOI 10.1136/bmj.310.6991.1387; LOCK S, 1991, DIFFICULT BALANCE ED, P15; Pierie JPEN, 1996, LANCET, V348, P1480, DOI 10.1016/S0140-6736(96)05016-7; SHARP DW, 1990, JAMA-J AM MED ASSOC, V263, P1390; Smith R, 1997, BRIT MED J, V315, P759	11	36	37	0	10	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	AUG 8	1998	352	9126					441	445		10.1016/S0140-6736(97)11510-0	http://dx.doi.org/10.1016/S0140-6736(97)11510-0			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	108EA	9708752				2022-12-28	WOS:000075252000011
J	Boers, M				Boers, M			Does sex of rheumatoid arthritis patients matter?	LANCET			English	Editorial Material									Free Univ Amsterdam Hosp, Dept Clin Epidemiol, NL-1007 MB Amsterdam, Netherlands	Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER	Boers, M (corresponding author), Free Univ Amsterdam Hosp, Dept Clin Epidemiol, NL-1007 MB Amsterdam, Netherlands.							ALLEBECK P, 1981, SCAND J RHEUMATOL, V10, P301, DOI 10.3109/03009748109095320; Boers M, 1997, LANCET, V350, P309, DOI 10.1016/S0140-6736(97)01300-7; ELLIOTT MJ, 1994, LANCET, V344, P1105, DOI 10.1016/S0140-6736(94)90628-9; Harrison BJ, 1996, J RHEUMATOL, V23, P1326; KIRWAN JR, 1995, NEW ENGL J MED, V333, P142, DOI 10.1056/NEJM199507203330302; NISSILA M, 1997, ARTHRITIS RHEUM S, V40, pS192; NISSILA M, 1997, ARTHRITIS RHEUM S, V40, pS193; NISSILA M, 1997, ARTHRITIS RHEUM S, V40, pS219; PINCUS T, 1988, J CLIN EPIDEMIOL, V41, P1037, DOI 10.1016/0895-4356(88)90072-8; SCOTT DL, 1987, LANCET, V1, P1108; SILMAN AJ, 1989, BR J RHEUMATOL S1, V28; vanZeben D, 1996, J RHEUMATOL, V23, P31; WEYLAND CM, 1998, ARTHRITIS RHEUM, V41, P817; WOLFE F, 1994, ARTHRITIS RHEUM-US, V37, P481, DOI 10.1002/art.1780370408	14	5	5	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 8	1998	352	9126					419	420		10.1016/S0140-6736(05)79182-0	http://dx.doi.org/10.1016/S0140-6736(05)79182-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	108EA	9708746				2022-12-28	WOS:000075252000005
J	Dolk, H; Vrijheid, M; Armstrong, B; Abramsky, L; Bianchi, F; Garne, E; Nelen, V; Robert, E; Scott, JES; Stone, D; Tenconi, R				Dolk, H; Vrijheid, M; Armstrong, B; Abramsky, L; Bianchi, F; Garne, E; Nelen, V; Robert, E; Scott, JES; Stone, D; Tenconi, R			Risk of congenital anomalies near hazardous-waste landfill sites in Europe: the EUROHAZCON study	LANCET			English	Article							LOW-BIRTH-WEIGHT; MALFORMATIONS; PROXIMITY; DEFECTS; HEALTH	Background Waste-disposal sites are a potential hazard to health. This study is a multicentre case-control study of the risk of congenital anomalies associated with residence near hazardous-waste landfill sites in Europe. Methods We used data from seven regional registers of congenital anomalies in five countries. We studied 1089 livebirths, stillbirths, and terminations of pregnancy with non-chromosomal congenital anomalies and 2366 control births without malformation, whose mothers resided within 7 km of a landfill site; 21 sites were included. A zone within 3 km radius of each site was defined as the "proximate zone" of most likely exposure to teratogens. Findings Residence within 3 km of a landfill site was associated with a significantly raised risk of congenital anomaly (295 eases/511 controls living 0-3 km from sites, 794/1855 living 3-7 hm from sites; combined odds ratio 1.33 [95% CI 1.11-1.59], adjusted for maternal age and socioeconomic status). There was a fairly consistent decrease in risk with distance away from the sites. A significantly raised odds ratio for residence within 3 km of a landfill site was found for neural-tube defects (odds ratio 1.86 [1.24-2.79]), malformations of the cardiac septa (1.49 [1.09-2.04]), and anomalies of great arteries and veins (1.81 [1.02-3.20]). Odds ratios of borderline significance were found for tracheo-oesophageal anomalies (2.25 [0.96-5.26]), hypospadias (1.96 [0.98-3.92]), and gastroschisis (3.19 [0.95-10.77]). There was little evidence of differences in risk between landfill sites but power to detect such differences was low. Interpretation This study shows a raised risk of congenital anomaly in babies whose mothers live close to landfill sites that handle hazardous chemical wastes, although there is a need for further investigation of whether the association of raised risk of congenital anomaly and residence near landfill sites is a causal one. Apparent differences between malformation subgroups should be interpreted cautiously.	Univ London London Sch Hyg & Trop Med, Dept Publ Hlth, Environm Epidemiol Unit, London WC1E 7HT, England; Northwick Pk Hosp, N Thames W Congenital Malformat Register, Harrow, Middx, England; CNR, Inst Clin Physiol, Tuscany EUROCAT Register, I-56100 Pisa, Italy; Odense Univ, Funen Cty EUROCAT Register, DK-5230 Odense, Denmark; Prov Inst Hyg, Antwerp EUROCAT Register, Antwerp, Belgium; Inst Europeen Genomutat, France Cent E Register Congenital Malformat, Lyon, France; Univ Newcastle Upon Tyne, No Congenital Abnormal Survey, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; Univ Glasgow, Glasgow EUROCAT Register, Glasgow G12 8QQ, Lanark, Scotland; Univ Padua, NE Italy REgistry Congenital Malformat, I-35100 Padua, Italy	University of London; London School of Hygiene & Tropical Medicine; Imperial College London; Consiglio Nazionale delle Ricerche (CNR); Istituto di Fisiologia Clinica (IFC-CNR); University of Southern Denmark; Newcastle University - UK; University of Glasgow; University of Padua	Dolk, H (corresponding author), Univ London London Sch Hyg & Trop Med, Dept Publ Hlth, Environm Epidemiol Unit, Keppel St, London WC1E 7HT, England.		Vrijheid, Martine/H-2702-2014; Bianchi, Fabrizio/F-7900-2015	Vrijheid, Martine/0000-0002-7090-1758; Bianchi, Fabrizio/0000-0002-3459-9301				ARMSTRONG BG, 1996, EPIDEMIOLOGY, V7, pS88; Breslow N. E., 1980, IARC SCI PUBLICATION, V32; Carstairs V., 1991, DEPRIVATION HLTH SCO; Croen LA, 1997, EPIDEMIOLOGY, V8, P347, DOI 10.1097/00001648-199707000-00001; *DEP ENV, 1978, COOP PROGR RES BEH H; DIGGLE PJ, 1994, J ROY STAT SOC A STA, V157, P433, DOI 10.2307/2983529; DOLK H, 1997, ONS LONGITUDINAL STU, P6; DOLK H, 1991, EUROCRAT REGISTRY DE, P1; Elwood, 1992, EPIDEMIOLOGY CONTROL; *EUR WORK GROUP, 1997, 7 SCI I PUBL HLTH L; GESCHWIND SA, 1992, AM J EPIDEMIOL, V135, P1197, DOI 10.1093/oxfordjournals.aje.a116226; GOLDMAN LR, 1985, HAZARD WASTE HAZARD, V2, P209, DOI 10.1089/hwm.1985.2.209; HEMMINKI K, 1980, INT ARCH OCC ENV HEA, V46, P93, DOI 10.1007/BF00378188; JONES KL, 1982, SMITHS RECOGNIZABLE; KNOX EG, 1991, FREQUENCIES SOCIAL V; Marshall EG, 1997, ARCH ENVIRON HEALTH, V52, P416, DOI 10.1080/00039899709602220; OLSEN J, 1993, SCAND J SOC MED, V21, P90, DOI 10.1177/140349489302100206; OLSHAN AF, 1991, AM J EPIDEMIOL, V134, P778; PARFITT JP, 1993, 12 U E ANGL ENV RISK; RENWICK M, 1992, ARCH DIS CHILD-FETAL, V67, P770; ROBERT E, 1988, Journal de Gynecologie Obstetrique et biologie de la Reproduction, V17, P601; SHAW GM, 1992, ARCH ENVIRON HEALTH, V47, P147, DOI 10.1080/00039896.1992.10118769; Smith TC, 1995, STAT MED, V14, P2685, DOI 10.1002/sim.4780142408; SOSNIAK WA, 1994, ARCH ENVIRON HEALTH, V49, P251, DOI 10.1080/00039896.1994.9937475; Toppari J, 1996, ENVIRON HEALTH PERSP, V104, P741, DOI 10.2307/3432709; UPTON AC, 1989, ANNU REV PUBL HEALTH, V10, P1; VIANNA NJ, 1984, SCIENCE, V226, P1217, DOI 10.1126/science.6505690	27	219	230	0	27	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	AUG 8	1998	352	9126					423	427		10.1016/S0140-6736(98)01352-X	http://dx.doi.org/10.1016/S0140-6736(98)01352-X			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	108EA	9708749				2022-12-28	WOS:000075252000008
J	Gherardi, RK; Coquet, M; Cherin, P; Authier, FJ; Laforet, P; Belec, L; Figarella-Branger, D; Mussini, JM; Pellissier, JF; Fardeau, M				Gherardi, RK; Coquet, M; Cherin, P; Authier, FJ; Laforet, P; Belec, L; Figarella-Branger, D; Mussini, JM; Pellissier, JF; Fardeau, M		Grp Etudes Rech Maladies Musculaires Acquises	Macrophagic myofasciitis: an emerging entity	LANCET			English	Article							TOXIC OIL SYNDROME; WHIPPLES DISEASE; MYOPATHY; INFECTION; HISTIOCYTOSIS; FASCIITIS; FEATURES; AIDS	Background An unusual inflammatory myopathy characterised by an infiltration of non-epithelioid histiocytic cells has been recorded with increasing frequency in the past 5 years in France. We reassessed some of these cases. Methods We did a retrospective analysis of 18 such cases seen in five myopathology centres between May, 1993, and December, 1997. The myopathological changes were reassessed at a clinopathology seminar. Findings Detailed clinical information was available for 14 patients. The main presumptive diagnoses were polymyositis and polymyalgia rheumatica. Symptoms included myalgias in 12 patients, arthralgias in nine, muscle weakness in six, pronounced asthenia in five, and fever in four. Abnormal laboratory findings were occasionally observed, and included raised creatine kinase concentrations, increased erythrocyte sedimentation rate, and myopathic electromyography. Muscle biopsy showed infiltration of the subcutaneous tissue, epimysium, perimysium, and perifascicular endomysium by sheets of large macrophages, with a finely granular PAS-positive content. Also present were occasional CD8 T cells, and inconspicuous muscle-fibre damage. Epithelioid and giant cells, necrosis, and mitotic figures were not seen. The images were easily distinguishable from sarcoid myopathy and fasciitis-panniculitis syndromes. Whipple's disease, Mycobacterium avium intracellulare infection, and malakoplakia could not be confirmed. Ten patients were treated with various combinations of steroids and antibiotics; symptoms improved in eight patients, and stabilised in two. Interpretation A new inflammatory muscle disorder of unknown cause, characterised by a distinctive pathological pattern of macrophagic myofasciitis, is emerging in France.	Univ Paris 12, Hop Henri Mondor, Dept Pathol, Grp Etud & Rech Muscle & Nerf,EA 2347, F-94010 Creteil, France; Hop Pellegrin, CHU Bordeaux, Dept Anat Pathol, Unite Myopathol, F-33076 Bordeaux, France; Grp Hosp Pitie Salpetriere, INSERM, U153, Serv Med Interne, F-75634 Paris, France; Grp Hosp Pitie Salpetriere, INSERM, U153, Inst Myol, F-75634 Paris, France; Hop Broussais, Microbiol Serv, F-75674 Paris, France; Univ Aix Marseille 2, Fac Med, Lab Biopathol Nerveuse & Musculaire, JE 2053, F-13284 Marseille 07, France; CHR, Lab Anat Pathol A, F-44000 Nantes, France	Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; CHU Bordeaux; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Aix-Marseille Universite; Nantes Universite; CHU de Nantes	Gherardi, RK (corresponding author), Univ Paris 12, Hop Henri Mondor, Dept Pathol, Grp Etud & Rech Muscle & Nerf,EA 2347, F-94010 Creteil, France.	gherardi@univ-paris12.fr		AUTHIER, Francois Jerome/0000-0002-0182-2052				ALONSORUIZ A, 1986, SEMIN ARTHRITIS RHEU, V15, P200, DOI 10.1016/0049-0172(86)90017-X; BANKER BQ, 1993, MYOLOGY, V1, P832; BANKER BQ, 1993, MYOLOGY, V2, P1461; CLINE MJ, 1994, BLOOD, V84, P2840; DALAKAS MC, 1991, NEW ENGL J MED, V325, P1487, DOI 10.1056/NEJM199111213252107; DALAKAS MC, 1990, NEW ENGL J MED, V322, P1098, DOI 10.1056/NEJM199004193221602; DOBBINS WO, 1997, PATHOLOGY INFECT DIS, V1, P897; Durand DV, 1997, MEDICINE, V76, P170, DOI 10.1097/00005792-199705000-00003; FRIEDLAND JS, 1990, MEDICINE, V69, P325, DOI 10.1097/00005792-199011000-00001; Frucht DM, 1996, J IMMUNOL, V157, P411; GAO IK, 1990, SCAND J RHEUMATOL, V19, P437, DOI 10.3109/03009749009097633; GHERARDI RK, 1994, NEUROPATH APPL NEURO, V20, P232, DOI 10.1111/j.1365-2990.1994.tb00964.x; GILLIN JS, 1983, GASTROENTEROLOGY, V85, P1187; KAUFMAN LD, 1990, MEDICINE, V69, P187, DOI 10.1097/00005792-199007000-00001; LACK EE, 1997, PATHOLOGY INFECT DIS, V2, P1647; Marth T, 1997, GASTROENTEROLOGY, V113, P442, DOI 10.1053/gast.1997.v113.pm9247462; MAYENO AN, 1995, CHEM RES TOXICOL, V8, P911, DOI 10.1021/tx00049a003; MHIRI C, 1991, ANN NEUROL, V29, P606, DOI 10.1002/ana.410290607; MICHELININORRIS MB, 1992, J INFECT DIS, V165, P702, DOI 10.1093/infdis/165.4.702; MIRANDA D, 1979, ARCH PATHOL LAB MED, V103, P302; Naschitz JE, 1996, MEDICINE, V75, P6, DOI 10.1097/00005792-199601000-00002; SATHE SS, 1994, J INFECT DIS, V170, P484, DOI 10.1093/infdis/170.2.484; SCHWARTZ DA, 1997, PATHOL LAB MED, V121, P776; SNOW JL, 1995, J AM ACAD DERMATOL, V33, P111, DOI 10.1016/0190-9622(95)90034-9; SPERBER K, 1993, J RHEUMATOL, V20, P803; SWASH M, 1977, GUT, V18, P800, DOI 10.1136/gut.18.10.800; WATT B, 1995, J CLIN PATHOL, V48, P701, DOI 10.1136/jcp.48.8.701; WRZOLEK MA, 1990, MUSCLE NERVE, V13, P508, DOI 10.1002/mus.880130607; Zelger BWH, 1996, AM J DERMATOPATH, V18, P490, DOI 10.1097/00000372-199610000-00008	29	169	175	0	10	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 1	1998	352	9125					347	352		10.1016/S0140-6736(98)02326-5	http://dx.doi.org/10.1016/S0140-6736(98)02326-5			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	106BU	9717921				2022-12-28	WOS:000075110500009
J	Wilcke, JTR				Wilcke, JTR			Personal paper - Late onset genetic disease: where ignorance is bliss, is it folly to inform relatives?	BRITISH MEDICAL JOURNAL			English	Article							HEREDITARY ALPHA(1)-ANTITRYPSIN DEFICIENCY; SURVIVAL		Rigshosp, Dept Cardiol B, DK-2100 Copenhagen O, Denmark	Rigshospitalet	Wilcke, JTR (corresponding author), Rigshosp, Dept Cardiol B, DK-2100 Copenhagen O, Denmark.							AYME S, 1993, NEUROMUSCULAR DISORD, V3, P571, DOI 10.1016/0960-8966(93)90118-4; BUIST SA, 1990, LUNG S, V168, P143; *DAN COUNC ETH, 1993, ETH MAPP HUM GEN; DAVISON C, 1994, SOC HLTH ILLNESS, V16, P540; Dworkin Gerald, 1982, MAKING HLTH CARE DEC, V3, P63; HOLM S, IN PRESS WHISPERED E; KIELSTEIN R, 1992, J MED PHILOS, V17, P395, DOI 10.1093/jmp/17.4.395; Nuffield Council on Bioethics, 1993, GEN SCREEN ETH ISS; Pirson Y, 1996, QJM-MON J ASSOC PHYS, V89, P803, DOI 10.1093/qjmed/89.11.803; SEERSHOLM N, 1994, THORAX, V49, P695, DOI 10.1136/thx.49.7.695; SEERSHOLM N, 1995, AM J RESP CRIT CARE, V152, P1922, DOI 10.1164/ajrccm.152.6.8520756; SEERSHOLM N, 1995, AM J RESP CRIT CARE, V151, P369, DOI 10.1164/ajrccm.151.2.7842193; SHAPIRO D, 1995, POLIT LIFE SCI, V14, P263, DOI 10.1017/S0730938400019225; SVEGER T, 1978, PEDIATRICS, V62, P22; THYMANN M, 1986, HUM HERED, V36, P19, DOI 10.1159/000153594; WERTZ DC, 1993, CLIN GENET, V44, P37	16	14	14	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	SEP 12	1998	317	7160					744	747		10.1136/bmj.317.7160.744	http://dx.doi.org/10.1136/bmj.317.7160.744			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	121CT	9732349	Green Published			2022-12-28	WOS:000075995100032
J	Carbon, C; Bax, RP				Carbon, C; Bax, RP			Regulating the use of antibiotics in the community	BRITISH MEDICAL JOURNAL			English	Article									Hop Bichat Claude Bernard, F-75877 Paris 18, France; SmithKline Beecham Pharmaceut, Harlow CM19 5AW, Essex, England	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; UDICE-French Research Universities; Universite Paris Cite; GlaxoSmithKline	Carbon, C (corresponding author), Hop Bichat Claude Bernard, F-75877 Paris 18, France.	claude.carbon@bch.ap-hop.paris.fr						Arason VA, 1996, BMJ-BRIT MED J, V313, P387; AUSTIN DJ, IN PRESS J THEOR BIO; Bax RP, 1997, CLIN INFECT DIS, V24, pS151, DOI 10.1093/clinids/24.Supplement_1.S151; Bax RP, 1998, NAT MED, V4, P545, DOI 10.1038/nm0598-545; Chopra I, 1996, JAMA-J AM MED ASSOC, V275, P401, DOI 10.1001/jama.275.5.401; Davey PG, 1996, BRIT MED J, V312, P613, DOI 10.1136/bmj.312.7031.613; Fidler DP, 1998, EMERG INFECT DIS, V4, P169, DOI 10.3201/eid0402.980204; Guillemot D, 1998, JAMA-J AM MED ASSOC, V279, P365, DOI 10.1001/jama.279.5.365; Guillemot D, 1998, J INFECT DIS, V177, P492, DOI 10.1086/517384; Guillemot D, 1998, J CLIN EPIDEMIOL, V51, P61, DOI 10.1016/S0895-4356(97)00221-7; *HOUS LORDS SEL CO, 1998, 7 HOUS LORDS SEL COM, P17; KAPLAN E, 1971, J INFECT DIS, V125, P490; LEVIN BR, 1998, NEW RESURGENT INFECT; LEVY SB, 1998, SCI AM, V278, P32, DOI DOI 10.1038/SCIENTIFICAMERICAN0398-46; PICHICHERO ME, 1995, ANN EMERG MED, V25, P390, DOI 10.1016/S0196-0644(95)70300-4; *PLRMA, 1997, FDC REP PINK SHEET, V59, P13; Seppala H, 1997, NEW ENGL J MED, V337, P441, DOI 10.1056/NEJM199708143370701; Sheldon TA, 1998, BRIT MED J, V317, P139, DOI 10.1136/bmj.317.7151.139	18	41	43	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	SEP 5	1998	317	7159					663	665		10.1136/bmj.317.7159.663	http://dx.doi.org/10.1136/bmj.317.7159.663			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	118GN	9728001	Green Published			2022-12-28	WOS:000075830200031
J	Hotson, JR; Baloh, RW				Hotson, JR; Baloh, RW			Acute vestibular syndrome	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							INFERIOR CEREBELLAR ARTERY; POSITIONAL VERTIGO; SQUIRREL-MONKEY; INFARCTION; SUPPRESSION; NEURONS; PHYSIOLOGY; NYSTAGMUS; TERRITORY; DISORDERS		Santa Clara Valley Med Ctr, San Jose, CA 95128 USA; Stanford Univ, Sch Med, Dept Neurol & Neurol Sci, Stanford, CA 94305 USA; Univ Calif Los Angeles, Sch Med, Div Otolaryngol Head & Neck Surg, Los Angeles, CA USA; Univ Calif Los Angeles, Sch Med, Dept Neurol, Los Angeles, CA 90024 USA	Santa Clara Valley Medical Center; Stanford University; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Hotson, JR (corresponding author), Santa Clara Valley Med Ctr, 751 S Bascom Ave, San Jose, CA 95128 USA.							ADAMS HP, 1994, STROKE, V25, P1901, DOI 10.1161/01.STR.25.9.1901; ALPERT JN, 1974, NEUROLOGY, V24, P891, DOI 10.1212/WNL.24.9.891; AMARENCO P, 1991, NEUROLOGY, V41, P973, DOI 10.1212/WNL.41.7.973; AMARENCO P, 1994, STROKE, V25, P105, DOI 10.1161/01.STR.25.1.105; AMARENCO P, 1990, BRAIN, V113, P139, DOI 10.1093/brain/113.1.139; ASCHAN G, 1956, J Laryngol Otol, V70, P497, DOI 10.1017/S0022215100053251; Baloh R.W., 1990, CLIN NEUROPHYSIOL; Baloh RW, 1996, OTOLARYNG HEAD NECK, V114, P586, DOI 10.1016/S0194-5998(96)70251-6; BALOH RW, 1987, NEUROLOGY, V37, P371, DOI 10.1212/WNL.37.3.371; BICKERSTAFF ER, 1961, LANCET, V1, P15; Brandt T, 1997, ADV NEUROL, V73, P297; Cass SP, 1997, ANN OTO RHINOL LARYN, V106, P182, DOI 10.1177/000348949710600302; *COMM HEAR EQ, 1995, ACTA OTO-LARYNGOL, V113, P181; DIX MR, 1952, P ROY SOC MED, V45, P341, DOI 10.1177/003591575204500604; DUNCAN GW, 1975, ARCH NEUROL-CHICAGO, V32, P364, DOI 10.1001/archneur.1975.00490480030002; Epley JM, 1996, OTOLARYNG CLIN N AM, V29, P323; FERNANDEZ C, 1976, J NEUROPHYSIOL, V39, P996, DOI 10.1152/jn.1976.39.5.996; Fetter M, 1996, BRAIN, V119, P755, DOI 10.1093/brain/119.3.755; FETTER M, 1988, J NEUROPHYSIOL, V59, P370, DOI 10.1152/jn.1988.59.2.370; FISHER CM, 1967, ARCHIV OTOLARYNGOL, V85, P529; GOLDBERG JM, 1971, J NEUROPHYSIOL, V34, P635, DOI 10.1152/jn.1971.34.4.635; Gomez CR, 1996, NEUROLOGY, V47, P94, DOI 10.1212/WNL.47.1.94; GRAD A, 1989, ARCH NEUROL-CHICAGO, V46, P281, DOI 10.1001/archneur.1989.00520390047014; GRENMAN R, 1985, ACTA OTO-LARYNGOL, P9; HARRIS JP, 1990, LARYNGOSCOPE, V100, P516; HEROS RC, 1982, STROKE, V13, P106, DOI 10.1161/01.STR.13.1.106; HOOD JD, 1979, BRAIN, V102, P785, DOI 10.1093/brain/102.4.785; HORNIG CR, 1994, STROKE, V25, P372, DOI 10.1161/01.STR.25.2.372; ISHIZAKI H, 1993, ACTA OTO-LARYNGOL, P67; Leigh R.J., 1991, NEUROLOGY EYE MOVEME, V2nd; LINSTROM CJ, 1993, J OTOLARYNGOL, V22, P401; MAZZONI A, 1969, ANN OTO RHINOL LARYN, V78, P797, DOI 10.1177/000348946907800413; MONSELL EM, 1995, OTOLARYNG HEAD NECK, V113, P181, DOI 10.1016/S0194-5998(95)70102-8; NORRVING B, 1995, ACTA NEUROL SCAND, V91, P43; OAS JG, 1992, NEUROLOGY, V42, P2274, DOI 10.1212/WNL.42.12.2274; Parent A., 1996, CARPENTERS HUMAN NEU, V9th. Edn; PEITERSEN E, 1974, HDB SENSORY PHYSL, V6, P267; POMPEIANO O, 1974, HDB SENSORY PHYSL, V6, P417; PROCTOR L, 1979, ANN OTO RHINOL LARYN, V88, P303, DOI 10.1177/000348947908800301; Schuknecht H, 1974, PATHOLOGY EAR; SCHUKNECHT HF, 1981, ANN OTO RHINOL LARYN, V90, P1; SELESNICK SH, 1993, LARYNGOSCOPE, V103, P431, DOI 10.1002/lary.5541030412; SELTZER S, 1986, LARYNGOSCOPE, V96, P37; Silvoniemi P, 1988, Acta Otolaryngol Suppl, V453, P1; SMITH BH, 1960, NEUROLOGY, V10, P465, DOI 10.1212/WNL.10.5.465; SYPERT GW, 1975, ARCH NEUROL-CHICAGO, V32, P357, DOI 10.1001/archneur.1975.00490480023001; TAKEMORI S, 1974, BRAIN RES, V72, P213, DOI 10.1016/0006-8993(74)90860-9; TAKEMORI S, 1977, ANN OTO RHINOL LARYN, V86, P80, DOI 10.1177/000348947708600113; UCHINO Y, 1982, J NEUROPHYSIOL, V48, P891, DOI 10.1152/jn.1982.48.4.891; UEMURA T, 1973, ACTA OTO-LARYNGOL, P1; ZEE DS, 1978, ANN NEUROL, V3, P373, DOI 10.1002/ana.410030422	51	184	204	0	11	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 3	1998	339	10					680	685		10.1056/NEJM199809033391007	http://dx.doi.org/10.1056/NEJM199809033391007			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	115WA	9725927				2022-12-28	WOS:000075688100007
J	Eastwood, R				Eastwood, R			Getting hooked on Marmite	LANCET			English	Editorial Material																			0	0	0	1	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	AUG 29	1998	352	9129					750	750		10.1016/S0140-6736(05)60877-X	http://dx.doi.org/10.1016/S0140-6736(05)60877-X			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	116MT	9729031				2022-12-28	WOS:000075729700076
J	Zhang, Y; Feng, XH; Derynck, R				Zhang, Y; Feng, XH; Derynck, R			Smad3 and Smad4 cooperate with c-Jun/c-Fos to mediate TGF-beta-induced transcription	NATURE			English	Article							GROWTH-FACTOR-BETA; SIGNALING PATHWAYS; RECEPTOR COMPLEX; BINDING PROTEIN; DOWN-REGULATION; EXPRESSION; PROLIFERATION; ACTIVATION; CYCLIN; GENES	Smad proteins transduce signals for transforming growth factor-beta (TGF-beta)-related factors'. Smad proteins activated by receptors for TGF-beta form complexes with Smad4. These com plexes are translocated into the nucleus and regulate ligand-induced gene transcription(2-4). 12-O-tetradecanoyl-13-acetate (TPA)-responsive gene promoter elements (TREs) are involved in the transcriptional responses of several genes to TGF-beta (refs 5-8), AP-1 transcription factors, composed of c-Jun and c-Fos, bind to and direct transcription from TREs, which are therefore known as AP1-binding sites(9). Here we show that Smad3 interacts directly with the TRE and that SmadS and Smad4 can activate TGF-beta-inducible transcription from the TRE in the absence of c-Jun and c-Fos, Smad3 and Smad4 also act together with c-Jun and c-Fos to activate transcription in response to TGF-beta, through a TGF-P-inducible association of c-Jun with Smad3 and an interaction of Smad3 and c-Fos, These interactions complement interactions between c-Jun and c-Fos, and between Smad3 and Smad4, This mechanism of transcriptional activation by TGF-P, through functional and physical interactions between Smad3-Smad4 and c-Jun-c-Fos, shows that Smad signalling and MAPK/JNK signalling converge at AP1-binding promoter sites.	Univ Calif San Francisco, Dept Growth & Dev, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Anat, Cell Biol Program, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Anat, Program Dev Biol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Derynck, R (corresponding author), Univ Calif San Francisco, Dept Growth & Dev, San Francisco, CA 94143 USA.	derynck@itsa.ucsf.edu	Zhang, Ying E/G-3657-2015	Zhang, Ying E/0000-0003-2753-7601				ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; de Caestecker MP, 1998, GENE DEV, V12, P1587, DOI 10.1101/gad.12.11.1587; DEGROOT RP, 1990, BIOCHEM BIOPH RES CO, V168, P1074, DOI 10.1016/0006-291X(90)91139-J; FELTS SJ, 1995, BIOCHEMISTRY-US, V34, P12355, DOI 10.1021/bi00038a032; Feng XH, 1998, GENE DEV, V12, P2153, DOI 10.1101/gad.12.14.2153; Feng XH, 1996, J BIOL CHEM, V271, P13123, DOI 10.1074/jbc.271.22.13123; FENG XH, 1995, J BIOL CHEM, V270, P24237, DOI 10.1074/jbc.270.41.24237; GRAYCAR JL, 1989, MOL ENDOCRINOL, V3, P1977, DOI 10.1210/mend-3-12-1977; Hata A, 1997, NATURE, V388, P82, DOI 10.1038/40424; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Jin G, 1997, J BIOL CHEM, V272, P26620, DOI 10.1074/jbc.272.42.26620; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KEETON MR, 1991, J BIOL CHEM, V266, P23048; Kretzschmar M, 1997, NATURE, V389, P618, DOI 10.1038/39348; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; Liu F, 1996, NATURE, V381, P620, DOI 10.1038/381620a0; LLOYD A, 1991, NATURE, V352, P632, DOI 10.1038/352635a0; Nakao A, 1997, EMBO J, V16, P5353, DOI 10.1093/emboj/16.17.5353; RENSHAW MW, 1995, MOL CELL BIOL, V15, P1286; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; Wu RY, 1997, MOL CELL BIOL, V17, P2521, DOI 10.1128/MCB.17.5.2521; YANG-YEN H-F, 1990, New Biologist, V2, P351; Yingling JM, 1997, MOL CELL BIOL, V17, P7019, DOI 10.1128/MCB.17.12.7019; Yoshizumi M, 1997, J BIOL CHEM, V272, P22259, DOI 10.1074/jbc.272.35.22259; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zhang Y, 1997, CURR BIOL, V7, P270, DOI 10.1016/S0960-9822(06)00123-0; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0	30	581	612	0	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 27	1998	394	6696					909	913		10.1038/29814	http://dx.doi.org/10.1038/29814			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	114LW	9732876				2022-12-28	WOS:000075611800053
J	Knipe, C				Knipe, C			Leading the way	BRITISH MEDICAL JOURNAL			English	Article																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 22	1998	317	7157					523	523						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	115AM	9712604				2022-12-28	WOS:000075641400026
J	Dutnall, RN; Tafrov, ST; Sternglanz, R; Ramakrishnan, V				Dutnall, RN; Tafrov, ST; Sternglanz, R; Ramakrishnan, V			Structure of the histone acetyltransferase Hat1: A paradigm for the GCN5-related N-acetyltransferase superfamily	CELL			English	Article							COENZYME-A BINDING; SACCHAROMYCES-CEREVISIAE; HUMAN GENES; YEAST; ACETYLATION; PROTEIN; INHIBITION; PROGRAM; H4	We have solved the crystal structure of the yeast histone acetyltransferase Hat1-acetyl coenzyme A (AcCoA) complex at 2.3 Angstrom resolution. Hat1 has an elongated, curved structure, and the AcCoA molecule is bound in a cleft on the concave surface of the protein, marking the active site of the enzyme. A channel of variable width and depth that runs across the protein is probably the binding site for the histone substrate. A model for histone H4 binding by Hat1 is discussed in terms of possible sources of specific lysine recognition by the enzyme. The structure of Hat1 provides a model for the structures of the catalytic domains of a protein superfamily that includes other histone acetyltransferases such as Gcn5 and CBP.	Univ Utah, Sch Med, Dept Biochem, Salt Lake City, UT 84132 USA; SUNY Stony Brook, Dept Biochem & Cell Biol, Stony Brook, NY 11794 USA	Utah System of Higher Education; University of Utah; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Ramakrishnan, V (corresponding author), Univ Utah, Sch Med, Dept Biochem, Salt Lake City, UT 84132 USA.			Ramakrishnan, V/0000-0002-4699-2194	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028220, R01GM055641, R56GM028220, R01GM042796] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 42796, GM55641, GM28220] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; Brownell JE, 1996, CURR OPIN GENET DEV, V6, P176, DOI 10.1016/S0959-437X(96)80048-7; BRUNGER AT, 1996, X PLOR VERSION 3 843; Candau R, 1997, EMBO J, V16, P555, DOI 10.1093/emboj/16.3.555; Coleman CS, 1996, BIOCHEM J, V316, P697, DOI 10.1042/bj3160697; CULLIS PM, 1982, J BIOL CHEM, V257, P2165; Eberharter A, 1996, FEBS LETT, V386, P75, DOI 10.1016/0014-5793(96)00401-2; Engel C, 1996, CURR OPIN STRUC BIOL, V6, P790, DOI 10.1016/S0959-440X(96)80009-1; ERWIN BG, 1984, BIOCHEMISTRY-US, V23, P4250, DOI 10.1021/bi00313a036; GERCHMAN SE, 1994, PROTEIN EXPRES PURIF, V5, P242, DOI 10.1006/prep.1994.1037; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Hilfiker A, 1997, EMBO J, V16, P2054, DOI 10.1093/emboj/16.8.2054; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kadonaga JT, 1998, CELL, V92, P307, DOI 10.1016/S0092-8674(00)80924-1; Kaufman PD, 1996, CURR OPIN CELL BIOL, V8, P369, DOI 10.1016/S0955-0674(96)80012-3; Kaufman PD, 1997, GENE DEV, V11, P345, DOI 10.1101/gad.11.3.345; KLEFF S, 1995, J BIOL CHEM, V270, P24674, DOI 10.1074/jbc.270.42.24674; Kolle D, 1998, FEBS LETT, V421, P109, DOI 10.1016/S0014-5793(97)01544-5; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kuo CH, 1996, IEEE SIGNAL PROC LET, V3, P269, DOI 10.1109/97.536598; Kuo MH, 1998, GENE DEV, V12, P627, DOI 10.1101/gad.12.5.627; Lu L, 1996, J BIOL CHEM, V271, P18920, DOI 10.1074/jbc.271.31.18920; Martinez-Balbas MA, 1998, EMBO J, V17, P2886, DOI 10.1093/emboj/17.10.2886; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; Neuwald AF, 1997, TRENDS BIOCHEM SCI, V22, P154, DOI 10.1016/S0968-0004(97)01034-7; NICHOLLS A, 1993, BIOPHYS J, V64, pA166; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Parthun MR, 1996, CELL, V87, P85, DOI 10.1016/S0092-8674(00)81325-2; RAMAKRISHNAN V, 1993, NATURE, V362, P219, DOI 10.1038/362219a0; Ramakrishnan V, 1997, METHOD ENZYMOL, V276, P538, DOI 10.1016/S0076-6879(97)76077-4; RAO ST, 1973, J MOL BIOL, V76, P241, DOI 10.1016/0022-2836(73)90388-4; Reifsnyder C, 1996, NAT GENET, V14, P42, DOI 10.1038/ng0996-42; RICHMAN R, 1988, J CELL BIOL, V106, P1017, DOI 10.1083/jcb.106.4.1017; Roth SY, 1996, CELL, V87, P5, DOI 10.1016/S0092-8674(00)81316-1; Ruiz-Garcia AB, 1998, J BIOL CHEM, V273, P12599, DOI 10.1074/jbc.273.20.12599; Smith ER, 1998, P NATL ACAD SCI USA, V95, P3561, DOI 10.1073/pnas.95.7.3561; SOBEL RE, 1995, P NATL ACAD SCI USA, V92, P1237, DOI 10.1073/pnas.92.4.1237; STANTON M, 1994, P SOC PHOTO-OPT INS, V2278, P16, DOI 10.1117/12.180020; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; Stryer L., 1995, BIOCHEMISTRY-US, V4th ed.; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TERCERO JC, 1992, J BIOL CHEM, V267, P20270; Terwilliger TC, 1997, METHOD ENZYMOL, V276, P530; Turner BM, 1998, CELL MOL LIFE SCI, V54, P21, DOI 10.1007/s000180050122; Verreault A, 1998, CURR BIOL, V8, P96, DOI 10.1016/S0960-9822(98)70040-5; Verreault A, 1996, CELL, V87, P95, DOI 10.1016/S0092-8674(00)81326-4; Wang L, 1998, GENE DEV, V12, P640, DOI 10.1101/gad.12.5.640; WONG LJC, 1983, BIOCHEMISTRY-US, V22, P4637, DOI 10.1021/bi00289a004; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0	52	189	194	2	11	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 21	1998	94	4					427	438		10.1016/S0092-8674(00)81584-6	http://dx.doi.org/10.1016/S0092-8674(00)81584-6			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	113GB	9727486	Bronze			2022-12-28	WOS:000075541100005
J	Aarset, H; Fagerli, UM; Opsjon, SL; Skarsvag, S				Aarset, H; Fagerli, UM; Opsjon, SL; Skarsvag, S			A nurse with a rash on her neck	LANCET			English	Article									Univ Trondheim Hosp, Dept Pathol, N-7006 Trondheim, Norway; Univ Trondheim Hosp, Dept Oncol, N-7006 Trondheim, Norway; Univ Trondheim Hosp, Dept Microbiol, N-7006 Trondheim, Norway	Norwegian University of Science & Technology (NTNU); Norwegian University of Science & Technology (NTNU); Norwegian University of Science & Technology (NTNU)	Aarset, H (corresponding author), Univ Trondheim Hosp, Dept Pathol, N-7006 Trondheim, Norway.							ECHEVARRIA JM, 1994, J MED VIROL, V43, P331, DOI 10.1002/jmv.1890430403; GAFFEY MJ, 1991, AM J CLIN PATHOL, V95, P709, DOI 10.1093/ajcp/95.5.709; HARRIS NL, 1994, BLOOD, V84, P1362; HARTSOCK RJ, 1968, CANCER, V21, P632, DOI 10.1002/1097-0142(196804)21:4<632::AID-CNCR2820210415>3.0.CO;2-O	4	1	1	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	AUG 15	1998	352	9127					540	540		10.1016/S0140-6736(98)05043-0	http://dx.doi.org/10.1016/S0140-6736(98)05043-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	111KC	9716059				2022-12-28	WOS:000075435300013
J	Rodenhuis, S; Richel, DJ; van der Wall, E; Schornagel, JH; Baars, JW; Koning, CCE; Peterse, JL; Borger, JH; Nooijen, WJ; Bakx, R; Dalesio, O; Rutgers, E				Rodenhuis, S; Richel, DJ; van der Wall, E; Schornagel, JH; Baars, JW; Koning, CCE; Peterse, JL; Borger, JH; Nooijen, WJ; Bakx, R; Dalesio, O; Rutgers, E			Randomised trial of high-dose chemotherapy and haemopoietic progenitor-cell support in operable breast cancer with extensive axillary lymph-node involvement	LANCET			English	Article							BONE-MARROW TRANSPLANTATION; ADJUVANT THERAPY; SOLID TUMORS; I-II; CARBOPLATIN; CYCLOPHOSPHAMIDE; THIOTEPA; WOMEN	Background Uncontrolled studies suggest that high-dose chemotherapy is beneficial in patients with breast cancer and multiple metastases to the axillary lymph nodes. Many physicians accept this treatment as standard care. We aimed to assess adjuvant high-dose chemotherapy in breast cancer in a phase II randomised trial. Methods 97 women aged younger than 60 years, who had breast cancer with extensive axillary-node metastases (confirmed by a tumour-positive infraclavicular lymph-node biopsy), received three courses of up-front chemotherapy (FE120C), This regimen consisted of cyclophosphamide 500 mg/m(2), epirubicin 120 mg/m(2), and 5-fuorouracil 500 mg/m(2) once weekly for 3 weeks, After surgery, stable patients or those who responded to chemotherapy were randomly assigned conventional therapy (fourth course of FE120C, followed by radiation therapy and 2 years of tamoxifen [40 patients]) or high-dose therapy (identical treatment but an additional high-dose regimen and peripheral-blood progenitor-cell [PBPC] support after the fourth FE120C course [41 patients]). This high-dose regimen comprised cyclophosphamide 6 g/m(2), thiotepa 480 mg/m(2), and carboplatin 1600 mg/m(2). The primary endpoint was overall and disease-free survival. All analyses were by intention to treat. Findings No patients died from toxic effects of chemotherapy. With a median follow-up of 49 (range 21-76) months, the 4-year overall and relapse-free survivals for all 97 patients were 75% and 54%, respectively. There was no significant difference in survival between the patients on conventional therapy and those on high-dose therapy. Interpretation High-dose therapy is associated with substantial cost and acute toxic effects, but also has potentially irreversible long-term effects. Until the benefit of this therapy is substantiated by large-scale phase III trials, high-dose chemotherapy should not be used in the adjuvant treatment of breast cancer, apart from in randomised studies.	Netherlands Canc Inst, Dept Med Oncol, NL-1066 CX Amsterdam, Netherlands; Netherlands Canc Inst, Dept Radiat Therapy, NL-1066 CX Amsterdam, Netherlands; Netherlands Canc Inst, Dept Clin Pathol, NL-1066 CX Amsterdam, Netherlands; Netherlands Canc Inst, Dept Clin Chem, NL-1066 CX Amsterdam, Netherlands; Netherlands Canc Inst, Biometr Dept, NL-1066 CX Amsterdam, Netherlands; Netherlands Canc Inst, Dept Surg Oncol, NL-1066 CX Amsterdam, Netherlands	Netherlands Cancer Institute; Netherlands Cancer Institute; Netherlands Cancer Institute; Netherlands Cancer Institute; Netherlands Cancer Institute; Netherlands Cancer Institute	Rodenhuis, S (corresponding author), Netherlands Canc Inst, Dept Med Oncol, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.	sroden@nki.nl	Rutgers, Emiel J T/C-5934-2015; Bakx, Roel/Q-8367-2016; koning, caro/A-5339-2008	Bakx, Roel/0000-0001-5884-2997				ABE O, 1992, LANCET, V339, P71; Antman KH, 1997, J CLIN ONCOL, V15, P1870, DOI 10.1200/JCO.1997.15.5.1870; Bartelink H, 1997, J CLIN ONCOL, V15, P207, DOI 10.1200/JCO.1997.15.1.207; Crump M, 1996, J CLIN ONCOL, V14, P66, DOI 10.1200/JCO.1996.14.1.66; DANFORTH DN, 1986, J CLIN ONCOL, V4, P655, DOI 10.1200/JCO.1986.4.5.655; DEGRAAF H, 1994, EUR J CANCER, V30A, P150, DOI 10.1016/0959-8049(94)90076-0; deVries EGE, 1996, LANCET, V348, P407, DOI 10.1016/S0140-6736(05)65026-X; DUTOIT RS, 1990, BRIT J SURG, V77, P163, DOI 10.1002/bjs.1800770216; EDER JP, 1990, J CLIN ONCOL, V8, P1239, DOI 10.1200/JCO.1990.8.7.1239; FREI E, 1988, CANCER RES, V48, P6417; FREI E, 1989, J CLIN ONCOL, V7, P515, DOI 10.1200/JCO.1989.7.4.515; GarciaCarbonero R, 1997, J CLIN ONCOL, V15, P3178, DOI 10.1200/JCO.1997.15.10.3178; Gianni AM, 1997, J CLIN ONCOL, V15, P2312, DOI 10.1200/JCO.1997.15.6.2312; Gianni AM, 1997, NEW ENGL J MED, V336, P1290, DOI 10.1056/NEJM199705013361804; Gradishar WJ, 1996, ANN INTERN MED, V125, P599, DOI 10.7326/0003-4819-125-7-199610010-00010; HAAGENSEN CD, 1976, DIS BREAST; Haioun C, 1997, J CLIN ONCOL, V15, P1131, DOI 10.1200/JCO.1997.15.3.1131; Hurd D D, 1995, J Natl Cancer Inst Monogr, P41; MARTIN M, 1992, J CLIN ONCOL, V10, P433, DOI 10.1200/JCO.1992.10.3.433; OBRIEN MER, 1993, J CLIN ONCOL, V11, P2112, DOI 10.1200/JCO.1993.11.11.2112; PETERS WP, 1986, J CLIN ONCOL, V4, P646, DOI 10.1200/JCO.1986.4.5.646; PETERS WP, 1993, J CLIN ONCOL, V11, P1132, DOI 10.1200/JCO.1993.11.6.1132; PHILIP T, 1995, NEW ENGL J MED, V333, P1540, DOI 10.1056/NEJM199512073332305; Rahman ZU, 1997, J CLIN ONCOL, V15, P3171, DOI 10.1200/JCO.1997.15.10.3171; RODENHUIS S, 1992, ANN ONCOL, V3, P855, DOI 10.1093/oxfordjournals.annonc.a058111; SCHAAKEKONING C, 1985, INT J RADIAT ONCOL, V11, P1759, DOI 10.1016/0360-3016(85)90028-8; SMIGEL K, 1995, J NATL CANCER I, V87, P952, DOI 10.1093/jnci/87.13.952; van Dam FSAM, 1998, J NATL CANCER I, V90, P210, DOI 10.1093/jnci/90.3.210; van Dongen J A, 1977, World J Surg, V1, P306; vanderWall E, 1996, BRIT J CANCER, V73, P1080, DOI 10.1038/bjc.1996.208; VANDERWALL E, 1995, BRIT J CANCER, V71, P857, DOI 10.1038/bjc.1995.165; vanderWall E, 1996, EUR J CANCER, V32A, P1490, DOI 10.1016/0959-8049(96)00129-3; VANDERWALL E, 1994, ANN ONCOL, V5, P795, DOI 10.1093/oxfordjournals.annonc.a059007; VANDERWALL E, 1995, CANCER TREAT REV, V21, P105, DOI 10.1016/0305-7372(95)90023-3; vanTienhoven G, 1995, EUR J CANCER, V31A, P1965, DOI 10.1016/0959-8049(95)00484-X	35	216	219	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 15	1998	352	9127					515	521		10.1016/S0140-6736(98)01350-6	http://dx.doi.org/10.1016/S0140-6736(98)01350-6			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	111KC	9716055				2022-12-28	WOS:000075435300009
J	Pershagen, G				Pershagen, G			Environmental epidemiology in public health	LANCET			English	Editorial Material							RISK		Karolinska Inst, Inst Environm Med, Dept Environm Epidemiol, S-17177 Stockholm, Sweden	Karolinska Institutet	Pershagen, G (corresponding author), Karolinska Inst, Inst Environm Med, Dept Environm Epidemiol, S-17177 Stockholm, Sweden.			Pershagen, Goran/0000-0002-9701-1130				Croen LA, 1997, EPIDEMIOLOGY, V8, P347, DOI 10.1097/00001648-199707000-00001; GESCHWIND SA, 1992, AM J EPIDEMIOL, V135, P1197, DOI 10.1093/oxfordjournals.aje.a116226; HERTZPICCIOTTO I, 1995, AM J PUBLIC HEALTH, V85, P484, DOI 10.2105/AJPH.85.4.484; LAWSON AB, 1998, DIS MAPPING RISK ASS; Marshall EG, 1997, ARCH ENVIRON HEALTH, V52, P416, DOI 10.1080/00039899709602220; Pershagen G, 1995, INT CONGR SER, V1092, P53; Snow J., 1855, MODE COMMUNICATION C; TAUBES G, 1995, SCIENCE, V269, P164, DOI 10.1126/science.7618077	8	2	3	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	AUG 8	1998	352	9126					417	417		10.1016/S0140-6736(05)79180-7	http://dx.doi.org/10.1016/S0140-6736(05)79180-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	108EA	9708744				2022-12-28	WOS:000075252000003
J	Meno, C; Shimono, A; Saijoh, Y; Yashiro, K; Mochida, K; Ohishi, S; Noji, S; Kondoh, H; Hamada, H				Meno, C; Shimono, A; Saijoh, Y; Yashiro, K; Mochida, K; Ohishi, S; Noji, S; Kondoh, H; Hamada, H			lefty-1 is required for left-right determination as a regulator of lefty-2 and nodal	CELL			English	Article							LEFT-RIGHT ASYMMETRY; SITUS-INVERSUS; BODY ASYMMETRY; EXPRESSION; LATERALITY; NOTOCHORD; XENOPUS; MOUSE; GENE; AXIS	lefty-1, leffy-2 and nodal are expressed on the left side of developing mouse embryos and are implicated in left-right (L-R) determination. The role of lefty-1 was examined by analyzing mutant mice lacking this gene. The lefty-1-deficient mice showed a variety of L-R positional defects in visceral organs. Unexpectedly, however, the most common feature of lefty-1(-/-) mice was thoracic left isomerism (rather than right isomerism). The lack of lefty-1 resulted in bilateral expression of nodal, lefty-2, and Pitx2 (a homeobox gene normally expressed on the left side). These observations suggest that the role of lefty-1 is to restrict the expression of lefty-2 and nodal to the left side, and that lefty-2 or nodal encodes a signal for "leftness."	Osaka Univ, Inst Mol & Cellular Biol, Div Mol Biol, Suita, Osaka 565, Japan; Osaka Univ, Inst Mol & Cellular Biol, Div Dev Biol, Suita, Osaka 565, Japan; Univ Tokushima, Fac Engn, Dept Biol Sci & Technol, Tokushima 770, Japan	Osaka University; Osaka University; Tokushima University	Hamada, H (corresponding author), Osaka Univ, Inst Mol & Cellular Biol, Div Mol Biol, 1-3 Yamada Oka, Suita, Osaka 565, Japan.		Noji, Sumihare/E-3047-2010; Hamada, Hiroshi/N-6374-2015	Hamada, Hiroshi/0000-0002-7196-5948; da shi, xiang zi/0000-0002-2256-905X; Saijoh, Yukio/0000-0002-7548-4789				Anderson RH, 1996, TRENDS CARDIOVAS MED, V6, P10, DOI 10.1016/1050-1738(95)00123-9; BROWN NA, 1991, CIBA F SYMP, V162, P182; BROWN NA, 1990, DEVELOPMENT, V109, P1; Chen JN, 1997, DEVELOPMENT, V124, P4373; Collignon J, 1996, NATURE, V381, P155, DOI 10.1038/381155a0; Danos MC, 1996, DEV BIOL, V177, P96, DOI 10.1006/dbio.1996.0148; FUJINAGA M, 1991, TERATOLOGY, V44, P453, DOI 10.1002/tera.1420440411; FUJINAGA M, 1991, DEV BIOL, V143, P203, DOI 10.1016/0012-1606(91)90067-D; Gage PJ, 1997, HUM MOL GENET, V6, P457, DOI 10.1093/hmg/6.3.457; Gebbia M, 1997, NAT GENET, V17, P305, DOI 10.1038/ng1197-305; Hummel K. P., 1959, Journal of Heredity, V50, P9; Hyatt BA, 1998, CELL, V93, P37, DOI 10.1016/S0092-8674(00)81144-7; ICARDO JM, 1991, CIRCULATION, V84, P2547, DOI 10.1161/01.CIR.84.6.2547; Isaac A, 1997, SCIENCE, V275, P1301, DOI 10.1126/science.275.5304.1301; KATOH K, 1987, CELL STRUCT FUNCT, V12, P575, DOI 10.1247/csf.12.575; KING T, 1997, CURR BIOL, V7, P212; Kitamura K, 1997, MECH DEVELOP, V67, P83, DOI 10.1016/S0925-4773(97)00110-X; Levin M, 1996, NATURE, V384, P321, DOI 10.1038/384321a0; Levin M, 1998, GENE DEV, V12, P763, DOI 10.1101/gad.12.6.763; Levin M, 1997, DEV BIOL, V189, P57, DOI 10.1006/dbio.1997.8662; LEVIN M, 1995, CELL, V82, P803, DOI 10.1016/0092-8674(95)90477-8; Logan M, 1998, CELL, V94, P307, DOI 10.1016/S0092-8674(00)81474-9; Lohr JL, 1997, DEVELOPMENT, V124, P1465; Lowe LA, 1996, NATURE, V381, P158, DOI 10.1038/381158a0; Lustig KD, 1996, DEVELOPMENT, V122, P3275; Melloy PG, 1998, DEV BIOL, V193, P77, DOI 10.1006/dbio.1997.8787; Meno C, 1997, GENES CELLS, V2, P513, DOI 10.1046/j.1365-2443.1997.1400338.x; Meno C, 1996, NATURE, V381, P151, DOI 10.1038/381151a0; Mucchielli ML, 1996, MOL CELL NEUROSCI, V8, P258, DOI 10.1006/mcne.1996.0062; Oh SP, 1997, GENE DEV, V11, P1812, DOI 10.1101/gad.11.14.1812; Pagan-Westphal SM, 1998, CELL, V93, P25, DOI 10.1016/S0092-8674(00)81143-5; Sampath K, 1997, DEVELOPMENT, V124, P3293; SAWAI S, 1991, NEW BIOL, V3, P861; Semina EV, 1996, NAT GENET, V14, P392, DOI 10.1038/ng1296-392; SEO JW, 1992, CIRCULATION, V86, P642, DOI 10.1161/01.CIR.86.2.642; Supp DM, 1997, NATURE, V389, P963, DOI 10.1038/40140; Varlet I, 1997, CURR OPIN GENET DEV, V7, P519, DOI 10.1016/S0959-437X(97)80080-9; WILKINSON DG, 1992, IN SITU HYBRIDIZATIO, P75; YOKOYAMA T, 1993, SCIENCE, V260, P679, DOI 10.1126/science.8480178; Yoshioka H, 1998, CELL, V94, P299, DOI 10.1016/S0092-8674(00)81473-7; YOST HJ, 1991, CIBA F SYMP, V162, P165; YOST HJ, 1992, NATURE, V357, P496	42	420	430	2	17	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	AUG 7	1998	94	3					287	297		10.1016/S0092-8674(00)81472-5	http://dx.doi.org/10.1016/S0092-8674(00)81472-5			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	109EN	9708731	Bronze			2022-12-28	WOS:000075308400005
J	Delledonne, M; Xia, YJ; Dixon, RA; Lamb, C				Delledonne, M; Xia, YJ; Dixon, RA; Lamb, C			Nitric oxide functions as a signal in plant disease resistance	NATURE			English	Article							OXIDATIVE BURST; ARABIDOPSIS-THALIANA; ACCUMULATION; SYNTHASES; ELICITOR; PROTEIN	Recognition of an avirulent pathogen triggers the rapid production of the reactive oxygen intermediates superoxide (O-2(-)) and hydrogen peroxide (H2O2)(1). This oxidative burst drives crosslinking of the cell wall(2), induces several plant genes involved in cellular protection and defence(3,4), and is necessary for the initiation of host cell death in the hypersensitive disease-resistance response(1,3). However, this burst is not enough to support a strong disease-resistance response(4,5). Here we show that nitric oxide, which acts as a signal in the immune, nervous and vascular systems(6), potentiates the induction of hypersensitive cell death in soybean cells by reactive oxygen intermediates and functions independently of such intermediates to induce genes for the synthesis of protective natural products. Moreover, inhibitors of nitric oxide synthesis compromise the hypersensitive disease-resistance response of Arabidopsis leaves to Pseudomonas syringae, promoting disease and bacterial growth. We conclude that nitric oxide plays a key role in disease resistance in plants.	Salk Inst Biol Studies, Plant Biol Lab, La Jolla, CA 92037 USA; Samuel Roberts Noble Fdn Inc, Div Plant Biol, Ardmore, OK 73402 USA; Univ Cattolica Sacro Cuore, Ist Genet, I-29100 Piacenza, Italy	Salk Institute; Noble Research Institute; Catholic University of the Sacred Heart	Lamb, C (corresponding author), Salk Inst Biol Studies, Plant Biol Lab, La Jolla, CA 92037 USA.		Xia, Yiji/GRR-5126-2022; Delledonne, Massimo/O-8685-2017	Delledonne, Massimo/0000-0002-7100-4581; Xia, Yiji/0000-0002-9543-8341				BERRIDGE MJ, 1993, NATURE, V365, P388, DOI 10.1038/365388a0; BOWLER C, 1994, CELL, V77, P73, DOI 10.1016/0092-8674(94)90236-4; BRADLEY DJ, 1992, CELL, V70, P21, DOI 10.1016/0092-8674(92)90530-P; CAMERON RK, 1994, PLANT J, V5, P715, DOI 10.1111/j.1365-313X.1994.00715.x; Chandra S, 1996, P NATL ACAD SCI USA, V93, P13393, DOI 10.1073/pnas.93.23.13393; Cueto M, 1996, FEBS LETT, V398, P159, DOI 10.1016/S0014-5793(96)01232-X; DEBENER T, 1991, PLANT J, V1, P289, DOI 10.1046/j.1365-313X.1991.t01-7-00999.x; DIXON RA, 1995, PLANT CELL, V7, P1085, DOI 10.1105/tpc.7.7.1085; DURNER J, IN PRESS P NATL ACAD; GARVEY EP, 1994, J BIOL CHEM, V269, P26669; Glazener JA, 1996, PLANT PHYSIOL, V110, P759, DOI 10.1104/pp.110.3.759; GRIFFITH OW, 1995, ANNU REV PHYSIOL, V57, P707, DOI 10.1146/annurev.ph.57.030195.003423; Groom QJ, 1996, PLANT J, V10, P515, DOI 10.1046/j.1365-313X.1996.10030515.x; GUO ZJ, 1994, J PLANT PHYSIOL, V144, P700, DOI 10.1016/S0176-1617(11)80664-4; HEVEL JM, 1994, METHOD ENZYMOL, V23, P251; Jabs T, 1997, P NATL ACAD SCI USA, V94, P4800, DOI 10.1073/pnas.94.9.4800; Jaffrey SR, 1996, SCIENCE, V274, P774, DOI 10.1126/science.274.5288.774; KEEN NT, 1991, THEOR APPL GENET, V81, P133, DOI 10.1007/BF00226123; Keller T, 1998, PLANT CELL, V10, P255, DOI 10.1105/tpc.10.2.255; Lamb C, 1997, ANNU REV PLANT PHYS, V48, P251, DOI 10.1146/annurev.arplant.48.1.251; LEVINE A, 1994, CELL, V79, P583, DOI 10.1016/0092-8674(94)90544-4; Levine A, 1996, CURR BIOL, V6, P427, DOI 10.1016/S0960-9822(02)00510-9; Murphy ME, 1994, METHOD ENZYMOL, V233, P241; NATHAN C, 1995, CELL, V82, P873, DOI 10.1016/0092-8674(95)90019-5; Ninnemann H, 1996, PHOTOCHEM PHOTOBIOL, V64, P393, DOI 10.1111/j.1751-1097.1996.tb02477.x; Noritake T, 1996, PLANT CELL PHYSIOL, V37, P113, DOI 10.1093/oxfordjournals.pcp.a028908; SCHMIDT HHHW, 1994, CELL, V78, P919, DOI 10.1016/0092-8674(94)90267-4; Shirasu K, 1997, PLANT CELL, V9, P261, DOI 10.1105/tpc.9.2.261; YAHRAUS T, 1995, PLANT PHYSIOL, V109, P1259, DOI 10.1104/pp.109.4.1259	29	1357	1665	3	224	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 6	1998	394	6693					585	588		10.1038/29087	http://dx.doi.org/10.1038/29087			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	107YN	9707120				2022-12-28	WOS:000075238700050
J	Raoult, D; Ndihokubwayo, JB; Tissot-Dupont, H; Roux, V; Faugere, B; Abegbinni, R; Birtles, RJ				Raoult, D; Ndihokubwayo, JB; Tissot-Dupont, H; Roux, V; Faugere, B; Abegbinni, R; Birtles, RJ			Outbreak of epidemic typhus associated with trench fever in Burundi	LANCET			English	Article							SEQUENCES	Background After a 12-year absence, epidemic typhus has re-emerged among the displaced population of Burundi. Following the outbreak of civil war in 1993, over 760 000 people now inhabit refugee camps, under appalling conditions. A typhus outbreak occurred among prisoners in a jail in N'Gozi in 1995. At the time, the disease was not recognised, and was referred to as sutama. Reports of sutama among the civilian population date back to late 1995 and, in association with body-louse infestation, the disease has subsequently swept across the higher and colder regions of the country. Methods During a field study in February, 1997, 102 refugees with sutama underwent clinical examination and interview. Serum samples were collected and infesting body lice removed, Microbiological analysis included antibody estimations and specific PCRs aimed at diagnosis of Rickettsia prowezekii, Bartonella quintana, and Borrelia recurrentis. Between January and September, 1997, nationwide epidemiological data on the prevalence and distribution of sutama was obtained through liaison with local health services. A second field study in March, 1997, entailed the collection of further serum samples from suspected cases of sutama in different regions of Burundi, Findings Most of the 102 patients with sutama during initial assessment presented with manifestations similar to those previously described for typhus in Africa, though skin eruptions occurred in only 25 (25%) cases. Microbiological testing revealed evidence of R prowazeki infection in 76 (75%) patients, confirming that most cases of clinically-diagnosed sutama were epidemic typhus, and supporting the reliabilty of clinical diagnosis as a basis for the nationwide surveillance of the disease. Up to September, 1997, 45 558 typhus cases were clinically diagnosed, most of which occurred in regions at an altitude of over 1500 m. Serological testing of 232 individuals from different regions of Burundi provided microbiological evidence to support clinical diagnoses in seven provinces, confirming the widespread nature of the outbreak. Serum from 13 of the original 102 patients and 19 (8%) of the 232 suspected cases had raised antibody titres against B quintana, A fatality rate of 15% among jail inmates fell to 0.5% after administration of a single dose of 200 mg doxycycline to suspected cases. Interpretation A gigantic outbreak of R prowazekii-induced typhus and a quintana-induced trench fever is continuing in Burundi. Transmission of both diseases to such a large number of people has followed a widespread epidemic of body-louse infestation. Diagnosis of typhus could be reliably made by means of clinical criteria, and the disease could be efficiently and easily treated by antibiotics, This epidemic highlights the appalling conditions in central-African refugee camps and the failure of public-health programmes to serve their inhabitants. Louse-associated disease remains a major health threat in this and other war-torn regions of the world.	Univ Mediterranee, Fac Med, WHO Reference Ctr Rickettsial Dis, CNRS,IPRESA 6020,Unite Rickettsies, Marseille, France; CHU Bujumbura, Bujumbura, Burundi; Hop Houphouet Boigny, Parasitol Lab, Marseille, France; WHO, Bujumbura, Burundi	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; World Health Organization	Raoult, D (corresponding author), Univ Mediterranee, Fac Med, WHO Reference Ctr Rickettsial Dis, CNRS,IPRESA 6020,Unite Rickettsies, Blvd Jean Moulin, Marseille, France.	Didier.Raoult@medicine.univ-mrs.fr	TISSOT-DUPONT, Hervé/P-5808-2016; RAOULT, Didier/A-8434-2008	RAOULT, Didier/0000-0002-0633-5974; Birtles, Richard/0000-0002-4216-5044				[Anonymous], 1993, B WORLD HEALTH ORGAN, V71, P293; Birtles RJ, 1996, INT J SYST BACTERIOL, V46, P891, DOI 10.1099/00207713-46-4-891; Bise G, 1997, T ROY SOC TROP MED H, V91, P133, DOI 10.1016/S0035-9203(97)90198-X; DESALLE R, 1992, SCIENCE, V257, P1933, DOI 10.1126/science.1411508; EREMEEVA ME, 1994, CLIN DIAGN LAB IMMUN, V1, P318, DOI 10.1128/CDLI.1.3.318-324.1994; FELSENFIELD O, 1971, BORRELIA STRAINS VEC; LaScola B, 1997, J CLIN MICROBIOL, V35, P2715, DOI 10.1128/JCM.35.11.2715-2727.1997; Maurin M, 1996, CLIN MICROBIOL REV, V9, P273, DOI 10.1128/CMR.9.3.273; Maurin M, 1997, J CLIN MICROBIOL, V35, P2283, DOI 10.1128/JCM.35.9.2283-2287.1997; NIKOYAGIZE E, 1976, THESIS U CLERMONT 1; ORMSBEE R, 1977, AM J EPIDEMIOL, V105, P261, DOI 10.1093/oxfordjournals.aje.a112382; PERINE PL, 1974, LANCET, V2, P742; PERINE PL, 1992, CLIN INFECT DIS, V14, P1149, DOI 10.1093/clinids/14.5.1149; Raoult D, 1997, EMERG INFECT DIS, V3, P357, DOI 10.3201/eid0303.970313; RAOULT D, 1995, FEMS IMMUNOL MED MIC, V11, P13, DOI 10.1111/j.1574-695X.1995.tb00073.x; REGNERY RL, 1991, J BACTERIOL, V173, P1576, DOI 10.1128/jb.173.5.1576-1589.1991; ROUX V, 1995, GENE, V156, P107, DOI 10.1016/0378-1119(94)00919-J; Roux V, 1997, INT J SYST BACTERIOL, V47, P252, DOI 10.1099/00207713-47-2-252; Saah A. J., 1990, Principles and practice of infectious diseases., P1476; TAYLOR RM, 1957, AM J TROP MED HYG, V6, P863, DOI 10.4269/ajtmh.1957.6.863; 1984, WKLY EPIDEMIOL REC, V6, P45; 1986, WKLY EPIDEMIOL REC, V7, P49; 1984, WKLY EPIDEMIOL REC, V59, P29	23	163	171	1	18	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 1	1998	352	9125					353	358		10.1016/S0140-6736(97)12433-3	http://dx.doi.org/10.1016/S0140-6736(97)12433-3			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	106BU	9717922				2022-12-28	WOS:000075110500010
J	Malissen, B				Malissen, B			Immunology - Translating affinity into response	SCIENCE			English	Article							AGONISTS; ZETA		CNRS Marseille Luminy, INSERM, Ctr Immunol, F-13288 Marseille 9, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite	Malissen, B (corresponding author), CNRS Marseille Luminy, INSERM, Ctr Immunol, Case 906, F-13288 Marseille 9, France.		Malissen, Bernard/AAK-4659-2020	Malissen, Bernard/0000-0003-1340-9342				ElHillal O, 1997, P NATL ACAD SCI USA, V94, P1919, DOI 10.1073/pnas.94.5.1919; Kersh EN, 1998, SCIENCE, V281, P572, DOI 10.1126/science.281.5376.572; Lyons DS, 1996, IMMUNITY, V5, P53, DOI 10.1016/S1074-7613(00)80309-X; MADRENAS J, 1995, SCIENCE, V267, P515, DOI 10.1126/science.7824949; MCKEITHAN TW, 1995, P NATL ACAD SCI USA, V92, P5042, DOI 10.1073/pnas.92.11.5042; Purbhoo MA, 1998, P NATL ACAD SCI USA, V95, P4527, DOI 10.1073/pnas.95.8.4527; SLOANLANCASTER J, 1994, CELL, V79, P913, DOI 10.1016/0092-8674(94)90080-9; Torigoe C, 1997, P NATL ACAD SCI USA, V94, P1372, DOI 10.1073/pnas.94.4.1372; Torigoe C, 1998, SCIENCE, V281, P568, DOI 10.1126/science.281.5376.568; Wofsy C, 1997, J IMMUNOL, V159, P5984	10	10	10	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 24	1998	281	5376					528	529		10.1126/science.281.5376.528	http://dx.doi.org/10.1126/science.281.5376.528			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	104KA	9705722				2022-12-28	WOS:000075012300029
J	Moller, H; Cortes, D; Engholm, G; Thorup, J				Moller, H; Cortes, D; Engholm, G; Thorup, J			Risk of testicular cancer with cryptorchidism and with testicular biopsy: cohort study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							BOYS; TESTIS		Danish Natl Res Fdn, Ctr Res Hlth & Social Stat, DK-2100 Copenhagen 0, Denmark; Natl Univ Hosp, Dept Pathol, DK-2100 Copenhagen 0, Denmark; Natl Univ Hosp, Dept Paediat Surg, DK-2100 Copenhagen 0, Denmark	Danmarks Grundforskningsfond	Moller, H (corresponding author), Danish Natl Res Fdn, Ctr Res Hlth & Social Stat, Sejrogade 11, DK-2100 Copenhagen 0, Denmark.	cerefo@inet.uni2.dk		Cortes, Dina/0000-0002-6852-6530; Thorup, Jorgen/0000-0003-3550-1107				CORTES D, 1994, J UROLOGY, V151, P722, DOI 10.1016/S0022-5347(17)35071-1; FORMAN D, 1994, BRIT MED J, V308, P1393, DOI 10.1136/bmj.308.6941.1393; GIWERCMAN A, 1987, J UROLOGY, V138, P1214, DOI 10.1016/S0022-5347(17)43553-1; Moller H, 1996, CANCER CAUSE CONTROL, V7, P264, DOI 10.1007/BF00051302; Swerdlow AJ, 1997, BRIT MED J, V314, P1507, DOI 10.1136/bmj.314.7093.1507	5	45	45	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 12	1998	317	7160					729	729		10.1136/bmj.317.7160.729	http://dx.doi.org/10.1136/bmj.317.7160.729			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	121CT	9732342	Green Submitted, Green Published, Bronze			2022-12-28	WOS:000075995100023
J	Sato, K; Aoki, M; Noyori, R				Sato, K; Aoki, M; Noyori, R			A "green" route to adipic acid: Direct oxidation of cyclohexenes with 30 percent hydrogen peroxide	SCIENCE			English	Article							EPOXIDATION; OLEFINS	Currently, the industrial production of adipic acid uses nitric aid oxidation of cyclohexanol or a cyclohexanol/cyclohexanone mixture. The nitrous oxide emission from this process measurably contributes to global warming and ozone depletion. Therefore, the development of an adipic acid production process that is Less damaging to the environment is an important subject in chemical research. Cyclohexene can now be oxidized directly to colorless crystalline adipic acid with aqueous 30 percent hydrogen peroxide under organic solvent- and halide-free conditions, which could provide an ideal solution to this serious problem.	Nagoya Univ, Dept Chem, Chikusa Ku, Nagoya, Aichi 4648602, Japan; Nagoya Univ, Res Ctr Mat Sci, Chikusa Ku, Nagoya, Aichi 4648602, Japan	Nagoya University; Nagoya University	Noyori, R (corresponding author), Nagoya Univ, Dept Chem, Chikusa Ku, Nagoya, Aichi 4648602, Japan.							Coperet C, 1997, CHEM COMMUN, P1565, DOI 10.1039/a703542j; Davis D. D., 1991, KIRKOTHMER ENCY CHEM, V1, P466; DICKINSON RE, 1986, NATURE, V319, P109, DOI 10.1038/319109a0; DRATHS KM, 1994, J AM CHEM SOC, V116, P399, DOI 10.1021/ja00080a057; FRANZ JE, 1965, J ORG CHEM, V30, P1488, DOI 10.1021/jo01016a035; Fujitani T., 1988, Jp. Pat., Patent No. 93746; GOSSER LW, 1987, Patent No. 4681751; ISHII Y, 1988, J ORG CHEM, V53, P3587, DOI 10.1021/jo00250a032; KNOF L, 1962, LIEBIGS ANN CHEM, V656, P183; MITSUI O, 1984, Patent No. 184138; MITSUI O, 1984, Patent No. 186929; NAGAHARA H, 1986, Patent No. 50930; NAGAHARA H, 1987, Patent No. 45541; REIMER RA, 1994, ENVIRON PROG, V13, P134, DOI 10.1002/ep.670130217; RUBOTTOM JM, 1978, TETRAHEDRON LETT, P4603; Rudolph J, 1997, J AM CHEM SOC, V119, P6189, DOI 10.1021/ja970623l; Sato K, 1997, J AM CHEM SOC, V119, P12386, DOI 10.1021/ja973412p; Sato K, 1997, B CHEM SOC JPN, V70, P905, DOI 10.1246/bcsj.70.905; Sato K, 1996, J ORG CHEM, V61, P8310, DOI 10.1021/jo961287e; Scott A, 1998, CHEM WEEK, V160, P37; THIEMENS MH, 1991, SCIENCE, V251, P932, DOI 10.1126/science.251.4996.932; VENTURELLO C, 1984, Patent No. 0122804; 1996, EUR CHEM NEWS, V66, P41	23	678	739	8	323	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 11	1998	281	5383					1646	1647		10.1126/science.281.5383.1646	http://dx.doi.org/10.1126/science.281.5383.1646			2	Multidisciplinary Sciences	Current Chemical Reactions (CCR-EXPANDED); Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	118TR	9733504				2022-12-28	WOS:000075856500037
J	Wilkinson, D; Squire, SB; Garner, P				Wilkinson, D; Squire, SB; Garner, P			Effect of preventive treatment for tuberculosis in adults infected with HIV: systematic review of randomised placebo controlled trials	BRITISH MEDICAL JOURNAL			English	Review							HUMAN-IMMUNODEFICIENCY-VIRUS; EPIDEMIOLOGY; THERAPY; AFRICA; RISK	Objective: To determine whether preventive treatment for tuberculosis in adults infected with HIV reduces the frequency of tuberculosis and overall mortality. Design: Systematic review and data synthesis of randomised placebo controlled trials. Main outcome measures: Active tuberculosis, mortality, and adverse drug reaction requiring cessation of the study regimen. Outcomes stratified by status of purified protein derivative skin test Results: Four trials comprising 4055 adults from Haiti, Kenya, the United States, and Uganda were included. All compared isoniazid (6-12 months) with placebo, and one trial also compared multidrug treatment for 3 months with placebo. Mean follow up was 15-33 months. Overall, frequency of tuberculosis (relative risk 0.57, 95% confidence interval 0.41 to 0.79) was reduced in those receiving preventive. treatment compared with placebo: mortality was not significantly reduced (0.93, 0.83 to 1.05), In subjects positive for purified protein derivative receiving preventive treatment, the risk of tuberculosis was reduced substantially (0.32, 0.19 to 0.51) and the risk of death was reduced moderately (0.73, 0.57 to 0.95) compared with those taking placebo. In adults negative for purified protein derivative receiving preventive treatment, the risk of tuberculosis (0.82, 0.50 to 1.36) and the risk of death (1.02, 0.89 to 1.17) were not reduced significantly. Adverse drug reactions were more frequent, but not significantly so, in patients receiving drug compared with placebo (1.45, 0.98 to 2.14), Conclusions: Preventive treatment given for 3-12 months protects against tuberculosis in adults infected with HIV, at least in the short to medium term. Protection is greatest in subjects positive for purified protein derivative, in whom death is also less frequent. Long term benefits remain to be shown.	S African Med Council, Ctr Epidemiol Res So Africa, ZA-3935 Mtubatuba, South Africa; Univ Liverpool, Liverpool Sch Trop Med, Trop Med Div, Liverpool L3 5QA, Merseyside, England; Univ Liverpool, Liverpool Sch Trop Med, Int Hlth Div, Liverpool L3 5QA, Merseyside, England	Liverpool School of Tropical Medicine; University of Liverpool; Liverpool School of Tropical Medicine; University of Liverpool	Wilkinson, D (corresponding author), S African Med Council, Ctr Epidemiol Res So Africa, POB 187, ZA-3935 Mtubatuba, South Africa.		Wilkinson, David/A-6207-2008; Garner, Paul/HII-5856-2022; Garner, Paul/Y-8385-2019	Wilkinson, David/0000-0002-7265-9846; Garner, Paul/0000-0002-0607-6941; Squire, Stephen/0000-0001-7173-9038				AISU T, 1995, AIDS, V9, P267, DOI 10.1097/00002030-199509030-00008; *AM THOR SOC, 1990, AM REV RESPIR DIS, V142, P1420; [Anonymous], 1990, MMWR Recomm Rep, V39, P1; DECOCK KM, 1992, JAMA-J AM MED ASSOC, V268, P1581, DOI 10.1001/jama.1992.03490120095035; DECOCK KM, 1995, LANCET, V345, P833, DOI 10.1016/S0140-6736(95)92967-3; Egger M, 1998, BMJ-BRIT MED J, V316, P61, DOI 10.1136/bmj.316.7124.61; Gordin FM, 1997, NEW ENGL J MED, V337, P315, DOI 10.1056/NEJM199707313370505; Halsey NA, 1998, LANCET, V351, P786, DOI 10.1016/S0140-6736(97)06532-X; Hawken MP, 1997, AIDS, V11, P875, DOI 10.1097/00002030-199707000-00006; *INT UN TUB LUNG D, 1994, TUBERCLE LUNG DIS, V75, P96; KOCHI A, 1991, TUBERCLE, V72, P1, DOI 10.1016/0041-3879(91)90017-M; NARAIN JP, 1992, TUBERCLE LUNG DIS, V73, P311, DOI 10.1016/0962-8479(92)90033-G; OBRIEN RJ, 1994, TUBERCULOSIS BACK FU, P151; PAPE JW, 1993, LANCET, V342, P268, DOI 10.1016/0140-6736(93)91817-6; SELWYN PA, 1989, NEW ENGL J MED, V320, P545, DOI 10.1056/NEJM198903023200901; SMALL PM, 1994, NEW ENGL J MED, V330, P1703, DOI 10.1056/NEJM199406163302402; WADHAWAN D, 1992, 8 INT C AIDS 3 SEX T; Whalen CC, 1997, NEW ENGL J MED, V337, P801, DOI 10.1056/NEJM199709183371201; Wilkinson D, 1997, TROP MED INT HEALTH, V2, P747, DOI 10.1046/j.1365-3156.1997.d01-386.x; WILKINSON D, 1998, INFECT DIS MOD COCHR	20	109	110	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	SEP 5	1998	317	7159					625	629		10.1136/bmj.317.7159.625	http://dx.doi.org/10.1136/bmj.317.7159.625			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	118GN	9727988	Green Submitted, Green Published, Bronze			2022-12-28	WOS:000075830200016
J	Cohn, JA; Friedman, KJ; Noone, PG; Knowles, MR; Silverman, LM; Jowell, PS				Cohn, JA; Friedman, KJ; Noone, PG; Knowles, MR; Silverman, LM; Jowell, PS			Relation between mutations of the cystic fibrosis gene and idiopathic pancreatitis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; CONGENITAL BILATERAL ABSENCE; VAS-DEFERENS; PARTIAL PENETRANCE; 5T ALLELE; CFTR GENE; CHILDREN; DISEASE	Background It is unknown whether genetic factors predispose patients to idiopathic pancreatitis, In patients with cystic fibrosis, mutations of the cystic fibrosis transmembrane conductance regulator (CFTR) gene typically cause pulmonary and pancreatic insufficiency while rarely causing pancreatitis. We examined whether idiopathic pancreatitis is associated with CFTR mutations in persons who do not have lung disease of cystic fibrosis. Methods We studied 27 patients (mean age at diagnosis, 36 years), 22 of whom were female, who had been referred for an evaluation of idiopathic pancreatitis. DNA was tested for 17 CFTR mutations and for the 5T allele in intron 8 of the CFTR gene. The 5T allele reduces the level of functional CFTR and is associated with an inherited form of infertility in males. Patients with two abnormal CFTR alleles were further evaluated for unrecognized cystic fibrosis-related lung disease, and bath base-line and CFTR-mediated ion transport were measured in the nasal mucosa. Results Ten patients with idiopathic chronic pancreatitis (37 percent) had at least one abnormal CFTR allele. Eight CFTR mutations were detected (prevalence ratio, 11:1; 95 percent confidence interval, 5 to 23; P<0.001). In three patients both alleles were affected (prevalence ratio, 80:1; 95 percent confidence interval, 17 to 379; P<0.001). These three patients did not have lung disease typical of cystic fibrosis on the basis of sweat testing, spirometry, or base-line nasal potential-difference measurements. Nonetheless, each had abnormal nasal cyclic AMP-mediated chloride transport. Conclusions In a group of patients referred for evaluation of idiopathic pancreatitis, there was a strong association between mutations in the CFTR gene and pancreatitis. The abnormal CFTR genotypes in these patients with pancreatitis resemble those associated with male infertility. (N Engl J Med 1998;339:653-8.) (C) 1998, Massachusetts Medical Society.	Duke Univ, Med Ctr, Durham, NC 27710 USA; Vet Affairs Med Ctr, Dept Med, Durham, NC 27705 USA; Univ N Carolina, Dept Pathol, Chapel Hill, NC USA; Univ N Carolina, Dept Lab Med, Chapel Hill, NC USA	Duke University; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Cohn, JA (corresponding author), Duke Univ, Med Ctr, Box 3378, Durham, NC 27710 USA.				NCRR NIH HHS [RR0006] Funding Source: Medline; NHLBI NIH HHS [HL34322] Funding Source: Medline; NIDDK NIH HHS [DK40701] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL034322] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK040701, R01DK040701] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANGUIANO A, 1992, JAMA-J AM MED ASSOC, V267, P1794, DOI 10.1001/jama.267.13.1794; ATLAS AB, 1992, J PEDIATR-US, V120, P756, DOI 10.1016/S0022-3476(05)80242-2; AXON ATR, 1984, GUT, V25, P1107, DOI 10.1136/gut.25.10.1107; BANK S, 1978, DIG DIS, V23, P178; BLUSTEIN PK, 1981, PEDIATRICS, V68, P387; CHILLON M, 1995, NEW ENGL J MED, V332, P1475, DOI 10.1056/NEJM199506013322204; CHU CS, 1993, NAT GENET, V3, P151, DOI 10.1038/ng0293-151; COSTES B, 1995, EUR J HUM GENET, V3, P285; Davis PB, 1996, AM J RESP CRIT CARE, V154, P1229, DOI 10.1164/ajrccm.154.5.8912731; DEANGELIS C, 1992, PANCREAS, V7, P193, DOI 10.1097/00006676-199203000-00010; Diem K., 1970, SCI TABLES, VSeventh; Dumur V, 1996, HUM GENET, V97, P7; Friedman KJ, 1997, HUM MUTAT, V10, P108, DOI 10.1002/(SICI)1098-1004(1997)10:2<108::AID-HUMU3>3.3.CO;2-3; GROSS V, 1989, INT J PANCREATOL, V4, P221; HABER P, 1995, J LAB CLIN MED, V125, P305; HAMOSH A, 1996, PEDIAT PULMONOL S13, V22, P104; HANAWA M, 1978, TOHOKU J EXP MED, V125, P59, DOI 10.1620/tjem.125.59; KAZAZIAN HH, 1994, HUM MUTAT, V4, P167; Kerem E, 1997, AM J RESP CRIT CARE, V155, P1914, DOI 10.1164/ajrccm.155.6.9196095; KIESEWETTER S, 1993, NAT GENET, V5, P274, DOI 10.1038/ng1193-274; KNOWLES MR, 1995, HUM GENE THER, V6, P445, DOI 10.1089/hum.1995.6.4-445; LIDDLE RA, IN PRESS TXB GASTROE; MARINO CR, 1991, J CLIN INVEST, V88, P712, DOI 10.1172/JCI115358; MASARYK TJ, 1983, DIGEST DIS SCI, V28, P874, DOI 10.1007/BF01317036; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; Oppenheimer E H, 1975, Perspect Pediatr Pathol, V2, P241; RaveHarel N, 1997, AM J HUM GENET, V60, P87; SHWACHMAN H, 1975, PEDIATRICS, V55, P86; STEER ML, 1995, NEW ENGL J MED, V332, P1482, DOI 10.1056/NEJM199506013322206; Stern RC, 1997, NEW ENGL J MED, V336, P487, DOI 10.1056/NEJM199702133360707; WELSH MJ, 1995, METABOLIC MOL BASES, V3, P3799; Whitcomb DC, 1996, NAT GENET, V14, P141, DOI 10.1038/ng1096-141; ZIELENSKI J, 1991, GENOMICS, V10, P229, DOI 10.1016/0888-7543(91)90504-8; Zielenski J, 1995, ANNU REV GENET, V29, P777, DOI 10.1146/annurev.ge.29.120195.004021	34	651	669	0	19	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 3	1998	339	10					653	658		10.1056/NEJM199809033391002	http://dx.doi.org/10.1056/NEJM199809033391002			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	115WA	9725922				2022-12-28	WOS:000075688100002
J	Hirschmann, JV				Hirschmann, JV			Methods for decreasing antibiotic use in otitis media	LANCET			English	Editorial Material									Vet Adm Med Ctr, Seattle, WA 98108 USA; Univ Washington, Sch Med, Seattle, WA USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Washington; University of Washington Seattle	Hirschmann, JV (corresponding author), Vet Adm Med Ctr, 1660 S Columbian Way, Seattle, WA 98108 USA.							DELMAR C, 1997, BRIT MED J, V314, P126; DOZYRSKYJ AL, 1998, JAMA-J AM MED ASSOC, V279, P1736; Froom J, 1997, BRIT MED J, V315, P98, DOI 10.1136/bmj.315.7100.98; Paradise JL, 1997, PEDIATRICS, V99, P318, DOI 10.1542/peds.99.3.318; Roark R, 1997, PEDIATR INFECT DIS J, V16, P376, DOI 10.1097/00006454-199704000-00008; VANBUCHEM FL, 1985, BRIT MED J, V290, P1033, DOI 10.1136/bmj.290.6474.1033; WILLIAMS RL, 1993, JAMA-J AM MED ASSOC, V270, P1344, DOI 10.1001/jama.270.11.1344	7	5	5	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	AUG 29	1998	352	9129					672	672		10.1016/S0140-6736(05)60818-5	http://dx.doi.org/10.1016/S0140-6736(05)60818-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	116MT	9728980				2022-12-28	WOS:000075729700008
J	Besarab, A; Bolton, WK; Browne, JK; Egrie, JC; Nissenson, AR; Okamoto, DM; Schwab, SJ; Goodkin, DA				Besarab, A; Bolton, WK; Browne, JK; Egrie, JC; Nissenson, AR; Okamoto, DM; Schwab, SJ; Goodkin, DA			The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RECOMBINANT-HUMAN-ERYTHROPOIETIN; LEFT-VENTRICULAR HYPERTROPHY; STAGE RENAL-DISEASE; DIALYSIS PATIENTS; BACTERIAL-INFECTIONS; ACCESS THROMBOSIS; ANEMIC PATIENTS; HEART-DISEASE; RISK; IRON	Background In patients with end-stage renal disease, anemia develops as a result of erythropoietin deficiency, and recombinant human erythropoietin (epoetin) is prescribed to correct the anemia partially. We examined the risks and benefits of normalizing the hematocrit in patients with cardiac disease who were undergoing hemodialysis. Methods We studied 1233 patients with clinical evidence of congestive heart failure or ischemic heart disease who were undergoing hemodialysis: 618 patients were assigned to receive increasing doses of epoetin to achieve and maintain a hematocrit of 42 percent, and 615 were assigned to receive doses of epoetin sufficient to maintain a hematocrit of 30 percent throughout the study. The median duration of treatment was 14 months. The primary end point was the length of time to death or a first nonfatal myocardial infarction. Results After 29 months, there were 183 deaths and 19 first nonfatal myocardial infarctions among the patients in the normal-hematocrit group and 150 deaths and 14 nonfatal myocardial infarctions among those in the low-hematocrit group (risk ratio for the normal-hematocrit group as compared with the low-hematocrit group, 1.3; 95 percent confidence interval, 0.9 to 1.9). Although the difference in event-free survival between the two groups did not reach the prespecified statistical stopping boundary, the study was halted. The causes of death in the two groups were similar. The mortality rates decreased with increasing hematocrit values in both groups. The patients in the normal-hematocrit group had a decline in the adequacy of dialysis and received intravenous iron dextran more often than those in the low-hematocrit group. Conclusions In patients with clinically evident congestive heart failure or ischemic heart disease who are receiving hemodialysis, administration of epoetin to raise their hematocrit to 42 percent is not recommended. (N Engl J Med 1998;339:584-90.) (C) 1998, Massachusetts Medical Society.	Amgen, Clin Res, Thousand Oaks, CA 91320 USA; Henry Ford Hosp, Div Nephrol & Hypertens, Detroit, MI 48202 USA; Univ Virginia, Hlth Sci Ctr, Div Nephrol, Dept Internal Med, Charlottesville, VA USA; Univ Calif Los Angeles, Div Nephrol, Dept Med, Los Angeles, CA USA; Duke Univ, Med Ctr, Div Nephrol, Dept Med, Durham, NC USA	Amgen; Henry Ford Health System; Henry Ford Hospital; University of Virginia; University of California System; University of California Los Angeles; Duke University	Goodkin, DA (corresponding author), Amgen, Clin Res, 1 Amgen Ctr Dr, Thousand Oaks, CA 91320 USA.		Besarab, Anatole/AAP-2569-2020; Wilson, Matthew H/K-3193-2013					Barany P., 1996, Journal of the American Society of Nephrology, V7, P1472; Benz R. L., 1996, Journal of the American Society of Nephrology, V7, P1473; Beusterien KM, 1996, J AM SOC NEPHROL, V7, P763; BRAUMANN KM, 1991, NEPHRON, V58, P129, DOI 10.1159/000186401; CANNELLA G, 1991, NEPHROL DIAL TRANSPL, V6, P31, DOI 10.1093/ndt/6.1.31; COLLINS A, 1994, J AM SOC NEPHROL, V5, P439; Collins A, 1997, J AM SOC NEPHROL, V8, p190A; COX DR, 1972, J R STAT SOC B, V34, P187; Eschbach J. W., 1993, Journal of the American Society of Nephrology, V4, P425; ESCHBACH JW, 1989, ANN INTERN MED, V111, P992, DOI 10.7326/0003-4819-111-12-992; ESCHBACH JW, 1993, SEMIN DIALYSIS, V6, P180, DOI 10.1111/j.1525-139X.1993.tb00292.x; EVANS RW, 1990, JAMA-J AM MED ASSOC, V263, P825; GOLDBERG N, 1992, AM HEART J, V124, P424, DOI 10.1016/0002-8703(92)90608-X; HOEN B, 1995, NEPHROL DIAL TRANSPL, V10, P377; Jennison C, 1990, STAT SCI, V5, P299, DOI DOI 10.1214/SS/1177012099; KUSUNOKI M, 1981, J CEREBR BLOOD F MET, V1, P413, DOI 10.1038/jcbfm.1981.45; LAN KKG, 1983, BIOMETRIKA, V70, P659, DOI 10.2307/2336502; LAUPACIS A, 1990, BMJ-BRIT MED J, V300, P573; LOWRIE EG, 1995, ANEMIA ESRD RELATED; LUNDIN AP, 1991, NEPHRON, V58, P315; MACDOUGALL I, 1990, LANCET, V335, P614; MARSH JT, 1991, KIDNEY INT, V39, P155, DOI 10.1038/ki.1991.20; MCHORNEY CA, 1993, MED CARE, V31, P247, DOI 10.1097/00005650-199303000-00006; MUIRHEAD N, 1993, SEMIN DIALYSIS, V6, P184, DOI 10.1111/j.1525-139X.1993.tb00293.x; Nissenson A. R., 1996, Journal of the American Society of Nephrology, V7, P1459; PARFREY PS, 1990, AM J NEPHROL, V10, P213, DOI 10.1159/000168084; PARFREY PS, 1991, J AM SOC NEPHROL, V2, P2; PASCUAL J, 1991, CLIN NEPHROL, V35, P280; *REN DAT SYST, 1996, USRDS 1996 ANN DAT R, P23; ROSTAND SG, 1990, CLIN DIALYSIS, P409; SALONEN JT, 1992, CIRCULATION, V86, P803, DOI 10.1161/01.CIR.86.3.803; SENNESAEL JJ, 1991, KIDNEY INT, V40, P121, DOI 10.1038/ki.1991.189; SILBERBERG JS, 1989, KIDNEY INT, V36, P286, DOI 10.1038/ki.1989.192; SULLIVAN JL, 1981, LANCET, V1, P1293; TIELEMANS CL, 1989, NEPHROL DIAL TRANSPL, V4, P883, DOI 10.1093/ndt/4.10.883; VEYS N, 1992, AM J KIDNEY DIS, V19, P358, DOI 10.1016/S0272-6386(12)80454-9; WIZEMANN V, 1992, NEPHRON, V62, P161, DOI 10.1159/000187026; ZEHNDER C, 1992, NEPHRON, V61, P21, DOI 10.1159/000186829	39	1673	1738	2	28	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 27	1998	339	9					584	590		10.1056/NEJM199808273390903	http://dx.doi.org/10.1056/NEJM199808273390903			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	113LR	9718377				2022-12-28	WOS:000075552900003
J	Snyder, LH; Grieve, KL; Brotchie, P; Andersen, RA				Snyder, LH; Grieve, KL; Brotchie, P; Andersen, RA			Separate body- and world-referenced representations of visual space in parietal cortex	NATURE			English	Article							NEURONS; MICROSTIMULATION; INFORMATION; HIPPOCAMPUS; PERCEPTION; SACCADE; PRIMATE; MONKEYS; GAZE; RATS	In order to direct a movement towards a visual stimulus, visual spatial information must be combined with postural information(1). For example, directing gaze (eye plus head) towards a visible target requires the combination of retinal image location with eye and head position to determine the location of the target relative to the body. Similarly, world-referenced postural information is required to determine where something lies in the world. Posterior parietal neurons recorded in monkeys combine visual information with eye and head position(2-4). if population of such cells could make up a distributed representation of target location in an extraretinal frame of reference(4-7) However, pre vious studies have not. distinguished between world-referenced and body-referenced signals(4,8). Here we report that modulations of visual signals (gain fields) in two adjacent cortical fields, LIP and 7a, are referenced to the body and to the world, respectively. This segregation of spatial information is consistent with a streaming of information, with one path carrying body-referenced information for the control of gaze, and the other carrying world-referenced information for navigation and other tasks that require an absolute frame of reference.	CALTECH, Div Biol, Pasadena, CA 91125 USA	California Institute of Technology	Andersen, RA (corresponding author), CALTECH, Div Biol, Pasadena, CA 91125 USA.	andersen@vis.caltech.edu	Snyder, Lawrence H/A-4593-2017					Aguirre GK, 1996, CEREB CORTEX, V6, P823, DOI 10.1093/cercor/6.6.823; Andersen R A, 1993, Curr Opin Neurobiol, V3, P171, DOI 10.1016/0959-4388(93)90206-E; ANDERSEN RA, 1985, SCIENCE, V230, P456, DOI 10.1126/science.4048942; ANDERSEN RA, 1983, J NEUROSCI, V3, P532; ANDERSEN RA, 1990, J COMP NEUROL, V296, P63; BARASH S, 1991, J NEUROPHYSIOL, V66, P1095, DOI 10.1152/jn.1991.66.3.1095; BAYLIS GC, 1994, EXP BRAIN RES, V98, P110; BROTCHIE PR, 1995, NATURE, V375, P232, DOI 10.1038/375232a0; Duhamel JR, 1997, NATURE, V389, P845, DOI 10.1038/39865; Fredrickson J M, 1966, Acta Otolaryngol, V61, P168, DOI 10.3109/00016486609127054; Freedman EG, 1997, J NEUROPHYSIOL, V78, P1669, DOI 10.1152/jn.1997.78.3.1669; GOODALE MA, 1992, TRENDS NEUROSCI, V15, P20, DOI 10.1016/0166-2236(92)90344-8; JONES GM, 1965, IEEE T BIO-MED ENG, VBM12, P54, DOI 10.1109/TBME.1965.4502350; KARNATH HO, 1994, EXP BRAIN RES, V101, P140; MCNAUGHTON BL, 1983, EXP BRAIN RES, V52, P41; MERGNER T, 1983, EXP BRAIN RES, V49, P198; POUGET A, 1995, ADV NEURAL INF PROCE, V7, P137; Robinson D.A., 1975, BASIC MECH OCULAR MO, P337; ROLL R, 1991, EXP BRAIN RES, V85, P423; Rolls ET, 1995, HIPPOCAMPUS, V5, P409, DOI 10.1002/hipo.450050504; SALINAS E, 1995, J NEUROSCI, V15, P6461; SHIBUTANI H, 1984, EXP BRAIN RES, V55, P1; Snyder LH, 1997, NATURE, V386, P167, DOI 10.1038/386167a0; SQUIRE LR, 1992, PSYCHOL REV, V99, P195, DOI 10.1037/0033-295X.99.2.195; Thier P, 1996, P NATL ACAD SCI USA, V93, P4962, DOI 10.1073/pnas.93.10.4962; VANESSEN DC, 1983, TRENDS NEUROSCI, V6, P370, DOI 10.1016/0166-2236(83)90167-4; VONHOLST E, 1950, NATURWISSENSCHAFTEN, V37, P464, DOI 10.1007/BF00622503; ZIPSER D, 1988, NATURE, V331, P679, DOI 10.1038/331679a0	28	343	343	0	18	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 27	1998	394	6696					887	891		10.1038/29777	http://dx.doi.org/10.1038/29777			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	114LW	9732870				2022-12-28	WOS:000075611800047
J	Carew-Shaw, MB				Carew-Shaw, MB			Edward Carew-Shaw - Obituary	BRITISH MEDICAL JOURNAL			English	Biographical-Item																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 22	1998	317	7157					544	544						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	115AM	9712623				2022-12-28	WOS:000075641400055
J	Li, HL; Zhu, H; Xu, CJ; Yuan, JY				Li, HL; Zhu, H; Xu, CJ; Yuan, JY			Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis	CELL			English	Article							CYTOCHROME-C; CELL-DEATH; SIGNALING COMPLEX; BCL-2; PROTEASE; BCL-X(L); RELEASE; BAX; INDUCTION; DOMAIN	We report here that BID, a BH3 domain-containing proapoptotic Bcl2 family member, is a specific proximal substrate of Casp8 in the Fas apoptotic signaling pathway. While full-length BID is localized in cytosol, truncated BID (tBID) translocates to mitochondria and thus transduces apoptotic signals from cytoplasmic membrane to mitochondria, tBID induces first the clustering of mitochondria around the nuclei and release of cytochrome c independent of caspase activity, and then the loss of mitochondrial membrane potential, cell shrinkage, and nuclear condensation in a caspase-dependent fashion. Coexpression of Bclx(L) inhibits all the apoptotic changes induced by tBID. Our results indicate that BID is a mediator of mitochondrial damage induced by Casp8.	Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Yuan, JY (corresponding author), Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA.			Zhu, Hong/0000-0002-2575-4031				Archambault J, 1998, J BIOL CHEM, V273, P27593, DOI 10.1074/jbc.273.42.27593; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Bossy-Wetzel E, 1998, EMBO J, V17, P37, DOI 10.1093/emboj/17.1.37; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; CHITTENDEN T, 1995, EMBO J, V14, P5589, DOI 10.1002/j.1460-2075.1995.tb00246.x; Clem RJ, 1998, P NATL ACAD SCI USA, V95, P554, DOI 10.1073/pnas.95.2.554; Conradt B, 1998, CELL, V93, P519, DOI 10.1016/S0092-8674(00)81182-4; Cosulich SC, 1997, CURR BIOL, V7, P913, DOI 10.1016/S0960-9822(06)00410-6; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; FernandesAlnemri T, 1996, P NATL ACAD SCI USA, V93, P7464, DOI 10.1073/pnas.93.15.7464; Hsu YT, 1997, J BIOL CHEM, V272, P13829, DOI 10.1074/jbc.272.21.13829; Hu YM, 1998, P NATL ACAD SCI USA, V95, P4386, DOI 10.1073/pnas.95.8.4386; Huang DCS, 1998, EMBO J, V17, P1029, DOI 10.1093/emboj/17.4.1029; Kelekar A, 1997, MOL CELL BIOL, V17, P7040, DOI 10.1128/MCB.17.12.7040; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Knudson CM, 1997, NAT GENET, V16, P358, DOI 10.1038/ng0897-358; Li F, 1997, J BIOL CHEM, V272, P30299, DOI 10.1074/jbc.272.48.30299; Li HL, 1997, J BIOL CHEM, V272, P21010, DOI 10.1074/jbc.272.34.21010; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Lustig KD, 1997, METHOD ENZYMOL, V283, P83; Medema JP, 1998, J BIOL CHEM, V273, P3388, DOI 10.1074/jbc.273.6.3388; Merry DE, 1997, ANNU REV NEUROSCI, V20, P245, DOI 10.1146/annurev.neuro.20.1.245; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; OLTVAI ZN, 1994, CELL, V79, P189, DOI 10.1016/0092-8674(94)90188-0; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Shimizu S, 1996, ONCOGENE, V13, P21; Shimizu S, 1998, P NATL ACAD SCI USA, V95, P1455, DOI 10.1073/pnas.95.4.1455; Srinivasan A, 1998, J BIOL CHEM, V273, P4523, DOI 10.1074/jbc.273.8.4523; Susin SA, 1996, J EXP MED, V184, P1331, DOI 10.1084/jem.184.4.1331; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; VanderHeiden MG, 1997, CELL, V91, P627, DOI 10.1016/S0092-8674(00)80450-X; Wang K, 1996, GENE DEV, V10, P2859, DOI 10.1101/gad.10.22.2859; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; Xue D, 1997, NATURE, V390, P305, DOI 10.1038/36889; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zhou Q, 1997, J BIOL CHEM, V272, P7797, DOI 10.1074/jbc.272.12.7797; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	43	3611	3779	1	195	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 21	1998	94	4					491	501		10.1016/S0092-8674(00)81590-1	http://dx.doi.org/10.1016/S0092-8674(00)81590-1			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	113GB	9727492	Bronze			2022-12-28	WOS:000075541100011
J	Elders, MJ; Albert, AE				Elders, MJ; Albert, AE			Adolescent pregnancy and sexual abuse	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							FATHERS		Univ Arkansas, Sch Med, Little Rock, AR 72204 USA; Harvard Univ, Sch Med, Boston, MA USA	University of Arkansas System; University of Arkansas Fayetteville; University of Arkansas Little Rock; Harvard University; Harvard Medical School	Elders, MJ (corresponding author), Arkansas Childrens Hosp, 800 Marshall St, Little Rock, AR 72202 USA.							*A GUTTM I, 1994, SEX AM TEEN; Abma J, 1998, FAM PLANN PERSPECT, V30, P12, DOI 10.2307/2991518; *AD CHILDR FAM, 1997, CHILD AB NEGL STAT S, V1; Adams JA, 1997, PEDIATR ANN, V26, P299, DOI 10.3928/0090-4481-19970501-07; BOYER D, 1992, FAM PLANN PERSPECT, V24, P4, DOI 10.2307/2135718; BOYER D, 1992, FAMILY PLANNING PERS, V24, P19; Donovan P, 1997, FAM PLANN PERSPECT, V29, P30, DOI 10.2307/2953351; Elstein S.G., 1997, SEXUAL RELATIONSHIPS; EMANS SJ, 1990, PEDIAT ADOLESCENT GY; ERICKSON PI, 1991, J ADOLESCENT HEALTH, V12, P319, DOI 10.1016/0197-0070(91)90007-9; ESPARZA DV, 1995, J OBSTET GYNECOL NEO, V25, P321; Farber EW, 1996, GEN HOSP PSYCHIAT, V18, P56, DOI 10.1016/0163-8343(95)00098-4; GERSHENSON H, 1989, J INTERPERS VIOLENCE, V4, P204; Henshaw SK, 1998, FAM PLANN PERSPECT, V30, P24, DOI 10.2307/2991522; Kenney JW, 1997, J ADOLESCENT HEALTH, V21, P3, DOI 10.1016/S1054-139X(97)00035-9; Kerns D L, 1994, Future Child, V4, P119, DOI 10.2307/1602527; LANDRY DJ, 1995, FAM PLANN PERSPECT, V27, P159, DOI 10.2307/2136260; Lindberg LD, 1997, FAM PLANN PERSPECT, V29, P61, DOI 10.2307/2953363; Males M, 1996, AM J PUBLIC HEALTH, V86, P565, DOI 10.2105/AJPH.86.4.565; MALES MA, 1995, LANCET, V346, P64, DOI 10.1016/S0140-6736(95)92105-2; MCANARNEY ER, 1990, AM J DIS CHILD, V144, P789, DOI 10.1001/archpedi.1990.02150310057027; MOORE KA, 1989, FAM PLANN PERSPECT, V21, P110, DOI 10.2307/2135660; MOORE KA, 1997, FACTS GLANCE; NAGY S, 1995, PEDIATRICS, V96, P944; STEVENSSIMON C, 1994, ARCH PEDIAT ADOL MED, V148, P23, DOI 10.1001/archpedi.1994.02170010025005; Stock JL, 1997, FAM PLANN PERSPECT, V29, P200, DOI 10.2307/2953395; STOCK JL, 1997, FAMILY PLANNING PERS, V29, P227; VANDEVEN AM, 1992, CURR OPIN OBSTET GYN, V4, P843; Widom CS, 1996, AM J PUBLIC HEALTH, V86, P1607, DOI 10.2105/AJPH.86.11.1607	29	20	20	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 19	1998	280	7					648	649		10.1001/jama.280.7.648	http://dx.doi.org/10.1001/jama.280.7.648			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	110ME	9718059				2022-12-28	WOS:000075384300036
J	Krumholz, HM; Radford, MJ; Wang, Y; Chen, J; Heiat, A; Marciniak, TA				Krumholz, HM; Radford, MJ; Wang, Y; Chen, J; Heiat, A; Marciniak, TA			National use and effectiveness of beta-blockers for the treatment of elderly patients after acute myocardial infarction - National cooperative cardiovascular project	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PRACTICE GUIDELINES; MEDICARE; BLOCKADE; QUALITY; TRIALS; DEATH; CARE	Context. - Despite the importance of beta-blockers for secondary prevention after acute myocardial infarction (AMI), several studies have suggested that they are substantially underutilized, particularly in older patients. Objectives. - To describe the contemporary national pattern of beta-blocker prescription at hospital discharge among patients aged 65 years or older with an AMI, to identify the most important predictors of the prescribed use of beta-blockers at discharge, and to determine the independent association between beta-blockers at discharge and mortality in clinical practice. Design. - Retrospective cohort study using data created from medical charts and administrative files. Setting. - Acute care nongovernmental hospitals in the United States. Patients. - National cohort of 115015 eligible patients aged 65 years or older who survived hospitalization with a confirmed AMI in 1994 or 1995. Main Outcome Measures. - beta-Blocker as a discharge medication and mortality in the year after discharge. Results. - Among the 45308 patients without contraindications to beta-blockers, 22665 (50.0%) had a beta-blocker as a discharge medication. There was significant variation by state, ranging from 30.3% to 77.1%. Of the 36795 patients who were not receiving beta-blocker therapy on admission, 16006 (43.5%) had therapy initiated on or before discharge. Demographic and clinical variables explained relatively little of the variation in the initiation of beta-blocker therapy. The prescribed use of calcium channel blockers at discharge had a strong negative association with the use of beta-blockers (odds ratio [OR] of beta-blocker use, 0.25; 95% confidence interval [CI], 0.24-0.26). The New England region had significantly higher use of beta-blocker therapy than the rest of the country. Compared with cardiologists, internists had similar rates (OR, 0.94; 95% CI, 0.90-1.00) and general and family practice physicians had lower rates (OR, 0.78; 95% CI, 0.73-0.83), After adjusting for potential confounders, beta-blockers were associated with a 14% lower risk of mortality at 1 year after discharge. The association with lower mortality was present in subgroups stratified by age, sex, and left ventricular ejection fraction. Conclusions. - Many ideal patients for beta-blocker therapy are not prescribed these drugs at discharge following AMI. The clinical and demographic characteristics of the patients do not explain much of the variation in the treatment pattern. Geographic factors and physician specialty are independently associated with the decision to use beta-blockers, Elderly patients who are prescribed beta-blockers at discharge have a better survival rate, consistent with the findings of randomized controlled trials of younger and lower-risk populations.	Yale Univ, Sch Med, Dept Med, Sect Cardiovasc Med, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Epidemiol & Publ Hlth, Sect Chron Dis Epidemiol, New Haven, CT 06520 USA; Yale New Haven Hosp, Ctr Outcomes Res & Evaluat, New Haven, CT USA; Connecticut Peer Review Org, Middletown, CT USA; Hlth Care Financing Adm, Baltimore, MD USA	Yale University; Yale University; Yale University	Krumholz, HM (corresponding author), Yale Univ, Sch Med, Dept Med, Sect Cardiovasc Med, 333 Cedar St,POB 208025, New Haven, CT 06520 USA.	harlan.krumholz@yale.edu	, Harlan/AAI-2875-2020	Radford, Martha/0000-0001-7503-9557				AGUSTI A, 1994, EUR J CLIN PHARMACOL, V46, P95; BRAND DA, 1995, J AM COLL CARDIOL, V26, P1432, DOI 10.1016/0735-1097(95)00362-2; ELLERBECK EF, 1995, JAMA-J AM MED ASSOC, V273, P1509, DOI 10.1001/jama.273.19.1509; FLEMING C, 1992, MED CARE, V30, P377, DOI 10.1097/00005650-199205000-00001; GURWITZ JH, 1992, AM J MED, V93, P605, DOI 10.1016/0002-9343(92)90192-E; Huff ED, 1997, J CLIN EPIDEMIOL, V50, P1395, DOI 10.1016/S0895-4356(97)00218-7; KARLSON BW, 1994, CLIN CARDIOL, V17, P311, DOI 10.1002/clc.4960170608; KESTENBAUM B, 1992, DEMOGRAPHY, V29, P565, DOI 10.2307/2061852; Marciniak TA, 1998, JAMA-J AM MED ASSOC, V279, P1351, DOI 10.1001/jama.279.17.1351; MEEHAN TP, 1995, ANN INTERN MED, V122, P928, DOI 10.7326/0003-4819-122-12-199506150-00007; Ryan TJ, 1996, J AM COLL CARDIOL, V28, P1328; SIAL SH, 1994, J GEN INTERN MED, V9, P599, DOI 10.1007/BF02600301; SMITH SC, 1995, CIRCULATION, V92, P2; Soumeral SB, 1997, JAMA-J AM MED ASSOC, V277, P115, DOI 10.1001/jama.277.2.115; WHITFORD DL, 1994, BMJ-BRIT MED J, V309, P1268, DOI 10.1136/bmj.309.6964.1268; YUSUF S, 1985, PROG CARDIOVASC DIS, V27, P335, DOI 10.1016/S0033-0620(85)80003-7	16	407	414	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 19	1998	280	7					623	629		10.1001/jama.280.7.623	http://dx.doi.org/10.1001/jama.280.7.623			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	110ME	9718054	Bronze			2022-12-28	WOS:000075384300031
J	Kahn, ML; Zheng, YW; Huang, W; Bigornia, V; Zeng, DW; Moff, S; Farese, RV; Tam, C; Coughlin, SR				Kahn, ML; Zheng, YW; Huang, W; Bigornia, V; Zeng, DW; Moff, S; Farese, RV; Tam, C; Coughlin, SR			A dual thrombin receptor system for platelet activation	NATURE			English	Article							MOLECULAR-CLONING; PEPTIDES; MECHANISM	Plalelet-dependent arterial thrombosis triggers most heart attacks and strokes. Because the coagulation protease thrombin is the most potent activator of platelets', identification of the platelet receptors for thrombin is critical for understanding thrombosis and haemostasis. Protease-activated receptor-1 (PAR1) is important for activation of human platelets by thrombin(2-6), but plays no apparent role in mouse platelet activation(7-9) PAR3 is a thrombin receptor that is expressed in mouse megakaryocytes(10). Here we report that thrombin responses in platelets from PAR3-deficient mice were markedly delayed and diminished but not absent. We have also identified PAR4, a new thrombin-activated receptor. PAR4 messenger RNA was detected in mouse megakaryocytes and a PAR4-activating peptide caused secretion and aggregation of PARS-deficient mouse platelets. Thus PAR3 is necessary for normal thrombin responses in mouse platelets, but a second PAR4-mediated mechanism for thrombin signalling exists. Studies with PAR-activating peptides suggest that PAR4 also functions in human platelets, which implies that an analogous dual-receptor system also operates isl humans. The identification of a two-receptor system for platelet activation by thrombin has important implications for the development of antithrombotic therapies.	Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94143 USA; Univ Calif San Francisco, Daiichi Res Ctr, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Gladstone Inst Cardiovasc Dis, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Cellular & Mol Pharmacol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco	Coughlin, SR (corresponding author), Univ Calif San Francisco, Cardiovasc Res Inst, Box 0130,505 Parnassus Ave, San Francisco, CA 94143 USA.	shaun.coughlin@quickmail.ucsf.edu		Tam-Amersdorfer, Carmen/0000-0003-3123-6342				BRASS LF, 1992, J BIOL CHEM, V267, P13795; CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; CHEN J, 1994, J BIOL CHEM, V269, P16041; Connolly AJ, 1996, NATURE, V381, P516, DOI 10.1038/381516a0; CONNOLLY TM, 1994, THROMB HAEMOSTASIS, V72, P627; DAVEY MG, 1967, NATURE, V216, P857, DOI 10.1038/216857a0; DERIAN CK, 1995, THROMB RES, V78, P505, DOI 10.1016/0049-3848(95)00084-5; GOODWIN CA, 1994, BIOCHEM BIOPH RES CO, V202, P321, DOI 10.1006/bbrc.1994.1930; Henriksen RA, 1997, ARTERIOSCL THROM VAS, V17, P3519, DOI 10.1161/01.ATV.17.12.3519; HUNG DT, 1992, J CLIN INVEST, V89, P1350, DOI 10.1172/JCI115721; Ishihara H, 1998, BLOOD, V91, P4152, DOI 10.1182/blood.V91.11.4152.411k22_4152_4157; Ishihara H, 1997, NATURE, V386, P502, DOI 10.1038/386502a0; ISHII K, 1993, J BIOL CHEM, V268, P9780; KETTNER C, 1979, THROMB RES, V14, P969, DOI 10.1016/0049-3848(79)90014-8; KRAMER RM, 1995, J BIOL CHEM, V270, P14816, DOI 10.1074/jbc.270.24.14816; LIU LW, 1991, J BIOL CHEM, V266, P16977; MATHEWS II, 1994, BIOCHEMISTRY-US, V33, P3266, DOI 10.1021/bi00177a018; Meiner VL, 1996, P NATL ACAD SCI USA, V93, P14041, DOI 10.1073/pnas.93.24.14041; MORTENSEN R, 1993, CURRENT PROTOCOLS MO; NOVAK EK, 1988, BRIT J HAEMATOL, V69, P371, DOI 10.1111/j.1365-2141.1988.tb02376.x; SCARBOROUGH RM, 1992, J BIOL CHEM, V267, P13146; SHUMAN MA, 1979, J CLIN INVEST, V63, P1211, DOI 10.1172/JCI109416; VASSALLO RR, 1992, J BIOL CHEM, V267, P6081; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; VU TKH, 1991, NATURE, V353, P674, DOI 10.1038/353674a0; WILLIAMS JA, 1988, P NATL ACAD SCI USA, V85, P4939, DOI 10.1073/pnas.85.13.4939; Xu WF, 1998, P NATL ACAD SCI USA, V95, P6642, DOI 10.1073/pnas.95.12.6642; ZHONG CZ, 1992, J BIOL CHEM, V267, P16975	28	817	847	2	50	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 13	1998	394	6694					690	694		10.1038/29325	http://dx.doi.org/10.1038/29325			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	110MD	9716134				2022-12-28	WOS:000075384200047
J	Burstein, GR; Gaydos, CA; Diener-West, M; Howell, MR; Zenilman, JM; Quinn, TC				Burstein, GR; Gaydos, CA; Diener-West, M; Howell, MR; Zenilman, JM; Quinn, TC			Incident Chlamydia trachomatis infections among inner-city adolescent females	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	Annual Meeting of the Society-for-Adolescent-Medicine	MAR 04-08, 1998	ATLANTA, GEORGIA	Soc Adolescent Med			TUBAL INFERTILITY; WOMEN; CLINICS; DISEASE; PREVALENCE; CERVICITIS; DIAGNOSIS; RISK; CARE	Context.-Adolescents are at highest risk for infection with Chlamydia trachomatis, an important preventable cause of pelvic inflammatory disease and subsequent tubal factor infertility in US women. Current guidelines for delivery of adolescent primary care services recommend yearly chlamydia screening for those adolescent females considered to be at risk. Objectives.-To describe the epidemiology of prevalent and incident chlamydia infection among adolescent females to assess the appropriate interval for chlamydia screening and to define risk factors that would identify adolescent females to target for screening. Design.-Prospective longitudinal study. Patients.-A consecutive sample of 3202 sexually active females 12 through 19 years old making 5360 patient visits over a 33-month period, January 1994 through September 1996. Setting.-Baltimore, Md, family planning, sexually transmitted disease, and school-based clinics. Intervention.-Testing for C trachomatis by polymerase chain reaction. Main Outcome Measures.-Prevalence and incidence of C trachomatis infections; predictors of positive test result for C trachomatis, Results.-Chlamydia infection was found in 771 first visits (24.1%) and 299 repeat visits (13.9%); 933 adolescent females (29.1%) had at least 1 positive test result. Females who were 14 years old had the highest age-specific chlamydia prevalence rate (63 [27.5%] of 229 cases; P=.01). The chlamydia incidence rate was 28.0 cases per 1000 person-months (95% confidence interval, 24.9-31.5 cases). The median time was 7.2 months to a first positive chlamydia test result and 6.3 months to a repeat positive test result among those with repeat visits. Independent predictors of chlamydia infection-reason for clinic visit, clinic type, prior sexually transmitted diseases, multiple or new partners, or inconsistent condom use-failed to identify a subset of adolescent females with the majority of infections. Conclusions.-A high prevalence and incidence of C trachomatis infection were found among adolescent females. We, therefore, recommend screening all sexually active adolescent females for chlamydia infection every 6 months, regardless of symptoms, prior infections, condom use, or multiple partner risks.	Johns Hopkins Univ, Div Infect Dis, Baltimore, MD 21205 USA	Johns Hopkins University	Burstein, GR (corresponding author), Johns Hopkins Univ, Div Infect Dis, 720 Rutland Ave,Room 1159, Baltimore, MD 21205 USA.	gburstei@welchlink.welch.jhu.edu	Quinn, Thomas/A-2494-2010; Gaydos, Charlotte A./E-9937-2010		NIAID NIH HHS [NIAID-P01-AI94016] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BEACK RK, 1992, COMPREHENSIVE ADOLES, P956; BLYTHE MJ, 1988, J PEDIATR-US, V112, P1000, DOI 10.1016/S0022-3476(88)80236-1; Borenstein PE, 1996, J ADOLESCENT HEALTH, V18, P203, DOI 10.1016/1054-139X(95)00013-I; BRUNHAM RC, 1985, J INFECT DIS, V152, P1275, DOI 10.1093/infdis/152.6.1275; *CDCP, 1997, MMWR-MORBID MORTAL W, V46, P819; *CDCP, 1993, MMWR-MORBID MORTAL W, V42, P6; Centers for Disease Control and Prevention Chlamydia trachomatis genital infections-United States, 1995, JAMA-J AM MED ASSOC, V277, P952; CHUTIVONGSE S, 1995, SEX TRANSM DIS, V22, P71; Cohen DA, 1998, PEDIATRICS, V101, part. no., DOI 10.1542/peds.101.1.e1; COURTNEY J, 1997, 12 M INT SOC SEX TRA; *DCDP, 1997, MMWR-MORBID MORTAL W, V46, P193; *DIV SEX TRANSM DI, 1997, SEX TRANSM DIS SURV; ELSTER AB, 1994, AMA GUIDELINES ADOLE; Eng TR, 1997, HIDDEN EPIDEMIC CONF, P28; FISHER M, 1987, J PEDIATR-US, V111, P617, DOI 10.1016/S0022-3476(87)80134-8; GANS GE, 1991, AMA PROFILES ADOLESC; Gaydos CA, 1998, J INFECT DIS, V177, P417, DOI 10.1086/514207; Genc M, 1996, ANN INTERN MED, V124, P1, DOI 10.7326/0003-4819-124-1_Part_1-199601010-00001; Gunn RA, 1997, SEX TRANSM DIS, V24, P90, DOI 10.1097/00007435-199702000-00006; HANDSFIELD HH, 1986, JAMA-J AM MED ASSOC, V255, P1730, DOI 10.1001/jama.255.13.1730; Hillis SD, 1998, SEX TRANSM DIS, V25, P5, DOI 10.1097/00007435-199801000-00002; HILLIS SD, 1994, AM J OBSTET GYNECOL, V170, P801, DOI 10.1016/S0002-9378(94)70286-1; Hook EW, 1997, J CLIN MICROBIOL, V35, P2133, DOI 10.1128/JCM.35.8.2133-2135.1997; HOOK EW, 1990, SEXUALLY TRANSMITTED, P149; Howell MR, 1998, SEX TRANSM DIS, V25, P108, DOI 10.1097/00007435-199802000-00008; Howell MR, 1998, ANN INTERN MED, V128, P277, DOI 10.7326/0003-4819-128-4-199802150-00005; Katz BP, 1996, SEX TRANSM DIS, V23, P226, DOI 10.1097/00007435-199605000-00011; KELVER ME, 1989, INT J FERTIL, V34, P42; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13; LIEU TA, 1993, AM J PUBLIC HEALTH, V83, P960, DOI 10.2105/AJPH.83.7.960; MAGDER LS, 1988, AM J EPIDEMIOL, V128, P298, DOI 10.1093/oxfordjournals.aje.a114970; MARLOTTE CK, 1990, AM J PUBLIC HEALTH, V80, P469; Marrazzo JM, 1997, ANN INTERN MED, V127, P796, DOI 10.7326/0003-4819-127-9-199711010-00004; Marrazzo JM, 1997, SEX TRANSM DIS, V24, P131, DOI 10.1097/00007435-199703000-00003; Mosure DJ, 1996, AM J EPIDEMIOL, V144, P997, DOI 10.1093/oxfordjournals.aje.a008870; Mosure DJ, 1997, J ADOLESCENT HEALTH, V20, P6, DOI 10.1016/S1054-139X(96)00157-7; Muller, 1990, SEXUALLY TRANSMITTED, P481; NATHANSON PG, 1997, 12 M INT SOC SEX TRA; NIENSTEIN LS, 1996, ADOLESCENT HLTH CARE, P46; Oh MK, 1996, J ADOLESCENT HEALTH, V18, P270, DOI 10.1016/1054-139X(95)00232-H; Oh MK, 1997, J ADOLESCENT HEALTH, V21, P80, DOI 10.1016/S1054-139X(96)00311-4; Orr DP, 1997, J ADOLESCENT HEALTH, V20, P3, DOI 10.1016/S1054-139X(96)00220-0; PAISARNTANTIWON.R, 1995, SEX TRANSM DIS, V23, P344; Quinn TC, 1996, J CLIN MICROBIOL, V34, P1401, DOI 10.1128/JCM.34.6.1401-1406.1996; RAPPO PD, 1995, PEDIATRICS, V96, P373; Schachter J, 1996, NEW ENGL J MED, V335, P1847, DOI 10.1056/NEJM199612123352417; Scholes D, 1996, NEW ENGL J MED, V334, P1362, DOI 10.1056/NEJM199605233342103; SELLORS JW, 1988, FERTIL STERIL, V49, P451; SELVIN S, 1991, MONOGRAPHS EPIDEMIOL, V17, P285; STERGACHIS A, 1993, AM J EPIDEMIOL, V138, P143, DOI 10.1093/oxfordjournals.aje.a116840; Thorpe EM, 1996, GENITOURIN MED, V72, P93; Thrall JS, 1998, J ADOLESCENT HEALTH, V22, P184, DOI 10.1016/S1054-139X(97)00205-X; US Preventive Services Task Force, 1996, GUID CLIN PREV SERV, P18; WESTROM L, 1990, SEXUALLY TRANSMITTED, P593; WINTER L, 1990, SEX TRANSM DIS, V17, P30, DOI 10.1097/00007435-199017010-00007; ZENILMAN JM, 1995, SEX TRANSM DIS, V22, P15, DOI 10.1097/00007435-199501000-00003	56	185	193	1	9	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 12	1998	280	6					521	526		10.1001/jama.280.6.521	http://dx.doi.org/10.1001/jama.280.6.521			6	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	108AY	9707141	Bronze			2022-12-28	WOS:000075244900027
J	Kjos, SL; Peters, RK; Xiang, A; Thomas, D; Schaefer, U; Buchanan, TA				Kjos, SL; Peters, RK; Xiang, A; Thomas, D; Schaefer, U; Buchanan, TA			Contraception and the risk of type 2 diabetes mellitus in Latina women with prior gestational diabetes mellitus	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INSULIN-RESISTANCE; GLUCOSE-TOLERANCE; CARBOHYDRATE-METABOLISM; ORAL-CONTRACEPTIVES; LIPID-METABOLISM; SERUM PROLACTIN; LACTATION; SECRETION; DYSFUNCTION; ESTRADIOL	Context.-Effective contraception is essential in women with prior gestational diabetes mellitus (GDM) but should not increase their already substantial risk of developing type 2 diabetes. Objective.-To determine whether exposure to low-dose oral contraceptives increases the risk of developing type 2 diabetes mellitus in women with recent GDM. Design.-Retrospective cohort study of 904 Latinas with GDM who gave birth between January 1987 and March 1994, in whom postpartum diabetes was excluded at 4 to 16 weeks post partum. Interventions.-At their initial postpartum visit, 443 women selected a nonhormonal form of contraception, 383 received a low-dose, estrogen-progestin combination oral contraceptive (OC), and 78 breast-feeding women received the progestin-only OC. When breast-feeding ended, patients initially taking progestin-only OCs were switched to combination OCs, Patients were followed up periodically with oral glucose tolerance tests for up to 7 1/2 years. Main Outcome Measures.-Person time was used to compute unadjusted average annual incidence rates of developing diabetes mellitus, as defined by the National Diabetes Data Group Criteria. Survival analysis was used to compute the unadjusted cumulative incidence rates and adjusted relative risks of diabetes mellitus. Results.-The unadjusted average annual incidence rates of type 2 diabetes mellitus were 8.7%, 10.4%, and 26.5%, respectively, for patients using nonhormonal forms of contraception, combination OCs, and progestin-only OCs. Cumulative incidence rates were virtually identical for patients with uninterrupted use of combination OCs and nonhormonal forms of contraception, but patients using progestin-only OCs developed diabetes mellitus more rapidly during the first 2 years of use. After adjustment for potential confounding factors, the use of progestin-only OCs almost tripled the risk of type 2 diabetes mellitus compared with equivalent use of low-dose combination OCs (adjusted relative risk, 2.87; 95% confidence interval, 1.57-5.27). The magnitude of this risk increased with duration of uninterrupted use. Conclusion.-Progestin-only OCs were associated with an increased risk of diabetes in breast-feeding Latinas with recent GDM and probably should be prescribed with caution, if at all, in these women. Long-term use of low-dose combination OCs did not increase the risk of type 2 diabetes compared with use of nonhormonal contraception. Thus, combination OCs do not appear to increase the risk of diabetes in non-breast-feeding women with recent GDM.	Univ So Calif, Sch Med, Dept Obstet & Gynecol, Los Angeles, CA 90033 USA; Univ So Calif, Sch Med, Dept Prevent Med, Los Angeles, CA 90033 USA; Univ So Calif, Sch Med, Dept Med, Los Angeles, CA 90033 USA	University of Southern California; University of Southern California; University of Southern California	Kjos, SL (corresponding author), Univ So Calif, Los Angeles Cty Med Ctr, Womens Hosp, 1240 N Mission Rd,Room L1017, Los Angeles, CA 90033 USA.	skjos@hsc.usc.edu			NIDDK NIH HHS [R01-DK-46374] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046374] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BATTIN DA, 1985, OBSTET GYNECOL, V65, P785; COX DR, 1972, J R STAT SOC B, V34, P187; DEFRONZO RA, 1988, DIABETES, V37, P667, DOI 10.2337/diab.37.6.667; DELVOYE P, 1978, AM J OBSTET GYNECOL, V130, P635, DOI 10.1016/0002-9378(78)90319-8; EIZIRIK DL, 1992, J CLIN INVEST, V90, P1263, DOI 10.1172/JCI115989; GODSLAND IF, 1990, NEW ENGL J MED, V323, P1375, DOI 10.1056/NEJM199011153232003; HAFFNER SM, 1995, DIABETES, V44, P1386, DOI 10.2337/diabetes.44.12.1386; HOUSSAY BA, 1954, ACTA ENDOCRINOL-COP, V17, P146; HOWIE PW, 1982, CLIN ENDOCRINOL, V17, P323, DOI 10.1111/j.1365-2265.1982.tb01597.x; KALKHOFF RK, 1982, AM J OBSTET GYNECOL, V142, P735; KJOS SL, 1990, AM J OBSTET GYNECOL, V163, P1822, DOI 10.1016/0002-9378(90)90757-X; KJOS SL, 1993, OBSTET GYNECOL, V82, P451; KJOS SL, 1995, DIABETES, V44, P586, DOI 10.2337/diabetes.44.5.586; KUNG AWC, 1987, CONTRACEPTION, V35, P257, DOI 10.1016/0010-7824(87)90027-8; LEAHY JL, 1992, DIABETES CARE, V15, P442, DOI 10.2337/diacare.15.3.442; LILLIOJA S, 1993, NEW ENGL J MED, V329, P1988, DOI 10.1056/NEJM199312303292703; LUYCKX AS, 1986, FERTIL STERIL, V45, P635; MARTIN BC, 1992, LANCET, V340, P925, DOI 10.1016/0140-6736(92)92814-V; METZGER BE, 1993, DIABETES CARE, V16, P1598, DOI 10.2337/diacare.16.12.1598; MOLSTEDPEDERSEN L, 1991, DIABETES, V40, P147, DOI 10.2337/diab.40.2.S147; *NAT DIAB DAT GROU, 1979, DIABETES, V29, P1039; PERLMAN JA, 1985, J CHRON DIS, V38, P857, DOI 10.1016/0021-9681(85)90110-9; Peters RK, 1996, LANCET, V347, P227, DOI 10.1016/S0140-6736(96)90405-5; Pettitt DJ, 1996, DIABETOLOGIA, V39, P1334, DOI 10.1007/s001250050579; RADBERG T, 1982, GYNECOL OBSTET INVES, V13, P17, DOI 10.1159/000299480; RIMM EB, 1992, DIABETOLOGIA, V35, P967, DOI 10.1007/BF00401427; RYAN EA, 1988, J CLIN ENDOCR METAB, V67, P341, DOI 10.1210/jcem-67-2-341; Schaefer UM, 1997, AM J OBSTET GYNECOL, V177, P1165, DOI 10.1016/S0002-9378(97)70035-8; SKOUBY SO, 1982, OBSTET GYNECOL, V59, P325; SKOUBY SO, 1985, AM J OBSTET GYNECOL, V153, P495, DOI 10.1016/0002-9378(85)90460-0; SKOUBY SO, 1987, J CLIN ENDOCR METAB, V64, P519, DOI 10.1210/jcem-64-3-519; SPELLACY WN, 1981, J REPROD MED, V26, P295; SPELLACY WN, 1971, AM J OBSTET GYNECOL, V114, P388; SPELLACY WN, 1981, J REPROD MED, V24, P415; TOWNER D, 1995, DIABETES CARE, V18, P1446, DOI 10.2337/diacare.18.11.1446; VANDERVANGE N, 1987, AM J OBSTET GYNECOL, V156, P918, DOI 10.1016/0002-9378(87)90355-3; VERMEULEN A, 1982, CONTRACEPTION, V26, P505, DOI 10.1016/0010-7824(82)90149-4; Wilcox JG, 1997, FERTIL STERIL, V67, P57, DOI 10.1016/S0015-0282(97)81856-0	38	107	114	0	6	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 12	1998	280	6					533	538		10.1001/jama.280.6.533	http://dx.doi.org/10.1001/jama.280.6.533			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	108AY	9707143	Bronze			2022-12-28	WOS:000075244900029
J	Mofenson, LM				Mofenson, LM			Perinatal transmission of HIV in women receiving zidovudine - Abstract and commentary	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							HUMAN-IMMUNODEFICIENCY-VIRUS; REDUCTION; INFANT; TYPE-1		NICHHD, Pediat Adolescent & Maternal AIDS Branch, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Mofenson, LM (corresponding author), NICHHD, Pediat Adolescent & Maternal AIDS Branch, Bethesda, MD 20892 USA.	LM65D@nih.gov	Mofenson, Lynne/P-9631-2019	Mofenson, Lynne/0000-0002-2818-9808				[Anonymous], 1998, MMWR Recomm Rep, V47, P1; CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801; Cooper ER, 1996, J INFECT DIS, V174, P1207, DOI 10.1093/infdis/174.6.1207; Kind C, 1998, AIDS, V12, P205, DOI 10.1097/00002030-199802000-00011; Landesman SH, 1996, NEW ENGL J MED, V334, P1617, DOI 10.1056/NEJM199606203342501; Mayaux MJ, 1997, J PEDIATR-US, V131, P857, DOI 10.1016/S0022-3476(97)70033-7; MOFENSON LM, 1995, PEDIATR INFECT DIS J, V14, P169, DOI 10.1097/00006454-199503000-00001; SEMPRINI AE, 1995, AIDS, V9, P913, DOI 10.1097/00002030-199508000-00013; Simonds RJ, 1998, AIDS, V12, P301, DOI 10.1097/00002030-199803000-00008; Sperling RS, 1996, NEW ENGL J MED, V335, P1621, DOI 10.1056/NEJM199611283352201	10	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 12	1998	280	6					569	570		10.1001/jama.280.6.569	http://dx.doi.org/10.1001/jama.280.6.569			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	108AY	9707153				2022-12-28	WOS:000075244900039
J	van Walraven, C; Naylor, CD				van Walraven, C; Naylor, CD			Do we know what inappropriate laboratory utilization is? - A systematic review of laboratory clinical audits	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							CEREBROSPINAL-FLUID; STOOL CULTURES; HOSPITALIZED-PATIENTS; EDUCATIONAL FEEDBACK; THEOPHYLLINE ASSAYS; PRACTICE GUIDELINES; REJECTION CRITERIA; DIAGNOSTIC-TESTS; RISK PREFERENCE; HOUSE STAFF	Objective.-Laboratory utilization has steadily increased, and some studies suggest inappropriate utilization. Therefore, we wished to assess studies that measure inappropriate laboratory use in light of methodological criteria. Design.-Systematic review of published studies. Data Sources.-MEDLINE, HEALTHSTAR, and EMBASE databases were searched from 1966 to September 1997 using a broad and inclusive strategy with no language restriction. In addition, the references of all retrieved studies and 3 textbooks on diagnostic testing were hand-searched. Study Selection.-All studies that provided and applied criteria for inappropriate laboratory use. Data Extraction.-Studies were categorized based on whether the criteria were implicit (objective criteria for inappropriate utilization not provided or very broad) or explicit. Guidelines for evaluation were applied to each study by a single reviewer. Data Synthesis.-Forty-four eligible studies were identified. Eleven studies used implicit criteria for inappropriate laboratory utilization and contained small numbers of patients or physicians. Most did not adequately assess the reliability of the implicit criteria. Thirty-three studies used explicit criteria based on the appropriateness of test choice, frequency, and timing, as well as the probability of a positive result. There were large variations in the estimates of inappropriate laboratory use (4.5%-95%). Evidence supporting the explicit criteria was frequently weak by the standards suggested for therapeutic maneuvers, but was nonetheless compelling based on principles of physiology, pharmacology, and probability. Conclusions.-Many studies identify inappropriate laboratory use based on implicit or explicit criteria that do not meet methodological standards suggested for audits of therapeutic maneuvers. Researchers should develop alternative evidentiary standards for measuring inappropriateness of laboratory test use.	Univ Toronto, Toronto, ON, Canada	University of Toronto	van Walraven, C (corresponding author), Sunnybrook Hlth Sci Ctr, Inst Clin Evaluat Sci, G Wing,2075 Bayview Ave, N York, ON M4N 3M5, Canada.							ALBRIGHT RE, 1991, AM J CLIN PATHOL, V95, P397, DOI 10.1093/ajcp/95.3.397; ALTSHULER CH, 1994, CLIN CHEM, V40, P1616; ASNIS DS, 1993, J CLIN MICROBIOL, V31, P1675, DOI 10.1128/JCM.31.6.1675-.1993; AXTADAM P, 1993, MED CARE, V31, P784, DOI 10.1097/00005650-199309000-00003; BAIGELMAN W, 1985, INTENS CARE MED, V11, P304, DOI 10.1007/BF00273541; BARBUT F, 1995, EUR J CLIN MICROBIOL, V14, P346, DOI 10.1007/BF02116530; BAREFORD D, 1990, BRIT MED J, V301, P1305, DOI 10.1136/bmj.301.6764.1305; BARTH JH, 1993, CLIN ENDOCRINOL, V39, P97, DOI 10.1111/j.1365-2265.1993.tb01757.x; BARTLETT RC, 1994, CLIN MICROBIOL REV, V7, P55, DOI 10.1128/CMR.7.1.55-88.1994; BECK JR, 1993, ARCH PATHOL LAB MED, V117, P33; BLOOMGARDEN Z, 1980, AM J PUBLIC HEALTH, V70, P525, DOI 10.2105/AJPH.70.5.525; BOLD AM, 1965, BRIT MED J, V2, P1051, DOI 10.1136/bmj.2.5469.1051; BOONFALLEUR L, 1995, INT J BIOMED COMPUT, V40, P17, DOI 10.1016/0020-7101(95)01118-X; BOWMAN RA, 1992, J CLIN PATHOL, V45, P838, DOI 10.1136/jcp.45.9.838; BRADY MT, 1989, AM J INFECT CONTROL, V17, P77, DOI 10.1016/0196-6553(89)90021-7; Branger PJ, 1995, NETH J MED, V47, P208, DOI 10.1016/0300-2977(95)00100-8; Brook R H, 1986, Int J Technol Assess Health Care, V2, P53; BugterMaessen AMA, 1996, FAM PRACT, V13, P254, DOI 10.1093/fampra/13.3.254; BUSH TM, 1993, ARCH INTERN MED, V153, P2363, DOI 10.1001/archinte.153.20.2363; BUSSEY HI, 1983, THER DRUG MONIT, V5, P245, DOI 10.1097/00007691-198309000-00002; CALDWELL G, 1985, LANCET, V1, P1117; Chitkara YK, 1996, ARCH INTERN MED, V156, P1445, DOI 10.1001/archinte.156.13.1445; CHURCH DL, 1995, AM J CLIN PATHOL, V103, P149; CLAGUE HW, 1983, THER DRUG MONIT, V5, P249, DOI 10.1097/00007691-198309000-00003; CLOUGH JD, 1989, CLEV CLIN J MED, V56, P245, DOI 10.3949/ccjm.56.3.245; CROWSON TW, 1984, JAMA-J AM MED ASSOC, V251, P70; DANIELS M, 1977, MED CARE, V15, P482, DOI 10.1097/00005650-197706000-00004; DANS PE, 1986, ANN INTERN MED, V104, P86, DOI 10.7326/0003-4819-104-1-86; Danzon P M, 1984, Health Care Financ Rev, V5, P23; Dickinson J C, 1987, Fam Pract Res J, V7, P12; DIXON RH, 1974, ARCH INTERN MED, V134, P1064, DOI 10.1001/archinte.134.6.1064; DOLAN JG, 1986, MED DECIS MAKING, V6, P216, DOI 10.1177/0272989X8600600406; DURANDZALESKI I, 1993, LANCET, V342, P150, DOI 10.1016/0140-6736(93)91349-Q; DURANDZALESKI I, 1997, ANN M INT SOC TECHN, V9, P181; Earle C, 1996, POSTGRAD MED J, V72, P77, DOI 10.1136/pgmj.72.844.77; EISENBERG JM, 1977, MED CARE, V15, P915, DOI 10.1097/00005650-197711000-00005; EPSTEIN AM, 1986, AM J MED, V80, P865, DOI 10.1016/0002-9343(86)90630-3; ERBAN SB, 1989, JAMA-J AM MED ASSOC, V262, P2428, DOI 10.1001/jama.262.17.2428; FAN K, 1993, J CLIN MICROBIOL, V31, P2233, DOI 10.1128/JCM.31.8.2233-2235.1993; FINEBERG HV, 1982, ANNU REV PUBL HEALTH, V3, P225, DOI 10.1146/annurev.pu.03.050182.001301; FINN AF, 1988, JAMA-J AM MED ASSOC, V259, P2549, DOI 10.1001/jama.259.17.2549; FLYNN TW, 1978, AM J HOSP PHARM, V35, P806, DOI 10.1093/ajhp/35.7.806; FOWKES FGR, 1985, BRIT MED J, V290, P488, DOI 10.1136/bmj.290.6467.488; GAMA R, 1992, ANN CLIN BIOCHEM, V29, P224, DOI 10.1177/000456329202900220; GIBB I, 1986, BRIT MED J, V293, P678, DOI 10.1136/bmj.293.6548.678; GOLDBERG GA, 1974, ANN INTERN MED, V81, P857, DOI 10.7326/0003-4819-81-6-857; GORTMAKER SL, 1988, MED CARE, V26, P631, DOI 10.1097/00005650-198806000-00011; GOTZ VP, 1982, DRUG INTEL CLIN PHAR, V16, P872, DOI 10.1177/106002808201601112; GREENLAW CW, 1979, AM J HOSP PHARM, V36, P1080, DOI 10.1093/ajhp/36.8.1080; GREENLAW CW, 1980, AM J HOSP PHARM, V37, P1466, DOI 10.1093/ajhp/37.11.1466a; Griffith CH, 1997, CRIT CARE MED, V25, P704, DOI 10.1097/00003246-199704000-00024; GRIVELL AR, 1982, MED J AUSTRALIA, V2, P326, DOI 10.5694/j.1326-5377.1982.tb132452.x; GROSS PA, 1988, AM J INFECT CONTROL, V16, P114, DOI 10.1016/0196-6553(88)90048-X; GUERNSEY BG, 1984, DRUG INTEL CLIN PHAR, V18, P906, DOI 10.1177/106002808401801113; Hartley R M, 1987, Am J Med, V82, P513, DOI 10.1016/0002-9343(87)90452-9; HAYWARD RA, 1987, LANCET, V1, P1; HYAMS KC, 1987, ARCH INTERN MED, V147, P48, DOI 10.1001/archinte.147.1.48; IBRAHIM H, 1991, Henry Ford Hospital Medical Journal, V39, P30; IVES TJ, 1984, J FAM PRACTICE, V19, P507; Jackson LM, 1996, IRISH J MED SCI, V165, P93, DOI 10.1007/BF02943791; JOHN R, 1988, CLIN CHEM, V34, P1110; JOLY JG, 1981, UNION MED CAN, V110, P989; KRAVITZ RL, 1995, JAMA-J AM MED ASSOC, V274, P632, DOI 10.1001/jama.274.8.632; KROENKE K, 1987, MED CARE, V25, P928, DOI 10.1097/00005650-198710000-00002; LEESE B, 1991, IS THERE TOO MUCH LA, P79; LEPAGE R, 1984, UNION MED CAN, V113, P526; LEVIN B, 1981, AM J HOSP PHARM, V38, P845, DOI 10.1093/ajhp/38.6.845; LEVINE M, 1988, THER DRUG MONIT, V10, P50, DOI 10.1097/00007691-198801000-00009; Lewis S, 1997, INT J TECHNOL ASSESS, V13, P501, DOI 10.1017/S0266462300009971; LEY C, 1994, JAMA-J AM MED ASSOC, V271, P460, DOI 10.1001/jama.271.6.460; LIPTZIN BA, 1972, SURGERY, V71, P247; LYON AW, 1995, AM J CLIN PATHOL, V103, P718; MARTIN TG, 1982, ANN EMERG MED, V11, P70, DOI 10.1016/S0196-0644(82)80299-0; MCCONNELL TS, 1982, HUM PATHOL, V13, P399, DOI 10.1016/S0046-8177(82)80229-3; MCGILLIVRAY DL, 1993, AM J DIS CHILD, V147, P870, DOI 10.1001/archpedi.1993.02160320072022; MCLEISH WA, 1985, CAN MED ASSOC J, V132, P616; MENON D, 1992, INFLUENCE ED INTERVE; MOLONEY TW, 1979, NEW ENGL J MED, V301, P1413, DOI 10.1056/NEJM197912273012603; MORRIS AJ, 1992, J CLIN MICROBIOL, V30, P3213, DOI 10.1128/JCM.30.12.3213-3216.1992; MOZES B, 1989, ARCH INTERN MED, V149, P1836, DOI 10.1001/archinte.149.8.1836; MURRAY PR, 1975, MAYO CLIN PROC, V50, P339; MYERS LP, 1985, WESTERN J MED, V143, P397; Naylor CD, 1996, JAMA-J AM MED ASSOC, V275, P1435, DOI 10.1001/jama.275.18.1435; Nightingale P G, 1994, Qual Health Care, V3, P23, DOI 10.1136/qshc.3.1.23; NIGHTINGALE SD, 1988, CHEST, V93, P684, DOI 10.1378/chest.93.4.684; NIGHTINGALE SD, 1988, MED CARE, V26, P84, DOI 10.1097/00005650-198801000-00009; OHKUBO A, 1995, JPN J CLIN PATHOL, V43, P647; *ONT MIN HLTH, 1994, LAB SERV REV REP MIN; *ONT MIN HLTH, 1995, SAL FEAT LAB IND ONT; Panzer RI, 1991, DIAGNOSTIC STRATEGIE; PEARCE GA, 1990, THER DRUG MONIT, V12, P250, DOI 10.1097/00007691-199005000-00007; PENGLIS S, 1984, Australian Journal of Hospital Pharmacy, V14, P138; PERKINS MD, 1995, J CLIN MICROBIOL, V33, P1486, DOI 10.1128/JCM.33.6.1486-1491.1995; Perraro F, 1992, Qual Assur Health Care, V4, P77; PITTERLE ME, 1985, AM J HOSP PHARM, V42, P1547, DOI 10.1093/ajhp/42.7.1547; RAFEH N, 1995, INT J QUAL HEALTH C, V7, P25, DOI 10.1093/intqhc/7.1.25; Rang M, 1972, Can Med Assoc J, V106, P122; REID MC, 1995, JAMA-J AM MED ASSOC, V274, P645, DOI 10.1001/jama.274.8.645; RHYNE RL, 1979, J FAM PRACTICE, V8, P1003; ROBERTS DE, 1993, CRIT CARE MED, V21, P1452, DOI 10.1097/00003246-199310000-00011; RODEWALD LE, 1991, J PEDIATR-US, V119, P363, DOI 10.1016/S0022-3476(05)82046-3; RUNGKANCHANASET.S, 1993, J MED ASS THAI S2, V76, P194; SACKETT DL, 1991, CLIN EPIDEMIOLOGY BA, P153; SANDLER G, 1984, BRIT MED J, V289, P973, DOI 10.1136/bmj.289.6450.973; SARGENTI C, 1985, DRUG INTEL CLIN PHAR, V19, P380, DOI 10.1177/106002808501900512; SAXENA S, 1993, ARCH PATHOL LAB MED, V117, P180; SCHECTMAN JM, 1991, ARCH INTERN MED, V151, P2163, DOI 10.1001/archinte.151.11.2163; SCHIFMAN RB, 1991, QUAL ASSUR UTILIZATI, V6, P182; SCHOENENBERGER RA, 1995, JAMA-J AM MED ASSOC, V274, P1622, DOI 10.1001/jama.274.20.1622; SEAH C S, 1983, SMJ Singapore Medical Journal, V24, P243; SHOWSTCK JA, 1982, NEW ENGL J MED, V211, P1336; SIEGEL DL, 1990, JAMA-J AM MED ASSOC, V263, P979, DOI 10.1001/jama.263.7.979; SLAUGHTER RL, 1978, AM J HOSP PHARM, V35, P1376, DOI 10.1093/ajhp/35.11.1376; Sox HC, 1987, COMMON DIAGNOSTIC TE; SPEICHER CE, 1993, RIGHT TEST PHYSICIAN; STIELL I, 1995, BRIT MED J, V311, P594, DOI 10.1136/bmj.311.7005.594; STUDNICKI J, 1993, ARCH PATHOL LAB MED, V117, P35; Thamer M, 1997, INT J TECHNOL ASSESS, V13, P526, DOI 10.1017/S026646230001000X; TIERNEY WM, 1987, ANN INTERN MED, V107, P569, DOI 10.7326/0003-4819-107-4-569; TIERNEY WM, 1988, JAMA-J AM MED ASSOC, V259, P1194, DOI 10.1001/jama.259.8.1194; TIERNEY WM, 1990, NEW ENGL J MED, V322, P1499, DOI 10.1056/NEJM199005243222105; TIERNEY WM, 1993, JAMA-J AM MED ASSOC, V269, P379, DOI 10.1001/jama.269.3.379; TURNBULL TL, 1990, ANN EMERG MED, V19, P373, DOI 10.1016/S0196-0644(05)82337-6; Valenstein P, 1996, ARCH PATHOL LAB MED, V120, P206; VALENSTEIN P, 1988, ARCH PATHOL LAB MED, V112, P238; VALENSTEIN PN, 1984, AM J CLIN PATHOL, V82, P444, DOI 10.1093/ajcp/82.4.444; VLASSES PH, 1982, HOSP PHARM, V17, P371; WACHTEL TJ, 1990, J GEN INTERN MED, V5, P335, DOI 10.1007/BF02600402; WELLS PS, 1995, LANCET, V345, P1326, DOI 10.1016/S0140-6736(95)92535-X; WENZ B, 1986, AM J CLIN PATHOL, V86, P298, DOI 10.1093/ajcp/86.3.298; WENZ B, 1989, AM J CLIN PATHOL, V92, P78, DOI 10.1093/ajcp/92.1.78; Williams S V, 1982, Inquiry, V19, P363; WING DS, 1989, THER DRUG MONIT, V11, P32, DOI 10.1097/00007691-198901000-00007; Wu A H, 1997, Conn Med, V61, P15; YOUNG DW, 1980, BRIT MED J, V281, P1610, DOI 10.1136/bmj.281.6255.1610	135	256	257	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 12	1998	280	6					550	558		10.1001/jama.280.6.550	http://dx.doi.org/10.1001/jama.280.6.550			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	108AY	9707147				2022-12-28	WOS:000075244900033
J	Logan, M; Pagan-Westphal, SM; Smith, DM; Paganessi, L; Tabin, CJ				Logan, M; Pagan-Westphal, SM; Smith, DM; Paganessi, L; Tabin, CJ			The transcription factor Pitx2 mediates situs-specific morphogenesis in response to left-right asymmetric signals	CELL			English	Article							SONIC HEDGEHOG; NODAL EXPRESSION; GENE	The mechanism by which asymmetric signals induce left-right-specific morphogenesis has been elusive. Pitx2 encodes a transcription factor expressed throughout the left lateral plate mesoderm and subsequently on the left side of asymmetric organs such as the heart and gut during organogenesis in the chick embryo. Pitx2 is induced by the asymmetric signals encoded by Nodal and Sonic hedgehog, and its expression is blocked by prior treatment with an antibody against Sonic hedgehog. Misexpression of Pitx2 on the right side of the embryo is sufficient to produce reversed heart looping and heart isomerisms, reversed body rotation, and reversed gut situs.	Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Tabin, CJ (corresponding author), Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA.							Ang SL, 1996, DEVELOPMENT, V122, P243; Apelqvist A, 1997, CURR BIOL, V7, P801, DOI 10.1016/S0960-9822(06)00340-X; Bao ZZ, 1997, J NEUROSCI, V17, P1425; Chiang C, 1996, NATURE, V383, P407, DOI 10.1038/383407a0; Collignon J, 1996, NATURE, V381, P155, DOI 10.1038/381155a0; Ericson J, 1996, CELL, V87, P661, DOI 10.1016/S0092-8674(00)81386-0; FURUKAWA T, 1997, CELL, V91, P1; Gage PJ, 1997, HUM MOL GENET, V6, P457, DOI 10.1093/hmg/6.3.457; GOULDING MD, 1991, EMBO J, V10, P1135, DOI 10.1002/j.1460-2075.1991.tb08054.x; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; Heymer J, 1997, MECH DEVELOP, V66, P5, DOI 10.1016/S0925-4773(97)00084-1; Hyatt BA, 1998, CELL, V93, P37, DOI 10.1016/S0092-8674(00)81144-7; Isaac A, 1997, SCIENCE, V275, P1301, DOI 10.1126/science.275.5304.1301; ISHIZUYAOKA A, 1983, ROUX ARCH DEV BIOL, V192, P171, DOI 10.1007/BF00848687; King T, 1997, CURR BIOL, V7, pR212, DOI 10.1016/S0960-9822(06)00103-5; Kitamura K, 1997, MECH DEVELOP, V67, P83, DOI 10.1016/S0925-4773(97)00110-X; Lamonerie T, 1996, GENE DEV, V10, P1284, DOI 10.1101/gad.10.10.1284; Laufer E, 1997, NATURE, V386, P366, DOI 10.1038/386366a0; Levin M, 1997, DEV BIOL, V189, P57, DOI 10.1006/dbio.1997.8662; LEVIN M, 1995, CELL, V82, P803, DOI 10.1016/0092-8674(95)90477-8; LOGAN M, 1998, IN PRESS DEVELOPMENT; Lohr JL, 1997, DEVELOPMENT, V124, P1465; Lowe LA, 1996, NATURE, V381, P158, DOI 10.1038/381158a0; MATSUO I, 1995, GENE DEV, V9, P2646, DOI 10.1101/gad.9.21.2646; Meno C, 1997, GENES CELLS, V2, P513, DOI 10.1046/j.1365-2443.1997.1400338.x; Meno C, 1996, NATURE, V381, P151, DOI 10.1038/381151a0; Morgan BA, 1996, METHOD CELL BIOL, V51, P185, DOI 10.1016/S0091-679X(08)60629-9; Mucchielli ML, 1997, DEV BIOL, V189, P275, DOI 10.1006/dbio.1997.8672; Nascone N, 1997, DEV BIOL, V189, P68, DOI 10.1006/dbio.1997.8635; Oh SP, 1997, GENE DEV, V11, P1812, DOI 10.1101/gad.11.14.1812; Ory DS, 1996, P NATL ACAD SCI USA, V93, P11400, DOI 10.1073/pnas.93.21.11400; Pagan-Westphal SM, 1998, CELL, V93, P25, DOI 10.1016/S0092-8674(00)81143-5; ROBERTS DJ, 1995, DEVELOPMENT, V121, P3163; RYAN AK, 1998, IN PRESS NATURE; Sampath K, 1997, DEVELOPMENT, V124, P3293; Semina EV, 1996, NAT GENET, V14, P392, DOI 10.1038/ng1296-392; St Amand TR, 1998, BIOCHEM BIOPH RES CO, V247, P100; Szeto DP, 1996, P NATL ACAD SCI USA, V93, P7706, DOI 10.1073/pnas.93.15.7706	38	369	377	0	11	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 7	1998	94	3					307	317		10.1016/S0092-8674(00)81474-9	http://dx.doi.org/10.1016/S0092-8674(00)81474-9			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	109EN	9708733	Bronze			2022-12-28	WOS:000075308400007
J	Piedra, ME; Icardo, JM; Albajar, M; Rodriguez-Rey, JC; Ros, MA				Piedra, ME; Icardo, JM; Albajar, M; Rodriguez-Rey, JC; Ros, MA			Pitx2 participates in the late phase of the pathway controlling left-right asymmetry	CELL			English	Article							SITUS-INVERSUS; EXPRESSION; MICE; GENE	Pitx2, a member of the bicoid-related family of homeobox-containing genes, is asymmetrically expressed in the left lateral plate mesoderm and derived tissues during chick and mouse development. Modifications of Pitx2 pattern of expression in the iv mouse mutation correlate with the situs alterations characteristic of the mutation. Misexpression experiments demonstrate that Shh and nodal positively regulate Pitx2 expression. Our results are compatible with a Pitx2 function in the late phase of the gene cascade controlling laterality.	Univ Cantabria, Fac Med, Dept Anat & Biol Celular, Santander 39011, Spain; Univ Cantabria, Fac Med, Hosp Univ Marques de Valdecilla, Santander 39011, Spain; Univ Cantabria, Fac Med, Dept Biol Mol, Santander 39011, Spain	Universidad de Cantabria; Hospital Universitario Marques de Valdecilla (HUMV); Universidad de Cantabria; Universidad de Cantabria	Ros, MA (corresponding author), Univ Cantabria, Fac Med, Dept Anat & Biol Celular, Santander 39011, Spain.		Ros, Maria A./K-8160-2014; Icardo, Jose Manuel/ABH-5431-2020	Ros, Maria A./0000-0002-1224-7671; Icardo, Jose Manuel/0000-0001-9543-2444; Rodriguez-Rey, Jose/0000-0002-8369-3118				BROWN NA, 1990, DEVELOPMENT, V109, P1; COLLIGNON J, 1996, NATURE, V381, P1919; Gage PJ, 1997, HUM MOL GENET, V6, P457, DOI 10.1093/hmg/6.3.457; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; Heymer J, 1997, MECH DEVELOP, V66, P5, DOI 10.1016/S0925-4773(97)00084-1; Hummel K. P., 1959, Journal of Heredity, V50, P9; Hyatt BA, 1998, CELL, V93, P37, DOI 10.1016/S0092-8674(00)81144-7; ICARDO JM, 1991, CIRCULATION, V84, P2547, DOI 10.1161/01.CIR.84.6.2547; Isaac A, 1997, SCIENCE, V275, P1301, DOI 10.1126/science.275.5304.1301; King T, 1997, CURR BIOL, V7, pR212, DOI 10.1016/S0960-9822(06)00103-5; Kitamura K, 1997, MECH DEVELOP, V67, P83, DOI 10.1016/S0925-4773(97)00110-X; LAYTON WM, 1993, TERATOLOGY, V47, P595, DOI 10.1002/tera.1420470611; Levin M, 1997, BIOESSAYS, V19, P287, DOI 10.1002/bies.950190406; Levin M, 1997, DEV BIOL, V189, P57, DOI 10.1006/dbio.1997.8662; LEVIN M, 1995, CELL, V82, P803, DOI 10.1016/0092-8674(95)90477-8; Lohr JL, 1997, DEVELOPMENT, V124, P1465; Lowe LA, 1996, NATURE, V381, P158, DOI 10.1038/381158a0; Meno C, 1997, GENES CELLS, V2, P513, DOI 10.1046/j.1365-2443.1997.1400338.x; Meno C, 1996, NATURE, V381, P151, DOI 10.1038/381151a0; Mucchielli ML, 1996, MOL CELL NEUROSCI, V8, P258, DOI 10.1006/mcne.1996.0062; Mucchielli ML, 1997, DEV BIOL, V189, P275, DOI 10.1006/dbio.1997.8672; NEW DAT, 1955, J EMBRYOL EXP MORPH, V3, P326; NIETO MA, 1994, SCIENCE, V264, P835, DOI 10.1126/science.7513443; NIETO MA, 1996, METHOD CELL BIOL, V51, P220; Pagan-Westphal SM, 1998, CELL, V93, P25, DOI 10.1016/S0092-8674(00)81143-5; Sampath K, 1997, DEVELOPMENT, V124, P3293; Semina EV, 1996, NAT GENET, V14, P392, DOI 10.1038/ng1296-392; Supp DM, 1997, NATURE, V389, P963, DOI 10.1038/40140; Varlet I, 1997, CURR OPIN GENET DEV, V7, P519, DOI 10.1016/S0959-437X(97)80080-9; YOST HJ, 1995, CELL, V82, P689, DOI 10.1016/0092-8674(95)90464-6; YUAN SP, 1995, DEV GENET, V17, P38, DOI 10.1002/dvg.1020170106	31	271	275	0	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	AUG 7	1998	94	3					319	324		10.1016/S0092-8674(00)81475-0	http://dx.doi.org/10.1016/S0092-8674(00)81475-0			6	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	109EN	9708734	Bronze			2022-12-28	WOS:000075308400008
J	Leaning, J				Leaning, J			Jonathan Mann - Obituary	BRITISH MEDICAL JOURNAL			English	Biographical-Item																			0	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	SEP 12	1998	317	7160					754	755		10.1136/bmj.317.7160.754	http://dx.doi.org/10.1136/bmj.317.7160.754			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	121CT	9732357	Green Published			2022-12-28	WOS:000075995100053
J	Stearne, MR; Palmer, SL; Hammersley, MS; Franklin, SL; Spivey, RS; Levy, JC; Tidy, CR; Bell, NJ; Steemson, J; Barrow, BA; Coster, R; Waring, K; Nolan, L; Truscott, E; Walravens, N; Cook, BL; Lampard, H; Merle, C; Parker, P; McVittie, J; Draisey, I; Murchison, LE; Brunt, AHE; Williams, MJ; Pearson, DW; Petrie, XMP; Lean, MEJ; Walmsley, D; Lyall, F; Christie, E; Church, J; Thomson, E; Farrow, A; Stowers, JM; Stowers, M; McHardy, K; Patterson, N; Wright, AD; Levi, NA; Shearer, AGI; Thompson, RJW; Taylor, G; Rayton, S; Bradbury, M; Glover, A; Smyth-Osbourne, A; Parkes, C; Graham, J; England, P; Gyde, S; Eagle, C; Chakrabarti, B; Smith, J; Sherwell, J; Kohner, EM; Dornhorst, A; Doddridge, MC; Dumskyj, M; Walji, S; Sharp, P; Sleightholm, M; Vanterpool, G; Rose, C; Frost, G; Roseblade, M; Elliott, S; Forrester, S; Foster, M; Myers, K; Chapman, R; Hayes, JR; Henry, TW; Featherston, MS; Archbold, GPR; Copeland, M; Harper, R; Richardson, I; Martin, S; Foster, M; Davison, HA; Hadden, DR; Kennedy, L; Atkinson, AB; Culbert, AM; Hegan, C; Tennet, H; Webb, N; Robinson, I; Holmes, J; Foster, M; Bell, PM; McCance, DR; Rutherford, J; Nesbitt, S; Spathis, AS; Hyer, S; Nanson, ME; James, JM; Tyrell, JM; Davis, C; Strugnell, P; Booth, M; Petrie, H; Clark, D; Rice, B; Hulland, S; Barron, JL; Yudkin, JS; Gould, BJ; Singer, J; Badenock, A; Walji, S; Eckert, M; Alibhai, K; Marriot, E; Cox, C; Price, R; Fernandez, M; Ryle, A; Clarke, S; Wallace, G; Mehmed, E; MacFarlane, S; Greenwood, RH; Wilson, J; Denholm, MJ; Temple, RC; Whitfield, K; Johnson, F; Munroe, C; Gorick, S; Duckworth, E; Flatman, M; Rainbow, S; Borthwick, LJ; Wheatcroft, DJ; Seaman, RJ; Christie, RA; Wheatcroft, W; Musk, P; White, J; McDougal, S; Bond, M; Raniga, P; Newton, RW; Jung, RT; Roxburgh, C; Kilgallon, B; Dick, L; Foster, M; Waugh, N; Kilby, S; Ellingford, A; Burns, J; Fox, CV; Holloway, MC; Coghill, HM; Hein, N; Fox, A; Cowan, W; Richard, M; Quested, K; Evans, SJ; Paisey, RB; Brown, NPR; Tucker, AJ; Paisey, R; Garrett, F; Hogg, J; Park, P; Williams, K; Harvey, P; Wilcocks, R; Mason, S; Frost, J; Warren, C; Rocket, P; Bower, L; Roland, JM; Brown, DJ; Youens, J; Stanton-King, K; Mungall, H; Ball, V; Maddison, W; Donnelly, D; King, S; Griffin, P; Smith, S; Church, S; Dunn, G; Wilson, A; Palmer, K; Brown, PM; Humphriss, D; Davidson, AJM; Rose, R; Armistead, L; Townsend, S; Poon, P; Peacock, IDA; Culverwell, NJC; Charlton, MH; Connolly, BPS; Peacock, J; Barrett, J; Wain, J; Beeston, W; King, G; Hill, PG; Boulton, AJM; Robertson, AM; Katoulis, V; Olukoga, A; McDonald, H; Kumar, S; Abouaesha, F; Abuaisha, B; Knowles, EA; Higgins, S; Booker, J; Sunter, J; Breislin, K; Parker, R; Raval, P; Curwell, J; Davenport, H; Shawcross, G; Prest, A; Grey, J; Cole, H; Sereviratne, C; Young, RJ; Dornan, TL; Clyne, JR; Gibson, M; O'Connell, I; Wong, LM; Wilson, SJ; Wright, KL; Wallace, C; McDowell, D; Burden, AC; Sellen, EM; Gregory, R; Roshan, M; Vaghela, N; Burden, M; Sherriff, C; Clarke, J; Grenfell, J; Tooke, JE; MacLeod, K; Searnark, C; Rammell, M; Pym, C; Stockman, J; Yeo, C; Piper, J; Leighton, L; Green, E; Hoyle, M; Jones, K; Hudson, A; James, AJ; Shore, A; Higham, A; Martin, B				Stearne, MR; Palmer, SL; Hammersley, MS; Franklin, SL; Spivey, RS; Levy, JC; Tidy, CR; Bell, NJ; Steemson, J; Barrow, BA; Coster, R; Waring, K; Nolan, L; Truscott, E; Walravens, N; Cook, BL; Lampard, H; Merle, C; Parker, P; McVittie, J; Draisey, I; Murchison, LE; Brunt, AHE; Williams, MJ; Pearson, DW; Petrie, XMP; Lean, MEJ; Walmsley, D; Lyall, F; Christie, E; Church, J; Thomson, E; Farrow, A; Stowers, JM; Stowers, M; McHardy, K; Patterson, N; Wright, AD; Levi, NA; Shearer, AGI; Thompson, RJW; Taylor, G; Rayton, S; Bradbury, M; Glover, A; Smyth-Osbourne, A; Parkes, C; Graham, J; England, P; Gyde, S; Eagle, C; Chakrabarti, B; Smith, J; Sherwell, J; Kohner, EM; Dornhorst, A; Doddridge, MC; Dumskyj, M; Walji, S; Sharp, P; Sleightholm, M; Vanterpool, G; Rose, C; Frost, G; Roseblade, M; Elliott, S; Forrester, S; Foster, M; Myers, K; Chapman, R; Hayes, JR; Henry, TW; Featherston, MS; Archbold, GPR; Copeland, M; Harper, R; Richardson, I; Martin, S; Foster, M; Davison, HA; Hadden, DR; Kennedy, L; Atkinson, AB; Culbert, AM; Hegan, C; Tennet, H; Webb, N; Robinson, I; Holmes, J; Foster, M; Bell, PM; McCance, DR; Rutherford, J; Nesbitt, S; Spathis, AS; Hyer, S; Nanson, ME; James, JM; Tyrell, JM; Davis, C; Strugnell, P; Booth, M; Petrie, H; Clark, D; Rice, B; Hulland, S; Barron, JL; Yudkin, JS; Gould, BJ; Singer, J; Badenock, A; Walji, S; Eckert, M; Alibhai, K; Marriot, E; Cox, C; Price, R; Fernandez, M; Ryle, A; Clarke, S; Wallace, G; Mehmed, E; MacFarlane, S; Greenwood, RH; Wilson, J; Denholm, MJ; Temple, RC; Whitfield, K; Johnson, F; Munroe, C; Gorick, S; Duckworth, E; Flatman, M; Rainbow, S; Borthwick, LJ; Wheatcroft, DJ; Seaman, RJ; Christie, RA; Wheatcroft, W; Musk, P; White, J; McDougal, S; Bond, M; Raniga, P; Newton, RW; Jung, RT; Roxburgh, C; Kilgallon, B; Dick, L; Foster, M; Waugh, N; Kilby, S; Ellingford, A; Burns, J; Fox, CV; Holloway, MC; Coghill, HM; Hein, N; Fox, A; Cowan, W; Richard, M; Quested, K; Evans, SJ; Paisey, RB; Brown, NPR; Tucker, AJ; Paisey, R; Garrett, F; Hogg, J; Park, P; Williams, K; Harvey, P; Wilcocks, R; Mason, S; Frost, J; Warren, C; Rocket, P; Bower, L; Roland, JM; Brown, DJ; Youens, J; Stanton-King, K; Mungall, H; Ball, V; Maddison, W; Donnelly, D; King, S; Griffin, P; Smith, S; Church, S; Dunn, G; Wilson, A; Palmer, K; Brown, PM; Humphriss, D; Davidson, AJM; Rose, R; Armistead, L; Townsend, S; Poon, P; Peacock, IDA; Culverwell, NJC; Charlton, MH; Connolly, BPS; Peacock, J; Barrett, J; Wain, J; Beeston, W; King, G; Hill, PG; Boulton, AJM; Robertson, AM; Katoulis, V; Olukoga, A; McDonald, H; Kumar, S; Abouaesha, F; Abuaisha, B; Knowles, EA; Higgins, S; Booker, J; Sunter, J; Breislin, K; Parker, R; Raval, P; Curwell, J; Davenport, H; Shawcross, G; Prest, A; Grey, J; Cole, H; Sereviratne, C; Young, RJ; Dornan, TL; Clyne, JR; Gibson, M; O'Connell, I; Wong, LM; Wilson, SJ; Wright, KL; Wallace, C; McDowell, D; Burden, AC; Sellen, EM; Gregory, R; Roshan, M; Vaghela, N; Burden, M; Sherriff, C; Clarke, J; Grenfell, J; Tooke, JE; MacLeod, K; Searnark, C; Rammell, M; Pym, C; Stockman, J; Yeo, C; Piper, J; Leighton, L; Green, E; Hoyle, M; Jones, K; Hudson, A; James, AJ; Shore, A; Higham, A; Martin, B		US Prospective Diabet Study Grp	Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39	BRITISH MEDICAL JOURNAL			English	Article							CONVERTING ENZYME-INHIBITION; CORONARY HEART-DISEASE; BETA-BLOCKADE; RANDOMIZED TRIALS; BLOOD-PRESSURE; NEPHROPATHY; HYPERTENSION; ENALAPRIL; MICROALBUMINURIA; MORTALITY	Objective: To determine whether tight control of blood pressure with either a beta blocker or an angiotensin converting enzyme inhibitor has a specific advantage or disadvantage in preventing the macrovascular and microvascular complications of type 2 diabetes. Design: Randomised controlled trial comparing an angiotensin converting enzyme inhibitor (captopril) with a beta blocker (atenolol) in patients with type 2 diabetes aiming at a blood pressure of < 150/ < 85 mm Hg. Setting 20 hospital based clinics in England, Scotland, and Northern Ireland. Subjects: 1148 hypertensive patients with type 2 diabetes(mean age 56 years, mean blood pressure 160/94 mm Hg). Of the 758 patients allocated to tight control of blood pressure, 400 were allocated to captopril and 358 to atenolol. 390 patients were allocated to less tight control of blood pressure. Main outcome measures: Predefined clinical end points, fatal and non-fatal, related to diabetes, death related to diabetes, and all cause mortality. Surrogate measures of microvascular and macrovascular disease included urinary albumin excretion and retinopathy assessed by retinal photography. Results: Captopril and atenolol were equally effective in reducing blood pressure to a mean of 144/83 mm Hg and 143/81 mm Hg respectively, with a similar proportion of patients (27% and 31%) requiring three or more antihypertensive treatments. More patients in the captopril group than the atenolol group took the allocated treatment: at their last clinic visit, 78% of those allocated captopril and 65% of those allocated atenolol were taking the drug (P < 0.0001). Captopril and atenolol were equally effective in reducing the risk of macrovascular end points. Similar proportions of patients in the true groups showed deterioration in retinopathy by two grades after nine years (31% in the captopril group and 37% in the atenolol group) and developed clinical grade albuminuria greater than or equal to 300 mg/l (5% and 9%). The proportion of patients with hypoglycaemic attacks was not different between groups, but mean weight gain in the atenolol group was greater (3.4 kg v 1.6 kg). Conclusion: Blood pressure lowering with captopril or atenolol was similarly effective in reducing the incidence of diabetic complications. This study provided no evidence that either drug has any specific beneficial or deleterious effect, suggesting that blood pressure reduction in itself may be more important than the treatment used.	Radcliffe Infirm, Diabet Res Labs, UK Prospect Diabet Study Grp, Oxford OX2 6HE, England; E Birmingham Dist Gen Hosp, Birmingham, W Midlands, England; Aberdeen Royal Infirm, Aberdeen, Scotland; Hammersmith Hosp, London, England; Belfast City Hosp, Belfast BT9 7AD, Antrim, North Ireland; Royal Victoria Hosp, Belfast BT12 6BA, Antrim, North Ireland; St Helier Hosp, Carshalton SM5 1AA, Surrey, England; Whittington Hosp, London N19 5NF, England; Norfolk & Norwich Hosp, Norwich NR1 3SR, Norfolk, England; Lister Hosp, Stevenage, Herts, England; Ninewells Hosp, Dundee DD1 9SY, Scotland; Northampton Hosp, Northampton, England; Peterborough Dist Gen Hosp, Peterborough, Cambs, England; Derbyshire Royal Infirm, Derby DE1 2QY, England; Manchester Royal Infirm, Manchester, Lancs, England; Hope Hosp, Salford M6 8HD, Lancs, England; Leicester Gen Hosp, Leicester, Leics, England; Royal Devon & Exeter Hosp, Exeter EX2 5DW, Devon, England	Radcliffe Infirmary; University of Oxford; University of Aberdeen; Imperial College London; Belfast City Hospital; St Helier Hospital; University of London; University College London; Norfolk & Norwich University Hospitals NHS Foundation Trust; Norfolk & Norwich University Hospital; Lister Hospital; University of Dundee; University of Manchester; University Hospitals of Leicester NHS Trust; Leicester General Hospital; University of Exeter	Stearne, MR (corresponding author), Radcliffe Infirm, Diabet Res Labs, UK Prospect Diabet Study Grp, Woodstock Rd, Oxford OX2 6HE, England.		kumar, sudhesh/D-6945-2013; Smith, Jane/B-6254-2009; Yudkin, John S/C-1988-2008	Manley, Susan/0000-0002-8298-4511; Frost, Gary/0000-0003-0529-6325				Andersson B, 1996, CIRCULATION, V94, P673, DOI 10.1161/01.CIR.94.4.673; [Anonymous], 1994, Diabet Med, V11, P773; CHAN JCN, 1992, BRIT MED J, V305, P981, DOI 10.1136/bmj.305.6860.981; Chaturvedi N, 1997, LANCET, V349, P1787, DOI 10.1016/S0140-6736(96)10244-0; COLLINS R, 1994, BRIT MED BULL, V50, P272, DOI 10.1093/oxfordjournals.bmb.a072892; COLLINS R, 1990, LANCET, V335, P827, DOI 10.1016/0140-6736(90)90944-Z; Cooper ME, 1998, LANCET, V352, P213, DOI 10.1016/S0140-6736(98)01346-4; Curb JD, 1996, JAMA-J AM MED ASSOC, V276, P1886, DOI 10.1001/jama.276.23.1886; GARG R, 1995, JAMA-J AM MED ASSOC, V273, P1450, DOI 10.1001/jama.273.18.1450; Heidenreich PA, 1997, J AM COLL CARDIOL, V30, P27, DOI 10.1016/S0735-1097(97)00104-6; HJELM M, 1991, BRIT MED J, V303, P469, DOI 10.1136/bmj.303.6800.469-a; KASISKE BL, 1993, ANN INTERN MED, V118, P129, DOI 10.7326/0003-4819-118-2-199301150-00009; Kumar A, 1998, BMJ-BRIT MED J, V316, P1921, DOI 10.1136/bmj.316.7149.1921; LAFFEL LMB, 1995, AM J MED, V99, P497, DOI 10.1016/S0002-9343(99)80226-5; LEBOVITZ HE, 1994, KIDNEY INT, V45, pS150; LEWIS EJ, 1993, NEW ENGL J MED, V329, P1456, DOI 10.1056/NEJM199311113292004; MARRE M, 1988, BMJ-BRIT MED J, V297, P1092, DOI 10.1136/bmj.297.6656.1092; PASSA P, 1987, DIABETES CARE, V10, P200, DOI 10.2337/diacare.10.2.200; RAVID M, 1994, KIDNEY INT, V45, pS161; Sawicki PT, 1998, DIABETOLOGIA, V41, P598, DOI 10.1007/s001250050953; SAWICKI PT, 1991, J INTERN MED, V229, P489, DOI 10.1111/j.1365-2796.1991.tb00382.x; Stearne MR, 1998, BMJ-BRIT MED J, V317, P703; YUSUF S, 1985, PROG CARDIOVASC DIS, V27, P335, DOI 10.1016/S0033-0620(85)80003-7	23	1147	1188	2	52	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	SEP 12	1998	317	7160					713	720						12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	121CT	9732338				2022-12-28	WOS:000075995100019
J	Goossens, H; Sprenger, MJW				Goossens, H; Sprenger, MJW			Community acquired infections and bacterial resistance	BRITISH MEDICAL JOURNAL			English	Article							HIGH-LEVEL RESISTANCE; STREPTOCOCCUS-PNEUMONIAE; TRAVELERS DIARRHEA; ESCHERICHIA-COLI; DRUG-THERAPY; SUSCEPTIBILITY; CIPROFLOXACIN; CARE; ERYTHROMYCIN; PREVALENCE		Univ Antwerp Hosp, Dept Clin Microbiol, B-2650 Edegem, Belgium; Natl Inst Publ Hlth & Environm, Dept Infect Dis Epidemiol, NL-3720 BA Bilthoven, Netherlands	University of Antwerp; Netherlands National Institute for Public Health & the Environment	Goossens, H (corresponding author), Univ Antwerp Hosp, Dept Clin Microbiol, B-2650 Edegem, Belgium.							ABADI FJR, 1995, J ANTIMICROB CHEMOTH, V35, P687, DOI 10.1093/jac/35.5.687; APPELBAUM PC, 1992, CLIN INFECT DIS, V15, P77, DOI 10.1093/clinids/15.1.77; Arason VA, 1996, BMJ-BRIT MED J, V313, P387; BARNES DM, 1995, J INFECT DIS, V171, P890, DOI 10.1093/infdis/171.4.890; Borzani M, 1997, J ANTIMICROB CHEMOTH, V40, P457, DOI 10.1093/jac/40.3.457; Campbell GD, 1998, CLIN INFECT DIS, V26, P1188, DOI 10.1086/520286; COFFEY TJ, 1995, ANTIMICROB AGENTS CH, V39, P1306, DOI 10.1128/AAC.39.6.1306; DUPONT HL, 1993, NEW ENGL J MED, V328, P1821, DOI 10.1056/NEJM199306243282507; FRIEDLAND IR, 1994, NEW ENGL J MED, V331, P377, DOI 10.1056/NEJM199408113310607; Frost JA, 1996, J ANTIMICROB CHEMOTH, V37, P85, DOI 10.1093/jac/37.1.85; Garcia-Bermejo I, 1998, ANTIMICROB AGENTS CH, V42, P989, DOI 10.1128/AAC.42.4.989; GARCIARODRIGUEZ JA, 1995, EUR J CLIN MICROBIOL, V14, P456, DOI 10.1007/BF02114906; Gleason PP, 1997, JAMA-J AM MED ASSOC, V278, P32, DOI 10.1001/jama.278.1.32; Glynn MK, 1998, NEW ENGL J MED, V338, P1333, DOI 10.1056/NEJM199805073381901; Guillemot D, 1998, JAMA-J AM MED ASSOC, V279, P365, DOI 10.1001/jama.279.5.365; Hermans PWM, 1997, J INFECT DIS, V175, P1413, DOI 10.1086/516474; Hoge CW, 1998, CLIN INFECT DIS, V26, P341, DOI 10.1086/516303; Holmes SJ, 1996, EPIDEMIOL REV, V18, P10, DOI 10.1093/oxfordjournals.epirev.a017913; JACOBY GA, 1994, CLIN INFECT DIS, V18, P951, DOI 10.1093/clinids/18.6.951; Kaczmarski E B, 1997, Commun Dis Rep CDR Rev, V7, pR55; Lehn N, 1996, J CLIN MICROBIOL, V34, P597, DOI 10.1128/JCM.34.3.597-602.1996; Nathwani D, 1996, BRIT MED J, V313, P1541, DOI 10.1136/bmj.313.7071.1541; *NETH REF LAB BACT, 1997, BACT MEN NETH ANN RE; OZEKI S, 1997, J CLIN MICROBIOL, V35, P2312; Pascual A, 1996, J CLIN MICROBIOL, V34, P588, DOI 10.1128/JCM.34.3.588-591.1996; PETRUCCELLI BP, 1992, J INFECT DIS, V165, P557, DOI 10.1093/infdis/165.3.557; Piddock LJV, 1995, J ANTIMICROB CHEMOTH, V36, P891, DOI 10.1093/jac/36.6.891; Pradier C, 1997, EUR J CLIN MICROBIOL, V16, P644, DOI 10.1007/BF01708553; SAEZNIETO JA, 1988, LANCET, V1, P1452; Seppala H, 1997, NEW ENGL J MED, V337, P441, DOI 10.1056/NEJM199708143370701; STAMM WE, 1993, NEW ENGL J MED, V329, P1329; Swartz MN, 1997, NEW ENGL J MED, V337, P491, DOI 10.1056/NEJM199708143370709; Threlfall EJ, 1997, LANCET, V349, P403, DOI 10.1016/S0140-6736(97)80024-4; Van Looveren Marleen, 1998, Clin Microbiol Infect, V4, P224; Witte W, 1998, SCIENCE, V279, P996, DOI 10.1126/science.279.5353.996	35	57	62	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	SEP 5	1998	317	7159					654	657		10.1136/bmj.317.7159.654	http://dx.doi.org/10.1136/bmj.317.7159.654			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	118GN	9727998	Green Published			2022-12-28	WOS:000075830200028
J	Pillay, D; Zambon, M				Pillay, D; Zambon, M			Antiviral drug resistance	BMJ-BRITISH MEDICAL JOURNAL			English	Article							MUCOCUTANEOUS HERPES-SIMPLEX; CONTROLLED TRIAL; VIRUS-INFECTION; ACYCLOVIR; TRANSMISSION; REPLICATION; ZIDOVUDINE; VARIANTS; PATIENT; AIDS		Univ Birmingham, Sch Med, Div Immun & Infect,Publ Hlth Lab Serv, Antiviral Susceptibil Reference Unit, Birmingham B15 2TT, W Midlands, England; Cent Publ Hlth Lab, Enter & Resp Virus Lab, London NW9 5HT, England	University of Birmingham; Public Health England	Pillay, D (corresponding author), Univ Birmingham, Sch Med, Div Immun & Infect,Publ Hlth Lab Serv, Antiviral Susceptibil Reference Unit, Birmingham B15 2TT, W Midlands, England.	D.Pillay@bham.ac.uk						[Anonymous], 1998, MMWR Recomm Rep, V47, P1; Ashcroft ME, 1998, INT J STD AIDS, V9, P361, DOI 10.1258/0956462981922287; Back NKT, 1996, EMBO J, V15, P4040, DOI 10.1002/j.1460-2075.1996.tb00777.x; Bartenschlager R, 1997, ANTIVIR CHEM CHEMOTH, V8, P281, DOI 10.1177/095632029700800401; BARTHOLOMEUSZ A, 1997, INT ANTIVIRAL NEWS, V5, P123; BELSHE RB, 1988, J VIROL, V62, P1508, DOI 10.1128/JVI.62.5.1508-1512.1988; Bowen EF, 1998, AIDS, V12, P605, DOI 10.1097/00002030-199806000-00009; COFFIN JM, 1996, ANTIVIRAL DRUG RESIS, P267; Havlir DV, 1996, ANN INTERN MED, V124, P984, DOI 10.7326/0003-4819-124-11-199606010-00006; HAYDEN FG, 1989, NEW ENGL J MED, V321, P1696, DOI 10.1056/NEJM198912213212502; Hayden FG, 1997, NEW ENGL J MED, V337, P874, DOI 10.1056/NEJM199709253371302; Hecht FM, 1998, NEW ENGL J MED, V339, P307, DOI 10.1056/NEJM199807303390504; Hirsch MS, 1998, JAMA-J AM MED ASSOC, V279, P1984, DOI 10.1001/jama.279.24.1984; *HOSP PHARM AUD ME, MONTHL SAL DAT; Imrie A, 1997, J INFECT DIS, V175, P1502, DOI 10.1086/516487; KOST RG, 1993, NEW ENGL J MED, V329, P1777, DOI 10.1056/NEJM199312093292405; KOZAL M, 1998, 2 INT WORKSH HIV DRU; Lai CL, 1998, NEW ENGL J MED, V339, P61, DOI 10.1056/NEJM199807093390201; Lalezari J, 1997, J INFECT DIS, V176, P892, DOI 10.1086/516542; Mendel DB, 1998, ANTIMICROB AGENTS CH, V42, P640, DOI 10.1128/AAC.42.3.640; Pillay D, 1998, Commun Dis Public Health, V1, P5; POTTAGE JC, 1995, INFECT AGENT DIS, V4, P115; REYES M, 1998, 11 INT C ANT RES SAN; SAFRIN S, 1991, NEW ENGL J MED, V325, P551, DOI 10.1056/NEJM199108223250805; VANVAERENBERGH K, 1998, 2 INT WORKSH HIV DRU; VEENSTRA J, 1995, CLIN INFECT DIS, V21, P556, DOI 10.1093/clinids/21.3.556	26	45	48	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 5	1998	317	7159					660	662		10.1136/bmj.317.7159.660	http://dx.doi.org/10.1136/bmj.317.7159.660			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	118GN	9728000	Green Published			2022-12-28	WOS:000075830200030
J	Williams, RJ; Ryan, MJ				Williams, RJ; Ryan, MJ			Surveillance of antimicrobial resistance - an international perspective	BRITISH MEDICAL JOURNAL			English	Article									WHO, Div Emerging & Other Communicable Dis Surveillanc, CH-1211 Geneva, Switzerland	World Health Organization	Williams, RJ (corresponding author), WHO, Div Emerging & Other Communicable Dis Surveillanc, CH-1211 Geneva, Switzerland.							HABIYAMBERE V, WHODAP987 WHO; Williams RJ, 1998, SCIENCE, V279, P1153, DOI 10.1126/science.279.5354.1153	2	15	18	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	SEP 5	1998	317	7159					651	651		10.1136/bmj.317.7159.651	http://dx.doi.org/10.1136/bmj.317.7159.651			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	118GN	9727996	Green Published			2022-12-28	WOS:000075830200026
J	Haissaguerre, M; Jais, P; Shah, DC; Takahashi, A; Hocini, M; Quiniou, G; Garrigue, S; Le Mouroux, A; Le Metayer, P; Clementy, J				Haissaguerre, M; Jais, P; Shah, DC; Takahashi, A; Hocini, M; Quiniou, G; Garrigue, S; Le Mouroux, A; Le Metayer, P; Clementy, J			Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RADIOFREQUENCY CATHETER ABLATION; MAZE PROCEDURE; HEART; OPERATION; THERAPY; DOGS	Background Atrial fibrillation, the most common sustained cardiac arrhythmia and a major cause of stroke, results from simultaneous reentrant wavelets. Its spontaneous initiation has not been studied. Methods We studied 45 patients with frequent episodes of atrial fibrillation (mean [+/-SD] duration, 344+/-326 minutes per 24 hours) refractory to drug therapy. The spontaneous initiation of atrial fibrillation was mapped with the use of multielectrode catheters designed to record the earliest electrical activity preceding the onset of atrial fibrillation and associated atrial ectopic beats. The accuracy of the mapping was confirmed by the abrupt disappearance of triggering atrial ectopic beats after ablation with local radio-frequency energy. Results A single point of origin of atrial ectopic beats was identified in 29 patients, two points of origin were identified in 9 patients, and three or four points of origin were identified in 7 patients, for a total of 69 ectopic foci. Three foci were in the right atrium, 1 in the posterior left atrium, and 65 (94 percent) in the pulmonary veins (31 in the left superior, 17 in the right superior, 11 in the left inferior, and 6 in the right inferior pulmonary vein). The earliest activation was found to have occurred 2 to 4 cm inside the veins, marked by a local depolarization preceding the atrial ectopic beats on the surface electrocardiogram by 106+/-24 msec. Atrial fibrillation was initiated by a sudden burst of rapid depolarizations (340 per minute). A local depolarization could also be recognized during sinus rhythm and abolished by radiofrequency ablation. During a follow-up period of 8+/-6 months after ablation, 28 patients (62 percent) had no recurrence of atrial fibrillation. Conclusions The pulmonary veins are an important source of ectopic beats, initiating frequent paroxysms of atrial fibrillation. These foci respond to treatment with radio-frequency ablation. (N Engl J Med 1998;339:659-66.) (C)1998, Massachusetts Medical Society.	Hop Cardiol Haut Leveque, F-33604 Bordeaux, France	CHU Bordeaux	Haissaguerre, M (corresponding author), Hop Cardiol Haut Leveque, Ave Magellan, F-33604 Bordeaux, France.							ALESSIE MA, 1990, CARDIAC ELECTROPHYSI, P548; AVITALL B, 1994, J AM COLL CARDIOL, V23, pA276; BLOUIN LT, 1991, PACE, V14, P807, DOI 10.1111/j.1540-8159.1991.tb04111.x; COSIO FG, 1993, AM J CARDIOL, V71, P705, DOI 10.1016/0002-9149(93)91014-9; COX JL, 1991, J THORAC CARDIOV SUR, V101, P406, DOI 10.1016/s0022-5223(19)36723-6; COX JL, 1993, ANN THORAC SURG, V56, P814, DOI 10.1016/0003-4975(93)90338-I; DEFAUW JJAMT, 1992, ANN THORAC SURG, V53, P564, DOI 10.1016/0003-4975(92)90312-R; ELVAN A, 1995, CIRCULATION, V91, P2235, DOI 10.1161/01.CIR.91.8.2235; FENELON G, 1997, PACING CLIN ELECTROP, V20, P1095; Garrey WE, 1914, AM J PHYSIOL, V33, P397, DOI 10.1152/ajplegacy.1914.33.3.397; Greenfield Ruth Ann, 1997, P465; HAINES DE, 1993, PACE, V16, P586, DOI 10.1111/j.1540-8159.1993.tb01630.x; HAINES DE, 1995, CIRCULATION, V92, P265; Haissaguerre M, 1996, J CARDIOVASC ELECTR, V7, P1132, DOI 10.1111/j.1540-8167.1996.tb00492.x; HAISSAGUERRE M, 1994, J CARDIOVASC ELECTR, V5, P743, DOI 10.1111/j.1540-8167.1994.tb01197.x; ITO M, 1967, JPN J PHYSIOL, V17, P174; Jais P, 1997, CIRCULATION, V95, P572, DOI 10.1161/01.CIR.95.3.572; JOSEPHSON ME, 1993, CLIN CARDIAC ELECTRO, P96; KONINGS KTS, 1994, CIRCULATION, V89, P1665, DOI 10.1161/01.CIR.89.4.1665; KOPECKY SL, 1987, NEW ENGL J MED, V317, P669, DOI 10.1056/NEJM198709103171104; KOSAKAI Y, 1995, CIRCULATION, V92, P359, DOI 10.1161/01.CIR.92.9.359; MOE GK, 1964, AM HEART J, V67, P200, DOI 10.1016/0002-8703(64)90371-0; MORILLO CA, 1995, CIRCULATION, V91, P1588, DOI 10.1161/01.CIR.91.5.1588; NATHAN H, 1966, CIRCULATION, V34, P412, DOI 10.1161/01.CIR.34.3.412; Prystowsky EN, 1996, CIRCULATION, V93, P1262, DOI 10.1161/01.CIR.93.6.1262; SCHEINMAN MM, 1982, JAMA-J AM MED ASSOC, V248, P851, DOI 10.1001/jama.248.7.851; SHYU KG, 1994, J AM COLL CARDIOL, V24, P392, DOI 10.1016/0735-1097(94)90293-3; Sih HJ, 1997, J CARDIOVASC ELECTR, V8, P1046, DOI 10.1111/j.1540-8167.1997.tb00628.x; SPACH MS, 1972, AM J CARDIOL, V30, P844, DOI 10.1016/0002-9149(72)90009-4; WELLENS HJJ, 1994, NEW ENGL J MED, V331, P944, DOI 10.1056/NEJM199410063311413; WEST TC, 1962, AM J PHYSIOL, V202, P232, DOI 10.1152/ajplegacy.1962.202.2.232; WIJFFELS MCEF, 1995, CIRCULATION, V92, P1954, DOI 10.1161/01.CIR.92.7.1954; WILLIAMSON BD, 1995, NEW ENGL J MED, V332, P479; WILLIAMSON BD, 1994, NEW ENGL J MED, V331, P910, DOI 10.1056/NEJM199410063311404; ZIPES DP, 1972, AM J CARDIOL, V29, P372, DOI 10.1016/0002-9149(72)90533-4; ZIPES DP, 1994, CATHETER ABLATION AR, P1; [No title captured]	37	5348	5826	3	262	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 3	1998	339	10					659	666		10.1056/NEJM199809033391003	http://dx.doi.org/10.1056/NEJM199809033391003			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	115WA	9725923				2022-12-28	WOS:000075688100003
J	Palepu, A; Carr, PL; Friedman, RH; Amos, H; Ash, AS; Moskowitz, MA				Palepu, A; Carr, PL; Friedman, RH; Amos, H; Ash, AS; Moskowitz, MA			Minority faculty and academic rank in medicine	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PROMOTION; WOMEN; SCHOOLS; MEN	Context.-Previous studies have found that fewer minority medical school faculty hold senior professorial ranks than do majority faculty and may not be promoted as rapidly. Objective.-To determine whether minority faculty were as likely as majority faculty to have attained senior rank (associate professor or full professor) after adjusting for other factors that typically influence promotion. Design.-A self-administered mailed survey of US medical school faculty using the Association of American Medical Colleges database. The sample was stratified by department, graduation cohort, and sex. Participants.-A stratified random sample of 3013 full-time faculty at 24 representative US medical schools. All underrepresented minority faculty at these schools were sampled. Main Outcome Measure.-Attainment of senior academic rank (associate professor or full professor). Results.-Of 3013 faculty surveyed, 1807 (60.0%) responded, including 1463 white (81.0%), 154 black (8.5%), 136 Asian (7.5%), and 54 Hispanic (3.0%), Overall, 980 faculty (54%) had attained senior academic rank, including 47 (30.5%) of 154 black faculty; 59 (43.4%) of 136 Asian faculty, 22 (40.8%) of 54 Hispanic faculty, and 852 (58.3%) of 1463 white faculty. White faculty had significantly more first-authored and total peer-reviewed publications than the other groups. After adjusting for the medical school, department, years as medical school faculty, number of peer-reviewed publications, receipt of research grant funding, proportion of time in clinical activities, sex, and tenure status, we found that the odds ratios of holding senior rank relative to white faculty were 0.33 (95% confidence interval [CI], 0.17-0.63) for black faculty, 0.36 (95% CI, 0.12-1.08) for Hispanic faculty, and 0.58 (95% CI, 0.30-1.12) for Asian faculty. Conclusions.-Minority faculty were less likely than white faculty to hold senior academic rank. This finding was not explained by potential confounders such as years as a faculty member or measures of academic productivity.	Boston Univ, Boston Med Ctr, Dept Med, Gen Internal Med Sect,MISU, Boston, MA 02118 USA; Massachusetts Gen Hosp, Dept Med, Div Gen Internal Med, Boston, MA 02114 USA; Harvard Univ, Dept Microbiol & Mol Genet, Boston, MA 02115 USA	Boston Medical Center; Boston University; Harvard University; Massachusetts General Hospital; Harvard University	Palepu, A (corresponding author), Boston Univ, Boston Med Ctr, Dept Med, Gen Internal Med Sect,MISU, DOB 1102,720 Harrison Ave, Boston, MA 02118 USA.	anita@hivnet.ubc.ca	Ash, Arlene/AAG-2914-2019	Ash, Arlene/0000-0002-8448-0253; Friedman, Robert/0000-0002-9440-2443; Palepu, Anita/0000-0002-7881-4800				APPLEGATE WB, 1990, AM J MED, V88, P263, DOI 10.1016/0002-9343(90)90152-4; *ASS AM MED COLL, 1996, US MED SCH FAC 1996; BICKEL J, 1991, ACAD MED, V66, P497, DOI 10.1097/00001888-199108000-00025; Breslow NE, 1980, INT AGENCY RES CANC, V1; BROOKMEYER R, 1987, BIOMETRICS, V43, P739, DOI 10.2307/2531529; Bruhn J G, 1997, Health Care Superv, V15, P32; CARR P, 1992, J GEN INTERN MED, V7, P418, DOI 10.1007/BF02599159; CARR PL, 1993, ANN INTERN MED, V119, P908, DOI 10.7326/0003-4819-119-9-199311010-00008; GIERDE C, 1994, FAM MED, V26, P361; Jones R F, 1993, Acad Med, V68, P588, DOI 10.1097/00001888-199308000-00002; Kaplan SH, 1996, NEW ENGL J MED, V335, P1282, DOI 10.1056/NEJM199610243351706; Levinson W, 1991, ANN INTERN MED, V114, P63; Likert R., 1932, ARCH PSYCHOL, V140, P5, DOI DOI 10.1108/17538331211269648; MCHUGH PR, 1994, ACAD MED, V69, P877, DOI 10.1097/00001888-199411000-00003; NICKENS HW, 1994, NEW ENGL J MED, V331, P472, DOI 10.1056/NEJM199408183310712; PETERSDORF RG, 1992, ACAD MED, V67, P73, DOI 10.1097/00001888-199202000-00003; PETERSDORF RG, 1994, ACAD MED, V69, P171, DOI 10.1097/00001888-199403000-00001; PETERSDORF RG, 1990, ACAD MED, V65, P663, DOI 10.1097/00001888-199011000-00001; PINN VW, 1984, J NATL MED ASSOC, V76, P857; SWIM JK, 1995, J PERS SOC PSYCHOL, V68, P199, DOI 10.1037/0022-3514.68.2.199; TESCH BJ, 1995, JAMA-J AM MED ASSOC, V273, P1022, DOI 10.1001/jama.273.13.1022; Williams RL, 1998, ACAD MED, V73, P333, DOI 10.1097/00001888-199803000-00023; WILSON DR, 1992, CLIN INVEST MED, V15, P257	23	118	118	0	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 2	1998	280	9					767	771		10.1001/jama.280.9.767	http://dx.doi.org/10.1001/jama.280.9.767			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	114LA	9729986	Bronze			2022-12-28	WOS:000075609900003
J	Beristain, CM				Beristain, CM			Health, memory, and human rights in Guatemala	LANCET			English	Editorial Material									REMHI, Project Archdiocese Guatemala, Santurtzi 48980, Bizkaia, Spain		Beristain, CM (corresponding author), REMHI, Project Archdiocese Guatemala, Capitan Mendizabal II-5B, Santurtzi 48980, Bizkaia, Spain.							*OF DER HUM ARZ GU, 1998, INF PROYECT REC MEM, V1; Pennebaker J., 1997, COLLECTIVE MEMORY PO; PERRENKLINGER G, 1996, TRAUMA INDIVIDUAL HE	3	2	2	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	AUG 29	1998	352	9129					733	734		10.1016/S0140-6736(05)60847-1	http://dx.doi.org/10.1016/S0140-6736(05)60847-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	116MT	9729008				2022-12-28	WOS:000075729700050
J	Cannon, CH; Peart, DR; Leighton, M				Cannon, CH; Peart, DR; Leighton, M			Tree species diversity in commercially logged Bornean rainforest	SCIENCE			English	Article							LOWLAND RAIN-FOREST; INDONESIA; RESERVE; UGANDA	The effects of commercial Logging on tree diversity in tropical rainforest are Largely unknown. In this study, selectively logged tropical rainforest in Indonesian Borneo is shown to contain high tree species richness, despite severe structural damage. Plots logged 8 years before sampling contained fewer species of trees greater than 20 centimeters in diameter than did similar-sized unlogged plots. However, in samples of the same numbers of trees (requiring a 50 percent Larger area), Logged forest contained as many tree species as unlogged forest. These findings warrant reassessment of the conservation potential of large tracts of commercially Logged tropical rainforest.	Duke Univ, Dept Bot, Durham, NC 27708 USA; Univ Malaysia Sarawak, Inst Biodivers & Environm Conservat, Kota Samarahan, Sarawak, Malaysia; Dartmouth Coll, Dept Biol Sci, Hanover, NH 03755 USA; Harvard Univ, Dept Anthropol, Cambridge, MA 02138 USA	Duke University; University of Malaysia Sarawak; Dartmouth College; Harvard University	Cannon, CH (corresponding author), Duke Univ, Dept Bot, Durham, NC 27708 USA.	chc2@duke.edu	Cannon, Charles H/D-7186-2012; Cannon, Charles/AAE-7715-2019	Cannon, Charles H/0000-0003-1901-0420; Cannon, Charles/0000-0003-1901-0420				BRUENIG E, 1996, CONSERVATION MANAGEM; CANNON CH, 1994, FOREST ECOL MANAG, V67, P49, DOI 10.1016/0378-1127(94)90007-8; CHAO A, 1992, J AM STAT ASSOC, V87, P210, DOI 10.2307/2290471; COLWELL RK, 1994, PHILOS T R SOC B, V345, P101, DOI 10.1098/rstb.1994.0091; Condit R, 1996, J ECOL, V84, P549, DOI 10.2307/2261477; CROME FHJ, 1992, FOREST ECOL MANAG, V49, P1, DOI 10.1016/0378-1127(92)90157-5; EWEL J, 1980, SPECIAL PUBL BIOTROP; HECK KL, 1975, ECOLOGY, V56, P1459, DOI 10.2307/1934716; Hill JK, 1995, J APPL ECOL, V32, P754, DOI 10.2307/2404815; KASENENE JM, 1991, FOREST ECOL MANAG, V46, P295, DOI 10.1016/0378-1127(91)90237-P; Nicholson D. I., 1988, Proceedings of the Ecological Society of Australia, V15, P61; Peet R.K., 1974, Annual Rev Ecol Syst, V5, P285, DOI 10.1146/annurev.es.05.110174.001441; PIELOU EC, 1966, J THEOR BIOL, V10, P370, DOI 10.1016/0022-5193(66)90133-0; PLUMPTRE AJ, 1994, J APPL ECOL, V31, P631, DOI 10.2307/2404154; Putz FE, 1996, BIOTROPICA, V28, P323, DOI 10.2307/2389196; THIOLLAY JM, 1992, CONSERV BIOL, V6, P47, DOI 10.1046/j.1523-1739.1992.610047.x; WHITE LJT, 1994, J TROP ECOL, V10, P313, DOI 10.1017/S0266467400007987; Whitmore T. C., 1997, P3	18	188	215	4	54	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 28	1998	281	5381					1366	1368		10.1126/science.281.5381.1366	http://dx.doi.org/10.1126/science.281.5381.1366			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	115LQ	9721105				2022-12-28	WOS:000075666800055
J	de Beer, T; Carter, RE; Lobel-Rice, KE; Sorkin, A; Overduin, M				de Beer, T; Carter, RE; Lobel-Rice, KE; Sorkin, A; Overduin, M			Structure and Asn-Pro-Phe binding pocket of the Eps15 homology domain	SCIENCE			English	Article							TYROSINE KINASE SUBSTRATE; ANGSTROM RESOLUTION; TERMINAL DOMAIN; EH DOMAIN; PROTEIN; NMR; ASSOCIATION	Eps15 homology (EH) domains are eukaryotic signaling modules that recognize proteins containing Asn-Pro-Phe (NPF) sequences. The structure of the central EH domain of Eps15 has been solved by heteronuclear magnetic resonance spectroscopy. The fold consists of a pair of EF hand motifs, the second of Which binds tightly to calcium. The NPF peptide is bound in a hydrophobic pocket between two a helices, and binding is mediated by a critical aromatic interaction as revealed by structure-based mutagenesis. The fold is predicted to be highly conserved among 30 identified EH domains and provides a structural basis for defining EH-mediated events in protein trafficking and growth factor signaling.	Univ Colorado, Hlth Sci Ctr, Dept Pharmacol, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Overduin, M (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Pharmacol, 4200 E 9th Ave, Denver, CO 80262 USA.		Overduin, Michael/AAG-3632-2020	Overduin, Michael/0000-0002-3114-6585; Sorkin, Alexander/0000-0002-4446-1920				ALTIERI AS, 1995, J AM CHEM SOC, V117, P7566, DOI 10.1021/ja00133a039; AVANTAGGIATO V, 1995, ONCOGENE, V11, P1191; BENEDETTI H, 1994, MOL BIOL CELL, V5, P1023, DOI 10.1091/mbc.5.9.1023; Benmerah A, 1996, J BIOL CHEM, V271, P12111, DOI 10.1074/jbc.271.20.12111; Benmerah A, 1998, J CELL BIOL, V140, P1055, DOI 10.1083/jcb.140.5.1055; BRUNGER AT, 1992, X PLOR VERSION 3 1; Carbone R, 1997, CANCER RES, V57, P5498; CHATTOPADHYAYA R, 1992, J MOL BIOL, V228, P1177, DOI 10.1016/0022-2836(92)90324-D; Cupers P, 1998, J BIOL CHEM, V273, P1847, DOI 10.1074/jbc.273.4.1847; DECLERCQ JP, 1991, J MOL BIOL, V220, P1017, DOI 10.1016/0022-2836(91)90369-H; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; DiFiore PP, 1997, TRENDS BIOCHEM SCI, V22, P411, DOI 10.1016/S0968-0004(97)01127-4; FALKE JJ, 1994, Q REV BIOPHYS, V27, P219, DOI 10.1017/S0033583500003012; FAZIOLI F, 1993, MOL CELL BIOL, V13, P5814, DOI 10.1128/MCB.13.9.5814; Fletcher CM, 1996, J BIOMOL NMR, V8, P292, DOI 10.1007/BF00410328; Haffner C, 1997, FEBS LETT, V419, P175, DOI 10.1016/S0014-5793(97)01451-8; Ikeda M, 1998, J BIOL CHEM, V273, P814, DOI 10.1074/jbc.273.2.814; Kay LE, 1997, BIOCHEM CELL BIOL, V75, P1, DOI 10.1139/o97-023; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; MUHANDIRAM DR, 1994, J MAGN RESON SER B, V103, P203, DOI 10.1006/jmrb.1994.1032; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Overduin M, 1996, J BIOMOL NMR, V7, P173; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Rogaia D, 1997, CANCER RES, V57, P799; Salcini AE, 1997, GENE DEV, V11, P2239, DOI 10.1101/gad.11.17.2239; SCHUMACHER C, 1995, J BIOL CHEM, V270, P15341, DOI 10.1074/jbc.270.25.15341; Strynadka NCJ, 1997, J MOL BIOL, V273, P238, DOI 10.1006/jmbi.1997.1257; SVENSSON LA, 1992, J MOL BIOL, V223, P601, DOI 10.1016/0022-2836(92)90976-Q; Tebar F, 1997, J BIOL CHEM, V272, P15413, DOI 10.1074/jbc.272.24.15413; Wendland B, 1998, J CELL BIOL, V141, P71, DOI 10.1083/jcb.141.1.71; WISHART DS, 1994, J BIOMOL NMR, V4, P171; WONG WT, 1995, P NATL ACAD SCI USA, V92, P9530, DOI 10.1073/pnas.92.21.9530; YAMABHAI M, UNPUB; Yamaguchi A, 1997, J BIOL CHEM, V272, P31230, DOI 10.1074/jbc.272.50.31230	34	109	113	1	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 28	1998	281	5381					1357	1360		10.1126/science.281.5381.1357	http://dx.doi.org/10.1126/science.281.5381.1357			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	115LQ	9721102				2022-12-28	WOS:000075666800052
J	Schmedt, C; Saijo, K; Niidome, T; Kuhn, R; Aizawa, S; Tarakhovsky, A				Schmedt, C; Saijo, K; Niidome, T; Kuhn, R; Aizawa, S; Tarakhovsky, A			Csk controls antigen receptor-mediated development and selection of T-lineage cells	NATURE			English	Article							THYMOCYTE DEVELOPMENT; TYROSINE KINASES; DEFICIENT MICE; GENE; INHIBITION; LCK; DISRUPTION; EXPRESSION; MATURATION; TRANSGENE	The development and function of alpha beta T lymphocytes depend on signals derived from pre-T and alpha beta T cell receptors (preTCR and alpha beta TCR) (reviewed in refs 1, 2). The engagement of these receptors leads to the activation of Lck and Fyn(3,4), which are protein tyrosine kinases (PTKs) of the Src family. It remains unclear to what extent the activation of Src-family PTKs can direct the differentiation steps triggered by preTCR and alpha beta TCR. Here we show that the inactivation of the negative regulator of Src-family PTKs, carboxy-terminal Src kinase (Csk)(5), in immature thymocytes abrogates the requirement for preTCR, alpha beta TCR and major histocompatibility complex (MHC) class II for the development of CD4(+)8(+) double-positive and CD4(+) single-positive thymocytes as well as peripheral CD4 alpha beta T-lineage cells. These data show that Csk and its substrates are required to establish preTCR/alpha beta TCR-mediated control over the development of alpha beta T cells.	Univ Cologne, Lab Lymphocyte Signalling, D-50931 Cologne, Germany; Univ Cologne, Inst Genet, Dept Immunol, D-50931 Cologne, Germany; Kumamoto Univ, Sch Med, Inst Mol Embryol & Genet, Dept Morphogenesis, Kumamoto 860, Japan	University of Cologne; University of Cologne; Kumamoto University	Tarakhovsky, A (corresponding author), Univ Cologne, Lab Lymphocyte Signalling, Weyertal 121, D-50931 Cologne, Germany.	sasha@mac.genetik.uni-koeln.de	Kühn, Ralf/U-1278-2017	Kühn, Ralf/0000-0003-1694-9803				AlberolaIla J, 1997, ANNU REV IMMUNOL, V15, P125, DOI 10.1146/annurev.immunol.15.1.125; ANDERSON SJ, 1992, EMBO J, V11, P4877, DOI 10.1002/j.1460-2075.1992.tb05594.x; GOSGROVE D, 1991, CELL, V66, P1051; Groves T, 1996, IMMUNITY, V5, P417, DOI 10.1016/S1074-7613(00)80498-7; GRUSBY MJ, 1991, SCIENCE, V253, P1417, DOI 10.1126/science.1910207; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; IMAMOTO A, 1993, CELL, V73, P1117, DOI 10.1016/0092-8674(93)90641-3; JAMESON SC, 1995, ANNU REV IMMUNOL, V13, P93, DOI 10.1146/annurev.iy.13.040195.000521; KONTGEN F, 1993, INT IMMUNOL, V5, P957, DOI 10.1093/intimm/5.8.957; Krotkova A, 1997, J EXP MED, V186, P767, DOI 10.1084/jem.186.5.767; KUHN R, 1995, SCIENCE, V269, P1427, DOI 10.1126/science.7660125; LEDBETTER JA, 1979, IMMUNOL REV, V47, P63, DOI 10.1111/j.1600-065X.1979.tb00289.x; Mombaerts P, 1995, Int Rev Immunol, V13, P43, DOI 10.3109/08830189509061737; MOMBAERTS P, 1994, IMMUNITY, V1, P261, DOI 10.1016/1074-7613(94)90077-9; MOMBAERTS P, 1992, NATURE, V360, P225, DOI 10.1038/360225a0; Moore TA, 1996, J IMMUNOL, V157, P2366; Murphy E, 1996, J EXP MED, V183, P901, DOI 10.1084/jem.183.3.901; NADA S, 1993, CELL, V73, P1125, DOI 10.1016/0092-8674(93)90642-4; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; Norment AM, 1997, J EXP MED, V185, P121, DOI 10.1084/jem.185.1.121; Saijo K, 1997, J EXP MED, V185, P351, DOI 10.1084/jem.185.2.351; SPRENT J, 1994, SCIENCE, V265, P1395, DOI 10.1126/science.8073282; SWAT W, 1993, EUR J IMMUNOL, V23, P739, DOI 10.1002/eji.1830230326; Torres RM, 1997, LAB PROTOCOLS CONDIT; vanOers NSC, 1996, IMMUNITY, V5, P429, DOI 10.1016/S1074-7613(00)80499-9; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; vonBoehmer H, 1997, ANNU REV IMMUNOL, V15, P433, DOI 10.1146/annurev.immunol.15.1.433; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; WILSON A, 1988, CELL IMMUNOL, V117, P312, DOI 10.1016/0008-8749(88)90121-9	29	118	120	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 27	1998	394	6696					901	904		10.1038/29802	http://dx.doi.org/10.1038/29802			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	114LW	9732874				2022-12-28	WOS:000075611800051
J	Kern, DG; Crausman, RS; Durand, KTH; Nayer, A; Kuhn, C				Kern, DG; Crausman, RS; Durand, KTH; Nayer, A; Kuhn, C			Flock worker's lung: Chronic interstitial lung disease in the nylon flocking industry	ANNALS OF INTERNAL MEDICINE			English	Article						lung diseases, interstitial; nylon; occupational diseases; pneumonia; bronchiolitis obliterans	OBLITERANS ORGANIZING PNEUMONIA; IDIOPATHIC PULMONARY FIBROSIS; HUMAN-IMMUNODEFICIENCY-VIRUS; HYPERSENSITIVITY PNEUMONITIS; BRONCHOALVEOLAR LAVAGE; BRONCHIOLITIS; ALVEOLITIS; EOSINOPHILS; DISORDERS; OUTBREAK	Background: Two young men working at a nylon flocking plant in Rhode Island developed interstitial lung disease of unknown cause. Similar clusters at the same company's Canadian plant were reported previously. Objective: To define the extent, clinicopathologic features, and potential causes of the apparent disease outbreak. Design: Case-finding survey and retrospective cohort study. Setting: Academic occupational medicine program. Patients: All workers employed at the Rhode Island plant on or after 15 June 1990. Measurements: Symptomatic employees had chest radiography, pulmonary function tests, high-resolution computed tomography, and serologic testing. Those with unexplained radiographic or pulmonary function abnormalities underwent bronchoalveolar lavage, lung biopsy, or both. The case definition of "flock worker's lung" required histologic evidence of interstitial lung disease (or lavage evidence of lung inflammation) not explained by another condition. Results: Eight cases of flock worker's lung were identified at the Rhode Isla nd plant. Th ree cases were characterized by a high proportion of eosinophils (25% to 40%) in ravage fluid. Six of the seven patients who had biopsy had histologic findings of nonspecific interstitial pneumonia, and the seventh had bronchiolitis obliterans organizing pneumonia. All seven of these patients had peribronchovascular interstitial lymphoid nodules, usually with germinal centers, and most had lymphocytic bronchiolitis and interstitial fibrosis. All improved after leaving work. Review of the Canadian tissue specimens showed many similar histologic findings. Among the 165-member study cohort, a 48-fold or greater increase was seen in the sex-adjusted incidence rate of all interstitial lung disease. Conclusions: Work in the nylon flocking industry poses substantial risk for a previously unrecognized occupational interstitial lung disease. Nylon fiber is the suspected cause of this condition.	Brown Univ, Mem Hosp Rhode Isl, Div Gen Internal Med, Pawtucket, RI 02860 USA; Brown Univ, Mem Hosp Rhode Isl, Div Pulm & Crit Care Med, Pawtucket, RI 02860 USA; Brown Univ, Mem Hosp Rhode Isl, Internal Med Residency Program, Pawtucket, RI 02860 USA; Brown Univ, Mem Hosp Rhode Isl, Dept Pathol, Pawtucket, RI 02860 USA	Brown University; Brown University; Brown University; Brown University	Kern, DG (corresponding author), Brown Univ, Mem Hosp Rhode Isl, Div Gen Internal Med, 111 Brewster St, Pawtucket, RI 02860 USA.	david_kern@brown.edu						AHLBOM A, 1993, BIOSTATISTICS EPIDEM, P122; ALLEN JN, 1990, AM REV RESPIR DIS, V142, P642, DOI 10.1164/ajrccm/142.3.642; *AM MED ASS, 1993, GUID EV PERM IMP, P162; [Anonymous], 1995, AM J RESP CRIT CARE, V152, P1107, DOI 10.1164/ajrccm.152.3.7663792; Calisti R, 1995, Med Lav, V86, P360; CARRINGTON CB, 1978, NEW ENGL J MED, V298, P801, DOI 10.1056/NEJM197804132981501; Centers for Disease Control and Prevention (CDC), 1997, MMWR Morb Mortal Wkly Rep, V46, P897; Clottens FL, 1997, OCCUP ENVIRON MED, V54, P376, DOI 10.1136/oem.54.6.376; COLBY TV, 1992, CHEST, V102, pS38, DOI 10.1378/chest.102.1_Supplement.38S; COLEMAN A, 1988, AM J SURG PATHOL, V12, P514, DOI 10.1097/00000478-198807000-00002; COSTABEL U, 1992, EUR RESPIR J, V5, P791; COULTAS DB, 1994, AM J RESP CRIT CARE, V150, P967, DOI 10.1164/ajrccm.150.4.7921471; CRAPO RO, 1982, B EUR PHYSIOPATH RES, V18, P419; CRAPO RO, 1981, AM REV RESPIR DIS, V123, P185; CRAPO RO, 1981, AM REV RESPIR DIS, V123, P659; DAVIS WB, 1984, J CLIN INVEST, V74, P269, DOI 10.1172/JCI111411; Drent M, 1996, AM J RESP CRIT CARE, V153, P736, DOI 10.1164/ajrccm.153.2.8564126; EPLER GR, 1985, NEW ENGL J MED, V312, P152, DOI 10.1056/NEJM198501173120304; *EUR CTR EC TOX CH, 1996, 69 EUR CTR EC TOX CH; FLEMING LE, 1991, J OCCUP ENVIRON MED, V33, P818, DOI 10.1097/00043764-199107000-00018; Gardner MJ, 1989, STAT CONFIDENCE, P59; GREEN FHY, 1988, PATHOLOGY OCCUPATION, P89; GRIFFITHS MH, 1995, THORAX, V50, P1141, DOI 10.1136/thx.50.11.1141; HOLLANDER A, 1994, OCCUP ENVIRON MED, V51, P73, DOI 10.1136/oem.51.2.73; JOHNSTON IDA, 1993, EUR RESPIR J, V6, P891; KADI FO, 1994, LANCET, V344, P962, DOI 10.1016/S0140-6736(94)92323-X; KATZENSTEIN ALA, 1994, AM J SURG PATHOL, V18, P136, DOI 10.1097/00000478-199402000-00003; KAWANAMI O, 1983, AM J PATHOL, V110, P275; LOCKEY JE, 1996, OCCUPATIONAL ENV RES, P330; Lohr RH, 1997, ARCH INTERN MED, V157, P1323, DOI 10.1001/archinte.157.12.1323; LOUGHEED MD, 1995, CHEST, V108, P1196, DOI 10.1378/chest.108.5.1196; MOYA C, 1994, LANCET, V344, P498, DOI 10.1016/S0140-6736(94)91896-1; MYERS JL, 1987, AM REV RESPIR DIS, V135, P880, DOI 10.1164/arrd.1987.135.4.880; NICHOLSON AG, 1995, HISTOPATHOLOGY, V26, P405; Nikulin M, 1997, FUND APPL TOXICOL, V35, P182, DOI 10.1006/faat.1996.2274; Pimentel J C, 1975, Thorax, V30, P204, DOI 10.1136/thx.30.2.204; REYES CN, 1982, CHEST, V81, P142, DOI 10.1378/chest.81.2.142; REYNOLDS HY, 1977, J CLIN INVEST, V59, P165, DOI 10.1172/JCI108615; ROHRBACH MS, 1994, AM J IND MED, V25, P97, DOI 10.1002/ajim.4700250125; RUTSTEIN DD, 1983, AM J PUBLIC HEALTH, V73, P1054, DOI 10.2105/AJPH.73.9.1054; SUTINEN S, 1983, EUR J RESPIR DIS, V64, P271; TRAVIS WD, 1992, HUM PATHOL, V23, P529, DOI 10.1016/0046-8177(92)90130-U; TRENTIN L, 1988, J ALLERGY CLIN IMMUN, V82, P577, DOI 10.1016/0091-6749(88)90967-0; WASHKO R, 1998, 960093 NIOSH US DHHS; WATTERS LC, 1987, AM REV RESPIR DIS, V135, P696; YOUSEM SA, 1985, HUM PATHOL, V16, P700, DOI 10.1016/S0046-8177(85)80155-6; YOUSEM SA, 1989, MAYO CLIN PROC, V64, P1373, DOI 10.1016/S0025-6196(12)65379-8; 1997, MMWR MORB MORTAL WKL, V46, P33	48	88	91	0	9	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 15	1998	129	4					261	+		10.7326/0003-4819-129-4-199808150-00001	http://dx.doi.org/10.7326/0003-4819-129-4-199808150-00001			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	109NP	9729178				2022-12-28	WOS:000075329100001
J	Leu, JY; Chua, PR; Roeder, GS				Leu, JY; Chua, PR; Roeder, GS			The meiosis-specific hop2 protein of S-cerevisiae ensures synapsis between homologous chromosomes	CELL			English	Article							SYNAPTONEMAL COMPLEX PROTEIN; SACCHAROMYCES-CEREVISIAE; MEIOTIC RECOMBINATION; SYNAPTIC ADJUSTMENT; ESCHERICHIA-COLI; GENE CONVERSION; RECA HOMOLOGS; YEAST; SEGREGATION; DNA	The hop2 mutant of S. cerevisiae displays a novel phenotype: meiotic chromosomes form nearly wild-type amounts of synaptonemal complex, but most chromosomes are engaged in synapsis with nonhomologous partners. The meiosis-specific Hop2 protein localizes to chromosomes prior to and during synapsis and in the absence of the double-strand breaks that initiate recombination. hop2 strains sustain a wild-type level of meiotic double-strand breaks, but these breaks remain unrepaired. The hop2 mutant arrests at the pachytene stage of meiotic prophase with the RecA-like protein Dmc1 located at numerous sites along synapsed chromosomes. We propose that the Hop2 protein functions to prevent synapsis between nonhomologous chromosomes.	Yale Univ, Howard Hughes Med Inst, New Haven, CT 06520 USA; Yale Univ, Dept Mol Cellular & Dev Biol, New Haven, CT 06520 USA; Yale Univ, Dept Genet, New Haven, CT 06520 USA	Howard Hughes Medical Institute; Yale University; Yale University; Yale University	Roeder, GS (corresponding author), Yale Univ, Howard Hughes Med Inst, New Haven, CT 06520 USA.		Leu, Jun-Yi/A-7364-2009	Leu, Jun-Yi/0000-0001-5445-2799	NIGMS NIH HHS [GM-28904] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028904] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALANI E, 1990, CELL, V61, P419, DOI 10.1016/0092-8674(90)90524-I; BISHOP DK, 1994, CELL, V79, P1081, DOI 10.1016/0092-8674(94)90038-8; BISHOP DK, 1992, CELL, V69, P439, DOI 10.1016/0092-8674(92)90446-J; BOJKO M, 1990, GENETICS, V124, P593; CAO L, 1990, CELL, V61, P1089, DOI 10.1016/0092-8674(90)90072-M; CARPENTER ATC, 1987, BIOESSAYS, V6, P232, DOI 10.1002/bies.950060510; Chua PR, 1998, CELL, V93, P349, DOI 10.1016/S0092-8674(00)81164-2; DERNBURG AF, 1995, TELOMERES, P295; DRESSER ME, 1988, J CELL BIOL, V106, P567, DOI 10.1083/jcb.106.3.567; ELLEDGE SJ, 1988, GENE, V70, P303, DOI 10.1016/0378-1119(88)90202-8; Goldman ASH, 1996, GENETICS, V144, P43; GOYON C, 1993, MOL CELL BIOL, V13, P373, DOI 10.1128/MCB.13.1.373; HOEKSTRA MF, 1991, METHOD ENZYMOL, V194, P329; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JENKINS G, 1992, J CELL SCI, V103, P415; JinksRobertson S, 1997, GENETICS, V146, P69; Kleckner N, 1996, P NATL ACAD SCI USA, V93, P8167, DOI 10.1073/pnas.93.16.8167; LOIDL J, 1991, CHROMOSOMA, V100, P221, DOI 10.1007/BF00344155; LOIDL J, 1994, J CELL BIOL, V125, P1191, DOI 10.1083/jcb.125.6.1191; Lydall D, 1996, NATURE, V383, P840, DOI 10.1038/383840a0; MENEES TM, 1992, MOL CELL BIOL, V12, P1340, DOI 10.1128/MCB.12.3.1340; MENEES TM, 1989, GENETICS, V123, P675; MITCHELL AP, 1994, MICROBIOL REV, V58, P56, DOI 10.1128/MMBR.58.1.56-70.1994; MOSES MJ, 1982, CHROMOSOMA, V84, P457, DOI 10.1007/BF00292848; Nairz K, 1997, GENE DEV, V11, P2272, DOI 10.1101/gad.11.17.2272; PARKER DR, 1969, MUTAT RES, V7, P393, DOI 10.1016/0027-5107(69)90110-9; Petes T. D., 1991, MOL CELLULAR BIOL YE, P407; Prinz S, 1997, GENETICS, V146, P781; ROCKMILL B, 1988, P NATL ACAD SCI USA, V85, P6057, DOI 10.1073/pnas.85.16.6057; ROCKMILL B, 1995, GENE DEV, V9, P2684, DOI 10.1101/gad.9.21.2684; ROCKMILL B, 1990, GENETICS, V126, P563; ROCKMILL B, 1998, IN PRESS GENES DEV; ROEDER GS, 1995, P NATL ACAD SCI USA, V92, P10450, DOI 10.1073/pnas.92.23.10450; Roeder GS, 1997, GENE DEV, V11, P2600, DOI 10.1101/gad.11.20.2600; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; SEARS ER, 1976, ANNU REV GENET, V10, P31, DOI 10.1146/annurev.ge.10.120176.000335; SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SYM M, 1993, CELL, V72, P365, DOI 10.1016/0092-8674(93)90114-6; SYM M, 1995, J CELL BIOL, V128, P455, DOI 10.1083/jcb.128.4.455; SYM M, 1994, CELL, V79, P283, DOI 10.1016/0092-8674(94)90197-X; Tettelin H, 1997, NATURE, V387, P81, DOI 10.1038/387s081; THOMPSON EA, 1989, MOL GEN GENET, V218, P293, DOI 10.1007/BF00331281; Tung KS, 1998, GENETICS, V149, P817; VOELKELMEIMAN K, 1990, GENETICS, V124, P561; VONWETTSTEIN D, 1984, ANNU REV GENET, V18, P331, DOI 10.1146/annurev.ge.18.120184.001555; WEINER BM, 1994, CELL, V77, P977, DOI 10.1016/0092-8674(94)90438-3; WEST SC, 1992, ANNU REV BIOCHEM, V61, P603, DOI 10.1146/annurev.bi.61.070192.003131	48	154	159	0	9	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 7	1998	94	3					375	386		10.1016/S0092-8674(00)81480-4	http://dx.doi.org/10.1016/S0092-8674(00)81480-4			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	109EN	9708739	hybrid			2022-12-28	WOS:000075308400013
J	Klingauf, J; Kavalali, ET; Tsien, RW				Klingauf, J; Kavalali, ET; Tsien, RW			Kinetics and regulation of fast endocytosis at hippocampal synapses	NATURE			English	Article							FROG NEUROMUSCULAR-JUNCTION; SYNAPTIC VESICLE MEMBRANE; CAPACITANCE MEASUREMENTS; TRANSMITTER RELEASE; EXOCYTOSIS; CELLS; CALCIUM; FUSION	Presynaptic nerve terminals often contain as few as a hundred vesicles(1,2) and so must recycle them soon after exocytosis to preserve synaptic transmission and presynaptic morphology(3,4) during repetitive firing. The kinetics(3,4) and mechanisms(5) of vesicular endocytosis and repriming have therefore been studied. Vesicles in hippocampal nerve terminals can become available to release their contents within similar to 40 s of the previous round of exocytosis(6,7). Studies using the styryl dye FM1-43 (ref. 3) have estimated the time constant for endocytosis as similar to 20-30 s (refs 4, 8), at least half of the total recycling time, which is much slower than endocytosis in other secretory systems(9-11). It seems paradoxical that the neurosecretory terminals that could benefit the most from rapid endocytosis do not use such a mechanism. Here we demonstrate the existence of fast endocytosis in hippocampal nerve terminals and derive its kinetics from fluorescence measurements using dyes with varying rates of membrane departitioning. The rapid mode of vesicular retrieval was much faster after exposure to staurosporine or elevated extracellular calcium. Thus hippocampal synapses take advantage of efficient mechanisms for endocytosis, and their vesicular retrieval is subject to modulatory control.	Stanford Univ, Med Ctr, Dept Mol & Cellular Physiol, Stanford, CA 94305 USA	Stanford University	Tsien, RW (corresponding author), Stanford Univ, Med Ctr, Dept Mol & Cellular Physiol, Stanford, CA 94305 USA.							Betz WJ, 1996, CURR OPIN NEUROBIOL, V6, P365, DOI 10.1016/S0959-4388(96)80121-8; BETZ WJ, 1993, J PHYSIOL-LONDON, V460, P287, DOI 10.1113/jphysiol.1993.sp019472; BURGOYNE RD, 1995, PFLUG ARCH EUR J PHY, V430, P213, DOI 10.1007/BF00374652; CECCARELLI B, 1980, J CELL BIOL, V87, P297, DOI 10.1083/jcb.87.1.297; Cremona O, 1997, CURR OPIN NEUROBIOL, V7, P323, DOI 10.1016/S0959-4388(97)80059-1; Engisch KL, 1998, J PHYSIOL-LONDON, V506, P591, DOI 10.1111/j.1469-7793.1998.591bv.x; Fesce Riccardo, 1994, Trends in Cell Biology, V4, P1, DOI 10.1016/0962-8924(94)90025-6; HARRIS KM, 1995, NEUROPHARMACOLOGY, V34, P1387, DOI 10.1016/0028-3908(95)00142-S; Henkel AW, 1996, CURR OPIN NEUROBIOL, V6, P350, DOI 10.1016/S0959-4388(96)80119-X; Henkel AW, 1995, J NEUROSCI, V15, P8246; HEUSER JE, 1973, J CELL BIOL, V57, P315, DOI 10.1083/jcb.57.2.315; Koenig JH, 1996, J CELL BIOL, V135, P797, DOI 10.1083/jcb.135.3.797; Kraszewski K, 1996, J NEUROSCI, V16, P5905; Lagnado L, 1996, NEURON, V17, P957, DOI 10.1016/S0896-6273(00)80226-3; LIU G, 1995, NATURE, V268, P1624; MALGAROLI A, 1992, NATURE, V357, P134, DOI 10.1038/357134a0; MILLER TM, 1984, J CELL BIOL, V98, P685, DOI 10.1083/jcb.98.2.685; Murthy VN, 1998, NATURE, V392, P497, DOI 10.1038/33152; PARSONS TD, 1994, NEURON, V13, P875, DOI 10.1016/0896-6273(94)90253-4; Plattner H, 1997, J MEMBRANE BIOL, V158, P197, DOI 10.1007/s002329900257; RAMASWAMI M, 1994, NEURON, V13, P363, DOI 10.1016/0896-6273(94)90353-0; Ryan TA, 1996, P NATL ACAD SCI USA, V93, P5567, DOI 10.1073/pnas.93.11.5567; RYAN TA, 1993, NEURON, V11, P713, DOI 10.1016/0896-6273(93)90081-2; Schikorski T, 1997, J NEUROSCI, V17, P5858; Smith C, 1997, J CELL BIOL, V139, P885, DOI 10.1083/jcb.139.4.885; Takei K, 1996, J CELL BIOL, V133, P1237, DOI 10.1083/jcb.133.6.1237; THOMAS P, 1994, J CELL BIOL, V124, P667, DOI 10.1083/jcb.124.5.667; VONGERSDORFF H, 1994, NATURE, V370, P652, DOI 10.1038/370652a0; Wu LG, 1996, NEURON, V17, P769, DOI 10.1016/S0896-6273(00)80208-1; ZIMMERBERG J, 1994, J CELL BIOL, V127, P1885, DOI 10.1083/jcb.127.6.1885	30	326	332	0	19	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 6	1998	394	6693					581	585		10.1038/29079	http://dx.doi.org/10.1038/29079			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	107YN	9707119				2022-12-28	WOS:000075238700049
J	Connolly, SJ				Connolly, SJ			Implantable cardioverter defibrillators - for whom?	LANCET			English	Editorial Material									McMaster Univ, Fac Hlth Sci, Hamilton, ON L8L 2X2, Canada	McMaster University	Connolly, SJ (corresponding author), McMaster Univ, Fac Hlth Sci, Hamilton, ON L8L 2X2, Canada.							Bigger JT, 1997, NEW ENGL J MED, V337, P1569, DOI 10.1056/NEJM199711273372201; BIGGER JT, 1998, PACE, V21, P818; Cairns JA, 1997, LANCET, V349, P675, DOI 10.1016/S0140-6736(96)08171-8; Connolly SJ, 1997, LANCET, V350, P1417; Gregoratos G, 1998, J AM COLL CARDIOL, V31, P1175; HINKLE LE, 1982, CIRCULATION, V65, P457, DOI 10.1161/01.CIR.65.3.457; Julian DG, 1997, LANCET, V349, P667, DOI 10.1016/S0140-6736(96)09145-3; LARSON GC, 1997, CIRCULATION S8, V96, P1; McAnulty J, 1997, NEW ENGL J MED, V337, P1576; Moss AJ, 1996, NEW ENGL J MED, V335, P1933, DOI 10.1056/NEJM199612263352601	10	3	3	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	AUG 1	1998	352	9125					338	340		10.1016/S0140-6736(05)60462-X	http://dx.doi.org/10.1016/S0140-6736(05)60462-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	106BU	9717916				2022-12-28	WOS:000075110500004
J	Findlay, CA; Macdonald, JF; Wallace, AM; Geddes, N; Donaldson, MDC				Findlay, CA; Macdonald, JF; Wallace, AM; Geddes, N; Donaldson, MDC			Lesson of the week - Childhood Cushing's syndrome induced by betamethasone nose drops, and repeat prescriptions	BRITISH MEDICAL JOURNAL			English	Review							ADRENAL SUPPRESSION		Royal Hosp Sick Children, Glasgow G3 8SJ, Lanark, Scotland	University of Glasgow	Donaldson, MDC (corresponding author), Royal Hosp Sick Children, Glasgow G3 8SJ, Lanark, Scotland.	donaldson@clinmed.gla.ac.uk						BEGG EJ, 1987, MED J AUSTRALIA, V146, P37, DOI 10.5694/j.1326-5377.1987.tb120124.x; Hardman JG, 1996, PHARM BASIS THERAPEU; HELFER EL, 1989, DRUGS, V38, P838, DOI 10.2165/00003495-198938050-00008; HEROMAN WM, 1980, J PEDIATR-US, V96, P500, DOI 10.1016/S0022-3476(80)80709-8; *NAT ASTHM CAMP, 1996, HAY FEV FACTSH; NUTTING CM, 1995, POSTGRAD MED J, V71, P231, DOI 10.1136/pgmj.71.834.231; STEVENS DJ, 1988, J LARYNGOL OTOL, V102, P219, DOI 10.1017/S0022215100104566; WILLEMS CED, 1994, EUR J PEDIATR, V153, P632, DOI 10.1007/s004310050202	8	43	43	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	SEP 12	1998	317	7160					739	740		10.1136/bmj.317.7160.739	http://dx.doi.org/10.1136/bmj.317.7160.739			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	121CT	9732346	Green Published			2022-12-28	WOS:000075995100026
J	McAllister, VL				McAllister, VL			Arnold Appleby - Obituary	BRITISH MEDICAL JOURNAL			English	Biographical-Item																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	SEP 5	1998	317	7159					685	685		10.1136/bmj.317.7159.685	http://dx.doi.org/10.1136/bmj.317.7159.685			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	118GN	9728015	Green Published			2022-12-28	WOS:000075830200065
J	Sims, JR; Hanson, EL				Sims, JR; Hanson, EL			Thromboangiitis obliterans (Buerger's disease)	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									USN Submarine, Med Res Lab, Groton, CT 06349 USA	United States Department of Defense; United States Navy	Sims, JR (corresponding author), USN Submarine, Med Res Lab, Groton, CT 06349 USA.								0	3	3	1	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 3	1998	339	10					672	672		10.1056/NEJM199809033391005	http://dx.doi.org/10.1056/NEJM199809033391005			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	115WA	9725925	Bronze			2022-12-28	WOS:000075688100005
J	Barzansky, B; Jonas, HS; Etzel, SI				Barzansky, B; Jonas, HS; Etzel, SI			Educational programs in US medical schools, 1997-1998	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								To describe the current status of medical education programs in the United States, we used data from the 1997-1998 Liaison Committee on Medical Education Annual Medical School Questionnaire, which had a 100% response rate, and from other sources. There were 96 733 full-time medical school faculty members, a 1.2% increase from 1996-1997. The 43 020 applicants for the class entering in 1997 represents an 8.4% decrease from 1996. The number of 1997 applicants who were members of underrepresented minority groups decreased 11.1% from 1996, and the number of entering underrepresented minority group students decreased 8.4%. More than half of medical schools reported that the number of inpatients available for medical student education had decreased in at least some of their clinical sites or in some disciplines during the past 2 years. Thirty-nine medical schools (31.2%) reported having more difficulty recruiting or retaining volunteer clinical faculty to participate in medical student teaching in 1997 than in 1995.	Amer Med Assoc, Div Undergrad Med Educ, Chicago, IL 60610 USA; Amer Med Assoc, Dept Res & Data Anal, Chicago, IL 60610 USA	American Medical Association; American Medical Association	Barzansky, B (corresponding author), Amer Med Assoc, Div Undergrad Med Educ, 515 N State St, Chicago, IL 60610 USA.							Barzansky B, 1997, JAMA-J AM MED ASSOC, V278, P744, DOI 10.1001/jama.278.9.744; Connor RA, 1997, HEALTH AFFAIR, V16, P62, DOI 10.1377/hlthaff.16.6.62; Fields SA, 1998, ACAD MED, V73, P95, DOI 10.1097/00001888-199801000-00019; *LIAFS COMM MED ED, 1997, FUNCT STRUCT MED SCH	4	28	28	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 2	1998	280	9					803	808		10.1001/jama.280.9.803	http://dx.doi.org/10.1001/jama.280.9.803			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	114LA	9729992				2022-12-28	WOS:000075609900009
J	Hoffman, PF; Kaufman, AJ; Halverson, GP; Schrag, DP				Hoffman, PF; Kaufman, AJ; Halverson, GP; Schrag, DP			A Neoproterozoic snowball earth	SCIENCE			English	Article							UPPER PROTEROZOIC SUCCESSIONS; LOW-LATITUDE GLACIATION; CARBON-DIOXIDE CLOUDS; ISOTOPIC COMPOSITIONS; 2 SUPERCONTINENTS; RAPITAN GROUP; EXCURSIONS; AUSTRALIA; GONDWANA; ROTATION	Negative carbon isotope anomalies in carbonate rocks bracketing Neoproterozoic glacial deposits in Namibia, combined with estimates of thermal subsidence history, suggest that biological productivity in the surface ocean collapsed for millions of years. This collapse can be explained by a global glaciation (that is, a snowball Earth), which ended abruptly when subaerial volcanic outgassing raised atmospheric carbon dioxide to about 350 times the modern Level. The rapid termination would have resulted in a warming of the snowball Earth to extreme greenhouse conditions. The transfer of atmospheric carbon dioxide to the ocean would result in the rapid precipitation of calcium carbonate in warm surface waters, producing the cap carbonate rocks observed globally.	Harvard Univ, Dept Earth & Planetary Sci, Cambridge, MA 02138 USA; Univ Maryland, Dept Geol, College Pk, MD 20742 USA	Harvard University; University System of Maryland; University of Maryland College Park	Hoffman, PF (corresponding author), Harvard Univ, Dept Earth & Planetary Sci, 20 Oxford St, Cambridge, MA 02138 USA.	hoffman@eps.harvard.edu		Halverson, Galen/0000-0003-3061-7928				Aitken J. D., 1991, GEOLOGICAL SURVEY CA, V404, P1; BOND GC, 1984, EARTH PLANET SC LETT, V70, P325, DOI 10.1016/0012-821X(84)90017-7; Brasier MD, 1998, GEOLOGY, V26, P555, DOI 10.1130/0091-7613(1998)026<0555:ABYOES>2.3.CO;2; BUICK R, 1995, CHEM GEOL, V123, P153, DOI 10.1016/0009-2541(95)00049-R; CALDEIRA K, 1992, NATURE, V359, P226, DOI 10.1038/359226a0; CALDEIRA K, 1991, GEOLOGY, V19, P204, DOI 10.1130/0091-7613(1991)019<0204:CPCPAT>2.3.CO;2; Canfield DE, 1996, NATURE, V382, P127, DOI 10.1038/382127a0; CARSON HL, 1987, ANNU REV GENET, V21, P405, DOI 10.1146/annurev.ge.21.120187.002201; CROWLEY TJ, 1993, J GEOPHYS RES-ATMOS, V98, P16723, DOI 10.1029/93JD01415; DALZIEL IWD, 1992, ANNU REV EARTH PL SC, V20, P501, DOI 10.1146/annurev.ea.20.050192.002441; DESMARAIS DJ, 1984, EARTH PLANET SC LETT, V69, P43, DOI 10.1016/0012-821X(84)90073-6; DORR JVN, 1973, ECON GEOL, V68, P1005, DOI 10.2113/gsecongeo.68.7.1005; Elderfield H, 1996, ANNU REV EARTH PL SC, V24, P191, DOI 10.1146/annurev.earth.24.1.191; Evans DA, 1997, NATURE, V386, P262, DOI 10.1038/386262a0; Fairchild I. J., 1993, SEDIMENTOLOGY REV, V1, P1; Forget F, 1997, SCIENCE, V278, P1273, DOI 10.1126/science.278.5341.1273; GREEN WJ, 1993, ANTARCTIC RES SERIES, V59; Grotzinger JP, 1995, PALAIOS, V10, P578, DOI 10.2307/3515096; HAMBREY MJ, 1981, EARTHS PREPLEISTOCEN; Harland W.B., 1964, INT J EARTH SCI, V54, P45, DOI [10.1007/BF01821169, DOI 10.1007/BF01821169]; HAY WW, 1990, J GEOL SOC LONDON, V147, P749, DOI 10.1144/gsjgs.147.5.0749; HEDGES JI, 1995, MAR CHEM, V49, P81, DOI 10.1016/0304-4203(95)00008-F; Hoffman P.P., 1996, COMMUNS GEOLOGICAL S, V11, P49; HOFFMAN PF, 1991, SCIENCE, V252, P1409, DOI 10.1126/science.252.5011.1409; Hoffman PF, 1998, GSA TODAY, V8, P1, DOI DOI 10.1130/GSAT01707GW.1; HOFMANN HJ, 1990, GEOLOGY, V18, P1199, DOI 10.1130/0091-7613(1990)018<1199:ERFIBI>2.3.CO;2; Holser W.T., 1984, PATTERNS CHANGE EART, P123, DOI DOI 10.1007/978-3-642-69317-5_8; James N.P., 1997, COOL WATER CARBONATE, V42, DOI [10.2110/pec.97.56, DOI 10.2110/PEC.97.56]; KAH LC, 1997, GEOL SOC AM ABSTR, V29, P115; KAUFMAN AJ, 1995, PRECAMBRIAN RES, V73, P27, DOI 10.1016/0301-9268(94)00070-8; KAUFMAN AJ, 1991, PRECAMBRIAN RES, V49, P301, DOI 10.1016/0301-9268(91)90039-D; Kaufman AJ, 1997, P NATL ACAD SCI USA, V94, P6600, DOI 10.1073/pnas.94.13.6600; Kennedy MJ, 1996, J SEDIMENT RES, V66, P1050, DOI 10.2110/jsr.66.1050; KENNEDY MJ, 1997, GEOL SOC AM ABSTR, V29, P196; Kirschvink J. L., 1992, PROTEROZOIC BIOSPHER, P51; Knoll A. H, 1992, ORIGIN EARLY EVOLUTI, P53; KNOLL AH, 1986, NATURE, V321, P832, DOI 10.1038/321832a0; KNOLL AH, 1994, P NATL ACAD SCI USA, V91, P6743, DOI 10.1073/pnas.91.15.6743; KNOLL AH, 1991, SCI AM, V265, P64, DOI 10.1038/scientificamerican1091-64; KNOLL AH, 1992, SCIENCE, V256, P622, DOI 10.1126/science.1585174; KUMP LR, 1991, GEOLOGY, V19, P299, DOI 10.1130/0091-7613(1991)019<0299:ICIESO>2.3.CO;2; MARSHALL HG, 1988, J GEOPHYS RES-ATMOS, V93, P791, DOI 10.1029/JD093iD01p00791; Martin H., 1965, PRECAMBRIAN GEOLOGY; MEERT JG, 1995, PRECAMBRIAN RES, V74, P225, DOI 10.1016/0301-9268(95)00012-T; Miller RM, 1997, SED BAS WOR, V3, P237; MORSE JW, 1990, CHEM GEOL, V82, P265, DOI 10.1016/0009-2541(90)90085-L; Nealson KH, 1997, J GEOPHYS RES-PLANET, V102, P23675, DOI 10.1029/97JE01996; Niklas K.J., 1997, EVOLUTIONARY BIOL PL; Park JK, 1997, CAN J EARTH SCI, V34, P34, DOI 10.1139/e17-003; PERYT TM, 1990, SEDIMENTOLOGY, V37, P279, DOI 10.1111/j.1365-3091.1990.tb00959.x; POWELL CM, 1993, GEOLOGY, V21, P889, DOI 10.1130/0091-7613(1993)021<0889:PCOTOT>2.3.CO;2; RAMPINO MR, 1994, J GEOL, V102, P439, DOI 10.1086/629685; ROBERTS JD, 1976, J GEOL, V84, P47, DOI 10.1086/628173; SCHMIDT PW, 1995, EARTH PLANET SC LETT, V134, P107, DOI 10.1016/0012-821X(95)00106-M; SOHL LE, 1997, GEOL SOC AM ABSTR, V29, P195; Sonett CP, 1996, SCIENCE, V273, P100, DOI 10.1126/science.273.5271.100; VANCAPPELLEN P, 1994, PALEOCEANOGRAPHY, V9, P677, DOI 10.1029/94PA01455; Vidal G, 1997, PALEOBIOLOGY, V23, P230, DOI 10.1017/S0094837300016808; WALTER MR, 1992, NATURE, V356, P673; Weil AB, 1998, EARTH PLANET SC LETT, V154, P13, DOI 10.1016/S0012-821X(97)00127-1; WILLIAMS GE, 1990, J PHYS EARTH, V38, P475, DOI 10.4294/jpe1952.38.475; WILLIAMS SN, 1992, GEOCHIM COSMOCHIM AC, V56, P1765, DOI 10.1016/0016-7037(92)90243-C; YOUNG GM, 1976, PRECAMBRIAN RES, V3, P137, DOI 10.1016/0301-9268(76)90030-9; YOUNG GM, 1995, GEOLOGY, V23, P153, DOI 10.1130/0091-7613(1995)023<0153:ANGDPO>2.3.CO;2; [No title captured]	65	1865	2087	26	822	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 28	1998	281	5381					1342	1346		10.1126/science.281.5381.1342	http://dx.doi.org/10.1126/science.281.5381.1342			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	115LQ	9721097				2022-12-28	WOS:000075666800047
J	Boring, L; Gosling, J; Cleary, M; Charo, IF				Boring, L; Gosling, J; Cleary, M; Charo, IF			Decreased lesion formation in CCR2(-/-) mice reveals a role for chemokines in the initiation of atherosclerosis	NATURE			English	Article							MONOCYTE CHEMOATTRACTANT PROTEIN-1; SMOOTH-MUSCLE CELLS; APOLIPOPROTEIN-E; DENSITY-LIPOPROTEIN; HYPERCHOLESTEROLEMIA; SUSCEPTIBILITY; EXPRESSION; RECEPTORS; INFECTION	Chemokines are proinflammatory cytokines that function in leukocyte chemoattraction and activation and have recently been shown to block the HIV-1 infection of target cells through interactions with chemokine receptors(1,2). In addition to their function in viral disease, chemokines have been implicated in the pathogenesis of atherosclerosis. Expression of the CC chemokine monocyte chemoattractant protein-1 (MCP-1) is upregulated in human atherosclerotic plaques(3,4), in arteries of primates on a hypercholesteralaemic diet(5) and in vascular endothelial and smooth muscle cells exposed to minimally modified lipids(5,6). ab determine whether MCP-1 is causally related to the development of atherosclerosis, we generated mice that lack CCR2, the receptor for MCP-1 (ref. 7), and crossed them with apolipoprotein (apo) E-null mice(8-10) which develop severe atherosclerosis. Here we show that the selective absence of CCR2 decreases lesion formation markedly in apoE(-/-) mice but has no effect on plasma lipid or lipoprotein concentrations. These data reveal a role for MCP-1 in the development of early atherosclerotic lesions and suggest that upregulation of this chemokine by minimally oxidized lipids is an important link between hyperlipidaemia and fatty streak formation.	Univ Calif San Francisco, Gladstone Inst Cardiovasc Dis, San Francisco, CA 94141 USA; Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94110 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94141 USA; Univ Calif San Francisco, Daiichi Res Ctr, San Francisco, CA 94141 USA	University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Charo, IF (corresponding author), Univ Calif San Francisco, Gladstone Inst Cardiovasc Dis, POB 419100, San Francisco, CA 94141 USA.							Boring L, 1997, J CLIN INVEST, V100, P2552, DOI 10.1172/JCI119798; Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; CUSHING SD, 1990, P NATL ACAD SCI USA, V87, P5134, DOI 10.1073/pnas.87.13.5134; Duverger N, 1996, SCIENCE, V273, P966, DOI 10.1126/science.273.5277.966; Gupta S, 1997, J CLIN INVEST, V99, P2752, DOI 10.1172/JCI119465; KRAAL G, 1987, SCAND J IMMUNOL, V26, P653, DOI 10.1111/j.1365-3083.1987.tb02301.x; NAKASHIMA Y, 1994, ARTERIOSCLER THROMB, V14, P133, DOI 10.1161/01.ATV.14.1.133; NELKEN NA, 1991, J CLIN INVEST, V88, P1121, DOI 10.1172/JCI115411; PLUMP AS, 1994, P NATL ACAD SCI USA, V91, P9607, DOI 10.1073/pnas.91.20.9607; PLUMP AS, 1992, CELL, V71, P343, DOI 10.1016/0092-8674(92)90362-G; PURCELLHUYNH DA, 1995, J CLIN INVEST, V95, P2246, DOI 10.1172/JCI117915; Suzuki H, 1997, NATURE, V386, P292, DOI 10.1038/386292a0; Veniant MM, 1997, J CLIN INVEST, V100, P180, DOI 10.1172/JCI119511; Yia-Herttuala S., 1991, P NATL ACAD SCI USA, V88, P5252; YU XH, 1992, P NATL ACAD SCI USA, V89, P6953, DOI 10.1073/pnas.89.15.6953; ZHANG SH, 1992, SCIENCE, V258, P468, DOI 10.1126/science.1411543	17	1577	1672	1	70	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 27	1998	394	6696					894	897		10.1038/29788	http://dx.doi.org/10.1038/29788			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	114LW	9732872				2022-12-28	WOS:000075611800049
J	Greenebaum, E				Greenebaum, E			Cytologic identification of oocytes in ovarian-cyst aspirates	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Coll Phys & Surg, New York, NY 10032 USA		Greenebaum, E (corresponding author), Coll Phys & Surg, New York, NY 10032 USA.								0	0	0	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 27	1998	339	9					604	604		10.1056/NEJM199808273390906	http://dx.doi.org/10.1056/NEJM199808273390906			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	113LR	9718380				2022-12-28	WOS:000075552900006
J	Sprang, ML; Neerhof, MG				Sprang, ML; Neerhof, MG			Rationale for banning abortions late in pregnancy	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							COMPLICATIONS; TERMINATION		Evanston NW Healthcare, Div Maternal Fetal Med, Evanston, IL 60201 USA; Northwestern Univ, Sch Med, Evanston, IL USA	NorthShore University Health System; Northwestern University	Sprang, ML (corresponding author), Evanston NW Healthcare, Div Maternal Fetal Med, 1000 Cent St,Suite 700, Evanston, IL 60201 USA.	mneerhof@nwu.edu						*A GUTTM I, 1996, FACTS BRIEF IND AB; *A GUTTM I, 1997, ISS BRIEF LIM US STA; ALLEN MC, 1993, NEW ENGL J MED, V329, P1597, DOI 10.1056/NEJM199311253292201; *AM MED ASS, 1997, 26 AMA BOARD TRUST; *AM VET MED ASS, 1993, J AM VET MED ASSOC, V202, P229; ATRASH HK, 1990, CONT OB GYN, V35, P58; CALLAHAN D, 1992, CLIN OBSTET GYNECOL, V35, P783, DOI 10.1097/00003081-199212000-00010; CASTADOT RG, 1986, FERTIL STERIL, V45, P5; *CTR REPR LAW POL, 1998, STAT BANS PART BIRTH; CUNNINGHAM FG, 1997, WILLIAMS OBSTET, P507; FILSHIE M, 1989, CONTRACEPTION SCI PR, P250; GIANELLI DM, 1996, AM MED NEWS     0819, P3; GIANELLI DM, 1997, AM MED NEWS     0303, P4; GIANELLI DM, 1996, AM MED NEWS     0415, P10; GIANELLI DM, 1997, AM MED NEWS     0303, P54; GIANELLI DM, 1997, AM MED NEWS     0303, P55; GIANELLI DM, 1996, AM MED NEWS     0415, P9; GIANELLI DM, 1997, AM MED NEWS     0303, P3; GIANELLI DM, 1995, AM MED NEWS     1225, P3; GIANELLI DM, 1995, AM MED NEWS     1120, P70; GIANELLI DM, 1997, AM MED NEWS     0303, P56; GIANNAKOULOPOULOS X, 1994, LANCET, V344, P77, DOI 10.1016/S0140-6736(94)91279-3; HAWKINS DF, 1979, HUMAN FERTILITY CONT, P237; HENTOFF N, 1996, WASHINGTON POST 0830, pA31; HOGUE CJR, 1982, EPIDEMIOL REV, V4, P66; JOUZAITIS C, 1997, CHICAGO TRIBUNE 0227, P3; Koonin Lisa M., 1996, Morbidity and Mortality Weekly Report, V45, P1; LaFerla G, 1986, Pancreas, V1, P160, DOI 10.1097/00006676-198603000-00009; LAWSON HW, 1994, AM J OBSTET GYNECOL, V171, P1365, DOI 10.1016/0002-9378(94)90162-7; LURIE S, 1993, CONTRACEPTION, V47, P475, DOI 10.1016/0010-7824(93)90099-S; LURIE S, 1991, J REPROD MED, V36, P786; PADAWER R, 1997, US TODAY        1117, pA17; SEELYE KQ, 1997, NY TIMES        0321, pA1; SEELYE KQ, 1997, NY TIMES        0321, pA14; STUBBLEFIELD PJ, 1996, OBSTET NORMAL PROBLE, P1243; SYKES P, 1993, NEW ZEAL MED J, V106, P83; Teixeira J, 1996, LANCET, V347, P624, DOI 10.1016/S0140-6736(96)91327-6; TIETZE C, 1983, INDUCED ABORTION WOR, P83; TOPPOZADA M, 1990, BAILLIERE CLIN OB GY, V4, P347; 1997, CHICAGO TRIBUNE 0303, P14	40	16	14	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 26	1998	280	8					744	747		10.1001/jama.280.8.744	http://dx.doi.org/10.1001/jama.280.8.744			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	111PM	9728651				2022-12-28	WOS:000075446900041
J	Xu, Y; Shen, ZZ; Wiper, DW; Wu, MZ; Morton, RE; Elson, P; Kennedy, AW; Belinson, J; Markman, M; Casey, G				Xu, Y; Shen, ZZ; Wiper, DW; Wu, MZ; Morton, RE; Elson, P; Kennedy, AW; Belinson, J; Markman, M; Casey, G			Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancers	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							XENOPUS OOCYTES; TUMOR-MARKERS; ASCITIC FLUID; SERUM-ALBUMIN; CELLS; IDENTIFICATION; PLATELETS; MESSENGER; CURRENTS; GROWTH	Context.-Lysophosphatidic acid (LPA) has been shown to stimulate proliferation of ovarian cancer cells and is present in the ascitic fluid of patients with ovarian cancer. Objectives.-To determine whether elevated levels of LPA are present in plasma from patients with ovarian cancer and other gynecologic malignancies compared with healthy controls and to evaluate whether an elevated LPA plasma level may be a biomarker for these diseases. Design.-A research assay was used to measure total LPA levels in plasma from healthy women and women with different diseases. All LPA assays and comparison of LPA levels and CA125 tan ovarian cancer biomarker) levels were performed by observers blinded to patient status or group. Setting.-The Cleveland Clinic Foundation. Participants.-A convenience sample of 48 healthy control women, 48 women with ovarian cancer, 36 women with other gynecologic cancers, 17 women with benign gynecologic diseases, 11 women with breast cancer, and 5 women with leukemias. Main Outcome Measures.-Total LPA levels in plasma Samples from patients and controls. Results.-Patients in the ovarian cancer group had significantly higher plasma LPA levels (mean, 8.6 mu mol/L; range, 1.0-43.1 mu mol/L) compared with the healthy control group (mean, 0.6 mu mol/L; range, <0.1-6.3 mu mol/L) (P<.001). Elevated plasma LPA levels were detected in 9 of 10 patients with stage I ovarian cancer, 24 of 24 patients with stage 11, III, and IV ovarian cancer, and 14 of 14 patients with recurrent ovarian cancer. Of 36 patients with other gynecologic cancers, 33 also showed higher LPA levels (mean, 14.9 mu mol/L; range, <0.1-63.2 mu mol/L), compared with healthy controls (P<.001). Elevated plasma LPA levels were detected in 5 of 48 controls and 4 of 17 patients with benign gynecologic diseases and in no women with breast cancer or leukemia. In comparison, among a subset of patients with ovarian cancer, 28 of 47 had elevated CA125 levels, including 2 of 9 patients with stage I disease. Conclusions.-Plasma LPA levels may represent a potential biomarker for ovarian cancer and other gynecologic cancers. However, these findings are preliminary and require confirmation in larger studies.	Cleveland Clin Fdn, Dept Gynecol & Obstet, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Cell Biol, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Biostat, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Ctr Canc, Cleveland, OH 44195 USA; Cleveland State Univ, Dept Chem, Cleveland, OH 44115 USA; Cleveland Clin Fdn, Dept Canc Biol, Cleveland, OH 44195 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation; Cleveland Clinic Foundation; Cleveland Clinic Foundation; University System of Ohio; Cleveland State University; Cleveland Clinic Foundation	Xu, Y (corresponding author), Cleveland Clin Fdn, Dept Canc Biol, NN10,9500 Euclid Ave, Cleveland, OH 44195 USA.							American Cancer Society, 1998, CANC FACTS FIG 1998; BAST RC, 1983, NEW ENGL J MED, V309, P883, DOI 10.1056/NEJM198310133091503; BEREK JS, 1995, CANCER-AM CANCER SOC, V76, P2092, DOI 10.1002/1097-0142(19951115)76:10+<2092::AID-CNCR2820761331>3.0.CO;2-T; Boente M P, 1996, Curr Probl Cancer, V20, P83; DURIEUX ME, 1993, TRENDS PHARMACOL SCI, V14, P249, DOI 10.1016/0165-6147(93)90021-B; EICHHOLTZ T, 1993, BIOCHEM J, V291, P677, DOI 10.1042/bj2910677; FARGHALY SA, 1992, GYNECOL OBSTET INVES, V34, P65, DOI 10.1159/000292728; Fleiss J. L., 1981, STAT METHODS RATES P, V2; GERRARD JM, 1989, BIOCHIM BIOPHYS ACTA, V1001, P282, DOI 10.1016/0005-2760(89)90112-4; Lehman EL, 1975, NONPARAMETRICS STAT; MILLS GB, 1990, J CLIN INVEST, V86, P851, DOI 10.1172/JCI114784; MILLS GB, 1988, CANCER RES, V48, P1066; MOOLENAAR WH, 1995, J BIOL CHEM, V270, P12949, DOI 10.1074/jbc.270.22.12949; Moolenaar Wouter H., 1994, Trends in Cell Biology, V4, P213, DOI 10.1016/0962-8924(94)90144-9; RUSTIN GJS, 1993, ANN ONCOL, V4, P71; SHEN Z, IN PRESS GYNECOL ONC; TAYLOR KJW, 1994, RADIOLOGY, V192, P1; TIGYI G, 1992, J BIOL CHEM, V267, P21360; TIGYI G, 1991, J BIOL CHEM, V266, P20602; TOKUMURA A, 1994, AM J PHYSIOL, V267, pC204, DOI 10.1152/ajpcell.1994.267.1.C204; WATSON SP, 1985, BIOCHEM J, V232, P61, DOI 10.1042/bj2320061; WHO, 1979, WHO HDB REP RES CANC; WOOLAS RP, 1993, JNCI-J NATL CANCER I, V85, P1748, DOI 10.1093/jnci/85.21.1748; XU Y, 1995, BIOCHEM J, V309, P933, DOI 10.1042/bj3090933; Xu Y, 1995, CLIN CANCER RES, V1, P1223; XU Y, 1996, OVARIAN CANC, V3, P121; ZWEIG MH, 1993, CLIN CHEM, V39, P561	27	516	571	0	27	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 26	1998	280	8					719	723		10.1001/jama.280.8.719	http://dx.doi.org/10.1001/jama.280.8.719			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	111PM	9728644	Bronze			2022-12-28	WOS:000075446900034
J	Wiesendanger, M; Scharff, MD; Edelmann, W				Wiesendanger, M; Scharff, MD; Edelmann, W			Somatic hypermutation, transcription, and DNA mismatch repair	CELL			English	Review							XERODERMA-PIGMENTOSUM; IMMUNOGLOBULIN GENES		Yeshiva Univ Albert Einstein Coll Med, Dept Cell Biol, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine	Scharff, MD (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Cell Biol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.							Bertocci B, 1998, IMMUNITY, V9, P257, DOI 10.1016/S1074-7613(00)80608-1; Cascalho M, 1998, SCIENCE, V279, P1207, DOI 10.1126/science.279.5354.1207; Dorner T, 1998, IMMUNOL REV, V162, P161, DOI 10.1111/j.1600-065X.1998.tb01439.x; Frey S, 1998, IMMUNITY, V9, P127, DOI 10.1016/S1074-7613(00)80594-4; Fukita Y, 1998, IMMUNITY, V9, P105, DOI 10.1016/S1074-7613(00)80592-0; Green NS, 1998, IMMUNOL REV, V162, P77, DOI 10.1111/j.1600-065X.1998.tb01431.x; Jacobs H, 1998, J EXP MED, V187, P1735, DOI 10.1084/jem.187.11.1735; Kelsoe G, 1996, Semin Immunol, V8, P179, DOI 10.1006/smim.1996.0022; Kim N, 1997, J EXP MED, V186, P413, DOI 10.1084/jem.186.3.413; Kolodner R, 1996, GENE DEV, V10, P1433, DOI 10.1101/gad.10.12.1433; Kuo P, 1997, MOL IMMUNOL, V34, P1011, DOI 10.1016/S0161-5890(97)00117-X; MacLennan ICM, 1997, IMMUNOL REV, V156, P53, DOI 10.1111/j.1600-065X.1997.tb00958.x; Mellon I, 1996, SCIENCE, V272, P557, DOI 10.1126/science.272.5261.557; Milstein C, 1998, P NATL ACAD SCI USA, V95, P8791, DOI 10.1073/pnas.95.15.8791; MODRICH P, 1991, ANNU REV GENET, V25, P229, DOI 10.1146/annurev.ge.25.120191.001305; Neuberger MS, 1998, IMMUNOL REV, V162, P107, DOI 10.1111/j.1600-065X.1998.tb01434.x; Peters A, 1996, IMMUNITY, V4, P57, DOI 10.1016/S1074-7613(00)80298-8; Phung QH, 1998, J EXP MED, V187, P1745, DOI 10.1084/jem.187.11.1745; Rada C, 1998, IMMUNITY, V9, P135, DOI 10.1016/S1074-7613(00)80595-6; Shen HM, 1998, SCIENCE, V280, P1750, DOI 10.1126/science.280.5370.1750; SHEN HM, 1997, MOL IMMUNOL, V34, P524; Sleckman BP, 1996, ANNU REV IMMUNOL, V14, P459, DOI 10.1146/annurev.immunol.14.1.459; Storb U, 1998, IMMUNOL REV, V162, P153; Tumas-Brundage K, 1996, Semin Immunol, V8, P141, DOI 10.1006/smim.1996.0018; Umar A, 1996, CELL, V87, P65, DOI 10.1016/S0092-8674(00)81323-9; Wade PA, 1997, TRENDS BIOCHEM SCI, V22, P128, DOI 10.1016/S0968-0004(97)01016-5; Wagner SD, 1996, INT IMMUNOL, V8, P701, DOI 10.1093/intimm/8.5.701; Weill JC, 1996, IMMUNOL TODAY, V17, P92, DOI 10.1016/0167-5699(96)80586-X	28	42	49	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	AUG 21	1998	94	4					415	418		10.1016/S0092-8674(00)81581-0	http://dx.doi.org/10.1016/S0092-8674(00)81581-0			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	113GB	9727483	Bronze			2022-12-28	WOS:000075541100002
J	Friedrichson, T; Kurzchalia, TV				Friedrichson, T; Kurzchalia, TV			Microdomains of GPI-anchored proteins in living cells revealed by crosslinking	NATURE			English	Article							EPITHELIAL-CELLS; DETERGENT INSOLUBILITY; MDCK CELLS; ALKALINE-PHOSPHATASE; CHOLESTEROL CONTENT; TYROSINE KINASE; CROSS-LINKING; MA104 CELLS; SURFACE; TRANSPORT	There is some discussion as to whether glycosyl-phosphatidylinositol(GPI)-anchored proteins occur in microdomains in the cell membrane(.1,2) These putative microdomains have been implicated in processes such as sorting in polarized cells(3-5) and signal transduction(6-8), Complexes enriched in GPI-anchored proteins, cholesterol and glycosphingolipids have been isolated from cell membranes by using non-ionic detergents: these complexes were thought to represent a clustered arrangement of GPI-anchored proteins(9,10). However, results obtained when clustering of GPI-anchored proteins induced by antibodies or by detergents was prevented support the idea of a dispersed surface distribution of GPI-anchored proteins at steady state(11-13). Here we use chemical crosslinking to show that membrane microdomains of a GPI-anchored protein exist at the surface in living cells. This clustering is specific for the GPI-anchored form, as two transmembrane forms bearing the same ectodomain do not form oligomers. Depletion of membrane cholesterol causes the clustering of GPI-anchored proteins to break up, whereas treatment of cells with detergent substantially increases the size of the complexes. We find that in living cells these GPI-anchored proteins reside in microdomains consisting of at least 15 molecules, which are much smaller than those seen after detergent extraction.	Max Delbruck Ctr Mol Med, Dept Cell Biol, D-13125 Berlin, Germany	Helmholtz Association; Max Delbruck Center for Molecular Medicine	Kurzchalia, TV (corresponding author), Max Delbruck Ctr Mol Med, Dept Cell Biol, Robert Rossle Str 10, D-13125 Berlin, Germany.							BROWN D, 1993, CURR OPIN IMMUNOL, V5, P349, DOI 10.1016/0952-7915(93)90052-T; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; CERNEUS DP, 1993, J BIOL CHEM, V268, P3150; CHANG WJ, 1992, J CELL BIOL, V118, P63, DOI 10.1083/jcb.118.1.63; FIEDLER K, 1994, EMBO J, V13, P1729, DOI 10.1002/j.1460-2075.1994.tb06437.x; FIEDLER K, 1993, BIOCHEMISTRY-US, V32, P6365, DOI 10.1021/bi00076a009; Fujimoto T, 1996, J HISTOCHEM CYTOCHEM, V44, P929, DOI 10.1177/44.8.8756764; HANADA K, 1995, J BIOL CHEM, V270, P6254, DOI 10.1074/jbc.270.11.6254; HANNAN LA, 1993, J CELL BIOL, V120, P353, DOI 10.1083/jcb.120.2.353; Harder T, 1997, CURR OPIN CELL BIOL, V9, P534, DOI 10.1016/S0955-0674(97)80030-0; Huang CF, 1997, MOL BIOL CELL, V8, P2365, DOI 10.1091/mbc.8.12.2365; KLEIN U, 1995, BIOCHEMISTRY-US, V34, P13784, DOI 10.1021/bi00042a009; KURZCHALIA T, 1995, TRENDS CELL BIOL, V5, P187, DOI 10.1016/S0962-8924(00)88990-4; KURZCHALIA TV, 1992, J CELL BIOL, V118, P1003, DOI 10.1083/jcb.118.5.1003; LISANTI MP, 1989, J CELL BIOL, V109, P2145, DOI 10.1083/jcb.109.5.2145; LISANTI MP, 1989, J CELL BIOL, V109, P2117, DOI 10.1083/jcb.109.5.2117; MATTER K, 1992, CELL, V71, P741, DOI 10.1016/0092-8674(92)90551-M; MAYOR S, 1994, SCIENCE, V264, P1948, DOI 10.1126/science.7516582; MAYOR S, 1995, MOL BIOL CELL, V6, P929, DOI 10.1091/mbc.6.7.929; RODGERS W, 1994, MOL CELL BIOL, V14, P5384, DOI 10.1128/MCB.14.8.5384; ROTHBERG KG, 1990, J CELL BIOL, V111, P2931, DOI 10.1083/jcb.111.6.2931; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; SCHEIFFELE P, 1995, NATURE, V378, P96, DOI 10.1038/378096a0; SCHNITZER JE, 1995, SCIENCE, V269, P1435, DOI 10.1126/science.7660128; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Smart EJ, 1996, J CELL BIOL, V134, P1169, DOI 10.1083/jcb.134.5.1169; STEFANOVA I, 1991, SCIENCE, V254, P1016, DOI 10.1126/science.1719635; Stulnig TM, 1997, J BIOL CHEM, V272, P19242, DOI 10.1074/jbc.272.31.19242; Varma R, 1998, NATURE, V394, P798, DOI 10.1038/29563; Weimbs T, 1997, TRENDS CELL BIOL, V7, P393, DOI 10.1016/S0962-8924(97)01130-6; Wu M, 1997, J MEMBRANE BIOL, V159, P137, DOI 10.1007/s002329900277	31	470	475	2	13	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 20	1998	394	6695					802	805		10.1038/29570	http://dx.doi.org/10.1038/29570			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	112PR	9723622	Green Accepted			2022-12-28	WOS:000075503600051
J	Lowy, FD				Lowy, FD			Medical progress - Staphylococcus aureus infections	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							PROSTHETIC VALVE ENDOCARDITIS; HUMAN-IMMUNODEFICIENCY-VIRUS; TUMOR-NECROSIS-FACTOR; SMALL-COLONY VARIANTS; INJECTION-DRUG USERS; TOXIC SHOCK SYNDROME; ENDOTHELIAL-CELLS; HUMAN MONOCYTES; CLINICAL MANIFESTATIONS; METHICILLIN RESISTANCE	Micrococcus, which, when limited in its extent and activity, causes acute suppurative inflammation (phlegmon), produces, when more extensive and intense in its action on the human system, the most virulent forms of septicemia and pyaemia.(1)	Montefiore Med Ctr, Dept Med, Div Infect Dis, Bronx, NY 10467 USA; Albert Einstein Coll Med, Dept Med, Bronx, NY 10467 USA; Albert Einstein Coll Med, Dept Microbiol, Bronx, NY 10467 USA; Albert Einstein Coll Med, Dept Immunol, Bronx, NY 10467 USA	Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Lowy, FD (corresponding author), Montefiore Med Ctr, Dept Med, Div Infect Dis, 111 E 210th St, Bronx, NY 10467 USA.				NATIONAL INSTITUTE ON DRUG ABUSE [R01DA011868, R01DA009656] Funding Source: NIH RePORTER; NIDA NIH HHS [DA09656, DA11868] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		Alston WK, 1997, J CELL PHYSIOL, V173, P102, DOI 10.1002/(SICI)1097-4652(199710)173:1<102::AID-JCP12>3.3.CO;2-5; [Anonymous], 1997, MMWR-MORBID MORTAL W, V46, P813; Archer Gordon L., 1994, Trends in Microbiology, V2, P343, DOI 10.1016/0966-842X(94)90608-4; Balaban N, 1998, SCIENCE, V280, P438, DOI 10.1126/science.280.5362.438; BANERJEE SN, 1991, AM J MED S3B, V91; Beekhuizen H, 1997, J IMMUNOL, V158, P774; BHAKDI S, 1991, MICROBIOL REV, V55, P733, DOI 10.1128/MMBR.55.4.733-751.1991; BOHACH GA, 1990, CRIT REV MICROBIOL, V17, P251, DOI 10.3109/10408419009105728; BONE RC, 1994, ARCH INTERN MED, V154, P26, DOI 10.1001/archinte.154.1.26; BRUMFITT W, 1989, NEW ENGL J MED, V320, P1188, DOI 10.1056/NEJM198905043201806; CASEWELL MW, 1986, J ANTIMICROB CHEMOTH, V18, P1; CASEY LC, 1993, ANN INTERN MED, V119, P771, DOI 10.7326/0003-4819-119-8-199310150-00001; CHAMBERS HF, 1983, MEDICINE, V62, P170, DOI 10.1097/00005792-198305000-00004; CHAMBERS HF, 1993, INFECT DIS CLIN N AM, V7, P69; Chambers HF, 1997, CLIN MICROBIOL REV, V10, P781, DOI 10.1128/CMR.10.4.781; CHESNEY PJ, 1981, JAMA-J AM MED ASSOC, V246, P741, DOI 10.1001/jama.246.7.741; CHEUNG AL, 1992, P NATL ACAD SCI USA, V89, P6462, DOI 10.1073/pnas.89.14.6462; CHEUNG AL, 1990, J INFECT DIS, V161, P1177, DOI 10.1093/infdis/161.6.1177; CHEUNG AL, 1994, J CLIN INVEST, V94, P1815, DOI 10.1172/JCI117530; CRIBIER B, 1992, DERMATOLOGY, V185, P175, DOI 10.1159/000247443; CROSSLEY KB, 1997, STAPHYLOCOCCI HUMAN; DEKIMPE SJ, 1995, P NATL ACAD SCI USA, V92, P10359, DOI 10.1073/pnas.92.22.10359; DOMINGUEZ MA, 1994, J CLIN MICROBIOL, V32, P2081, DOI 10.1128/JCM.32.9.2081-2087.1994; DRAKE TA, 1988, J INFECT DIS, V157, P749, DOI 10.1093/infdis/157.4.749; DUGDALE DC, 1990, AM J MED, V89, P137, DOI 10.1016/0002-9343(90)90290-T; DWORKIN RJ, 1989, LANCET, V2, P1071; Edmond MB, 1996, ANN INTERN MED, V124, P329, DOI 10.7326/0003-4819-124-3-199602010-00008; ELEK SD, 1957, BRIT J EXP PATHOL, V38, P573; EMORI TG, 1993, CLIN MICROBIOL REV, V6, P428, DOI 10.1128/CMR.6.4.428-442.1993; ESPERSEN F, 1986, ARCH INTERN MED, V146, P1118, DOI 10.1001/archinte.146.6.1118; FANG GD, 1993, ANN INTERN MED, V119, P560, DOI 10.7326/0003-4819-119-7_Part_1-199310010-00003; Fattom AI, 1996, INFECT IMMUN, V64, P1659, DOI 10.1128/IAI.64.5.1659-1665.1996; FERNANDEZGUERRERO ML, 1995, CLIN INFECT DIS, V20, P16, DOI 10.1093/clinids/20.1.16; FOSTER TJ, 1994, FEMS MICROBIOL LETT, V118, P199, DOI 10.1016/0378-1097(94)90504-5; FOSTER TJ, 1997, MOL ASPECTS HOST PAT, P67; Fowler VG, 1997, J AM COLL CARDIOL, V30, P1072, DOI 10.1016/S0735-1097(97)00250-7; Freedman J D, 1991, Adv Intern Med, V36, P363; HAMILL RJ, 1986, INFECT IMMUN, V54, P833, DOI 10.1128/IAI.54.3.833-836.1986; HARRIS TO, 1993, INFECT IMMUN, V61, P3175, DOI 10.1128/IAI.61.8.3175-3183.1993; Heldman AW, 1996, AM J MED, V101, P68, DOI 10.1016/S0002-9343(96)00070-8; HEUMANN D, 1994, INFECT IMMUN, V62, P2715, DOI 10.1128/IAI.62.7.2715-2721.1994; Hiramatsu K, 1997, J ANTIMICROB CHEMOTH, V40, P135, DOI 10.1093/jac/40.1.135; Ing M, 1997, STAPHYLOCOCCI HUMAN, P331; JERNIGAN JA, 1993, ANN INTERN MED, V119, P304, DOI 10.7326/0003-4819-119-4-199308150-00010; Ji GY, 1995, P NATL ACAD SCI USA, V92, P12055, DOI 10.1073/pnas.92.26.12055; KARAKAWA WW, 1988, INFECT IMMUN, V56, P1090, DOI 10.1128/IAI.56.5.1090-1095.1988; KARCHMER AW, 1991, ANN INTERN MED, V115, P739, DOI 10.7326/0003-4819-115-9-739; KESSLER CM, 1991, J INFECT DIS, V164, P101, DOI 10.1093/infdis/164.1.101; KLUYTMANS JAJW, 1995, J INFECT DIS, V171, P216, DOI 10.1093/infdis/171.1.216; KORZENIOWSKI O, 1982, ANN INTERN MED, V97, P496, DOI 10.7326/0003-4819-97-4-496; KREISWIRTH B, 1993, SCIENCE, V259, P227, DOI 10.1126/science.8093647; Lee JC, 1997, INFECT IMMUN, V65, P4146, DOI 10.1128/IAI.65.10.4146-4151.1997; Lee JC, 1996, TRENDS MICROBIOL, V4, P162, DOI 10.1016/0966-842X(96)10021-4; LEVINE DP, 1991, ANN INTERN MED, V115, P674, DOI 10.7326/0003-4819-115-9-674; LIBMAN H, 1984, ARCH INTERN MED, V144, P541, DOI 10.1001/archinte.144.3.541; LOWY FD, 1988, J ULTRA MOL STRUCT R, V98, P137, DOI 10.1016/S0889-1605(88)80906-6; MARANTZ PR, 1987, ANN INTERN MED, V106, P823, DOI 10.7326/0003-4819-106-6-823; MARRACK P, 1990, SCIENCE, V248, P1066; Michel M, 1997, LANCET, V349, P1901, DOI 10.1016/S0140-6736(96)11192-2; MILLER MH, 1978, ANTIMICROB AGENTS CH, V14, P336, DOI 10.1128/AAC.14.3.336; MORENO F, 1995, CLIN INFECT DIS, V21, P1308, DOI 10.1093/clinids/21.5.1308; MOY JA, 1990, J AM ACAD DERMATOL, V22, P893, DOI 10.1016/0190-9622(90)70120-7; MUSHER DM, 1994, MEDICINE, V73, P186, DOI 10.1097/00005792-199407000-00002; MUSSER JM, 1992, J CLIN MICROBIOL, V30, P2058, DOI 10.1128/JCM.30.8.2058-2063.1992; MYLOTTE JM, 1987, REV INFECT DIS, V9, P891; NOBLE WC, 1967, J HYG-CAMB, V65, P567, DOI 10.1017/S002217240004609X; NOBLE WC, 1992, FEMS MICROBIOL LETT, V93, P195; Novick R.P., 1990, MOL BIOL STAPHYLOCOC, P1; OGAWA SK, 1985, INFECT IMMUN, V50, P218, DOI 10.1128/IAI.50.1.218-224.1985; Ogston A, 1882, J Anat Physiol, V17, P24; PANLILIO AL, 1992, INFECT CONT HOSP EP, V13, P582; PATTI JM, 1994, ANNU REV MICROBIOL, V48, P585, DOI 10.1146/annurev.mi.48.100194.003101; PATTI JM, 1994, INFECT IMMUN, V62, P152, DOI 10.1128/IAI.62.1.152-161.1994; PENG HL, 1988, J BACTERIOL, V170, P4365, DOI 10.1128/jb.170.9.4365-4372.1988; PETERSON PK, 1978, J CLIN INVEST, V61, P597, DOI 10.1172/JCI108971; PROCTOR RA, 1995, CLIN INFECT DIS, V20, P95, DOI 10.1093/clinids/20.1.95; Pulvirenti JJ, 1996, CLIN INFECT DIS, V22, P40, DOI 10.1093/clinids/22.1.40; RAAD II, 1992, CLIN INFECT DIS, V14, P75, DOI 10.1093/clinids/14.1.75; RAHAL JJ, 1986, AM J MED, V81, P43, DOI 10.1016/0002-9343(86)90180-4; REAGAN DR, 1991, ANN INTERN MED, V114, P101, DOI 10.7326/0003-4819-114-2-101; Ribera E, 1996, ANN INTERN MED, V125, P969, DOI 10.7326/0003-4819-125-12-199612150-00005; SANABRIA TJ, 1990, ARCH INTERN MED, V150, P1305, DOI 10.1001/archinte.150.6.1305; SANCHES IS, 1995, J CLIN MICROBIOL, V33, P1243, DOI 10.1128/JCM.33.5.1243-1246.1995; Sandre RM, 1996, CLIN INFECT DIS, V22, P276, DOI 10.1093/clinids/22.2.276; SANFORD BA, 1989, P SOC EXP BIOL MED, V191, P163; SANFORD MD, 1994, CLIN INFECT DIS, V19, P1123, DOI 10.1093/clinids/19.6.1123; SCHABERG DR, 1986, ANTIMICROB AGENTS CH, V30, P817, DOI 10.1128/AAC.30.6.817; SCHWALBE RS, 1987, NEW ENGL J MED, V316, P927, DOI 10.1056/NEJM198704093161507; SHEAGREN JN, 1984, NEW ENGL J MED, V310, P1368, DOI 10.1056/NEJM198405243102107; Sherertz RJ, 1996, ANN INTERN MED, V124, P539, DOI 10.7326/0003-4819-124-6-199603150-00001; Shuter J, 1996, INFECT IMMUN, V64, P310, DOI 10.1128/IAI.64.1.310-318.1996; Sieradzki K, 1997, J BACTERIOL, V179, P2557, DOI 10.1128/jb.179.8.2557-2566.1997; Speller DCE, 1997, LANCET, V350, P323, DOI 10.1016/S0140-6736(97)12148-1; SPIKA JS, 1982, J INFECT DIS, V146, P227, DOI 10.1093/infdis/146.2.227; Steinberg JP, 1996, CLIN INFECT DIS, V23, P255, DOI 10.1093/clinids/23.2.255; TAKEI S, 1993, J CLIN INVEST, V91, P602, DOI 10.1172/JCI116240; Tenover FC, 1998, J CLIN MICROBIOL, V36, P1020, DOI 10.1128/JCM.36.4.1020-1027.1998; TIMMERMAN CP, 1993, INFECT IMMUN, V61, P4167, DOI 10.1128/IAI.61.10.4167-4172.1993; TOMPKINS DC, 1990, J CLIN INVEST, V85, P1248, DOI 10.1172/JCI114560; TRUCKSIS M, 1991, ANN INTERN MED, V114, P424, DOI 10.7326/0003-4819-114-5-424; TSAO MMP, 1984, REV INFECT DIS, V6, P783; TUAZON CU, 1975, JAMA-J AM MED ASSOC, V231, P1272, DOI 10.1001/jama.231.12.1272; TUAZON CU, 1974, J INFECT DIS, V129, P725, DOI 10.1093/infdis/129.6.725; VAUDAUX P, 1993, J INFECT DIS, V167, P633, DOI 10.1093/infdis/167.3.633; VERCELLOTTI GM, 1984, J LAB CLIN MED, V103, P34; Verdrengh M, 1997, INFECT IMMUN, V65, P2517, DOI 10.1128/IAI.65.7.2517-2521.1997; Verdrengh M, 1996, INFECT IMMUN, V64, P2804, DOI 10.1128/IAI.64.7.2804-2807.1996; Vesga O, 1996, J INFECT DIS, V173, P739, DOI 10.1093/infdis/173.3.739; WALDVOGEL FA, 1995, MANDELL DOUGLAS BENN, V2, P1754; WALEV I, 1995, EMBO J, V14, P1607, DOI 10.1002/j.1460-2075.1995.tb07149.x; WEINKE T, 1992, EUR J CLIN MICROBIOL, V11, P985, DOI 10.1007/BF01967787; WEINSTEIN HJ, 1959, NEW ENGL J MED, V260, P1303, DOI 10.1056/NEJM195906252602601; WENZEL RP, 1995, J HOSP INFECT, V31, P13, DOI 10.1016/0195-6701(95)90079-9; WERGELAND HI, 1989, J CLIN MICROBIOL, V27, P1286, DOI 10.1128/JCM.27.6.1286-1291.1989; Wilkinson BJ, 1997, STAPHYLOCOCCI HUMAN, P1; WILSON WR, 1995, JAMA-J AM MED ASSOC, V274, P1706, DOI 10.1001/jama.274.21.1706; WU T, 1994, ANTIMICROB AGENTS CH, V38, P729, DOI 10.1128/AAC.38.4.729; Yao L, 1997, INFECT IMMUN, V65, P3889, DOI 10.1128/IAI.65.9.3889-3895.1997; YAO L, 1995, INFECT IMMUN, V63, P1835, DOI 10.1128/IAI.63.5.1835-1839.1995; YU VL, 1986, NEW ENGL J MED, V315, P91, DOI 10.1056/NEJM198607103150204; YU VL, 1994, ANN THORAC SURG, V58, P1073, DOI 10.1016/0003-4975(94)90458-8; Yzerman EPF, 1996, J INFECT DIS, V173, P914, DOI 10.1093/infdis/173.4.914; ZIMMERLI W, 1984, J CLIN INVEST, V73, P1191, DOI 10.1172/JCI111305; 1984, J INFECT DIS, V6, P122; 1997, MMWR MORB MORTAL WKL, V46, P851; 1997, MMWR MORB MORTAL WKL, V46, P626	126	4195	4435	20	570	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 20	1998	339	8					520	532		10.1056/NEJM199808203390806	http://dx.doi.org/10.1056/NEJM199808203390806			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	111PN	9709046				2022-12-28	WOS:000075447000006
J	Britt, R; Valman, B				Britt, R; Valman, B			Harry Variot Langwill Finlay - Obituary	BRITISH MEDICAL JOURNAL			English	Biographical-Item																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 15	1998	317	7156					479	479						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	112JF	9703551				2022-12-28	WOS:000075490200059
J	Selwyn, PA				Selwyn, PA			Prospects for improvement in physicians' communication skills and in prevention of HIV infection	LANCET			English	Editorial Material									Yale Univ, Sch Med, AIDS Program, New Haven, CT 06510 USA	Yale University	Selwyn, PA (corresponding author), Yale Univ, Sch Med, AIDS Program, 333 Cedar St, New Haven, CT 06510 USA.							[Anonymous], AIDS BEHAV; Epstein RM, 1998, ANN INTERN MED, V128, P435, DOI 10.7326/0003-4819-128-6-199803150-00003; Fallowfield L, 1998, J CLIN ONCOL, V16, P1961, DOI 10.1200/JCO.1998.16.5.1961; LEMP GF, 1994, JAMA-J AM MED ASSOC, V272, P449, DOI 10.1001/jama.272.6.449; MAKADON HJ, 1995, ANN INTERN MED, V123, P715, DOI 10.7326/0003-4819-123-9-199511010-00010; MCKUSKER J, 1994, DRUG ALCOHOL DEPEN, V34, P129; Stein MD, 1998, ARCH INTERN MED, V158, P253, DOI 10.1001/archinte.158.3.253	7	4	4	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	AUG 15	1998	352	9127					506	506		10.1016/S0140-6736(05)79247-3	http://dx.doi.org/10.1016/S0140-6736(05)79247-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	111KC	9716053				2022-12-28	WOS:000075435300007
J	Struthers, AD; Cuschieri, A				Struthers, AD; Cuschieri, A			Cardiovascular consequences of laparoscopic surgery	LANCET			English	Editorial Material							ABDOMINAL-WALL LIFT; HEART-FAILURE; TRANSESOPHAGEAL ECHOCARDIOGRAPHY; NONCARDIAC SURGERY; CHOLECYSTECTOMY; PNEUMOPERITONEUM; ANESTHESIA; PRESSURE; ISCHEMIA; POSTURE		Univ Dundee, Ninewells Hosp & Med Sch, Dept Clin Pharmacol & Therapeut, Dundee DD1 9SY, Scotland; Univ Dundee, Ninewells Hosp & Med Sch, Dept Surg, Dundee DD1 9SY, Scotland	University of Dundee; University of Dundee	Struthers, AD (corresponding author), Univ Dundee, Ninewells Hosp & Med Sch, Dept Clin Pharmacol & Therapeut, Dundee DD1 9SY, Scotland.		Cuschieri, Alfred/O-4092-2019; Cuschieri, Alfred/A-7634-2013	Cuschieri, Alfred/0000-0003-0764-5947; Struthers, Allan/0000-0002-2926-2528				ARAKI K, 1993, WORLD J SURG, V17, P105, DOI 10.1007/BF01655719; Atherton JJ, 1997, LANCET, V349, P1720, DOI 10.1016/S0140-6736(96)05109-4; BANTING S, 1993, SURG ENDOSC-ULTRAS, V7, P57, DOI 10.1007/BF00591240; BLAKE DW, 1991, ANESTH ANALG, V73, P441; CHARLSON ME, 1989, ANN SURG, V210, P637, DOI 10.1097/00000658-198911000-00012; CHIU AW, 1995, J AM COLL SURGEONS, V181, P397; Clavell AL, 1996, J CLIN INVEST, V97, P1286, DOI 10.1172/JCI118544; COHN JN, 1991, NEW ENGL J MED, V325, P303, DOI 10.1056/NEJM199108013250502; COUTURE P, 1996, ANESTH ANALG       S, V82, P79; CUNNINGHAM AJ, 1993, BRIT J ANAESTH, V70, P621, DOI 10.1093/bja/70.6.621; Derouin M, 1996, ANESTH ANALG, V82, P119, DOI 10.1097/00000539-199601000-00021; DEZIEL DJ, 1993, AM J SURG, V165, P9, DOI 10.1016/S0002-9610(05)80397-6; EAGLE KM, 1996, CIRCULATION, V93, P278; EISENBERG MJ, 1992, JAMA-J AM MED ASSOC, V268, P210, DOI 10.1001/jama.268.2.210; FEIG BW, 1994, SURGERY, V116, P733; Gannedahl P, 1996, ACTA ANAESTH SCAND, V40, P160, DOI 10.1111/j.1399-6576.1996.tb04414.x; HARMAN PK, 1982, ANN SURG, V196, P594, DOI 10.1097/00000658-198211000-00015; Harris SN, 1996, ANESTH ANALG, V83, P482, DOI 10.1097/00000539-199609000-00007; JORIS J, 1993, BRIT J ANAESTH, V70, P17; JORIS JL, 1993, ANESTH ANALG, V76, P1067; Koivusalo AM, 1996, BRIT J SURG, V83, P1532, DOI 10.1002/bjs.1800831112; MANGANO DT, 1994, NEW ENGL J MED, V330, P663; MEHTA J, 1977, CIRCULATION, V55, P370, DOI 10.1161/01.CIR.55.2.370; ODEBERG S, 1994, ACTA ANAESTH SCAND, V38, P276, DOI 10.1111/j.1399-6576.1994.tb03889.x; OLeary E, 1996, BRIT J ANAESTH, V76, P640, DOI 10.1093/bja/76.5.640; Ortega AE, 1996, J AM COLL SURGEONS, V183, P249; SAFRAN D, 1993, SURG GYNECOL OBSTET, V176, P548; STEVENSON LW, 1986, CIRCULATION, V74, P1303, DOI 10.1161/01.CIR.74.6.1303	28	62	65	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	AUG 15	1998	352	9127					568	570		10.1016/S0140-6736(97)11478-7	http://dx.doi.org/10.1016/S0140-6736(97)11478-7			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	111KC	9716077				2022-12-28	WOS:000075435300045
J	Geiger, H; Naraghi, R; Schobel, HP; Frank, H; Sterzel, RB; Fahlbusch, R				Geiger, H; Naraghi, R; Schobel, HP; Frank, H; Sterzel, RB; Fahlbusch, R			Decrease of blood pressure by ventrolateral medullary decompression in essential hypertension	LANCET			English	Article							NITRIC-OXIDE; NEUROVASCULAR COMPRESSION; BRAIN-STEM; OBLONGATA; RATS	Background About 20% of adults worldwide will develop hypertension. Studies and clinical observations suggest an association between hypertension and pulsatile compression of the ventrolateral medulla oblongata by a looping artery. We investigated whether neurosurgical microvascular decompression substantially decreases blood pressure long-term in patients with severe essential hypertension. Methods We included eight patients who had received three or more antihypertensive drugs without adequate control of blood pressure, intolerable side-effects, or both. All patients underwent microvascular decompression at the root-entry zone of cranial nerves IX and X after neurovascular compression of the ventrolateral medulla oblongata was seen on magnetic-resonance angiography. Findings 3 months after surgery, blood pressure and antihypertensive regimens had decreased substantially in three patients. Four patients who were followed up for more than 1 year became normotensive, but their antihypertensive regimens remained the same as those at 3 months. One patient did not improve. No complications associated with decompression occurred. One patient experienced a transient vocal-cord paresis after the laryngeal part of the vagus nerve was manoeuvered during surgery. Interpretation We showed a direct causal relation between raised blood pressure and irritation of cranial nerves IX and X. A subgroup of patients with essential hypertension may exist who have secondary forms of hypertension related to neurovascular compression at the ventrolateral medulla and who may be successfully treated with decompression.	Univ Frankfurt, Dept Internal Med 4, Div Nephrol, D-60590 Frankfurt, Germany; Univ Erlangen Nurnberg, Clin Neurosurg, D-8520 Erlangen, Germany; Univ Erlangen Nurnberg, Med Clin 4, D-8520 Erlangen, Germany	Goethe University Frankfurt; University of Erlangen Nuremberg; University of Erlangen Nuremberg	Geiger, H (corresponding author), Univ Frankfurt, Dept Internal Med 4, Div Nephrol, Theodor Stern Kai 7, D-60590 Frankfurt, Germany.			Naraghi, Ramin/0000-0003-3643-791X				AKIMURA T, 1995, AM J NEURORADIOL, V16, P401; CHALMERS J, 1991, J HYPERTENS, V9, P675, DOI 10.1097/00004872-199108000-00001; GIFFORD RW, 1993, ARCH INTERN MED, V153, P154; GRANATA A, 1985, AM J PHYSIOL, V17, pH547; HANSEN J, 1994, HYPERTENSION, V24, P439, DOI 10.1161/01.HYP.24.4.439; Hirooka Y, 1996, J HYPERTENS, V14, P1317, DOI 10.1097/00004872-199611000-00010; JANNETTA PJ, 1985, ANN SURG, V202, P253, DOI 10.1097/00000658-198508000-00018; JANNETTA PJ, 1985, ANN SURG, V201, P391, DOI 10.1097/00000658-198503000-00023; Morimoto S, 1997, HYPERTENSION, V29, P514, DOI 10.1161/01.HYP.29.1.514; Morimoto S, 1997, HYPERTENSION, V30, P77, DOI 10.1161/01.HYP.30.1.77; NARAGHI R, 1994, LANCET, V344, P1466, DOI 10.1016/S0140-6736(94)90289-5; NARAGHI R, 1992, J NEUROSURG, V77, P103, DOI 10.3171/jns.1992.77.1.0103; PALKOVITS M, 1995, CLIN EXP HYPERTENS, V17, P101, DOI 10.3109/10641969509087058; Tseng CJ, 1996, HYPERTENSION, V27, P36, DOI 10.1161/01.HYP.27.1.36; TSUCHIHASHI T, 1994, HYPERTENSION, V24, P648, DOI 10.1161/01.HYP.24.6.648; Yamamoto I, 1991, Neurol Med Chir (Tokyo), V31, P1, DOI 10.2176/nmc.31.1	16	88	92	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	AUG 8	1998	352	9126					446	449		10.1016/S0140-6736(97)11343-5	http://dx.doi.org/10.1016/S0140-6736(97)11343-5			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	108EA	9708753				2022-12-28	WOS:000075252000012
J	Lewis, SL				Lewis, SL			Aetiology of transient global amnesia	LANCET			English	Article							DURAL ARTERIOVENOUS MALFORMATION; SUPERIOR VENA-CAVA; SPREADING DEPRESSION; VENOUS ISCHEMIA; THROMBOSIS; SINUS; OCCLUSION; BRAIN; MRI	The pathophysiology of transient global amnesia (TGA) has been obscure since the definition of this syndrome more than 30 years ago. Current hypotheses include migraine, seizure, or transient cerebral arterial ischaemia. However, none of these potential mechanisms explain both the absence of other neurological signs or symptoms during TGA, and its frequent precipitating activities: many of which would be expected to result in marked increases in venous return from the arms to the superior vena cava. Patients with TGA also commonly have a Valsalva manoeuvre at the onset of attacks. I suggest that a Valsalva manoeuvre, blocking venous return through the superior vena cava, may allow brief retrograde transmission of high venous pressure from the arms to the cerebral venous system, resulting in venous ischaemia to the diencephalon or mesial temporal lobes and to TGA.	Rush Presbyterian St Lukes Med Ctr, Dept Neurol Sci, Chicago, IL 60612 USA	Rush University	Lewis, SL (corresponding author), Rush Presbyterian St Lukes Med Ctr, Dept Neurol Sci, 1725 W Harrison St,Suite 1106, Chicago, IL 60612 USA.	slewis@neuro.rush.edu	Lewis, Steven L./AAW-8925-2020					ATTARIAN S, 1995, REV NEUROL-FRANCE, V151, P552; ATTUBATO MJ, 1994, AM J CARDIOL, V74, P408, DOI 10.1016/0002-9149(94)90417-0; BORGOHAIN R, 1995, J NEUROL NEUROSUR PS, V58, P514, DOI 10.1136/jnnp.58.4.514; Caplan L, 1985, HDB CLIN NEUROLOGY, V1, P205; CRAWFORD SC, 1995, ARCH NEUROL-CHICAGO, V52, P1101, DOI 10.1001/archneur.1995.00540350095021; DRESSER LP, 1987, AM J SURG, V154, P220, DOI 10.1016/0002-9610(87)90185-1; FISHER CM, 1982, ARCH NEUROL-CHICAGO, V39, P605, DOI 10.1001/archneur.1982.00510220003001; FISHER CM, 1964, ACTA NEUROL SCAND, V40, P7; FUKUDA M, 1993, PEDIATR RADIOL, V23, P53, DOI 10.1007/BF02020224; GONZALEZFAJARDO JA, 1994, J THORAC CARDIOV SUR, V107, P1044, DOI 10.1016/S0022-5223(94)70379-5; GUIDOTTI M, 1989, J NEUROL NEUROSUR PS, V52, P320, DOI 10.1136/jnnp.52.3.320; HASEGAWA Y, 1995, J CEREBR BLOOD F MET, V15, P179, DOI 10.1038/jcbfm.1995.23; HASEGAWA Y, 1994, NEUROLOGY, V44, P1484, DOI 10.1212/WNL.44.8.1484; HODGES JR, 1990, J NEUROL NEUROSUR PS, V53, P834, DOI 10.1136/jnnp.53.10.834; HODGES JR, 1990, BRAIN, V113, P639, DOI 10.1093/brain/113.3.639; Hodges JR, 1998, ANN NEUROL, V43, P151, DOI 10.1002/ana.410430203; Hodges JR, 1991, TRANSIENT AMNESIA CL; ITO M, 1995, NEUROSURGERY, V37, P1187, DOI 10.1227/00006123-199512000-00019; Klotzsch C, 1996, ARCH NEUROL-CHICAGO, V53, P504, DOI 10.1001/archneur.1996.00550060046014; Koroshetz WJ, 1997, ANN NEUROL, V41, P565, DOI 10.1002/ana.410410502; KURATA A, 1994, J NEUROSURG, V80, P552, DOI 10.3171/jns.1994.80.3.0552; KUROKAWA Y, 1990, SURG NEUROL, V34, P390, DOI 10.1016/0090-3019(90)90242-H; LAURITZEN M, 1994, BRAIN, V117, P199, DOI 10.1093/brain/117.1.199; MOHRMAN DE, 1991, CARDIOVASCULAR PHYSL, P146; NAKADA T, 1985, NEUROSURGERY, V17, P653, DOI 10.1227/00006123-198510000-00021; OKAY NH, 1969, RADIOLOGY, V92, P1493, DOI 10.1148/92.7.1493; OLESEN J, 1986, ACTA NEUROL SCAND, V73, P219; SCHMIDEK HH, 1985, NEUROSURGERY, V17, P663, DOI 10.1227/00006123-198510000-00024; Strupp M, 1998, ANN NEUROL, V43, P164, DOI 10.1002/ana.410430206; TOKAHASHI Y, 1996, KURUME MED J, V43, P223; ZORZON M, 1995, STROKE, V26, P1536, DOI 10.1161/01.STR.26.9.1536	31	185	192	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 1	1998	352	9125					397	399		10.1016/S0140-6736(98)01442-1	http://dx.doi.org/10.1016/S0140-6736(98)01442-1			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	106BU	9717945				2022-12-28	WOS:000075110500044
J	Palmer, C				Palmer, C			The Taliban's war on women	LANCET			English	Editorial Material									Phys Human Rights, Boston, MA 02116 USA		Palmer, C (corresponding author), Phys Human Rights, 100 Boylston St,Suite 702, Boston, MA 02116 USA.								0	5	5	1	10	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	AUG 29	1998	352	9129					734	734		10.1016/S0140-6736(05)60848-3	http://dx.doi.org/10.1016/S0140-6736(05)60848-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	116MT	9729009				2022-12-28	WOS:000075729700051
J	Rawles, J; Sinclair, C; Jennings, K; Ritchie, L; Waugh, N				Rawles, J; Sinclair, C; Jennings, K; Ritchie, L; Waugh, N			Call to needle times after acute myocardial infarction in urban and rural areas in northeast Scotland: prospective observational study	BRITISH MEDICAL JOURNAL			English	Article							GUIDELINES	Objective: To determine call to needle times and consider how best to provide timely thrombolytic treatment for patients with acute myocardial infarction. Design: Prospective observational study. Setting: City, suburban, and country practices referring patients to a single district general hospital in northeast Scotland. Subjects: 1046 patients with suspected acute myocardial infarction given thrombolytic treatment. Main outcome measures: Time from patients' calls for medical help until receipt of opiate or thrombolytic treatment, measured against a call to needle time of 90 minutes or less, as proposed by the British Heart Foundation. Results: General practitioners were the first medical contact in 97% (528/544) of calls by country patients and 68% (340/502) of city and suburban patients. When opiate was given by general practitioners, median call to opiate time was about 30 minutes (95% Within 90 minutes) in city, suburbs, and country; call to opiate delay was about 60 minutes in city and subul ban patients calling "999" for an ambulance. One third of country patients received thrombolytic treatment from their general practitioners with a median call to thrombolysis time of 45 minutes (93% within 90 minutes); this compares with 150 minutes (5% within 90 minutes) when this treatment was deferred until after hospital admission. In the city and suburbs, no thrombolytic treatment was given outside hospital, and only a minority of patients received it within 90 minutes of calling; median call to thrombolysis time was 95 (46% within 90 minutes) minutes. Conclusions: The first medical contact after acute myocardial infarction is most commonly with a general practitioner. This contact provides the optimum opportunity to give thrombolytic treatment within the British Heart Foundation's guideline.	Univ Aberdeen, Aberdeen Royal Infirm, Med Assessment Res Unit, Aberdeen AB25 2NZ, Scotland; Aberdeen Royal Infirm, Dept Cardiol, Aberdeen, Scotland; Univ Aberdeen, Dept Gen Practice & Primary Care, Aberdeen AB25 2NZ, Scotland; Grampian Hlth Board, Aberdeen AB15 6RE, Scotland	University of Aberdeen; University of Aberdeen; University of Aberdeen	Rawles, J (corresponding author), Univ Aberdeen, Aberdeen Royal Infirm, Med Assessment Res Unit, Aberdeen AB25 2NZ, Scotland.							Banerjee S, 1998, J ROY COLL PHYS LOND, V32, P36; CANNON CP, 1994, J THROMB THROMBOLYS, V1, P27; CAPEWELL S, 1997, HLTH B, V55, P399; COBBE SM, 1994, BMJ-BRIT MED J, V308, P216, DOI 10.1136/bmj.308.6923.216; LIDDELL R, 1996, 67 SCOTT OFF; RAWLES J, 1995, DRUGS, V50, P615, DOI 10.2165/00003495-199550040-00004; Rawles JM, 1997, J AM COLL CARDIOL, V30, P1181, DOI 10.1016/S0735-1097(97)00299-4; WESTON CFM, 1994, BMJ-BRIT MED J, V308, P767, DOI 10.1136/bmj.308.6931.767; 1994, DRUG THERAPEUTICS B, V32, P65	9	33	33	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 29	1998	317	7158					576	578		10.1136/bmj.317.7158.576	http://dx.doi.org/10.1136/bmj.317.7158.576			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	117EK	9721115	Green Published, Bronze			2022-12-28	WOS:000075767800019
J	Evan, G; Littlewood, T				Evan, G; Littlewood, T			A matter of life and cell death	SCIENCE			English	Review							WILD-TYPE P53; DRUG-INDUCED APOPTOSIS; TUMOR-NECROSIS-FACTOR; MYC-INDUCED APOPTOSIS; DEPENDENT PROTEIN-KINASE; CD95 APO-1/FAS SYSTEM; FACTOR-I RECEPTOR; E1B 19K PROTEIN; S-PHASE ENTRY; C-MYC	In multicellular organisms, mutations in somatic cells affecting critical genes that regulate cell proliferation and survival cause fatal cancers. Repair of the damage is one obvious option, although the relative inconsequence of individual cells in metazoans means that it is often a "safer" strategy to ablate the offending cell. Not surprisingly, corruption of the machinery that senses or implements DNA damage greatly predisposes to cancer. Nonetheless, even when oncogenic mutations do occur, there exist potent mechanisms that Limit the expansion of affected cells by suppressing their proliferation or triggering their suicide. Growing understanding of these innate mechanisms is suggesting novel therapeutic strategies for cancer.	Imperial Canc Res Fund Labs, London WC2A 3PX, England	Cancer Research UK	Evan, G (corresponding author), Imperial Canc Res Fund Labs, 44 Lincolns Inn Fields, London WC2A 3PX, England.							Adams PD, 1996, CURR TOP MICROBIOL, V208, P79; Agah R, 1997, J CLIN INVEST, V100, P2722, DOI 10.1172/JCI119817; Alarcon RM, 1996, CANCER RES, V56, P4315; AMATI B, 1993, EMBO J, V12, P5083, DOI 10.1002/j.1460-2075.1993.tb06202.x; Amati Bruno, 1998, Frontiers in Bioscience, V3, pD250; An B, 1996, FEBS LETT, V399, P158, DOI 10.1016/S0014-5793(96)01311-7; Aragane Y, 1998, J CELL BIOL, V140, P171, DOI 10.1083/jcb.140.1.171; ASKEW DS, 1991, ONCOGENE, V6, P1915; ATTARDI LD, 1996, EMBO J, V15, P3702; Berry DE, 1996, ONCOGENE, V12, P1809; Bian JH, 1997, MOL CELL BIOL, V17, P6330, DOI 10.1128/MCB.17.11.6330; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; Boulakia CA, 1996, ONCOGENE, V12, P529; Bouvet M, 1998, CANCER RES, V58, P2288; Brady HJM, 1996, EMBO J, V15, P6991, DOI 10.1002/j.1460-2075.1996.tb01091.x; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CHIOU SK, 1994, J VIROL, V68, P6553, DOI 10.1128/JVI.68.10.6553-6566.1994; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; DARNERON KM, 1994, SCIENCE, V265, P1582; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; delPeso L, 1997, SCIENCE, V278, P687; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; Dou QP, 1997, J CELL BIOCHEM, V64, P586; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; ELSON A, 1995, ONCOGENE, V11, P181; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Fattman CL, 1997, J CELL BIOCHEM, V67, P399; Fearnhead HO, 1997, GENE DEV, V11, P1266, DOI 10.1101/gad.11.10.1266; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; Flint J, 1997, ANNU REV GENET, V31, P177, DOI 10.1146/annurev.genet.31.1.177; FREEMAN RS, 1994, NEURON, V12, P343, DOI 10.1016/0896-6273(94)90276-3; Friedlander P, 1996, MOL CELL BIOL, V16, P4961; Friesen C, 1997, LEUKEMIA, V11, P1833, DOI 10.1038/sj.leu.2400827; Fukasawa K, 1997, ONCOGENE, V15, P1295, DOI 10.1038/sj.onc.1201482; Fulda S, 1997, CANCER RES, V57, P3823; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; GOODING LR, 1991, J VIROL, V65, P3083, DOI 10.1128/JVI.65.6.3083-3094.1991; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; Haber DA, 1997, CELL, V91, P555, DOI 10.1016/S0092-8674(00)80441-9; Han JH, 1996, GENE DEV, V10, P461, DOI 10.1101/gad.10.4.461; Han JW, 1997, CANCER RES, V57, P176; Hansen R, 1997, CURR OPIN GENET DEV, V7, P46, DOI 10.1016/S0959-437X(97)80108-6; Hansen RS, 1996, ONCOGENE, V13, P995; HARRINGTON EA, 1994, CURR OPIN GENET DEV, V4, P120, DOI 10.1016/0959-437X(94)90100-7; Heise C, 1997, NAT MED, V3, P639, DOI 10.1038/nm0697-639; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; Hsieh JK, 1997, GENE DEV, V11, P1840, DOI 10.1101/gad.11.14.1840; HSU B, 1995, ONCOGENE, V11, P175; Huang DCS, 1997, EMBO J, V16, P4628, DOI 10.1093/emboj/16.15.4628; Hueber AO, 1997, SCIENCE, V278, P1305, DOI 10.1126/science.278.5341.1305; Hunt KK, 1997, CANCER RES, V57, P4722; Hurford RK, 1997, GENE DEV, V11, P1447, DOI 10.1101/gad.11.11.1447; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; Jackson SP, 1997, INT J BIOCHEM CELL B, V29, P935, DOI 10.1016/S1357-2725(97)00006-X; Janicke RU, 1996, EMBO J, V15, P6969, DOI 10.1002/j.1460-2075.1996.tb01089.x; Johnson David G., 1998, Frontiers in Bioscience, V3, pD447; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Kasibhatla S, 1998, MOL CELL, V1, P543, DOI 10.1016/S1097-2765(00)80054-4; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; KLEFSTROM J, 1994, EMBO J, V13, P5442, DOI 10.1002/j.1460-2075.1994.tb06879.x; Kowalik TF, 1998, CELL GROWTH DIFFER, V9, P113; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; LAHTI JM, 1995, MOL CELL BIOL, V15, P1; Lee MH, 1996, GENE DEV, V10, P1621, DOI 10.1101/gad.10.13.1621; LI CJ, 1995, SCIENCE, V268, P429, DOI 10.1126/science.7716549; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Linette GP, 1996, P NATL ACAD SCI USA, V93, P9545, DOI 10.1073/pnas.93.18.9545; Linke SP, 1996, GENE DEV, V10, P934, DOI 10.1101/gad.10.8.934; Lloyd AC, 1997, GENE DEV, V11, P663, DOI 10.1101/gad.11.5.663; Los M, 1997, BLOOD, V90, P3118, DOI 10.1182/blood.V90.8.3118; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; Ludwig RL, 1996, MOL CELL BIOL, V16, P4952; MARTINOU I, 1995, J CELL BIOL, V128, P201, DOI 10.1083/jcb.128.1.201; MARVEL J, 1994, ONCOGENE, V9, P1117; Mayo LD, 1997, CANCER RES, V57, P5013; McCurrach ME, 1997, P NATL ACAD SCI USA, V94, P2345, DOI 10.1073/pnas.94.6.2345; MEIKRANTZ W, 1994, P NATL ACAD SCI USA, V91, P3754, DOI 10.1073/pnas.91.9.3754; MIYASHITA T, 1994, CANCER RES, V54, P3131; Muller M, 1997, J CLIN INVEST, V99, P403, DOI 10.1172/JCI119174; MYMRYK JS, 1994, ONCOGENE, V9, P1187; Newton K, 1998, EMBO J, V17, P706, DOI 10.1093/emboj/17.3.706; Nip J, 1997, MOL CELL BIOL, V17, P1049, DOI 10.1128/MCB.17.3.1049; Nishimori H, 1997, ONCOGENE, V15, P2145, DOI 10.1038/sj.onc.1201542; Nitta M, 1997, ONCOGENE, V15, P561, DOI 10.1038/sj.onc.1201210; OHLSSON R, 1989, EMBO J, V8, P1993, DOI 10.1002/j.1460-2075.1989.tb03606.x; OReilly LA, 1997, J IMMUNOL, V159, P2301; OReilly LA, 1996, EMBO J, V15, P6979, DOI 10.1002/j.1460-2075.1996.tb01090.x; OWENSCHAUB LB, 1995, MOL CELL BIOL, V15, P3032; Packham G, 1995, Curr Top Microbiol Immunol, V194, P283; PAN HC, 1994, GENE DEV, V8, P1285, DOI 10.1101/gad.8.11.1285; Pierzchalski P, 1997, EXP CELL RES, V234, P57, DOI 10.1006/excr.1997.3604; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Prisco M, 1997, MOL CELL BIOL, V17, P1084, DOI 10.1128/MCB.17.3.1084; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; Querido E, 1997, J VIROL, V71, P3526, DOI 10.1128/JVI.71.5.3526-3533.1997; RAMQVIST T, 1993, ONCOGENE, V8, P1495; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; RAYCHAUDHURI P, 1991, GENE DEV, V5, P1200, DOI 10.1101/gad.5.7.1200; Reap EA, 1997, P NATL ACAD SCI USA, V94, P5750, DOI 10.1073/pnas.94.11.5750; RENZING J, 1995, ONCOGENE, V10, P1865; RIDLEY AJ, 1988, EMBO J, V7, P1635, DOI 10.1002/j.1460-2075.1988.tb02990.x; Rudolph B, 1996, EMBO J, V15, P3065, DOI 10.1002/j.1460-2075.1996.tb00669.x; SABBATINI P, 1995, MOL CELL BIOL, V15, P1060; SABBATINI P, 1995, GENE DEV, V9, P2184, DOI 10.1101/gad.9.17.2184; SAITO Y, 1995, ONCOGENE, V11, P1013; Sakamuro D, 1995, ONCOGENE, V11, P2411; Samuelson AV, 1997, P NATL ACAD SCI USA, V94, P12094, DOI 10.1073/pnas.94.22.12094; Sarasin A, 1997, CANCER DETECT PREV, V21, P406; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Shan B, 1996, P NATL ACAD SCI USA, V93, P679, DOI 10.1073/pnas.93.2.679; Shaw M, 1997, FEBS LETT, V416, P307, DOI 10.1016/S0014-5793(97)01235-0; Sheard MA, 1997, INT J CANCER, V73, P757, DOI 10.1002/(SICI)1097-0215(19971127)73:5<757::AID-IJC24>3.0.CO;2-1; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SHI L, 1994, SCIENCE, V263, P1143, DOI 10.1126/science.8108732; SHI YF, 1992, SCIENCE, V257, P212, DOI 10.1126/science.1378649; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Shim H, 1998, P NATL ACAD SCI USA, V95, P1511, DOI 10.1073/pnas.95.4.1511; Shisler J, 1996, J VIROL, V70, P68, DOI 10.1128/JVI.70.1.68-77.1996; STRASSER A, 1990, NATURE, V348, P331, DOI 10.1038/348331a0; Tan XQ, 1997, J BIOL CHEM, V272, P9613; Trudel M, 1997, J EXP MED, V186, P1873, DOI 10.1084/jem.186.11.1873; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; WALSH C, 1988, IMMUNITY, V8, P439; Wang J, 1996, SCIENCE, V273, P359, DOI 10.1126/science.273.5273.359; WANG YS, 1993, CELL GROWTH DIFFER, V4, P467; WHITE E, 1987, J VIROL, V61, P426, DOI 10.1128/JVI.61.2.426-435.1987; WHITE E, 1991, J VIROL, V65, P2968, DOI 10.1128/JVI.65.6.2968-2978.1991; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; Xu Y, 1996, GENE DEV, V10, P2401, DOI 10.1101/gad.10.19.2401; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4; Yamasaki L, 1998, NAT GENET, V18, P360, DOI 10.1038/ng0498-360; Yeh WC, 1998, SCIENCE, V279, P1954, DOI 10.1126/science.279.5358.1954; YEW PR, 1994, GENE DEV, V8, P190, DOI 10.1101/gad.8.2.190; Yin CY, 1997, NATURE, V385, P637, DOI 10.1038/385637a0; ZHAN QM, 1994, ONCOGENE, V9, P3743; Zhang JK, 1998, NATURE, V392, P296, DOI 10.1038/32681; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424; Zornig M, 1998, CURR BIOL, V8, P467, DOI 10.1016/S0960-9822(98)70182-4; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	147	1295	1399	3	81	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 28	1998	281	5381					1317	1322		10.1126/science.281.5381.1317	http://dx.doi.org/10.1126/science.281.5381.1317			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	115LQ	9721090				2022-12-28	WOS:000075666800041
J	Tweed, D; Haslwanter, T; Fetter, M				Tweed, D; Haslwanter, T; Fetter, M			Optimizing gaze control in three dimensions	SCIENCE			English	Article							EYE-HEAD COORDINATION; 3-DIMENSIONAL EYE; MOVEMENTS; SACCADES; POSITION; VELOCITY; TORSION; SHIFTS; SYSTEM; LAW	Horizontal and vertical movements of the human eye bring new objects to the center of the visual field, but torsional movements rotate the visual world about its center. Ocular torsion stays near zero during head-fixed gaze shifts, and eye movements to Visual targets are thought to be driven by purely horizontal and vertical commands. Here, analysis of eye-head gaze shifts revealed that gaze commands were three-dimensional, with a separate neural control system for torsion. Active torsion optimized gaze control as no two-dimensional system could have, stabilizing the retinal image as quickly as possible when it would otherwise have spun around the fixation point.	Univ Western Ontario, Dept Physiol, London, ON, Canada; Univ Western Ontario, Dept Appl Math, London, ON N6A 5B9, Canada; Univ Tubingen, Dept Neurol, D-7400 Tubingen, Germany	Western University (University of Western Ontario); Western University (University of Western Ontario); Eberhard Karls University of Tubingen	Tweed, D (corresponding author), Univ Toronto, Dept Physiol, Med Sci Bldg 3207,1 Kings Coll Circle, Toronto, ON M5S 1A8, Canada.							BALLIET R, 1978, INVEST OPHTH VIS SCI, V17, P303; CARPENTR RHS, 1988, MOVEMENTS EYES; DUHAMEL JR, 1992, SCIENCE, V255, P90, DOI 10.1126/science.1553535; FERMAN L, 1987, VISION RES, V27, P929, DOI 10.1016/0042-6989(87)90009-5; GUITTON D, 1987, J NEUROPHYSIOL, V58, P427, DOI 10.1152/jn.1987.58.3.427; HASLWANTER T, 1995, VISION RES, V35, P1727, DOI 10.1016/0042-6989(94)00257-M; HEPP K, 1995, VISION RES, V35, P3237, DOI 10.1016/0042-6989(95)00104-M; HEPP K, 1997, VISION RES, V37, P1939; LAURUTIS VP, 1986, J PHYSIOL-LONDON, V373, P209, DOI 10.1113/jphysiol.1986.sp016043; MERTON PA, 1956, J PHYSIOL-LONDON, V132, pP25; MILLER E F 2nd, 1962, Acta Otolaryngol, V54, P479, DOI 10.3109/00016486209126967; MINKEN AWH, 1993, EXP BRAIN RES, V93, P521, DOI 10.1007/BF00229367; PETROV AP, 1973, VISION RES, V13, P2465, DOI 10.1016/0042-6989(73)90244-7; RADAU P, 1994, J NEUROPHYSIOL, V72, P2840, DOI 10.1152/jn.1994.72.6.2840; ROBINSON DA, 1963, IEEE T BIO-MED ENG, VBM10, P137, DOI 10.1109/TBMEL.1963.4322822; ROUCOUX A, 1980, PROGR OCULOMOTOR RES, P309; STRAUMANN D, 1995, VISION RES, V35, P3321, DOI 10.1016/0042-6989(95)00091-R; TWEED D, 1994, J NEUROPHYSIOL, V72, P1425, DOI 10.1152/jn.1994.72.3.1425; TWEED D, 1995, J NEUROPHYSIOL, V73, P766, DOI 10.1152/jn.1995.73.2.766; TWEED D, 1987, J NEUROPHYSIOL, V58, P832, DOI 10.1152/jn.1987.58.4.832; TWEED D, 1990, VISION RES, V30, P111, DOI 10.1016/0042-6989(90)90131-4; TWEED D, 1990, VISION RES, V30, P97, DOI 10.1016/0042-6989(90)90130-D; Tweed D, 1997, J NEUROPHYSIOL, V77, P654, DOI 10.1152/jn.1997.77.2.654; von Helmholtz H., 1867, HDB PHYSL OPTIK, VVol. 9, DOI 10.1007/BF01708548; WESTHEIMER G, 1957, J OPT SOC AM, V47, P967, DOI 10.1364/JOSA.47.000967	25	62	62	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 28	1998	281	5381					1363	1366		10.1126/science.281.5381.1363	http://dx.doi.org/10.1126/science.281.5381.1363			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	115LQ	9721104				2022-12-28	WOS:000075666800054
J	Zandi, E; Chen, Y; Karin, M				Zandi, E; Chen, Y; Karin, M			Direct phosphorylation of I kappa B by IKK alpha and IKK beta: Discrimination between free and NF-kappa B-bound substrate	SCIENCE			English	Article							CASEIN KINASE-II; CONSTITUTIVE PHOSPHORYLATION; TRANSCRIPTION FACTOR; ACTIVATION; DEGRADATION; SIGNAL; DISSOCIATION; PROTEOLYSIS; SUFFICIENT; EXPRESSION	A large protein complex mediates the phosphorylation of the inhibitor of kappa B (I kappa B), which results in the activation of nuclear factor kappa B (NF-kappa B). Two subunits of this complex, I kappa B kinase alpha (IKK alpha) and I kappa B kinase beta (IKK beta), are required for NF-kappa B activation. Purified recombinant IKK alpha and IKK beta expressed in insect cells were used to demonstrate that each protein can directly phosphorylate I kappa B proteins. IKK alpha and IKK beta were found to form both homodimers and heterodimers. Both IKK alpha and IKK beta phosphorylated I kappa B bound to NF-kappa B more efficiently than they phosphorylated free I kappa B. This result explains how free I kappa B can accumulate in cells in which IKK is still active and thus can contribute to the termination of NF-kappa B activation.	Univ Calif San Diego, Dept Pharmacol, Lab Gene Regulat & Signal Transduct, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Karin, M (corresponding author), Univ Calif San Diego, Dept Pharmacol, Lab Gene Regulat & Signal Transduct, 9500 Gilman Dr, La Jolla, CA 92093 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI043477] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 43477] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALKALAY I, 1995, MOL CELL BIOL, V15, P1294; ARENZANASEISDEDOS F, 1995, MOL CELL BIOL, V15, P2689; Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506; BARROGA CF, 1995, P NATL ACAD SCI USA, V92, P7637, DOI 10.1073/pnas.92.17.7637; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; Chen FE, 1998, NATURE, V391, P410, DOI 10.1038/34956; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; DiDonato J, 1996, MOL CELL BIOL, V16, P1295; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; DIDONATO JA, 1995, MOL CELL BIOL, V15, P1302; McElhinny JA, 1996, MOL CELL BIOL, V16, P899; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Schwarz EM, 1996, MOL CELL BIOL, V16, P3554; Stancovski I, 1997, CELL, V91, P299, DOI 10.1016/S0092-8674(00)80413-4; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; THOMPSON JE, 1995, CELL, V80, P573, DOI 10.1016/0092-8674(95)90511-1; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; WHITESIDE ST, 1995, MOL CELL BIOL, V15, P5339; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; ZANDI E, UNPUB	24	387	409	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 28	1998	281	5381					1360	1363		10.1126/science.281.5381.1360	http://dx.doi.org/10.1126/science.281.5381.1360			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	115LQ	9721103				2022-12-28	WOS:000075666800053
J	Bilezikian, JP; Morishima, A; Bell, J; Grumbach, MM				Bilezikian, JP; Morishima, A; Bell, J; Grumbach, MM			Increased bone mass as a result of estrogen therapy in a man with aromatase deficiency	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Proceedings Paper	19th Annual Meeting of the American-Society-for-Bone-and-Mineral-Research	SEP 10-14, 1997	CINCINNATI, OHIO	Amer Soc Bone & Mineral Res			HYPERGONADOTROPIC HYPOGONADISM; GONADOTROPIN-SECRETION; POSTMENOPAUSAL WOMEN; MULTICYSTIC OVARIES; ADOLESCENT GIRLS; MINERAL DENSITY; SEX STEROIDS; MEN; FEMALE; TESTOSTERONE		Columbia Presbyterian Med Ctr, Coll Phys & Surg, Dept Med, New York, NY 10032 USA; Columbia Presbyterian Med Ctr, Coll Phys & Surg, Dept Pharmacol, New York, NY 10032 USA; Columbia Presbyterian Med Ctr, Coll Phys & Surg, Dept Pediat, New York, NY 10032 USA; Univ Calif San Francisco, Dept Pediat, San Francisco, CA 94143 USA	Columbia University; NewYork-Presbyterian Hospital; Columbia University; NewYork-Presbyterian Hospital; Columbia University; NewYork-Presbyterian Hospital; University of California System; University of California San Francisco	Bilezikian, JP (corresponding author), Columbia Presbyterian Med Ctr, Coll Phys & Surg, Dept Med, 630 W 168th St,Rm PH8-Stern, New York, NY 10032 USA.							Anderson FH, 1997, J BONE MINER RES, V12, P472, DOI 10.1359/jbmr.1997.12.3.472; ASSCHEMAN H, 1994, METABOLISM, V43, P935, DOI 10.1016/0026-0495(94)90170-8; BACHRACH LK, 1990, PEDIATRICS, V86, P440; BAGATELL CJ, 1994, J CLIN ENDOCR METAB, V78, P855, DOI 10.1210/jc.78.4.855; BAGATELL CJ, 1994, J ANDROL, V15, P15; BAGATELL CJ, 1994, J CLIN ENDOCR METAB, V79, P561, DOI 10.1210/jc.79.2.561; BERNECKER PM, 1995, J BONE MINER RES, V10, pS445; Bonjour Jean-Philippe, 1996, P465; CAGNACCI A, 1992, J CLIN ENDOCR METAB, V74, P1396, DOI 10.1210/jc.74.6.1396; Carani C, 1997, NEW ENGL J MED, V337, P91, DOI 10.1056/NEJM199707103370204; CARTER DR, 1992, J BONE MINER RES, V7, P137; CENTER JR, 1997, J BONE MINER RES, V12, pS368; CONTE FA, 1994, J CLIN ENDOCR METAB, V78, P1287, DOI 10.1210/jc.78.6.1287; Davis SR, 1996, J CLIN ENDOCR METAB, V81, P2759, DOI 10.1210/jc.81.8.2759; FINKELSTEIN JS, 1991, J CLIN ENDOCR METAB, V73, P621, DOI 10.1210/jcem-73-3-621; FINKELSTEIN JS, 1987, ANN INTERN MED, V106, P354, DOI 10.7326/0003-4819-106-3; FINKELSTEIN JS, 1992, NEW ENGL J MED, V326, P600, DOI 10.1056/NEJM199202273260904; Genant HK, 1996, J BONE MINER RES, V11, P707; GODSLAND IF, 1993, METABOLISM, V42, P846, DOI 10.1016/0026-0495(93)90058-V; Greendale GA, 1997, J BONE MINER RES, V12, P1833, DOI 10.1359/jbmr.1997.12.11.1833; HARADA N, 1992, AM J HUM GENET, V51, P666; HARADA N, 1992, J BIOL CHEM, V267, P4781; HEANEY RP, 1994, J BONE MINER RES, V9, P1515; ITO Y, 1993, P NATL ACAD SCI USA, V90, P11673, DOI 10.1073/pnas.90.24.11673; KATZMAN DK, 1991, J CLIN ENDOCR METAB, V73, P1332, DOI 10.1210/jcem-73-6-1332; Khosla S, 1998, J CLIN ENDOCR METAB, V83, P2266, DOI 10.1210/jc.83.7.2266; Kletter GB, 1997, J CLIN ENDOCR METAB, V82, P4010, DOI 10.1210/jc.82.12.4010; KORACH KS, 1994, SCIENCE, V266, P1524, DOI 10.1126/science.7985022; Lindsay Robert, 1996, P1063; LUBAHN DB, 1993, P NATL ACAD SCI USA, V90, P11162, DOI 10.1073/pnas.90.23.11162; MILLER VT, 1995, JAMA-J AM MED ASSOC, V273, P199, DOI 10.1001/jama.1995.03520270033028; MORISHIMA A, 1995, J CLIN ENDOCR METAB, V80, P3689, DOI 10.1210/jc.80.12.3689; Mullis PE, 1997, J CLIN ENDOCR METAB, V82, P1739, DOI 10.1210/jc.82.6.1739; ORWOLL ES, 1995, ENDOCR REV, V16, P87, DOI 10.1210/er.16.1.87; Portrat-Doyen S., 1996, Hormone Research (Basel), V46, P4; SHARP SC, 1995, DIABETES REV, V1, P318; SHOZU M, 1991, J CLIN ENDOCR METAB, V72, P560, DOI 10.1210/jcem-72-3-560; Slemenda CW, 1997, J CLIN INVEST, V100, P1755, DOI 10.1172/JCI119701; SMITH EP, 1995, NEW ENGL J MED, V332, P131; Vanderschueren D, 1997, ENDOCRINOLOGY, V138, P2301, DOI 10.1210/en.138.6.2301; VANDERSCHUEREN D, 1995, CALCIFIED TISSUE INT, V56, P341, DOI 10.1007/BF00301598; WARREN MP, 1986, NEW ENGL J MED, V314, P1348, DOI 10.1056/NEJM198605223142104; WARREN MP, 1986, NEW ENGL J MED, V315, P905; *WRIT GROUP PEPI T, 1995, JAMA-J AM MED ASSOC, V274, P1676	44	453	465	0	5	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 27	1998	339	9					599	603		10.1056/NEJM199808273390905	http://dx.doi.org/10.1056/NEJM199808273390905			5	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	113LR	9718379				2022-12-28	WOS:000075552900005
J	West, SK; Duncan, DD; Munoz, B; Rubin, GS; Fried, LP; Bandeen-Roche, K; Schein, OD				West, SK; Duncan, DD; Munoz, B; Rubin, GS; Fried, LP; Bandeen-Roche, K; Schein, OD			Sunlight exposure and risk of lens opacities in a population-based study - The Salisbury Eye Evaluation Project	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ULTRAVIOLET-LIGHT EXPOSURE; CATARACT; PREVALENCE; RADIATION; BALTIMORE	Context.-Exposure to UV-B radiation in sunlight has been shown to increase the risk of cataract formation in high-risk occupational groups, but risk to the population has not been quantified. Objectives.-To determine the ocular exposure to UV-B radiation in sunlight for a population of older persons and to determine the association between UV-B and lens opacities. Design.-The Salisbury Eye Evaluation project, a population-based cohort of older adults. Setting.-Salisbury, Md. Participants.-A total of 2520 community-dwelling 65-year-old to 84-year-old adults in Salisbury, Md, from 1993 to 1995, of whom 26.4% were African Americans. Main Outcome Measure-Association of photographically documented cortical opacity 3/16 or greater in at least 1 eye with ocular UV-B exposure, reported in Maryland sun-years of exposure. Results.-The odds of cortical opacity increased with increasing ocular exposure to UV-B (odds ratio [OR], 1.10; 95% confidence interval [CI], 1.02-1.20). The relationship was similar for women (OR, 1.14; 95% CI, 1.00-1.30) and for African Americans (OR, 1.18; 95% CI, 1.04-1.33). Analyses of the ocular dose by each age group after the age of 30 years showed no vulnerable age group, suggesting damage is based on cumulative exposure. Conclusions.-Although this population of older Americans has relatively low ocular exposure to UV-B in sunlight, there is still an association between ocular exposure and increasing odds of cortical opacity. Our study found an association among African Americans, which, to our knowledge, has not been reported previously. All sex and racial groups would benefit from simple methods to avoid ocular sun exposure.	Johns Hopkins Univ, Wilmer Eye Inst, Baltimore, MD 21287 USA	Johns Hopkins University; Johns Hopkins Medicine	West, SK (corresponding author), Johns Hopkins Univ, Wilmer Eye Inst, Room 129,600 N Wolfe St, Baltimore, MD 21287 USA.				NATIONAL INSTITUTE ON AGING [P01AG010184] Funding Source: NIH RePORTER; NIA NIH HHS [P01-AG10184] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ARMITAGE P, 1985, STAT METHODS MED RES, P469; BAILEY IL, 1991, INVEST OPHTH VIS SCI, V32, P422; BOCHOW TW, 1989, ARCH OPHTHALMOL-CHIC, V107, P369, DOI 10.1001/archopht.1989.01070010379027; BRILLIANT LB, 1983, AM J EPIDEMIOL, V118, P250, DOI 10.1093/oxfordjournals.aje.a113632; COLLMAN GW, 1988, AM J PUBLIC HEALTH, V78, P1459, DOI 10.2105/AJPH.78.11.1459; CRUICKSHANKS KJ, 1992, AM J PUBLIC HEALTH, V82, P1658, DOI 10.2105/AJPH.82.12.1658; DOLEZAL JM, 1989, AM J EPIDEMIOL, V129, P559, DOI 10.1093/oxfordjournals.aje.a115168; Duncan DD, 1997, INVEST OPHTH VIS SCI, V38, P1003; Duncan DD, 1997, PHOTOCHEM PHOTOBIOL, V66, P701; DUNCAN DD, 1995, PHOTOCHEM PHOTOBIOL, V62, P94, DOI 10.1111/j.1751-1097.1995.tb05244.x; Harding J., 1991, CATARACT BIOCH EPIDE; HILLER R, 1977, AM J EPIDEMIOL, V105, P450, DOI 10.1093/oxfordjournals.aje.a112404; HOLLOWS F, 1981, LANCET, V2, P1249; HOOVER RN, 1980, LANCET, V1, P837; KUPFER C, 1984, T OPHTHAL SOC UK, V104, P1; Leske MC, 1997, ARCH OPHTHALMOL-CHIC, V115, P105, DOI 10.1001/archopht.1997.01100150107018; LESKE MC, 1991, ARCH OPHTHALMOL-CHIC, V109, P244, DOI 10.1001/archopht.1991.01080020090051; MUNOZ B, IN PRESS ANN EPIDEMI; Peters AL, 1996, JAMA-J AM MED ASSOC, V276, P1246, DOI 10.1001/jama.276.15.1246; PITTS DG, 1976, NIOSH PUBLICATION, P1; ROSENTHAL FS, 1986, AM J PUBLIC HEALTH, V76, P1216, DOI 10.2105/AJPH.76.10.1216; ROSINI F, 1994, ANN EPIDEMIOL, V4, P266; SCHACHAT AP, 1995, ARCH OPHTHALMOL-CHIC, V113, P728, DOI 10.1001/archopht.1995.01100060054032; SMITH AH, 1980, AM J EPIDEMIOL, V112, P787, DOI 10.1093/oxfordjournals.aje.a113051; SOMMER A, 1991, NEW ENGL J MED, V325, P1412, DOI 10.1056/NEJM199111143252004; STEINBERG EP, 1993, ARCH OPHTHALMOL-CHIC, V111, P1041, DOI 10.1001/archopht.1993.01090080037016; TAYLOR HR, 1988, NEW ENGL J MED, V319, P1429, DOI 10.1056/NEJM198812013192201; Thylefors B, 1995, OPHTHAL EPIDEMIOL, V2, P5; TIELSCH JM, 1991, JAMA-J AM MED ASSOC, V266, P369, DOI 10.1001/jama.266.3.369; WEST SK, 1988, INVEST OPHTH VIS SCI, V29, P73; West SK, 1997, INVEST OPHTH VIS SCI, V38, P72; WEST SK, 1993, CURR EYE RES, V12, P123, DOI 10.3109/02713689308999480; WEST SK, IN PRESS AM J EPIDEM; WONG L, 1993, J EPIDEMIOL COMMUN H, V47, P46, DOI 10.1136/jech.47.1.46	34	184	190	1	14	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 26	1998	280	8					714	718		10.1001/jama.280.8.714	http://dx.doi.org/10.1001/jama.280.8.714			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	111PM	9728643	Bronze			2022-12-28	WOS:000075446900033
J	Bilek, SL; Lay, T				Bilek, SL; Lay, T			Variation of interplate fault zone properties with depth in the Japan subduction zone	SCIENCE			English	Article							LARGE EARTHQUAKE OCCURRENCE; TSUNAMI EARTHQUAKE; SANRIKU-OKI; RUPTURE PROCESS; DECEMBER 28; TRENCH; ASPERITY; ACCRETIONARY; SEISMICITY; MECHANISM	The depth dependence of physical properties along the Japan subduction zone interface was explored using teleseismic recordings of earthquake signals. Broadband body waves were inverted to determine the duration of rupture and source depth for 40 interplate thrust earthquakes located offshore of Honshu between 1989 and 1995. After scaling for differences in seismic moment, there is a systematic decrease in rupture duration with increasing depth along the subducting plate interface. This indicates increases in rupture velocity or stress drop with depth, Likely related to variation in rigidity of sediments on the megathrust.	Univ Calif Santa Cruz, Inst Tecton, Santa Cruz, CA 95064 USA; Univ Calif Santa Cruz, Dept Earth Sci, Santa Cruz, CA 95064 USA	University of California System; University of California Santa Cruz; University of California System; University of California Santa Cruz	Bilek, SL (corresponding author), Univ Calif Santa Cruz, Inst Tecton, Santa Cruz, CA 95064 USA.		Lay, Thorne/ABE-6272-2021					ABE K, 1981, PHYS EARTH PLANET IN, V27, P194, DOI 10.1016/0031-9201(81)90016-9; FUKAO Y, 1979, J GEOPHYS RES, V84, P2303, DOI 10.1029/JB084iB05p02303; Hartog JR, 1996, GEOPHYS RES LETT, V23, P2037, DOI 10.1029/96GL02063; Heki K, 1997, NATURE, V386, P595, DOI 10.1038/386595a0; Heki K, 1997, GEOPHYS RES LETT, V24, P3285, DOI 10.1029/97GL03316; IDE S, 1993, GEOPHYS RES LETT, V20, P863, DOI 10.1029/93GL00683; KANAMORI H, 1975, B SEISMOL SOC AM, V65, P1073; KANAMORI H, 1993, NATURE, V361, P714, DOI 10.1038/361714a0; Kanamori H., 1972, PHYS EARTH PLANET IN, V6, P246, DOI DOI 10.1016/0031-9201(72)90058-1; KAWASAKI I, 1995, J PHYS EARTH, V43, P105, DOI 10.4294/jpe1952.43.105; LAY T, 1982, EARTHQUAKE PRED RES, V1, P3; Nakayama W, 1997, B SEISMOL SOC AM, V87, P918; PELAYO AM, 1992, J GEOPHYS RES-SOL EA, V97, P15321, DOI 10.1029/92JB01305; PELAYO AM, 1990, GEOPHYS RES LETT, V17, P661, DOI 10.1029/GL017i006p00661; RUFF L, 1980, PHYS EARTH PLANET IN, V23, P240, DOI 10.1016/0031-9201(80)90117-X; RUFF LJ, 1994, PURE APPL GEOPHYS, V142, P101, DOI 10.1007/BF00875970; RUFF LJ, 1989, GEOPHYS RES LETT, V16, P1043, DOI 10.1029/GL016i009p01043; RUFF LJ, 1992, TECTONOPHYSICS, V211, P61, DOI 10.1016/0040-1951(92)90051-7; SATAKE K, 1994, GEOPHYS RES LETT, V21, P2519, DOI 10.1029/94GL02338; SCHWARTZ SY, 1985, J GEOPHYS RES-SOLID, V90, P8613, DOI 10.1029/JB090iB10p08613; SUAREZ G, 1993, J GEOPHYS RES-SOL EA, V98, P15825, DOI 10.1029/93JB00234; SUYEHIRO K, 1994, J GEOPHYS RES-SOL EA, V99, P22331, DOI 10.1029/94JB01337; Tanioka Y, 1996, GEOPHYS RES LETT, V23, P1465, DOI 10.1029/96GL01132; Tanioka Y, 1997, ISL ARC, V6, P261, DOI 10.1111/j.1440-1738.1997.tb00176.x; Tanioka Y, 1996, GEOPHYS RES LETT, V23, P1549, DOI 10.1029/96GL01479; TICHELAAR BW, 1991, J GEOPHYS RES-SOLID, V96, P11997, DOI 10.1029/91JB00200; TICHELAAR BW, 1993, J GEOPHYS RES-SOL EA, V98, P2017, DOI 10.1029/92JB02045; TICHELAAR BW, 1993, J GEOPHYS RES-SOL EA, V98, P15829, DOI 10.1029/93JB00702; VIDALE JE, 1993, NATURE, V365, P45, DOI 10.1038/365045a0; VONHUENE R, 1989, TECTONOPHYSICS, V160, P75, DOI 10.1016/0040-1951(89)90385-5; VONHUENE R, 1994, J GEOPHYS RES-SOL EA, V99, P22349, DOI 10.1029/94JB01198; VROLIJK P, 1990, GEOLOGY, V18, P703, DOI 10.1130/0091-7613(1990)018<0703:OTMROS>2.3.CO;2; ZHANG Z, 1992, J GEOPHYS RES, V91, P537	33	37	38	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 21	1998	281	5380					1175	1178		10.1126/science.281.5380.1175	http://dx.doi.org/10.1126/science.281.5380.1175			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	113CE	9712578				2022-12-28	WOS:000075531200048
J	Cousineau, B; Smith, D; Lawrence-Cavanagh, S; Mueller, JE; Yang, J; Mills, D; Manias, D; Dunny, G; Lambowitz, AM; Belfort, M				Cousineau, B; Smith, D; Lawrence-Cavanagh, S; Mueller, JE; Yang, J; Mills, D; Manias, D; Dunny, G; Lambowitz, AM; Belfort, M			Retrohoming of a bacterial group II intron: Mobility via complete reverse splicing, independent of homologous DNA recombination	CELL			English	Article							YEAST MITOCHONDRIAL-DNA; DOUBLE-STRANDED DNA; ESCHERICHIA-COLI; LACTOCOCCUS-LACTIS; RNA; SITE; TRANSCRIPTION; TRANSPOSITION; REQUIREMENTS; INVASION	The mobile group II intron of Lactococcus lactis, LI.LtrB, provides the opportunity to analyze the homing pathway in genetically tractable bacterial systems. Here, we show that LI.LtrB mobility occurs by an RNA-based retrohoming mechanism in both Escherichia coli and L. lactis. Surprisingly, retrohoming occurs efficiently in the absence of RecA function, with a relaxed requirement for flanking exon homology and without coconversion of exon markers. These results lead to a model for bacterial retrohoming in which the intron integrates into recipient DNA by complete reverse splicing and serves as the template for cDNA synthesis. The retrohoming reaction is completed in unprecedented fashion by a DNA repair event that is independent of homologous recombination between the alleles. Thus, LI.LtrB has many features of retrotransposons, with practical and evolutionary implications.	New York State Dept Hlth, Wadsworth Ctr, Mol Genet Program, Albany, NY 12201 USA; SUNY Albany, Sch Publ Hlth, Albany, NY 12201 USA; Ohio State Univ, Dept Mol Genet, Columbus, OH 43210 USA; Ohio State Univ, Dept Biochem, Columbus, OH 43210 USA; Univ Minnesota, Dept Microbiol, Minneapolis, MN 55455 USA; Univ Texas, Dept Biochem & Chem, Inst Mol & Cellular Biol, Austin, TX 78712 USA; Univ Texas, Dept Microbiol, Inst Mol & Cellular Biol, Austin, TX 78712 USA	State University of New York (SUNY) System; Wadsworth Center; State University of New York (SUNY) System; State University of New York (SUNY) Albany; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University of Minnesota System; University of Minnesota Twin Cities; University of Texas System; University of Texas Austin; University of Texas System; University of Texas Austin	Belfort, M (corresponding author), New York State Dept Hlth, Wadsworth Ctr, Mol Genet Program, POB 22002, Albany, NY 12201 USA.		Mills, David Andrew/G-2282-2011; Mills, David/GXF-1821-2022	Mills, David Andrew/0000-0003-1913-9865; Belfort, Marlene/0000-0002-1592-5618	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039422, R01GM037949, R37GM039422] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM37949, GM44844, GM39422] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARTOLOME B, 1991, GENE, V102, P75, DOI 10.1016/0378-1119(91)90541-I; BELFORT M, 1990, METHOD ENZYMOL, V181, P521; BELFORT M, 1987, COLD SPRING HARB SYM, V52, P181, DOI 10.1101/SQB.1987.052.01.023; BOEKE JD, 1985, CELL, V40, P491, DOI 10.1016/0092-8674(85)90197-7; CLYMAN J, 1992, GENE DEV, V6, P1269, DOI 10.1101/gad.6.7.1269; Curcio MJ, 1996, CELL, V84, P9, DOI 10.1016/S0092-8674(00)80987-3; Derr LK, 1998, GENETICS, V148, P937; Eskes R, 1997, CELL, V88, P865, DOI 10.1016/S0092-8674(00)81932-7; Guo HT, 1997, EMBO J, V16, P6835, DOI 10.1093/emboj/16.22.6835; Kuzminov A, 1997, J BACTERIOL, V179, P880, DOI 10.1128/jb.179.3.880-888.1997; LAZOWSKA J, 1994, EMBO J, V13, P4963, DOI 10.1002/j.1460-2075.1994.tb06823.x; LUAN DD, 1993, CELL, V72, P595, DOI 10.1016/0092-8674(93)90078-5; Matsuura M, 1997, GENE DEV, V11, P2910, DOI 10.1101/gad.11.21.2910; MICHEL F, 1995, ANNU REV BIOCHEM, V64, P435, DOI 10.1146/annurev.bi.64.070195.002251; Mills DA, 1996, J BACTERIOL, V178, P3531, DOI 10.1128/jb.178.12.3531-3538.1996; Mills DA, 1997, J BACTERIOL, V179, P6107, DOI 10.1128/jb.179.19.6107-6111.1997; MORAN JV, 1995, MOL CELL BIOL, V15, P2828; Mueller JE, 1996, GENE DEV, V10, P351, DOI 10.1101/gad.10.3.351; Mueller JE, 1996, GENE DEV, V10, P2158, DOI 10.1101/gad.10.17.2158; MUELLER MW, 1993, NATURE, V366, P174, DOI 10.1038/366174a0; Parker MM, 1996, GENETICS, V143, P1057; QUIRK SM, 1989, CELL, V56, P455, DOI 10.1016/0092-8674(89)90248-1; Sambrook J., 2002, MOL CLONING LAB MANU; SELLEM CH, 1993, NATURE, V366, P176, DOI 10.1038/366176a0; SHARP PA, 1991, SCIENCE, V254, P663, DOI 10.1126/science.1948046; Shearman C, 1996, MOL MICROBIOL, V21, P45, DOI 10.1046/j.1365-2958.1996.00610.x; Stahl MM, 1997, GENETICS, V147, P961; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; THALER DS, 1987, J MOL BIOL, V195, P75, DOI 10.1016/0022-2836(87)90328-7; WALKER GC, 1984, MICROBIOL REV, V48, P60, DOI 10.1128/MMBR.48.1.60-93.1984; Yang J, 1996, NATURE, V381, P332, DOI 10.1038/381332a0; YANG J, 1998, IN PRESS J MOL BIOL; ZHANG A, 1995, RNA, V1, P783; ZIMMERLY S, 1995, CELL, V83, P529, DOI 10.1016/0092-8674(95)90092-6; ZIMMERLY S, 1995, CELL, V82, P545, DOI 10.1016/0092-8674(95)90027-6	35	167	171	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	AUG 21	1998	94	4					451	462		10.1016/S0092-8674(00)81586-X	http://dx.doi.org/10.1016/S0092-8674(00)81586-X			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	113GB	9727488	Bronze			2022-12-28	WOS:000075541100007
J	Johnson, DW; Jacobson, S; Edney, PC; Hadfield, P; Mundy, ME; Schuh, S				Johnson, DW; Jacobson, S; Edney, PC; Hadfield, P; Mundy, ME; Schuh, S			A comparison of nebulized budesonide, intramuscular dexamethasone, and placebo for moderately severe group	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DOUBLE-BLIND; CROUP; CONTROVERSY; TRIALS	Background In children with croup, treatment with nebulized budesonide decreases symptoms, but it is uncertain how budesonide compares with dexamethasone, the conventional therapy for croup, and whether either reduces the rate of hospitalization. Methods We performed a double-blind, randomized trial involving 144 children with moderately severe croup. The children were treated with racepinephrine and a single dose of 4 mg of nebulized budesonide (48 children), 0.6 mg of intramuscular dexamethasone per kilogram of body weight (47 children), or placebo (49 children). The children were assessed before treatment and then hourly for five hours after treatment. Physicians who were unaware of the treatment assignments determined the children's need for further treatment and hospitalization. Results The characteristics of the groups were similar at base line, including the types of viruses identified, the types of croup, and the clinical severity of the illness. The overall rates of hospitalization were 71 percent in the placebo group (35 of 49 children), 38 percent in the budesonide group (18 of 48 children), and 23 percent in the dexamethasone group (11 of 47 children) (unadjusted P=0.001 for the comparison of budesonide with placebo, P<0.001 for the comparison of dexamethasone with placebo, and P=0.18 for the comparison of budesonide with dexamethasone). Children treated with budesonide or dexamethasone had a greater improvement in croup scores than those given placebo (P=0.03 and P<0.001, respectively), and those treated with dexamethasone had a greater improvement than those treated with budesonide (P=0.003). Conclusions In children with moderately severe croup, treatment with intramuscular dexamethasone or nebulized budesonide resulted in more rapid clinical improvement than did the administration of placebo, with dexamethasone offering the greatest improvement. Treatment with either glucocorticoid resulted in fewer hospitalizations. (N Engl J Med 1998; 339:498-503.) (C)1998, Massachusetts Medical Society.	Univ Calgary, Alberta Childrens Hosp, Dept Paediat, Child Hlth Res Unit, Calgary, AB T2T 5C7, Canada; Univ Toronto, Hosp Sick Children, Dept Paediat, Toronto, ON M5G 1X8, Canada; Asta Pharma AG, Mississauga, ON, Canada	Alberta Childrens Hospital; University of Calgary; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)	Johnson, DW (corresponding author), Univ Calgary, Alberta Childrens Hosp, Dept Paediat, Child Hlth Res Unit, 1820 Richmond Rd SW, Calgary, AB T2T 5C7, Canada.							Altman D.G., 1991, PRACTICAL STAT MED R; CHERRY JD, 1979, J PEDIATR-US, V94, P352, DOI 10.1016/S0022-3476(79)80883-5; CHERRY JD, 1992, TXB PEDIAT INFECT DI, V1, P209; DAUM RS, 1992, TXB PEDIAT INFECT DI, V1, P197; DENNY FW, 1983, PEDIATRICS, V71, P871; Fitzgerald D, 1996, PEDIATRICS, V97, P722; Geelhoed GC, 1995, PEDIATR PULM, V20, P355, DOI 10.1002/ppul.1950200604; GEELHOED GC, 1997, GROUP PEDIAT PULMONO, V23, P370; GELLER NL, 1987, BIOMETRICS, V43, P213, DOI 10.2307/2531962; Godden CW, 1997, ARCH DIS CHILD, V76, P155, DOI 10.1136/adc.76.2.155; Hess D, 1996, CHEST, V110, P498, DOI 10.1378/chest.110.2.498; HUSBY S, 1993, ARCH DIS CHILD, V68, P352, DOI 10.1136/adc.68.3.352; Johnson DW, 1996, ARCH PEDIAT ADOL MED, V150, P349, DOI 10.1001/archpedi.1996.02170290015002; Klassen TP, 1996, PEDIATRICS, V97, P463; KLASSEN TP, 1994, NEW ENGL J MED, V331, P285, DOI 10.1056/NEJM199408043310501; LOEW D, 1986, EUR J CLIN PHARMACOL, V30, P225, DOI 10.1007/BF00614309; Neter J, 1985, APPL LINEAR REGRESSI; NORMAN GR, 1989, J CLIN EPIDEMIOL, V42, P1097, DOI 10.1016/0895-4356(89)90051-6; Roberts Gregory W., 1993, Australian Journal of Hospital Pharmacy, V23, P35; SHAPIRO SS, 1965, BIOMETRIKA, V52, P591, DOI 10.1093/biomet/52.3-4.591; SIMONSSON BG, 1982, EUR J RESPIR DIS, V63, P7; STOKES M, 1995, CATEGORICAL DATA ANA; TUNNESSEN WW, 1980, J PEDIATR-US, V96, P751; WESTLEY CR, 1978, AM J DIS CHILD, V132, P484, DOI 10.1001/archpedi.1978.02120300044008	24	86	89	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 20	1998	339	8					498	503		10.1056/NEJM199808203390802	http://dx.doi.org/10.1056/NEJM199808203390802			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	111PN	9709042				2022-12-28	WOS:000075447000002
J	McNally, NJ; Williams, HC; Phillips, DR; Smallman-Raynor, M; Lewis, S; Venn, A; Britton, J				McNally, NJ; Williams, HC; Phillips, DR; Smallman-Raynor, M; Lewis, S; Venn, A; Britton, J			Atopic eczema and domestic water hardness	LANCET			English	Article							DERMATITIS; ASTHMA	Background The environment plays an important part in the aetiology of atopic eczema, but specific causes are unknown. Exposure to hard water is thought to be a risk factor for eczema. We undertook an ecological study of the relation between domestic water hardness and the prevalence of eczema among Nottinghamshire schoolchildren. Methods Questionnaire details of 1-year period and lifetime prevalence of eczema were obtained from parents of 4141 randomly selected primary-school children and 3499 secondary-school children in southern Nottinghamshire. Geographical information systems (GIS) were used to link the geographical distribution of eczema prevalence with domestic water-hardness data (four categories). Adjustment was made for potential confounding by sex, age, socioeconomic status, and access to health care. Findings Among the primary-school children there was a significant direct relation between both 1-year period and lifetime prevalence of eczema and water hardness, both before and after adjustment for confounders. The 1-year period prevalence was 17.3% (261/1509) in the highest water-hardness category and 12.0% (94/786) in the lowest (adjusted odds ratio 1.54 [95% CI 1.19-1.99] p for trend <0.001). The corresponding values for lifetime prevalence were 25.4% (384/1509) and 21.2% (167/786; adjusted odds ratio 1.28 [1.04-1.58], p for trend=0.02). Eczema prevalence trends in the secondary-school population were not significant (adjusted odds ratio for highest compared with lowest hardness category for 1-year prevalence 1.03 [0.79-1.33], p for trend=0.46; for lifetime prevalence 0.99 [0.83-1.23], p for trend=0.93). Eczema prevalence in primary-school children increased in relation to chlorine content of water, but the trend across four chlorine-content categories was not independently significant after adjustment for confounders. Interpretation Exposure to hard water in the home may increase the risk of eczema in children of primary-school age.	Univ Nottingham, Dept Geog, Hlth Res Grp, Nottingham NG7 2RD, England; Univ Hosp, Queens Med Ctr, Dept Dermatol, Nottingham, England; City Hosp, Div Resp Med, Nottingham NG5 1PB, England	University of Nottingham; Nottingham University Hospital NHS Trust; University of Nottingham; University of Nottingham	McNally, NJ (corresponding author), Univ Nottingham, Dept Geog, Hlth Res Grp, Nottingham NG7 2RD, England.		Britton, John R/G-9705-2011	McNally, Nick/0000-0002-0434-2302; Smallman-Raynor, Matthew/0000-0002-0942-7209; williams, hywel/0000-0002-5646-3093				ASHER MI, 1995, EUR RESPIR J, V8, P483, DOI 10.1183/09031936.95.08030483; ATHERTON DJ, 1994, ECZEMA CHILDHOOD FAC; GATRELL AC, 1991, ENVIRON PLANN A, V23, P1447, DOI 10.1068/a231447; GATRELL AC, 1991, INT J GEOGR INF SYST, V3, P395; GIGGS JA, 1988, SOC SCI MED, V26, P79, DOI 10.1016/0277-9536(88)90047-0; GIGGS JA, 1980, T I BRIT GEOGR, V5, P229, DOI 10.2307/622266; GOLDING J, 1986, BIRTH 5 STUDY HLTH B, P171; Gray NF., 1994, DRINKING WATER QUALI, P21; MORREN MA, 1994, J AM ACAD DERMATOL, V31, P467, DOI 10.1016/S0190-9622(94)70213-6; *OFF POP CENS SURV, 1985, OPCS CENTR POSTC DIR; Ogawa Hideoki, 1993, Journal of Dermatological Science, V5, P197, DOI 10.1016/0923-1811(93)90767-J; *OPCS, 1991, CENS POP; Popescu CM, 1998, BRIT J DERMATOL, V138, P436, DOI 10.1046/j.1365-2133.1998.02121.x; STRACHAN DP, 1995, CLIN EXP ALLERGY, V25, P791, DOI 10.1111/j.1365-2222.1995.tb00019.x; TAYLOR B, 1984, LANCET, V2, P1255, DOI 10.1016/S0140-6736(84)92805-8; Townsend PP., 1988, HLTH DEPRIVATION INE; Venn A, 1998, EUR RESPIR J, V11, P1324, DOI 10.1183/09031936.98.11061324; Venn A, 1998, BRIT MED J, V316, P1945, DOI 10.1136/bmj.316.7149.1945; WAHLGREN CF, 1992, ALLERGY, V47, P65, DOI 10.1111/j.1398-9995.1992.tb05091.x; WHO, 1993, RECOMMENDATIONS, V1, P1; WILLIAMS HC, 1995, BRIT MED J, V311, P1241, DOI 10.1136/bmj.311.7015.1241; Williams HC, 1996, BRIT J DERMATOL, V135, P12	22	109	112	0	16	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	AUG 15	1998	352	9127					527	531		10.1016/S0140-6736(98)01402-0	http://dx.doi.org/10.1016/S0140-6736(98)01402-0			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	111KC	9716057				2022-12-28	WOS:000075435300011
J	Gans, HA; Arvin, AM; Galinus, J; Logan, L; DeHovitz, R; Maldonado, Y				Gans, HA; Arvin, AM; Galinus, J; Logan, L; DeHovitz, R; Maldonado, Y			Deficiency of the humoral immune response to measles vaccine in infants immunized at age 6 months	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HERPES-SIMPLEX VIRUS; CELL-MEDIATED-IMMUNITY; T-CELLS; CD40 LIGAND; NEUTRALIZATION TEST; INTERFERON-GAMMA; EDMONSTON-ZAGREB; DENDRITIC CELLS; UNITED-STATES; ANTIBODY	Context.-Measles causes serious morbidity in infants, with the highest risk among those who are 6 to 12 months of age. In the United States, measles vac cine has been given at age 12 to 15 months to minimize interference by passive antibodies and to achieve the high seroprevalence required for herd immunity. Infants of mothers with vaccine-induced immunity may lose passively acquired antibodies before 12 months, leaving them susceptible to measles infection. Objective.-To assess the immunogenicity of measles vaccine in infants younger than 12 months. Design.-Cohort study conducted before and after measles immunization. Setting.-Pediatric clinic in Pale Alto, Calif. Participants.-Infants 6 (n = 27), 9 (n = 26), and 12 (n = 34) months of age were enrolled; 72 provided both initial and follow-up samples. Main Outcome Measures.-Evaluation of immunogenicity before and 12 weeks after measles vaccination, including measles neutralizing antibody titers, measles-specific T-cell proliferation, and cytokine profiles. Results.-Measles neutralizing antibodies were present before vaccination in 52% (12/23), 35% (7/20), and 0% (0/22) of 6-, 9-, and 12-month-old infants, respectively. in the absence of detectable passive antibodies, geometric mean titers after vaccination were significantly lower in 6-month-old infants compared with 9-month-old infants (27 vs 578, P =.01) and 12-month-old infants (27 vs 972, P=.001). The seroconversion rate, defined as a 4-fold rise in antibody titer, in these 6-month-old infants was only 67%, and only 36% of these infants achieved seroprotective neutralizing antibody titers of 120 or higher after vaccination compared with 100% of 9- and 12-month-old infants lacking detectable passive antibody prior to vaccination. T-cell proliferation and cytokine responses to measles did not differ with age. Conclusions.-Humoral immunity was deficient in 6-month-old infants given measles vaccine, even in the absence of detectable passively acquired neutralizing antibodies. Comparison of their responses with those of 9- and 12-month-old infants indicates that a developmental maturation pf the immune response to measles may occur during the first year of life, which affects the immunogenicity Of measles vaccine.	Stanford Univ, Dept Pediat, Sch Med, Stanford, CA 94305 USA; Palo Alto Med Fdn, Dept Pediat, Palo Alto, CA 94301 USA	Stanford University; Palo Alto Medical Foundation Research Institute	Gans, HA (corresponding author), Stanford Univ, Dept Pediat, Sch Med, G-312, Stanford, CA 94305 USA.	drhayley@leland.stanford.edu			NIAID NIH HHS [AI37127] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI037127] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AABY P, 1991, EXPANDED PROGRAMME I; ALBRECHT P, 1977, J PEDIATR-US, V91, P715, DOI 10.1016/S0022-3476(77)81021-4; ALBRECHT P, 1981, J VIROL METHODS, V3, P251, DOI 10.1016/0166-0934(81)90062-8; Atkinson William L., 1992, Morbidity and Mortality Weekly Report, V41, P1; BABBOTT FL, 1954, AM J MED SCI, V228, P334; BLACK FL, 1976, VIRAL INFECTIONS HUM, P297; BLACK FL, 1989, PROG MED VIROL, V36, P1; BRUGNONI D, 1994, EUR J IMMUNOL, V24, P1919, DOI 10.1002/eji.1830240831; BURCHETT SK, 1992, J INFECT DIS, V165, P813, DOI 10.1093/infdis/165.5.813; CAUX C, 1994, J EXP MED, V180, P1263, DOI 10.1084/jem.180.4.1263; CHEN RT, 1990, J INFECT DIS, V162, P1036, DOI 10.1093/infdis/162.5.1036; CHERRY JD, 1972, J PEDIATR-US, V81, P217, DOI 10.1016/S0022-3476(72)80287-7; CHERRY JD, 1992, TXB PEDIATRIC INFECT, P1591; CLEMENTS CJ, 1995, CURR TOP MICROBIOL, V191, P13; CUTTS FT, 1994, VACCINE, V12, P1311, DOI 10.1016/S0264-410X(94)80057-7; GINDLER JS, 1992, PEDIATR INFECT DIS J, V11, P841, DOI 10.1097/00006454-199210000-00007; GRIFFIN DE, 1995, CURR TOP MICROBIOL, V191, P117; GRIFFIN DE, 1993, J INFECT DIS, V168, P275, DOI 10.1093/infdis/168.2.275; GRIFFIN DE, 1994, J INFECT DIS, V170, pS24, DOI 10.1093/infdis/170.Supplement_1.S24; HARDY GE, 1970, AM J EPIDEMIOL, V91, P286, DOI 10.1093/oxfordjournals.aje.a121138; HAYWARD AR, 1984, J IMMUNOL, V133, P2469; HUNT DWC, 1994, BLOOD, V84, P4333, DOI 10.1182/blood.V84.12.4333.bloodjournal84124333; Hussey GD, 1996, J INFECT DIS, V173, P1320, DOI 10.1093/infdis/173.6.1320; JOHNSON CE, 1994, PEDIATRICS, V93, P939; Karp CL, 1996, SCIENCE, V273, P228, DOI 10.1126/science.273.5272.228; Kennedy MK, 1996, EUR J IMMUNOL, V26, P370, DOI 10.1002/eji.1830260216; Klaus S J, 1994, Semin Immunol, V6, P279, DOI 10.1006/smim.1994.1036; KRUGMAN RD, 1977, J PEDIATR-US, V91, P766, DOI 10.1016/S0022-3476(77)81036-6; LENNON JL, 1986, J PEDIATR-US, V108, P671, DOI 10.1016/S0022-3476(86)81039-3; LINNEMANN CC, 1982, PEDIATRICS, V69, P332; MALDONADO YA, 1995, PEDIATRICS, V96, P447; Markowitz LE, 1996, PEDIATRICS, V97, P53; MARKOWITZ LE, 1990, PEDIATR INFECT DIS J, V9, P101, DOI 10.1097/00006454-199002000-00008; Markowitz LE, 1994, VACCINES, P229; Martinez X, 1997, P NATL ACAD SCI USA, V94, P8726, DOI 10.1073/pnas.94.16.8726; MCGRAW TT, 1986, PEDIATRICS, V77, P45; MURPHY MD, 1984, PEDIATRICS, V74, P90; NONOYAMA S, 1995, J CLIN INVEST, V95, P66, DOI 10.1172/JCI117677; Oxenius A, 1996, J EXP MED, V183, P2209, DOI 10.1084/jem.183.5.2209; PABST HF, 1992, PEDIATR INFECT DIS J, V11, P525, DOI 10.1097/00006454-199207000-00004; PASS RF, 1981, INFECT IMMUN, V34, P166, DOI 10.1128/IAI.34.1.166-170.1981; Peter G, 1997, 1997 RED BOOK REPORT, P344; RATNAM S, 1995, J CLIN MICROBIOL, V33, P811, DOI 10.1128/JCM.33.4.811-815.1995; SCHLUEDERBERG A, 1973, AM J EPIDEMIOL, V97, P402, DOI 10.1093/oxfordjournals.aje.a121521; SCHMITT E, 1994, EUR J IMMUNOL, V24, P793, DOI 10.1002/eji.1830240403; SHASBY DM, 1977, NEW ENGL J MED, V296, P585, DOI 10.1056/NEJM197703172961102; SHELTON JD, 1978, PEDIATRICS, V62, P961; Siegrist CA, 1997, VACCINE, V15, P798, DOI 10.1016/S0264-410X(96)00253-8; STETLER HC, 1986, PEDIATRICS, V77, P471; Stuber E, 1996, J EXP MED, V183, P693, DOI 10.1084/jem.183.2.693; SULLENDER WM, 1987, J INFECT DIS, V155, P28, DOI 10.1093/infdis/155.1.28; VANESSEN D, 1995, NATURE, V378, P620, DOI 10.1038/378620a0; WARD BJ, 1993, CLIN IMMUNOL IMMUNOP, V67, P171, DOI 10.1006/clin.1993.1061; WARD BJ, 1995, J INFECT DIS, V172, P1591, DOI 10.1093/infdis/172.6.1591; WEDGWOOD JF, 1994, MT SINAI J MED, V61, P406; WILKINS J, 1979, J PEDIATR-US, V94, P865, DOI 10.1016/S0022-3476(79)80203-6; YEAGER AS, 1977, JAMA-J AM MED ASSOC, V237, P347, DOI 10.1001/jama.237.4.347; 1997, MMWR MORB MORTAL WKL, V46, P766	58	208	214	1	8	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 12	1998	280	6					527	532		10.1001/jama.280.6.527	http://dx.doi.org/10.1001/jama.280.6.527			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	108AY	9707142	Bronze			2022-12-28	WOS:000075244900028
J	Darling, M				Darling, M			Low-dose aspirin not for pre-eclampsia	LANCET			English	Editorial Material									Rotunda Hosp, Dublin 1, Ireland		Darling, M (corresponding author), Rotunda Hosp, Dublin 1, Ireland.							[Anonymous], 1996, Br J Obstet Gynaecol, V103, P39; BEROYZ G, 1994, LANCET, V343, P619; Caritis S, 1998, NEW ENGL J MED, V338, P701, DOI 10.1056/NEJM199803123381101; Golding J, 1998, BRIT J OBSTET GYNAEC, V105, P293, DOI 10.1111/j.1471-0528.1998.tb10089.x; PARAZZINI F, 1993, LANCET, V341, P396; Rotchell YE, 1998, BRIT J OBSTET GYNAEC, V105, P286, DOI 10.1111/j.1471-0528.1998.tb10088.x; SIBAI BM, 1993, NEW ENGL J MED, V329, P1213, DOI 10.1056/NEJM199310213291701	7	8	9	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 1	1998	352	9125					342	342		10.1016/S0140-6736(05)60465-5	http://dx.doi.org/10.1016/S0140-6736(05)60465-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	106BU	9717919				2022-12-28	WOS:000075110500007
J	Loukides, S; Kharitonov, S; Wodehouse, T; Cole, PJ; Barnes, PJ				Loukides, S; Kharitonov, S; Wodehouse, T; Cole, PJ; Barnes, PJ			Effect of arginine on mucociliary function in primary ciliary dyskinesia	LANCET			English	Article							BEAT FREQUENCY; NITRIC-OXIDE		Natl Heart & Lung Inst, Imperial Coll Sch Med, Dept Thorac Med, London SW3 6LY, England	Imperial College London	Barnes, PJ (corresponding author), Natl Heart & Lung Inst, Imperial Coll Sch Med, Dept Thorac Med, Dovehouse St, London SW3 6LY, England.			Barnes, Peter/0000-0002-5122-4018				GREENSTORM M, 1988, QJ MED, V253, P925; JAIN B, 1993, BIOCHEM BIOPH RES CO, V191, P83, DOI 10.1006/bbrc.1993.1187; LUNDBERG JON, 1994, EUR RESPIR J, V7, P1501, DOI 10.1183/09031936.94.07081501; Sapienza MA, 1998, THORAX, V53, P172, DOI 10.1136/thx.53.3.172; SCHUIL PJ, 1995, ACTA OTO-LARYNGOL, V115, P438, DOI 10.3109/00016489509139344	5	56	57	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	AUG 1	1998	352	9125					371	372		10.1016/S0140-6736(05)60471-0	http://dx.doi.org/10.1016/S0140-6736(05)60471-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	106BU	9717932				2022-12-28	WOS:000075110500020
J	Lucas, A				Lucas, A			Collaborative research with infant formula companies should not always be censored	BRITISH MEDICAL JOURNAL			English	Article							BREAST-MILK; EARLY DIET; PRETERM		Inst Child Hlth, MRC, Childhood Nutr Res Ctr, London WC1N 1EH, England	University of London; University College London	Lucas, A (corresponding author), Inst Child Hlth, MRC, Childhood Nutr Res Ctr, 30 Guilford St, London WC1N 1EH, England.							Bishop NJ, 1996, ACTA PAEDIATR, V85, P230, DOI 10.1111/j.1651-2227.1996.tb13999.x; Falkner F, 1997, INT CHILD HLTH, Vviii, P1; FALL CHD, 1992, BRIT MED J, V304, P801, DOI 10.1136/bmj.304.6830.801; FALL CHD, 1992, FETAL INFANT ORIGINS, P275; FOSTER K, 1995, INFANT FEEDING; LUCAS A, 1990, LANCET, V336, P1519, DOI 10.1016/0140-6736(90)93304-8; LUCAS A, 1994, ARCH DIS CHILD, V71, P288, DOI 10.1136/adc.71.4.288; LUCAS A, 1990, LANCET, V335, P1477, DOI 10.1016/0140-6736(90)93026-L; LUCAS A, 1992, LANCET, V339, P261, DOI 10.1016/0140-6736(92)91329-7; MOTT GE, 1991, CIBA F SYMP, V156, P56; ROTHMAN J, 1998, MARKETING RES TODAY, P86; Wise J, 1997, BRIT MED J, V314, P167	12	6	6	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 1	1998	317	7154					337	338						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	110YQ	9729080				2022-12-28	WOS:000075409500034
J	Dunn, MR; Miller, RS; Richter, TH				Dunn, MR; Miller, RS; Richter, TH			Graduate medical education, 1997-1998	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INITIAL EMPLOYMENT STATUS	In response to growing concerns that continued unlimited governmental funding of graduate medical education (GME) would lead to a physician surplus, Congress enacted provisions in the Balanced Budget Act (BBA) of 1997 to limit further growth, as well as to encourage reductions in GME. The measures incorporated in this section of the BBA reflect recommendations made by a number of major professional associations. The question now is how effective these efforts will be and whether they will produce unintended or deleterious consequences. We report the changes occurring in GME from 1993 to 1997, focusing on changes prior to and since the enactment of the BBA. The total number of residents in GME programs has remained relatively constant from 1993 to 1997. The number of residents entering GME programs without prior GME experience has also remained constant; however, over the same period, the number entering a new program with some prior GME experience has fallen by 5.8%. The number of international medical graduates in all GME programs has increased 12.4% during this same period, while the number of US allopathic medical school graduates has decreased 4.4%. As federal and state initiatives are introduced to change the number and distribution of GME positions, it is critical that the American Medical Association and other professional organizations monitor GME tracking data more systematically and accurately than ever before.	Amer Med Assoc, Div Grad Med Educ, Chicago, IL 60610 USA	American Medical Association	Dunn, MR (corresponding author), Amer Med Assoc, Div Grad Med Educ, 515 N State St, Chicago, IL 60610 USA.							*BUR HLTH PROF, 1996, 7 BUR HLTH PROF; *COUNC GRAD MED ED, 1994, 4 US DEP HLTH HUM SE; Council on Graduate Medical Education, 1998, 10 US DEP HLTH HUM S; Dunn MR, 1996, JAMA-J AM MED ASSOC, V276, P710, DOI 10.1001/jama.276.9.710; Ginsburg JA, 1998, ANN INTERN MED, V128, P142; *I MED, 1996, NAT PHYS WORKF OPT B; Iglehart JK, 1998, NEW ENGL J MED, V338, P402, DOI 10.1056/NEJM199802053380620; Miller RS, 1996, JAMA-J AM MED ASSOC, V275, P708, DOI 10.1001/jama.275.9.708; Miller RS, 1998, JAMA-J AM MED ASSOC, V280, P777, DOI 10.1001/jama.280.9.777; Miller RS, 1997, JAMA-J AM MED ASSOC, V277, P1699, DOI 10.1001/jama.277.21.1699; MITKA M, 1997, AM MED NEWS     0120, P1; MITKA M, 1997, AM MED NEWS     0224, P72; MITKA M, 1997, AM MED NEWS     0224, P74; Pew Health Professions Commission, 1995, CRIT CHALL REV HLTH	14	45	45	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 2	1998	280	9					809	812		10.1001/jama.280.9.809	http://dx.doi.org/10.1001/jama.280.9.809			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	114LA	9729993				2022-12-28	WOS:000075609900010
J	Miller, RS; Dunn, MR; Richter, TH; Whitcomb, ME				Miller, RS; Dunn, MR; Richter, TH; Whitcomb, ME			Employment-Seeking experiences of resident physicians completing training during 1996	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Context.-Studies analyzing the physician workforce have concluded that the United States is verging on a physician oversupply, yet we lack persuasive evidence that this is resulting in physician underemployment and/or unemployment. Objective.-To determine the degree to which graduating residents have difficulty finding or are unable to find employment in their primary career choices. Design.-Two 1-page surveys sent separately to residents and to program directors to collect information on the employment status of residents who were completing a graduate medical education program at the end of the 1995-1996 academic year. Setting.-A total of 25 067 resident physicians scheduled in the spring of 1996 to complete a residency program accredited by the Accreditation Council on Graduate Medical Education, and 4569 program directors in 31 specialties and subspecialties. Main Outcome Measure.-Both the graduates' employment status and the degree of difficulty they experienced securing a practice position, as reported by resident physicians and program directors. Results.-After 6 months of data collection, 12 135 (48.4%) of 25 067 resident physicians responded to the survey. Of the respondents, 11 200 had completed their training, and 7628 (68.1%) were attempting to enter the workforce, 28.4% were seeking additional training, and 3.5% were fulfilling their military obligations. Of the 7628 resident physicians who sought employment, 67.3% obtained clinical practice positions in their specialties, 15.5% took academic positions, 5.0% found clinical positions in other specialties, 5.1% had other plans, and 7.1% did not yet have positions but were actively looking. In addition, 22.4% of resident physicians who found clinical positions reported significant difficulty finding them. The subgroup reporting greater difficulty finding clinical positions included international medical graduates (more than 40%), those completing programs in the Pacific or East North Central region, and those in several specialties. The 1996 graduating residents reported significantly higher rates of difficulty finding suitable employment than program directors reported for their graduates (22.4% vs 6.0%); however, the percentage of graduates reported by both groups as entering the workforce was the same (68.1%). Program directors reported an unemployment rate of only 1.2%, for their 1996 graduates, which was less than the rate reported by the resident physicians (7.1%). Conclusions.-Resident physicians' direct reports of their employment-seeking experiences differ from what program directors report. Program directors accurately determined the number of residents pursuing further training. however, they did not have complete information about the employment difficulties experienced by their graduates. Based on graduates' reports, we conclude that employment difficulties are greatest among international medical graduates and vary by specialty and geographic region.	Amer Med Assoc, Div Grad Med Educ, Chicago, IL 60610 USA; Assoc Amer Coll, Div Med Educ, Washington, DC USA	American Medical Association	Miller, RS (corresponding author), Amer Med Assoc, Div Grad Med Educ, 515 N State St, Chicago, IL 60610 USA.							*BUR HLTH PROF, 1996, 7 BUR HLTH PROF; *COUNC GRAD MED ED, 1994, 4 US DEP HLTH HUM SE; Council on Graduate Medical Education, 1998, 10 US DEP HLTH HUM S; Ginsburg JA, 1998, ANN INTERN MED, V128, P142; *I MED, 1996, NAT PHYS WORKF OPT B; Miller RS, 1996, JAMA-J AM MED ASSOC, V275, P708, DOI 10.1001/jama.275.9.708; Miller RS, 1997, JAMA-J AM MED ASSOC, V277, P1699, DOI 10.1001/jama.277.21.1699; MITKA M, 1997, AM MED NEWS     0224, P72; MITKA M, 1997, AM MED NEWS     0224, P74; Pew Health Professions Commission, 1995, CRIT CHALL REV HLTH; RINEHARDT UW, 1994, INQUIRY, V31, P250	11	55	56	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 2	1998	280	9					777	783		10.1001/jama.280.9.777	http://dx.doi.org/10.1001/jama.280.9.777			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	114LA	9729988				2022-12-28	WOS:000075609900005
J	Oei, SG; Helmerhorst, FM; Bloemenkamp, KWM; Hollants, FAM; Meerpoel, DEM; Keirse, MJNC				Oei, SG; Helmerhorst, FM; Bloemenkamp, KWM; Hollants, FAM; Meerpoel, DEM; Keirse, MJNC			Effectiveness of the postcoital test: randomised controlled trial	BRITISH MEDICAL JOURNAL			English	Article							INTRAUTERINE INSEMINATION	Objectives: To investigate the impact of the postcoital test on the pregnancy rate among subfertile couples and on the number of other diagnostic tests and treatments. Design: Randomised controlled study. Setting: A university and two non-university teaching hospitals in the Netherlands. Subjects: New couples at infertility clinics, 1 March 1993 to 1 October 1995; randomisation to an intervention group (series of infertility investigations that include the postcoital test) or to a control group (series excluding the test). Main outcome measure: Cumulative pregnancy rate. Results: Of 736 consecutive new couples, 444 fulfilled the inclusion criteria and consented to participate (intervention group, 227; control group, 217). Treatment was given more often in the intervention group than in the control group (54% v 41%; difference 13% (95% confidence interval 4% to 22%)). Yet cumulative pregnancy rates at 24 months in the intervention group (49% (42% to 55%)) and the control group (48% (42% to 55%)) were closely similar (difference 1% (-9.0% to 9.0%)). Conclusion: Routine use of the postcoital test in infertility investigations leads to more tests and treatments but has no significant effect on the pregnancy rate.	Leiden Univ, Med Ctr, Dept Obstet Gynaecol & Reprod Med, NL-2300 RC Leiden, Netherlands; St Joseph Hosp, Dept Obstet & Gynaecol, NL-5500 MB Veldhoven, Netherlands; Flinders Univ S Australia, Dept Obstet & Gynaecol, Adelaide, SA 5042, Australia	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Flinders University South Australia	Helmerhorst, FM (corresponding author), Leiden Univ, Med Ctr, Dept Obstet Gynaecol & Reprod Med, POB 9600, NL-2300 RC Leiden, Netherlands.							ALLMAN RM, 1985, JAMA-J AM MED ASSOC, V254, P246, DOI 10.1001/jama.254.2.246; EISENBERG JM, 1984, ARCH INTERN MED, V144, P715, DOI 10.1001/archinte.144.4.715; FRIEDMAN A, 1989, INT J FERTIL, V34, P199; GLAZENER CMA, 1987, BRIT J OBSTET GYNAEC, V94, P774, DOI 10.1111/j.1471-0528.1987.tb03725.x; GRIFFITH CS, 1990, AM J OBSTET GYNECOL, V162, P615, DOI 10.1016/0002-9378(90)90969-E; KIRBY CA, 1991, FERTIL STERIL, V56, P102; OEI SG, 1995, HUM REPROD, V10, P1711, DOI 10.1093/oxfordjournals.humrep.a136160; OEI SG, 1995, BRIT J OBSTET GYNAEC, V102, P621; PUTTERMAN C, 1995, NEW ENGL J MED, V333, P1208, DOI 10.1056/NEJM199511023331809; ROWE PJ, 1993, WHO MANUAL STANDARDI; Sims JM, 1866, CLIN NOTES UTERINE S; THIBAULT GE, 1994, NEW ENGL J MED, V331, P1216, DOI 10.1056/NEJM199411033311809; VANDEHELDER AB, 1990, J IN VITRO FERTIL EM, V7, P358; VELDE ERT, 1989, FERTIL STERIL, V51, P182	14	56	56	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 22	1998	317	7157					502	505						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	115AM	9712594				2022-12-28	WOS:000075641400017
J	Potter, J; Langhorne, P; Roberts, M				Potter, J; Langhorne, P; Roberts, M			Routine protein energy supplementation in adults: Systematic review	BRITISH MEDICAL JOURNAL			English	Article							OBSTRUCTIVE PULMONARY-DISEASE; RANDOMIZED CLINICAL-TRIAL; NUTRITIONAL SUPPORT; BODY-COMPOSITION; ELDERLY PATIENTS; DIETARY SUPPLEMENTATION; MUSCLE FUNCTION; MALNOURISHED PATIENTS; ENTERAL NUTRITION; IMMUNE FUNCTION		Victoria Infirm NHS Trust, Victoria Geriatr Unit, Glasgow G41 3DX, Lanark, Scotland; Univ Glasgow, Glasgow Royal Infirm Trust, Dept Med, Acad Sect Geriatr Med, Glasgow G4 0SF, Lanark, Scotland	University of Glasgow	Potter, J (corresponding author), Vicroria Infirm NHS Trust, Dept Med Elderly, Mansionhouse Unit, Glasgow G41 3DX, Lanark, Scotland.							Allison SP, 1995, HOSP UPDATE      FEB, P55; BAKER JP, 1982, NEW ENGL J MED, V306, P969, DOI 10.1056/NEJM198204223061606; BASTOW MD, 1983, BRIT MED J, V287, P1589, DOI 10.1136/bmj.287.6405.1589; Bracken Michael B., 1992, P13; BUNKER VW, 1994, BRIT J BIOMED SCI, V51, P128; BUNOUT D, 1989, EUR J CLIN NUTR, V43, P615; BURR ML, 1984, BRIT J NUTR, V51, P165, DOI 10.1079/BJN19840020; Chalmers I, 1995, SYSTEMATIC REV; CHANDRA RK, 1992, LANCET, V340, P1124, DOI 10.1016/0140-6736(92)93151-C; CHANDRA RK, 1985, BRIT MED J, V291, P705, DOI 10.1136/bmj.291.6497.705; CHANDRA RK, 1990, AGE AGEING, V19, P25; CHIARELLI A, 1990, AM J CLIN NUTR, V51, P1035, DOI 10.1093/ajcn/51.6.1035; DELMI M, 1990, LANCET, V335, P1013, DOI 10.1016/0140-6736(90)91073-J; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; EFTHIMIOU J, 1988, AM REV RESPIR DIS, V137, P1075, DOI 10.1164/ajrccm/137.5.1075; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; ELKORT RJ, 1981, JPEN-PARENTER ENTER, V5, P385, DOI 10.1177/0148607181005005385; EVANS WK, 1987, J CLIN ONCOL, V5, P113, DOI 10.1200/JCO.1987.5.1.113; FIATARONE MA, 1994, NEW ENGL J MED, V330, P1769, DOI 10.1056/NEJM199406233302501; FIATARONE MA, 1993, J GERONTOL, V48, P77, DOI 10.1093/geronj/48.Special_Issue.77; GALANOS AN, 1994, J AM GERIATR SOC, V42, P368, DOI 10.1111/j.1532-5415.1994.tb07483.x; Ganzoni A, 1994, Schweiz Rundsch Med Prax, V83, P13; GROSS PA, 1988, ARCH INTERN MED, V148, P562, DOI 10.1001/archinte.148.3.562; HANKEY CR, 1993, J HUM NUTR DIET, V6, P317, DOI 10.1111/j.1365-277X.1993.tb00377.x; HEYMSFIELD SB, 1982, AM J CLIN NUTR, V36, P680, DOI 10.1093/ajcn/36.4.680; Hwang T L, 1991, J Formos Med Assoc, V90, P993; JEBB SA, 1993, AM J CLIN NUTR, V58, P455, DOI 10.1093/ajcn/58.4.455; KELLY SM, 1984, AM REV RESPIR DIS, V130, P33; KLIPSTEINGROBUSCH K, 1995, BRIT J NUTR, V73, P323, DOI 10.1079/BJN19950033; KNOWLES JB, 1988, CHEST, V93, P979; LARSSON J, 1990, CLIN NUTR, V9, P179, DOI 10.1016/0261-5614(90)90017-M; Lennard-Jones J E, 1992, POSITIVE APPROACH NU; LESOURD B, 1995, NUTR REV, V53, pS86; LEWIS MI, 1987, AM REV RESPIR DIS, V135, P1062; LOPES J, 1982, AM J CLIN NUTR, V36, P602, DOI 10.1093/ajcn/36.4.602; MARCIA E, 1991, NUTRITION, V7, P205; MCWHIRTER JP, 1994, BRIT MED J, V308, P945, DOI 10.1136/bmj.308.6934.945; MEREDITH CN, 1992, J AM GERIATR SOC, V40, P155, DOI 10.1111/j.1532-5415.1992.tb01937.x; NAYAL H, 1992, NUTRITION, V8, P13; Olin AO, 1996, JPEN-PARENTER ENTER, V20, P93, DOI 10.1177/014860719602000293; OTTE KE, 1989, JPEN-PARENTER ENTER, V13, P152, DOI 10.1177/0148607189013002152; PETO R, 1987, STAT MED, V6, P233, DOI 10.1002/sim.4780060306; POTTER J, 1995, AGE AGEING, V24, P131, DOI 10.1093/ageing/24.2.131; RANA SK, 1992, CLIN NUTR, V11, P337, DOI 10.1016/0261-5614(92)90084-4; REILLY JJ, 1994, BRIT J NUTR, V72, P33, DOI 10.1079/BJN19940007; ROEBOTHAN BV, 1994, AGE AGEING, V23, P49, DOI 10.1093/ageing/23.1.49; ROGERS RM, 1992, AM REV RESPIR DIS, V146, P1511, DOI 10.1164/ajrccm/146.6.1511; RUSSELL DM, 1983, AM J CLIN NUTR, V38, P229, DOI 10.1093/ajcn/38.2.229; SAGAR S, 1979, BMJ-BRIT MED J, V1, P293, DOI 10.1136/bmj.1.6159.293; SCHOLS AMWJ, 1995, AM J RESP CRIT CARE, V152, P1268, DOI 10.1164/ajrccm.152.4.7551381; SCHROEDER D, 1991, JPEN-PARENTER ENTER, V15, P376, DOI 10.1177/0148607191015004376; SHULKA HS, 1984, INDIAN J MED RES, V80, P339; SHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408; SMITH RC, 1985, BRIT J SURG, V72, P458, DOI 10.1002/bjs.1800720619; Souba WW, 1996, BRIT MED J, V312, P864; SPIRTOS NM, 1988, AM J OBSTET GYNECOL, V158, P1285, DOI 10.1016/0002-9378(88)90358-4; VIR CS, 1980, GERONTOLOGY, V1, P3; VONMEYENFELDT MF, 1992, CLIN NUTR, V11, P180, DOI 10.1016/0261-5614(92)90026-M; WHITTAKER JS, 1990, AM REV RESPIR DIS, V142, P283, DOI 10.1164/ajrccm/142.2.283; WINDSOR JA, 1988, ANN SURG, V208, P209, DOI 10.1097/00000658-198808000-00013; WOO J, 1994, AGE AGEING, V23, P40, DOI 10.1093/ageing/23.1.40	61	134	135	1	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 22	1998	317	7157					495	501						9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	115AM	9712593	Green Submitted, Bronze, Green Published			2022-12-28	WOS:000075641400015
J	de Quervain, DJF; Roozendaal, B; McGaugh, JL				de Quervain, DJF; Roozendaal, B; McGaugh, JL			Stress and glucocorticoids impair retrieval of long-term spatial memory	NATURE			English	Article							DECLARATIVE MEMORY; CORTICOSTERONE; PERFORMANCE; RAT	Extensive evidence from animal and human studies indicates that stress and glucocorticoids influence cognitive function(1-11). Previous studies have focused exclusively on glucocorticoid effects on acquisition and long-term storage of newly acquired information. Here we report that stress and glucocorticoids also affect memory retrieval. We show that rats have impaired performance in a water-maze spatial task after being given footshock 30 min before retention testing but are not impaired when footshock is given 2 min or 4 h before testing. These time-dependent effects on retention performance correspond to the circulating corticosterone levels at the time of testing, which suggests that the retention impairment is directly related to increased adrenocortical function. In support of this idea, we find that suppression of corticosterone synthesis with metyrapone blocks the stress-induced retention impairment. In addition, systemic corticosterone administered to non-stressed rats 30 min before retention testing induces dose-dependent retention impairment. The impairing effects of stress and glucocorticoids on retention are not due to disruption of spatial navigation per se. Our results indicate that besides the well described effects of stress and glucocorticoids on acquisition and consolidation processes, glucocorticoids also affect memory retrieval mechanisms.	Univ Calif Irvine, Ctr Neurobiol Learning & Memory, Irvine, CA 92697 USA; Univ Calif Irvine, Dept Psychobiol, Irvine, CA 92697 USA	University of California System; University of California Irvine; University of California System; University of California Irvine	Roozendaal, B (corresponding author), Univ Calif Irvine, Ctr Neurobiol Learning & Memory, Irvine, CA 92697 USA.		Roozendaal, Benno/B-8403-2013	de Quervain, Dominique/0000-0001-7131-2464				Conrad CD, 1996, BEHAV NEUROSCI, V110, P1321, DOI 10.1037/0735-7044.110.6.1321; DEBOER SF, 1990, PHYSIOL BEHAV, V47, P1117, DOI 10.1016/0031-9384(90)90361-7; DEKLOET ER, 1991, FRONT NEUROENDOCRIN, V12, P955; JOELS M, 1994, ANN NY ACAD SCI, V746, P166; Kirschbaum C, 1996, LIFE SCI, V58, P1475, DOI 10.1016/0024-3205(96)00118-X; LUINE V, 1994, BRAIN RES, V639, P167, DOI 10.1016/0006-8993(94)91778-7; Luine Victoria, 1996, Physiology and Behavior, V59, P27, DOI 10.1016/0031-9384(95)02016-0; LUINE VN, 1993, BRAIN RES, V616, P65, DOI 10.1016/0006-8993(93)90193-Q; Lupien SJ, 1997, BRAIN RES REV, V24, P1, DOI 10.1016/S0165-0173(97)00004-0; Lupien SJ, 1997, J CLIN ENDOCR METAB, V82, P2070, DOI 10.1210/jc.82.7.2070; MCEWEN BS, 1994, HORM BEHAV, V28, P396, DOI 10.1006/hbeh.1994.1036; Monk TH, 1997, J SLEEP RES, V6, P9, DOI 10.1046/j.1365-2869.1997.00023.x; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; NEWCOMER JW, 1994, J NEUROSCI, V14, P2047; OITZL MS, 1992, BEHAV NEUROSCI, V106, P62, DOI 10.1037/0735-7044.106.1.62; ORCHINIK M, 1994, ANN NY ACAD SCI, V746, P101; Roozendaal B, 1996, NEUROBIOL LEARN MEM, V65, P1, DOI 10.1006/nlme.1996.0001; Roozendaal B, 1996, PSYCHONEUROENDOCRINO, V21, P681, DOI 10.1016/S0306-4530(96)00028-5; Sandi C, 1997, EUR J NEUROSCI, V9, P637, DOI 10.1111/j.1460-9568.1997.tb01412.x; SHORS TJ, 1992, SCIENCE, V257, P537, DOI 10.1126/science.1636089; THOMAS DN, 1994, ANN NY ACAD SCI, V746, P467	21	867	908	1	79	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 20	1998	394	6695					787	790		10.1038/29542	http://dx.doi.org/10.1038/29542			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	112PR	9723618				2022-12-28	WOS:000075503600047
J	Yoshioka, H; Meno, C; Koshiba, K; Sugihara, M; Itoh, H; Ishimaru, Y; Inoue, T; Ohuchi, H; Semina, EV; Murray, JC; Hamada, H; Noji, S				Yoshioka, H; Meno, C; Koshiba, K; Sugihara, M; Itoh, H; Ishimaru, Y; Inoue, T; Ohuchi, H; Semina, EV; Murray, JC; Hamada, H; Noji, S			Pitx2, a bicoid-type homeobox gene, is involved in a lefty-signaling pathway in determination of left-right asymmetry	CELL			English	Article							RETROVIRAL VECTORS; EXPRESSION; MOUSE	Signaling molecules such as Activin, Sonic hedgehog, Nodal, Lefty, and Vg1 have been found to be involved in determination of left-right (L-R) asymmetry in the chick, mouse, or frog. However, a common signaling pathway has not yet been identified in vertebrates. We report that Pitx2, a bicoid-type homeobox gene expressed asymmetrically in the left lateral plate mesoderm, may be involved in determination of L-R asymmetry in both mouse and chick. Since Pitx2 appears to be downstream of lefty-1 in the mouse pathway, we examined whether mouse Lefty proteins could affect the expression of Pitx2 in the chick. Our results indicate that a common pathway from lefty-1 to Pitx2 likely exists for determination of L-R asymmetry in vertebrates.	Univ Tokushima, Fac Engn, Dept Biol Sci & Technol, Tokushima 7708506, Japan; Osaka Univ, Inst Mol & Cellular Biol, Osaka 5650871, Japan; Univ Iowa, Dept Pediat, Iowa City, IA 52242 USA; Univ Iowa, Dept Sci Biol, Iowa City, IA 52242 USA; Kyoto Univ, Grad Sch, Fac Pharmaceut Sci, Dept Biochem Genet, Kyoto 6068501, Japan	Tokushima University; Osaka University; University of Iowa; University of Iowa; Kyoto University	Noji, S (corresponding author), Univ Tokushima, Fac Engn, Dept Biol Sci & Technol, 2-1 Minami Jyosanjima Cho, Tokushima 7708506, Japan.		Noji, Sumihare/E-3047-2010; Hamada, Hiroshi/N-6374-2015	Hamada, Hiroshi/0000-0002-7196-5948				Collignon J, 1996, NATURE, V381, P155, DOI 10.1038/381155a0; FEKETE DM, 1993, MOL CELL BIOL, V13, P2604, DOI 10.1128/MCB.13.4.2604; Gage PJ, 1997, HUM MOL GENET, V6, P457, DOI 10.1093/hmg/6.3.457; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; Hummel K. P., 1959, Journal of Heredity, V50, P9; Isaac A, 1997, SCIENCE, V275, P1301, DOI 10.1126/science.275.5304.1301; King T, 1997, CURR BIOL, V7, pR212, DOI 10.1016/S0960-9822(06)00103-5; Kitamura K, 1997, MECH DEVELOP, V67, P83, DOI 10.1016/S0925-4773(97)00110-X; Kuwana T, 1996, INT J DEV BIOL, V40, P1061; LAYTON WM, 1976, J HERED, V67, P336, DOI 10.1093/oxfordjournals.jhered.a108749; Levin M, 1997, BIOESSAYS, V19, P287, DOI 10.1002/bies.950190406; Levin M, 1997, DEV BIOL, V189, P57, DOI 10.1006/dbio.1997.8662; LEVIN M, 1995, CELL, V82, P803, DOI 10.1016/0092-8674(95)90477-8; Meno C, 1997, GENES CELLS, V2, P513, DOI 10.1046/j.1365-2443.1997.1400338.x; Meno C, 1996, NATURE, V381, P151, DOI 10.1038/381151a0; Mucchielli ML, 1996, MOL CELL NEUROSCI, V8, P258, DOI 10.1006/mcne.1996.0062; NEW DAT, 1955, J EMBRYOL EXP MORPH, V3, P320; NOHNO T, 1995, BIOCHEM BIOPH RES CO, V206, P33, DOI 10.1006/bbrc.1995.1005; Ohuchi H, 1997, DEVELOPMENT, V124, P2235; Pagan-Westphal SM, 1998, CELL, V93, P25, DOI 10.1016/S0092-8674(00)81143-5; Semina EV, 1996, NAT GENET, V14, P392, DOI 10.1038/ng1296-392; Varlet I, 1997, CURR OPIN GENET DEV, V7, P519, DOI 10.1016/S0959-437X(97)80080-9; WILKINSON DG, 1992, IN SITU HYBRIDIZATIO, P75; YOST HJ, 1995, CELL, V82, P689, DOI 10.1016/0092-8674(95)90464-6	25	308	311	0	10	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 7	1998	94	3					299	305		10.1016/S0092-8674(00)81473-7	http://dx.doi.org/10.1016/S0092-8674(00)81473-7			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	109EN	9708732	Bronze			2022-12-28	WOS:000075308400006
J	Peters, R; Sikorski, R				Peters, R; Sikorski, R			The heat is on!	SCIENCE			English	Article									Medsite Commun, Boston, MA USA		Peters, R (corresponding author), Medsite Commun, Boston, MA USA.							Dahiyat BI, 1997, SCIENCE, V278, P82, DOI 10.1126/science.278.5335.82; Malakauskas SM, 1998, NAT STRUCT BIOL, V5, P470, DOI 10.1038/nsb0698-470	2	0	0	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 17	1998	281	5375					368	369		10.1126/science.281.5375.368	http://dx.doi.org/10.1126/science.281.5375.368			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	102HR	9705715				2022-12-28	WOS:000074918800038
J	Butler, CC; Rollnick, S; Pill, R; Maggs-Rapport, F; Stott, N				Butler, CC; Rollnick, S; Pill, R; Maggs-Rapport, F; Stott, N			Understanding the culture of prescribing: qualitative study of general practitioners' and patients' perceptions of antibiotics for sore throats	BMJ-BRITISH MEDICAL JOURNAL			English	Article							RESPIRATORY-INFECTIONS; PRESCHOOL-CHILDREN; RANDOMIZED TRIAL; EXPECTATIONS; PENICILLIN; CARE; POPULATION; PHYSICIANS; STRATEGIES; RESISTANCE	Objectives: To better understand reasons for antibiotics being prescribed for sore throats despite well known evidence that they are generally of little help. Design: Qualitative study with semi-structured interviews. Setting: General practices in South Wales. Subjects: 21 general practitioners and 17 of their patients who had recently consulted for a sore throat or upper respiratory tract infection. Main outcome measures: Subjects' experience of management of the illness, patients' expectations, beliefs about antibiotic treatment for sore throats, and ideas for reducing prescribing. Results: Doctors knew of the evidence for marginal effectiveness yet often prescribed for good relationships with patients Possible patient benefit outweighed theoretical community risk from resistant bacteria. Most doctors found prescribing "against the evidence" uncomfortable and realised this probably increased workload, Explanations of the distinction between virus and bacterium often led to perceived confusion. Clinicians were divided on the value of leaflets and national campaigns, but several favoured patient empowerment for self care by other members of the primary care team. Patient expectations were seldom made explicit, and many were not met A third of patients had a clear expectation for antibiotics, and mothers were more likely to accept non-antibiotic treatment for their children than for themselves. Satisfaction was not necessarily related to receiving antibiotics, with many seeking reassurance, further information, and pain relief. Conclusions: This prescribing decision is greatly influenced by considerations of the doctor-patient relationship. Consulting strategies that make patient expectations explicit without damaging relationships might reduce unwanted antibiotics. Repeating evidence for lack or effectiveness is unlikely to change doctors' prescribing, but information about risk to individual patients might. Emphasising positive aspects of non-antibiotic treatment and lack of efficacy in general might be helpful.	Univ Wales Coll Med, Llanedeyrn Hlth Ctr, Dept Gen Practice, Cardiff CF3 7PN, S Glam, Wales; Univ Wales Coll Med, Dept Dent Publ Hlth, Lansdowne Hosp, Cardiff CF4 4XN, S Glam, Wales	Cardiff University; Cardiff University	Rollnick, S (corresponding author), Univ Wales Coll Med, Llanedeyrn Hlth Ctr, Dept Gen Practice, Cardiff CF3 7PN, S Glam, Wales.	genpract@cf.ac.uk	Butler, Christopher C/B-5048-2009	Butler, Christopher/0000-0002-0102-3453; Rapport, Frances/0000-0002-4428-2826				BRADLEY CP, 1992, BRIT MED J, V304, P294, DOI 10.1136/bmj.304.6822.294; BRITTEN N, 1994, BRIT J GEN PRACT, V44, P465; BRITTEN N, 1995, FAM PRACT, V12, P104, DOI 10.1093/fampra/12.1.104; BRITTEN N, 1995, BRIT MED J, V311, P251, DOI 10.1136/bmj.311.6999.251; CAMPION PD, 1984, BRIT MED J, V288, P1426, DOI 10.1136/bmj.288.6428.1426; Cartwright A., 1981, GEN PRACTICE REVISIT; CHERIAN T, 1994, JAMA-J AM MED ASSOC, V271, P695, DOI 10.1001/jama.271.9.695; Cockburn J, 1997, BRIT MED J, V315, P520, DOI 10.1136/bmj.315.7107.520; COMAROFF J, 1976, SOCIOL REV, V24, P79, DOI 10.1111/j.1467-954X.1976.tb00574.x; Dagnelie CF, 1996, BRIT J GEN PRACT, V46, P589; Davey PG, 1996, BRIT MED J, V312, P613, DOI 10.1136/bmj.312.7031.613; DELMAR CB, 1997, ACUTE RESP INFECT MO; DEMELKER RA, 1991, BRIT J GEN PRACT, V41, P504; Dowell SF, 1997, AM FAM PHYSICIAN, V55, P1647; Glaser B.G., 1965, AWARENESS DYING; Gonzales R, 1997, JAMA-J AM MED ASSOC, V278, P901, DOI 10.1001/jama.278.11.901; Hamm RM, 1996, J FAM PRACTICE, V43, P56; Hart CA, 1998, BMJ-BRIT MED J, V316, P1255, DOI 10.1136/bmj.316.7140.1255; HAWKLEY PM, 1998, LANCET, V351, P1208; Herold BC, 1998, JAMA-J AM MED ASSOC, V279, P593, DOI 10.1001/jama.279.8.593; HERZ MJ, 1988, FAM PRACT, V5, P196, DOI 10.1093/fampra/5.3.196; Hickner JM, 1998, J FAM PRACTICE, V46, P119; Howe RW, 1997, BRIT J GEN PRACT, V47, P280; Kai J, 1996, BRIT MED J, V313, P987; Kai J, 1996, BRIT MED J, V313, P983; KUYVENHOVEN MM, 1993, FAM PRACT, V10, P266; Little P, 1996, FAM PRACT, V13, P317, DOI 10.1093/fampra/13.3.317; Little P, 1997, BRIT MED J, V315, P350; Little P, 1997, BMJ-BRIT MED J, V314, P722, DOI 10.1136/bmj.314.7082.722; Mainous AG, 1998, J FAM PRACTICE, V46, P142; Mainous AG, 1997, J FAM PRACTICE, V45, P75; Mainous AG, 1996, J FAM PRACTICE, V42, P357; MCCAIG LF, 1995, JAMA-J AM MED ASSOC, V273, P214, DOI 10.1001/jama.273.3.214; NAVA JM, 1994, CLIN INFECT DIS, V19, P884, DOI 10.1093/clinids/19.5.884; Nyquist AC, 1998, JAMA-J AM MED ASSOC, V279, P875, DOI 10.1001/jama.279.11.875; SCHWARTZ RK, 1989, SOC SCI MED, V28, P577, DOI 10.1016/0277-9536(89)90252-9; Seppala H, 1997, NEW ENGL J MED, V337, P441, DOI 10.1056/NEJM199708143370701; *SHOUS LORDS SEL C, 1998, RES ANT OTH ANT AG; STOTT NCH, 1979, BRIT MED J, V1, P29, DOI 10.1136/bmj.1.6155.29; Swartz MN, 1997, NEW ENGL J MED, V337, P491, DOI 10.1056/NEJM199708143370709; TAN TQ, 1993, PEDIATRICS, V92, P761; VINSON DC, 1993, J FAM PRACTICE, V37, P23; VIRJI A, 1991, FAM PRACT, V8, P314, DOI 10.1093/fampra/8.4.314; WHITFIELD MJ, 1981, PRACTITIONER, V225, P234	44	472	480	0	45	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 5	1998	317	7159					637	642		10.1136/bmj.317.7159.637	http://dx.doi.org/10.1136/bmj.317.7159.637			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	118GN	9727992	Green Submitted, Green Accepted, Green Published, Bronze			2022-12-28	WOS:000075830200022
J	Elphic, RC; Lawrence, DJ; Feldman, WC; Barraclough, BL; Maurice, S; Binder, AB; Lucey, PG				Elphic, RC; Lawrence, DJ; Feldman, WC; Barraclough, BL; Maurice, S; Binder, AB; Lucey, PG			Lunar Fe and Ti abundances: Comparison of lunar prospector and Clementine data	SCIENCE			English	Article							NEUTRON	The Lunar Prospector neutron spectrometer data correlate well with iron and titanium abundances obtained through analysis of Clementine spectral reflectance data. With the iron and titanium dependence removed, the neutron spectrometer data also reveal regions with enhanced amounts of gadolinium and samarium, incompatible rare earth elements that are enriched in the final phases of magma crystallization. These regions are found mainly around the ramparts of the Imbrium impact basin but not around the other basins, including the much larger and deeper South Pole-Aitken basin. This result confirms the compositional uniqueness of the surface and interior of the Imbrium region.	Univ Calif Los Alamos Natl Lab, Los Alamos, NM 87545 USA; Observ Midi Pyrenees, F-31400 Toulouse, France; Lunar Res Inst, Gilroy, CA 95020 USA; Univ Hawaii, Hawaii Inst Geophys & Planetol, Honolulu, HI 96822 USA	United States Department of Energy (DOE); Los Alamos National Laboratory; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; University of Hawaii System	Elphic, RC (corresponding author), Univ Calif Los Alamos Natl Lab, MS D466, Los Alamos, NM 87545 USA.		Lawrence, David J/E-7463-2015	Lawrence, David J/0000-0002-7696-6667				Blewett DT, 1997, J GEOPHYS RES-PLANET, V102, P16319, DOI 10.1029/97JE01505; CLARK PE, 1998, P LUNAR PLANET SCI C, V29, P1501; DRAKE DM, 1988, J GEOPHYS RES-SOLID, V93, P6353, DOI 10.1029/JB093iB06p06353; Feldman WC, 1998, SCIENCE, V281, P1489, DOI 10.1126/science.281.5382.1489; FELDMAN WC, 1991, GEOPHYS RES LETT, V18, P2157, DOI 10.1029/91GL02618; Feldman WC, 1998, SCIENCE, V281, P1496, DOI 10.1126/science.281.5382.1496; HASKIN LA, 1991, LUNAR SOURCEBOOK, P167; Lawrence DJ, 1998, SCIENCE, V281, P1484, DOI 10.1126/science.281.5382.1484; LINGENFELTER RE, 1972, EARTH PLANET SC LETT, V16, P355, DOI 10.1016/0012-821X(72)90153-7; Lucey P.G., 1996, LUNAR PLANET SCI, V27, P781; Lucey PG, 1998, J GEOPHYS RES-PLANET, V103, P3679, DOI 10.1029/97JE03019; LUCEY PG, 1995, SCIENCE, V268, P1150, DOI 10.1126/science.268.5214.1150; Reedy RC, 1998, METEORIT PLANET SCI, V33, pA127	13	75	81	1	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 4	1998	281	5382					1493	1496		10.1126/science.281.5382.1493	http://dx.doi.org/10.1126/science.281.5382.1493			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	116RJ	9727972				2022-12-28	WOS:000075738100036
J	Lin, RP; Mitchell, DL; Curtis, DW; Anderson, KA; Carlson, CW; McFadden, J; Acuna, MH; Hood, LL; Binder, A				Lin, RP; Mitchell, DL; Curtis, DW; Anderson, KA; Carlson, CW; McFadden, J; Acuna, MH; Hood, LL; Binder, A			Lunar surface magnetic fields and their interaction with the solar wind: Results from lunar prospector	SCIENCE			English	Article							IMPACT BASINS	The magnetometer and electron reflectometer experiment on the Lunar Prospector spacecraft has obtained maps of Lunar crustal magnetic fields and observed the interaction between the solar wind and regions of strong crustal magnetic fields at high selenographic Latitude (30 degrees S to 80 degrees S) and Low (similar to 100 kilometers) altitude. Electron reflection maps of the regions antipodal to the Imbrium and Serenitatis impact basins, extending to 80 degrees S Latitude, show that crustal magnetic fields fill most of the antipodal zones of those basins. This finding provides further evidence for the hypothesis that basin-forming impacts result in magnetization of the lunar crust at their antipodes. The crustal magnetic fields of the Imbrium antipode region are strong enough to deflect the solar wind and form a miniature (100 to several hundred kilometers across) magnetosphere, magnetosheath, and bow shock system.	Univ Calif Berkeley, Space Sci Lab, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Phys, Berkeley, CA 94720 USA; NASA, Goddard Space Flight Ctr, Greenbelt, MD 20771 USA; Lunar Res Inst, Gilroy, CA 95020 USA; Univ Arizona, Lunar & Planetary Lab, Tucson, AZ 85721 USA	University of California System; University of California Berkeley; University of California System; University of California Berkeley; National Aeronautics & Space Administration (NASA); NASA Goddard Space Flight Center; University of Arizona	Mitchell, DL (corresponding author), Univ Calif Berkeley, Space Sci Lab, Berkeley, CA 94720 USA.	mitchell@ssl.berkeley.edu						ACUNA MH, 1992, J GEOPHYS RES-PLANET, V97, P7799, DOI 10.1029/92JE00344; Acuna MH, 1998, SCIENCE, V279, P1676, DOI 10.1126/science.279.5357.1676; Anderson K. A., 1975, Space Science Instrumentation, V1, P439; ANDERSON KA, 1979, EARTH PLANET SC LETT, V46, P107, DOI 10.1016/0012-821X(79)90068-2; ANDERSON KA, 1977, EARTH PLANET SC LETT, V34, P141, DOI 10.1016/0012-821X(77)90115-7; Cisowski S. M., 1983, Journal of Geophysical Research, V88, P691, DOI 10.1029/JB088iS02p0A691; COLBURN DS, 1967, SCIENCE, V158, P1040, DOI 10.1126/science.158.3804.1040; COLEMAN PJ, 1972, P LUNAR PLANET SCI C, V3, P2271; DYAL P, 1974, REV GEOPHYS, V12, P568, DOI 10.1029/RG012i004p00568; DYAL P, 1972, NATURE, V236, P381, DOI 10.1038/236381a0; DYAL P, 1974, P LUNAR PLANET SCI C, V5, P3059; DYAL P, 1973, P LUNAR PLANET SCI C, V4, P2925; FAIRFIELD DH, 1974, J GEOPHYS RES, V79, P1368, DOI 10.1029/JA079i010p01368; Fuller M., 1974, Moon, V9, P57, DOI 10.1007/BF00565392; FULLER M, 1987, GEOMAGN AERON, V2, P306; GOLDSTEIN BE, 1974, J GEOPHYS RES, V79, P23, DOI 10.1029/JA079i001p00023; HOLLWEG JV, 1970, J GEOPHYS RES, V75, P1209, DOI 10.1029/JA075i007p01209; HOOD L, 1981, J GEOPHYS RES S, V92, pE396; HOOD LL, 1980, SCIENCE, V208, P49, DOI 10.1126/science.208.4439.49; HOOD LL, 1979, SCIENCE, V204, P53, DOI 10.1126/science.204.4388.53; HOOD LL, 1984, J GEOPHYS RES, V89, pC211, DOI 10.1029/JB089iS01p0C211; HOOD LL, 1991, J GEOPHYS RES-SOLID, V96, P9837, DOI 10.1029/91JB00308; LIN RP, 1988, ICARUS, V74, P529, DOI 10.1016/0019-1035(88)90119-4; LIN RP, 1979, PHYS EARTH PLANET IN, V20, P271, DOI 10.1016/0031-9201(79)90050-5; MERRILL RT, 1996, MAGNETIC FIELD EARTH, V63, P217; NESS NF, 1968, J GEOPHYS RES, V73, P3421, DOI 10.1029/JA073i011p03421; Runcorn S. K., 1980, P LUNAR PLANET SCI C, V11, P1867; RUNCORN SK, 1982, PHYS EARTH PLANET IN, V29, P135, DOI 10.1016/0031-9201(82)90068-1; RUSSELL CT, 1975, J GEOPHYS RES-SPACE, V80, P4700, DOI 10.1029/JA080i034p04700; RUSSELL CT, 1978, P LUNAR PLANET SCI C, V5, P2747; SISCOE GL, 1969, J GEOPHYS RES, V74, P59, DOI 10.1029/JA074i001p00059; SISCOE GL, 1972, J GEOPHYS RES, V77, P6042, DOI 10.1029/JA077i031p06042; SONETT CP, 1982, REV GEOPHYS, V20, P411, DOI 10.1029/RG020i003p00411; SONETT CP, 1972, J GEOPHYS RES, V77, P588, DOI 10.1029/JA077i004p00588; WILHELMS DE, 1984, NASA, P107; [No title captured]	36	186	196	2	31	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 4	1998	281	5382					1480	1484		10.1126/science.281.5382.1480	http://dx.doi.org/10.1126/science.281.5382.1480			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	116RJ	9727969				2022-12-28	WOS:000075738100033
J	Jones, RF; Ganem, JL; Williams, DJ; Krakower, JY				Jones, RF; Ganem, JL; Williams, DJ; Krakower, JY			Review of US medical school finances, 1996-1997	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Based on data from the Annual Medical School Questionnaire of the Liaison Committee on Medical Education, to which 100% of schools responded, the revenues that supported the programs and activities of the 125 accredited medical schools in the United States totaled $34 897 million in 1996-1997, A large proportion (78.9%) of these revenues was derived from 3 sources: practice plans, grants and contracts, and hospital support. Both public and private medical schools, in aggregate, have continued to experience growth throughout the last decade but at a progressively slower rate, primarily because of a slowing in the growth of practice plan revenues. Federal revenues supporting research in public and private medical schools since 1992-1993 have grown at annualized, constant-dollar rates of 5.6% and 4%, respectively. Growth in state and local appropriations to public medical schools has tended to lag behind inflation. Growth in reported revenues from endowments that are used to support programs at private medical schools is on the rise. The aggregate numbers mask considerable variation among schools with regard to changes in financing. A small, but appreciable, number of schools have witnessed a constant-dollar decline in their total practice plan revenues since 1992-1993. The financial data reviewed in this report demonstrate the continued dependence of medical schools on faculty-generated sources of revenue and confirm the perception that medical schools, as a group, are experiencing constraints on the growth of their enterprises.	Assoc Amer Med Coll, Sect Inst & Fac Studies, Washington, DC 20037 USA	Association of American Medical Colleges	Krakower, JY (corresponding author), Assoc Amer Med Coll, Sect Inst & Fac Studies, 2450 N St NW, Washington, DC 20037 USA.							*ASS AM MED COLL, 1996, FIN MED SCH REP ASS; Ganem JL, 1997, JAMA-J AM MED ASSOC, V278, P755	2	10	10	1	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 2	1998	280	9					813	818		10.1001/jama.280.9.813	http://dx.doi.org/10.1001/jama.280.9.813			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	114LA	9729994				2022-12-28	WOS:000075609900011
J	Douglas, C				Douglas, C			On staying calm	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 29	1998	317	7158					606	606		10.1136/bmj.317.7158.606	http://dx.doi.org/10.1136/bmj.317.7158.606			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	117EK	9721138	Green Published			2022-12-28	WOS:000075767800051
J	Rees, J				Rees, J			FGFR2 mutations and acne	LANCET			English	Editorial Material									Univ Newcastle Upon Tyne, Sch Med, Dept Dermatol, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England	Newcastle University - UK	Rees, J (corresponding author), Univ Newcastle Upon Tyne, Sch Med, Dept Dermatol, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.							GOLDSTEIN JI, 1993, A GARROD INDIVIDUALI; JACKSON R, 1976, BRIT J DERMATOL, V95, P349, DOI 10.1111/j.1365-2133.1976.tb00835.x; Shuster S., 1978, DERMATOLOGY INTERNAL, P116	3	6	6	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	AUG 29	1998	352	9129					668	669		10.1016/S0140-6736(05)60814-8	http://dx.doi.org/10.1016/S0140-6736(05)60814-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	116MT	9728976				2022-12-28	WOS:000075729700004
J	Serruys, PW; van Hout, B; Bonnier, H; Legrand, V; Garcia, E; Macaya, C; Sousa, E; van der Giessen, W; Colombo, A; Seabra-Gomes, R; Kiemeneij, F; Ruygrok, P; Ormiston, J; Emanuelsson, H; Fajadet, J; Haude, M; Klugmann, S; Morel, MA				Serruys, PW; van Hout, B; Bonnier, H; Legrand, V; Garcia, E; Macaya, C; Sousa, E; van der Giessen, W; Colombo, A; Seabra-Gomes, R; Kiemeneij, F; Ruygrok, P; Ormiston, J; Emanuelsson, H; Fajadet, J; Haude, M; Klugmann, S; Morel, MA		Benestent Study Grp	Randomised comparison of implantation of heparin-coated stents with balloon angioplasty in selected patients with coronary artery disease (Benestent II)	LANCET			English	Article							PALMAZ-SCHATZ STENTS; FOLLOW-UP; PLACEMENT; RESTENOSIS; THERAPY; ANGINA; PTCA	Background The multicentre, randomised Benestent-II study investigated a strategy of implantation of a heparin-coated Palmar-Schatz stent plus antiplatelet drugs compared with the use of balloon angioplasty in selected patients with stable or stabilised unstable angina, with one or more de-novo lesions, less than 18 mm long, in vessels of diameter 3 mm or more. Methods 827 patients were randomly assigned stent implantation (414 patients) or standard balloon angioplasty (413 patients). The primary clinical endpoint was event-free survival at 6 months, including death, myocardial infarction, and the need for revascularisation. The secondary endpoints were the restenosis rate at 6 months and the cost-effectiveness at 12 months. There was also one-to-one subrandomisation to either clinical and angiographic follow-up or clinical follow-up alone. Analyses were by intention to treat. Findings Four patients (one stent group, three angioplasty group) were excluded from analysis since no lesion was found. At 6 months, a primary clinical endpoint had occurred in 53 (12.8%) of 413 patients in the stent group and 79 (19.3%) of 410 in the angioplasty group (p=0.013). This significant difference in clinical outcome was maintained at 12 months. In the subgroup assigned angiographic follow-up, the mean minimum lumen diameter was greater in the stent group than in the balloon-angioplasty group, (1.89 [SD 0.65] vs 1.66 [0.57] mm, p=0.0002), which corresponds to restenosis rates (diameter stenosis greater than or equal to 50%) of 16% and 31% (p=0.0008). In the group assigned clinical follow-up alone, event-free survival rate at 12 months was higher in the stent group than the balloon-angioplasty group (0.89 vs 0.79, p=0.004) at a cost of an additional 2085 Dutch guilders (US$1020) per patient. Interpretation Over 12-month follow-up, a strategy of elective stenting with heparin-coated stents is more effective but also more costly than balloon angioplasty.	Univ Rotterdam Hosp, Ctr Thorax, Rotterdam, Netherlands; Erasmus Univ, Inst Med Technol, NL-3015 GD Rotterdam, Netherlands; Catharina Hosp, Eindhoven, Netherlands; CHU, Liege, Belgium; Gregorio Maranon, Madrid, Spain; Univ Hosp San Carlos, Madrid, Spain; Inst Dante Pazzanese, Sao Paulo, Brazil; Ctr Cuore Columbus, Milan, Italy; Hosp Santa Cruz, Linda A Velha, Portugal; Onze Lieve Vrouw Hosp, Amsterdam, Netherlands; Green Lane Hosp, Auckland 3, New Zealand; Sahlgrenska Hosp, Gothenburg, Sweden; Clin Pasteur, Toulouse, France; Univ Essen Gesamthsch, Essen, Germany; Osped Maggiore Trieste, Trieste, Italy	Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Catharina Hospital; University of Liege; General University Gregorio Maranon Hospital; Hospital Clinico San Carlos; Instituto Dante Pazzanese de Cardiologia; Onze Lieve Vrouwe Gasthuis Hospital; Sahlgrenska University Hospital; University of Duisburg Essen	Serruys, PW (corresponding author), Erasmus Univ, Interuniv Cardiol Inst Netherlands, Heartctr, Dept Intervent Cardiol, Dr Molewaterplein 40, NL-3015 GD Rotterdam, Netherlands.	serruys@card.azr.nl						BERTRAND ME, 1990, CIRCULATION, V82, P190; BLACK WC, 1990, MED DECIS MAKING, V10, P212, DOI 10.1177/0272989X9001000308; BLACKBURN H, 1960, CIRCULATION, V21, P1160, DOI 10.1161/01.CIR.21.6.1160; BRAUNWALD E, 1989, CIRCULATION, V80, P410, DOI 10.1161/01.CIR.80.2.410; CHRONOS NAF, 1996, AM J COLL CARDIOL SA, V27, P904; DORROS G, 1983, CIRCULATION, V67, P723, DOI 10.1161/01.CIR.67.4.723; ELLIS SG, 1989, AM J CARDIOL, V63, P30, DOI 10.1016/0002-9149(89)91071-0; ERBEL R, 1996, AM J COLL CARDIOL SA, V27, P139; ESCANED J, 1993, AM HEART J, V126, P1326, DOI 10.1016/0002-8703(93)90530-M; FIELLER EC, 1954, J ROY STAT SOC B, V16, P175; FISCHMAN DL, 1994, NEW ENGL J MED, V331, P496, DOI 10.1056/NEJM199408253310802; Gawaz M, 1996, CIRCULATION, V94, P279, DOI 10.1161/01.CIR.94.3.279; GREENLAND S, 1985, BIOMETRICS, V41, P55, DOI 10.2307/2530643; Hardhammar PA, 1996, CIRCULATION, V93, P423, DOI 10.1161/01.CIR.93.3.423; Herrman JPR, 1996, INT J CARDIAC IMAG, V12, P21, DOI 10.1007/BF01798114; Migrino RQ, 1997, CIRCULATION, V96, P116; *PALM BALL EXP STE, 1994, 900043 PMA PALM SCHA; PASSAMANI E, 1985, NEW ENGL J MED, V312, P932; RUPPRECHT HJ, IN PRESS AM HEART J; Schomig A, 1996, NEW ENGL J MED, V334, P1084, DOI 10.1056/NEJM199604253341702; SERRUYS PW, 1991, NEW ENGL J MED, V324, P13, DOI 10.1056/NEJM199101033240103; Serruys PW, 1996, CIRCULATION, V93, P412, DOI 10.1161/01.CIR.93.3.412; SERRUYS PW, 1994, NEW ENGL J MED, V331, P489, DOI 10.1056/NEJM199408253310801; SERRUYS PW, 1995, CIRCULATION, V91, P1891, DOI 10.1161/01.CIR.91.6.1891; SERRUYS PW, IN PRESS INT J CARDI; Topol EJ, 1998, LANCET, V352, P87, DOI 10.1016/S0140-6736(98)85010-1; TOPOL EJ, 1994, NEW ENGL J MED, V331, P539, DOI 10.1056/NEJM199408253310811; Van Hout B A, 1996, Semin Interv Cardiol, V1, P263; van Hout BA, 1998, EUR HEART J, V19, pD59; VANDENBRAND M, 1990, EUR HEART J, V11, P765; VANHOUT B, 1996, HEALTH ECON, V3, P309	31	480	500	1	13	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 29	1998	352	9129					673	681		10.1016/S0140-6736(97)11128-X	http://dx.doi.org/10.1016/S0140-6736(97)11128-X			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	116MT	9728982				2022-12-28	WOS:000075729700010
J	Yang, XL; Chang, HY; Baltimore, D				Yang, XL; Chang, HY; Baltimore, D			Essential role of CED-4 oligomerization in CED-3 activation and apoptosis	SCIENCE			English	Article							DEATH REGULATORS CED-9; CELL-DEATH; CYTOCHROME-C; ELEGANS; PROTEIN; ENCODES; DATP	Control,of the activation of apoptosis is important both in development and in protection against cancer. In the classic genetic model Caenorhabditis elegans,;the pro-apoptotic protein CED-4 activates the CED-3 caspase and is inhibited by the Bcl-2-like protein CED-9, Both processes are mediated by protein-protein interaction. Facilitating the proximity of CED-3 zymogen molecules was found to induce caspase activation and cell death. CED-4 protein oligomerized in cells and in vitro. This oligomerization induced CED-3 proximity and competed with CED-4:CED-9 interaction. Mutations that abolished CED-4 oligomerization inactivated its ability to activate CED-3, Thus, the mechanism of control is that CED-3 in CED-3:CED-4 complexes is activated by CED-4 oligomerization, which is inhibited by binding of CED-9 to CED-4.	MIT, Dept Biol, Cambridge, MA 02139 USA; CALTECH, Pasadena, CA 91125 USA	Massachusetts Institute of Technology (MIT); California Institute of Technology	Baltimore, D (corresponding author), MIT, Dept Biol, 77 Massachusetts Ave, Cambridge, MA 02139 USA.				NATIONAL CANCER INSTITUTE [R01CA051462] Funding Source: NIH RePORTER; NCI NIH HHS [CA51462] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Amara JF, 1997, P NATL ACAD SCI USA, V94, P10618, DOI 10.1073/pnas.94.20.10618; Chinnaiyan AM, 1997, NATURE, V388, P728, DOI 10.1038/41913; Chinnaiyan AM, 1997, SCIENCE, V275, P1122, DOI 10.1126/science.275.5303.1122; Conradt B, 1998, CELL, V93, P519, DOI 10.1016/S0092-8674(00)81182-4; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; Hengartner MO, 1997, NATURE, V388, P714, DOI 10.1038/41873; HORVITZ HR, 1994, COLD SPRING HARB SYM, V59, P377, DOI 10.1101/SQB.1994.059.01.042; Hu YM, 1998, P NATL ACAD SCI USA, V95, P4386, DOI 10.1073/pnas.95.8.4386; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Muzio M, 1998, J BIOL CHEM, V273, P2926, DOI 10.1074/jbc.273.5.2926; Ottilie S, 1997, CELL DEATH DIFFER, V4, P526, DOI 10.1038/sj.cdd.4400288; Shaham S, 1996, CELL, V86, P201, DOI 10.1016/S0092-8674(00)80092-6; Spector MS, 1997, NATURE, V385, P653, DOI 10.1038/385653a0; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; Steller H, 1998, P NATL ACAD SCI USA, V95, P5421, DOI 10.1073/pnas.95.10.5421; van der Biezen EA, 1998, CURR BIOL, V8, pR226, DOI 10.1016/S0960-9822(98)70145-9; Wu DY, 1997, SCIENCE, V275, P1126, DOI 10.1126/science.275.5303.1126; Yang XL, 1998, MOL CELL, V1, P319, DOI 10.1016/S1097-2765(00)80032-5; Yang XL, 1997, CELL, V89, P1067, DOI 10.1016/S0092-8674(00)80294-9; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; ZHOU H, 1997, CELL, V90, P405	23	224	240	1	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 28	1998	281	5381					1355	1357		10.1126/science.281.5381.1355	http://dx.doi.org/10.1126/science.281.5381.1355			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	115LQ	9721101				2022-12-28	WOS:000075666800051
J	Ahmed, S				Ahmed, S			Miss Stepney till the end	BRITISH MEDICAL JOURNAL			English	Article																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 22	1998	317	7157					525	525						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	115AM	9712606				2022-12-28	WOS:000075641400028
J	Botterill, I; Miller, G; Dexter, S; Martin, I				Botterill, I; Miller, G; Dexter, S; Martin, I			Deaths after delayed recognition of percutaneous endoscopic gastrostomy tube migration	BRITISH MEDICAL JOURNAL			English	Review									Gen Infirm, Dept Surg, Ctr Digest Dis, Leeds LS1 3EX, W Yorkshire, England	Leeds General Infirmary; University of Leeds	Botterill, I (corresponding author), Gen Infirm, Dept Surg, Ctr Digest Dis, Leeds LS1 3EX, W Yorkshire, England.							FEUSSNER H, 1989, ENDOSCOPY, V21, P45, DOI 10.1055/s-2007-1012895; Foutch P, 1992, GASTROINTEST ENDOSC, V2, P231; GAUDERER MWL, 1980, J PEDIATR SURG, V15, P872, DOI 10.1016/S0022-3468(80)80296-X; GOTTFRIED EB, 1986, GASTROINTEST ENDOSC, V32, P397, DOI 10.1016/S0016-5107(86)71919-6	4	17	18	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 22	1998	317	7157					524	525						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	115AM	9712605				2022-12-28	WOS:000075641400027
J	Collins, GW; Da Silva, LB; Celliers, P; Gold, DM; Foord, ME; Wallace, RJ; Ng, A; Weber, SV; Budil, KS; Cauble, R				Collins, GW; Da Silva, LB; Celliers, P; Gold, DM; Foord, ME; Wallace, RJ; Ng, A; Weber, SV; Budil, KS; Cauble, R			Measurements of the equation of state of deuterium at the fluid insulator-metal transition	SCIENCE			English	Article							SHOCKED LIQUID DEUTERIUM; LOW-MASS STARS; MOLECULAR-HYDROGEN; DENSE HYDROGEN; GIANT PLANETS; TEMPERATURE-MEASUREMENTS; BROWN DWARFS; DISSOCIATION; JUPITER; PLASMAS	A high-intensity laser was used to shock-compress liquid deuterium to pressures from 22 to 340 gigapascals. In this regime deuterium is predicted to transform from an insulating molecular fluid to an atomic metallic fluid. Shock densities and pressures, determined by radiography, revealed an increase in compressibility near 100 gigapascals indicative of such a transition. Velocity interferometry measurements, obtained by reflecting a laser probe directly off the shock front in flight, demonstrated that deuterium shocked above 55 gigapascals has an electrical conductivity characteristic of a liquid metal and independently confirmed the radiography.	Univ Calif Lawrence Livermore Natl Lab, Livermore, CA 94550 USA; Univ British Columbia, Vancouver, BC V6T 1Z1, Canada	United States Department of Energy (DOE); Lawrence Livermore National Laboratory; University of California System; University of British Columbia	Cauble, R (corresponding author), Univ Calif Lawrence Livermore Natl Lab, Livermore, CA 94550 USA.		Collins, Gilbert/ABH-2158-2020	Celliers, Peter/0000-0001-7600-1227				ASHCROFT N, 1995, PHYS WORLD, V8, P43; BARBEE TW, 1989, PHYS REV LETT, V62, P1150, DOI 10.1103/PhysRevLett.62.1150; BARKER LM, 1972, J APPL PHYS, V43, P4669, DOI 10.1063/1.1660986; CAMPBELL EM, 1991, LASER PART BEAMS, V9, P209, DOI 10.1017/S0263034600003293; Chabrier G, 1997, ASTRON ASTROPHYS, V327, P1039; CHABRIER G, 1992, ASTROPHYS J, V391, P817, DOI 10.1086/171390; CHACHAM H, 1991, PHYS REV LETT, V66, P10963; DaSilva LB, 1997, PHYS REV LETT, V78, P483, DOI 10.1103/PhysRevLett.78.483; EGGERT JH, 1991, PHYS REV LETT, V66, P671; FRIEDLI C, 1977, PHYS REV B, V16, P662, DOI 10.1103/PhysRevB.16.662; Gupta YM, 1997, SCIENCE, V277, P909, DOI 10.1126/science.277.5328.909; HAAN SW, 1995, PHYS PLASMAS, V2, P2480, DOI 10.1063/1.871209; Holmes NC, 1995, PHYS REV B, V52, P15835, DOI 10.1103/PhysRevB.52.15835; Hubbard WB, 1997, PHYS PLASMAS, V4, P2011, DOI 10.1063/1.872570; HUBBARD WB, 1981, SCIENCE, V214, P145, DOI 10.1126/science.214.4517.145; KERLEY G, 1980, J CHEM PHYS, V73, P460; KERLEY GI, 1972, LA4776 LOS AL LAB; Lenosky TJ, 1997, PHYS REV B, V56, P5164, DOI 10.1103/PhysRevB.56.5164; Magro WR, 1996, PHYS REV LETT, V76, P1240, DOI 10.1103/PhysRevLett.76.1240; MILITZER B, 1998, STRONGLY COUPLED COU; Narayana C, 1998, NATURE, V393, P46, DOI 10.1038/29949; NELLIS WJ, 1995, SCIENCE, V269, P1249, DOI 10.1126/science.7652570; NELLIS WJ, 1983, J CHEM PHYS, V79, P1480, DOI 10.1063/1.445938; REINHOLZ H, 1995, PHYS REV E, V52, P5368, DOI 10.1103/PhysRevE.52.5368; ROGERS FJ, 1986, ASTROPHYS J, V310, P723, DOI 10.1086/164725; ROSS M, 1983, J CHEM PHYS, V79, P1487, DOI 10.1063/1.445939; Ross M, 1998, PHYS REV B, V58, P669, DOI 10.1103/PhysRevB.58.669; SAUMON D, 1992, ASTROPHYS J, V391, P827, DOI 10.1086/171391; SAUMON D, 1991, PHYS REV A, V44, P5122, DOI 10.1103/PhysRevA.44.5122; SAUMON D, 1995, ASTROPHYS J SUPPL S, V99, P713, DOI 10.1086/192204; Saumon D, 1996, ASTROPHYS J, V460, P993, DOI 10.1086/177027; SMOLUCHO.R, 1967, NATURE, V215, P691, DOI 10.1038/215691a0; SWENSON FJ, 1996, ASTROPHYS J, V456, P902; VANHORN HM, 1991, SCIENCE, V252, P384, DOI 10.1126/science.252.5004.384; Weir ST, 1996, PHYS REV LETT, V76, P1860, DOI 10.1103/PhysRevLett.76.1860; Wigner E, 1935, J CHEM PHYS, V3, P764, DOI 10.1063/1.1749590	36	334	343	1	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 21	1998	281	5380					1178	1181		10.1126/science.281.5380.1178	http://dx.doi.org/10.1126/science.281.5380.1178			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	113CE	9712579				2022-12-28	WOS:000075531200049
J	Hatch, EE; Palmer, JR; Titus-Ernstoff, L; Noller, KL; Kaufman, RH; Mittendorf, R; Robboy, SJ; Hyer, M; Cowan, CM; Adam, E; Colton, T; Hartge, P; Hoover, RN				Hatch, EE; Palmer, JR; Titus-Ernstoff, L; Noller, KL; Kaufman, RH; Mittendorf, R; Robboy, SJ; Hyer, M; Cowan, CM; Adam, E; Colton, T; Hartge, P; Hoover, RN			Cancer risk in women exposed to diethylstilbestrol in utero	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BREAST-CANCER; FOLLOW-UP; STILBESTROL THERAPY; YOUNG-WOMEN; PREGNANCY; MOTHERS; ADENOCARCINOMA; ESTROGENS; VAGINA	Context. - The association between in utero exposure to diethylstilbestrol (DES) and clear cell adenocarcinoma (CCA) of the vagina and cervix is well known, yet there has been no systematic study of DES-exposed daughters to determine whether they have an increased risk of other cancers, As many as 3 million women in the United States may have been exposed to DES in utero. Objective. - To determine whether women exposed to DES in utero have a higher risk of cancer after an average of 16 years of follow-up. Design. - A cohort study with mailed questionnaires and medical record review of reported cancer outcomes. Participants. - A cohort of 4536 DES-exposed daughters (of whom 81% responded) and 1544 unexposed daughters (of whom 79% responded) who were first identified in the mid-1970s. Main Outcome Measures. - Cancer incidence in DES-exposed daughters compared with population-based rates and compared with cancer incidence in unexposed daughters. Results. - To date, DES-exposed daughters have not experienced an increased risk for all cancers (rate ratio, 0.96; 95% confidence interval [CI], 0.58-1.56) or for individual cancer sites, except for CCA. Three cases of vaginal CCA occurred among the exposed daughters, resulting in a standardized incidence ratio of 40.7 (95% CI, 13.1-126.2) in comparison with population-based incidence rates. The rate ratio for breast cancer was 1.18 (95% CI, 0.56-2.49); adjustment for known risk factors did not alter this result. Conclusions. - Thus far, DES-exposed daughters show no increased cancer risk, except for CCA. Nevertheless, because exposed daughters included in our study were, on average, only 38 years old at last follow-up, continued surveillance is warranted to determine whether any increases in cancer risk occur during the menopausal years.	NCI, Div Canc Epidemiol & Genet, Bethesda, MD 20892 USA; Boston Univ, Sch Publ Hlth, Stone Epidemiol Unit, Boston, MA USA; Dartmouth Hitchcock Med Ctr, Norris Cotton Canc Ctr, Lebanon, NH 03766 USA; Univ Massachusetts, Med Ctr, Dept Obstet & Gynecol, Worcester, MA USA; Baylor Coll Med, Dept Obstet & Gynecol, Houston, TX 77030 USA; Univ Chicago, Dept Obstet & Gynecol, Chicago, IL 60637 USA; Duke Univ, Med Ctr, Dept Pathol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Obstet & Gynecol, Durham, NC 27710 USA; Informat Management Serv, Rockville, MD USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Boston University; Dartmouth College; Norris Cotton Cancer Center; University of Massachusetts System; University of Massachusetts Worcester; Baylor College of Medicine; University of Chicago; Duke University; Duke University	Hatch, EE (corresponding author), NCI, Div Canc Epidemiol & Genet, 6130 Execut Blvd,MSC7362, Bethesda, MD 20892 USA.			Hatch, Elizabeth/0000-0001-7901-3928; Palmer, Julie/0000-0002-6534-335X				BIBBO M, 1977, OBSTET GYNECOL, V49, P1; BIBBO M, 1978, NEW ENGL J MED, V298, P763, DOI 10.1056/NEJM197804062981403; BRAUN MM, 1995, CANCER CAUSE CONTROL, V6, P519, DOI 10.1007/BF00054160; BRESLOW NE, 1987, IARC SCI PUBLICATION, V88; Calle EE, 1996, AM J EPIDEMIOL, V144, P645, DOI 10.1093/oxfordjournals.aje.a008976; COLTON T, 1993, JAMA-J AM MED ASSOC, V269, P2096, DOI 10.1001/jama.269.16.2096; DIECKMANN WJ, 1953, AM J OBSTET GYNECOL, V66, P1062; Dodds EC, 1938, NATURE, V141, P247, DOI 10.1038/141247b0; EKBOM A, 1992, LANCET, V340, P1015, DOI 10.1016/0140-6736(92)93019-J; GREENBERG ER, 1984, NEW ENGL J MED, V311, P1393, DOI 10.1056/NEJM198411293112201; GREENWALD P, 1971, NEW ENGL J MED, V285, P390, DOI 10.1056/NEJM197108122850707; Guisti RM, 1995, ANN INTERN MED, V122, P778; HADJIMICHAEL OC, 1984, J NATL CANCER I, V73, P831; HERBST AL, 1981, AM J OBSTET GYNECOL, V141, P1019; HERBST AL, 1971, NEW ENGL J MED, V284, P878, DOI 10.1056/NEJM197104222841604; HORNSBY PP, 1994, AM J OBSTET GYNECOL, V170, P709, DOI 10.1016/S0002-9378(94)70268-3; HUBBY MM, 1981, DEV EFFECTS DES PREG; Huckell C, 1996, LANCET, V348, P331, DOI 10.1016/S0140-6736(96)24031-0; LABARTHE D, 1978, OBSTET GYNECOL, V51, P453, DOI 10.1097/00006250-197804000-00014; MARSELOS M, 1993, EUR J CANCER, V29A, P149, DOI 10.1016/0959-8049(93)90597-9; MELNICK S, 1987, NEW ENGL J MED, V316, P514, DOI 10.1056/NEJM198702263160905; NOLLER KL, 1974, MED CLIN N AM, V58, P739; Ries L, 1994, NIH PUBLICATION, V94-2789; ROBBOY SJ, 1981, AM J OBSTET GYNECOL, V140, P579, DOI 10.1016/0002-9378(81)90236-2; ROBBOY SJ, 1984, JAMA-J AM MED ASSOC, V252, P2979, DOI 10.1001/jama.252.21.2979; SMITH OW, 1949, NEW ENGL J MED, V241, P562, DOI 10.1056/NEJM194910132411503; Thompson W D, 1990, Epidemiology, V1, P101, DOI 10.1097/00001648-199003000-00004; TRICHOPOULOS D, 1990, LANCET, V335, P939, DOI 10.1016/0140-6736(90)91000-Z; VESSEY MP, 1983, BRIT J OBSTET GYNAEC, V90, P1007, DOI 10.1111/j.1471-0528.1983.tb06438.x	29	138	141	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 19	1998	280	7					630	634		10.1001/jama.280.7.630	http://dx.doi.org/10.1001/jama.280.7.630			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	110ME	9718055	Bronze			2022-12-28	WOS:000075384300032
J	Nayak, A; Zastrow, DJ; Lickteig, R; Zahniser, NR; Browning, MD				Nayak, A; Zastrow, DJ; Lickteig, R; Zahniser, NR; Browning, MD			Maintenance of late-phase LTP is accompanied by PKA-dependent increase in AMPA receptor synthesis	NATURE			English	Article							LONG-TERM POTENTIATION; SILENT SYNAPSES; CA1 REGION; INDUCTION; PHOSPHORYLATION; NEURONS; BRAIN; CREB	Long-term potentiation (LTP) is a form of synaptic plasticity that has been extensively studied as a putative mechanism underlying learning and memory. A late phase of LTP occurring 3-5 hours after stimulation and depending on transcription, protein synthesis and cyclic-AMP-dependent protein kinase (protein kinase A, or PKA) has been described(1-3), but it is not known whether transcription of presynaptic and/or postsynaptic genes is required to support late-phase LTP. Here we show that late-phase LTP can be obtained in rat hippocampal CA1 mini-slices in which the cell bodies of presynaptic Schaffer collateral/ commissural fibres are rr moved. Thus, transcription of presynaptic genes is not necessary to support maintenance of late-phase LTP. The AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate) receptor is the predominant mediator of the ionotropic response to synaptically released glutamate in the hippocampus and it has been implicated in LTP maintenance. We find that synthesis of AMPA receptor subunits is increased three hours after LTP induction: this effect on the synthesis of the AMPA receptor is blocked by inhibitors of PKA and of transcription. Our results support the idea of a postsynaptic mechanism maintaining late-phase LTP, in which AMPA receptor synthesis is increased as a result of PKA-dependent gene transcription.	Univ Colorado, Hlth Sci Ctr, Dept Pharmacol, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Program Neurosci, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Nayak, A (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Pharmacol, 4200 E 9th Ave, Denver, CO 80262 USA.							Barria A, 1997, SCIENCE, V276, P2042, DOI 10.1126/science.276.5321.2042; BARTSCH D, 1995, CELL, V83, P979, DOI 10.1016/0092-8674(95)90213-9; Davis GW, 1996, NEURON, V17, P669, DOI 10.1016/S0896-6273(00)80199-3; FREY U, 1989, NEUROSCI LETT, V97, P135, DOI 10.1016/0304-3940(89)90152-3; FREY U, 1988, BRAIN RES, V452, P57, DOI 10.1016/0006-8993(88)90008-X; FREY U, 1993, SCIENCE, V260, P1661, DOI 10.1126/science.8389057; HAYCOCK JW, 1988, P NATL ACAD SCI USA, V85, P1677, DOI 10.1073/pnas.85.5.1677; Isaac JTR, 1997, NEURON, V18, P269, DOI 10.1016/S0896-6273(00)80267-6; LIAO DZ, 1995, NATURE, V375, P400, DOI 10.1038/375400a0; MAREN S, 1993, P NATL ACAD SCI USA, V90, P9654, DOI 10.1073/pnas.90.20.9654; Martin KC, 1996, NEURON, V17, P567, DOI 10.1016/S0896-6273(00)80188-9; Nayak AS, 1996, P NATL ACAD SCI USA, V93, P15451, DOI 10.1073/pnas.93.26.15451; NGUYEN PV, 1994, SCIENCE, V265, P1104, DOI 10.1126/science.8066450; PARFITT KD, 1992, HIPPOCAMPUS, V2, P59, DOI 10.1002/hipo.450020108; Snell LD, 1996, MOL BRAIN RES, V40, P71; STONE LM, 1994, J NEUROSCI, V14, P301; Voronin LL, 1996, NEUROSCIENCE, V74, P323, DOI 10.1016/0306-4522(96)00207-2; WENTHOLD RJ, 1992, J BIOL CHEM, V267, P501	18	175	176	0	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 13	1998	394	6694					680	683		10.1038/29305	http://dx.doi.org/10.1038/29305			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	110MD	9716131				2022-12-28	WOS:000075384200044
J	Lee, SE; Moore, JK; Holmes, A; Umezu, K; Kolodner, RD; Haber, JE				Lee, SE; Moore, JK; Holmes, A; Umezu, K; Kolodner, RD; Haber, JE			Saccharomyces Ku70, Mre11/Rad50, and RPA proteins regulate adaptation to G2/M arrest after DNA damage	CELL			English	Article							STRAND-BREAK REPAIR; END-JOINING REPAIR; HOMOLOGOUS RECOMBINATION; BINDING PROTEIN; CELL-CYCLE; ILLEGITIMATE RECOMBINATION; MEIOTIC RECOMBINATION; A PHOSPHORYLATION; CEREVISIAE; YEAST	Saccharomyces cells suffering a single unrepairable double-strand break (DSB) exhibit a long, but transient arrest at G2/M. hdf1 cells, lacking Ku70p, fail to escape from this RAD9/RAD17-dependent checkpoint. The effect of hdf1 results from its accelerated 5' to 3' degradation of the broken chromosome. Permanent arrest in hdf1 cells is suppressed by rad50 or mre11 deletions that retard this degradation. Wild-type HDF1 cells also become permanently arrested when they experience two unrepairable DSBs. Both DSB-induced arrest conditions are suppressed by a mutation in the single-strand binding protein, RPA. We suggest that escape from the DNA damage-induced G2/M checkpoint depends on the extent of ssDNA created at broken chromosome ends. RPA appears to play a key intermediate step in this adaptation.	Brandeis Univ, Dept Biol, Rosenstiel Ctr MS029, Waltham, MA 02454 USA; Brandeis Univ, Keck Inst Cellular Visualizat, Rosenstiel Ctr MS029, Waltham, MA 02454 USA; Dana Farber Canc Inst, Charles A Dana Div Human Canc Genet, Boston, MA 02115 USA	Brandeis University; Brandeis University; Harvard University; Dana-Farber Cancer Institute	Haber, JE (corresponding author), Brandeis Univ, Dept Biol, Rosenstiel Ctr MS029, Waltham, MA 02454 USA.			Haber, James/0000-0002-1878-0610	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F31GM070122, R37GM020056, R01GM050006, R01GM020056] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM20056, GM50006, GM70122] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abramova NA, 1997, P NATL ACAD SCI USA, V94, P7186, DOI 10.1073/pnas.94.14.7186; ALANI E, 1987, GENETICS, V116, P541, DOI 10.1534/genetics.112.541.test; ALANI E, 1990, CELL, V61, P419, DOI 10.1016/0092-8674(90)90524-I; Barnes G, 1997, P NATL ACAD SCI USA, V94, P867, DOI 10.1073/pnas.94.3.867; BOEKE JD, 1984, MOL GEN GENET, V197, P345, DOI 10.1007/BF00330984; BOUBNOV NV, 1995, MOL CELL BIOL, V15, P5700; Boulton SJ, 1996, EMBO J, V15, P5093, DOI 10.1002/j.1460-2075.1996.tb00890.x; Boulton SJ, 1998, EMBO J, V17, P1819, DOI 10.1093/emboj/17.6.1819; Brush GS, 1996, P NATL ACAD SCI USA, V93, P15075, DOI 10.1073/pnas.93.26.15075; Carney JP, 1998, CELL, V93, P477, DOI 10.1016/S0092-8674(00)81175-7; CARTY MP, 1994, EMBO J, V13, P2114, DOI 10.1002/j.1460-2075.1994.tb06487.x; de la Torre-Ruiz MA, 1998, EMBO J, V17, P2687, DOI 10.1093/emboj/17.9.2687; DUTTA A, 1993, NATURE, V365, P79, DOI 10.1038/365079a0; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; FELDMANN H, 1993, J BIOL CHEM, V268, P12895; Feldmann H, 1996, J BIOL CHEM, V271, P27765, DOI 10.1074/jbc.271.44.27765; Fried LM, 1996, P NATL ACAD SCI USA, V93, P13825, DOI 10.1073/pnas.93.24.13825; Gravel S, 1998, SCIENCE, V280, P741, DOI 10.1126/science.280.5364.741; HABER JE, 1995, BIOESSAYS, V17, P609, DOI 10.1002/bies.950170707; IVANOV EL, 1994, MOL CELL BIOL, V14, P3414, DOI 10.1128/MCB.14.5.3414; IVANOV EL, 1992, GENETICS, V132, P651; Jackson SP, 1996, CURR OPIN GENET DEV, V6, P19, DOI 10.1016/S0959-437X(96)90005-2; JOHZUKA K, 1995, GENETICS, V139, P1521; KOSTRIKEN R, 1983, CELL, V35, P167, DOI 10.1016/0092-8674(83)90219-2; KRAMER KM, 1993, GENE DEV, V7, P2345, DOI 10.1101/gad.7.12a.2345; KRAMER KM, 1994, MOL CELL BIOL, V14, P1293, DOI 10.1128/MCB.14.2.1293; Laroche T, 1998, CURR BIOL, V8, P653, DOI 10.1016/S0960-9822(98)70252-0; Lee SE, 1997, MOL CELL BIOL, V17, P1425, DOI 10.1128/MCB.17.3.1425; Lewis LK, 1998, MOL CELL BIOL, V18, P1891, DOI 10.1128/MCB.18.4.1891; LIU VF, 1993, MOL CELL BIOL, V13, P7222, DOI 10.1128/MCB.13.12.7222; Longhese MP, 1996, NUCLEIC ACIDS RES, V24, P3533, DOI 10.1093/nar/24.18.3533; LYDALL D, 1995, SCIENCE, V270, P1488, DOI 10.1126/science.270.5241.1488; Lydall D, 1997, MOL GEN GENET, V256, P638, DOI 10.1007/s004380050612; Malkova A, 1996, P NATL ACAD SCI USA, V93, P7131, DOI 10.1073/pnas.93.14.7131; MALONE RE, 1980, P NATL ACAD SCI-BIOL, V77, P503, DOI 10.1073/pnas.77.1.503; Milne GT, 1996, MOL CELL BIOL, V16, P4189; Moore JK, 1996, MOL CELL BIOL, V16, P2164, DOI 10.1128/mcb.16.5.2164; Morrow DM, 1997, GENETICS, V147, P371; Nugent CI, 1998, CURR BIOL, V8, P657, DOI 10.1016/S0960-9822(98)70253-2; OGAWA H, 1995, ADV BIOPHYS, V31, P67, DOI 10.1016/0065-227X(95)99383-Z; Park MS, 1996, J BIOL CHEM, V271, P18996, DOI 10.1074/jbc.271.31.18996; PAULOVICH AG, 1995, CELL, V82, P841, DOI 10.1016/0092-8674(95)90481-6; Porter SE, 1996, NUCLEIC ACIDS RES, V24, P582, DOI 10.1093/nar/24.4.582; RAY BL, 1991, MOL CELL BIOL, V11, P5372, DOI 10.1128/MCB.11.10.5372; SANDELL LL, 1993, CELL, V75, P729, DOI 10.1016/0092-8674(93)90493-A; Siede W, 1996, GENETICS, V142, P91; SMITH J, 1995, MOL CELL BIOL, V15, P1632; SUGAWARA N, 1992, MOL CELL BIOL, V12, P563, DOI 10.1128/MCB.12.2.563; Toczyski DP, 1997, CELL, V90, P1097, DOI 10.1016/S0092-8674(00)80375-X; Tsubouchi H, 1998, MOL CELL BIOL, V18, P260, DOI 10.1128/MCB.18.1.260; Tsukamoto Y, 1996, GENETICS, V142, P383; Tsukamoto Y, 1997, NATURE, V388, P900, DOI 10.1038/42288; Tsukamoto Y, 1996, NUCLEIC ACIDS RES, V24, P2067, DOI 10.1093/nar/24.11.2067; Umezu K, 1998, GENETICS, V148, P989; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; WEAVER DT, 1995, TRENDS GENET, V11, P388, DOI 10.1016/S0168-9525(00)89121-0; WEINERT TA, 1993, GENETICS, V134, P63; WHITE CI, 1990, EMBO J, V9, P663, DOI 10.1002/j.1460-2075.1990.tb08158.x	58	617	622	0	14	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 7	1998	94	3					399	409		10.1016/S0092-8674(00)81482-8	http://dx.doi.org/10.1016/S0092-8674(00)81482-8			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	109EN	9708741	Bronze			2022-12-28	WOS:000075308400015
J	Ryan, AK; Blumberg, B; Rodriguez-Esteban, C; Yonei-Tamura, S; Tamura, K; Tsukui, T; de la Pena, J; Sabbagh, W; Greenwald, J; Choe, S; Norris, DP; Robertson, EJ; Evans, RM; Rosenfeld, MG; Belmonte, JCI				Ryan, AK; Blumberg, B; Rodriguez-Esteban, C; Yonei-Tamura, S; Tamura, K; Tsukui, T; de la Pena, J; Sabbagh, W; Greenwald, J; Choe, S; Norris, DP; Robertson, EJ; Evans, RM; Rosenfeld, MG; Belmonte, JCI			Pitx2 determines left-right asymmetry of internal organs in vertebrates	NATURE			English	Article							NODAL EXPRESSION; MICE DEFICIENT; LIMB BUD; GENE; DEFECTS; TRANSCRIPTION; INITIATION; ACTIVINS; INDUCE; AXIS	The handedness of visceral organs is conserved among vertebrates anal is regulated by asymmetric signals relayed by molecules such as Shh, Nodal and activin. The gene Pitx2 is expressed in the left lateral plate mesoderm and, subsequently, In the left heart and gut of mouse, chick and Xenopus embryos. Misexpression of Shh and Nodal induces Pitx2 expression, whereas inhibition of activin signalling blocks it. Misexpression of Pitx2 alters the relative position of organs and the direction of body rotation In chick and Xenopus embryos. Changes in Pitx2 expression are evident in mouse mutants with laterality defects. Thus, Pitx2 seems to serve as a critical downstream transcription target that mediates left-right asymmetry in vertebrates.	Salk Inst Biol Studies, La Jolla, CA 92037 USA; Howard Hughes Med Inst, La Jolla, CA 92037 USA; Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA; Univ Calif San Diego, Howard Hughes Med Inst, La Jolla, CA 92093 USA	Salk Institute; Howard Hughes Medical Institute; Harvard University; Howard Hughes Medical Institute; University of California System; University of California San Diego	Belmonte, JCI (corresponding author), Salk Inst Biol Studies, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.	belmonte@salk.edu		Evans, Ronald/0000-0002-9986-5965				Biben C, 1997, GENE DEV, V11, P1357, DOI 10.1101/gad.11.11.1357; Blumberg B, 1997, DEVELOPMENT, V124, P373; Blumberg B, 1998, GENE DEV, V12, P1269, DOI 10.1101/gad.12.9.1269; BURN J, 1991, CIBA F SYMP, V162, P282; Chiang C, 1996, NATURE, V383, P407, DOI 10.1038/383407a0; CHO KWY, 1991, CELL, V67, P1111, DOI 10.1016/0092-8674(91)90288-A; Collignon J, 1996, NATURE, V381, P155, DOI 10.1038/381155a0; DONALSON CJ, UNPUB BIOCHEMISTRY; Gage PJ, 1997, HUM MOL GENET, V6, P457, DOI 10.1093/hmg/6.3.457; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; Heymer J, 1997, MECH DEVELOP, V66, P5, DOI 10.1016/S0925-4773(97)00084-1; HIROFUMI A, 1998, P NATL ACAD SCI USA, V95, P4573; Hyatt BA, 1996, NATURE, V384, P62, DOI 10.1038/384062a0; Hyatt BA, 1998, CELL, V93, P37, DOI 10.1016/S0092-8674(00)81144-7; Isaac A, 1997, SCIENCE, V275, P1301, DOI 10.1126/science.275.5304.1301; Kosaki K, 1998, SEMIN CELL DEV BIOL, V9, P89, DOI 10.1006/scdb.1997.0187; Lamonerie T, 1996, GENE DEV, V10, P1284, DOI 10.1101/gad.10.10.1284; Lander A, 1998, SEMIN CELL DEV BIOL, V9, P35, DOI 10.1006/scdb.1997.0185; Levin M, 1997, BIOESSAYS, V19, P287, DOI 10.1002/bies.950190406; Levin M, 1998, GENE DEV, V12, P763, DOI 10.1101/gad.12.6.763; Levin M, 1997, DEV BIOL, V189, P57, DOI 10.1006/dbio.1997.8662; LEVIN M, 1995, CELL, V82, P803, DOI 10.1016/0092-8674(95)90477-8; LOGAN M, IN PRESS CELL; LOHR JL, 1997, DEVELOPMENT, V124, P1467; Lowe LA, 1996, NATURE, V381, P158, DOI 10.1038/381158a0; Lustig KD, 1996, DEVELOPMENT, V122, P3275; MATZUK MM, 1995, NATURE, V374, P354, DOI 10.1038/374354a0; MATZUK MM, 1995, NATURE, V374, P360, DOI 10.1038/374360a0; MATZUK MM, 1995, NATURE, V374, P356, DOI 10.1038/374356a0; Melloy PG, 1998, DEV BIOL, V193, P77, DOI 10.1006/dbio.1997.8787; Meno C, 1997, GENES CELLS, V2, P513, DOI 10.1046/j.1365-2443.1997.1400338.x; Meno C, 1996, NATURE, V381, P151, DOI 10.1038/381151a0; MENO C, IN PRESS CELL; MORGAN BA, 1992, NATURE, V358, P236, DOI 10.1038/358236a0; Mucchielli ML, 1996, MOL CELL NEUROSCI, V8, P258, DOI 10.1006/mcne.1996.0062; NEW DAT, 1955, J EMBRYOL EXP MORPH, V3, P326; Oh SP, 1997, GENE DEV, V11, P1812, DOI 10.1101/gad.11.14.1812; Pagan-Westphal SM, 1998, CELL, V93, P25, DOI 10.1016/S0092-8674(00)81143-5; Sampath K, 1997, DEVELOPMENT, V124, P3293; Semina EV, 1996, NAT GENET, V14, P392, DOI 10.1038/ng1296-392; Splitt MP, 1996, J MED GENET, V33, P498, DOI 10.1136/jmg.33.6.498; SRIVASTAVA D, 1995, SCIENCE, V270, P1995, DOI 10.1126/science.270.5244.1995; STERN CD, 1995, DEV BIOL, V172, P192, DOI 10.1006/dbio.1995.0015; Supp DM, 1998, SEMIN CELL DEV BIOL, V9, P77, DOI 10.1006/scdb.1997.0186; Supp DM, 1997, NATURE, V389, P963, DOI 10.1038/40140; Szeto DP, 1996, P NATL ACAD SCI USA, V93, P7706, DOI 10.1073/pnas.93.15.7706; VASSALLI A, 1994, GENE DEV, V8, P414, DOI 10.1101/gad.8.4.414; Vogel A, 1996, DEVELOPMENT, V122, P1737; WILKINSON DG, 1993, IN SITU HYBRIDISATIO; Wood WB, 1997, ANNU REV CELL DEV BI, V13, P53; YONEI S, 1995, DEV BIOL, V170, P542, DOI 10.1006/dbio.1995.1235	51	425	434	0	31	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 6	1998	394	6693					545	551		10.1038/29004	http://dx.doi.org/10.1038/29004			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	107YN	9707115				2022-12-28	WOS:000075238700037
J	Silverstein, MJ				Silverstein, MJ			Fortnightly review - Ductal carcinoma in situ of the breast	BRITISH MEDICAL JOURNAL			English	Review							IN-SITU; INTRADUCTAL CARCINOMA; CONSERVING SURGERY; DEFINITIVE IRRADIATION; LOCAL RECURRENCE; LYMPH-NODE; CANCER; HETEROZYGOSITY; CLASSIFICATION; BIOPSY		Univ So Calif, Norris Canc Ctr, Los Angeles, CA 90033 USA; Breast Ctr, Van Nuys, CA 91405 USA	University of Southern California	Silverstein, MJ (corresponding author), Univ So Calif, Norris Canc Ctr, 1441 Eastlake Ave,Room 7415A, Los Angeles, CA 90033 USA.							Albertini JJ, 1996, JAMA-J AM MED ASSOC, V276, P1818, DOI 10.1001/jama.276.22.1818; BELLAMY COC, 1993, HUM PATHOL, V24, P16, DOI 10.1016/0046-8177(93)90057-N; DouglasJones AG, 1996, HISTOPATHOLOGY, V29, P397, DOI 10.1046/j.1365-2559.1996.d01-513.x; FISHER B, 1993, NEW ENGL J MED, V328, P1581, DOI 10.1056/NEJM199306033282201; Fisher B, 1998, J CLIN ONCOL, V16, P441, DOI 10.1200/JCO.1998.16.2.441; FISHER ER, 1995, CANCER-AM CANCER SOC, V75, P1310, DOI 10.1002/1097-0142(19950315)75:6<1310::AID-CNCR2820750613>3.0.CO;2-G; Fujii H, 1996, CANCER RES, V56, P1493; GIULIANO AE, 1995, ANN SURG, V222, P394, DOI 10.1097/00000658-199509000-00016; HANSEN N, 1997, DUCTAL CARCINOMA IN, P577; HOLLAND R, 1997, DUCTAL CARCINOMA IN, P233; KRAG DN, 1993, SURG ONCOL, V2, P335, DOI 10.1016/0960-7404(93)90064-6; LAGIOS MD, 1989, CANCER, V63, P619; LAGIOS MD, 1993, NEW ENGL J MED, V21, P1577; LAKHANI SR, 1995, J CLIN PATHOL, V48, P611, DOI 10.1136/jcp.48.7.611; Landis SH, 1998, CA-CANCER J CLIN, V48, P6, DOI 10.3322/canjclin.48.1.6; NEMOTO T, 1980, CANCER, V45, P2917, DOI 10.1002/1097-0142(19800615)45:12<2917::AID-CNCR2820451203>3.0.CO;2-M; PAGE DL, 1995, CANCER, V75, P1219, DOI 10.1002/1097-0142(19950315)75:6<1219::AID-CNCR2820750602>3.0.CO;2-X; PAGE DL, 1995, CANCER, V76, P1197, DOI 10.1002/1097-0142(19951001)76:7<1197::AID-CNCR2820760715>3.0.CO;2-0; RADFORD DM, 1995, CANCER RES, V55, P5180; RECHT A, 1997, DUCTAL CARCINOMA IN, P347; Schwartz GF, 1997, CANCER, V80, P1798; SIBBERING MD, 1997, DUCTAL CARCINOMA IN, P367; Silverstein M. J., 1997, Breast Cancer Research and Treatment, V46, P23; SILVERSTEIN MJ, 1995, LANCET, V345, P1154; Silverstein MJ, 1998, J CLIN ONCOL, V16, P1367, DOI 10.1200/JCO.1998.16.4.1367; SILVERSTEIN MJ, 1995, EUR J CANCER, V31A, P1425, DOI 10.1016/0959-8049(95)00283-O; Silverstein MJ, 1996, CANCER-AM CANCER SOC, V77, P2267, DOI 10.1002/(SICI)1097-0142(19960601)77:11<2267::AID-CNCR13>3.0.CO;2-V; SILVERSTEIN MJ, 1987, CANCER, V59, P1819, DOI 10.1002/1097-0142(19870515)59:10<1819::AID-CNCR2820591023>3.0.CO;2-V; Silverstein MJ, 1997, DUCTAL CARCINOMA IN, P271; SILVERSTEIN MJ, 1997, DUCTAL CARCINOMA IN, P333; SILVERSTEIN MJ, 1997, DUCTAL CARCINOMA IN; SILVERSTEIN MJ, 1998, P AN M AM SOC CLIN, V17, pA120; Solin LJ, 1996, J CLIN ONCOL, V14, P754, DOI 10.1200/JCO.1996.14.3.754; SOLIN LJ, 1993, CANCER-AM CANCER SOC, V71, P2532, DOI 10.1002/1097-0142(19930415)71:8<2532::AID-CNCR2820710817>3.0.CO;2-0; SOLIN LJ, 1994, INT J RADIAT ONCOL, V30, P3, DOI 10.1016/0360-3016(94)90512-6; STRATTON MR, 1995, J PATHOL, V175, P195, DOI 10.1002/path.1711750207	36	40	42	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	SEP 12	1998	317	7160					734	739		10.1136/bmj.317.7160.734	http://dx.doi.org/10.1136/bmj.317.7160.734			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	121CT	9732345	Green Published			2022-12-28	WOS:000075995100025
J	Stearne, MR; Palmer, SL; Hammersley, MS; Franklin, SL; Spivey, RS; Levy, JC; Tidy, CR; Bell, NJ; Steemson, J; Barrow, BA; Coster, R; Waring, K; Nolan, J; Truscott, E; Walravens, N; Cook, L; Lampard, H; Merle, C; Parker, P; McVittie, J; Draisey, I; Murchison, LE; Brunt, AHE; Williams, MJ; Pearson, DW; Petrie, XMP; Lean, MEJ; Walmsley, D; Lyall, MJ; Christie, E; Church, J; Thomson, E; Farrow, A; Stowers, JM; Stowers, M; McHardy, K; Patterson, N; Wright, AD; Levi, NA; Shearer, ACI; Thompson, RJW; Taylor, G; Rayton, S; Bradbury, M; Glover, A; Smyth-Osbourne, A; Parkes, C; Graham, J; England, P; Gyde, S; Eagle, C; Chakrabarti, B; Smith, J; Sherwell, J; Kohner, EM; Dornhurst, A; Doddridge, MC; Dumskyj, M; Walji, S; Sharp, P; Sleightholm, M; Vanterpool, G; Rose, C; Frost, G; Roseblade, M; Elliott, S; Forrester, S; Foster, M; Myers, K; Chapman, R; Hayes, JR; Henry, RW; Featherston, MS; Archbold, GPR; Copeland, M; Harper, R; Richardson, I; Martin, S; Foster, M; Davison, HA; Hadden, DR; Kennedy, L; Atkinson, AB; Culbert, AM; Hegan, C; Tennet, H; Webb, N; Robinson, I; Holmes, J; Foster, M; Bell, PM; McCance, DR; Rutherford, J; Nesbitt, S; Spathis, AS; Hyer, S; Nanson, ME; James, LM; Tyrell, JM; Davis, C; Strugnell, P; Booth, M; Petrie, H; Clark, D; Rice, B; Hulland, S; Barron, JL; Yudkin, JS; Gould, BJ; Singer, J; Badenock, A; Walji, S; Eckert, M; Alibhai, K; Marriot, E; Cox, C; Price, R; Fernandez, M; Ryle, A; Clarke, S; Wallace, G; Mehmed, E; MacFarlane, S; Greenwood, RH; Wilson, J; Denholm, MJ; Temple, RC; Whitfield, K; Johnson, F; Munroe, C; Gorick, S; Duckworth, E; Flatman, M; Rainbow, S; Borthwick, LJ; Wheatcroft, DJ; Seaman, RJ; Christie, RA; Wheatcroft, W; Musk, P; White, J; McDougal, S; Bond, M; Raniga, P; Newton, RW; Jung, RT; Roxburgh, C; Kilgallon, B; Dick, L; Foster, M; Waugh, N; Kilby, S; Ellingford, A; Burns, J; Fox, CV; Holloway, MC; Coghill, HM; Hein, N; Fox, A; Cowan, W; Richard, M; Quested, K; Evans, SJ; Paisey, RB; Brown, NPR; Tucker, AJ; Paisey, R; Garrett, F; Hogg, J; Park, P; Williams, K; Harvey, P; Wilcocks, R; Mason, S; Frost, J; Warren, C; Rocket, P; Bower, L; Roland, JM; Brown, DJ; Youens, J; Stanton-King, K; Mungall, H; Ball, V; Maddison, W; Donnelly, D; King, S; Griffin, P; Smith, S; Church, S; Dunn, G; Wilson, A; Palmer, K; Brown, PM; Humphriss, D; Davidson, AJM; Rose, R; Armistead, L; Townsend, S; Poon, P; Peacock, IDA; Culverwell, NJC; Charlton, MH; Connolly, BPS; Peacock, J; Barrett, J; Wain, J; Beeston, W; King, G; Hill, PG; Boulton, AJM; Robertson, AM; Katoulis, V; Olukoga, A; McDonald, H; Kumar, S; Abouaesha, F; Abuaisha, B; Knowles, EA; Higgins, S; Booker, J; Sunter, J; Breislin, K; Parker, R; Raval, P; Curwell, J; Davenport, H; Shawcross, G; Prest, A; Grey, J; Cole, H; Sereviratne, C; Young, RJ; Dornan, TL; Clyne, JR; Gibson, M; O'Connell, I; Wong, LM; Wilson, SJ; Wright, KL; Wallace, C; McDowell, D; Burden, AC; Sellen, EM; Gregory, R; Roshan, M; Vaghela, N; Burden, M; Sherriff, C; Clarke, J; Grenfell, J; Tooke, JE; MacLeod, K; Searnark, C; Rammell, M; Pym, C; Stockman, J; Yeo, C; Piper, J; Leighton, L; Green, E; Hoyle, M; Jones, K; Hudson, A; James, AJ; Shore, A; Higham, A; Martin, B				Stearne, MR; Palmer, SL; Hammersley, MS; Franklin, SL; Spivey, RS; Levy, JC; Tidy, CR; Bell, NJ; Steemson, J; Barrow, BA; Coster, R; Waring, K; Nolan, J; Truscott, E; Walravens, N; Cook, L; Lampard, H; Merle, C; Parker, P; McVittie, J; Draisey, I; Murchison, LE; Brunt, AHE; Williams, MJ; Pearson, DW; Petrie, XMP; Lean, MEJ; Walmsley, D; Lyall, MJ; Christie, E; Church, J; Thomson, E; Farrow, A; Stowers, JM; Stowers, M; McHardy, K; Patterson, N; Wright, AD; Levi, NA; Shearer, ACI; Thompson, RJW; Taylor, G; Rayton, S; Bradbury, M; Glover, A; Smyth-Osbourne, A; Parkes, C; Graham, J; England, P; Gyde, S; Eagle, C; Chakrabarti, B; Smith, J; Sherwell, J; Kohner, EM; Dornhurst, A; Doddridge, MC; Dumskyj, M; Walji, S; Sharp, P; Sleightholm, M; Vanterpool, G; Rose, C; Frost, G; Roseblade, M; Elliott, S; Forrester, S; Foster, M; Myers, K; Chapman, R; Hayes, JR; Henry, RW; Featherston, MS; Archbold, GPR; Copeland, M; Harper, R; Richardson, I; Martin, S; Foster, M; Davison, HA; Hadden, DR; Kennedy, L; Atkinson, AB; Culbert, AM; Hegan, C; Tennet, H; Webb, N; Robinson, I; Holmes, J; Foster, M; Bell, PM; McCance, DR; Rutherford, J; Nesbitt, S; Spathis, AS; Hyer, S; Nanson, ME; James, LM; Tyrell, JM; Davis, C; Strugnell, P; Booth, M; Petrie, H; Clark, D; Rice, B; Hulland, S; Barron, JL; Yudkin, JS; Gould, BJ; Singer, J; Badenock, A; Walji, S; Eckert, M; Alibhai, K; Marriot, E; Cox, C; Price, R; Fernandez, M; Ryle, A; Clarke, S; Wallace, G; Mehmed, E; MacFarlane, S; Greenwood, RH; Wilson, J; Denholm, MJ; Temple, RC; Whitfield, K; Johnson, F; Munroe, C; Gorick, S; Duckworth, E; Flatman, M; Rainbow, S; Borthwick, LJ; Wheatcroft, DJ; Seaman, RJ; Christie, RA; Wheatcroft, W; Musk, P; White, J; McDougal, S; Bond, M; Raniga, P; Newton, RW; Jung, RT; Roxburgh, C; Kilgallon, B; Dick, L; Foster, M; Waugh, N; Kilby, S; Ellingford, A; Burns, J; Fox, CV; Holloway, MC; Coghill, HM; Hein, N; Fox, A; Cowan, W; Richard, M; Quested, K; Evans, SJ; Paisey, RB; Brown, NPR; Tucker, AJ; Paisey, R; Garrett, F; Hogg, J; Park, P; Williams, K; Harvey, P; Wilcocks, R; Mason, S; Frost, J; Warren, C; Rocket, P; Bower, L; Roland, JM; Brown, DJ; Youens, J; Stanton-King, K; Mungall, H; Ball, V; Maddison, W; Donnelly, D; King, S; Griffin, P; Smith, S; Church, S; Dunn, G; Wilson, A; Palmer, K; Brown, PM; Humphriss, D; Davidson, AJM; Rose, R; Armistead, L; Townsend, S; Poon, P; Peacock, IDA; Culverwell, NJC; Charlton, MH; Connolly, BPS; Peacock, J; Barrett, J; Wain, J; Beeston, W; King, G; Hill, PG; Boulton, AJM; Robertson, AM; Katoulis, V; Olukoga, A; McDonald, H; Kumar, S; Abouaesha, F; Abuaisha, B; Knowles, EA; Higgins, S; Booker, J; Sunter, J; Breislin, K; Parker, R; Raval, P; Curwell, J; Davenport, H; Shawcross, G; Prest, A; Grey, J; Cole, H; Sereviratne, C; Young, RJ; Dornan, TL; Clyne, JR; Gibson, M; O'Connell, I; Wong, LM; Wilson, SJ; Wright, KL; Wallace, C; McDowell, D; Burden, AC; Sellen, EM; Gregory, R; Roshan, M; Vaghela, N; Burden, M; Sherriff, C; Clarke, J; Grenfell, J; Tooke, JE; MacLeod, K; Searnark, C; Rammell, M; Pym, C; Stockman, J; Yeo, C; Piper, J; Leighton, L; Green, E; Hoyle, M; Jones, K; Hudson, A; James, AJ; Shore, A; Higham, A; Martin, B		US Prospective Diabetes Study Grp	Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CORONARY HEART-DISEASE; STAGE RENAL-DISEASE; ANTIHYPERTENSIVE TREATMENT; HYPERTENSION; MELLITUS; MORTALITY; STROKE; MORBIDITY; TRIAL; MEN	Objective: To determine whether tight control of blood pressure prevents macrovascular and microvascular complications in patients with type 2 diabetes. Design: Randomised controlled trial comparing tight control of blood pressure aiming at a blood pressure of <150/85 mm Hg (with the use of an angiotensin converting enzyme inhibitor captopril or a beta blocker atenolol as main treatment) with less tight control aiming at a blood pressure of <.180/105 mm Hg. Setting 20 hospital based clinics in England, Scotland, and Northern Ireland. Subjects: 1148 hypertensive patients with type 2 diabetes (mean age 56, mean blood pressure at entry 160/94 mm Hg); 758 patients were allocated to tight control of blood pressure and 390 patients to less tight control with a median follow up of 8.4 years. Main outcome measures: Predefined clinical end points, fatal and non-fatal, related to diabetes, deaths related to diabetes, and all cause mortality. Surrogate measures of microvascular disease included urinary albumin excretion and retinal photography. Results: Mean blood pressure during follow up was significantly reduced in the group assigned tight blood pressure control (144/82 mm Hg) compared with the group assigned to less tight control (154/87 mm Hg) (P< 0.0001). Reductions in risk in the group assigned to tight control compared with that assigned to less tight control were 24% in diabetes related end points (95% confidence interval 8% to 38%) (P= 0.0046), 32% in deaths related to diabetes (6% to 51%) (P= 0.019), 44% in strokes (11% to 65%) (P= 0.013), and 37% in microvascular end points (11% to 56%) (P= 0.0092), predominantly owing to a reduced risk of retinal photocoagulation. There was a non-significant reduction in all cause mortality. After nine years of follow up the group assigned to tight blood pressure control also had a 34% reduction in risk in the proportion of patients with deterioration of retinopathy by two steps (99% confidence interval 11% to 50%) (P= 0.0004) and a 47% reduced risk (7% to 70%) (P = 0.004) of deterioration in visual acuity by three lines of the early treatment of diabetic retinopathy study (ETDRS) chart. After nine years of follow up 29% of patients in the group assigned to tight control required three or more treatments to lower blood pressure to achieve target blood pressures. Conclusion: Tight blood pressure control in patients with hypertension and type 2 diabetes achieves a clinically important reduction in the risk of deaths related to diabetes, complications related to diabetes, progression of diabetic retinopathy, and deterioration in visual acuity.	Radcliffe Infirm, Diabet Res Labs, UK Prospect Diabet Study Grp, Oxford OX2 6HE, England; Aberdeen Royal Infirm, Aberdeen, Scotland; Birmingham Gen Hosp, Birmingham, W Midlands, England; Hammersmith Hosp, London, England; City Hosp, Belfast, Antrim, North Ireland; Royal Victoria Hosp, Belfast BT12 6BA, Antrim, North Ireland; St Helier Hosp, Carshalton SM5 1AA, Surrey, England; Whittington Hosp, London N19 5NF, England; Norfolk & Norwich Hosp, Norwich NR1 3SR, Norfolk, England; Ninewells Hosp, Dundee DD1 9SY, Scotland; Lister Hosp, Stevenage, Herts, England; Northhampton Hosp, Northampton, England; Peterborough Dist Gen Hosp, Peterborough, Cambs, England; Derbyshire Royal Infirm, Derby DE1 2QY, England; Manchester Royal Infirm, Manchester, Lancs, England; Hope Hosp, Salford M6 8HD, Lancs, England; Leicester Gen Hosp, Leicester, Leics, England; Royal Devon & Exeter Hosp, Exeter EX2 5DW, Devon, England	Radcliffe Infirmary; University of Oxford; University of Aberdeen; University of Birmingham; Imperial College London; St Helier Hospital; University of London; University College London; Norfolk & Norwich University Hospitals NHS Foundation Trust; Norfolk & Norwich University Hospital; University of Dundee; Lister Hospital; University of Manchester; University Hospitals of Leicester NHS Trust; Leicester General Hospital; University of Exeter	Stearne, MR (corresponding author), Radcliffe Infirm, Diabet Res Labs, UK Prospect Diabet Study Grp, Woodstock Rd, Oxford OX2 6HE, England.		Yudkin, John S/C-1988-2008; Smith, Jane/B-6254-2009	Frost, Gary/0000-0003-0529-6325; gibson, martin/0000-0002-1331-1524; stratton, irene/0000-0003-1172-7865; Manley, Susan/0000-0002-8298-4511				ALBERTI KGMM, 1994, DIABETIC MED, V11, P899, DOI 10.1111/j.1464-5491.1994.tb00376.x; American Diabetes Association, 1998, DIABETES CARE, V21, pS23, DOI [10.2337/diacare.21.1.S23, DOI 10.2337/DIACARE.21.1.S23]; [Anonymous], 1994, Diabet Med, V11, P773; [Anonymous], 1985, PREV MED, V14, P312; [Anonymous], 1997, ARCH INTERN MED, V157, P2413; Bauduceau B, 1996, DIABETES METAB, V22, P64; *BRIT DIAB ASS, 1982, HUM NUTR-APPL NUTR, V36, P378; British Multicentre Study Group, 1984, DIABETOLOGIA, V26, P109; COLLINS R, 1994, BRIT MED BULL, V50, P272, DOI 10.1093/oxfordjournals.bmb.a072892; COLLINS R, 1990, LANCET, V335, P827, DOI 10.1016/0140-6736(90)90944-Z; CULL C, 1993, DIABETOLOGIA, V36, P1021; Curb JD, 1996, JAMA-J AM MED ASSOC, V276, P1886, DOI 10.1001/jama.276.23.1886; DAHLOF B, 1991, LANCET, V338, P1281, DOI 10.1016/0140-6736(91)92589-T; DAVIES E G, 1989, Eye (London), V3, P764; GARCIA MJ, 1974, DIABETES, V23, P105, DOI 10.2337/diab.23.2.105; Hansson L, 1998, LANCET, V351, P1755, DOI 10.1016/S0140-6736(98)04311-6; Harris MI, 1995, DIABETES AM; Klag MJ, 1996, NEW ENGL J MED, V334, P13, DOI 10.1056/NEJM199601043340103; KLEIN R, 1989, OPHTHALMOLOGY, V96, P1501; Kohner EM, 1998, ARCH OPHTHALMOL-CHIC, V116, P297, DOI 10.1001/archopht.116.3.297; MANLEY SE, 1992, CLIN CHEM, V38, P2294; MANLEY SE, 1994, DIABETIC MED, V11, P534; MANSON JE, 1991, ARCH INTERN MED, V151, P1141, DOI 10.1001/archinte.151.6.1141; MEADE TW, 1992, BMJ-BRIT MED J, V304, P405; MOGENSEN CE, 1994, J INTERN MED, V235, P297, DOI 10.1111/j.1365-2796.1994.tb01080.x; MOGENSEN CE, 1995, LANCET, V346, P1080, DOI 10.1016/S0140-6736(95)91747-0; Nelson RG, 1996, NEW ENGL J MED, V335, P1636, DOI 10.1056/NEJM199611283352203; PARVING HH, 1987, BRIT MED J, V294, P1443, DOI 10.1136/bmj.294.6585.1443; PARVING HH, 1987, BMJ-BRIT MED J, V297, P1086; PERNEGER TV, 1994, ANN INTERN MED, V121, P912, DOI 10.7326/0003-4819-121-12-199412150-00002; PRESCOTTCLARKE P, 1997, HLTH SURVEY ENGLAND; PROBSTFIELD JL, 1991, JAMA-J AM MED ASSOC, V265, P3255; RAVID M, 1994, KIDNEY INT, V45, pS161; *RR ASS, 1994, BLOOD PRESS DIAB EV; SANDERSON S, 1996, HLTH TRENDS, V28, P117; STAMLER J, 1993, DIABETES CARE, V16, P434, DOI 10.2337/diacare.16.2.434; Stearne MR, 1998, BRIT MED J, V317, P713; TAN MH, 1992, CAN MED ASSOC J, V147, P697; TURNER RC, 1993, J HYPERTENS, V11, P319; Turner RC, 1998, BMJ-BRIT MED J, V316, P823, DOI 10.1136/bmj.316.7134.823; TURNER RC, 1993, J HYPERTENS, V11, P309; TURNER RC, 1991, DIABETOLOGIA, V34, P877; Turner RC, 1998, LANCET, V352, P837, DOI 10.1016/s0140-6736(98)07019-6	43	5335	5481	7	162	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 12	1998	317	7160					703	713						17	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	121CT	9732337				2022-12-28	WOS:000075995100018
J	Greenhalgh, T				Greenhalgh, T			Some experience necessary	BRITISH MEDICAL JOURNAL			English	Editorial Material													Greenhalgh, Trisha/B-1825-2015	Greenhalgh, Trisha/0000-0003-2369-8088					0	0	0	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	SEP 5	1998	317	7159					687	687		10.1136/bmj.317.7159.687	http://dx.doi.org/10.1136/bmj.317.7159.687			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	118GN	9728016	Green Published			2022-12-28	WOS:000075830200076
J	Feldman, WC; Maurice, S; Binder, AB; Barraclough, BL; Elphic, RC; Lawrence, DJ				Feldman, WC; Maurice, S; Binder, AB; Barraclough, BL; Elphic, RC; Lawrence, DJ			Fluxes of fast and epithermal neutrons from lunar prospector: Evidence for water ice at the lunar poles	SCIENCE			English	Article							MERCURY RADAR; MOON; CLEMENTINE; STABILITY; DEPOSITS; IMAGES; MARS	Maps of epithermal- and fast-neutron fluxes measured by Lunar Prospector were used to search for deposits enriched in hydrogen at both lunar poles. Depressions in epithermal fluxes were observed close to permanently shaded areas at both poles. The peak depression at the North Pole is 4.6 percent below the average epithermal flux intensity at Lower latitudes, and that at the South Pole is 3.0 percent below the Low-Latitude average. No measurable depression in fast neutrons is seen at either pole. These data are consistent with deposits of hydrogen in the form of water ice that are covered by as much as 40 centimeters of desiccated regolith within permanently shaded craters near both poles.	Univ Calif Los Alamos Natl Lab, Los Alamos, NM 87545 USA; Observ Midi Pyrenees, F-31400 Toulouse, France; Lunar Res Inst, Gilroy, CA 95020 USA	United States Department of Energy (DOE); Los Alamos National Laboratory; Universite de Toulouse; Universite Toulouse III - Paul Sabatier	Feldman, WC (corresponding author), Univ Calif Los Alamos Natl Lab, MS D-466, Los Alamos, NM 87545 USA.		Lawrence, David J/E-7463-2015	Lawrence, David J/0000-0002-7696-6667				ALCOUFFE RE, 1995, LA7369M LANL; ARNOLD JR, 1979, J GEOPHYS RES, V84, P5659, DOI 10.1029/JB084iB10p05659; Butler BJ, 1997, J GEOPHYS RES-PLANET, V102, P19283, DOI 10.1029/97JE01347; BUTLER BJ, 1993, J GEOPHYS RES-PLANET, V98, P15003, DOI 10.1029/93JE01581; BUTLER BJ, 1994, THESIS CALTECH PASAD; BYRD RC, 1994, LA12833MS LANL; FEDLMAN WC, IN PRESS NUCL INST A; FELDMAN WC, 1991, NUCL INSTRUM METH A, V306, P350, DOI 10.1016/0168-9002(91)90342-N; Feldman WC, 1998, SCIENCE, V281, P1489, DOI 10.1126/science.281.5382.1489; Feldman WC, 1997, J GEOPHYS RES-PLANET, V102, P25565, DOI 10.1029/97JE02353; FELDMAN WC, 1993, J GEOPHYS RES-PLANET, V98, P20855, DOI 10.1029/93JE02325; FELDMAN WC, 1991, GEOPHYS RES LETT, V18, P2157, DOI 10.1029/91GL02618; HARMON JK, 1992, SCIENCE, V258, P640, DOI 10.1126/science.258.5082.640; Harmon JK, 1997, ADV SPACE RES-SERIES, V19, P1487, DOI 10.1016/S0273-1177(97)00347-5; INGERSOLL AP, 1992, ICARUS, V100, P40, DOI 10.1016/0019-1035(92)90016-Z; JEANLOZ R, 1995, SCIENCE, V268, P1455, DOI 10.1126/science.7770770; LANZEROTTI LJ, 1981, J GEOPHYS RES, V86, P3949, DOI 10.1029/JB086iB05p03949; MORGAN TH, 1991, J GEOPHYS RES-SPACE, V96, P1351, DOI 10.1029/90JA02127; Nozette S, 1996, SCIENCE, V274, P1495, DOI 10.1126/science.274.5292.1495; SHOEMAKER EM, 1994, SCIENCE, V266, P1851, DOI 10.1126/science.266.5192.1851; Simpson RV, UNPUB; SLADE MA, 1992, SCIENCE, V258, P635, DOI 10.1126/science.258.5082.635; Stacy NJS, 1997, SCIENCE, V276, P1527, DOI 10.1126/science.276.5318.1527; *US GEOL SURV, 1981, SURF REL MAPS LUN PO; Vaniman D., 1991, LUNAR SOURCEBOOK, P5; WATSON K, 1961, J GEOPHYS RES, V66, P3033, DOI 10.1029/JZ066i009p03033; [No title captured]	27	398	418	2	73	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 4	1998	281	5382					1496	1500		10.1126/science.281.5382.1496	http://dx.doi.org/10.1126/science.281.5382.1496			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	116RJ	9727973				2022-12-28	WOS:000075738100037
J	Wright, CM; Callum, J; Birks, E; Jarvis, S				Wright, CM; Callum, J; Birks, E; Jarvis, S			Effect of community based management in failure to thrive: randomised controlled trial	BRITISH MEDICAL JOURNAL			English	Article							TO-THRIVE; NONORGANIC FAILURE; ORGANIC FAILURE; WEIGHT-GAIN; INTERVENTION; CHILDREN; GROWTH	Objective: To evaluate the effectiveness of a health visitor led intervention for failure to thrive in children under 2 years old. Design: Controlled trial, randomised by primary care practice. Setting: Newcastle upon Tyne health district. Intervention: Structured health visitor management, with dietetic, paediatric, and social work input as required. Subjects: 229 children (120 in intervention practices and 109 in control practices) were identified as failing to thrive by population screening during the first 2 years of life. Follow up was by home visit of a research nurse and review of the childrens' records at age 3 years. Main outcome measures: Follow up weight and height aid number of routinely collected weights. Results: 95 of the 97 families offered intervention completed at least the initial assessment At follow up, 187 (82%) records were reviewed, and these suggested that 15 (16%) controls were lost to follow up immediately after the screening weight was taken compared with only one child in the intervention group. In the 134 (58%) families who consented to home visits, children in the intervention group were significantly heavier and taller and were reported to have better appetites than childen in the control group, although both groups were equally satisfied by the services they had received. When the children were last weighed, 91 (76%) in the intervention group had recovered from their failure to thrive compared xith 60 (55%) in the control group (P < 0.001). Conclusion: In failure to thrive, health visitor intervention, with limited specialist support, can significantly improve growth compared with conventional management.	Univ Newcastle, Dept Child Hlth, Gateshead NE8 1EB, Tyne & Wear, England; Newcastle City Hlth Trust, Arthurs Hill Clin, Parkin Serv, Newcastle Upon Tyne NE4 6BT, Tyne & Wear, England	Newcastle University - UK; Newcastle University - UK	Wright, CM (corresponding author), Univ Newcastle, Dept Child Hlth, Donald Court House, Gateshead NE8 1EB, Tyne & Wear, England.	cm.wright@ncl.ac.uk			Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BARKER DJP, 1989, LANCET, V2, P577; BATCHELOR J, 1990, FAILURE FIND FAILURE; BITHONEY WG, 1989, J DEV BEHAV PEDIATR, V10, P27; BLACK MM, 1995, PEDIATRICS, V95, P807; Corbett SS, 1996, ACTA PAEDIATR, V85, P1278, DOI 10.1111/j.1651-2227.1996.tb13911.x; DROTAR D, 1988, J PEDIATR PSYCHOL, V13, P281, DOI 10.1093/jpepsy/13.2.281; FREEMAN JV, 1995, ARCH DIS CHILD, V73, P17, DOI 10.1136/adc.73.1.17; HAYNES CF, 1984, CHILD ABUSE NEGLECT, V8, P229, DOI 10.1016/0145-2134(84)90012-7; KRISTIANSSON B, 1987, CHILD ABUSE NEGLECT, V11, P35, DOI 10.1016/0145-2134(87)90031-7; SKUSE D, 1994, J CHILD PSYCHOL PSYC, V35, P521, DOI 10.1111/j.1469-7610.1994.tb01738.x; SKUSE DH, 1985, ARCH DIS CHILD, V60, P173, DOI 10.1136/adc.60.2.173; WOODEHOUSE G, 1996, MULTILEVEL MODELLING; Wright CM, 1996, CHILD CARE HLTH DEV, V22, P223, DOI 10.1111/j.1365-2214.1996.tb00425.x; WRIGHT CM, 1994, ACTA PAEDIATR, V83, P351, DOI 10.1111/j.1651-2227.1994.tb18118.x	14	51	52	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 29	1998	317	7158					571	574		10.1136/bmj.317.7158.571	http://dx.doi.org/10.1136/bmj.317.7158.571			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	117EK	9721113	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000075767800017
J	Weinstein, DC; Marden, J; Carnevali, F; Hemmati-Brivanlou, A				Weinstein, DC; Marden, J; Carnevali, F; Hemmati-Brivanlou, A			FGF-mediated mesoderm induction involves the Src-family kinase Laloo	NATURE			English	Article							EARLY XENOPUS DEVELOPMENT; MAP KINASE; REQUIRES FGF; SIGNALING PATHWAYS; NEURAL INDUCTION; EARLY RESPONSE; EXPRESSION; EMBRYOS; PROTEIN; RNA	During embryogenesis, inductive interactions underlie the development of much of the body plan. In Xenopus laevis factors secreted from the vegetal pole induce mesoderm in the adjacent marginal zone; members of both the transforming growth factor-beta (TGF-beta) and fibroblast growth factor (FGF) ligand families seem to have critical roles in this process(1). Here we report the identification and characterization of laloo a novel participant in the signal transduction cascade linking extracellular, mesoderm-inducing signals to the nucleus, where alteration of cell fate is driven by changes in gene expression. Overexpression of laloo, a member of the Src-related gene family, in Xenopus embryos gives rise to ectopic posterior structures that frequently contain axial tissue. Laloo induces mesoderm in Xenopus ectodermal explants; this induction is blocked by reagents that disrupt the FGF signalling pathway. Conversely, expression of a dominant-inhibitory Laloo mutant blocks mesoderm induction by FGF and causes severe posterior truncations in vivo. This work provides the first evidence that a Src-related kinase is involved in vertebrate mesoderm induction.	Rockefeller Univ, Dept Mol Vertebrate Embryol, New York, NY 10021 USA	Rockefeller University	Hemmati-Brivanlou, A (corresponding author), Rockefeller Univ, Dept Mol Vertebrate Embryol, 1230 York Ave, New York, NY 10021 USA.	brvnlou@rockvax.rockefeller.edu		Weinstein, Daniel/0000-0001-7832-9285	NICHD NIH HHS [HD 32105-01] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R55HD032105, R01HD032105] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AMAYA E, 1991, CELL, V66, P257, DOI 10.1016/0092-8674(91)90616-7; BASSEZ T, 1990, DEVELOPMENT, V110, P955; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; CORNELL RA, 1994, DEVELOPMENT, V120, P453; GOTOH Y, 1995, EMBO J, V14, P2491, DOI 10.1002/j.1460-2075.1995.tb07246.x; HARRIS WA, 1991, NEURON, V6, P499, DOI 10.1016/0896-6273(91)90053-3; HEMMATIBRIVANLOU A, 1994, CELL, V77, P273, DOI 10.1016/0092-8674(94)90319-0; ISAACS HV, 1994, EMBO J, V13, P4469, DOI 10.1002/j.1460-2075.1994.tb06769.x; KINTNER CR, 1984, NATURE, V308, P67, DOI 10.1038/308067a0; KINTNER CR, 1987, DEVELOPMENT, V99, P311; KLEIN PS, 1994, ENDOCR REV, V15, P326, DOI 10.1210/er.15.3.326; KRIEG PA, 1989, DEV BIOL, V133, P93, DOI 10.1016/0012-1606(89)90300-X; Kroll KL, 1996, DEVELOPMENT, V122, P3173; LABONNE C, 1994, DEVELOPMENT, V120, P463; LABONNE C, 1995, DEVELOPMENT, V121, P1475; LaBonne C, 1997, DEV BIOL, V183, P9, DOI 10.1006/dbio.1996.8497; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; Lustig KD, 1996, DEVELOPMENT, V122, P4001; MACNICOL AM, 1993, CELL, V73, P571, DOI 10.1016/0092-8674(93)90143-E; MOHUN TJ, 1984, NATURE, V311, P716, DOI 10.1038/311716a0; NORTHROP J, 1995, DEV BIOL, V172, P242, DOI 10.1006/dbio.1995.0019; Parsons JT, 1997, CURR OPIN CELL BIOL, V9, P187, DOI 10.1016/S0955-0674(97)80062-2; SASAI Y, 1994, CELL, V79, P779, DOI 10.1016/0092-8674(94)90068-X; SCHULTEMERKER S, 1995, CURR BIOL, V5, P62, DOI 10.1016/S0960-9822(95)00017-0; SMITH JC, 1991, CELL, V67, P79, DOI 10.1016/0092-8674(91)90573-H; SMITH WC, 1991, CELL, V67, P753, DOI 10.1016/0092-8674(91)90070-F; TANG TL, 1995, CELL, V80, P473, DOI 10.1016/0092-8674(95)90498-0; UMBHAUER M, 1995, NATURE, V376, P58, DOI 10.1038/376058a0; WHITMAN M, 1992, NATURE, V357, P252, DOI 10.1038/357252a0; WRIGHT CVE, 1990, DEVELOPMENT, V109, P225	30	75	76	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 27	1998	394	6696					904	908		10.1038/29808	http://dx.doi.org/10.1038/29808			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	114LW	9732875				2022-12-28	WOS:000075611800052
J	Weinstein, JN				Weinstein, JN			A 45-year-old man with low back pain and a numb left foot	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							EXPERIMENTAL LUMBAR RADICULOPATHY; NERVE ROOT IRRITATION; INTERVERTEBRAL DISC; SPINE; RAT		Dartmouth Coll, Surg Outcomes Assessment Program, Hanover, NH 03755 USA; Dartmouth Hitchcock Med Ctr, Multidisciplinary Spine Ctr, Hanover, NH USA; Dartmouth Hitchcock Med Ctr, Patient Preference Lab, Hanover, NH USA	Dartmouth College; Dartmouth College; Dartmouth College	Weinstein, JN (corresponding author), Beth Israel Deaconess Med Ctr, Div Gen Med & Primary Care, 330 Brookline Ave,LY318, Boston, MA 02215 USA.							ARMSTRONG JR, 1951, J BONE JOINT SURG BR, V33, P31, DOI 10.1302/0301-620X.33B1.31; Atlas SJ, 1996, SPINE, V21, P1777, DOI 10.1097/00007632-199608010-00011; Bessette L, 1996, SPINE, V21, P259, DOI 10.1097/00007632-199602010-00001; Bigos S, 1994, ACUTE LOW BACK PAIN; BODEN SD, 1990, J BONE JOINT SURG AM, V72A, P403, DOI 10.2106/00004623-199072030-00013; CHERKIN D, 1998, HMO RES NETW C MAY 8; DEYO RA, 1992, JAMA-J AM MED ASSOC, V268, P760, DOI 10.1001/jama.268.6.760; Deyo Richard A., 1995, P55; DINARELLO CA, 1987, NEW ENGL J MED, V317, P940, DOI 10.1056/NEJM198710083171506; DIROSA M, 1986, AGENTS ACTIONS, V17, P284; DONELSON R, 1991, SPINE, V16, pS206, DOI 10.1097/00007632-199106001-00006; HAKELIUS A, 1970, ACTA ORTHOP SCAND, P1; HANLEY EN, 1989, J BONE JOINT SURG AM, V71A, P719, DOI 10.2106/00004623-198971050-00013; Hanley EN, 1996, LOW BACK PAIN: A SCIENTIFIC AND CLINICAL OVERVIEW, P113; HANLEY EN, 1992, BRIS MYER Z, P125; JAMISON RN, 1991, CLIN J PAIN, V7, P311, DOI 10.1097/00002508-199112000-00010; JENSEN MC, 1994, NEW ENGL J MED, V331, P69, DOI 10.1056/NEJM199407143310201; Katz JN, 1997, SPINE, V22, P1123, DOI 10.1097/00007632-199705150-00012; Kawakami M, 1996, SPINE, V21, P2101, DOI 10.1097/00007632-199609150-00009; KAWAKAMI M, 1994, SPINE, V19, P1795, DOI 10.1097/00007632-199408150-00002; KAWAKAMI M, 1994, SPINE, V19, P1780, DOI 10.1097/00007632-199408150-00001; KELSEY J L, 1975, Rheumatology and Rehabilitation, V14, P144, DOI 10.1093/rheumatology/14.3.144; KELSEY JL, 1984, SPINE, V9, P608, DOI 10.1097/00007632-198409000-00012; KELSEY JL, 1980, SPINE, V5, P133, DOI 10.1097/00007632-198003000-00007; KOSTUIK JP, 1986, J BONE JOINT SURG AM, V68A, P386, DOI 10.2106/00004623-198668030-00011; MALMIVAARA A, 1995, NEW ENGL J MED, V332, P351, DOI 10.1056/NEJM199502093320602; Malter AD, 1996, SPINE, V21, P1048, DOI 10.1097/00007632-199605010-00011; McCulloch JA, 1990, LUMBAR SPINE, P393; MCLAIN R, 1996, LOW BACK PAIN SCI CL; Olmarker Kjell, 1995, P11; PRAEMER A, 1997, MUSCULOSKELETAL COND; RENFREW DL, 1991, AM J NEURORADIOL, V12, P1003; SAAL JA, 1989, SPINE, V14, P431, DOI 10.1097/00007632-198904000-00018; SPANGFORT EV, 1972, ACTA ORTHOP SCAND, P1; Spengler D M, 1979, Spine (Phila Pa 1976), V4, P129, DOI 10.1097/00007632-197903000-00006; SPITZER WO, 1987, SPINE, V12, pS1; THOMBURYJ, 1993, RADIOLOGY, V186, P731; vanTulder MW, 1997, SPINE, V22, P2128, DOI 10.1097/00007632-199709150-00012; VIDEMAN T, 1996, LOW BACK PAIN SCI CR; VonKorff M, 1996, SPINE, V21, P2833, DOI 10.1097/00007632-199612150-00004; WADDELL G, 1990, LUMBAR SPINE, P38; WEBER H, 1983, SPINE, V8, P131, DOI 10.1097/00007632-198303000-00003; Weinstein JN, 1996, SPINE, V21, P905, DOI 10.1097/00007632-199604150-00001; WEINSTEIN JN, 1996, LOW BACK PAIN SCI CL; Wennberg JE, 1998, DARTMOUTH ATLAS HLTH; WIESEL S, 1989, SEM SPIN SURG LUMB D	46	10	10	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 26	1998	280	8					730	736		10.1001/jama.280.8.730	http://dx.doi.org/10.1001/jama.280.8.730			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	111PM	9728646				2022-12-28	WOS:000075446900036
J	McClure, SJ; Caruana, L; Davie, AP; Goldthorp, S; McMurray, JJV				McClure, SJ; Caruana, L; Davie, AP; Goldthorp, S; McMurray, JJV			Cohort study of plasma natriuretic peptides for identifying left ventricular systolic dysfunction in primary care	BRITISH MEDICAL JOURNAL			English	Article							HEART-FAILURE; DIASTOLIC DYSFUNCTION; ATRIAL; BRAIN; ECHOCARDIOGRAPHY; DIAGNOSIS; MANAGEMENT; COMMUNITY; MORTALITY	Objectives: To determine whether blood natriuretic peptide concentrations are helpful in identifying or excluding left ventricular systolic dysfunction in stable survivors of acute myocardial infarction. Design: Comparison of blood natriuretic peptide concentrations with echocardiographic assessment of left ventricular systolic function in a general practice population. Setting: Practices in Western District of Glasgow audit group. Subjects: 134 long term survivors of myocardial infarction recalled for echocardiography as part of a primary care secondary prevention audit. Main outcome measures: Area under the receiver operating curve for brain natriuretic peptide and N-terminal atrial natriuretic peptide. Results: Brain natriuretic peptide was of some diagnostic utility in identifying the minority of subjects with severe left ventricular dysfunction (area under curve = 0.73) but was unable to discriminate between patients with moderately severe dysfunction and those with preserved left ventricular function (area under curve for moderate or severe dysfunction = 0.54). The corresponding values for N-terminal atrial natriuretic peptide for severe and moderate or severe dysfunction were 0.55 and 0.56 respectively. Conclusions: Blood natriuretic peptide concentrations are not useful in identifying important left ventricular systolic dysfunction in stable survivors of myocardial infarction.	Univ Glasgow, Western Infirm, Dept Cardiol, Glasgow G11 6NT, Lanark, Scotland; Stn Rd Surg, Glasgow, Lanark, Scotland	University of Glasgow	McMurray, JJV (corresponding author), Univ Glasgow, Western Infirm, Dept Cardiol, Glasgow G11 6NT, Lanark, Scotland.		mcmurray, John/B-2467-2013	mcmurray, John/0000-0002-6317-3975				BUCKLEY MG, 1993, J HUM HYPERTENS, V7, P245; CHOY AMJ, 1994, BRIT HEART J, V72, P16; Christian TF, 1997, AM J CARDIOL, V79, P1295, DOI 10.1016/S0002-9149(97)00108-2; Cowie MR, 1997, LANCET, V350, P1349, DOI 10.1016/S0140-6736(97)06031-5; DARGIE HJ, 1994, BMJ-BRIT MED J, V308, P321, DOI 10.1136/bmj.308.6924.321; Davidson NC, 1996, AM J CARDIOL, V77, P828, DOI 10.1016/S0002-9149(97)89176-X; DAVIDSON NC, 1995, CIRCULATION, V91, P1276; Davie AP, 1996, BRIT MED J, V313, P300, DOI 10.1136/bmj.313.7052.300c; Davis KM, 1996, J GERONTOL A-BIOL, V51, pM95, DOI 10.1093/gerona/51A.3.M95; FRANCIS CM, 1995, BRIT MED J, V310, P634, DOI 10.1136/bmj.310.6980.634; Friedl W, 1996, HEART, V76, P129, DOI 10.1136/hrt.76.2.129; GARG R, 1995, JAMA-J AM MED ASSOC, V273, P1450, DOI 10.1001/jama.273.18.1450; Jensen-Urstad K, 1998, AM J CARDIOL, V81, P538, DOI 10.1016/S0002-9149(97)00964-8; LANG CC, 1994, AM HEART J, V127, P1635, DOI 10.1016/0002-8703(94)90401-4; McDonagh TA, 1998, LANCET, V351, P9, DOI 10.1016/S0140-6736(97)03034-1; MURDOCH DR, 1997, HEART, V78, P549; NICKLAS JM, 1992, NEW ENGL J MED, V327, P685; NORTHRIDGE DB, 1989, BRIT MED J, V299, P603, DOI 10.1136/bmj.299.6699.603; Omland T, 1996, HEART, V76, P232, DOI 10.1136/hrt.76.3.232; REMES J, 1991, EUR HEART J, V12, P315, DOI 10.1093/oxfordjournals.eurheartj.a059896; RIHAL CS, 1995, AM J CARDIOL, V75, P220, DOI 10.1016/0002-9149(95)80023-L; ROBB SD, 1997, J AM COLL CARDIOL, V29, P965; SANDERSON JE, 1995, BRIT HEART J, V74, P502; STRUTHERS AD, 1995, Q J MED, V273, P1450; Tsutamoto T, 1997, AM HEART J, V134, P910, DOI 10.1016/S0002-8703(97)80014-2; WHEELDON NM, 1993, Q J MED, V86, P17; Willenheimer RB, 1997, SCAND CARDIOVASC J, V31, P9, DOI 10.3109/14017439709058063; Yamamoto K, 1996, HYPERTENSION, V28, P988, DOI 10.1161/01.HYP.28.6.988	28	72	72	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 22	1998	317	7157					516	519						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	115AM	9712601				2022-12-28	WOS:000075641400024
J	Vescoli, V; Degiorgi, L; Henderson, W; Gruner, C; Starkey, KP; Montgomery, LK				Vescoli, V; Degiorgi, L; Henderson, W; Gruner, C; Starkey, KP; Montgomery, LK			Dimensionality-driven insulator-to-metal transition in the Bechgaard salts	SCIENCE			English	Article							SPIN-DENSITY WAVES; ORGANIC CONDUCTORS; SUPERCONDUCTORS; SPECTRA	Optical experiments were conducted on a series of organic linear chain conductors with different values of the interchain single-electron transfer integral t(b), which quantifies the degree of anisotropy. Electron-electron interactions together with Umklapp scattering resulted in a correlation gap and an insulating state for small t(b). An insulator-to-metal transition was observed when t(b) exceeded a critical value, on the order of the correlation gap E-gap. The absence of a plasma edge on the insulator side of the transition for polarization perpendicular to the chains suggests that the electrons are confined to the chains. The optical features of the metallic state. when contrasted with the magnetic properties, are suggestive of spin-charge separation.	ETH Zurich, Festkorperphys Lab, CH-8093 Zurich, Switzerland; Univ Calif Los Angeles, Dept Phys, Los Angeles, CA 90095 USA; Indiana Univ, Dept Chem, Bloomington, IN 47405 USA	Swiss Federal Institutes of Technology Domain; ETH Zurich; University of California System; University of California Los Angeles; Indiana University System; Indiana University Bloomington	Vescoli, V (corresponding author), ETH Zurich, Festkorperphys Lab, CH-8093 Zurich, Switzerland.							ANDERSON PW, 1995, P NATL ACAD SCI USA, V92, P6668, DOI 10.1073/pnas.92.15.6668; BALICAS L, 1994, J PHYS I, V4, P1539, DOI 10.1051/jp1:1994205; Bourbonnais C, 1997, SYNTHETIC MET, V84, P19, DOI 10.1016/S0379-6779(97)80657-1; BOURBONNAIS C, 1991, INT J MOD PHYS B, V5, P1033, DOI 10.1142/S0217979291000547; Bourbonnais C., 1995, STRONGLY INTERACTING, P307; BROWN SB, COMMUNICATION; BULUT N, 1994, PHYS REV LETT, V72, P705, DOI 10.1103/PhysRevLett.72.705; DARDEL B, 1993, EUROPHYS LETT, V24, P687, DOI 10.1209/0295-5075/24/8/011; DONOVAN S, 1993, INT J INFRARED MILLI, V14, P2359; Dressel M, 1996, PHYS REV LETT, V77, P398, DOI 10.1103/PhysRevLett.77.398; Dressel M., COMMUNICATION; DUCASSE L, 1986, J PHYS C SOLID STATE, V19, P3805, DOI 10.1088/0022-3719/19/20/016; Giamarchi T, 1997, PHYSICA B, V230, P975, DOI 10.1016/S0921-4526(96)00768-5; Gorkov LP, 1996, J PHYS I, V6, P1697, DOI 10.1051/jp1:1996183; GORKOV LP, UNPUB; Grant P. M., 1983, J PHYS C SOLID STATE, V44, pC3, DOI [10.1051/jphyscol/1983152, DOI 10.1051/JPHYSCOL/1983152]; JACOBSEN CS, 1981, PHYS REV LETT, V46, P1142, DOI 10.1103/PhysRevLett.46.1142; Jerome D, 1996, NATO ADV SCI INST SE, V354, P141; JEROME D, 1982, ADV PHYS, V31, P229; JEROME D, 1987, P NATO STUDY I LOW D, V155; KLEMME BJ, 1995, PHYS REV LETT, V75, P2408, DOI 10.1103/PhysRevLett.75.2408; Mila F, 1996, PHYS REV LETT, V76, P287, DOI 10.1103/PhysRevLett.76.287; MONTGOMERY LK, 1994, APPL PHYSICS SERIES, P138; MORI H, 1994, J PHYS SOC JPN, V63, P1693; Moser J, 1998, EUR PHYS J B, V1, P39, DOI 10.1007/s100510050150; PEDRON D, 1994, PHYS REV B, V49, P10893, DOI 10.1103/PhysRevB.49.10893; PENC K, 1994, PHYS REV B, V50, P11429, DOI 10.1103/PhysRevB.50.11429; SCHULZ HJ, 1991, INT J MOD PHYS B, V5, P57, DOI 10.1142/S0217979291000055; Schwartz A, 1998, PHYS REV B, V58, P1261, DOI 10.1103/PhysRevB.58.1261; STRONG SP, 1994, PHYS REV LETT, V73, P1007, DOI 10.1103/PhysRevLett.73.1007; Suzumura Y, 1998, PHYS REV B, V57, P15040, DOI 10.1103/PhysRevB.57.R15040; TOMONAGA S, 1950, PROG THEOR PHYS, V5, P554; VESCOLI V, UNPUB; WZIETEK P, 1993, J PHYS I, V3, P171, DOI 10.1051/jp1:1993123; Zwick F, 1997, PHYS REV LETT, V79, P3982, DOI 10.1103/PhysRevLett.79.3982	36	228	228	2	26	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 21	1998	281	5380					1181	1184		10.1126/science.281.5380.1181	http://dx.doi.org/10.1126/science.281.5380.1181			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	113CE	9712580				2022-12-28	WOS:000075531200050
J	Harris, CM; Wolpert, DM				Harris, CM; Wolpert, DM			Signal-dependent noise determines motor planning	NATURE			English	Article							SACCADIC EYE-MOVEMENTS; DRAWING MOVEMENTS; ARM MOVEMENTS; MODEL; COORDINATION	When we make saccadic eye movements or goal-directed arm movements, there is an infinite number of possible trajectories that the eye or arm could take to reach the target(1,2). However, humans show highly stereotyped trajectories in which velocity profiles of both the eye and hand are smooth and symmetric for brief movements(3,4). Here we present a unifying theory of eye and arm movements based on the single physiological assumption that the neural control signals are corrupted by noise whose variance increases with the size of the control signal. We propose that in the presence of such signal-dependent noise, the shape of a trajectory is selected to minimize the variance of the final eye or arm position. This minimum-variance theory accurately predicts the trajectories of both saccades and arm movements and the speed-accuracy trade-off described by Fitt's law(5). These profiles are robust to changes in the dynamics of the eye or arm, as found empirically(6,7) 7. Moreover, the relation between path curvature and hand velocity during drawing movements reproduces the empirical 'two-thirds power law'(8,9). This theory provides a simple and powerful unifying perspective for both eye and arm movement control.	Great Ormond St Hosp Sick Children, Dept Ophthalmol, London WC1N 3JH, England; Great Ormond St Hosp Sick Children, Visual Sci Unit, London WC1N 3JH, England; UCL, Inst Child Hlth, London WC1N 3JH, England; UCL, Inst Neurol, Sobell Dept Neurophysiol, London WC1N 3BG, England	University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; University of London; University College London; University of London; University College London	Harris, CM (corresponding author), Great Ormond St Hosp Sick Children, Dept Ophthalmol, Great Ormond St, London WC1N 3JH, England.			Harris, Chris/0000-0003-0452-8518; Wolpert, Daniel/0000-0003-2011-2790	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Bernstein N, 1967, COORDINATION REGULAT; BrashersKrug T, 1996, NATURE, V382, P252, DOI 10.1038/382252a0; CLAMANN HP, 1969, BIOPHYS J, V9, P1233, DOI 10.1016/S0006-3495(69)86448-9; COLLEWIJN H, 1988, J PHYSIOL-LONDON, V404, P157, DOI 10.1113/jphysiol.1988.sp017284; ENDERLE JD, 1987, IEEE T BIO-MED ENG, V34, P43, DOI 10.1109/TBME.1987.326014; FITTS PM, 1954, J EXP PSYCHOL, V47, P381, DOI 10.1037/h0055392; FLASH T, 1985, J NEUROSCI, V5, P1688, DOI 10.1523/jneurosci.05-07-01688.1985; Goodbody SJ, 1998, J NEUROPHYSIOL, V79, P1825, DOI 10.1152/jn.1998.79.4.1825; Gurevich T, 1997, SELF ORG COMPUTATION, P423, DOI 10.1016/S0166-4115(97)80015-5; HARRIS CM, 1990, J NEUROPHYSIOL, V63, P877, DOI 10.1152/jn.1990.63.4.877; Harris CM, 1998, J NEUROSCI METH, V83, P73, DOI 10.1016/S0165-0270(98)00063-6; HARRIS CM, 1995, VISION RES, V35, P691, DOI 10.1016/0042-6989(94)00163-G; HOGAN N, 1984, J NEUROSCI, V4, P2745; JEANNEROD M, 1988, OUP PSYCHOL SER, V5; Kawato M, 1996, ATTENTION PERFORM, VXVI, P335; KELSO JAS, 1979, SCIENCE, V203, P1029, DOI 10.1126/science.424729; LACKNER JR, 1994, J NEUROPHYSIOL, V72, P299, DOI 10.1152/jn.1994.72.1.299; LACQUANITI F, 1983, ACTA PSYCHOL, V54, P115, DOI 10.1016/0001-6918(83)90027-6; Matthews PBC, 1996, J PHYSIOL-LONDON, V492, P597, DOI 10.1113/jphysiol.1996.sp021332; MEYER DE, 1988, PSYCHOL REV, V95, P340, DOI 10.1037/0033-295X.95.3.340; MORASSO P, 1981, EXP BRAIN RES, V42, P223; ROBINSON DA, 1986, BIOL CYBERN, V55, P43, DOI 10.1007/BF00363977; Sainburg R. L., 1995, Society for Neuroscience Abstracts, V21, P686; SHADMEHR R, 1994, J NEUROSCI, V14, P3208; UNO Y, 1989, BIOL CYBERN, V61, P89, DOI 10.1007/BF00204593; VANDERHLEM FCT, IN PRESS BIOMECHANIC; VANGISBERGEN JAM, 1981, J NEUROPHYSIOL, V45, P417, DOI 10.1152/jn.1981.45.3.417; VIVIANI P, 1991, J EXP PSYCHOL HUMAN, V17, P198, DOI 10.1037/0096-1523.17.1.198; Wolpert DM, 1997, TRENDS COGN SCI, V1, P209, DOI 10.1016/S1364-6613(97)01070-X; WOLPERT DM, 1995, SCIENCE, V269, P1880, DOI 10.1126/science.7569931	30	1656	1668	5	143	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 20	1998	394	6695					780	784		10.1038/29528	http://dx.doi.org/10.1038/29528			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	112PR	9723616				2022-12-28	WOS:000075503600045
J	Hack, M; Cohen, AR				Hack, M; Cohen, AR			Acetazolamide plus furosemide for periventricular dilatation: lessons for drug therapy in children	LANCET			English	Editorial Material							HYDROCEPHALUS		Case Western Reserve Univ, Rainbow Babies & Childrens Hosp, Sch Med, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University Hospital; University Hospitals of Cleveland; Rainbow Babies & Children's Hospital	Hack, M (corresponding author), Case Western Reserve Univ, Rainbow Babies & Childrens Hosp, Sch Med, Cleveland, OH 44106 USA.							Alvarez JA, 1998, NEUROSURG CLIN N AM, V9, P405; FERNELL E, 1994, ARCH DIS CHILD-FETAL, V70, pF123, DOI 10.1136/fn.70.2.F123; HACK M, 1995, FUTURE CHILD, V5, P176, DOI 10.2307/1602514; Hudgins RJ, 1997, PEDIATR NEUROSURG, V26, P281, DOI 10.1159/000121207; *MED EC, 1996, PHYS DESK REF; Roth Patrick A., 1996, P2707; SHINNAR S, 1985, J PEDIATR-US, V107, P31, DOI 10.1016/S0022-3476(85)80609-0; Silverman W. A., 1980, RETROLENTAL FIBROPLA; Volpe J., 1995, NEUROLOGY NEWBORN; Whitelaw A, 1996, ARCH DIS CHILD-FETAL, V75, pF20, DOI 10.1136/fn.75.1.F20; WHITELAW A, 1994, ARCH DIS CHILD-FETAL, V70, pF129	11	7	7	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	AUG 8	1998	352	9126					418	419		10.1016/S0140-6736(05)79181-9	http://dx.doi.org/10.1016/S0140-6736(05)79181-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	108EA	9708745				2022-12-28	WOS:000075252000004
J	Blusztajn, JK				Blusztajn, JK			Developmental neuroscience - Choline, a vital amine	SCIENCE			English	Editorial Material							MEMORY		Boston Univ, Sch Med, Dept Pathol & Lab Med, Boston, MA 02118 USA	Boston University	Blusztajn, JK (corresponding author), Boston Univ, Sch Med, Dept Pathol & Lab Med, Boston, MA 02118 USA.	jbluszta@bu.edu		/0000-0001-8438-3122				BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BLUSZTAJN JK, 1983, SCIENCE, V221, P614, DOI 10.1126/science.6867732; Cermak JM, 1998, FASEB J, V12, P349, DOI 10.1096/fasebj.12.3.349; EAGLE H, 1955, J EXP MED, V102, P595, DOI 10.1084/jem.102.5.595; FIBIGER HC, 1991, TRENDS NEUROSCI, V14, P220, DOI 10.1016/0166-2236(91)90117-D; Food and Nutrition Board IOM, 1998, DIETARY REFERENCE IN; GARNER SC, 1995, J NUTR, V125, P2851; HolmesMcNary MQ, 1997, DEV BRAIN RES, V101, P9, DOI 10.1016/S0165-3806(97)00044-8; HolmesMcNary MQ, 1996, AM J CLIN NUTR, V64, P572, DOI 10.1093/ajcn/64.4.572; MECK WH, 1989, BEHAV NEUROSCI, V103, P1234, DOI 10.1037/0735-7044.103.6.1234; Meck WH, 1997, NEUROREPORT, V8, P3045, DOI 10.1097/00001756-199709290-00009; Meck WH, 1997, NEUROREPORT, V8, P2831, DOI 10.1097/00001756-199709080-00005; Pyapali GK, 1998, J NEUROPHYSIOL, V79, P1790, DOI 10.1152/jn.1998.79.4.1790; Tsai AY, 1998, FASEB J, V12, pA235; Williams CL, 1998, BRAIN RES, V794, P225, DOI 10.1016/S0006-8993(98)00229-7; ZEISEL SH, 1994, ANNU REV NUTR, V14, P269, DOI 10.1146/annurev.nu.14.070194.001413; ZEISEL SH, 1991, FASEB J, V5, P2093, DOI 10.1096/fasebj.5.7.2010061; ZEISEL SH, 1998, FASEB J, V12, P3049	18	307	317	4	30	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 7	1998	281	5378					794	795		10.1126/science.281.5378.794	http://dx.doi.org/10.1126/science.281.5378.794			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	108ZD	9714685				2022-12-28	WOS:000075295600039
J	Kim, KK; Kim, R; Kim, SH				Kim, KK; Kim, R; Kim, SH			Crystal structure of a small heat-shock protein	NATURE			English	Article							ELECTRON-DENSITY MAPS; ALPHA-CRYSTALLIN; MOLECULAR CHAPERONE; IN-VITRO; 2.8-ANGSTROM; FAMILY; DOMAIN	The principal heat-shock proteins that have chaperone activity (that is, they protect newly made proteins from misfolding) belong to five conserved classes: HSP100, HSP90, HSP70, HSP60 and the small heat-shock proteins (sHSPs). The sHSPs can form large multimeric structures and have a wide range of cellular functions, including endowing cells with thermotolerance in vivo(1,2) and being able to act as molecular chaperones in vitro(3-8); sHSPs do this by forming stable complexes with folding intermediates of their protein substrates(9,10). However, there is little information available about these structures or the mechanism by which substrates are protected from thermal denaturation by sHSPs. Here we report the crystal structure of a small heat-shock protein from Methanococcus jannaschii, a hyperthermophilic archaeon. The monomeric folding unit is a composite beta-sandwich in which one of the beta-strands comes from a neighbouring molecule. Twenty-four monomers form a hollow spherical complex of octahedral symmetry, with eight trigonal and six square 'windows'. The sphere has an outer diameter of 120 Angstrom and an inner diameter of 65 Angstrom.	Univ Calif Berkeley, Lawrence Berkeley Lab, Phys Biosci Div, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; University of California System; University of California Berkeley	Kim, SH (corresponding author), Univ Calif Berkeley, Lawrence Berkeley Lab, Phys Biosci Div, 220 Melvin Calvin Lab, Berkeley, CA 94720 USA.							BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; BRUNGER A, 1993, XPLOR VERSION 3 1; CASPERS GJ, 1995, J MOL EVOL, V40, P238, DOI 10.1007/BF00163229; Chang ZY, 1996, J BIOL CHEM, V271, P7218, DOI 10.1074/jbc.271.12.7218; COWTAN KD, 1993, ACTA CRYSTALLOGR D, V49, P148, DOI 10.1107/S0907444992007698; Ehrnsperger M, 1997, EMBO J, V16, P221, DOI 10.1093/emboj/16.2.221; *GCG, 1991, GEN COMP GROUP PROGR; HORWITZ J, 1992, P NATL ACAD SCI USA, V89, P10449, DOI 10.1073/pnas.89.21.10449; Hunt JF, 1996, NATURE, V379, P37, DOI 10.1038/379037a0; JACOB U, 1993, J BIOL CHEM, V268, P1517; JAENICKE R, 1993, CURR BIOL, V3, P234, DOI 10.1016/0960-9822(93)90342-L; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kim KK, 1998, J STRUCT BIOL, V121, P76, DOI 10.1006/jsbi.1998.3969; KIM R, IN PRESS P NATL ACAD; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEE GJ, 1995, J BIOL CHEM, V270, P10432, DOI 10.1074/jbc.270.18.10432; Lee GJ, 1997, EMBO J, V16, P659, DOI 10.1093/emboj/16.3.659; Leroux MR, 1997, J BIOL CHEM, V272, P12847, DOI 10.1074/jbc.272.19.12847; Leroux MR, 1997, J BIOL CHEM, V272, P24646, DOI 10.1074/jbc.272.39.24646; MERCK KB, 1993, MOL BIOL REP, V18, P209, DOI 10.1007/BF01674432; MERCK KB, 1993, J BIOL CHEM, V268, P1046; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; Plater ML, 1996, J BIOL CHEM, V271, P28558, DOI 10.1074/jbc.271.45.28558; SCHIRMER EC, 1994, PLANT CELL, V6, P1899, DOI 10.1105/tpc.6.12.1899; TSENG TS, 1992, PLANT MOL BIOL, V18, P963, DOI 10.1007/BF00019209; VANDENIJSSEL PRLA, 1994, FEBS LETT, V355, P54, DOI 10.1016/0014-5793(94)01175-3; Yeh CH, 1997, P NATL ACAD SCI USA, V94, P10967, DOI 10.1073/pnas.94.20.10967	27	772	819	1	62	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 6	1998	394	6693					595	599		10.1038/29106	http://dx.doi.org/10.1038/29106			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	107YN	9707123				2022-12-28	WOS:000075238700053
J	Krause, R; Buhring, M; Hopfenmuller, W; Holick, MF; Sharma, AM				Krause, R; Buhring, M; Hopfenmuller, W; Holick, MF; Sharma, AM			Ultraviolet B and blood pressure	LANCET			English	Article									Boston Univ, Med Ctr, Dept Med, Vitamin D Skin & Bone Res Lab, Boston, MA 02118 USA; Free Univ Berlin, Klinikum Benjamin Franklin, Inst Med Stat, Dept Nat Med, Berlin, Germany; Free Univ Berlin, Klinikum Benjamin Franklin, Dept Internal Med, Div Endocrinol & Nephrol, Berlin, Germany	Boston University; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Holick, MF (corresponding author), Boston Univ, Med Ctr, Dept Med, Vitamin D Skin & Bone Res Lab, Boston, MA 02118 USA.			Holick, Michael/0000-0001-6023-9062	NCRR NIH HHS [MO1RR 00533] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000533] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		HOLICK MF, 1987, FASEB J, V46, P1876; Malabanan A, 1998, LANCET, V351, P805, DOI 10.1016/S0140-6736(05)78933-9; MCCARRON DA, 1987, ANN INTERN MED, V107, P919, DOI 10.7326/0003-4819-107-6-919; Rostand SG, 1997, HYPERTENSION, V30, P150, DOI 10.1161/01.HYP.30.2.150; WEISHAAR RE, 1989, ENDOCR REV, V10, P351, DOI 10.1210/edrv-10-3-351	5	385	403	0	11	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	AUG 29	1998	352	9129					709	710		10.1016/S0140-6736(05)60827-6	http://dx.doi.org/10.1016/S0140-6736(05)60827-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	116MT	9728997				2022-12-28	WOS:000075729700025
J	Daley, J; Hartman, EE				Daley, J; Hartman, EE			A 28-year-old woman with multiple moles, 1 year later	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																		Robinson JK, 1997, JAMA-J AM MED ASSOC, V278, P1693, DOI 10.1001/jama.278.20.1693	1	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 26	1998	280	8					736	736		10.1001/jama.280.8.736	http://dx.doi.org/10.1001/jama.280.8.736			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	111PM	9728647				2022-12-28	WOS:000075446900037
J	Valegard, K; van Scheltinga, ACT; Lloyd, MD; Hara, T; Ramaswamy, S; Perrakis, A; Thompson, A; Lee, HJ; Baldwin, JE; Schofield, CJ; Hajdu, J; Andersson, I				Valegard, K; van Scheltinga, ACT; Lloyd, MD; Hara, T; Ramaswamy, S; Perrakis, A; Thompson, A; Lee, HJ; Baldwin, JE; Schofield, CJ; Hajdu, J; Andersson, I			Structure of a cephalosporin synthase	NATURE			English	Article							DEACETOXYCEPHALOSPORIN-C SYNTHASE; STREPTOMYCES-CLAVULIGERUS; ESCHERICHIA-COLI; REFINEMENT	Penicillins and cephalosporins are among the most widely used therapeutic agents. These antibiotics are produced from fermentation-derived materials as their chemical synthesis is not commercially viable. Unconventional steps in their biosynthesis are catalysed by Fe(II)-dependent oxidases/oxygenases; isopenicillin N synthase (IPNS)(1,2) creates in one step the bicyclic nucleus of penicillins, and deacetoxycephalosporin C synthase (DAOCS) catalyses the expansion of the penicillin nucleus into the nucleus of cephalosporins. Both enzymes use dioxygen-derived ferryl intermediates in catalysis but, in contrast to IPNS, the ferryl form of DAOCS is produced by the oxidative splitting of a cosubstrate, 2-oxoglutarate (alpha-ketoglutarate). This route of controlled ferryl formation and reaction is common to many mononuclear ferrous enzymes(3), which participate in a broader range of reactions than their well-characterized counterparts, the haem enzymes, Here we report the first crystal structure of a 2-oxoacid-dependent oxygenase, High-resolution structures for apo-DAOCS, the enzyme complexed with Fe(II), and with Fe(II) and 2-oxoglutarate, were obtained from merohedrally twinned crystals. Using a model based on these structures, we propose a mechanism for ferryl formation.	Swedish Univ Agr Sci, Dept Mol Biol, S-75124 Uppsala, Sweden; Uppsala Univ, Dept Biochem, S-75123 Uppsala, Sweden; Univ Oxford, Dyson Perrins Lab, Oxford Ctr Mol Sci, Oxford OX1 3QY, England; European Mol Biol Lab, ILL, F-38042 Grenoble 9, France	Swedish University of Agricultural Sciences; Uppsala University; University of Oxford; European Molecular Biology Laboratory (EMBL); Institut Laue-Langevin (ILL)	Andersson, I (corresponding author), Swedish Univ Agr Sci, Dept Mol Biol, Box 590, S-75124 Uppsala, Sweden.	christopher.schofield@chemistry.oxford.ac.uk; inger@xray.bmc.uu.se	Subramanian, Ramaswamy/Q-8671-2019; Perrakis, Anastassis/E-8704-2013; Lloyd, Matthew/AAX-6048-2021	Subramanian, Ramaswamy/0000-0002-6709-190X; Perrakis, Anastassis/0000-0002-1151-6227; Lloyd, Matthew/0000-0002-4821-4361; Schofield, Christopher/0000-0002-0290-6565				ABRAHAM EP, 1961, BIOCHEM J, V79, P377, DOI 10.1042/bj0790377; ABRAHAM EP, 1956, BIOCHEM J, V63, P628, DOI 10.1042/bj0630628; Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Baldwin J. E., 1992, CHEM BETA LACTAMS, P1; BROTZU G, 1948, LAVORI I IGIENE CAGL, P1; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; DOTZLAF JE, 1989, J BIOL CHEM, V264, P10219; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; FISHER RG, 1980, ACTA CRYSTALLOGR A, V36, P755, DOI 10.1107/S0567739480001520; Hegg EL, 1997, EUR J BIOCHEM, V250, P625, DOI 10.1111/j.1432-1033.1997.t01-1-00625.x; HODGKIN DC, 1961, BIOCHEM J, V79, P393, DOI 10.1042/bj0790393; JONES TA, 1990, CRYSTALLOGRAPHIC MOD, P189; KOVACEVIC S, 1989, J BACTERIOL, V171, P754, DOI 10.1128/jb.171.2.754-760.1989; LAMZIN VS, 1993, ACTA CRYSTALLOGR D, V49, P129, DOI 10.1107/S0907444992008886; Landman O, 1997, FEBS LETT, V405, P172, DOI 10.1016/S0014-5793(97)00180-4; Lester DR, 1997, PLANT CELL, V9, P1435, DOI 10.1105/tpc.9.8.1435; MORGAN N, 1994, BIOORG MED CHEM LETT, V4, P1595, DOI 10.1016/S0960-894X(01)80573-4; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Myllyharju J, 1997, EMBO J, V16, P1173, DOI 10.1093/emboj/16.6.1173; NEWTON GGF, 1955, NATURE, V175, P548, DOI 10.1038/175548a0; OTWINOWSKI Z, 1993, DATA COLLECTION PROC, P55; Perrakis A, 1997, ACTA CRYSTALLOGR D, V53, P448, DOI 10.1107/S0907444997005696; PRESCOTT AG, 1993, J EXP BOT, V44, P849, DOI 10.1093/jxb/44.5.849; ROACH PL, 1995, NATURE, V375, P700, DOI 10.1038/375700a0; Roach PL, 1997, NATURE, V387, P827, DOI 10.1038/42990; Schofield CJ, 1997, CURR OPIN STRUC BIOL, V7, P857, DOI 10.1016/S0959-440X(97)80158-3; Sheldrick GM, 1997, METHOD ENZYMOL, V277, P319, DOI 10.1016/S0076-6879(97)77018-6; YOSHIDA M, 1978, P NATL ACAD SCI USA, V75, P6253, DOI 10.1073/pnas.75.12.6253; Zhang ZH, 1997, BIOCHEMISTRY-US, V36, P15999, DOI 10.1021/bi971823c	30	301	307	1	53	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 20	1998	394	6695					805	809		10.1038/29575	http://dx.doi.org/10.1038/29575			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	112PR	9723623				2022-12-28	WOS:000075503600052
J	Andreone, P; Zignego, AL; Cursaro, C; Gramenzi, A; Gherlinzoni, F; Fiorino, S; Giannini, C; Boni, P; Sabattini, E; Pileri, S; Tura, S; Bernardi, M				Andreone, P; Zignego, AL; Cursaro, C; Gramenzi, A; Gherlinzoni, F; Fiorino, S; Giannini, C; Boni, P; Sabattini, E; Pileri, S; Tura, S; Bernardi, M			Prevalence of monoclonal gammopathies in patients with hepatitis C virus infection	ANNALS OF INTERNAL MEDICINE			English	Article							MULTIPLE-MYELOMA; CRYOGLOBULINEMIA; CLASSIFICATION; LYMPHOMA	Background: An association between monoclonal gammopathies and chronic liver diseases has been reported. Objective: To determine the prevalence of monoclonal gammopathies in patients with chronic hepatitis C virus (HCV) infection and the possible association of monoclonal gammopathies with HCV genotypes. Design: Prospective study. Setting: Departments of internal medicine and hematology at two university hospitals in Italy. Patients: 239 HCV-positive and 98 HCV-negative patients with chronic liver diseases were recruited consecutively. Measurements: Clinical data were gathered, liver histologic examination was done, serum immunoglobulin and cryoglobulin levels were measured, and immunoelectrophoresis was done for monoclonal component detection. Patients with monoclonal gammopathy had serum HCV RNA measured and HCV genotype determined by polymerase chain reaction and had histologic examination of bone marrow. Results: Monoclonal band was detected in 11% of HCV-positive patients and in 1% of HCV-negative patients (P = 0.004). The prevalence of HCV genotype 2a/c was higher in patients with monoclonal gammopathies than in those without (50% compared with 18%; P = 0.009). Conclusion: The prevalence of monoclonal gammopathies in patients with HCV-related chronic liver disease is striking and is often associated with genotype 2a/c infection.	Univ Bologna, Dipartimento Med Interna Cardioangiol & Epatol, Serv Semeiot Med, I-40138 Bologna, Italy; Univ Bologna, Ist Ematol & Oncol Med, Serv Anat Patol, I-40138 Bologna, Italy; Policlin S Orsola, Lab Centralizzato, I-40138 Bologna, Italy; Univ Florence, Ist Med Interna, I-50134 Florence, Italy	University of Bologna; University of Bologna; IRCCS Azienda Ospedaliero-Universitaria di Bologna; University of Florence	Andreone, P (corresponding author), Univ Bologna, Dipartimento Med Interna Cardioangiol & Epatol, Serv Semeiot Med, Via Massarenti 9, I-40138 Bologna, Italy.	andreone@med.unibo.it	Sabattini, Elena/K-6720-2016; Andreone, Pietro/K-8050-2016; Pileri, Stefano/AAP-6337-2020; Zignego, Anna Linda/AAL-8205-2021	Sabattini, Elena/0000-0002-4136-3591; Andreone, Pietro/0000-0002-4794-9809; Cursaro, Carmela/0000-0002-5644-2508				AXELSSON U, 1966, ACTA MED SCAND, V179, P235; BARTL R, 1987, AM J CLIN PATHOL, V87, P342, DOI 10.1093/ajcp/87.3.342; BROUET JC, 1974, AM J MED, V57, P775, DOI 10.1016/0002-9343(74)90852-3; ELLMAN LL, 1969, GASTROENTEROLOGY, V57, P138; ENGLISOVA M, 1968, SCAND J GASTROENTERO, V3, P413, DOI 10.3109/00365526809180138; FERRI C, 1995, LANCET, V346, P1426, DOI 10.1016/S0140-6736(95)92442-6; GRAMENZI A, 1991, BRIT J CANCER, V63, P769, DOI 10.1038/bjc.1991.172; HARRIS NL, 1994, BLOOD, V84, P1361; HEER M, 1984, LIVER, V4, P255; MALACRIDA V, 1987, J CLIN PATHOL, V40, P793, DOI 10.1136/jcp.40.7.793; Mangia A, 1996, LEUKEMIA, V10, P1209; MICHITAKA K, 1994, GASTROENTEROLOGY, V106, P1603, DOI 10.1016/0016-5085(94)90417-0; Mussini C, 1995, CLIN EXP RHEUMATOL, V13, pS45; PAWLOTSKY JM, 1995, ANN INTERN MED, V122, P169, DOI 10.7326/0003-4819-122-3-199502010-00002; Pileri SA, 1997, J CLIN PATHOL, V50, P2, DOI 10.1136/jcp.50.1.2; PONTISSO P, 1995, J VIRAL HEPATITIS, V2, P33, DOI 10.1111/j.1365-2893.1995.tb00069.x; RIEDEL DA, 1992, HEMATOL ONCOL CLIN N, V6, P225, DOI 10.1016/S0889-8588(18)30341-1; SALMON SE, 1989, CANC PRINCIPLES PRAC, P1884; TANAKA H, 1989, BLOOD, V74, P1718; Zignego AL, 1996, ANN INTERN MED, V124, P31, DOI 10.7326/0003-4819-124-1_Part_1-199601010-00006	20	89	90	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 15	1998	129	4					294	298		10.7326/0003-4819-129-4-199808150-00005	http://dx.doi.org/10.7326/0003-4819-129-4-199808150-00005			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	109NP	9729182				2022-12-28	WOS:000075329100005
J	Enriquez, J				Enriquez, J			Genomics - Genomics and the World's economy	SCIENCE			English	Article									David Rockefeller Ctr, Cambridge, MA 02138 USA		Enriquez, J (corresponding author), David Rockefeller Ctr, 61 Kirkland St, Cambridge, MA 02138 USA.	enriquez@fas.harvard.edu						Balter M, 1997, SCIENCE, V275, P1729, DOI 10.1126/science.275.5307.1729; *BURR CO, 1997, BIOT 97 AL 4 QUART R; CARTER M, 1997, GENZYME TRANSGENICS; DALY MJ, 1997, DESIGN CONSTRUCTION; de Lange T, 1998, SCIENCE, V279, P334, DOI 10.1126/science.279.5349.334; ENRFQUEZ J, 1998, 150 ANN M AM ASS ADV; ENRIQUEZ J, 1997, TECHNOLOGY CRISIS FU; ENRIQUEZ J, IN PRESS GENE RES GL; Ermler U, 1997, SCIENCE, V278, P1457, DOI 10.1126/science.278.5342.1457; FLYNN J, 1996, BUS WEEK        0304, P80; GOLDBERG R, 1998, PRIV PUBL SCI AC CON; KAISER J, 1997, SCIENCE, V277, P1751; LERHMANN S, 1997, NATURE, V385, P189; Masood E, 1997, NATURE, V387, P6; Normile D, 1997, SCIENCE, V278, P1700, DOI 10.1126/science.278.5344.1700; Pennisi E, 1998, SCIENCE, V280, P193; Roush W, 1997, SCIENCE, V278, P1039, DOI 10.1126/science.278.5340.1039; Swinbanks D, 1998, RES TECHNOL MANAGE, V41, P2; Tacket CO, 1998, NAT MED, V4, P607, DOI 10.1038/nm0598-607; *US PTO, 1996, HEARING REQUEST COMM; 1996, HUM GENOME NEWS  JUL, V8, P1; 1998, CHEM MARK REP, V253, P9; 1997, NATURE, V387, P753	23	60	61	2	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 14	1998	281	5379					925	926		10.1126/science.281.5379.925	http://dx.doi.org/10.1126/science.281.5379.925			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	110ZK	9722465				2022-12-28	WOS:000075412700025
J	Schmid, DS				Schmid, DS			Role of HHV-8 in Kaposi sarcoma - Abstract and commentary	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							DNA-SEQUENCES; HERPESVIRUS; ANTIBODIES; INFECTION; ANTIGENS		Ctr Dis Control & Prevent, Viral Immunol Sect, Atlanta, GA 30333 USA	Centers for Disease Control & Prevention - USA	Schmid, DS (corresponding author), Ctr Dis Control & Prevent, Viral Immunol Sect, Atlanta, GA 30333 USA.							BERAL V, 1990, LANCET, V335, P123, DOI 10.1016/0140-6736(90)90001-L; Blauvelt A, 1997, J INFECT DIS, V176, P771, DOI 10.1086/517298; Chang Y, 1996, ARCH INTERN MED, V156, P202, DOI 10.1001/archinte.156.2.202; Chuck S, 1996, J INFECT DIS, V173, P248, DOI 10.1093/infdis/173.1.248; DUPIN N, 1995, LANCET, V345, P761, DOI 10.1016/S0140-6736(95)90642-8; Gao SJ, 1996, NAT MED, V2, P925, DOI 10.1038/nm0896-925; Gao SJ, 1996, NEW ENGL J MED, V335, P233, DOI 10.1056/NEJM199607253350403; Kedes DH, 1997, J CLIN INVEST, V100, P2606, DOI 10.1172/JCI119804; Kedes DH, 1996, NAT MED, V2, P918, DOI 10.1038/nm0896-918; Lennette ET, 1996, LANCET, V348, P858, DOI 10.1016/S0140-6736(96)03240-0; Martin JN, 1998, NEW ENGL J MED, V338, P948, DOI 10.1056/NEJM199804023381403; Miller G, 1996, NEW ENGL J MED, V334, P1292, DOI 10.1056/NEJM199605163342003; MOORE PS, 1995, NEW ENGL J MED, V332, P1181, DOI 10.1056/NEJM199505043321801; Simpson GR, 1996, LANCET, V348, P1133, DOI 10.1016/S0140-6736(96)07560-5; WHITBY D, 1995, LANCET, V346, P799, DOI 10.1016/S0140-6736(95)91619-9	15	4	4	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 12	1998	280	6					570	571		10.1001/jama.280.6.570	http://dx.doi.org/10.1001/jama.280.6.570			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	108AY	9707154				2022-12-28	WOS:000075244900040
J	Strathdee, SA; Palepu, A; Cornelisse, PGA; Yip, B; O'Shaughnessy, MV; Montaner, JSG; Schechter, MT; Hogg, RS				Strathdee, SA; Palepu, A; Cornelisse, PGA; Yip, B; O'Shaughnessy, MV; Montaner, JSG; Schechter, MT; Hogg, RS			Barriers to use of free antiretroviral therapy in injection drug users	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HIV; ZIDOVUDINE; INFECTION; ACCESS	Context.-In British Columbia, human immunodeficiency virus (HIV)-infected persons eligible for antiretroviral therapy may receive it free but the extent to which HIV-infected injection drug users access it is unknown. Objective.-To identify patient and physician characteristics associated with antiretroviral therapy utilization in HIV-infected injection drug users. Design.-Prospective cohort study with record linkage between survey data and data from a provincial HIV/AIDS (acquired immunodeficiency syndrome) drug treatment program. Setting.-British Columbia, where antiretroviral therapies are offered free to all persons with HIV infection with CD4 cell counts less than 0.50x10(9)/L (500/mu L) and/or HIV-1 RNA levels higher than 5000 copies/mL. Subjects.-A total of 177 HIV-infected injection drug users eligible for antiretroviral therapy, recruited through the prospective cohort study since May 1996. Main Outcome Measures.-Patient use of antiretroviral drugs through the provincial drug treatment program and physician experience treating HIV infection. Results.-After a median of 11 months after first eligibility, only 71 (40%) of 177 patients had received any antiretroviral drugs, primarily double combinations (47/ 71 [66%]). Both patient and physician characteristics were associated with use of antiretroviral drugs. After adjusting for CD4 cell count and HIV-1 RNA level at eligibility, odds of not receiving antiretrovirals were increased more than 2-fold for females (odds ratio [OR], 2.53; 95% confidence interval [CI], 1.08-5.93) and 3-fold for those not currently enrolled in drug or alcohol treatment programs (OR, 3.49; 95% CI, 1.45-8.40), Younger drug users were less likely to receive therapy (OR, 0.47/ 10-y increase; 95% CI, 0.28-0.80). Those with physicians having the least experience treating persons with HIV infection were more than 5 times less likely to receive therapy (OR, 5.55; 95% CI, 2.49-12.37). Conclusions.-Despite free antiretroviral therapy, many HIV-infected injection drug users are not receiving it. Public health efforts should target younger and female drug users, and physicians with less experience treating HIV infection.	St Pauls Hosp, British Columbia Ctr Excellence HIV AIDS, Vancouver, BC V6Z 1Y6, Canada; Univ British Columbia, Fac Med, Dept Hlth Care & Epidemiol, Vancouver, BC, Canada; Univ British Columbia, Fac Med, Dept Med, Vancouver, BC, Canada	B.C. Centre for Excellence in HIV/AIDS; St. Paul's Hospital; University of Saskatchewan; University of British Columbia; University of British Columbia	Hogg, RS (corresponding author), St Pauls Hosp, British Columbia Ctr Excellence HIV AIDS, 608 1081 Burrard St, Vancouver, BC V6Z 1Y6, Canada.		Hogg, Robert S/B-2783-2012; Strathdee, Steffanie A/B-9042-2009; Montaner, Julio/K-7621-2012	Hogg, Robert S/0000-0003-3463-5488; Schechter, Martin/0000-0001-6063-2155; Palepu, Anita/0000-0002-7881-4800				Bangsberg D, 1997, JAMA-J AM MED ASSOC, V278, P63, DOI 10.1001/jama.278.1.63; Cardo DM, 1997, NEW ENGL J MED, V337, P1485, DOI 10.1056/NEJM199711203372101; Carpenter CCJ, 1997, JAMA-J AM MED ASSOC, V277, P1962, DOI 10.1001/jama.277.24.1962; Celentano DD, 1998, JAMA-J AM MED ASSOC, V280, P544, DOI 10.1001/jama.280.6.544; GRAHAM NMH, 1994, J CLIN EPIDEMIOL, V47, P1003, DOI 10.1016/0895-4356(94)90115-5; Hammer SM, 1997, NEW ENGL J MED, V337, P725, DOI 10.1056/NEJM199709113371101; Heath KV, 1997, CLIN INVEST MED, V20, P381; HELLINGER FJ, 1993, HEALTH SERV RES, V28, P543; Hogg RS, 1998, JAMA-J AM MED ASSOC, V279, P450, DOI 10.1001/jama.279.6.450; Kitahata MM, 1996, NEW ENGL J MED, V334, P701, DOI 10.1056/NEJM199603143341106; MARKSON LE, 1994, ARCH INTERN MED, V154, P1497, DOI 10.1001/archinte.154.13.1497; MONTANER JSG, 1996, THERAPEUTIC GUIDELIN; MOORE RD, 1994, NEW ENGL J MED, V330, P763, DOI 10.1056/NEJM199403173301107; MOR V, 1992, MED CARE, V30, P17, DOI 10.1097/00005650-199201000-00002; OCONNOR PG, 1992, AM J MED, V93, P382, DOI 10.1016/0002-9343(92)90166-9; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; PALEPU A, 1997, CAN J INFECT DIS, V8, pA27; Patrick DM, 1997, INT J STD AIDS, V8, P437, DOI 10.1258/0956462971920497; STEIN MD, 1991, J GEN INTERN MED, V6, P35, DOI 10.1007/BF02599388; Strathdee SA, 1997, AIDS, V11, pF59, DOI 10.1097/00002030-199708000-00001; Vernazza PL, 1997, AIDS, V11, P1249, DOI 10.1097/00002030-199710000-00008	21	444	450	0	9	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 12	1998	280	6					547	549		10.1001/jama.280.6.547	http://dx.doi.org/10.1001/jama.280.6.547			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	108AY	9707146	Bronze			2022-12-28	WOS:000075244900032
J	Flore, O; Rafii, S; Ely, S; O'Leary, JJ; Hyjek, EM; Cesarman, E				Flore, O; Rafii, S; Ely, S; O'Leary, JJ; Hyjek, EM; Cesarman, E			Transformation of primary human endothelial cells by Kaposi's sarcoma-associated herpesvirus	NATURE			English	Article							DNA-SEQUENCES; INFECTION; LYMPHOMA	Kaposi's sarcoma-associated herpesvirus (KSHV), or human herpesvirus 8, is invariably present in Kaposi's sarcoma lesions(1,2) KSHV contains several viral oncogenes and serological evidence suggests that KSHV infection is necessary for the development of Kaposi's sarcoma, but cellular transformation by this virus has not so far been demonstrated. KSHV is found in the microvascular endothelial cells in Kaposi's sarcoma lesions and in the spindle 'tumour' cells(3,4), which are also thought to be of endothelial origin. Here we investigate the biological consequences of infecting human primary endothelial cells with purified KSHV particles. We find that infection causes long-term proliferation and survival of these cells, which are associated with the acquisition of telomerase activity and anchorage-independent growth. KSHV was present in only a subset of cells, and paracrine mechanisms were found to be responsible for the survival of uninfected cells. Their survival may have been mediated by upregulation of a receptor for vascular endothelial growth factor. Our results indicate that transformation of endothelial cells by KSHV, as well as paracrine mechanisms that are induced by this virus, may be critical in the pathogenesis of Kaposi's sarcoma.	Cornell Univ, Coll Med, Dept Pathol, New York, NY 10021 USA; Cornell Univ, Coll Med, Dept Med, Div Hematol Oncol, New York, NY 10021 USA; Univ Cagliari, Dipartimento Med Interna, I-09100 Cagliari, Italy; Coombe Womens Hosp, Dept Pathol, Dublin, Ireland; St James Hosp, Dublin 8, Ireland; Trinity Coll Dublin, Dublin, Ireland	Cornell University; Cornell University; University of Cagliari; Trinity College Dublin; Trinity College Dublin; Trinity College Dublin	Cesarman, E (corresponding author), Cornell Univ, Coll Med, Dept Pathol, New York, NY 10021 USA.	ecesarm@mail.med.cornell.edu						Arvanitakis L, 1996, BLOOD, V88, P2648, DOI 10.1182/blood.V88.7.2648.bloodjournal8872648; BOSHOFF C, 1995, NAT MED, V1, P1274, DOI 10.1038/nm1295-1274; Cesarman E, 1996, J VIROL, V70, P8218, DOI 10.1128/JVI.70.11.8218-8223.1996; Chan SR, 1998, VIROLOGY, V240, P118, DOI 10.1006/viro.1997.8911; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; Hewett PW, 1996, BIOCHEM BIOPH RES CO, V221, P697, DOI 10.1006/bbrc.1996.0659; Kedes DH, 1996, NAT MED, V2, P918, DOI 10.1038/nm0896-918; Kennedy MM, 1997, J CLIN PATHOL-MOL PA, V50, P96, DOI 10.1136/mp.50.2.96; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kim NW, 1997, NUCLEIC ACIDS RES, V25, P2595, DOI 10.1093/nar/25.13.2595; MIECZYSLAW AP, 1995, METH CELL SCI, V17, P1; Miller G, 1997, J VIROL, V71, P314, DOI 10.1128/JVI.71.1.314-324.1997; MOORE PS, 1995, NEW ENGL J MED, V332, P1181, DOI 10.1056/NEJM199505043321801; OLEARY J, 1997, PCR IN SITU HYBRIDIC; RAFII S, 1995, BLOOD, V86, P3353, DOI 10.1182/blood.V86.9.3353.bloodjournal8693353; REED JA, IN PRESS BLOOD; Renne R, 1996, NAT MED, V2, P342, DOI 10.1038/nm0396-342; RIENKE U, 1975, FED PROC, V34, P71; RYCHLIK W, 1990, NUCLEIC ACIDS RES, V18, P6409, DOI 10.1093/nar/18.21.6409; Watanabe Y, 1997, EXP CELL RES, V233, P340, DOI 10.1006/excr.1997.3583	20	325	334	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 6	1998	394	6693					588	592		10.1038/29093	http://dx.doi.org/10.1038/29093			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	107YN	9707121				2022-12-28	WOS:000075238700051
J	Bix, M; Locksley, RM				Bix, M; Locksley, RM			Independent and epigenetic regulation of the interleukin-4 alleles in CD4(+) T cells	SCIENCE			English	Article							GENE-EXPRESSION; DEFICIENT MICE; COEXPRESSION; LYMPHOCYTES; INTERFERON; GENERATION; RECEPTOR; CLONES; GAMMA	How an individual effector T cell acquires a particular cytokine expression pattern from many possible patterns remains unclear. CD4(+) T cells from F-1 mice, which allowed assignment of the parental origin of interleukin-4 (IL-4) transcripts, were divided into clones that expressed IL-4 biallelically or monoallelically from either allele. The allelic pattern was transmitted as a stable epigenetic trait. Regulation of cytokine expression by a mechanism that treats each allele independently suggests a probabilistic process by which a diverse repertoire of combinatorially assorted cytokine gene expression patterns could be generated among the clonally related daughters of a single precursor cell.	Univ Calif San Francisco, Howard Hughes Med Inst, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Immunol Microbiol, San Francisco, CA 94143 USA	Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Locksley, RM (corresponding author), Univ Calif San Francisco, Howard Hughes Med Inst, Box 0654,C-443,521 Parnassus Ave, San Francisco, CA 94143 USA.			Bix, Mark/0000-0003-4617-0497	NHLBI NIH HHS [HL56385] Funding Source: Medline; NIAID NIH HHS [AI26918] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL056385, P01HL056385] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI026918, R01AI026918] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Abbas AK, 1996, NATURE, V383, P787, DOI 10.1038/383787a0; ASSENMACHER M, 1994, EUR J IMMUNOL, V24, P1097, DOI 10.1002/eji.1830240513; BIX M, UNPUB; BUCY RP, 1994, J EXP MED, V180, P1251, DOI 10.1084/jem.180.4.1251; BUCY RP, 1995, P NATL ACAD SCI USA, V92, P7565, DOI 10.1073/pnas.92.16.7565; Chess A, 1998, SCIENCE, V279, P2067, DOI 10.1126/science.279.5359.2067; CHESS A, 1994, CELL, V78, P823, DOI 10.1016/S0092-8674(94)90562-2; Cross MA, 1997, CURR OPIN GENET DEV, V7, P609, DOI 10.1016/S0959-437X(97)80007-X; Held W, 1997, EUR J IMMUNOL, V27, P2876, DOI 10.1002/eji.1830271120; HELD W, 1995, NATURE, V376, P355, DOI 10.1038/376355a0; Hollander GA, 1998, SCIENCE, V279, P2118, DOI 10.1126/science.279.5359.2118; KELSO A, 1988, P NATL ACAD SCI USA, V85, P9189, DOI 10.1073/pnas.85.23.9189; KELSO A, 1995, EUR J IMMUNOL, V25, P1168, DOI 10.1002/eji.1830250506; KIOUSSIS D, 1998, MOL BIOL B CELL T CE, P31; KUHN R, 1991, SCIENCE, V254, P707, DOI 10.1126/science.1948049; Melo JV, 1996, LEUKEMIA, V10, P1217; WU H, 1995, CELL, V83, P59, DOI 10.1016/0092-8674(95)90234-1; ZIJLSTRA M, 1990, NATURE, V344, P742, DOI 10.1038/344742a0	18	204	205	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 28	1998	281	5381					1352	1354		10.1126/science.281.5381.1352	http://dx.doi.org/10.1126/science.281.5381.1352			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	115LQ	9721100				2022-12-28	WOS:000075666800050
J	Eccles, M; Freemantle, N; Mason, J				Eccles, M; Freemantle, N; Mason, J		N England Non-Steroidal Anti-Inflammat	North of England evidence based guideline development project: summary guideline for non-steroidal anti-inflammatory drugs versus basic analgesia in treating the pain of degenerative arthritis	BRITISH MEDICAL JOURNAL			English	Article							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; GASTROINTESTINAL COMPLICATIONS; RHEUMATOID-ARTHRITIS; CONTROLLED TRIAL; DOUBLE-BLIND; OSTEOARTHRITIS; METAANALYSIS; PREVENTION; KNEE		Univ Newcastle Upon Tyne, Ctr Hlth Serv Res, Newcastle Upon Tyne NE2 4AA, Tyne & Wear, England; Univ York, Ctr Hlth Econ, York YO1 5DD, N Yorkshire, England	Newcastle University - UK; University of York - UK	Eccles, M (corresponding author), Univ Newcastle Upon Tyne, Ctr Hlth Serv Res, Newcastle Upon Tyne NE2 4AA, Tyne & Wear, England.		Eccles, Martin P/AAD-4029-2020; Mason, James M/D-9904-2011	Mason, James M/0000-0001-9210-4082; Freemantle, Nick/0000-0001-5807-5740				BRADLEY JD, 1992, J RHEUMATOL, V19, P1950; *BRIT MED ASS ROYA, 1996, BRIT NAT FORM; deCraen AJM, 1996, BRIT MED J, V313, P321, DOI 10.1136/bmj.313.7053.321; Eccles M, 1998, BRIT MED J, V316, P1232, DOI 10.1136/bmj.316.7139.1232; EHSANULLAH RSB, 1988, BRIT MED J, V297, P1017, DOI 10.1136/bmj.297.6655.1017; GOTZSCHE PC, 1989, CONTROL CLIN TRIALS, V10, P31, DOI 10.1016/0197-2456(89)90017-2; HAWKEY CJ, 1996, GUT               S1, V39, pW5; HAWKEY CJ, 1996, GUT               S1, V38, pT155; Henry D, 1996, BRIT MED J, V312, P1563, DOI 10.1136/bmj.312.7046.1563; Koch M, 1996, ARCH INTERN MED, V156, P2321, DOI 10.1001/archinte.156.20.2321; LEVINE LR, 1993, ARCH INTERN MED, V153, P2249; MCCORMICK A, 1995, MORBIDITY STAT G MB5; *N ENGL EV BAS GUI, 1997, NONST ANT DRUGS NSAI; PARR G, 1989, BRIT J CLIN PHARMACO, V27, P235, DOI 10.1111/j.1365-2125.1989.tb05356.x; PO LAW, 1998, BRIT MED J, V315, P1565; ROCHON PA, 1994, ARCH INTERN MED, V154, P157, DOI 10.1001/archinte.154.2.157; SILVERSTEIN FE, 1995, ANN INTERN MED, V123, P241, DOI 10.7326/0003-4819-123-4-199508150-00001; WILLIAMS HJ, 1993, ARTHRITIS RHEUM-US, V36, P1196, DOI 10.1002/art.1780360904	18	114	118	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 22	1998	317	7157					526	530						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	115AM	9712607				2022-12-28	WOS:000075641400029
J	Laffan, M; Tuddenham, E				Laffan, M; Tuddenham, E			Science, medicine, and the future - Assessing thrombotic risk	BRITISH MEDICAL JOURNAL			English	Review							ACTIVATED PROTEIN-C; FACTOR-V-LEIDEN; INHERITED THROMBOPHILIA; COAGULATION; RESISTANCE; FAMILIES		Hammersmith Hosp, Imperial Coll, Dept Haematol, Sch Med, London W12 0NN, England; Hammersmith Hosp, MRC, Haemostasis Res Grp, Imperial Coll,Sch Med,Clin Sci Ctr, London, England	Imperial College London; Imperial College London	Laffan, M (corresponding author), Hammersmith Hosp, Imperial Coll, Dept Haematol, Sch Med, London W12 0NN, England.		Tuddenham, Edward/AAS-6196-2020	Tuddenham, Edward/0000-0001-8955-2909				BAUER KA, 1994, BAILLIERE CLIN HAEM, V7, P523, DOI 10.1016/S0950-3536(05)80097-6; BERTINA RM, 1994, NATURE, V369, P64, DOI 10.1038/369064a0; COOPER DN, 1997, VENOUS THROMBOSIS GE; DAHLBACK B, 1993, P NATL ACAD SCI USA, V90, P1004, DOI 10.1073/pnas.90.3.1004; KOELEMAN BPC, 1994, BLOOD, V84, P1031; Lane DA, 1996, THROMB HAEMOSTASIS, V76, P651; Lane DA, 1996, THROMB HAEMOSTASIS, V76, P824; Poort SR, 1996, BLOOD, V88, P3698, DOI 10.1182/blood.V88.10.3698.bloodjournal88103698; vanBoven HH, 1996, THROMB HAEMOSTASIS, V75, P417; Vandenbroucke JP, 1996, BRIT MED J, V313, P1127, DOI 10.1136/bmj.313.7065.1127; vantVeer C, 1997, BLOOD, V90, P3067, DOI 10.1182/blood.V90.8.3067	11	45	46	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 22	1998	317	7157					520	523						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	115AM	9712603				2022-12-28	WOS:000075641400025
J	Oderda, G; Palli, D; Saieva, C; Chiorboli, E; Bona, G				Oderda, G; Palli, D; Saieva, C; Chiorboli, E; Bona, G		Italian Study Grp Short Stature H pylori	Short stature and Helicobacter pylori infection in Italian children: prospective multicentre hospital based case-control study	BRITISH MEDICAL JOURNAL			English	Article							GROWTH		Univ Torino, Pediat Clin, I-28100 Novara, Italy; Azienda Osped Careggi, Unita Operat Epidemiol, Ctr Studio & Prevenz Oncol, I-50131 Florence, Italy	University of Turin; University of Florence; Azienda Ospedaliero Universitaria Careggi	Oderda, G (corresponding author), Univ Torino, Pediat Clin, I-28100 Novara, Italy.		Saieva, Calogero/AAC-2611-2019	Saieva, Calogero/0000-0002-0117-1608; tumino, rosario/0000-0003-2666-414X; PALLI, Domenico/0000-0002-5558-2437				BANATVALA N, 1993, J INFECT DIS, V168, P219, DOI 10.1093/infdis/168.1.219; Coste J, 1997, BRIT MED J, V315, P708, DOI 10.1136/bmj.315.7110.708; PATEL P, 1994, BMJ-BRIT MED J, V309, P1119, DOI 10.1136/bmj.309.6962.1119; Perri F, 1997, ARCH DIS CHILD, V77, P46, DOI 10.1136/adc.77.1.46; RAYMOND J, 1994, J CLIN MICROBIOL, V32, P461, DOI 10.1128/JCM.32.2.461-463.1994	5	42	43	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 22	1998	317	7157					514	515						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	115AM	9712599	Bronze, Green Published			2022-12-28	WOS:000075641400022
J	Starr, JM; Inch, S; Cross, S; MacLennan, WJ; Deary, IJ				Starr, JM; Inch, S; Cross, S; MacLennan, WJ; Deary, IJ			Blood pressure and ageing: longitudinal cohort study	BRITISH MEDICAL JOURNAL			English	Article									Univ Edinburgh, Geriatr Med Unit, Edinburgh EH3 9EW, Midlothian, Scotland; Univ Edinburgh, Dept Psychol, Edinburgh EH8 9JZ, Midlothian, Scotland	University of Edinburgh; University of Edinburgh	Starr, JM (corresponding author), Royal Victoria Hosp, Edinburgh EH4 2DN, Midlothian, Scotland.		Starr, John/C-8951-2011; Deary, Ian J/C-6297-2009	Deary, Ian J/0000-0002-1733-263X				Bush T L, 1989, Aging (Milano), V1, P39; LANDAHL S, 1986, HYPERTENSION, V8, P1044, DOI 10.1161/01.HYP.8.11.1044; Office of Population Censuses and Surveys, 1991, STAND OCC CLASS; Starr J.M., 1996, EPIDEMIOLOGY OLD AGE; Starr JM, 1997, AGE AGEING, V26, P295, DOI 10.1093/ageing/26.4.295	5	15	15	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 22	1998	317	7157					513	514						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	115AM	9712598				2022-12-28	WOS:000075641400021
J	Zhu, LP; Helmberger, DV				Zhu, LP; Helmberger, DV			Moho offset across the northern margin of the Tibetan Plateau	SCIENCE			English	Article							DISCONTINUITY; TOPOGRAPHY; VELOCITIES; TOMOGRAPHY; EVOLUTION; STRENGTH; REGIONS; BENEATH; PHASES; WAVES	Anomalous double-pulse teleseismic P-wave arrivals were observed at one station near the northern margin of the Tibetan Plateau. The azimuthal dependence of the waveform distortion and its absence at nearby stations indicated that the distortion was produced by receiver-side crustal heterogeneity. Modeling of the three-component data revealed a 15- to 20-kilometer Moho offset that occurs over a narrow Lateral range of Less than 5 kilometers. This east-west-striking offset separates the thick Tibetan Plateau crust from the Qaidam Basin crust. Such a sharp crustal thickness change implies a weak Tibetan Plateau crust that thickens vertically in response to penetration by India from the south and to blockage caused by a strong Qaidam Basin crust to the north.	CALTECH, Seismol Lab, Pasadena, CA 91125 USA	California Institute of Technology	Zhu, LP (corresponding author), Univ So Calif, So Calif Earthquake Ctr, Los Angeles, CA 90089 USA.		Zhu, Lupei/B-3997-2009	Zhu, Lupei/0000-0002-6640-1718				BRANDON C, 1986, J GEOPHYS RES-SOLID, V91, P6547, DOI 10.1029/JB091iB06p06547; DEWEY JF, 1988, PHILOS T R SOC A, V327, P379, DOI 10.1098/rsta.1988.0135; ENGLAND P, 1985, NATURE, V315, P297, DOI 10.1038/315297a0; HILTERMAN FJ, 1975, GEOPHYSICS, V40, P745, DOI 10.1190/1.1440565; KENNETT BLN, 1991, GEOPHYS J INT, V105, P429, DOI 10.1111/j.1365-246X.1991.tb06724.x; LANGSTON CA, 1977, B SEISMOL SOC AM, V67, P1029; MARAUYAMA S, 1989, EVOLUTION PACIFIC OC, P75; MOLNAR P, 1981, EARTH PLANET SC LETT, V52, P107, DOI 10.1016/0012-821X(81)90213-2; NEELE F, 1992, GEOPHYS J INT, V109, P670, DOI 10.1111/j.1365-246X.1992.tb00124.x; NI J, 1983, GEOPHYS J ROY ASTR S, V72, P665, DOI 10.1111/j.1365-246X.1983.tb02826.x; OWENS TJ, 1993, B SEISMOL SOC AM, V83, P1959; Owens TJ, 1997, NATURE, V387, P37, DOI 10.1038/387037a0; Rodgers AJ, 1998, J GEOPHYS RES-SOL EA, V103, P7137, DOI 10.1029/97JB03535; SCOTT P, 1983, GEOPHYS J ROY ASTR S, V72, P237, DOI 10.1111/j.1365-246X.1983.tb02815.x; VANDERLEE S, 1994, PHYS EARTH PLANET IN, V86, P147, DOI 10.1016/0031-9201(94)05066-X; WESTAWAY R, 1995, J GEOPHYS RES-SOL EA, V100, P15173, DOI 10.1029/95JB01310; Wittlinger G, 1996, EARTH PLANET SC LETT, V139, P263, DOI 10.1016/0012-821X(95)00235-5; Yin A., 1996, TECTONIC EVOLUTION A, P442; ZHAO LS, 1993, GEOPHYS J INT, V115, P1070, DOI 10.1111/j.1365-246X.1993.tb01510.x; ZHAO WL, 1985, TECTONICS, V4, P359, DOI 10.1029/TC004i004p00359; ZHU L, 1998, THESIS CALTECH PASAD; Zhu LP, 1995, B SEISMOL SOC AM, V85, P1531	22	113	135	2	25	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 21	1998	281	5380					1170	1172		10.1126/science.281.5380.1170	http://dx.doi.org/10.1126/science.281.5380.1170			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	113CE	9712576				2022-12-28	WOS:000075531200046
J	He, QS; Viljanen, MK; Arvilommi, H; Aittanen, B; Mertsola, J				He, QS; Viljanen, MK; Arvilommi, H; Aittanen, B; Mertsola, J			Whooping cough caused by Bordetella pertussis and Bordetella parapertussis in an immunized population	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							POLYMERASE CHAIN-REACTION; INFECTION; TOXIN	Context. - The prevalence of Bordetella pertussis and Bordetella parapertussis infections among outpatients in an immunized population is not known. Objective. - To study the prevalence of these infections in outpatients with paroxysmal cough in Finland, where the pertussis vaccine coverage of 4 doses is 98%. Design. - Prospective cohort study. Setting. - Thirty-two health centers in southwestern Finland. Patients. - A total of 584 patients with paroxysmal cough seen at local health centers from October 1994 through March 1997 from whom nasopharyngeal swabs were collected. Main Outcome Measures.-Prevalence of positive cultures for a pertussis or B parapertussis and/or positive polymerase chain reaction (PCR) results and frequency of symptoms in those with pertussis and parapertussis. Results. - A total of 153 subjects (26.2%) had Bordetella infection by culture or PCR: 93 (60.8%) had B pertussis infection, 49 (32.0%) had B parapertussis infection, and 11 (7.2%) had both. Of these cases, 39 (25.5%) had positive cultures and 95 (62.1%) had positive PCR results for B pertussis, and 19 (12.4%) had positive cultures and 55 (35.9%) had positive PCR results for B parapertussis. At the time of diagnosis, no difference was found in the frequency of symptoms between patients with B parapertussis infection and those with B pertussis infection. Bordetella parapertussis infection was as common as a pertussis infection in children before school entry, whereas in schoolchildren and adults, B pertussis infection was more common than B parapertussis infection (P < .001). Conclusion. - Bordetella infections are common in an immunized population, and B parapertussis infections apparently are more prevalent than previously documented.	Natl Publ Hlth Inst, Dept Turku, FIN-20520 Turku, Finland; Univ Turku, Dept Pediat, Turku, Finland	Finland National Institute for Health & Welfare; University of Turku	He, QS (corresponding author), Natl Publ Hlth Inst, Dept Turku, Kiinamyllynkatu 13, FIN-20520 Turku, Finland.		Mertsola, Jussi/AAE-3460-2021					ARICO B, 1987, J BACTERIOL, V169, P2847, DOI 10.1128/jb.169.6.2847-2853.1987; BORSKA K, 1972, J HYG EPID MICROB IM, V16, P159; ELDERING G, 1952, AM J PUBLIC HEALTH, V42, P27, DOI 10.2105/AJPH.42.1.27; He Q, 1996, EUR J CLIN MICROBIOL, V15, P793, DOI 10.1007/BF01701521; He QS, 1996, J INFECT DIS, V174, P1288, DOI 10.1093/infdis/174.6.1288; HE QS, 1993, J CLIN MICROBIOL, V31, P642, DOI 10.1128/JCM.31.3.642-645.1993; HEININGER U, 1994, PEDIATR INFECT DIS J, V13, P306, DOI 10.1097/00006454-199404000-00011; KHALEF N, 1993, INFECT IMMUN, V61, P486; LAUTROP H, 1971, LANCET, V1, P1195; LINNEMANN CC, 1977, AM J DIS CHILD, V131, P560, DOI 10.1001/archpedi.1977.02120180074014; Mastrantonio P, 1997, DEV BIOL STAND, V89, P255; MERTSOLA J, 1985, EUR J CLIN MICROBIOL, V4, P123, DOI 10.1007/BF02013576; Miller JJ, 1941, J PEDIATR-US, V19, P229, DOI 10.1016/S0022-3476(41)80066-3; MINK CM, 1992, CLIN INFECT DIS, V14, P464, DOI 10.1093/clinids/14.2.464; Stehr K, 1998, PEDIATRICS, V101, P1, DOI 10.1542/peds.101.1.1; VANDERZEE A, 1993, J CLIN MICROBIOL, V31, P2134, DOI 10.1128/JCM.31.8.2134-2140.1993; VONKONIG CHW, 1994, EUR J CLIN MICROBIOL, V13, P455, DOI 10.1007/BF01974634; VYSOKA-BURIANOVA B., 1963, J HYG EPIDEMIOL MICROBIOL IMMUNOL, V7, P472; Willems RJL, 1998, VACCINE, V16, P410, DOI 10.1016/S0264-410X(97)80919-X	19	86	95	0	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 19	1998	280	7					635	637		10.1001/jama.280.7.635	http://dx.doi.org/10.1001/jama.280.7.635			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	110ME	9718056				2022-12-28	WOS:000075384300033
J	Garg, A; Shiau, J; Guyatt, G				Garg, A; Shiau, J; Guyatt, G			The ineffectiveness of immunosuppressive therapy in lymphocytic myocarditis: An overview	ANNALS OF INTERNAL MEDICINE			English	Review							IDIOPATHIC DILATED CARDIOMYOPATHY; TERM FOLLOW-UP; ACTIVE MYOCARDITIS; THYMIC HORMONES; DISEASE; TRIAL; PREDNISONE; INTERFERON	Background: The use of immunosuppressive therapy for myocarditis is controversial. Purpose: To review the literature on the effectiveness of immunosuppressive therapy in biopsy-proven lymphocytic myocarditis. Data Sources: Two authors independently searched MEDLINE and other medical databases from 1980 to 26 June 1997. Study Selection: Randomized, controlled trials; matched-cohort studies; and case-control studies of patients with biopsy-proven myocarditis (Dallas criteria or a mean of greater than or equal to 2.5 lymphocytes per high-power field) for which any form of immunosuppressive treatment was used. The outcomes of interest were mortality and change in left ventricular ejection fraction. Data Extraction: 6 of 374 studies satisfied the selection criteria. Data Synthesis: In survivors, left: ventricular function in myocarditis improved approximately 10% over 6 months without immunosuppressive treatment. Prednisone alone did not improve survival (P >0.2) or left ventricular function (P >0.11). Prednisone combined with azathioprine or cyclosporine did not improve survival (P >0.2) or left ventricular function (P >0.2) in three studies. However, one small matched-cohort study showed improvement in children (P <0.01). Neither interferon nor thymic hormone improved survival or left ventricular function. Conclusions: Immunosuppressive therapy is ineffective in lymphocytic myocarditis. Current therapy in lymphocytic myocarditis seems to be limited to supportive measures or transplantation.	McMaster Univ, Hlth Sci Ctr, Dept Med, Hamilton, ON L8N 3Z5, Canada	McMaster University; University of Manitoba; Children's Hospital Research Institute of Manitoba	Shiau, J (corresponding author), McMaster Univ, Hlth Sci Ctr, Dept Med, Room 3W10 B,1200 Main St W, Hamilton, ON L8N 3Z5, Canada.	shiauj@fhs.mcmaster.ca	Garg, Amit X/G-3295-2011					Aretz H T, 1987, Am J Cardiovasc Pathol, V1, P3; CAMARGO PR, 1995, PEDIATR CARDIOL, V16, P61, DOI 10.1007/BF00796819; Cooper LT, 1997, NEW ENGL J MED, V336, P1860, DOI 10.1056/NEJM199706263362603; DEC GW, 1994, NEW ENGL J MED, V331, P1564, DOI 10.1056/NEJM199412083312307; DEC GW, 1985, NEW ENGL J MED, V312, P885, DOI 10.1056/NEJM198504043121404; DRUCKER NA, 1994, CIRCULATION, V89, P252, DOI 10.1161/01.CIR.89.1.252; GUYATT GH, 1994, JAMA-J AM MED ASSOC, V271, P59, DOI 10.1001/jama.271.1.59; Hahn EA, 1995, EUR HEART J, V16, P162, DOI 10.1093/eurheartj/16.suppl_O.162; LANGE LG, 1994, NEW ENGL J MED, V330, P1129; LATHAM RD, 1989, AM HEART J, V117, P876, DOI 10.1016/0002-8703(89)90626-1; Maisch B, 1995, EUR HEART J, V16, P173, DOI 10.1093/eurheartj/16.suppl_O.173; MAISCH B, 1994, POSTGRAD MED J, V70, pS29; MASON JW, 1995, NEW ENGL J MED, V333, P269, DOI 10.1056/NEJM199508033330501; Miric M, 1996, HEART, V75, P596, DOI 10.1136/hrt.75.6.596; MIRIC M, 1994, FEMS IMMUNOL MED MIC, V10, P65, DOI 10.1016/0928-8244(94)90016-7; Miric M, 1995, EUR HEART J, V16, P150, DOI 10.1093/eurheartj/16.suppl_O.150; OLINDE KD, 1994, ANNU REV MED, V45, P481; OXMAN AD, 1992, ANN INTERN MED, V116, P78, DOI 10.7326/0003-4819-116-1-78; PARRILLO JE, 1989, NEW ENGL J MED, V321, P1061, DOI 10.1056/NEJM198910193211601; SHANES JG, 1987, CIRCULATION, V75, P401, DOI 10.1161/01.CIR.75.2.401; YUSUF S, 1991, JAMA-J AM MED ASSOC, V266, P93, DOI 10.1001/jama.266.1.93	21	20	22	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 15	1998	129	4					317	322		10.7326/0003-4819-129-4-199808150-00009	http://dx.doi.org/10.7326/0003-4819-129-4-199808150-00009			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	109NP	9729186				2022-12-28	WOS:000075329100008
J	Fahlke, C; Rhodes, TH; Desai, RR; George, AL				Fahlke, C; Rhodes, TH; Desai, RR; George, AL			Pore stoichiometry of a voltage-gated chloride channel	NATURE			English	Article							TORPEDO ELECTROPLAX; POTASSIUM CHANNELS; ION-CHANNEL; ARCHITECTURE; SITE	Ion channels allow ions to pass through cell membranes by forming aqueous permeation pathways (pores). In contrast to most known ion channels, which have single pores, a chloride channel belonging to the CIC family(1) (Torpeno ClC-0) has functional features that suggest that it has a unique 'double-barrelled' architecture in which each of two subunits forms an independent pore. This model is based on single-channel recordings of ClC-0 that has two equally spaced and independently gated conductance states(2-4), Other ClC isoforms do not behave in this way(5,6), raising doubts about the applicability of the model to all CIC channels. Here we determine the pore stoichiometry of another CIC isoform, human ClC-1, by chemically modifying cysteines that have been substituted for other amino acids located within the CIC ion-selectivity filter(7). The ClC-1 channel can be rendered completely susceptible to block by methanethiosulphonate reagents when only one of the two subunits contains substituted cysteines. Thiol side chains placed at corresponding positions in both subunits can form intersubunit disulphide bridges and coordinate Cd2+, indicating that the pore-forming regions from each subunit line the same conduction pathway. We conclude that human ClC-1 has a single functional pore.	Vanderbilt Univ, Sch Med, Dept Med Nephrol & Pharmacol, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Ctr Mol Neurosci, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University	Fahlke, C (corresponding author), Vanderbilt Univ, Sch Med, Dept Med Nephrol & Pharmacol, 221 Kirkland Hall, Nashville, TN 37232 USA.		Fahlke, Christoph/G-3635-2013	Fahlke, Christoph/0000-0001-8602-9952				Benitah JP, 1996, P NATL ACAD SCI USA, V93, P7392, DOI 10.1073/pnas.93.14.7392; Benitah JP, 1997, BIOPHYS J, V73, P603, DOI 10.1016/S0006-3495(97)78096-2; CAREAGA CL, 1992, J MOL BIOL, V226, P1219, DOI 10.1016/0022-2836(92)91063-U; CARTER PJ, 1984, CELL, V38, P835, DOI 10.1016/0092-8674(84)90278-2; Cheung M, 1997, J GEN PHYSIOL, V109, P289, DOI 10.1085/jgp.109.3.289; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Duan D, 1997, NATURE, V390, P417, DOI 10.1038/37151; Fahlke C, 1997, P NATL ACAD SCI USA, V94, P2729, DOI 10.1073/pnas.94.6.2729; Fahlke C, 1997, J GEN PHYSIOL, V109, P93, DOI 10.1085/jgp.109.1.93; Fahlke C, 1997, NATURE, V390, P529, DOI 10.1038/37391; Fersht A., 1985, ENZYME STRUCTURE MEC; GLUSKER JP, 1991, ADV PROTEIN CHEM, V42, P1; HEGINBOTHAM L, 1992, NEURON, V8, P483, DOI 10.1016/0896-6273(92)90276-J; HIDALGO P, 1995, SCIENCE, V268, P307, DOI 10.1126/science.7716527; JENTSCH TJ, 1994, CURR TOP MEMBR, V42, P35, DOI 10.1016/S0070-2161(08)60817-5; LI M, 1994, CURR BIOL, V4, P110, DOI 10.1016/S0960-9822(94)00026-6; Ludewig U, 1996, NATURE, V383, P340, DOI 10.1038/383340a0; MALINOWSKA DH, 1995, AM J PHYSIOL-CELL PH, V268, pC191, DOI 10.1152/ajpcell.1995.268.1.C191; MIDDLETON RE, 1994, BIOCHEMISTRY-US, V33, P13189, DOI 10.1021/bi00249a005; Middleton RE, 1996, NATURE, V383, P337, DOI 10.1038/383337a0; MILLER C, 1982, PHILOS T ROY SOC B, V299, P401, DOI 10.1098/rstb.1982.0140; ROBERTS DD, 1986, BIOCHEMISTRY-US, V25, P5595, DOI 10.1021/bi00367a038; ROOT MJ, 1994, SCIENCE, V265, P1852, DOI 10.1126/science.7522344; Rychkov GY, 1997, J PHYSIOL-LONDON, V501, P355, DOI 10.1111/j.1469-7793.1997.355bn.x	24	56	57	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 13	1998	394	6694					687	690		10.1038/29319	http://dx.doi.org/10.1038/29319			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	110MD	9716133				2022-12-28	WOS:000075384200046
J	Andrulis, ED; Neiman, AM; Zappulla, DC; Sternglanz, R				Andrulis, ED; Neiman, AM; Zappulla, DC; Sternglanz, R			Perinuclear localization of chromatin facilitates transcriptional silencing	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE; SIR4 PROTEINS; YEAST; TELOMERES; RAP1; HETEROCHROMATIN; RETENTION; NUCLEUS; DOMAIN; MOTIFS	Transcriptional silencing in Saccharomyces cerevisiae at the HM mating-type loci and telomeres occurs through the formation of a heterochromatin-like structure. HM silencing is regulated by cis-acting elements, termed silencers, and by trans-acting factors that bind to the silencers. These factors attract the four SIR (silent information regulator) proteins, three of which (SIR2-4) spread from the silencers to alter chromatin, hence silencing nearby genes(1-4). We show here that an HMR locus with a defective silencer can be silenced by anchoring the locus to the nuclear periphery. This was accomplished by fusing integral membrane proteins to the GAL4 DNA-binding domain and overproducing the hybrid proteins, causing them to accumulate in the endoplasmic reticulum and the nuclear membrane. We expressed the hybrid proteins in a strain carrying an HMR silencer with GALA-binding sites (UAS(G)) replacing silencer elements, causing the silencer to become anchored to the nuclear periphery and leading to silencing of a nearby reporter gene. This silencing required the hybrids of the GAL4 DNA-binding domain with membrane proteins, the UASG sites and the SIR proteins. Our results indicate that perinuclear localization helps to establish transcriptionally silent chromatin.	SUNY Stony Brook, Dept Biochem & Cell Biol, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Sternglanz, R (corresponding author), SUNY Stony Brook, Dept Biochem & Cell Biol, Stony Brook, NY 11794 USA.	rolf@life.bio.sunysb.edu	Zappulla, David/C-7818-2009	Zappulla, David/0000-0001-8242-3493				BRAND AH, 1985, CELL, V41, P41, DOI 10.1016/0092-8674(85)90059-5; BUCK SW, 1995, GENE DEV, V9, P370, DOI 10.1101/gad.9.3.370; CHIEN CT, 1993, CELL, V75, P531, DOI 10.1016/0092-8674(93)90387-6; Dean N, 1996, GLYCOBIOLOGY, V6, P73, DOI 10.1093/glycob/6.1.73; FUNABIKI H, 1993, J CELL BIOL, V121, P961, DOI 10.1083/jcb.121.5.961; Gotta M, 1996, J CELL BIOL, V134, P1349, DOI 10.1083/jcb.134.6.1349; Harlow E., 1988, ANTIBODIES LAB MANUA; HECHT A, 1995, CELL, V80, P583, DOI 10.1016/0092-8674(95)90512-X; Hecht A, 1996, NATURE, V383, P92, DOI 10.1038/383092a0; HIRAOKA Y, 1990, J CELL BIOL, V111, P2815, DOI 10.1083/jcb.111.6.2815; KAISER CA, 1990, CELL, V61, P723, DOI 10.1016/0092-8674(90)90483-U; Karaoglu D, 1997, J BIOL CHEM, V272, P32513, DOI 10.1074/jbc.272.51.32513; KHOSRAVIFAR R, 1991, P NATL ACAD SCI USA, V88, P6264, DOI 10.1073/pnas.88.14.6264; KINSELLA BT, 1992, J BIOL CHEM, V267, P3940; MA J, 1987, CELL, V51, P113, DOI 10.1016/0092-8674(87)90015-8; MACHAMER CE, 1993, MOL BIOL CELL, V4, P695, DOI 10.1091/mbc.4.7.695; Maillet L, 1996, GENE DEV, V10, P1796, DOI 10.1101/gad.10.14.1796; Marcand S, 1996, GENE DEV, V10, P1297, DOI 10.1101/gad.10.11.1297; Marshall WF, 1996, MOL BIOL CELL, V7, P825, DOI 10.1091/mbc.7.5.825; MUNRO S, 1991, EMBO J, V10, P3577, DOI 10.1002/j.1460-2075.1991.tb04924.x; PRINGLE JR, 1991, METHOD ENZYMOL, V194, P565; RENAULD H, 1993, GENE DEV, V7, P1133, DOI 10.1101/gad.7.7a.1133; STONE EM, 1991, MOL CELL BIOL, V11, P2253, DOI 10.1128/MCB.11.4.2253; StrahlBolsinger S, 1997, GENE DEV, V11, P83, DOI 10.1101/gad.11.1.83; Triolo T, 1996, NATURE, V381, P251, DOI 10.1038/381251a0; ZUFFEREY R, 1995, EMBO J, V14, P4949, DOI 10.1002/j.1460-2075.1995.tb00178.x	26	378	387	1	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 6	1998	394	6693					592	595		10.1038/29100	http://dx.doi.org/10.1038/29100			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	107YN	9707122				2022-12-28	WOS:000075238700052
J	Shotyk, W; Weiss, D; Appleby, PG; Cheburkin, AK; Frei, R; Gloor, M; Kramers, JD; Reese, S; Van der Knaap, WO				Shotyk, W; Weiss, D; Appleby, PG; Cheburkin, AK; Frei, R; Gloor, M; Kramers, JD; Reese, S; Van der Knaap, WO			History of atmospheric lead deposition since 12,370 C-14 yr BP from a peat bog, Jura Mountains, Switzerland	SCIENCE			English	Article							GREENLAND ICE; CONTINENTAL-CRUST; YOUNGER-DRYAS; ISOTOPIC COMPOSITION; UNITED-KINGDOM; LAKE-SEDIMENTS; HEAVY-METALS; TRACE-METALS; POLLUTION; PB	A continuous record of atmospheric Lead since 12,370 carbon-14 years before the present (C-14 yr BP) is preserved in a Swiss peat bog. Enhanced fluxes caused by climate changes reached their maxima 10,590 C-14: y, BP (Younger Dryas) and 8230 C-14 yr BP. Soil erosion caused by forest clearing and agricultural tillage increased Lead deposition after 5320 C-14 yr BP. Increasing lead/scandium and decreasing Lead-206/lead-207 beginning 3000 C-14 yr BP indicate the beginning of Lead pollution from mining and smelting, and anthropogenic sources have dominated Lead emissions ever since. The greatest Lead flux(15.7 milligrams per square meter per year in A.D. 1979) was 1570 times the natural, background value (0.01 milligram per square meter per year from 8030 to 5320 C-14 yr BP).	Univ Bern, Inst Geol, CH-3012 Bern, Switzerland; Univ Liverpool, Dept Math Sci, Environm Radiometr Res Ctr, Liverpool L69 3BX, Merseyside, England; Ukrainian Acad Sci, Inst Geol, UA-252054 Kiev 54, Ukraine; Univ Copenhagen, Inst Geol, DK-1350 Copenhagen M, Denmark; Swiss Fed Inst Forest Snow & Landscape Res, CH-8903 Birmensdorf, Switzerland; Univ Bern, Inst Phys, Radiocarbon Lab, CH-3012 Bern, Switzerland; Univ Bern, Inst Geobot, CH-3013 Bern, Switzerland	University of Bern; University of Liverpool; National Academy of Sciences Ukraine; University of Copenhagen; Swiss Federal Institutes of Technology Domain; Swiss Federal Institute for Forest, Snow & Landscape Research; University of Bern; University of Bern	Shotyk, W (corresponding author), Univ Bern, Inst Geol, Baltzerstr 1, CH-3012 Bern, Switzerland.	shotyk@geo.unibe.ch	Frei, Robert/N-6798-2014; Shotyk, William/E-7026-2010	Frei, Robert/0000-0001-7708-9881; Shotyk, William/0000-0002-2584-8388; Appleby, Peter/0000-0002-6945-1841; Weiss, Dominik/0000-0001-8074-9430				Alley RB, 1997, GEOLOGY, V25, P483, DOI 10.1130/0091-7613(1997)025<0483:HCIAPW>2.3.CO;2; Andersen BG, 1994, ICE AGE WORLD; Appleby PG, 1997, WATER AIR SOIL POLL, V100, P223, DOI 10.1023/A:1018380922280; Bacon JR, 1996, ENVIRON SCI TECHNOL, V30, P2511, DOI 10.1021/es950839s; Belokopytov I., 1955, TORFYANAYA PROMYSHLE, V8, P9; BENOTHMAN D, 1989, EARTH PLANET SC LETT, V94, P1, DOI 10.1016/0012-821X(89)90079-4; Birch L, 1996, WATER RES, V30, P679, DOI 10.1016/0043-1354(95)00231-6; BLUNIER T, 1995, NATURE, V374, P46, DOI 10.1038/374046a0; Bowen H. J. M., 1979, Environmental chemistry of the elements.; Brannvall ML, 1997, WATER AIR SOIL POLL, V100, P243, DOI 10.1023/A:1018360106350; CANDELONE JP, 1995, J GEOPHYS RES-ATMOS, V100, P16605, DOI 10.1029/95JD00989; Cheburkin AK, 1996, FRESEN J ANAL CHEM, V354, P688; CHOW TJ, 1972, SCIENCE, V176, P510, DOI 10.1126/science.176.4034.510; CLYMO RS, 1994, PHILOS T R SOC LON B, V305, P487; COLEMAN DO, 1985, HIST MONITORING; DAMMAN AWH, 1986, CAN J BOT, V64, P384, DOI 10.1139/b86-055; DANSGAARD W, 1989, NATURE, V339, P532, DOI 10.1038/339532a0; DAU JHC, 1923, NEUES HDB TORF; DAVIS MD, 1986, CIVILISATIONS HIST; Day Joan, 1991, IND REVOLUTION METAL; DEBEAULIEU JL, 1994, FESTSCHRIFT G LANG; Downes H, 1987, GEOL SOC SPEC PUBL, V30, P517; Eicher U., 1980, MITTEILUNGEN NATURFO, V37, P65; ERNST WHO, 1974, LANDESAMT NATURKUNDE, V2, P3; Farmer JG, 1996, ENVIRON SCI TECHNOL, V30, P3080, DOI 10.1021/es960162o; Farmer JG, 1997, WATER AIR SOIL POLL, V100, P253, DOI 10.1023/A:1018320425006; Forshell H., 1992, INCEPTION COPPER MIN; GLOOSCHENKO WA, 1986, AQUAT BOT, V25, P179, DOI 10.1016/0304-3770(86)90053-7; GLOOSCHENKO WA, 1986, TOXIC METALS ATMOSPH, P508; Gorres M, 1997, WATER AIR SOIL POLL, V100, P355, DOI 10.1023/A:1018324525914; GROGLER N, 1966, Z NATURFORSCH PT A, VA 21, P1167; GROUSSET FE, 1994, ENVIRON SCI TECHNOL, V28, P1605, DOI 10.1021/es00058a011; HAJDAS I, 1993, CLIM DYNAM, V9, P107, DOI 10.1007/BF00209748; Hong SM, 1996, EARTH PLANET SC LETT, V143, P233, DOI 10.1016/0012-821X(96)00137-9; HONG SM, 1994, SCIENCE, V265, P1841, DOI 10.1126/science.265.5180.1841; Hurst RW, 1996, ENVIRON SCI TECHNOL, V30, pA304, DOI 10.1021/es962319i; JOHNSEN SJ, 1992, NATURE, V359, P311, DOI 10.1038/359311a0; JORAY M, 1942, MAT LEVE GEOBOTANIQU; Kempter H, 1997, WATER AIR SOIL POLL, V100, P367, DOI 10.1023/A:1018376509985; Kramers JD, 1997, CHEM GEOL, V139, P75, DOI 10.1016/S0009-2541(97)00027-2; LEE JA, 1973, NATURE, V245, P216, DOI 10.1038/245216a0; LEE JA, 1974, NATURE, V2, P3; LISTER GS, 1988, QUATERNARY RES, V29, P129, DOI 10.1016/0033-5894(88)90056-7; LIVETT EA, 1988, ADV ECOL RES, V18, P65; MacKenzie AB, 1997, SCI TOTAL ENVIRON, V203, P115, DOI 10.1016/S0048-9697(97)00139-3; Martin MH, 1979, P BRISTOL NATURALIST, V37, P91; MartinezCortizas A, 1997, WATER AIR SOIL POLL, V100, P387, DOI 10.1023/A:1018312223189; MASHALL PD, 1995, IN PRESS INT S BEG M; MAYEWSKI PA, 1993, SCIENCE, V261, P195, DOI 10.1126/science.261.5118.195; MCCORMICK M, IN PRESS COMMUNICATI; Monna F, 1997, ENVIRON SCI TECHNOL, V31, P2277, DOI 10.1021/es960870+; Mook W.G., 1981, P 1 INT S 14 C ARCH, V8, P31; Moor HC, 1996, ENVIRON SCI TECHNOL, V30, P2928, DOI 10.1021/es950895t; MORRAL FR, 1990, CIM BULL, V83, P150; MULLER K, 1982, THESIS U BERNE SWITZ; Muller N., 1995, TELMA, V25, P143; Norton SA, 1997, WATER AIR SOIL POLL, V100, P271, DOI 10.1023/A:1018380610893; Nriagu J. O., 1983, LEAD LEAD POISONING; NRIAGU JO, 1993, J GREAT LAKES RES, V19, P175, DOI 10.1016/S0380-1330(93)71207-1; Olendrzynski Krzysztof, 1996, Environmental Reviews, V4, P300, DOI 10.1139/a96-016; PETEET D, 1995, QUATERN INT, V28, P93, DOI 10.1016/1040-6182(95)00049-O; PETIT D, 1984, ATMOS ENVIRON, V18, P1189, DOI 10.1016/0004-6981(84)90150-1; PETITMAIRE N, 1997, PAGES WORKSHOP REPOR, V972, P55; Rosman KJR, 1997, ENVIRON SCI TECHNOL, V31, P3413, DOI 10.1021/es970038k; SCHUTZ L, 1989, NATO ASI SERIES, V282; SETTLE DM, 1980, SCIENCE, V207, P1167, DOI 10.1126/science.6986654; SHOTYK W, 1988, EARTH-SCI REV, V25, P95, DOI 10.1016/0012-8252(88)90067-0; Shotyk W, 1997, WATER AIR SOIL POLL, V100, P297, DOI 10.1023/A:1018384711802; Shotyk W, 1996, WATER AIR SOIL POLL, V90, P375, DOI 10.1007/BF00282657; Shotyk W, 1996, EARTH PLANET SC LETT, V145, pE1, DOI 10.1016/S0012-821X(96)00197-5; Shotyk William, 1996, Environmental Reviews, V4, P149, DOI 10.1139/a96-010; Stager JC, 1997, SCIENCE, V276, P1834, DOI 10.1126/science.276.5320.1834; Steinmann P, 1997, CHEM GEOL, V138, P25, DOI 10.1016/S0009-2541(96)00171-4; Steinmann P, 1997, GEOCHIM COSMOCHIM AC, V61, P1143, DOI 10.1016/S0016-7037(96)00401-2; STEUER H, 1993, THESIS STUTTGART; STEWART C, 1994, ENVIRON POLLUT, V86, P243, DOI 10.1016/0269-7491(94)90164-3; STUIVER M, 1993, RADIOCARBON, V35, P215, DOI 10.1017/S0033822200013904; SUGDEN CL, 1993, ENVIRON GEOCHEM HLTH, V15, P59, DOI 10.1007/BF02627823; TAYLOR SR, 1995, REV GEOPHYS, V33, P241, DOI 10.1029/95RG00262; VANGEEL B, 1989, ACTA BOT NEERL, V38, P467, DOI 10.1111/j.1438-8677.1989.tb01377.x; VILE MA, 1995, WATER AIR SOIL POLL, V79, P89, DOI 10.1007/BF01100432; Walraven N, 1997, J GEOCHEM EXPLOR, V59, P47, DOI 10.1016/S0375-6742(96)00056-8; WARDENAAR ECP, 1987, CAN J BOT, V65, P1772, DOI 10.1139/b87-243; WEDEPOHL KH, 1995, GEOCHIM COSMOCHIM AC, V59, P1217, DOI 10.1016/0016-7037(95)00038-2; Weiss D, 1997, WATER AIR SOIL POLL, V100, P311, DOI 10.1023/A:1018341029549; WEISS D, 1998, THESIS U BERNE SWITZ; WEISS D, UNPUB; Wessels M, 1995, AQUAT SCI, V57, P291, DOI 10.1007/BF00878394	88	612	630	6	175	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 11	1998	281	5383					1635	1640		10.1126/science.281.5383.1635	http://dx.doi.org/10.1126/science.281.5383.1635			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	118TR	9733502				2022-12-28	WOS:000075856500035
J	Gaydos, CA; Howell, MR; Pare, B; Clark, KL; Ellis, DA; Hendrix, RM; Gaydos, JC; McKee, KT; Quinn, TC				Gaydos, CA; Howell, MR; Pare, B; Clark, KL; Ellis, DA; Hendrix, RM; Gaydos, JC; McKee, KT; Quinn, TC			Chlamydia trachomatis infections in female military recruits	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LIGASE CHAIN-REACTION; PELVIC INFLAMMATORY DISEASE; FIRST-VOID URINE; REACTION ASSAY; UNITED-STATES; WOMEN; DIAGNOSIS; PREVALENCE; ADOLESCENTS; RISK	Background. Asymptomaticgenital Chlamydia trachomatis infections in women can lead to pelvic inflammatory disease, infertility, and ectopic pregnancy. To design a chlamydia-control program, we conducted a large survey of women in the U.S. military. Methods From January 1996 through December 1997, urine samples from 13,204 new female U.S. Army recruits from 50 states were screened by ligase chain reaction for C. trachomatis infection. Information on potential risk factors was obtained by questionnaire. With multivariate analysis, we identified criteria for a screening program. Results The overall prevalence of chlamydial infection was 9.2 percent, with a peak of 12.2 percent among the 17-year-old recruits. The prevalence was 15 percent or more among the recruits from five southern states. The following risk factors were independently associated with chlamydial infection: having ever had vaginal sex (odds ratio for infection, 5.9), being 25 years of age or less (odds ratio, 3.0), being black (odds ratio, 3.4), having had more than one sex partner in the previous 90 days (odds ratio, 1.4), having had a new partner in the previous 90 days (odds ratio, 1.3), having had a partner in the previous 90 days who did not always use condoms (odds ratio, 1.4), and having ever had a sexually transmitted disease (odds ratio, 1.2). A screening program for subjects 25 years of age or less (87.9 per cent of our sample) would have identified 95.3 percent of the infected women. Conclusions. Among female military recruits, the prevalence of chlamydial infection is high. A control program that screens female recruits who are 25 years old or younger with urine DNA-amplification assays has the potential to reduce infection, transmission, and the sequelae of chlamydial infection. (N Engl J Med 1998;339:739-44.) (C) 1998, Massachusetts Medical Society.	Johns Hopkins Univ, Sch Med, Div Infect Dis, Baltimore, MD 21205 USA; Walter Reed Army Med Ctr, Walter Reed Army Inst Res, Washington, DC 20307 USA; USA, Med Dept Act, Ft Jackson, SC USA; Henry M Jackson Fdn, Rockville, MD USA; Womack Army Med Ctr, Ft Bragg, NC USA; NIAID, NIH, Bethesda, MD 20892 USA	Johns Hopkins University; United States Department of Defense; United States Army; Walter Reed Army Institute of Research (WRAIR); Walter Reed National Military Medical Center; Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc; United States Department of Defense; United States Army; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Gaydos, CA (corresponding author), Johns Hopkins Univ, Sch Med, Div Infect Dis, 720 Rutland Ave,1159 Ross Res Bldg, Baltimore, MD 21205 USA.		Gaydos, Charlotte A./E-9937-2010; Quinn, Thomas/A-2494-2010					ADDISS DG, 1993, SEX TRANSM DIS, V20, P28, DOI 10.1097/00007435-199301000-00006; BOYD RS, 1991, MIL MED, V156, P420, DOI 10.1093/milmed/156.8.420; CATES W, 1991, AM J OBSTET GYNECOL, V164, P1771, DOI 10.1016/0002-9378(91)90559-A; CATTERSON ML, 1993, MIL MED, V158, P618, DOI 10.1093/milmed/158.9.618; CHERNESKY MA, 1994, J CLIN MICROBIOL, V32, P2682, DOI 10.1128/JCM.32.11.2682-2685.1994; Emerson LAC, 1997, MIL MED, V162, P87, DOI 10.1093/milmed/162.2.87; Eng TR, 1997, HIDDEN EPIDEMIC CONF, P28; Gaydos CA, 1998, J CLIN MICROBIOL, V36, P1300, DOI 10.1128/JCM.36.5.1300-1304.1998; Gaydos CA, 1998, J INFECT DIS, V177, P417, DOI 10.1086/514207; Hillis SD, 1996, NEW ENGL J MED, V334, P1399, DOI 10.1056/NEJM199605233342111; Howell MR, 1998, SEX TRANSM DIS, V25, P108, DOI 10.1097/00007435-199802000-00008; Howell MR, 1998, ANN INTERN MED, V128, P277, DOI 10.7326/0003-4819-128-4-199802150-00005; Jensen IP, 1997, LANCET, V349, P329, DOI 10.1016/S0140-6736(05)62829-2; Katz BP, 1996, SEX TRANSM DIS, V23, P226, DOI 10.1097/00007435-199605000-00011; LEE HH, 1995, LANCET, V345, P213, DOI 10.1016/S0140-6736(95)90221-X; MALONE JD, 1993, SEX TRANSM DIS, V20, P294, DOI 10.1097/00007435-199309000-00011; Marrazzo JM, 1997, ANN INTERN MED, V127, P796, DOI 10.7326/0003-4819-127-9-199711010-00004; Marrazzo JM, 1997, SEX TRANSM DIS, V24, P131, DOI 10.1097/00007435-199703000-00003; Mosure DJ, 1996, AM J EPIDEMIOL, V144, P997, DOI 10.1093/oxfordjournals.aje.a008870; Mosure DJ, 1997, J ADOLESCENT HEALTH, V20, P6, DOI 10.1016/S1054-139X(96)00157-7; Oh MK, 1996, J ADOLESCENT HEALTH, V18, P270, DOI 10.1016/1054-139X(95)00232-H; PFAFF JA, 1991, MIL MED, V156, P362, DOI 10.1093/milmed/156.7.362; Quinn TC, 1996, JAMA-J AM MED ASSOC, V276, P1737, DOI 10.1001/jama.276.21.1737; QUINN TC, 1992, ADV HOST DEFENSE MEC, V8, P1; SCHACHTER J, 1995, J INFECT DIS, V172, P1411, DOI 10.1093/infdis/172.5.1411; STAMM WE, 1988, ANN INTERN MED, V108, P710, DOI 10.7326/0003-4819-108-5-710; Stamm WE, 1990, SEXUALLY TRANSMITTED, P181; Stary A, 1996, SEX TRANSM DIS, V23, P97, DOI 10.1097/00007435-199603000-00002; STERGACHIS A, 1993, AM J EPIDEMIOL, V138, P143, DOI 10.1093/oxfordjournals.aje.a116840; VANDOORNUM GJJ, 1995, J CLIN MICROBIOL, V33, P2042, DOI 10.1128/JCM.33.8.2042-2047.1995; WASHINGTON AE, 1991, JAMA-J AM MED ASSOC, V266, P2565, DOI 10.1001/jama.266.18.2565; WASHINGTON AE, 1987, JAMA-J AM MED ASSOC, V257, P2070, DOI 10.1001/jama.257.15.2070; WEINSTOCK HS, 1992, AM J EPIDEMIOL, V135, P41, DOI 10.1093/oxfordjournals.aje.a116200; ZENILMAN JM, 1995, SEX TRANSM DIS, V22, P15, DOI 10.1097/00007435-199501000-00003; 1997, MMWR MORB MORTAL WKL, V46, P928; 1997, MMWR MORB MORTAL WKL, V46, P193; 1993, MMWR MORB MORTAL WKL, V42, P1; 1997, MMWR MORB MORTAL WKL, V46, P819	38	194	200	0	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 10	1998	339	11					739	744		10.1056/NEJM199809103391105	http://dx.doi.org/10.1056/NEJM199809103391105			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	116RF	9731090	Bronze			2022-12-28	WOS:000075737800005
J	Schwoebel, V; Decludt, B; de Benoist, AC; Haeghebaert, S; Torrea, G; Vincent, V; Grosset, J				Schwoebel, V; Decludt, B; de Benoist, AC; Haeghebaert, S; Torrea, G; Vincent, V; Grosset, J			Multidrug resistant tuberculosis in France 1992-4: two case-control studies	BRITISH MEDICAL JOURNAL			English	Article; Proceedings Paper	XIth International Conference on AIDS	JUL 07-13, 1996	VANCOUVER, CANADA				MYCOBACTERIUM-TUBERCULOSIS		Fac Med Pitie Salpetriere, Ctr Natl Reference Surveillance TB, Serv Bacteriol, F-75634 Paris 13, France; Inst Pasteur, Ctr Natl Reference Mycobacteries, F-75724 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Schwoebel, V (corresponding author), European Ctr Epidemiol Monitoring AIDS, F-94415 St Maurice, France.							Bifani PJ, 1996, JAMA-J AM MED ASSOC, V275, P452, DOI 10.1001/jama.275.6.452; SCHWOEBEL V, 1994, TUBERCLE LUNG DIS, V75, P44, DOI 10.1016/0962-8479(94)90101-5; VANEMBDEN JDA, 1993, J CLIN MICROBIOL, V31, P406, DOI 10.1128/JCM.31.2.406-409.1993; 1996, MMWR, V45, P330; 1995, COMMUN DIS REP CDR W, V5, P161	5	21	21	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	SEP 5	1998	317	7159					630	631		10.1136/bmj.317.7159.630	http://dx.doi.org/10.1136/bmj.317.7159.630			4	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	118GN	9727990	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000075830200018
J	Struelens, MJ				Struelens, MJ			The epidemiology of antimicrobial resistance in hospital acquired infections: problems and possible solutions	BRITISH MEDICAL JOURNAL			English	Article							MULTIRESISTANT ACINETOBACTER-BAUMANNII; INTENSIVE-CARE UNITS; STAPHYLOCOCCUS-AUREUS; ANTIBIOTIC-RESISTANCE; DRUG-RESISTANCE; NOSOCOMIAL INFECTION; ENTEROCOCCUS-FAECIUM; FECAL CARRIAGE; VANCOMYCIN; EMERGENCE		Free Univ Brussels, Hop Erasme, Dept Clin Microbiol, B-1070 Brussels, Belgium	Universite Libre de Bruxelles; Vrije Universiteit Brussel	Struelens, MJ (corresponding author), Free Univ Brussels, Hop Erasme, Dept Clin Microbiol, 808 Route Lennik, B-1070 Brussels, Belgium.	marc.struelens@ulb.ac.be		Struelens, Marc/0000-0001-5150-4944				BATES JH, 1995, CHEST, V108, P1690, DOI 10.1378/chest.108.6.1690; Bonten MJM, 1996, LANCET, V348, P1615, DOI 10.1016/S0140-6736(96)02331-8; *CDC, 1997, MMWR-MORBID MORTAL W, V46, P813; CHOW JW, 1991, ANN INTERN MED, V115, P585, DOI 10.7326/0003-4819-115-8-585; COHEN ML, 1992, SCIENCE, V257, P1050, DOI 10.1126/science.257.5073.1050; DeGheldre Y, 1997, J CLIN MICROBIOL, V35, P152, DOI 10.1128/JCM.35.1.152-160.1997; Endtz HP, 1997, J CLIN MICROBIOL, V35, P3026, DOI 10.1128/JCM.35.12.3026-3031.1997; Flaherty JP, 1996, INFECT CONT HOSP EP, V17, P236; FRIEDEN TR, 1993, LANCET, V342, P76, DOI 10.1016/0140-6736(93)91285-T; Gold HS, 1996, NEW ENGL J MED, V335, P1445, DOI 10.1056/NEJM199611073351907; Goldmann DA, 1996, JAMA-J AM MED ASSOC, V275, P234, DOI 10.1001/jama.275.3.234; GOULD IM, 1994, J ANTIMICROB CHEMOTH, V34, P21; Guerrero A, 1997, LANCET, V350, P1738, DOI 10.1016/S0140-6736(97)07567-3; Hiramatsu K, 1997, LANCET, V350, P1670, DOI 10.1016/S0140-6736(97)07324-8; JORDENS JZ, 1994, J ANTIMICROB CHEMOTH, V34, P515, DOI 10.1093/jac/34.4.515; KARANFIL LV, 1992, INFECT CONT HOSP EP, V13, P195, DOI 10.1086/646509; LARSON E, 1995, J HOSP INFECT, V30, P88, DOI 10.1016/0195-6701(95)90010-1; Livermore DM, 1996, J ANTIMICROB CHEMOTH, V38, P409, DOI 10.1093/jac/38.3.409; LORTHOLARY O, 1995, CLIN INFECT DIS, V20, P790, DOI 10.1093/clinids/20.4.790; MCGOWAN JE, 1983, REV INFECT DIS, V5, P1033; MULLIGAN ME, 1993, AM J MED, V94, P313, DOI 10.1016/0002-9343(93)90063-U; RICHARD P, 1994, J INFECT DIS, V170, P377, DOI 10.1093/infdis/170.2.377; SCHLAES DM, 1997, CLIN INFECT DIS, V25, P584; SHAY DK, 1995, J INFECT DIS, V172, P993, DOI 10.1093/infdis/172.4.993; STRUELENS MJ, 1993, J HOSP INFECT, V25, P15, DOI 10.1016/0195-6701(93)90005-K; Struelens MJ, 1996, INFECT CONT HOSP EP, V17, P503; Towner KJ, 1997, J MED MICROBIOL, V46, P721, DOI 10.1099/00222615-46-9-721; Vandenbroucke-Grauls CMJE, 1998, REV MED MICROBIOL, V9, P109; VINCENT JL, 1995, JAMA-J AM MED ASSOC, V274, P639, DOI 10.1001/jama.274.8.639; VOSS A, 1994, EUR J CLIN MICROBIOL, V13, P50, DOI 10.1007/BF02026127	30	108	110	0	8	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	SEP 5	1998	317	7159					652	654		10.1136/bmj.317.7159.652	http://dx.doi.org/10.1136/bmj.317.7159.652			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	118GN	9727997	Green Published			2022-12-28	WOS:000075830200027
J	Konopliv, AS; Binder, AB; Hood, LL; Kucinskas, AB; Sjogren, WL; Williams, JG				Konopliv, AS; Binder, AB; Hood, LL; Kucinskas, AB; Sjogren, WL; Williams, JG			Improved gravity field of the moon from lunar prospector	SCIENCE			English	Article							ISOSTATIC COMPENSATION; BASIN FORMATION; CLEMENTINE; TECTONICS; EVOLUTION; MOMENTS; VENUS	An improved gravity model from Doppler tracking of the Lunar Prospector (LP) spacecraft reveals three new Large mass concentrations (mascons) on the nearside of the moon beneath the impact basins Mare Humboltianum, Mendel-Ryberg, and Schiller-Zucchius, where the Latter basin has no visible mare fill. Although there is no direct measurement of the Lunar farside gravity, LP partially resolves four mascons in the Large farside basins of Hertzsprung, Coulomb-Sarton, Freundlich-Sharonov, and Mare Moscoviense. The center of each of these basins contains a gravity maximum relative to the surrounding basin. The improved normalized polar moment of inertia (0.3932 +/- 0.0002) is consistent with an iron core with a radius of 220 to 450 kilometers.	CALTECH, Jet Prop Lab, Pasadena, CA 91109 USA; Lunar Res Inst, Gilroy, CA 95020 USA; Univ Arizona, Lunar & Planetary Lab, Tucson, AZ 85721 USA	California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL); University of Arizona	Konopliv, AS (corresponding author), CALTECH, Jet Prop Lab, 4800 Oak Grove Dr, Pasadena, CA 91109 USA.							AKIM EL, 1966, DOKL AKAD NAUK SSSR+, V170, P799; Arkani-Hamed J, 1998, J GEOPHYS RES-PLANET, V103, P3709, DOI 10.1029/97JE02815; ARKANIHAMED J, 1973, P LUNAR PLANET SCI C, V4, P2673; Bills BG, 1995, J GEOPHYS RES-PLANET, V100, P26297, DOI 10.1029/95JE03100; BILLS BG, 1980, J GEOPHYS RES, V85, P1013, DOI 10.1029/JB085iB02p01013; BINDER AB, 1980, J GEOPHYS RES, V85, P4872, DOI 10.1029/JB085iB09p04872; BRATT SR, 1985, J GEOPHYS RES-SOLID, V90, P2415, DOI 10.1029/JB090iB14p12415; BRATT SR, 1985, J GEOPHYS RES-SOLID, V90, P3049, DOI 10.1029/JB090iB04p03049; Cameron AGW, 1997, ICARUS, V126, P126, DOI 10.1006/icar.1996.5642; CAMERON AGW, 1998, 29 LUN PLAN SCI C LU; Canup RM, 1996, ICARUS, V119, P427, DOI 10.1006/icar.1996.0028; DICKEY JO, 1994, SCIENCE, V265, P482, DOI 10.1126/science.265.5171.482; HEAD JW, 1976, REV GEOPHYS, V14, P265, DOI 10.1029/RG014i002p00265; HOOD LL, 1987, J GEOPHYS RES, V92, P396; Kaula W.M., 1966, THEORY SATELLITE GEO; KAULA WM, 1969, SCIENCE, V166, P1581, DOI 10.1126/science.166.3913.1581; KUCINSKAS AB, 1994, ICARUS, V112, P104, DOI 10.1006/icar.1994.1172; Kucinskas AB, 1996, J GEOPHYS RES-PLANET, V101, P4725, DOI 10.1029/95JE02979; Lawson CL., 1995, SOLVING LEAST SQUARE; Lemoine FGR, 1997, J GEOPHYS RES-PLANET, V102, P16339, DOI 10.1029/97JE01418; Melosh H.J., 1978, LUNAR PLANETARY SCI, V9, P3513; MELOSH HJ, 1978, GEOPHYS RES LETT, V5, P985, DOI 10.1029/GL005i011p00985; Moyer T.D., 1971, MATH FORMULATION DOU; MUELLER S, 1988, J GEOPHYS RES-SOLID, V93, P6338, DOI 10.1029/JB093iB06p06338; MULLER PM, 1968, SCIENCE, V161, P680, DOI 10.1126/science.161.3842.680; Neumann GA, 1996, J GEOPHYS RES-PLANET, V101, P16841, DOI 10.1029/96JE01246; Newsom H.E., 1986, ORIGIN EARTH MOON, P203; PHILLIPS RJ, 1972, J GEOPHYS RES, V77, P7106, DOI 10.1029/JB077i035p07106; RIES JC, 1992, GEOPHYS RES LETT, V19, P529, DOI 10.1029/92GL00259; Smith DE, 1997, J GEOPHYS RES-PLANET, V102, P1591, DOI 10.1029/96JE02940; SOLOMON SC, 1982, J GEOPHYS RES, V87, P3975, DOI 10.1029/JB087iB05p03975; SOLOMON SC, 1980, REV GEOPHYS, V18, P107, DOI 10.1029/RG018i001p00107; SOLOMON SC, 1979, J GEOPHYS RES, V84, P1667, DOI 10.1029/JB084iB04p01667; SPUDIS PD, 1994, SCIENCE, V266, P1848, DOI 10.1126/science.266.5192.1848; Taylor S. R., 1982, PLANETARY SCI LUNAR; Wieczorek MA, 1998, J GEOPHYS RES-PLANET, V103, P1715, DOI 10.1029/97JE03136; WILLEMANN RJ, 1981, P LUNAR PLANET SCI B, V12, P837; Williams JG, 1996, PLANET SPACE SCI, V44, P1077, DOI 10.1016/0032-0633(95)00154-9; Williams KK, 1998, ICARUS, V131, P107, DOI 10.1006/icar.1997.5856; WISE DU, 1970, J GEOPHYS RES, V75, P261, DOI 10.1029/JB075i002p00261; ZUBER MT, 1994, SCIENCE, V266, P1839, DOI 10.1126/science.266.5192.1839	41	217	269	2	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 4	1998	281	5382					1476	1480		10.1126/science.281.5382.1476	http://dx.doi.org/10.1126/science.281.5382.1476			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	116RJ	9727968				2022-12-28	WOS:000075738100032
J	Orr, PJ; Briggs, DEG; Kearns, SL				Orr, PJ; Briggs, DEG; Kearns, SL			Cambrian Burgess Shale animals replicated in clay minerals	SCIENCE			English	Article							FOSSIL PRESERVATION; EVOLUTION; TAPHONOMY; GREENLAND; TISSUE; DECAY	Although the evolutionary importance of the Burgess Share is universally acknowledged, there is disagreement on the mode of preservation of the fossils after burial. Elemental mapping demonstrates that the relative abundance of elements varies between different anatomical features of the specimens. These differences reflect the compositions of the minerals that replicated the decaying organism, which were controlled by contrasts in tissue chemistry. Delicate morphological details are replicated in the elemental maps, showing that authigenic mineralization was fundamental to preserving these fossils, even though some organic remains are also present.	Univ Bristol, Dept Earth Sci, Bristol BS8 1RJ, Avon, England	University of Bristol	Orr, PJ (corresponding author), Univ Oxford, Dept Earth Sci, Parks Rd, Oxford OX1 3PR, England.			Orr, Patrick/0000-0002-6740-1656				Allison P.A., 1991, TAPHONOMY RELEASING, DOI 10.1007/978-1-4899-5034-5; BEVERIDGE TJ, 1985, CAN J EARTH SCI, V22, P1893, DOI 10.1139/e85-204; Briggs D.E.G., 1994, FOSSILS BURGESS SHAL; BRIGGS DEG, 1993, LETHAIA, V26, P275, DOI 10.1111/j.1502-3931.1993.tb01532.x; BRIGGS DEG, 1994, PALAIOS, V9, P431, DOI 10.2307/3515135; Briggs DEG, 1997, J PALEONTOL, V71, P22, DOI 10.1017/S0022336000038919; BUDD G, 1993, NATURE, V364, P709, DOI 10.1038/364709a0; BUTTERFIELD NJ, 1990, PALEOBIOLOGY, V16, P272, DOI 10.1017/S0094837300009994; Butterfield NJ, 1996, LETHAIA, V29, P109, DOI 10.1111/j.1502-3931.1996.tb01845.x; Conway Morris S., 1998, CRUCIBLE CREATION BU; Conway Morris S., 1990, PALAEOBIOLOGY SYNTHE, P270; DAVIDSON EH, 1995, SCIENCE, V270, P1319, DOI 10.1126/science.270.5240.1319; Dunn KA, 1997, GEOLOGY, V25, P1119, DOI 10.1130/0091-7613(1997)025<1119:EOLFPB>2.3.CO;2; Fortey RA, 1996, BIOL J LINN SOC, V57, P13, DOI 10.1006/bijl.1995.0002; GABBOTT SE, 1995, NATURE, V374, P800, DOI 10.1038/374800a0; Gabbott SE, 1998, PALAEONTOLOGY, V41, P631; HOU XG, 1991, ZOOL SCRIPTA, V20, P295; HOU XG, 1997, FOSSILS STRATA, V45; JACKSON KS, 1978, EARTH-SCI REV, V14, P97, DOI 10.1016/0012-8252(78)90001-6; KONHAUSER KO, 1993, GEOLOGY, V21, P1103, DOI 10.1130/0091-7613(1993)021<1103:MSAMPB>2.3.CO;2; LAGALY G, 1984, PHILOS T R SOC A, V311, P315, DOI 10.1098/rsta.1984.0031; MORRIS SC, 1995, PHILOS T ROY SOC B, V347, P305, DOI 10.1098/rstb.1995.0029; MORRIS SC, 1986, PALAEONTOLOGY, V29, P423; MORRIS SC, 1977, SPEC PAP PALAEONTOL, V20; MORTLAND M. M., 1970, Advances in Agronomy, V22, P75, DOI 10.1016/S0065-2113(08)60266-7; ODOM IE, 1984, PHILOS T R SOC A, V311, P391, DOI 10.1098/rsta.1984.0036; Towe KM, 1996, LETHAIA, V29, P107; Valentine JW, 1996, DEV BIOL, V173, P373, DOI 10.1006/dbio.1996.0033; Walcott Charles D., 1912, Smithsonian Institution Miscellaneous Collection, V57; WHITTINGTON HB, 1971, 1969 P N AM PAL CONV, V1, P1170; Williams A., 1997, LETHAIA, V29, P349; Wray GA, 1996, SCIENCE, V274, P568, DOI 10.1126/science.274.5287.568	32	162	168	1	33	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 21	1998	281	5380					1173	1175		10.1126/science.281.5380.1173	http://dx.doi.org/10.1126/science.281.5380.1173			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	113CE	9712577				2022-12-28	WOS:000075531200047
J	Winzeler, EA; Richards, DR; Conway, AR; Goldstein, AL; Kalman, S; McCullough, MJ; McCusker, JH; Stevens, DA; Wodicka, L; Lockhart, DJ; Davis, RW				Winzeler, EA; Richards, DR; Conway, AR; Goldstein, AL; Kalman, S; McCullough, MJ; McCusker, JH; Stevens, DA; Wodicka, L; Lockhart, DJ; Davis, RW			Direct allelic variation scanning of the yeast genome	SCIENCE			English	Article							SACCHAROMYCES-CEREVISIAE; OLIGONUCLEOTIDE ARRAYS; GENETIC-LINKAGE; HUMAN DNA; SEQUENCE; HYBRIDIZATION; POLYMORPHISMS; SELECTION; STRAINS	As more genomes are sequenced. the identification and characterization of the causes of heritable variation within a species will be increasingly important. It is demonstrated that allelic variation in any two isolates of a species can be scanned, mapped, and scored directly and efficiently without allele-specific polymerase chain reaction. without creating new strains or constructs, and without knowing the specific nature of the variation. A total of 3714 biallelic markers, spaced about every 3.5 kilobases, were identified by analyzing the patterns obtained when total genomic DNA from two different strains of yeast was hybridized to high-density oligonucleotide arrays. The markers were then used to simultaneously map a multidrug-resistance locus and four other Loci with high resolution (11 to 64 kilobases).	Stanford Univ, Dept Biochem, Sch Med, Stanford, CA 94305 USA; Duke Univ, Med Ctr, Dept Microbiol, Durham, NC 27710 USA; Stanford Univ, Dept Med, Sch Med, Stanford, CA 94305 USA; Affymetrix, Santa Clara, CA 95051 USA	Stanford University; Duke University; Stanford University; Affymetrix	Winzeler, EA (corresponding author), Stanford Univ, Dept Biochem, Sch Med, Stanford, CA 94305 USA.		Winzeler, Elizabeth/AAP-6752-2020; McCullough, Michael/C-3295-2014	Winzeler, Elizabeth/0000-0002-4049-2113; McCullough, Michael/0000-0001-7829-4684	NHGRI NIH HHS [HG00185-01, 1R01 HG01633] Funding Source: Medline; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG001633] Funding Source: NIH RePORTER	NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		ALANI E, 1987, GENETICS, V116, P541, DOI 10.1534/genetics.112.541.test; BALZI E, 1994, J BIOL CHEM, V269, P2206; BOEHNKE M, 1994, AM J HUM GENET, V55, P379; CHATTOO BB, 1979, GENETICS, V93, P51; Chee M, 1996, SCIENCE, V274, P610, DOI 10.1126/science.274.5287.610; Cherry JM, 1997, NATURE, V387, P67, DOI 10.1038/387s067; Collins FS, 1997, SCIENCE, V278, P1580, DOI 10.1126/science.278.5343.1580; CONNER BJ, 1983, P NATL ACAD SCI-BIOL, V80, P278, DOI 10.1073/pnas.80.1.278; Dietrich FS, 1997, NATURE, V387, P78, DOI 10.1038/387s078; FODOR SPA, 1991, SCIENCE, V251, P767, DOI 10.1126/science.1990438; Lockhart DJ, 1996, NAT BIOTECHNOL, V14, P1675, DOI 10.1038/nbt1296-1675; MCCUSKER JH, 1994, GENETICS, V136, P1261; MORTIMER RK, 1986, GENETICS, V113, P35; NELSON SF, 1993, NAT GENET, V4, P11, DOI 10.1038/ng0593-11; ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766; PEASE AC, 1994, P NATL ACAD SCI USA, V91, P5022, DOI 10.1073/pnas.91.11.5022; PETES TD, 1991, MOL CELLULAR BIOL YE, V1, P407; Schafer AJ, 1998, NAT BIOTECHNOL, V16, P33, DOI 10.1038/nbt0198-33; Sherman F., 1974, METHODS YEAST GENETI; Underhill PA, 1997, GENOME RES, V7, P996, DOI 10.1101/gr.7.10.996; Wang DG, 1998, SCIENCE, V280, P1077, DOI 10.1126/science.280.5366.1077; WINZELER EA, UNPUB; Wodicka L, 1997, NAT BIOTECHNOL, V15, P1359, DOI 10.1038/nbt1297-1359	23	306	334	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 21	1998	281	5380					1194	1197		10.1126/science.281.5380.1194	http://dx.doi.org/10.1126/science.281.5380.1194			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	113CE	9712584				2022-12-28	WOS:000075531200054
J	Wolf, E; Vassilev, A; Makino, Y; Sali, A; Nakatani, Y; Burley, SK				Wolf, E; Vassilev, A; Makino, Y; Sali, A; Nakatani, Y; Burley, SK			Crystal structure of a GCN5-related N-acetyltransferase: Serratia marcescens aminoglycoside 3-N-acetyltransferase	CELL			English	Article							COENZYME-A BINDING; PROTEIN STRUCTURES; ANOMALOUS DIFFRACTION; HISTONE ACETYLATION; GENE; RECOGNITION; CHROMATIN; ALIGNMENT; PROGRAM; ERRORS	The X-ray structure of a canonical GCN5-related N-acetyltransferase (GNAT), Serratia marcescens aminoglycoside 3-N-acetyltransferase, bound to coenzyme A (CoA) has been determined at 2.3 Angstrom resolution. The single domain alpha/beta protein resembles a cupped right hand wrapped around a cylinder and consists of a highly curved, six-stranded beta sheet of mixed polarity that is sandwiched between four alpha helices. The structure includes all four conserved GNAT motifs (C, D, A, and B) and represents the catalytic core of this large enzyme superfamily. Acetyl CoA recognition is mediated by a beta alpha structure derived from GNAT motif A, which presents an invariant Arg/Gln-X-X-Gly-X-Gly/Ala segment for hydrogen bonding with the cofactor. Motif B contributes acidic residues to the binding site for the positively charged antibiotic substrate.	Rockefeller Univ, Lab Mol Biophys, New York, NY 10021 USA; Rockefeller Univ, Howard Hughes Med Inst, New York, NY 10021 USA; NICHHD, Lab Mol Growth Regulat, NIH, Bethesda, MD 20892 USA	Rockefeller University; Howard Hughes Medical Institute; Rockefeller University; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Burley, SK (corresponding author), Rockefeller Univ, Lab Mol Biophys, 1230 York Ave, New York, NY 10021 USA.		Wolf, Eva/G-7340-2014	Vassilev, Alex/0000-0002-5483-3791; Burley, Stephen K./0000-0002-2487-9713	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054762, R29GM054762] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM54762] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; ALLFREY VG, 1964, P NATL ACAD SCI USA, V51, P786, DOI 10.1073/pnas.51.5.786; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Brunger AT, 1997, METHOD ENZYMOL, V277, P366, DOI 10.1016/S0076-6879(97)77021-6; BRUNGER AT, 1998, IN PRESS ACTA CRYS D; Cohen SL, 1996, STRUCTURE, V4, P1013, DOI 10.1016/S0969-2126(96)00108-6; Coleman CS, 1996, BIOCHEM J, V316, P697, DOI 10.1042/bj3160697; De Angelis J, 1998, J BIOL CHEM, V273, P3045, DOI 10.1074/jbc.273.5.3045; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; Engel C, 1996, CURR OPIN STRUC BIOL, V6, P790, DOI 10.1016/S0959-440X(96)80009-1; GILSON MK, 1988, J COMPUT CHEM, V9, P327, DOI 10.1002/jcc.540090407; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; HENDRICKSON WA, 1991, SCIENCE, V254, P51, DOI 10.1126/science.1925561; Hilfiker A, 1997, EMBO J, V16, P2054, DOI 10.1093/emboj/16.8.2054; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; JANIN J, 1995, BIOCHIMIE, V77, P497, DOI 10.1016/0300-9084(96)88166-1; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kuo MH, 1998, GENE DEV, V12, P627, DOI 10.1101/gad.12.5.627; LAMBERT T, 1993, ANTIMICROB AGENTS CH, V37, P2093, DOI 10.1128/AAC.37.10.2093; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; Leslie AGW, 1990, CRYSTALLOGRAPHIC COM; Lu L, 1996, J BIOL CHEM, V271, P18920, DOI 10.1074/jbc.271.31.18920; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Michael G., 1975, ENZYMES, V11, P61, DOI 10.1016/S1874-6047(08)60210-3; Miller GH, 1997, CLIN INFECT DIS, V24, pS46, DOI 10.1093/clinids/24.Supplement_1.S46; Mizzen CA, 1998, CELL MOL LIFE SCI, V54, P6, DOI 10.1007/s000180050121; Neuwald AF, 1997, TRENDS BIOCHEM SCI, V22, P154, DOI 10.1016/S0968-0004(97)01034-7; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NIKOLOV DB, 1992, NATURE, V360, P40, DOI 10.1038/360040a0; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; RATHER PN, 1993, J BACTERIOL, V175, P6492, DOI 10.1128/jb.175.20.6492-6498.1993; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Sanchez R, 1997, PROTEINS, P50; SANDER C, 1991, PROTEINS, V9, P56, DOI 10.1002/prot.340090107; SCHWOCHO LR, 1995, ANTIMICROB AGENTS CH, V39, P1790, DOI 10.1128/AAC.39.8.1790; SHAW KJ, 1993, MICROBIOL REV, V57, P138, DOI 10.1128/MMBR.57.1.138-163.1993; SIPPL MJ, 1993, PROTEINS, V17, P355, DOI 10.1002/prot.340170404; Smith ER, 1998, P NATL ACAD SCI USA, V95, P3561, DOI 10.1073/pnas.95.7.3561; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; TERAN FJ, 1992, ANTIMICROB CHEMOTHER, V28, P333; TERCERO JC, 1992, J BIOL CHEM, V267, P20270; Wade PA, 1997, TRENDS BIOCHEM SCI, V22, P128, DOI 10.1016/S0968-0004(97)01016-5; Wang L, 1998, GENE DEV, V12, P640, DOI 10.1101/gad.12.5.640; WILLIAMS JW, 1979, J ANTIBIOT, V32, P1147, DOI 10.7164/antibiotics.32.1147; WOLODKO WT, 1994, J BIOL CHEM, V269, P10883; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0	49	184	196	1	22	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 21	1998	94	4					439	449		10.1016/S0092-8674(00)81585-8	http://dx.doi.org/10.1016/S0092-8674(00)81585-8			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	113GB	9727487	Bronze			2022-12-28	WOS:000075541100006
J	Prandoni, P; Bagatella, P; Bernardi, E; Girolami, B; Rossi, L; Scarano, L; Marchiori, A; Piccioli, A; Girolami, A				Prandoni, P; Bagatella, P; Bernardi, E; Girolami, B; Rossi, L; Scarano, L; Marchiori, A; Piccioli, A; Girolami, A			Use of an algorithm for administering subcutaneous heparin in the treatment of deep venous thrombosis	ANNALS OF INTERNAL MEDICINE			English	Article							PROXIMAL-VEIN THROMBOSIS; INITIAL TREATMENT; NOMOGRAM; THERAPY; TRIAL; HOME	Background: Despite the widespread use of subcutaneous heparin in the initial treatment of deep venous thrombosis, there are no guidelines for achieving adequate anticoagulation with this drug. Objective: To implement a weight-based algorithm for the administration of subcutaneous unfractionated heparin after an intravenous loading dose. Design: Prospective cohort study. Setting: University hospital. Participants: 70 outpatients with proximal venous thrombosis. Intervention: An intravenous bolus of heparin followed by a subcutaneous injection of heparin in doses adjusted for body weight. Subsequent adjustments of the subcutaneous heparin dose were scheduled twice daily according to the algorithm; the activated partial thromboplastin time (aPTT) was measured in the mid-interval (target range, 50 to 90 seconds). Results: The therapeutic threshold aPTT (greater than or equal to 50 seconds) was achieved in 61 patients (87%) within 24 hours and in 69 patients (99%) within 48 hours. In 7 patients (10%), a supratherapeutic aPTT lasted more than 12 hours. No major bleeding episodes or cases of heparin-induced thrombocytopenia were seen. Three patients (4.3% [95% CI, 0.9 % to 12.0 %]) had recurrent thromboembolism during 3 months of follow-up. Conclusion: The administration of subcutaneous heparin according to a weight-based algorithm allows the rapid achievement of effective and safe anticoagulation in patients with deep venous thrombosis.	Univ Padua, Sch Med, Inst Med Semeiot, I-35128 Padua, Italy	University of Padua	Prandoni, P (corresponding author), Univ Padua, Sch Med, Inst Med Semeiot, Via Osped Civile 105, I-35128 Padua, Italy.							CIPOLLE RJ, 1981, CLIN PHARMACOL THER, V29, P387, DOI 10.1038/clpt.1981.53; CRUICKSHANK MK, 1991, ARCH INTERN MED, V151, P333, DOI 10.1001/archinte.151.2.333; Ginsberg JS, 1996, NEW ENGL J MED, V335, P1816, DOI 10.1056/NEJM199612123352407; HIRSH J, 1995, CHEST, V108, pS258, DOI 10.1378/chest.108.4_Supplement.258S; HOMMES DW, 1992, ANN INTERN MED, V116, P279, DOI 10.7326/0003-4819-116-4-279; Hull RD, 1997, ARCH INTERN MED, V157, P2317, DOI 10.1001/archinte.157.20.2317; Hull RD, 1997, ARCH INTERN MED, V157, P2562, DOI 10.1001/archinte.157.22.2562; HULL RD, 1986, NEW ENGL J MED, V315, P1109, DOI 10.1056/NEJM198610303151801; HULL RD, 1992, ARCH INTERN MED, V152, P1589, DOI 10.1001/archinte.152.8.1589; Koopman MMW, 1996, NEW ENGL J MED, V334, P682, DOI 10.1056/NEJM199603143341102; Levine M, 1996, NEW ENGL J MED, V334, P677, DOI 10.1056/NEJM199603143341101; LEVINE MN, 1994, ARCH INTERN MED, V154, P49, DOI 10.1001/archinte.154.1.49; PRANDONI P, 1993, CIRCULATION, V88, P1730, DOI 10.1161/01.CIR.88.4.1730; Raschke RA, 1996, ARCH INTERN MED, V156, P1645, DOI 10.1001/archinte.156.15.1645; RASCHKE RA, 1993, ANN INTERN MED, V119, P874, DOI 10.7326/0003-4819-119-9-199311010-00002; tenCate JW, 1997, NEW ENGL J MED, V337, P657; VREIM CE, 1990, JAMA-J AM MED ASSOC, V263, P2753; Weitz JI, 1997, NEW ENGL J MED, V337, P688, DOI 10.1056/NEJM199709043371007; White RH, 1997, ARCH INTERN MED, V157, P2468, DOI 10.1001/archinte.157.21.2468	19	19	20	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 15	1998	129	4					299	302		10.7326/0003-4819-129-4-199808150-00006	http://dx.doi.org/10.7326/0003-4819-129-4-199808150-00006			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	109NP	9729183				2022-12-28	WOS:000075329100006
J	Woo, RA; McLure, KG; Lees-Miller, SP; Rancourt, DE; Lee, PWK				Woo, RA; McLure, KG; Lees-Miller, SP; Rancourt, DE; Lee, PWK			DNA-dependent protein kinase acts upstream of p53 in response to DNA damage	NATURE			English	Article							V(D)J RECOMBINATION; GENE-EXPRESSION; SCID MUTATION; CELL-LINES; REPAIR	The tumour suppressor p53 becomes activated as a transcription factor in response to DNA damage(1-3), but the mechanism for this activation is unclear. A good candidate for an upstream activator of p53 is the DNA-dependent protein kinase (DNA-PK) that depends on the presence of DNA breaks for its activity(4-6). Here we investigate the link between DNA damage and the activation of DNA-PK and of p53. To determine whether DNA-PK is an upstream mediator of the p53 DNA-damage response, we analysed a severe combined-immunodeficiency (SCID) mouse cen Line, SCGR11 (reb 7, 8), and the human glioma cell line M059J (ref. 9), Both cell lines lack any detectable DNA-PK activity. We find that p53 is incapable of binding to DNA in the absence of DNA-PK, that DNA-PK is necessary but not sufficient for activation of p53 sequence-specific DNA binding, and that this activation occurs in response to DNA damage. Our results establish DNA-PK as a link between DNA damage and p53 activation, and reveal the existence of a mammalian DNA-damage-response pathway.	Univ Calgary, Dept Microbiol & Infect Dis, Calgary, AB T2N 4N1, Canada; Univ Calgary, Dept Biol Sci, Calgary, AB T2N 4N1, Canada; Univ Calgary, Dept Biochem & Mol Biol, Calgary, AB T2N 4N1, Canada	University of Calgary; University of Calgary; University of Calgary	Lee, PWK (corresponding author), Univ Calgary, Dept Microbiol & Infect Dis, Calgary, AB T2N 4N1, Canada.			Lees-Miller, Susan/0000-0001-5809-2516				ABBONDANZO SJ, 1993, METHOD ENZYMOL, V225, P803; Anderson Carl W., 1992, Critical Reviews in Eukaryotic Gene Expression, V2, P283; BLUNT T, 1995, CELL, V80, P813, DOI 10.1016/0092-8674(95)90360-7; Bogue MA, 1996, GENE DEV, V10, P553, DOI 10.1101/gad.10.5.553; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; ELDIERY WS, 1993, CELL, V75, P817; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; Guidos CJ, 1996, GENE DEV, V10, P2038, DOI 10.1101/gad.10.16.2038; HARPER JW, 1993, CELL, V75, P805; HENDRICKSON EA, 1991, P NATL ACAD SCI USA, V88, P4061, DOI 10.1073/pnas.88.10.4061; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; Huang LC, 1996, CANCER RES, V56, P2940; Jhappan C, 1997, NAT GENET, V17, P483, DOI 10.1038/ng1297-483; KASTAN MB, 1991, CANCER RES, V51, P6304; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; LEESMILLER SP, 1995, SCIENCE, V267, P1183, DOI 10.1126/science.7855602; McLure KG, 1998, EMBO J, V17, P3342, DOI 10.1093/emboj/17.12.3342; MILNER J, 1991, MOL CELL BIOL, V11, P12, DOI 10.1128/MCB.11.1.12; MOROZOV VE, 1994, J BIOL CHEM, V269, P16684; Nacht M, 1996, GENE DEV, V10, P2055, DOI 10.1101/gad.10.16.2055; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; SKUP D, 1980, P NATL ACAD SCI-BIOL, V77, P152, DOI 10.1073/pnas.77.1.152; TISHLER RB, 1993, CANCER RES, V53, P2212; WONG H, 1994, ANAL BIOCHEM, V223, P251, DOI 10.1006/abio.1994.1581; Zhu CM, 1996, CELL, V86, P379, DOI 10.1016/S0092-8674(00)80111-7	28	284	302	21	33	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 13	1998	394	6694					700	704		10.1038/29343	http://dx.doi.org/10.1038/29343			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	110MD	9716137				2022-12-28	WOS:000075384200050
J	Stone, JH				Stone, JH			HELLP syndrome: Hemolysis, elevated liver enzymes, and low platelets	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SEVERE PREECLAMPSIA-ECLAMPSIA; PREGNANCY; HYPERTENSION; COUNT; ABNORMALITIES; MANAGEMENT; WOMEN		Johns Hopkins Univ, Dept Med, Div Rheumatol, Baltimore, MD 21205 USA	Johns Hopkins University	Stone, JH (corresponding author), Johns Hopkins Univ, Dept Med, Div Rheumatol, 1830 E Monument St,Suite 7500, Baltimore, MD 21205 USA.							BALLERMANN BJ, 1996, PRINCIPLES PRACTICE, P396; BARTON JR, 1992, AM J OBSTET GYNECOL, V167, P1538, DOI 10.1016/0002-9378(92)91735-S; BELL WR, 1991, NEW ENGL J MED, V325, P398, DOI 10.1056/NEJM199108083250605; Davidge ST, 1996, AM J OBSTET GYNECOL, V174, P1008, DOI 10.1016/S0002-9378(96)70341-1; DEWOLF F, 1980, BRIT J OBSTET GYNAEC, V87, P678; DEWOLF F, 1973, AM J OBSTET GYNECOL, V117, P833, DOI 10.1016/0002-9378(73)90500-0; Fish Ray, 1993, Journal of Emergency Medicine, V11, P169, DOI 10.1016/0736-4679(93)90515-9; GOODLIN RC, 1991, AM J OBSTET GYNECOL, V164, P1577, DOI 10.1016/0002-9378(91)91439-4; GREER IA, 1985, AM J OBSTET GYNECOL, V152, P113, DOI 10.1016/S0002-9378(85)80195-2; Hinchey J, 1996, NEW ENGL J MED, V334, P494, DOI 10.1056/NEJM199602223340803; KINCAIDSMITH P, 1991, AM J KIDNEY DIS, V17, P144, DOI 10.1016/S0272-6386(12)81119-X; KOULLAPIS EN, 1982, BRIT J OBSTET GYNAEC, V89, P617, DOI 10.1111/j.1471-0528.1982.tb04715.x; MANAS KJ, 1985, NEW ENGL J MED, V312, P424, DOI 10.1056/NEJM198502143120707; MARTIN JN, 1990, AM J OBSTET GYNECOL, V162, P126, DOI 10.1016/0002-9378(90)90835-U; Martin JN, 1997, AM J OBSTET GYNECOL, V177, P1011, DOI 10.1016/S0002-9378(97)70005-X; McCrae KR, 1997, SEMIN HEMATOL, V34, P148; MILLIEZ J, 1990, OBSTET GYNECOL, V75, P975; PRITCHARD JA, 1954, NEW ENGL J MED, V250, P89, DOI 10.1056/NEJM195401212500301; REUBINOFF BE, 1991, INT J GYNECOL OBSTET, V36, P95, DOI 10.1016/0020-7292(91)90762-T; Roberts JM, 1995, HOSP PRACT, V30, P25, DOI 10.1080/21548331.1995.11443299; Roberts JM, 1995, HOSP PRACT, V30, P31; SIBAI BM, 1995, AM J OBSTET GYNECOL, V172, P125, DOI 10.1016/0002-9378(95)90099-3; SIBAI BM, 1986, AM J OBSTET GYNECOL, V155, P501, DOI 10.1016/0002-9378(86)90266-8; SIBAI BM, 1990, AM J OBSTET GYNECOL, V162, P311, DOI 10.1016/0002-9378(90)90376-I; SIBAI BM, 1993, AM J OBSTET GYNECOL, V169, P1000, DOI 10.1016/0002-9378(93)90043-I; TAYLOR RN, 1990, J CLIN ENDOCR METAB, V71, P1675, DOI 10.1210/jcem-71-6-1675; THIAGARAJAH S, 1984, AM J OBSTET GYNECOL, V150, P1; VISSER W, 1995, BRIT J OBSTET GYNAEC, V102, P111, DOI 10.1111/j.1471-0528.1995.tb09062.x; WEINSTEIN L, 1982, AM J OBSTET GYNECOL, V142, P159, DOI 10.1016/S0002-9378(16)32330-4	29	49	56	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 12	1998	280	6					559	562		10.1001/jama.280.6.559	http://dx.doi.org/10.1001/jama.280.6.559			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	108AY	9707148				2022-12-28	WOS:000075244900034
J	Guillebaud, J				Guillebaud, J			Time for emergency contraception with levonorgestrel alone	LANCET			English	Editorial Material									UCL, Dept Gynaecol, London W1P 1LB, England; Margaret Pyke Ctr Study & Training Family Planning, London W1P 1LB, England	University of London; University College London; University of London; University College London	Guillebaud, J (corresponding author), UCL, Dept Gynaecol, London W1P 1LB, England.							Glasier A, 1998, NEW ENGL J MED, V339, P1, DOI 10.1056/NEJM199807023390101; Glasier A, 1997, NEW ENGL J MED, V337, P1058, DOI 10.1056/NEJM199710093371507; Grimes DA, 1997, NEW ENGL J MED, V337, P1078, DOI 10.1056/NEJM199710093371510; HO PC, 1993, HUM REPROD, V8, P389, DOI 10.1093/oxfordjournals.humrep.a138057; KUBBA A, 1998, RECOMMENDATIONS CLIN; MANN R, 1991, PHARM MED LAW, V8, P103; PAINTIN D, 1995, PROVISION EMERGENCY; YUZPE AA, 1982, FERTIL STERIL, V37, P508	8	14	14	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	AUG 8	1998	352	9126					416	417		10.1016/S0140-6736(98)22032-0	http://dx.doi.org/10.1016/S0140-6736(98)22032-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	108EA	9708743				2022-12-28	WOS:000075252000002
J	Delanty, N; Vaughan, CJ; French, JA				Delanty, N; Vaughan, CJ; French, JA			Medical causes of seizures	LANCET			English	Review							NEW-ONSET SEIZURES; NONCONVULSIVE STATUS EPILEPTICUS; ALCOHOL-WITHDRAWAL SEIZURES; INTENSIVE-CARE UNIT; CONTINUOUS EEG; EPILEPSY; COMPLICATIONS; MAGNESIUM; EMERGENCY; PHENYTOIN	Seizures are commonly encountered in patients who do not have epilepsy. Factors that may provoke such seizures include organ failure, electrolyte imbalance, medication and medication withdrawal, and hypersensitive encephalopathy. There is usually one underlying cause, which may be reversible in some patients. A full assessment should be done to rule out primary neurological disease. Treatment of seizures in medically ill patients is aimed at correction of the underlying cause with appropriate short-term anticonvulsant medication. Phenytoin is ineffective in the management of seizures secondary to alcohol withdrawal, and in those due to theophylline or isoniazid toxicity. Control of blood pressure is important in patients with renal failure and seizures. Non-convulsive status epilepticus should be considered in any patient with confusion or coma of unclear cause, and electroencephalography should be done at the earliest opportunity. Most ill patients with secondary seizures do not have epilepsy, and this should be explained to patients and their families. Only those patients with recurrent seizures and uncorrectable predisposing factors need long-term treatment with anticonvulsant medication.	Hosp Univ Penn, Dept Neurol, Philadelphia, PA 19104 USA; Cornell Univ, Med Ctr, New York Hosp, Dept Med, New York, NY 10021 USA	University of Pennsylvania; Pennsylvania Medicine; Cornell University; NewYork-Presbyterian Hospital	Delanty, N (corresponding author), Hosp Univ Penn, Dept Neurol, 3400 Spruce St, Philadelphia, PA 19104 USA.	normandy@mail.med.upenn.edu	Delanty, Norman/F-8756-2011; French, Jacqueline A/G-6795-2013	French, Jacqueline A/0000-0003-2242-8027; Delaney, Norman/0000-0002-3953-9842				AITKEN ML, 1987, CHEST, V91, P10, DOI 10.1378/chest.91.1.10; ALLDREDGE BK, 1989, NEUROLOGY, V39, P1037, DOI 10.1212/WNL.39.8.1037; ALLDREDGE BK, 1989, AM J MED, V87, P645, DOI 10.1016/S0002-9343(89)80397-3; Avoli M, 1997, CAN J PHYSIOL PHARM, V75, P526, DOI 10.1139/cjpp-75-5-526; AVOLI M, 1991, ANN NEUROL, V30, P589, DOI 10.1002/ana.410300412; Balzan MV, 1996, POSTGRAD MED J, V72, P470, DOI 10.1136/pgmj.72.850.470; BECCARI M, 1994, INT J ARTIF ORGANS, V17, P5, DOI 10.1177/039139889401700102; BERGEN DC, 1994, INT J ARTIF ORGANS, V17, P247, DOI 10.1177/039139889401700501; Berkovic SF, 1997, CURR OPIN NEUROL, V10, P110, DOI 10.1097/00019052-199704000-00007; BLECK TP, 1993, CRIT CARE MED, V21, P98, DOI 10.1097/00003246-199301000-00019; Bleck TP, 1996, BAILLIERE CLIN NEUR, V5, P565; BODNER RA, 1995, NEUROLOGY, V45, P219, DOI 10.1212/WNL.45.2.219; Boggs J, 1997, TREATMENT EPILEPSY P, P753; Boggs JG, 1997, EPILEPSIA, V38, pS55, DOI 10.1111/j.1528-1157.1997.tb04540.x; Brust J C, 1992, Trans Am Clin Climatol Assoc, V103, P176; Bylesjo I, 1996, EPILEPSIA, V37, P230, DOI 10.1111/j.1528-1157.1996.tb00018.x; CELESIA GG, 1988, ARCH NEUROL-CHICAGO, V45, P781, DOI 10.1001/archneur.1988.00520310099023; CHADWICK D, 1994, LANCET, V343, P89, DOI 10.1016/S0140-6736(94)90820-6; CHANCE JF, 1991, ANN EMERG MED, V20, P520, DOI 10.1016/S0196-0644(05)81606-3; Chinnery PF, 1997, J NEUROL NEUROSUR PS, V63, P559, DOI 10.1136/jnnp.63.5.559; CLINTON JE, 1987, ANN EMERG MED, V16, P319, DOI 10.1016/S0196-0644(87)80179-8; Cockey GH, 1996, AM J CLIN ONCOL-CANC, V19, P32, DOI 10.1097/00000421-199602000-00007; Cooling David S., 1993, Journal of Emergency Medicine, V11, P415, DOI 10.1016/0736-4679(93)90244-2; Cooper AJ, 1997, J ACCID EMERG MED, V14, P183; DAGGETT P, 1982, POSTGRAD MED J, V58, P737, DOI 10.1136/pgmj.58.686.737; DALMAU J, 1992, MEDICINE, V71, P59, DOI 10.1097/00005792-199203000-00001; Delanty N, 1997, NEUROLOGY, V49, P686, DOI 10.1212/WNL.49.3.686; DEVINSKY O, 1991, NEUROLOGY, V41, P369, DOI 10.1212/WNL.41.3.369; DICHTER MA, 1987, SCIENCE, V237, P157, DOI 10.1126/science.3037700; EARNEST MP, 1976, EPILEPSIA, V17, P387, DOI 10.1111/j.1528-1157.1976.tb04450.x; Elder GH, 1997, LANCET, V349, P1613, DOI 10.1016/S0140-6736(96)09070-8; Engel Jerome Jr., 1994, Emergency Medicine Clinics of North America, V12, P895; FAVALE E, 1995, NEUROLOGY, V45, P1926, DOI 10.1212/WNL.45.10.1926; FEINBERG WM, 1988, NEUROLOGY, V38, P127, DOI 10.1212/WNL.38.1.127; Freedland Eric S., 1993, Journal of Emergency Medicine, V11, P463, DOI 10.1016/0736-4679(93)90251-2; Freedland Eric S., 1993, Journal of Emergency Medicine, V11, P605, DOI 10.1016/0736-4679(93)90317-Z; FRENCH J, 1995, CURR OPIN NEUROL, V8, P117, DOI 10.1097/00019052-199504000-00005; GARCIA PA, 1994, NEUROL CLIN, V12, P85, DOI 10.1016/S0733-8619(18)30112-9; Gilbert DL, 1997, J PAIN SYMPTOM MANAG, V14, P118, DOI 10.1016/S0885-3924(97)00017-1; GRONDAHL TO, 1993, J NEUROSURG, V78, P938, DOI 10.3171/jns.1993.78.6.0938; HAAS HL, 1984, J PHYSIOL-LONDON, V354, P185, DOI 10.1113/jphysiol.1984.sp015371; Hagen N, 1997, J PAIN SYMPTOM MANAG, V14, P51, DOI 10.1016/S0885-3924(97)00001-8; Hall W, 1997, LANCET, V349, P1897, DOI 10.1016/S0140-6736(97)04572-8; Harris CR, 1997, J TOXICOL-CLIN TOXIC, V35, P321, DOI 10.3109/15563659709001220; HENRY JA, 1992, LANCET, V340, P384, DOI 10.1016/0140-6736(92)91469-O; Hinchey J, 1996, NEW ENGL J MED, V334, P494, DOI 10.1056/NEJM199602223340803; Hosford DA, 1997, CURR OPIN NEUROL, V10, P115, DOI 10.1097/00019052-199704000-00008; JACOBSEN M, 1994, OCCUP ENVIRON MED, V51, P429, DOI 10.1136/oem.51.6.429; Jagoda A, 1997, MT SINAI J MED, V64, P249; JORDAN KG, 1993, J CLIN NEUROPHYSIOL, V10, P445, DOI 10.1097/00004691-199310000-00006; Kaplan PW, 1996, EPILEPSIA, V37, P643, DOI 10.1111/j.1528-1157.1996.tb00628.x; KILPATRICK CJ, 1992, ARCH NEUROL-CHICAGO, V49, P509, DOI 10.1001/archneur.1992.00530290097017; King MA, 1997, LANCET, V350, P716, DOI 10.1016/S0140-6736(05)63516-7; Kirk Mark, 1997, Emergency Medicine Clinics of North America, V15, P427, DOI 10.1016/S0733-8627(05)70309-6; KIZER KW, 1994, WESTERN J MED, V161, P59; Koppel BS, 1996, EPILEPSIA, V37, P875, DOI 10.1111/j.1528-1157.1996.tb00041.x; KRAUSS GL, 1995, NEUROLOGY, V45, P594, DOI 10.1212/WNL.45.3.594; KRUMHOLZ A, 1991, ARCH NEUROL-CHICAGO, V48, P842, DOI 10.1001/archneur.1991.00530200084023; Kunisaki Thomas A., 1994, Emergency Medicine Clinics of North America, V12, P1027; LEO RJ, 1991, DICP ANN PHARMAC, V25, P351, DOI 10.1177/106002809102500403; LIPTON SA, 1994, NEW ENGL J MED, V330, P613; LIU JE, 1994, J NEUROL SCI, V123, P6, DOI 10.1016/0022-510X(94)90196-1; LOR E, 1994, ANN PHARMACOTHER, V28, P1035, DOI 10.1177/106002809402800908; Louis ED, 1996, ANN NEUROL, V40, P561, DOI 10.1002/ana.410400404; LUCAS MJ, 1995, NEW ENGL J MED, V333, P201, DOI 10.1056/NEJM199507273330401; MALOUF R, 1985, ANN NEUROL, V17, P421, DOI 10.1002/ana.410170502; Marquet P, 1996, LANCET, V348, P1070, DOI 10.1016/S0140-6736(96)05459-1; MCENERY PT, 1989, J PEDIATR-US, V115, P532, DOI 10.1016/S0022-3476(89)80276-8; MCNAMARA JO, 1994, J NEUROSCI, V14, P3413; Minton NA, 1996, AM J EMERG MED, V14, P606, DOI 10.1016/S0735-6757(96)90111-4; MITCHELL I, 1994, LANCET, V343, P579, DOI 10.1016/S0140-6736(94)91525-3; Moore PM, 1997, ANN NY ACAD SCI, V823, P1, DOI 10.1111/j.1749-6632.1997.tb48376.x; NG SKC, 1990, AM J EPIDEMIOL, V132, P47, DOI 10.1093/oxfordjournals.aje.a115642; Olsen RW, 1997, EPILEPSIA, V38, P399, DOI 10.1111/j.1528-1157.1997.tb01728.x; PACIA SV, 1994, NEUROLOGY, V44, P1408, DOI 10.1212/WNL.44.8.1408; PATCHELL RA, 1994, ANN NEUROL, V36, P688, DOI 10.1002/ana.410360503; Pellegrino Thomas R., 1994, Emergency Medicine Clinics of North America, V12, P925; Pennacchio LA, 1996, SCIENCE, V271, P1731, DOI 10.1126/science.271.5256.1731; Posner JB, 1995, NEUROLOGIC COMPLICAT; Repetto MR, 1997, J TOXICOL-CLIN TOXIC, V35, P1; RIGGS JE, 1995, NEUROLOGY GEN MED, P321; Roach GW, 1996, NEW ENGL J MED, V335, P1857, DOI 10.1056/NEJM199612193352501; RosenbergAdamsen S, 1996, BRIT J ANAESTH, V76, P552, DOI 10.1093/bja/76.4.552; Salloum E, 1997, CANCER, V79, P1009, DOI 10.1002/(SICI)1097-0142(19970301)79:5<1009::AID-CNCR18>3.0.CO;2-5; Schwartz RH, 1997, PEDIATRICS, V100, P705, DOI 10.1542/peds.100.4.705; Shakil AO, 1996, J HEPATOL, V24, P48, DOI 10.1016/S0168-8278(96)80185-1; Small SL, 1996, ANN NEUROL, V40, P575, DOI 10.1002/ana.410400406; Spiller HA, 1997, J TOXICOL-CLIN TOXIC, V35, P361, DOI 10.3109/15563659709043367; Stecker MM, 1998, EPILEPSIA, V39, P18, DOI 10.1111/j.1528-1157.1998.tb01269.x; Stein D A, 1991, Oncology (Williston Park), V5, P33; STEINLEIN OK, 1995, NAT GENET, V11, P201, DOI 10.1038/ng1095-201; SUTHERLAND MJ, 1994, ANAESTH INTENS CARE, V22, P733, DOI 10.1177/0310057X9402200620; Thomas RJ, 1997, ARCH INTERN MED, V157, P605, DOI 10.1001/archinte.157.6.605; Thomas SV, 1997, SEIZURE, V6, P107, DOI 10.1016/S1059-1311(97)80063-5; TOWNE AR, 1994, EPILEPSIA, V35, P27, DOI 10.1111/j.1528-1157.1994.tb02908.x; TRAYNELIS SF, 1988, J NEUROPHYSIOL, V59, P259, DOI 10.1152/jn.1988.59.1.259; Ueda Y, 1997, EPILEPSY RES, V26, P329, DOI 10.1016/S0920-1211(96)00901-1; VANPAESSCHEN W, 1995, EPILEPSIA, V36, P146; WATTANAGOON Y, 1994, T ROY SOC TROP MED H, V88, P426, DOI 10.1016/0035-9203(94)90415-4; WHANG R, 1994, ANN PHARMACOTHER, V28, P220, DOI 10.1177/106002809402800213; White CM, 1997, ANN PHARMACOTHER, V31, P178, DOI 10.1177/106002809703100209; WIJDICKS EFM, 1994, ANN NEUROL, V35, P239, DOI 10.1002/ana.410350219; Wijdicks EFM, 1996, NEUROLOGY, V47, P1523, DOI 10.1212/WNL.47.6.1523; WIJDICKS EFM, 1993, NEUROLOGY, V43, P1042, DOI 10.1212/WNL.43.5.1042; WINDEBANK AJ, 1995, NEUROLOGY GEN MED, P367; WONG MC, 1990, ARCH NEUROL-CHICAGO, V47, P640, DOI 10.1001/archneur.1990.00530060048015; WOOD JD, 1972, J NEUROCHEM, V19, P1527, DOI 10.1111/j.1471-4159.1972.tb05097.x; YOUNG D, 1994, NEUROSCIENCE, V58, P245, DOI 10.1016/0306-4522(94)90032-9; Young GB, 1996, NEUROLOGY, V47, P83; ZAK R, 1994, ANN NEUROL, V36, P113, DOI 10.1002/ana.410360122; ZIEVE L, 1969, ANN NY ACAD SCI, V162, P732, DOI 10.1111/j.1749-6632.1969.tb13005.x	111	109	113	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 1	1998	352	9125					383	390		10.1016/S0140-6736(98)02158-8	http://dx.doi.org/10.1016/S0140-6736(98)02158-8			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	106BU	9717943	hybrid			2022-12-28	WOS:000075110500042
J	Peters, R; Sikorski, R				Peters, R; Sikorski, R			Chemical weddings	SCIENCE			English	Article													Wood, David W/B-2992-2012					EVANS TC, IN PRESS PROTEIN SCI; Muir TW, 1998, P NATL ACAD SCI USA, V95, P6705, DOI 10.1073/pnas.95.12.6705; Severinov K, 1998, J BIOL CHEM, V273, P16205, DOI 10.1074/jbc.273.26.16205	3	1	1	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 17	1998	281	5375					367	368		10.1126/science.281.5375.367	http://dx.doi.org/10.1126/science.281.5375.367			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	102HR	9705714				2022-12-28	WOS:000074918800037
J	Beswick, MA; Choi, N; Harmer, CN; Hopkins, AD; McPartlin, M; Wright, DS				Beswick, MA; Choi, N; Harmer, CN; Hopkins, AD; McPartlin, M; Wright, DS			Low-temperature synthesis of zintl compounds with a single-source molecular precursor	SCIENCE			English	Article							POST-TRANSITION-ELEMENTS; MAIN-GROUP ELEMENTS; ANIONS; COMPLEXES; CLUSTERS; CUBANE	Thermolysis of the heterobimetallic phosphinidene complex {[Sb(PCy)(3)](2)L(i)6 . 6HNMe(2)} (Cy = C(6)H(11)) at 303 to 313 kelvin gives Zintl compounds containing (Sb(7))(3-) anions. The complex thus constitutes a stable molecular single-source precursor to Zintl compounds and provides a potential Low-temperature route to photoactive alkali metal antimonates. The new chemical reaction involved, which is driven thermodynamically by the formation of P-P bonds, has implications in the Low-temperature synthesis of other technologically important materials (such as gallium arsenide).	Univ Cambridge, Dept Chem, Cambridge CB2 1EW, England; Univ N London, Sch Chem, London N7 8DB, England	University of Cambridge; London Metropolitan University	Beswick, MA (corresponding author), Univ Cambridge, Dept Chem, Lensfield Rd, Cambridge CB2 1EW, England.	dsw1000@cus.cam.ac.uk						Allan RE, 1996, J CHEM SOC DALTON, P4153, DOI 10.1039/dt9960004153; ALLAN RE, 1996, J CHEM SOC CHEM COMM, P1501; AOLPHSON DG, 1976, J AM CHEM SOC, V98, P7234; BART JCJ, 1969, ACTA CRYSTALL B-STRU, VB 25, P762, DOI 10.1107/S0567740869002937; BECKER G, 1982, Z ANORG ALLG CHEM, V492, P15, DOI 10.1002/zaac.19824920103; Beswick MA, 1997, CHEM COMMUN, P1879; CHARLES S, 1993, J AM CHEM SOC, V115, P5837, DOI 10.1021/ja00066a067; CHARLES S, 1994, J AM CHEM SOC, V116, P8077, DOI 10.1021/ja00097a014; CORBETT JD, 1985, CHEM REV, V85, P383, DOI 10.1021/cr00069a003; Corbett JD, 1997, STRUCT BOND, V87, P157, DOI 10.1007/BFb0018034; CRITCHLOW SC, 1984, INORG CHEM, V23, P770, DOI 10.1021/ic00174a026; Driess M, 1996, ANGEW CHEM INT EDIT, V35, P2507, DOI 10.1002/anie.199625071; Driess M., 1996, ANGEW CHEM, V108, P2688; JOHANNIS A, 1892, CR HEBD ACAD SCI, V114, P587; JOHANNIS A, 1891, CR HEBD ACAD SCI, V113, P795; KANE D, UNPUB; Korber N, 1997, ANGEW CHEM INT EDIT, V36, P1512, DOI 10.1002/anie.199715121; KORBER N, 1997, ANGEW CHEM, V109, P1575; PAVER MA, 1995, ANGEW CHEM INT EDIT, V34, P1545, DOI 10.1002/anie.199515451; PAVER MA, 1995, ANGEW CHEM, V107, P1677; SCHERER OJ, 1992, STUD INORG CHEM, V14, P193; *SIEM AN INSTR, 1994, SHELXTL PC VERS 5 03; STALKE D, 1993, J APPL CRYSTALLOGR, V26, P615; SUMMER AH, 1968, PHOTOEMISSION MAT; VONSCHNERING HG, 1981, ANGEW CHEM INT EDIT, V20, P33, DOI 10.1002/anie.198100331; VONSCHNERING HG, 1981, ANGEW CHEM, V93, P44; WALKER N, 1983, ACTA CRYSTALLOGR A, V39, P158, DOI 10.1107/S0108767383000252; Zintl E, 1931, Z PHYS CHEM A-CHEM T, V154, P1; Zintl E, 1931, Z PHYS CHEM A-CHEM T, V154, P92; Zintl E, 1932, Z PHYS CHEM B-CHEM E, V16, P183	30	57	58	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 4	1998	281	5382					1500	1501		10.1126/science.281.5382.1500	http://dx.doi.org/10.1126/science.281.5382.1500			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	116RJ	9727974				2022-12-28	WOS:000075738100038
J	Binder, AB				Binder, AB			Lunar prospector: Overview	SCIENCE			English	Article							SINGLE-IMPACT HYPOTHESIS; MOON; ORIGIN	Lunar Prospector is providing a global map of the composition of the moon and analyzing the moon's gravity and magnetic fields. It has been in a polar orbit around the moon since 16 January 1998. Neutron flux data show that there is abundant H, and hence probably abundant water ice, in the Lunar polar regions. Gamma-ray and neutron data reveal the distribution of Fe, Ti, and other major and trace elements on the moon. The data delineate the global distributions of a key trace element-rich component of lunar materials called KREEP and of the major rock types. Magnetic mapping shows that the Lunar magnetic fields are strong antipodal to Mare Imbrium and Mare Serenitatis and has discovered the smallest known magnetosphere, magnetosheath, and bow shock complex in the solar system. Gravity mapping has delineated seven new gravity anomalies and shown that the moon has a small Fe-rich core of about 300 km radius.	Lunar Res Inst, Gilroy, CA 95020 USA		Binder, AB (corresponding author), Lunar Res Inst, 1800 Sunrise Dr, Gilroy, CA 95020 USA.	abinder@mail.arc.nasa.gov						BENZ W, 1986, ICARUS, V66, P515, DOI 10.1016/0019-1035(86)90088-6; Blewett DT, 1997, J GEOPHYS RES-PLANET, V102, P16319, DOI 10.1029/97JE01505; Cameron AGW, 1997, ICARUS, V126, P126, DOI 10.1006/icar.1996.5642; Canup RM, 1996, ICARUS, V119, P427, DOI 10.1006/icar.1996.0028; Elphic RC, 1998, SCIENCE, V281, P1493, DOI 10.1126/science.281.5382.1493; Feldman WC, 1998, SCIENCE, V281, P1489, DOI 10.1126/science.281.5382.1489; Konopliv AS, 1998, SCIENCE, V281, P1476, DOI 10.1126/science.281.5382.1476; Lawrence DJ, 1998, SCIENCE, V281, P1484, DOI 10.1126/science.281.5382.1484; Lin RP, 1998, SCIENCE, V281, P1480, DOI 10.1126/science.281.5382.1480; Lucey PG, 1998, J GEOPHYS RES-PLANET, V103, P3679, DOI 10.1029/97JE03019; LUCEY PG, 1995, SCIENCE, V268, P1150, DOI 10.1126/science.268.5214.1150; Nozette S, 1996, SCIENCE, V274, P1495, DOI 10.1126/science.274.5292.1495	12	138	153	1	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 4	1998	281	5382					1475	1476		10.1126/science.281.5382.1475	http://dx.doi.org/10.1126/science.281.5382.1475			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	116RJ	9727967				2022-12-28	WOS:000075738100031
J	Curry, SJ; Grothaus, LC; McAfee, T; Pabiniak, C				Curry, SJ; Grothaus, LC; McAfee, T; Pabiniak, C			Use and cost effectiveness of smoking-cessation services under four insurance plans in a health maintenance organization	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							OFFICE VISIT COPAYMENTS; SELF-HELP MATERIALS; NICOTINE GUM; SMOKERS; ADJUNCT; TRIAL; CARE; QUIT	Background Lack of information about the effect of insurance coverage on the demand for and use of smoking-cessation services has prevented widescale adoption of coverage for such services. Methods In a longitudinal, natural experiment, we compared the use and cost effectiveness of three forms of coverage with those of a standard form of coverage for smoking-cessation services that included a behavioral program and nicotine-replacement therapy. The study involved seven employers and a total of 90,005 adult enrollees. The standard plan offered 50 percent coverage of the behavioral program and full coverage of nicotine-replacement therapy. The other plans offered 50 percent coverage of both the behavioral program and nicotine-replacement therapy (reduced coverage), full coverage of the behavioral program and 50 percent coverage of nicotine-replacement therapy (flipped coverage), or full coverage of both the behavioral program and nicotine-replacement therapy. Results Estimated annual rates of use of smoking-cessation services ranged from 2.4 percent (among smokers with reduced coverage) to 10 percent (among those with full coverage). Smoking-cessation rates ranged from 28 percent (among users with full coverage) to 38 percent (among those with standard coverage). The estimated percentage of all smokers who would quit smoking per year as a result of using the services ranged from 0.7 percent (with reduced coverage) to 2.8 percent (with full coverage). The average cost to the health plan per user who quit smoking ranged from $797 (with standard coverage) to $1,171 (with full coverage). The annual cost per smoker ranged from $6 (with reduced coverage) to $33 (with full coverage). The annual cost per enrollee ranged from $0.89 (with reduced coverage) to $4.92 (with full coverage). Conclusions Use of smoking-cessation services varies according to the extent of coverage, with the highest rates of use among smokers with full coverage. Although the rate of smoking cessation among the benefit users with full coverage was lower than the rates among users with plans requiring copayments, the effect on the overall prevalence of smoking was greater with full coverage than with the cost-sharing plans. (N Engl J Med 1998;339:673-9.) (C)1998, Massachusetts Medical Society.	Grp Hlth Cooperat Puget Sound, Ctr Hlth Studies, Seattle, WA 98101 USA; Grp Hlth Cooperat Puget Sound, Dept Prevent Care, Seattle, WA 98101 USA; Univ Washington, Sch Publ Hlth & Community Med, Dept Hlth Serv, Seattle, WA 98195 USA	Group Health Cooperative; Group Health Cooperative; University of Washington; University of Washington Seattle	Curry, SJ (corresponding author), Grp Hlth Cooperat Puget Sound, Ctr Hlth Studies, 1730 Minor Ave,Suite 1600, Seattle, WA 98101 USA.							CHERKIN DC, 1990, INQUIRY-J HEALTH CAR, V27, P24; CHERKIN DC, 1989, MED CARE, V27, P1036, DOI 10.1097/00005650-198911000-00005; COX JL, 1990, J FAM PRACTICE, V31, P278; Cromwell J, 1997, JAMA-J AM MED ASSOC, V278, P1759, DOI 10.1001/jama.278.21.1759; CUMMINGS SR, 1989, JAMA-J AM MED ASSOC, V261, P75, DOI 10.1001/jama.261.1.75; CURRY SJ, 1995, J CONSULT CLIN PSYCH, V63, P1005, DOI 10.1037/0022-006X.63.6.1005; Fiore MC, 1996, AHCPR PUBLICATION, V96-0692; Fiscella K, 1996, JAMA-J AM MED ASSOC, V275, P1247, DOI 10.1001/jama.275.16.1247; Fishman P, 1997, HEALTH AFFAIR, V16, P239, DOI 10.1377/hlthaff.16.3.239; GLASGOW RE, 1993, ADDICT BEHAV, V18, P511, DOI 10.1016/0306-4603(93)90068-K; HUGHES JR, 1991, PREV MED, V20, P486, DOI 10.1016/0091-7435(91)90046-7; Hunter DJ, 1997, BRIT MED J, V315, P50, DOI 10.1136/bmj.315.7099.50; JOHNSON RE, 1991, DICP ANN PHARMAC, V25, P730, DOI 10.1177/106002809102500705; LILLIARD LA, 1986, R3266HCFA RAND PUBL; NEWHOUSE JP, 1981, NEW ENGL J MED, V305, P1501, DOI 10.1056/NEJM198112173052504; ORLEANS CT, 1991, J CONSULT CLIN PSYCH, V59, P439, DOI 10.1037/0022-006X.59.3.439; OSTER G, 1986, JAMA-J AM MED ASSOC, V256, P1315, DOI 10.1001/jama.256.10.1315; PARKINSON MD, 1992, TOBACCO CONTROL S, V1, pS52; PROCHASKA JO, 1983, J CONSULT CLIN PSYCH, V51, P390, DOI 10.1037/0022-006X.51.3.390; Saunders KW, 1994, PHARMACOEPIDEM DR S, P171; Schauffler H H, 1997, Tob Control, V6 Suppl 1, pS81; Schlesselman JJ, 1982, CASE CONTROL STUDIES; Simon GE, 1996, AM J PSYCHIAT, V153, P331; Wasley MA, 1997, PREV MED, V26, P264, DOI 10.1006/pmed.1996.0127	24	239	239	0	8	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 3	1998	339	10					673	679		10.1056/NEJM199809033391006	http://dx.doi.org/10.1056/NEJM199809033391006			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	115WA	9725926				2022-12-28	WOS:000075688100006
J	Sharer, N; Schwarz, M; Malone, G; Howarth, A; Painter, J; Super, M; Braganza, J				Sharer, N; Schwarz, M; Malone, G; Howarth, A; Painter, J; Super, M; Braganza, J			Mutations of the cystic fibrosis gene in patients with chronic pancreatitis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Proceedings Paper	British-Society-of-Gastroenterology Autumn Meeting	SEP 18-20, 1996	MANCHESTER, ENGLAND	British Soc Gastroenterol			RISK FACTOR; CFTR GENE	Background The pancreatic lesions of cystic fibrosis develop in utero and closely resemble those of chronic pancreatitis. Therefore, we hypothesized that mutations of the cystic fibrosis transmembrane conductance regulator (CFTR) gene may be more common than expected among patients with chronic pancreatitis. Methods We studied 134 consecutive patients with chronic pancreatitis (alcohol-related disease in 71, hyperparathyroidism in 2, hypertriglyceridemia in 1, and idiopathic disease in 60). We examined DNA for 22 mutations of the CFTR gene that together account for 95 percent of all mutations in patients with cystic fibrosis in the northwest of England. We also determined the length of the noncoding sequence of thymidines in intron 8, since the shorter the sequence, the lower the proportion of normal CFTR messenger RNA. Results The 94 male and 40 female patients ranged in age from 16 to 86 years. None had a mutation on both copies of the CFTR gene. Eighteen patients (13.4 percent), including 12 without alcoholism, had a CFTR mutation on one chromosome, as compared with a frequency of 5.3 percent among 600 local unrelated partners of persons with a family history of cystic fibrosis (P<0.001). A total of 10.4 percent of the patients had the 5T allele in intron 8 (14 of 134), which is twice the expected frequency (P=0.008). Four patients were heterozygous for both a CFTR mutation and the 5T allele. Patients with a CFTR mutation were younger than those with no mutations (P=0.03). None had the combination of sinopulmonary disease, high sweat electrolyte concentrations, and low nasal potential-difference values that are diagnostic of cystic fibrosis. Conclusions Mutations of the CFTR gene and the 5T genotype are associated with chronic pancreatitis. (N Engl J Med 1998;339:645-52.) (C) 1998, Massachusetts Medical Society.	Manchester Royal Infirm, Pancreatobiliary Unit, Manchester M13 9WL, Lancs, England; Univ Manchester, Manchester Royal Infirm, Dept Med, Manchester M13 9WL, Lancs, England; Royal Manchester Childrens Hosp, Reg Genet Serv, Manchester M27 1HA, Lancs, England	University of Manchester; University of Manchester; Royal Manchester Children's Hospital	Braganza, J (corresponding author), Manchester Royal Infirm, Pancreatobiliary Unit, Oxford Rd, Manchester M13 9WL, Lancs, England.							ANDERSON MP, 1992, AM J PHYSIOL, V263, pL1, DOI 10.1152/ajplung.1992.263.1.L1; Armitage P., 2001, STAT METHODS MED RES; AYGALENQ P, 1994, GASTROEN CLIN BIOL, V18, P907; BANK S, 1978, DIG DIS, V23, P178; BILTON D, 1994, DRUG INVEST, V8, P10, DOI 10.1007/BF03257422; BRAGANZA JM, 1986, MED HYPOTHESES, V20, P233, DOI 10.1016/0306-9877(86)90129-5; BRAGANZA JM, 1983, CLIN CHIM ACTA, V130, P339, DOI 10.1016/0009-8981(83)90308-X; Braganza JM, 1996, QJM-INT J MED, V89, P243; BRAGANZA JM, 1991, PATHOGENESIS OF PANCREATITIS, P178; BRAGANZA JM, 1982, GASTROENTEROLOGY, V82, P1341; BURGER J, 1991, LANCET, V337, P974, DOI 10.1016/0140-6736(91)91603-R; CHILLON M, 1995, NEW ENGL J MED, V332, P1475, DOI 10.1056/NEJM199506013322204; CHU CS, 1993, NAT GENET, V3, P151, DOI 10.1038/ng0293-151; Cohn JA, 1997, GASTROENTEROLOGY, V112, pA434; DELISLE RC, 1995, AM J PHYSIOL-GASTR L, V268, pG717, DOI 10.1152/ajpgi.1995.268.4.G717; FERRIE RM, 1992, AM J HUM GENET, V51, P251; GIBSON LE, 1959, PEDIATRICS, V23, P545; HANAWA M, 1978, TOHOKU J EXP MED, V125, P59, DOI 10.1620/tjem.125.59; KIESEWETTER S, 1993, NAT GENET, V5, P274, DOI 10.1038/ng1193-274; KRISTIDIS P, 1992, AM J HUM GENET, V50, P1178; Lebenthal Emanuel, 1993, P1041; LENCH N, 1988, LANCET, V1, P1356; LONGNECKER DS, 1991, PATHOGENESIS OF PANCREATITIS, P3; MCNAMEE R, 1994, OCCUP ENVIRON MED, V51, P631, DOI 10.1136/oem.51.9.631; MIDDLETON PG, 1994, EUR RESPIR J, V7, P2050; Miller PW, 1996, AM J HUM GENET, V59, P45; MORRIS AP, 1994, ANNU REV PHYSIOL, V56, P371; NORTON ID, 1995, GASTROENTEROLOGY, V108, pA380; PARIS J, 1969, LILLE MED, V14, P588; PEMBERTON PW, 1991, CLIN CHIM ACTA, V199, P253, DOI 10.1016/0009-8981(91)90119-W; PORTA EA, 1964, AM J CLIN PATHOL, V42, P451, DOI 10.1093/ajcp/42.5.451; Quesnel LB, 1998, J ANTIMICROB CHEMOTH, V41, P215, DOI 10.1093/jac/41.2.215; Ravnik-Glavac Metka, 1996, Pfluegers Archiv European Journal of Physiology, V431, pR191, DOI 10.1007/BF02346333; RIORDAN JR, 1989, SCIENCE, V245, P1437; SANDILANDS D, 1990, GASTROENTEROLOGY, V98, P766, DOI 10.1016/0016-5085(90)90300-P; Scheele GA, 1996, PANCREAS, V12, P1, DOI 10.1097/00006676-199601000-00001; Stern RC, 1997, NEW ENGL J MED, V336, P487, DOI 10.1056/NEJM199702133360707; SUPER M, 1992, EUR J PEDIATR, V151, P108, DOI 10.1007/BF01958953; SUPER M, 1994, BRIT MED J, V308, P1462, DOI 10.1136/bmj.308.6942.1462; Talamini G, 1996, PANCREAS, V12, P131, DOI 10.1097/00006676-199603000-00004; Whitcomb DC, 1996, NAT GENET, V14, P141, DOI 10.1038/ng1096-141; Whiteley G, 1994, PANCREAS, V9, pA807; Worning H, 1989, Int J Pancreatol, V5 Suppl, P1	43	678	691	0	12	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 3	1998	339	10					645	652		10.1056/NEJM199809033391001	http://dx.doi.org/10.1056/NEJM199809033391001			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	115WA	9725921				2022-12-28	WOS:000075688100001
J	Yoshikawa, H; Ueno, Y; Nakamura, N; Tomimoto, S				Yoshikawa, H; Ueno, Y; Nakamura, N; Tomimoto, S			Hands up for angina	LANCET			English	Article									Sei Yu Mem Hosp, Dept Internal Med, Wakayama, Japan		Yoshikawa, H (corresponding author), Sei Yu Mem Hosp, Dept Internal Med, 715 Iwase, Wakayama, Japan.							Eden KC, 1939, BRIT J SURG, V27, P111, DOI 10.1002/bjs.18002710508; GODFREY NF, 1983, CHEST, V83, P461, DOI 10.1378/chest.83.3.461; ROOS DB, 1976, AM J SURG, V132, P771, DOI 10.1016/0002-9610(76)90456-6; Urschel H C Jr, 1973, Ann Thorac Surg, V16, P239; WRIGHT IS, 1945, AM HEART J, V29, P1	5	5	6	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	AUG 29	1998	352	9129					702	702		10.1016/S0140-6736(98)05008-9	http://dx.doi.org/10.1016/S0140-6736(98)05008-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	116MT	9728988				2022-12-28	WOS:000075729700016
J	Kaiser, BN; Finnegan, PM; Tyerman, SD; Whitehead, LF; Bergersen, FJ; Day, DA; Udvardi, MK				Kaiser, BN; Finnegan, PM; Tyerman, SD; Whitehead, LF; Bergersen, FJ; Day, DA; Udvardi, MK			Characterization of an ammonium transport protein from the peribacteroid membrane of soybean nodules	SCIENCE			English	Article							SACCHAROMYCES-CEREVISIAE; ION-CHANNEL; IDENTIFICATION; ATPASE; FAMILY; PLANTS; CELLS; NH4+	Nitrogen-fixing bacteroids in Legume root nodules are surrounded by the plant-derived peribacteroid membrane, which controls nutrient transfer between the symbionts, A nodule complementary DNA (GmSAT1) encoding an ammonium transporter has been isolated from soybean. GmSAT1 is preferentially transcribed in nodules and immunoblotting indicates that GmSAT1 is Located on the peribacteroid membrane. [C-14]methylammonium uptake and patch-clamp analysis of yeast expressing GmSAT1 demonstrated that it shares properties with a soybean peribacteroid membrane NH4+ channel described elsewhere. GmSAT1 is likely to be involved in the transfer of fixed nitrogen from the bacteroid to the host.	Australian Natl Univ, Div Biochem & Mol Biol, Canberra, ACT 0200, Australia; Flinders Univ S Australia, Dept Biol, Adelaide, SA 5001, Australia	Australian National University; Flinders University South Australia	Day, DA (corresponding author), Australian Natl Univ, Div Biochem & Mol Biol, Canberra, ACT 0200, Australia.		Day, David/F-6325-2011; Tyerman, Steve D/F-9056-2010; Kaiser, Brent N/O-7458-2015; Kaiser, Brent/L-6092-2019; Udvardi, Michael/GPX-4653-2022; Finnegan, Patrick M/B-3469-2011	Day, David/0000-0001-7967-2173; Tyerman, Steve D/0000-0003-2455-1643; Kaiser, Brent N/0000-0001-6167-2423; Kaiser, Brent/0000-0001-6167-2423; Udvardi, Michael/0000-0001-9850-0828; Finnegan, Patrick M/0000-0001-5021-1138				BERTL A, 1995, P NATL ACAD SCI USA, V92, P2701, DOI 10.1073/pnas.92.7.2701; DELVES AC, 1986, PLANT PHYSIOL, V82, P588, DOI 10.1104/pp.82.2.588; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DUFOUR JP, 1988, METHOD ENZYMOL, V157, P513; Harlow E., 1988, ANITBODIES LAB MANUA; HURKMAN WJ, 1986, PLANT PHYSIOL, V81, P802, DOI 10.1104/pp.81.3.802; KAISER B, UNPUB; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARINI AM, 1994, EMBO J, V13, P3456, DOI 10.1002/j.1460-2075.1994.tb06651.x; Marini AM, 1997, MOL CELL BIOL, V17, P4282, DOI 10.1128/MCB.17.8.4282; Minn AJ, 1997, NATURE, V385, P353, DOI 10.1038/385353a0; NINNEMANN O, 1994, EMBO J, V13, P3464, DOI 10.1002/j.1460-2075.1994.tb06652.x; PUISSANT C, 1990, BIOTECHNIQUES, V8, P148; RAMOS F, 1979, EUR J BIOCHEM, V94, P409, DOI 10.1111/j.1432-1033.1979.tb12908.x; ROST B, 1995, PROTEIN SCI, V4, P521; Roth E, 1988, MOL GENETICS PLANT M, P220; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; Schubert U, 1996, FEBS LETT, V398, P12, DOI 10.1016/S0014-5793(96)01146-5; SERRANO R, 1988, METHOD ENZYMOL, V157, P533; SMITH FW, 1995, P NATL ACAD SCI USA, V92, P9373, DOI 10.1073/pnas.92.20.9373; Supek F, 1996, P NATL ACAD SCI USA, V93, P5105, DOI 10.1073/pnas.93.10.5105; TYERMAN SD, 1995, NATURE, V378, P629, DOI 10.1038/378629a0; Udvardi MK, 1997, ANNU REV PLANT PHYS, V48, P493, DOI 10.1146/annurev.arplant.48.1.493; YANG LJO, 1990, PLANTA, V182, P437, DOI 10.1007/BF02411397	26	67	71	1	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 21	1998	281	5380					1202	1206		10.1126/science.281.5380.1202	http://dx.doi.org/10.1126/science.281.5380.1202			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	113CE	9712587				2022-12-28	WOS:000075531200057
J	Roth, DB; Craig, NL				Roth, DB; Craig, NL			VDJ recombination: A transposase goes to work	CELL			English	Review							V(D)J RECOMBINATION; CHROMOSOMAL TRANSLOCATIONS; INITIATION; PRODUCTS		Baylor Coll Med, Howard Hughes Med Inst, Dept Immunol & Microbiol, Houston, TX 77030 USA; Baylor Coll Med, Howard Hughes Med Inst, Dept Pathol, Houston, TX 77030 USA; Baylor Coll Med, Howard Hughes Med Inst, Dept Mol & Human Genet, Houston, TX 77030 USA; Johns Hopkins Univ, Sch Med, Howard Hughes Med Inst, Dept Genet & Mol Biol, Baltimore, MD 21205 USA	Baylor College of Medicine; Howard Hughes Medical Institute; Baylor College of Medicine; Howard Hughes Medical Institute; Baylor College of Medicine; Howard Hughes Medical Institute; Howard Hughes Medical Institute; Johns Hopkins University	Roth, DB (corresponding author), Baylor Coll Med, Howard Hughes Med Inst, Dept Immunol & Microbiol, Houston, TX 77030 USA.							Agrawal A, 1998, NATURE, V394, P744, DOI 10.1038/29457; Bogue M, 1996, CURR OPIN IMMUNOL, V8, P175, DOI 10.1016/S0952-7915(96)80055-0; COEN ES, 1989, MOBILE DNA, P413; CRAIG NL, 1995, SCIENCE, V270, P253, DOI 10.1126/science.270.5234.253; ENGELS WR, 1990, CELL, V62, P515, DOI 10.1016/0092-8674(90)90016-8; Gorbunova V, 1997, GENETICS, V145, P1161; Grindley NDF, 1995, CELL, V83, P1063, DOI 10.1016/0092-8674(95)90132-9; HAGEMANN AT, 1993, GENETICS, V133, P9; Han JO, 1997, MOL CELL BIOL, V17, P2226, DOI 10.1128/MCB.17.4.2226; Hiom K, 1998, CELL, V94, P463, DOI 10.1016/S0092-8674(00)81587-1; KORSMEYER SJ, 1992, ANNU REV IMMUNOL, V10, P785, DOI 10.1146/annurev.immunol.10.1.785; Melek M, 1998, SCIENCE, V280, P301, DOI 10.1126/science.280.5361.301; MIZUUCHI K, 1992, J BIOL CHEM, V267, P21273; Nakajima PB, 1997, MOL CELL BIOL, V17, P2631, DOI 10.1128/MCB.17.5.2631; RAMSDEN DA, 1995, GENE DEV, V9, P2409, DOI 10.1101/gad.9.19.2409; SAEDLER H, 1996, CURR TOPICS MICROBIO, V204; Sarnovsky RJ, 1996, EMBO J, V15, P6348, DOI 10.1002/j.1460-2075.1996.tb01024.x; Steen SB, 1997, EMBO J, V16, P2656, DOI 10.1093/emboj/16.10.2656; THOMPSON CB, 1995, IMMUNITY, V3, P531, DOI 10.1016/1074-7613(95)90124-8; TYCKO B, 1990, CANCER CELL-MON REV, V2, P1; vanGent DC, 1996, SCIENCE, V271, P1592, DOI 10.1126/science.271.5255.1592	21	90	102	2	15	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	AUG 21	1998	94	4					411	414		10.1016/S0092-8674(00)81580-9	http://dx.doi.org/10.1016/S0092-8674(00)81580-9			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	113GB	9727482	hybrid			2022-12-28	WOS:000075541100001
J	Sockanathan, S; Jessell, TM				Sockanathan, S; Jessell, TM			Motor neuron-derived retinoid signaling specifies the subtype identity of spinal motor neurons	CELL			English	Article							LIM HOMEOBOX GENES; CHICK-EMBRYO; MOUSE EMBRYOGENESIS; SONIC HEDGEHOG; EXPRESSION; ACID; CORD; SPECIFICATION; COLUMN; DIFFERENTIATION	The diversification of neuronal cell types in the vertebrate central nervous system depends on inductive signals provided by local organizing cell groups of both neural and nonneural origin. The influence of signals provided by postmitotic neurons on the fate of neurons born at subsequent development stages, however, remains unclear. We provide evidence that a retinoid-mediated signal provided by one subset of early-born spinal motor neurons imposes a local variation in the number of motor neurons generated at different axial levels and also specifies the identity of a later-born subset of motor neurons. Thus, in the vertebrate central nervous system the distinct fates of late-born neurons may be acquired in response to signals provided by early-born neurons.	Columbia Univ, Howard Hughes Med Inst, Dept Biochem & Mol Biophys, New York, NY 10032 USA	Columbia University; Howard Hughes Medical Institute	Jessell, TM (corresponding author), Columbia Univ, Howard Hughes Med Inst, Dept Biochem & Mol Biophys, New York, NY 10032 USA.							ANGEVINE JB, 1961, NATURE, V192, P766, DOI 10.1038/192766b0; Appel B, 1995, DEVELOPMENT, V121, P4117; BOEHM MF, 1994, J MED CHEM, V37, P408, DOI 10.1021/jm00029a013; Coghill GE, 1933, J COMP NEUROL, V57, P327, DOI 10.1002/cne.900570205; COLBERT MC, 1993, P NATL ACAD SCI USA, V90, P6572, DOI 10.1073/pnas.90.14.6572; Curtiss J, 1998, BIOESSAYS, V20, P58, DOI 10.1002/(SICI)1521-1878(199801)20:1&lt;58::AID-BIES9&gt;3.0.CO;2-O; DOLLE P, 1994, MECH DEVELOP, V45, P91, DOI 10.1016/0925-4773(94)90023-X; Ensini M, 1998, DEVELOPMENT, V125, P969; Ericson J, 1996, CELL, V87, P661, DOI 10.1016/S0092-8674(00)81386-0; Ericson J, 1997, COLD SPRING HARB SYM, V62, P451; ERICSON J, 1992, SCIENCE, V256, P1555, DOI 10.1126/science.1350865; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; HAMBURGER V, 1975, J COMP NEUROL, V160, P535, DOI 10.1002/cne.901600408; Hatten M E, 1993, Curr Opin Neurobiol, V3, P38, DOI 10.1016/0959-4388(93)90033-U; HOLLYDAY M, 1977, BRAIN RES, V132, P197, DOI 10.1016/0006-8993(77)90416-4; HOLLYDAY M, 1980, J COMP NEUROL, V194, P143, DOI 10.1002/cne.901940108; Lala DS, 1996, NATURE, V383, P450, DOI 10.1038/383450a0; LANDMESSER L, 1978, J PHYSIOL-LONDON, V284, P371, DOI 10.1113/jphysiol.1978.sp012545; Liem KF, 1997, CELL, V91, P127, DOI 10.1016/S0092-8674(01)80015-5; MCCAFFERY P, 1994, P NATL ACAD SCI USA, V91, P7194, DOI 10.1073/pnas.91.15.7194; MCCONNELL SK, 1995, NEURON, V15, P761, DOI 10.1016/0896-6273(95)90168-X; Morgan BA, 1996, METHOD CELL BIOL, V51, P185, DOI 10.1016/S0091-679X(08)60629-9; OPPENHEIM RW, 1989, DEV BIOL, V133, P468, DOI 10.1016/0012-1606(89)90050-X; Pearlman AL, 1998, CURR OPIN NEUROBIOL, V8, P45, DOI 10.1016/S0959-4388(98)80007-X; Pfaff S, 1998, CURR OPIN NEUROBIOL, V8, P27, DOI 10.1016/S0959-4388(98)80005-6; Pignatello MA, 1997, TOXICOL APPL PHARM, V142, P319, DOI 10.1006/taap.1996.8047; PRASAD A, 1991, J COMP NEUROL, V307, P237, DOI 10.1002/cne.903070207; RAKIC P, 1974, SCIENCE, V183, P425, DOI 10.1126/science.183.4123.425; ROSSANT J, 1991, GENE DEV, V5, P1333, DOI 10.1101/gad.5.8.1333; RUBERTE E, 1990, DEVELOPMENT, V108, P213; SCHAERENWIEMERS N, 1993, HISTOCHEMISTRY, V100, P431, DOI 10.1007/BF00267823; SMITH SM, 1994, DEV DYNAM, V200, P14, DOI 10.1002/aja.1002000103; SOLOMIN L, 1988, IN PRESS NATURE; TAIRA M, 1994, DEVELOPMENT, V120, P1525; TANABE Y, 1995, CURR BIOL, V5, P651, DOI 10.1016/S0960-9822(95)00130-8; Tanabe Y, 1996, SCIENCE, V274, P1115, DOI 10.1126/science.274.5290.1115; TSUCHIDA T, 1994, CELL, V79, P957, DOI 10.1016/0092-8674(94)90027-2; VarelaEchavarria A, 1996, MOL CELL NEUROSCI, V8, P242, DOI 10.1006/mcne.1996.0061; Wang XS, 1996, J BIOL CHEM, V271, P16288, DOI 10.1074/jbc.271.27.16288; WHITELAW V, 1983, J NEUROSCI, V3, P1199; YAMAGATA T, 1984, BRAIN RES DEV BRAIN, V77, P163; Zhao D, 1996, EUR J BIOCHEM, V240, P15, DOI 10.1111/j.1432-1033.1996.0015h.x	42	323	327	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	AUG 21	1998	94	4					503	514		10.1016/S0092-8674(00)81591-3	http://dx.doi.org/10.1016/S0092-8674(00)81591-3			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	113GB	9727493	hybrid			2022-12-28	WOS:000075541100012
J	Amiel, SA				Amiel, SA			Hypoglycaemia avoidance - technology and knowledge	LANCET			English	Editorial Material							NOCTURNAL HYPOGLYCEMIA; DIABETIC-PATIENTS; ACTING INSULIN		Univ London Kings Coll, Sch Med, Dept Med, London SE5 9PJ, England	University of London; King's College London	Amiel, SA (corresponding author), Univ London Kings Coll, Sch Med, Dept Med, London SE5 9PJ, England.							BINDER C, 1984, DIABETES CARE, V7, P188, DOI 10.2337/diacare.7.2.188; BOYLE PJ, 1994, P NATL ACAD SCI USA, V91, P9352, DOI 10.1073/pnas.91.20.9352; CRANSTON I, 1994, LANCET, V344, P283, DOI 10.1016/S0140-6736(94)91336-6; Fanelli C, 1998, DIABETES, V47, pA109; FRANCIS AJ, 1983, BRIT MED J, V286, P1173, DOI 10.1136/bmj.286.6372.1173; GALE EAM, 1979, LANCET, V1, P1049; GEORGE E, 1995, DIABETOLOGIA, V38, P1183, DOI 10.1007/s001250050410; Heinemann L, 1996, DIABETIC MED, V13, P625, DOI 10.1002/(SICI)1096-9136(199607)13:7<625::AID-DIA134>3.3.CO;2-U; HELLER SR, 1997, DIABETES S1, V46, pA151; HOME PD, 1984, DIABET MED, V1; JACOBS AJM, 1997, DIABETES CARE, V20, P1279; KANE K, 1998, DIABETOLOGIA, V41, P322; MATYKA K, 1996, DIABET MED S3, V13, pA39; PRAMMING S, 1991, DIABETIC MED, V8, P217, DOI 10.1111/j.1464-5491.1991.tb01575.x; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; WHINCUP G, 1987, ARCH DIS CHILD, V62, P333, DOI 10.1136/adc.62.4.333	16	11	11	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	AUG 15	1998	352	9127					502	503		10.1016/S0140-6736(05)79244-8	http://dx.doi.org/10.1016/S0140-6736(05)79244-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	111KC	9716050				2022-12-28	WOS:000075435300004
J	Salam, MA; Dhar, U; Khan, WA; Bennish, ML				Salam, MA; Dhar, U; Khan, WA; Bennish, ML			Randomised comparison of ciprofloxacin suspension and pivmecillinam for childhood shigellosis	LANCET			English	Article							ORAL CIPROFLOXACIN; NALIDIXIC-ACID; CHILDREN; THERAPY; TRIAL	Background Infections caused by multiply resistant Shigella species are a major cause of childhood morbidity and mortality in Third World countries. The fluoroquinolone agent ciprofloxacin is active in vitro against these strains of bacteria, but has not been routinely used to treat acute childhood infections because of concern that quinolones may cause arthropathy in children. We undertook a randomised double-blind study to test the effects of ciprofloxacin treatment in children with shigella dysentery. Methods We compared the efficacy and toxic effects of ciprofloxacin suspension (10 mg/kg every 12 h for 5 days, maximum individual dose 500 mg) with those of pivmecillinam tablets (15-20 mg/kg every 8 h for 5 days, maximum individual dose 300 mg). We enrolled 143 children aged 2-15 years with dysentery of 72 h or less duration. Patients stayed in hospital for 6 days, and were followed up 7, 30, and 180 days after hospital discharge. Joint symptoms and function were assessed daily for 6 days. Clinical success was defined as the absence of frank dysentery on day 3, and on day 5 no bloody-mucoid stools, one or no watery stool, six or fewer total stools, and no fever. If no shigella were isolated from faecal samples on day 3 or thereafter, treatment was judged bacteriologically successful. Findings 13 patients were excluded since they did not meet eligibility criteria; 10 withdrew before day 5, Thus 120 patients (60 in each group) completed the study. Treatment was clinically successful in 48 (80%) of 60 patients who received ciprofloxacin and in 39 (65%) of 60 patients who received pivmecillinam (p=0.10). Treatment was bacteriologically successful in all of the patients receiving ciprofloxacin, and in 54 (90%) of the patients receiving pivmecillinam (p=0.03). Joint pain after treatment began in 13 (18%) of 71 patients who received ciprofloxacin and 16 (22%) of 72 patients who received pivmecillinam (p>0.2), and no patient had signs of arthritis. Interpretation In our trial, ciprofloxacin suspension and pivmecillinam had the same clinical efficacy. Ciprofloxacin had greater bacteriological efficacy and was not associated with the development of arthropathy. We conclude that ciprofloxacin is an effective and safe drug for use in multiply resistant childhood shigellosis.	Tufts Univ, New England Med Ctr, Sch Med, Tupper Res Inst,Div Geog Med & Infect Dis, Boston, MA 02111 USA; Int Ctr Diarrhoeal Dis Res, Dhaka 1000, Bangladesh	Tufts Medical Center; Tufts University; International Centre for Diarrhoeal Disease Research (ICDDR)	Bennish, ML (corresponding author), Tufts Univ, New England Med Ctr, Sch Med, Tupper Res Inst,Div Geog Med & Infect Dis, Boston, MA 02111 USA.	mbennish@es.nemc.org						BAVDEKAR A, 1991, Indian Journal of Pediatrics, V58, P335, DOI 10.1007/BF02754962; Bennish Michael L., 1995, P1499; BENNISH ML, 1990, J INFECT DIS, V162, P711, DOI 10.1093/infdis/162.3.711; BENNISH ML, 1992, ANN INTERN MED, V117, P727, DOI 10.7326/0003-4819-117-9-727; BENNISH ML, 1991, REV INFECT DIS, V13, pS245; BLACKWELDER WC, 1982, CONTROL CLIN TRIALS, V3, P345, DOI 10.1016/0197-2456(82)90024-1; Burkhardt JE, 1997, CLIN INFECT DIS, V25, P1196, DOI 10.1086/516119; Caudill TS, 1996, ARCH FAM MED, V5, P201, DOI 10.1001/archfami.5.4.201; Church DA, 1997, PEDIATR INFECT DIS J, V16, P97, DOI 10.1097/00006454-199701000-00031; CRUCIANI M, 1989, INFECTION, V17, P65, DOI 10.1007/BF01646878; DAGAN R, 1990, INFECTION, V18, P237, DOI 10.1007/BF01643396; FONTAINE O, 1989, REV INFECT DIS, V11, pS1145; Freifeld A, 1997, PEDIATR INFECT DIS J, V16, P140, DOI 10.1097/00006454-199701000-00039; FRIEDEN TR, 1990, JAMA-J AM MED ASSOC, V264, P1438, DOI 10.1001/jama.264.11.1438; Gendrel D, 1997, CLIN INFECT DIS, V24, P83, DOI 10.1093/clinids/24.1.83; Hampel B, 1997, PEDIATR INFECT DIS J, V16, P127, DOI 10.1097/00006454-199701000-00036; HIEN TT, 1995, CLIN INFECT DIS, V20, P917, DOI 10.1093/clinids/20.4.917; Khan WA, 1996, LANCET, V348, P296, DOI 10.1016/S0140-6736(96)01180-4; Khan WA, 1997, ANN INTERN MED, V126, P697, DOI 10.7326/0003-4819-126-9-199705010-00004; Krol GJ, 1995, J PHARMACEUT BIOMED, V14, P181, DOI 10.1016/0731-7085(95)01611-2; LANG R, 1992, PEDIATR INFECT DIS J, V11, P925, DOI 10.1097/00006454-199211110-00004; PEAR R, 1997, NY TIMES        0813, P17; PELTOLA H, 1992, ANTIMICROB AGENTS CH, V36, P1086, DOI 10.1128/AAC.36.5.1086; Richard DA, 1997, PEDIATR INFECT DIS J, V16, P572, DOI 10.1097/00006454-199706000-00007; RONSMANS C, 1991, REV INFECT DIS, V13, pS351; Rubio TT, 1997, PEDIATR INFECT DIS J, V16, P112, DOI 10.1097/00006454-199701000-00033; SALAM MA, 1988, J PEDIATR-US, V113, P901, DOI 10.1016/S0022-3476(88)80029-5; SALAM MA, 1995, ANN INTERN MED, V123, P505, DOI 10.7326/0003-4819-123-7-199510010-00005; SCHAAD UB, 1987, INFECTION, V15, P165, DOI 10.1007/BF01646040; Vincent S., 1989, THEORY APPL MICROBIO	30	59	60	1	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 15	1998	352	9127					522	527		10.1016/S0140-6736(97)11457-X	http://dx.doi.org/10.1016/S0140-6736(97)11457-X			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	111KC	9716056				2022-12-28	WOS:000075435300010
J	Yusuf, S; Flather, M; Pogue, J; Hunt, D; Varigos, J; Piegas, L; Avezum, A; Anderson, J; Keltai, M; Budaj, A; Fox, K; Ceremuzynski, L				Yusuf, S; Flather, M; Pogue, J; Hunt, D; Varigos, J; Piegas, L; Avezum, A; Anderson, J; Keltai, M; Budaj, A; Fox, K; Ceremuzynski, L		OASIS Registry Investigators	Variations between countries in invasive cardiac procedures and outcomes in patients with suspected unstable angina or myocardial infarction without initial ST elevation	LANCET			English	Article							THROMBOLYSIS; TRIAL	Background There are wide variations between countries in the use of invasive cardiac catheterisation and revascularisation procedures for patients with acute ischaemic syndromes. We studied the relation between rates of such procedures and rates of cardiovascular death, myocardial infarction, stroke, refractory angina, and major bleeding in a prospective, registry-based study in six countries with widely varying intervention rates. Methods 7987 consecutive patients presenting with unstable angina or suspected myocardial infarction without ST-segment elevation were recruited prospectively from 95 hospitals in six countries and followed up for 6 months. Findings The rates of all procedures were highest in patients in Brazil and the USA, intermediate in Canada acid Australia, and lowest in Hungary and Poland. There were no significant differences in rates of cardiovascular death or myocardial infarction among these countries (47% overall [range 3.7-5.6] at 7 days; 11% overall [9-12] at 6 months), For the countries with the highest rates of invasive procedures (59%) versus the rest (21%) there was no difference in rate of cardiovascular death or myocardial infarction (adjusted odds ratio 0.88 at 7 days and 1.0 at 6 months). Rates of stroke were higher in Brazil and the USA than in the countries with lower intervention rates (adjusted odds ratio at 7 days 3.0, p=0.012; at 6 months 1.8, p=0.004) but rates of refractory angina at 7 days (0.7, p<0.001) and readmission for unstable angina at 0.83 (10.6% vs 12.5%, p=0.05) and for refractory angina of 1.25 (19.3% vs 16.1%, p=0.09). Interpretation Higher rates of invasive and revascularisation procedures were associated with lower rates of refractory angina or readmission for unstable angina, no apparent reducton in cardiovascular death or myocardial infarction, but with higher rates of stroke. Randomised trials should assess the relative impact of conservative and more aggressive approaches to invasive cardiac procedures and revascularisations in patients with unstable angina.	McMaster Univ, Hamilton, ON, Canada; Royal Brompton Hosp, London SW3 6LY, England; Royal Melbourne Hosp, Melbourne, Vic, Australia; OASIS Off, Melbourne, Vic, Australia; Dante Pazzanese Cardiol Inst, Sao Paulo, Brazil; Univ Utah, Latter Day St Hosp, Salt Lake City, UT 84143 USA; Hungarian Inst Cardiol, Budapest, Hungary; Grochowski Hosp, Warsaw, Poland; Univ Edinburgh, Edinburgh, Midlothian, Scotland	McMaster University; Royal Brompton Hospital; Royal Melbourne Hospital; Instituto Dante Pazzanese de Cardiologia; Utah System of Higher Education; University of Utah; Centre of Postgraduate Medical Education - Poland; University of Edinburgh	Yusuf, S (corresponding author), Hamilton Gen Hosp, 237 Barton St E, Hamilton, ON L8L 2X2, Canada.	yusufs@fhs.csu.mcmaster.ca	Avezum, Alvaro/AAP-7687-2020; Avezum, Alvaro AA/K-6137-2016	Avezum, Alvaro AA/0000-0002-3073-6890; Piegas, Leopoldo/0000-0003-1021-817X; Yusuf, Salim/0000-0003-4776-5601; Budaj, Andrzej/0000-0002-6395-2098				ANDERSON HV, 1995, J AM COLL CARDIOL, V26, P1643, DOI 10.1016/0735-1097(95)00404-1; BODEN WE, IN PRESS N ENGL J ME; Cannon CP, 1997, J AM COLL CARDIOL, V30, P133, DOI 10.1016/S0735-1097(97)00160-5; Chamberlain DA, 1997, LANCET, V350, P461; Every NR, 1997, CIRCULATION, V96, P1770, DOI 10.1161/01.CIR.96.6.1770; Madsen JK, 1997, CIRCULATION, V96, P748; Pilote L, 1996, NEW ENGL J MED, V335, P1198, DOI 10.1056/NEJM199610173351606; ROULEAU JL, 1993, NEW ENGL J MED, V328, P779, DOI 10.1056/NEJM199303183281108; Tu JV, 1997, NEW ENGL J MED, V336, P1500, DOI 10.1056/NEJM199705223362106; WILLIAMS DO, 1992, CIRCULATION, V85, P533, DOI 10.1161/01.CIR.85.2.533; YUSUF S, 1994, LANCET, V344, P563, DOI 10.1016/S0140-6736(94)91963-1	11	322	336	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	AUG 15	1998	352	9127					507	514		10.1016/S0140-6736(97)11162-X	http://dx.doi.org/10.1016/S0140-6736(97)11162-X			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	111KC	9716054				2022-12-28	WOS:000075435300008
J	McCarron, DA				McCarron, DA			Biomedicine - Diet and blood pressure the paradigm shift	SCIENCE			English	Editorial Material							RANDOMIZED CONTROLLED TRIALS; METAANALYSIS; CALCIUM; SODIUM; SALT		Oregon Hlth Sci Univ, Portland, OR 97201 USA	Oregon Health & Science University	McCarron, DA (corresponding author), Oregon Hlth Sci Univ, Portland, OR 97201 USA.	mccarron@ohsu.edu						ALDERMAN MH, 1995, HYPERTENSION, V25, P1144, DOI 10.1161/01.HYP.25.6.1144; Alderman MH, 1998, LANCET, V351, P781, DOI 10.1016/S0140-6736(97)09092-2; Appel LJ, 1997, NEW ENGL J MED, V336, P1117, DOI 10.1056/NEJM199704173361601; BILEZIKIAN JP, 1994, JAMA-J AM MED ASSOC, V272, P1942, DOI 10.1001/jama.1994.03520240070044; Black HR, 1997, ARCH INTERN MED, V157, P2413; Bucher HC, 1996, JAMA-J AM MED ASSOC, V275, P1016, DOI 10.1001/jama.275.13.1016; ELLIOTT P, 1988, BRIT MED J, V297, P319; Graudal NA, 1998, JAMA-J AM MED ASSOC, V279, P1383, DOI 10.1001/jama.279.17.1383; KOLATA G, 1982, SCIENCE, V216, P38, DOI 10.1126/science.7063868; MCCARRON DA, 1984, SCIENCE, V224, P1392, DOI 10.1126/science.6729459; MCCARRON DA, 1982, SCIENCE, V217, P267, DOI 10.1126/science.7089566; Midgley JP, 1996, JAMA-J AM MED ASSOC, V275, P1590, DOI 10.1001/jama.275.20.1590; MUNTZEL M, 1992, AM J HYPERTENS, V5, pS1, DOI 10.1093/ajh/5.4S.1S; *NAT RES COUNC COM, 1989, DIET HLTH IMPL RED C, P665; Pickering TG, 1997, ARCH INTERN MED, V157, P596, DOI 10.1001/archinte.157.6.596; SWALES JD, 1988, BRIT MED J, V297, P307, DOI 10.1136/bmj.297.6644.307; Whelton PK, 1997, ARCH INTERN MED, V157, P657, DOI 10.1001/archinte.157.6.657	17	51	52	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 14	1998	281	5379					933	934		10.1126/science.281.5379.933	http://dx.doi.org/10.1126/science.281.5379.933			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	110ZK	9722467				2022-12-28	WOS:000075412700030
J	DeAngelis, GC; Cumming, BG; Newsome, WT				DeAngelis, GC; Cumming, BG; Newsome, WT			Cortical area MT and the perception of stereoscopic depth	NATURE			English	Article							VISUAL AREA; MACAQUE MONKEY; RHESUS-MONKEY; CORTEX; PERFORMANCE; SENSITIVITY; DISPARITY; NEURONS; MICROSTIMULATION; MECHANISMS	Stereopsis is the perception of depth based on small positional differences between images formed on the two retinae (known as binocular disparity). Neurons that respond selectively to binocular disparity were first described three decades ago(1,2), and have since been observed in many visual areas of the primate brain, including V1, V2, V3, MT and MST3-8. Although disparity-selective neurons are thought to form the neural substrate for stereopsis, the mere existence of disparity-selective neurons does not guarantee that they contribute to stereoscopic depth perception. Some disparity-selective neurons may play other roles, such as guiding vergence eye movementsg(9,10). Thus, the roles of different visual areas in stereopsis remain poorly defined. Here we show that visual area MT is important in stereoscopic vision: electrical stimulation of clusters of disparity-selective MT neurons can bias perceptual judgements of depth, and the bias is predictable from the disparity preference of neurons at the stimulation site. These results show that behaviourally relevant signals concerning stereoscopic depth are present in MT.	Stanford Univ, Sch Med, Howard Hughes Med Inst, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Neurobiol, Stanford, CA 94305 USA; Univ Oxford, Physiol Lab, Oxford OX1 3PT, England	Howard Hughes Medical Institute; Stanford University; Stanford University; University of Oxford	Newsome, WT (corresponding author), Stanford Univ, Sch Med, Howard Hughes Med Inst, Stanford, CA 94305 USA.		Newsome, William T./W-7171-2019	DeAngelis, Gregory/0000-0002-1635-1273				Albright T D, 1993, Rev Oculomot Res, V5, P177; ALBRIGHT TD, 1984, J NEUROPHYSIOL, V51, P16, DOI 10.1152/jn.1984.51.1.16; BARLOW HB, 1967, J PHYSIOL-LONDON, V193, P327, DOI 10.1113/jphysiol.1967.sp008360; Bradley DC, 1998, NATURE, V392, P714, DOI 10.1038/33688; BRITTEN KH, 1992, J NEUROSCI, V12, P4745; Cox DR., 1989, ANAL BINARY DATA; Cumming BG, 1997, NATURE, V389, P280, DOI 10.1038/38487; Deangelis G. C., 1996, Society for Neuroscience Abstracts, V22, P717; Dodd J. V., 1997, Society for Neuroscience Abstracts, V23, P1125; FELLEMAN DJ, 1987, J NEUROPHYSIOL, V57, P889, DOI 10.1152/jn.1987.57.4.889; HUBEL DH, 1970, NATURE, V225, P41, DOI 10.1038/225041a0; JUDGE SJ, 1980, VISION RES, V20, P535, DOI 10.1016/0042-6989(80)90128-5; Masson GS, 1997, NATURE, V389, P283, DOI 10.1038/38496; MAUNSELL JHR, 1983, J NEUROPHYSIOL, V49, P1148, DOI 10.1152/jn.1983.49.5.1148; MURASUGI CM, 1993, J NEUROSCI, V13, P1719; PETTIGREW JD, 1968, EXP BRAIN RES, V6, P391; POGGIO GF, 1988, J NEUROSCI, V8, P4531; POGGIO GF, 1977, J NEUROPHYSIOL, V40, P1392, DOI 10.1152/jn.1977.40.6.1392; ROBINSON DA, 1963, IEEE T BIO-MED ENG, VBM10, P137, DOI 10.1109/TBMEL.1963.4322822; ROY JP, 1992, J NEUROSCI, V12, P2478; SALZMAN CD, 1994, SCIENCE, V264, P231, DOI 10.1126/science.8146653; SALZMAN CD, 1992, J NEUROSCI, V12, P2331; SCHILLER PH, 1993, VISUAL NEUROSCI, V10, P717, DOI 10.1017/S0952523800005423	23	300	303	1	30	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 13	1998	394	6694					677	680		10.1038/29299	http://dx.doi.org/10.1038/29299			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	110MD	9716130				2022-12-28	WOS:000075384200043
J	Robertson, R				Robertson, R			Unacceptable practices - Prison to the community in one, totally unprepared, step	BRITISH MEDICAL JOURNAL			English	Editorial Material									Edinburgh Drug Addict Study, Edinburgh, Midlothian, Scotland		Robertson, R (corresponding author), Edinburgh Drug Addict Study, Edinburgh, Midlothian, Scotland.							*HOM OFF, 1996, DRUG MIS PRIS SYST 3; Seaman SR, 1998, BRIT MED J, V316, P426, DOI 10.1136/bmj.316.7129.426	2	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	SEP 12	1998	317	7160					757	757		10.1136/bmj.317.7160.757	http://dx.doi.org/10.1136/bmj.317.7160.757			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	121CT	9732360	Green Published			2022-12-28	WOS:000075995100063
J	Illingworth, SC				Illingworth, SC			John Richard Bernard - Obituary	BRITISH MEDICAL JOURNAL			English	Biographical-Item																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 29	1998	317	7158					605	605		10.1136/bmj.317.7158.605	http://dx.doi.org/10.1136/bmj.317.7158.605			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	117EK	9721137	Green Published			2022-12-28	WOS:000075767800045
J	Scally, G				Scally, G			Recent advances - Public health	BRITISH MEDICAL JOURNAL			English	Review									NHS Execut S & W, Bristol BS12 6SR, Avon, England		Scally, G (corresponding author), NHS Execut S & W, Bristol BS12 6SR, Avon, England.							Barker D. J. P., 1994, MOTHERS BABIES DIS L; Cochrane A. L, 1972, PUBLIC HEALTH, DOI DOI 10.1016/S0033-3506(73)80082-4; Department of Health, 1992, POL REQ AV COMP SPEC; Donaldson LJ, 1998, J EPIDEMIOL COMMUN H, V52, P73, DOI 10.1136/jech.52.2.73; GRAUNT J, 1962, NATURAL POLITICAL OB; GRAY JM, 1995, PROGR PUBLIC HLTH; Hackshaw AK, 1997, BMJ-BRIT MED J, V315, P980, DOI 10.1136/bmj.315.7114.980; Kuh D, 1997, LIFE COURSE APPROACH; LAW MR, 1997, BRIT MED J, V315, P9732; MCKEE M, 1997, PROGR PUBLIC HLTH; *NHS EX, 1997, POP SCREEN PROST CAN; Prescott-Clarke P., 1998, HLTH SURVEY ENGLAND; SCALLY G, 1997, PROGR PUBLIC HLTH; Wilson JMG, 1968, PRINCIPLES PRACTICE	14	1	1	0	66	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 29	1998	317	7158					584	586		10.1136/bmj.317.7158.584	http://dx.doi.org/10.1136/bmj.317.7158.584			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	117EK	9721119	Green Published			2022-12-28	WOS:000075767800021
J	Stein, MB; Liebowitz, MR; Lydiard, RB; Pitts, CD; Bushnell, W; Gergel, I				Stein, MB; Liebowitz, MR; Lydiard, RB; Pitts, CD; Bushnell, W; Gergel, I			Paroxetine treatment of generalized social phobia (social anxiety disorder) - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NATIONAL-COMORBIDITY-SURVEY; PRIMARY-CARE PATIENTS; DOUBLE-BLIND; DEPRESSED-PATIENTS; MENTAL-DISORDERS; FLUOXETINE; PLACEBO; PREVALENCE; MULTICENTER; SERTRALINE	Context.-The generalized type of social phobia (social anxiety disorder) is a severe and often disabling form of social anxiety that affects approximately 5% of the general population. Earlier research has shown monoamine oxidase inhibitors or benzodiazepines to be effective in treating this condition, but neither has achieved widespread use. Objective.-To compare the efficacy of paroxetine, a selective serotonin reuptake inhibitor, with placebo in adults with generalized social phobia. Design.-Twelve-week, multicenter, randomized, double-blind trial. Setting.-Thirteen centers across the United States and 1 in Canada. Participants.-Between April 13, 1995, and February 28, 1996, 187 persons meeting Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition criteria for generalized social phobia were randomized land 183 returned for at least 1 efficacy assessment) to treatment. Intervention.-After a 1-week, single-blind, placebo, run-in period, patients received a double-blind, 1 I-week course of either paroxetine or matching-image placebo. The initial daily dosage of paroxetine (or placebo) was 20 mg with increases of 10 mg/d weekly (flexible dosing to a maximum of 50 mg/d) permitted after the second week of treatment. Main Outcome Measures.-Number of responders based on the Clinical Global Impression Global Improvement Item ("much improved";or "very much improved"); mean change from baseline on the Liebowitz Social Anxiety Scale total score. Results.-Fifty (55.0%) of 91 persons taking paroxetine and 22 (23.9%) of 92 persons taking placebo were much improved or very much improved at the end of treatment (odds ratio [OR], 3.88; 95% confidence interval [CI], 2.81-5.36). Mean Liebowitz Social Anxiety Scale total scores were reduced by 39.1% (the mean baseline score of 78.0 declined by a mean of 30.5 points at follow-up) in the paroxetine group compared with 17.4% (the mean baseline score of 83.5 declined 14.5 points at follow-up) in the placebo group, a difference of 21.7% (95% CI, 8.7%-34.7%) favoring paroxetine. Conclusions.-Paroxetine is an effective treatment for patients with generalized social phobia. Short-term (ie, 11-week) treatment results in substantial and clinically meaningful reductions in symptoms and disability. Future research should test whether these may be further reduced by extended treatment or supplementation with specific educational-cognitive-behavioral techniques.	Univ Calif San Diego, Dept Psychiat 0985, La Jolla, CA 92093 USA; Columbia Univ Coll Phys & Surg, Dept Psychiat, New York, NY 10032 USA; Med Univ S Carolina, Dept Psychiat, Charleston, SC 29425 USA; SmithKline Beecham Pharmaceut, Clin Res Dev & Med Affairs N Amer, Collegeville, PA USA	University of California System; University of California San Diego; Columbia University; Medical University of South Carolina; GlaxoSmithKline	Stein, MB (corresponding author), Univ Calif San Diego, Dept Psychiat 0985, 9500 Gilman Dr, La Jolla, CA 92093 USA.	mstein@ucsd.edu						American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th ed., DOI DOI 10.1001/JAMA.1994.03520100096; ANDREWS JM, 1994, AM J MED S6A, V97, P24; Antony MM, 1997, PSYCHIATRY, P1037; BERK M, 1995, J CLIN PSYCHIAT, V56, P36; BLACK B, 1992, J CLIN PSYCHOPHARM, V12, P293; Burrows G, 1997, EUR ARCH PSY CLIN N, V247, P71; COHN CK, 1990, J CLIN PSYCHIAT, V51, P28; DAVIDSON JRT, 1993, J CLIN PSYCHOPHARM, V13, P423; denBoer JA, 1997, BRIT MED J, V315, P796; DEWILDE J, 1993, ACTA PSYCHIAT SCAND, V87, P141; FIFER SK, 1994, ARCH GEN PSYCHIAT, V51, P740; First M.B., 2016, STRUCTURED CLIN INTE; Hazen A, 1995, SOCIAL PHOBIA CLIN R, P3; HEIMBERG RG, 1995, SOCIAL PHOBIA DIAGNO, P261; JEFFERSON JW, 1995, J CLIN PSYCHIAT, V56, P18; KATZELNICK DJ, 1995, AM J PSYCHIAT, V152, P1368; Kessler RC, 1998, AM J PSYCHIAT, V155, P613, DOI 10.1176/ajp.155.5.613; KESSLER RC, 1994, ARCH GEN PSYCHIAT, V51, P8; LEIBOWITZ MR, 1987, MODERN PROBLEMS PHAR, V22, P152; LEIBOWITZ MR, 1995, SOCIAL PHOBIA DIAGNO, P261; LEON AC, 1992, SOC PSYCH PSYCH EPID, V27, P78, DOI 10.1007/BF00788510; LIEBOWITZ MR, 1985, ARCH GEN PSYCHIAT, V42, P729; LIEBOWITZ MR, 1993, J CLIN PSYCHIAT, V54, P31; LIEBOWITZ MR, 1992, ARCH GEN PSYCHIAT, V49, P290; Lydiard RB, 1996, J CONSULT CLIN PSYCH, V64, P660; Magee WJ, 1996, ARCH GEN PSYCHIAT, V53, P159; MARSHALL RD, 1994, J CLIN PSYCHIAT, V55, P33; Mattick R.P., 1995, SOCIAL PHOBIA CLIN R, P189; Noyes R, 1997, J CLIN PSYCHOPHARM, V17, P247, DOI 10.1097/00004714-199708000-00002; Offord DR, 1996, CAN J PSYCHIAT, V41, P559, DOI 10.1177/070674379604100904; RINGOLD AL, 1994, J CLIN PSYCHIAT, V55, P363; SAFREN SA, 1997, ANXIETY, V4, P126; SCHNEIER FR, 1992, ARCH GEN PSYCHIAT, V49, P282; SCHNEIER FR, 1994, J CLIN PSYCHIAT, V55, P322; SCHNEIER FR, 1992, J CLIN PSYCHOPHARM, V12, P62; Scholing A, 1996, BEHAV RES THER, V34, P447, DOI 10.1016/0005-7967(96)00010-1; Schonfeld WH, 1997, J AFFECT DISORDERS, V43, P105, DOI 10.1016/S0165-0327(96)01416-4; SPITZER RL, 1995, JAMA-J AM MED ASSOC, V274, P1511, DOI 10.1001/jama.274.19.1511; SPITZER RL, 1994, JAMA-J AM MED ASSOC, V272, P1749, DOI 10.1001/jama.272.22.1749; STEIN M, 1994, AM J PSYCHIAT, V11, P408; Stein MB, 1996, LANCET, V347, P1131, DOI 10.1016/S0140-6736(96)90604-2; Stein MB, 1996, ARCH GEN PSYCHIAT, V53, P169; Stein MB, 1996, J CLIN PSYCHOPHARM, V16, P218, DOI 10.1097/00004714-199606000-00005; STERNBACH H, 1990, J CLIN PSYCHOPHARM, V10, P230, DOI 10.1097/00004714-199006000-00024; Taylor S, 1996, J BEHAV THER EXP PSY, V27, P1, DOI 10.1016/0005-7916(95)00058-5; VANAMERINGEN M, 1993, J CLIN PSYCHIAT, V54, P27; VANVLIET IM, 1994, PSYCHOPHARMACOLOGY, V115, P128, DOI 10.1007/BF02244762; WATSON D, 1969, J CONSULT CLIN PSYCH, V33, P448, DOI 10.1037/h0027806; Weiller E., 1996, British Journal of Psychiatry, V168, P169, DOI 10.1192/bjp.168.2.169	49	298	301	1	24	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 26	1998	280	8					708	713		10.1001/jama.280.8.708	http://dx.doi.org/10.1001/jama.280.8.708			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	111PM	9728642	Bronze			2022-12-28	WOS:000075446900032
J	Sieger, MT; Simpson, WC; Orlando, TM				Sieger, MT; Simpson, WC; Orlando, TM			Production of O-2 on icy satellites by electronic excitation of low-temperature water ice	NATURE			English	Article							D2O ICE; GANYMEDE; OXYGEN; IONS	The signature of condensed molecular oxygen has been reported in recent optical-reflectance measurements of the jovian moon Ganymede(1), and a tenuous oxygen atmosphere has been observed on Europa(2). The surfaces of these moons contain large amounts of water ice, and it is thought that O-2 is formed by the sputtering of ice by energetic particles from the jovian magnetosphere(3-8). Understanding how O-2 might be formed from low-temperature ice is crucial for theoretical and experimental simulations of the surfaces and atmospheres of icy bodies in the Solar System. Here we report laboratory measurements of the threshold energy, cross-section and temperature dependence of O-2 production by electronic excitation of ice in vacuum, following electron-beam irradiation. Molecular oxygen is formed by direct excitation and dissociation of a stable precursor molecule, rather than (as has been previously thought) by diffusion and chemical recombination of precursor fragments. The large cross-section for O-2 production suggests that electronic excitation plays an important part in the formation of O-2 on Ganymede and Europa.	Pacific NW Lab, WR Wiley Environm Mol Sci Lab, Richland, WA 99352 USA	United States Department of Energy (DOE); Pacific Northwest National Laboratory	Orlando, TM (corresponding author), Pacific NW Lab, WR Wiley Environm Mol Sci Lab, MS K8-88,POB 999, Richland, WA 99352 USA.	tm_orlando@pnl.gov	Sieger, Matthew/B-4261-2011	Sieger, Matthew/0000-0001-7387-3660				Bednarek J, 1996, J AM CHEM SOC, V118, P9387, DOI 10.1021/ja960518w; BROWN WL, 1982, NUCL INSTRUM METHODS, V198, P1, DOI 10.1016/0167-5087(82)90043-6; BROWN WL, 1978, PHYS REV LETT, V40, P1027, DOI 10.1103/PhysRevLett.40.1027; Calvin WM, 1996, GEOPHYS RES LETT, V23, P673, DOI 10.1029/96GL00450; Calvin WM, 1997, ICARUS, V130, P505, DOI 10.1006/icar.1997.5842; HALL DT, 1995, NATURE, V373, P677, DOI 10.1038/373677a0; Ip WH, 1997, GEOPHYS RES LETT, V24, P2631, DOI 10.1029/97GL02814; Johnson R.E., 1990, ENERGETIC CHARGED PA, DOI [10.1007/978-3-642-48375-2, DOI 10.1007/978-3-642-48375-2]; Johnson RE, 1997, J GEOPHYS RES-PLANET, V102, P10985, DOI 10.1029/97JE00068; JOHNSON RE, 1981, SCIENCE, V212, P1027, DOI 10.1126/science.212.4498.1027; Johnson RE, 1996, REV MOD PHYS, V68, P305, DOI 10.1103/RevModPhys.68.305; KIMMEL GA, 1995, PHYS REV LETT, V75, P2606, DOI 10.1103/PhysRevLett.75.2606; Lacombe S, 1997, PHYS REV LETT, V79, P1146, DOI 10.1103/PhysRevLett.79.1146; LANZEROTTI LJ, 1978, GEOPHYS RES LETT, V5, P155, DOI 10.1029/GL005i002p00155; Noll KS, 1997, GEOPHYS RES LETT, V24, P1139, DOI 10.1029/97GL00876; Noll KS, 1996, SCIENCE, V273, P341, DOI 10.1126/science.273.5273.341; REIMANN CT, 1984, SURF SCI, V147, P227, DOI 10.1016/0039-6028(84)90177-8; Sieger MT, 1997, PHYS REV B, V56, P4925, DOI 10.1103/PhysRevB.56.4925; Simpson WC, 1997, J CHEM PHYS, V107, P8668, DOI 10.1063/1.475019; SPENCER JR, 1995, J GEOPHYS RES-PLANET, V100, P19049, DOI 10.1029/95JE01503; TAUB IA, 1968, J CHEM PHYS, V49, P2499, DOI 10.1063/1.1670446; Vidal RA, 1997, SCIENCE, V276, P1839, DOI 10.1126/science.276.5320.1839; WESTLEY MS, 1995, NATURE, V373, P405, DOI 10.1038/373405a0	23	134	135	1	22	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 6	1998	394	6693					554	556		10.1038/29015	http://dx.doi.org/10.1038/29015			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	107YN	9707116				2022-12-28	WOS:000075238700039
J	Snijders, RJM; Noble, P; Sebire, N; Souka, A; Nicolaides, KH				Snijders, RJM; Noble, P; Sebire, N; Souka, A; Nicolaides, KH		Fetal Med Fdn First Trimester Screening Grp	UK multicentre project on assessment of risk of trisomy 21 by maternal age and fetal nuchal-translucency thickness at 10-14 weeks of gestation	LANCET			English	Article							CHROMOSOMAL DEFECTS; TWIN PREGNANCIES; FIRST-TRIMESTER	Background Prenatal diagnosis of trisomy 21 currently relies on assessment of risk followed by invasive testing in the 5% of pregnancies at the highest estimated risk. Selection of the high-risk group by a combination of maternal age and second-trimester maternal serum biochemistry gives a detection rate of about 60%. We investigated assessment of risk by a combination of maternal age and fetal nuchal-translucency thickness, measured by ultrasonography at 10-14 weeks of gestation. Methods The risk of trisomy 21 was estimated for 96 127 women of median age 31 years (range 14-49) with singleton pregnancies. Ultrasonography was done by 306 appropriately trained sonographers in 22 centres, Risk of trisomy 21 was calculated from the maternal age and gestational-age-related prevalence, multiplied by a likelihood ratio depending on the deviation from normal in nuchal-translucency thickness for crown-rump length. The distribution of risks was investigated and the sensitivity of a cut-off risk of 1 in 300 was calculated. Phenotype was assessed by fetal karyotyping or clinical examination of liveborn infants. Findings The estimated trisomy-21 risk, from maternal age and fetal nuchal-translucency thickness, was 1 in 300 or higher in 7907 (8.3%) of 95 476 normal pregnancies, 268 (82.2%) of 326 with trisomy 21, and 253 (77.9%) of 325 with other chromosomal defects. The 5% of the study population with the highest estimated risk included 77% of trisomy-21 cases, Interpretation Selection of the high-risk group for invasive testing by this method allows the detection of about 80% of affected pregnancies, However, even this method of risk assessment requires about 30 invasive tests for identification of one affected fetus.	Kings Coll London, Sch Med & Dent, Dept Obstet & Gynaecol, Harris Birthright Res Ctr Fetal Med, London, England	University of London; King's College London	Nicolaides, KH (corresponding author), Fetal Med Fdn, 8 Devonshite Pl, London W1N 1PB, England.		sebire, neil J/C-4960-2008	Sebire, Neil/0000-0001-5348-9063; Snijders, Rosalinde/0000-0003-1809-7886; Nicolaides, Kypros/0000-0003-1266-0711				*32 STUD GROUP ROY, 1997, SCREEN DOWN SYNDR FI, P353; Braithwaite JM, 1996, BRIT J OBSTET GYNAEC, V103, P82, DOI 10.1111/j.1471-0528.1996.tb09520.x; HECHT CA, 1994, PRENATAL DIAG, V14, P729, DOI 10.1002/pd.1970140814; Hyett J, 1997, AM J MED GENET, V69, P207, DOI 10.1002/(SICI)1096-8628(19970317)69:2<207::AID-AJMG18>3.0.CO;2-P; Hyett JA, 1997, ULTRASOUND OBST GYN, V10, P242, DOI 10.1046/j.1469-0705.1997.10040242.x; NICOLAIDES KH, 1994, BRIT J OBSTET GYNAEC, V101, P782, DOI 10.1111/j.1471-0528.1994.tb11946.x; NICOLAIDES KH, 1992, BRIT MED J, V304, P867, DOI 10.1136/bmj.304.6831.867; Pandya PP, 1995, BRIT J OBSTET GYNAEC, V102, P957, DOI 10.1111/j.1471-0528.1995.tb10902.x; PANDYA PP, 1995, ULTRASOUND OBST GYN, V5, P15, DOI 10.1046/j.1469-0705.1995.05010015.x; Pandya PP, 1996, ULTRASOUND OBST GYN, V7, P170, DOI 10.1046/j.1469-0705.1996.07030170.x; Sebire NJ, 1996, BRIT J OBSTET GYNAEC, V103, P999, DOI 10.1111/j.1471-0528.1996.tb09550.x; Sebire NJ, 1997, BRIT J OBSTET GYNAEC, V104, P1203, DOI 10.1111/j.1471-0528.1997.tb10948.x; Sepulveda W, 1996, ULTRASOUND OBST GYN, V7, P421, DOI 10.1046/j.1469-0705.1996.07060421.x; Snijders RJM, 1996, ULTRASOUND OBST GYN, V7, P216, DOI 10.1046/j.1469-0705.1996.07030216.x; SNIJDERS RJM, 1995, FETAL DIAGN THER, V10, P356, DOI 10.1159/000264259; Souka AP, 1997, ULTRASOUND OBST GYN, V10, P429, DOI 10.1046/j.1469-0705.1997.10060429.x; SZABO J, 1995, ULTRASOUND OBST GYN, V5, P161, DOI 10.1046/j.1469-0705.1995.05030161.x; Taipale P, 1997, NEW ENGL J MED, V337, P1654, DOI 10.1056/NEJM199712043372303; VILLE Y, 1992, ULTRASOUND OBST GYN, V2, P314, DOI 10.1046/j.1469-0705.1992.02050314.x; WALD NJ, 1988, BRIT MED J, V297, P883, DOI 10.1136/bmj.297.6653.883	20	1144	1215	0	43	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	AUG 1	1998	352	9125					343	346		10.1016/S0140-6736(97)11280-6	http://dx.doi.org/10.1016/S0140-6736(97)11280-6			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	106BU	9717920				2022-12-28	WOS:000075110500008
J	Kasper, J; Meyers, AF				Kasper, J; Meyers, AF			The UDHR and the physician's role	LANCET			English	Editorial Material									Boston Univ, Sch Med, Dept Gen Acad Pediat, Boston, MA 02118 USA	Boston University	Kasper, J (corresponding author), Boston Univ, Sch Med, Dept Gen Acad Pediat, 91 E Concord St, Boston, MA 02118 USA.			Meyers, Alan/0000-0002-1138-0024				EISENBERG L, 1984, AM J MED, V77, P524, DOI 10.1016/0002-9343(84)90114-1; United Nations Development Program, 1996, HUM DEV REP 1996; WHO (World Health Organization), 1998, WORLD HLTH REP 1998	3	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	AUG 29	1998	352	9129					733	733		10.1016/S0140-6736(98)08117-3	http://dx.doi.org/10.1016/S0140-6736(98)08117-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	116MT	9729007	hybrid			2022-12-28	WOS:000075729700049
J	Woods, WG				Woods, WG			Unravelling mysteries of neuroblastoma	LANCET			English	Editorial Material							N-MYC; STAGE		S Carolina Canc Ctr, Columbia, SC 29203 USA		Woods, WG (corresponding author), S Carolina Canc Ctr, Columbia, SC 29203 USA.							BESSHO F, 1991, J PEDIATR-US, V119, P237, DOI 10.1016/S0022-3476(05)80733-4; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; Brodeur GM, 1997, J PEDIAT HEMATOL ONC, V19, P93, DOI 10.1097/00043426-199703000-00001; BRODEUR GM, 1987, CANCER RES, V47, P4248; CAITIEBERRY RP, 1997, PEDIATR CLIN N AM, V44, P919; ESTEVE J, 1995, BRIT J CANCER, V71, P1125, DOI 10.1038/bjc.1995.219; NAKAGAWARA A, 1993, NEW ENGL J MED, V328, P847, DOI 10.1056/NEJM199303253281205; PRITCHARD J, 1994, LANCET, V344, P869, DOI 10.1016/S0140-6736(94)92834-7; TREUNER J, 1995, EUR J CANCER, V31A, P565, DOI 10.1016/0959-8049(95)00034-G; Woods WG, 1996, LANCET, V348, P1682, DOI 10.1016/S0140-6736(96)06020-5; WOODS WG, 1992, PEDIATRICS, V89, P114	11	0	0	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	AUG 29	1998	352	9129					667	668		10.1016/S0140-6736(05)60813-6	http://dx.doi.org/10.1016/S0140-6736(05)60813-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	116MT	9728975				2022-12-28	WOS:000075729700003
J	Baggeroer, AB; Birdsall, TG; Clark, C; Colosi, JA; Cornuelle, BD; Costa, D; Dushaw, BD; Dzieciuch, M; Forbes, AMG; Hill, C; Howe, BM; Marshall, J; Menemenlis, D; Mercer, JA; Metzger, K; Munk, W; Spindel, RC; Stammer, D; Worcester, PF; Wunsch, C				Baggeroer, AB; Birdsall, TG; Clark, C; Colosi, JA; Cornuelle, BD; Costa, D; Dushaw, BD; Dzieciuch, M; Forbes, AMG; Hill, C; Howe, BM; Marshall, J; Menemenlis, D; Mercer, JA; Metzger, K; Munk, W; Spindel, RC; Stammer, D; Worcester, PF; Wunsch, C		ATOC Consortium	Ocean climate change: Comparison of acoustic tomography, satellite altimetry, and modeling	SCIENCE			English	Article							CENTRAL NORTH PACIFIC; SEA-LEVEL; CIRCULATION MODEL; VARIABILITY; TRANSMISSIONS; ASSIMILATION	Comparisons of gyre-scale acoustic and direct thermal measurements of heat content in the Pacific Ocean, satellite altimeter measurements of sea surface height, and results from a general circulation model show that only about half of the seasonal and year-to-year changes in sea level are attributable to thermal expansion. Interpreting climate change signals from fluctuations in sea Level is therefore complicated. The annual cycle of heat flux is 150 +/- 25 watts per square meter (peak-to-peak, corresponding to a 0.2 degrees C vertically averaged temperature cycle); an interannual-change of similar magnitude is also detected. Meteorological estimates of surface heat flux, if accurate, require a Large seasonal cycle in the advective heat flux.	MIT, Dept Earth Atmospher & Planetary Sci, Cambridge, MA 02139 USA; MIT, Dept Ocean Engn, Cambridge, MA 02139 USA; Univ Michigan, Dept Comp Sci & Elect Engn, Ann Arbor, MI 48109 USA; Cornell Univ, Ornithol Lab, Ithaca, NY 14853 USA; Woods Hole Oceanog Inst, Dept Appl Ocean Phys & Engn, Woods Hole, MA 02543 USA; Univ Calif San Diego, Scripps Inst Oceanog, La Jolla, CA 92093 USA; Univ Calif Santa Cruz, Dept Biol, Santa Cruz, CA 95064 USA; Univ Washington, Appl Phys Lab, Seattle, WA 98105 USA; CSIRO, Div Oceanog, Hobart, Tas 7001, Australia	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); University of Michigan System; University of Michigan; Cornell University; Woods Hole Oceanographic Institution; University of California System; University of California San Diego; Scripps Institution of Oceanography; University of California System; University of California Santa Cruz; University of Washington; University of Washington Seattle; Commonwealth Scientific & Industrial Research Organisation (CSIRO)	Wunsch, C (corresponding author), MIT, Dept Earth Atmospher & Planetary Sci, Cambridge, MA 02139 USA.		Dzieciuch, Matthew/AAM-6469-2021; Menemenlis, Dimitris/G-8091-2017; Dzieciuch, Matthew/F-9342-2013; Howe, Bruce/J-2807-2012; Costa, Daniel/E-2616-2013	Dzieciuch, Matthew/0000-0001-7926-7602; Cornuelle, Bruce/0000-0003-2110-3319; Howe, Bruce/0000-0001-5711-5253; Costa, Daniel/0000-0002-0233-5782				*ATOC INSTR GROUP, 1995, OCEANS 95, V3, P1483; BARNIER B, 1995, J MARINE SYST, V6, P363, DOI 10.1016/0924-7963(94)00034-9; COLOSI JA, 1994, J ACOUST SOC AM, V96, P452, DOI 10.1121/1.411331; Daley R., 1991, ATMOSPHERIC DATA ANA; DUSHAW BD, 1993, J PHYS OCEANOGR, V23, P2650, DOI 10.1175/1520-0485(1993)023<2650:VOHCIT>2.0.CO;2; DUSHAW BD, 1994, J GEOPHYS RES-OCEANS, V99, P3263, DOI 10.1029/93JC03335; Dushaw BD, 1997, PROG OCEANOGR, V40, P337, DOI 10.1016/S0079-6611(98)00008-1; FRANKEL AS, IN PRESS CAN J ZOOL; FU LL, 1994, J GEOPHYS RES-OCEANS, V99, P24369, DOI 10.1029/94JC01761; Fukumori I, 1998, J GEOPHYS RES-OCEANS, V103, P5493, DOI 10.1029/97JC02907; Fukumori I, 1995, J GEOPHYS RES-OCEANS, V100, P25027, DOI 10.1029/95JC02083; GILL AE, 1973, DEEP-SEA RES, V20, P141, DOI 10.1016/0011-7471(73)90049-1; GILSON J, IN PRESS J GEOPHYS R; HOWE BM, 1996, 396 U WASH APPL PHYS; Levitus S., 1994, NOAA ATLAS NESDIS, V4; Levitus S. R., 1994, NOAA ATLAS NESDIS, V3; Marshall J, 1997, J GEOPHYS RES-OCEANS, V102, P5753, DOI 10.1029/96JC02775; MEIER MF, 1984, SCIENCE, V226, P1418, DOI 10.1126/science.226.4681.1418; Menemenlis D, 1997, J ATMOS OCEAN TECH, V14, P1420, DOI 10.1175/1520-0426(1997)014<1420:LOAOGC>2.0.CO;2; Menemenlis D, 1997, NATURE, V385, P618, DOI 10.1038/385618a0; MENEMENLIS D, IN PRESS MON WEATHER; Moisan JR, 1998, J PHYS OCEANOGR, V28, P401, DOI 10.1175/1520-0485(1998)028<0401:TSHBOT>2.0.CO;2; MUNK W, 1982, PHILOS T R SOC A, V307, P439, DOI 10.1098/rsta.1982.0120; Munk W., 1995, OCEAN ACOUSTIC TOMOG; Nerem RS, 1997, GEOPHYS RES LETT, V24, P1331, DOI 10.1029/97GL01288; PATULLO J, 1955, J MAR RES, V14, P88; Stammer D, 1996, J GEOPHYS RES-OCEANS, V101, P18409, DOI 10.1029/96JC01150; Stammer D, 1997, J GEOPHYS RES-OCEANS, V102, P20987, DOI 10.1029/97JC01475; White WB, 1995, J GEOPHYS RES-OCEANS, V100, P24943, DOI 10.1029/95JC02332; WORCESTER PF, UNPUB J ACOUST SOC A; Wunsch C, 1998, ANNU REV EARTH PL SC, V26, P219, DOI 10.1146/annurev.earth.26.1.219; Wunsch C, 1995, J GEOPHYS RES-OCEANS, V100, P24895, DOI 10.1029/95JC01783; Wunsch C, 1997, J PHYS OCEANOGR, V27, P1770, DOI 10.1175/1520-0485(1997)027<1770:TVPOOH>2.0.CO;2; WUNSCH C, 1972, REV GEOPHYS SPACE GE, V10, P1, DOI 10.1029/RG010i001p00001; WUNSCH C, 1996, OCEAN CIRCULATION IN	35	61	61	1	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 28	1998	281	5381					1327	1332						6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	115LQ	9721093				2022-12-28	WOS:000075666800043
J	Moghaddam, B; Adams, BW				Moghaddam, B; Adams, BW			Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats	SCIENCE			English	Article							NONCOMPETITIVE NMDA ANTAGONIST; EXCITATORY AMINO-ACIDS; SCHIZOPHRENIA; DYSFUNCTION; KETAMINE; CORTEX; MGLUR3; DIZOCILPINE; HYPOTHESIS; LY354740	Glutamatergic abnormalities have been associated with several psychiatric disorders, including schizophrenia and addiction. Group II metabotropic glutamate receptors were targeted to normalize glutamatergic disruptions associated with an animal model of schizophrenia, the phencyclidine model. An agonist of this group of receptors, at a dose that was without effects on spontaneous activity and corticolimbic dopamine neurotransmission, attenuated the disruptive effects of phencyclidine on working memory, stereotypy, Locomotion, and cortical glutamate efflux. This behavioral reversal occurred in spite of sustained dopamine hyperactivity. Thus, targeting this group of receptors may present a nondopaminergic: therapeutic strategy for treatment of psychiatric disorders.	Yale Univ, Sch Med, Dept Psychiat, Vet Adm Med Ctr, West Haven, CT 06516 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Connecticut Healthcare System; Yale University	Moghaddam, B (corresponding author), Yale Univ, Sch Med, Dept Psychiat, Vet Adm Med Ctr, 116A-2, West Haven, CT 06516 USA.	bita.moghaddam@yale.edu						Adams B, 1998, J NEUROSCI, V18, P5545, DOI 10.1523/JNEUROSCI.18-14-05545.1998; ANAND A, 1997, SOC NEUR ABSTR, V23; Battaglia G, 1997, NEUROSCI LETT, V229, P161, DOI 10.1016/S0304-3940(97)00442-4; BENES FM, 1992, CEREB CORTEX, V2, P503, DOI 10.1093/cercor/2.6.503; Bleuler E., 1950, DEMENTIA PRAECOX GRO; BUBSER M, 1995, J NEURAL TRANSM-GEN, V101, P115, DOI 10.1007/BF01271550; Bunney Blynn Garland, 1995, P1205; BURNS RS, 1976, CLIN TOXICOL, V9, P477; CARLSSON A, 1993, NEW GENERATION ANTIP, V4, P118; CARLSSON M, 1989, J NEURAL TRANSM, V75, P221, DOI 10.1007/BF01258633; Conn PJ, 1997, ANNU REV PHARMACOL, V37, P205, DOI 10.1146/annurev.pharmtox.37.1.205; Coyle JT, 1996, HARVARD REV PSYCHIAT, V3, P241, DOI 10.3109/10673229609017192; DEAKIN JFW, 1989, J NEUROCHEM, V52, P1781, DOI 10.1111/j.1471-4159.1989.tb07257.x; DEAKIN JFW, 1990, BRIT J PSYCHIAT, V157, P459, DOI 10.1192/bjp.157.3.459; EAST SJ, 1995, EUR J PHARMACOL, V277, P117, DOI 10.1016/0014-2999(95)00119-6; GOLDMANRAKIC PS, 1991, AM PSYCHOP, P1; Helton DR, 1998, J PHARMACOL EXP THER, V284, P651; IVERSEN SD, 1995, BEHAV PHARMACOL, V6, P478; JAVITT DC, 1991, AM J PSYCHIAT, V148, P1301; KIM JS, 1980, NEUROSCI LETT, V20, P379, DOI 10.1016/0304-3940(80)90178-0; KRYSTAL JH, 1994, ARCH GEN PSYCHIAT, V51, P199, DOI 10.1001/archpsyc.1994.03950030035004; LAHTI AC, 1995, NEUROPSYCHOPHARMACOL, V13, P9, DOI 10.1016/0893-133X(94)00131-I; LOVINGER DM, 1995, J NEUROPHYSIOL, V73, P1076, DOI 10.1152/jn.1995.73.3.1076; LUBY ED, 1959, ARCH NEURO PSYCHIATR, V81, P363, DOI 10.1001/archneurpsyc.1959.02340150095011; LYON N, 1986, J PSYCHIAT RES, V20, P137, DOI 10.1016/0022-3956(86)90013-0; Malhotra AK, 1996, NEUROPSYCHOPHARMACOL, V14, P301, DOI 10.1016/0893-133X(95)00137-3; Moghaddam B, 1997, J NEUROSCI, V17, P2921; NAKANISHI S, 1994, ANNU REV BIOPH BIOM, V23, P319, DOI 10.1146/annurev.bb.23.060194.001535; OGREN SO, 1994, NEUROPSYCHOPHARMACOL, V11, P167, DOI 10.1038/sj.npp.1380103; OLNEY JW, 1995, ARCH GEN PSYCHIAT, V52, P998; Petralia RS, 1996, NEUROSCIENCE, V71, P949, DOI 10.1016/0306-4522(95)00533-1; ROBBINS TW, 1990, SCHIZOPHRENIA BULL, V16, P391, DOI 10.1093/schbul/16.3.391; SCHMIDT WJ, 1994, J NEURAL TRANSM-SUPP, P63; SCHOEPP DD, 1993, TRENDS PHARMACOL SCI, V14, P13, DOI 10.1016/0165-6147(93)90107-U; Schoepp DD, 1997, NEUROPHARMACOLOGY, V36, P1, DOI 10.1016/S0028-3908(96)00160-8; Tamminga CA, 1998, CRIT REV NEUROBIOL, V12, P21, DOI 10.1615/CritRevNeurobiol.v12.i1-2.20; TSAI GC, 1995, ARCH GEN PSYCHIAT, V52, P829; WILLINS DL, 1993, PHARMACOL BIOCHEM BE, V46, P881, DOI 10.1016/0091-3057(93)90217-H; Wroblewska B, 1997, J NEUROCHEM, V69, P174	39	848	889	0	29	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 28	1998	281	5381					1349	1352		10.1126/science.281.5381.1349	http://dx.doi.org/10.1126/science.281.5381.1349			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	115LQ	9721099				2022-12-28	WOS:000075666800049
J	Wagner, AD; Schacter, DL; Rotte, M; Koutstaal, W; Maril, A; Dale, AM; Rosen, BR; Buckner, RL				Wagner, AD; Schacter, DL; Rotte, M; Koutstaal, W; Maril, A; Dale, AM; Rosen, BR; Buckner, RL			Building memories: Remembering and forgetting of verbal experiences as predicted by brain activity	SCIENCE			English	Article							EPISODIC MEMORY; FUNCTIONAL MRI; RETRIEVAL; HUMANS; SYSTEMS; MODEL; FMRI; PET	A fundamental question about human memory is why some experiences are remembered whereas others are forgotten. Brain activation during word encoding was measured using blocked and event-related functional magnetic resonance imaging to examine how neural activation differs for subsequently remembered and subsequently forgotten experiences. Results revealed that the ability to later remember a verbal experience is predicted by the magnitude of activation in left prefrontal and temporal cortices during that experience. These findings provide direct evidence that left prefrontal and temporal regions jointly promote memory formation for verbalizable events.	Harvard Univ, Sch Med, Massachusetts Gen Hosp, NMR Ctr, Charlestown, MA 02129 USA; Harvard Univ, Dept Psychol, Cambridge, MA 02138 USA; Washington Univ, Dept Psychol, St Louis, MO 63130 USA; Otto Von Guericke Univ, D-39120 Magdeburg, Germany	Harvard University; Massachusetts General Hospital; Harvard University; Washington University (WUSTL); Otto von Guericke University	Wagner, AD (corresponding author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, NMR Ctr, Charlestown, MA 02129 USA.		Dale, Anders M/A-5180-2010; Li, Chong/F-4265-2015	Schacter, Daniel/0000-0002-2460-6061; Wagner, Anthony/0000-0003-0624-4543	NATIONAL INSTITUTE ON AGING [R37AG008441, R01AG008441] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R03DC003245] Funding Source: NIH RePORTER; NIA NIH HHS [AG05778, AG08441] Funding Source: Medline; NIDCD NIH HHS [DC03245-02] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		Brewer JB, 1998, SCIENCE, V281, P1185, DOI 10.1126/science.281.5380.1185; Buckner RL, 1998, NEURON, V20, P285, DOI 10.1016/S0896-6273(00)80456-0; Buckner RL, 1998, P NATL ACAD SCI USA, V95, P891, DOI 10.1073/pnas.95.3.891; Buckner RL, 1998, NEUROIMAGE, V7, P151, DOI 10.1006/nimg.1998.0327; Buckner RL, 1996, PSYCHON B REV, V3, P149, DOI 10.3758/BF03212413; Cohen N. J., 1993, MEMORY AMNESIA HIPPO; CRAIK FIM, 1972, J VERB LEARN VERB BE, V11, P671, DOI 10.1016/S0022-5371(72)80001-X; Dale AM, 1997, HUM BRAIN MAPP, V5, P329, DOI 10.1002/(SICI)1097-0193(1997)5:5<329::AID-HBM1>3.0.CO;2-5; DEMB JB, 1995, J NEUROSCI, V15, P5870; DEsposito M, 1997, NEUROIMAGE, V6, P113, DOI 10.1006/nimg.1997.0281; Dolan RJ, 1997, NATURE, V388, P582, DOI 10.1038/41561; FABIANI M, 1995, J EXP PSYCHOL LEARN, V21, P224, DOI 10.1037/0278-7393.21.1.224; Fernandez G, 1998, J NEUROSCI, V18, P1841; Fiez JA, 1996, J NEUROSCI, V16, P808; FLETCHER PC, 1995, BRAIN, V118, P401, DOI 10.1093/brain/118.2.401; Gabrieli JDE, 1996, PSYCHOL SCI, V7, P278, DOI 10.1111/j.1467-9280.1996.tb00374.x; Gabrieli JDE, 1997, SCIENCE, V276, P264, DOI 10.1126/science.276.5310.264; HALGREN E, 1987, HUM NEUROBIOL, V6, P129; JONIDES J, 1993, NATURE, V363, P623, DOI 10.1038/363623a0; KAPUR S, 1994, P NATL ACAD SCI USA, V91, P2008, DOI 10.1073/pnas.91.6.2008; MOSCOVITCH M, 1992, J COGNITIVE NEUROSCI, V4, P257, DOI 10.1162/jocn.1992.4.3.257; Nyberg L, 1996, PSYCHON B REV, V3, P135, DOI 10.3758/BF03212412; PALLER KA, 1987, ELECTROEN CLIN NEURO, V67, P360, DOI 10.1016/0013-4694(87)90124-6; PETERSEN SE, 1988, NATURE, V331, P585, DOI 10.1038/331585a0; SANQUIST TF, 1980, PSYCHOPHYSIOLOGY, V17, P568, DOI 10.1111/j.1469-8986.1980.tb02299.x; SCOVILLE WB, 1957, J NEUROL NEUROSUR PS, V20, P11, DOI 10.1136/jnnp.20.1.11; SQUIRE LR, 1992, PSYCHOL REV, V99, P195, DOI 10.1037/0033-295X.99.2.195; Stern CE, 1996, P NATL ACAD SCI USA, V93, P8660, DOI 10.1073/pnas.93.16.8660; SUZUKI WA, 1994, J COMP NEUROL, V350, P497, DOI 10.1002/cne.903500402; Tulving E, 1996, CEREB CORTEX, V6, P71, DOI 10.1093/cercor/6.1.71; Wagner AD, 1997, J COGNITIVE NEUROSCI, V9, P714, DOI 10.1162/jocn.1997.9.6.714; Zarahn E, 1997, NEUROIMAGE, V5, P179, DOI 10.1006/nimg.1997.0263	32	1212	1229	4	116	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 21	1998	281	5380					1188	1191		10.1126/science.281.5380.1188	http://dx.doi.org/10.1126/science.281.5380.1188			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	113CE	9712582	Green Submitted			2022-12-28	WOS:000075531200052
J	Dale, GL; Alberio, L				Dale, GL; Alberio, L			Is there a correlation between raised erythropoietin and thrombotic events in sickle-cell anaemia?	LANCET			English	Article							RECOMBINANT-HUMAN-ERYTHROPOIETIN; VASCULAR OCCLUSION; DISEASE; STROKE; ANEMIA; ASPIRIN; HEMODIALYSIS; PROPHYLAXIS; HISTORY; TRIAL	Children with sickle-cell anaemia are predisposed to thrombotic strokes, the aetiology of which is unclear. We propose that erythropoietin, produced in response to chronic anaemia, is responsible for changes in platelet reactivity with a resulting increase in thromboses. Th is hypothesis is based on reports of en ha need aggregability of erythropoietin-driven platelets and an increased rate of thrombosis in patients receiving large doses of recombinant erythropoietin. Experiments in animals have shown that erythropoietin stimulates synthesis of platelets, that erythropoietin-driven platelets are hyper-reactive compared with age-matched control platelets, and that erythropoietin is pro-thrombotic. These data suggest that erythropoietin-dependent changes in platelet reactivity may potentiate thrombosis in sickle-cell anaemia, particularly in children who, compared with adults, have markedly higher erythropoietin concentrations and incidence of strokes.	Univ Oklahoma, Hlth Sci Ctr, Dept Med, Oklahoma City, OK 73190 USA	University of Oklahoma System; University of Oklahoma Health Sciences Center	Dale, GL (corresponding author), Univ Oklahoma, Hlth Sci Ctr, Dept Med, CHB-271,POB 26901, Oklahoma City, OK 73190 USA.			Alberio, Lorenzo/0000-0001-9686-9920	NHLBI NIH HHS [HL53585] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL053585] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADAMS RJ, 1995, J CHILD NEUROL, V10, P75, DOI 10.1177/088307389501000201; Akins PT, 1996, STROKE, V27, P1002, DOI 10.1161/01.STR.27.5.1002; ANDRE M, 1991, NOUV REV FR HEMATOL, V33, P299; BALKARAN B, 1992, J PEDIATR-US, V120, P360, DOI 10.1016/S0022-3476(05)80897-2; Beutler E., 1995, WILLIAMS HEMATOLOGY, P616; Bunn HF, 1997, NEW ENGL J MED, V337, P762, DOI 10.1056/NEJM199709113371107; CASES A, 1992, KIDNEY INT, V42, P668, DOI 10.1038/ki.1992.333; CHAPLIN H, 1980, THROMB HAEMOSTASIS, V43, P218; ERSLEV AJ, 1991, NEW ENGL J MED, V324, P1339, DOI 10.1056/NEJM199105093241907; FRANCIS RB, 1991, BLOOD COAGUL FIBRIN, V2, P341, DOI 10.1097/00001721-199104000-00018; FRANCIS RB, 1991, BLOOD, V77, P1405; French JA, 1997, BLOOD, V89, P4591, DOI 10.1182/blood.V89.12.4591; GLAUSER TA, 1995, J CHILD NEUROL, V10, P88, DOI 10.1177/088307389501000203; GREENBERG J, 1983, J PEDIATR-US, V102, P781, DOI 10.1016/S0022-3476(83)80258-3; HIRSH J, 1996, BRIT J HAEMATOL, V12, P44; Houston PE, 1997, AM J MED, V103, P192, DOI 10.1016/S0002-9343(97)00129-0; ISHIBASHI T, 1987, J CLIN INVEST, V79, P286, DOI 10.1172/JCI112796; KOOISTRA MP, 1994, NEPHROL DIAL TRANSPL, V9, P1115, DOI 10.1093/ndt/9.8.1115; LAUPACIS A, 1990, BMJ-BRIT MED J, V300, P573; Lipski DA, 1996, SURGERY, V119, P354, DOI 10.1016/S0039-6060(96)80124-3; MULLERSOYANO A, 1976, BLOOD, V47, P807; PALEK J, 1995, WILLIAMS HEMATOLOGY, P536; PEGELOW CH, 1995, J PEDIATR-US, V126, P896, DOI 10.1016/S0022-3476(95)70204-0; POWARS D, 1978, AM J MED, V65, P461, DOI 10.1016/0002-9343(78)90772-6; SEMPLE MJ, 1984, THROMB HAEMOSTASIS, V51, P303; Serjeant GR, 1997, BRIT J HAEMATOL, V97, P253, DOI 10.1046/j.1365-2141.1997.02701.x; SHERWOOD JB, 1986, BLOOD, V67, P46; Solovey A, 1997, NEW ENGL J MED, V337, P1584, DOI 10.1056/NEJM199711273372203; WINEARLS CG, 1986, LANCET, V2, P1175, DOI 10.1016/S0140-6736(86)92192-6; Wolf RF, 1997, THROMB HAEMOSTASIS, V78, P1505; Wolf RF, 1997, THROMB HAEMOSTASIS, V77, P1020	31	24	24	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 15	1998	352	9127					566	567		10.1016/S0140-6736(97)11506-9	http://dx.doi.org/10.1016/S0140-6736(97)11506-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	111KC	9716076				2022-12-28	WOS:000075435300044
J	Dunea, G				Dunea, G			It's the quality that counts	BRITISH MEDICAL JOURNAL			English	Editorial Material									Cook Cty Hosp, Chicago, IL 60612 USA	John H Stroger Junior Hospital Cook County	Dunea, G (corresponding author), Cook Cty Hosp, Chicago, IL 60612 USA.								0	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 15	1998	317	7156					480	480						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	112JF	9703552				2022-12-28	WOS:000075490200061
J	Topol, E; Califf, R; Simoons, M; Diaz, R; Paolasso, E; Klein, W; Boland, J; DeBacker, G; Armstrong, P; Corbalan, R; Isaza, D; Widimsky, P; Urrutia, C; Luomanmaki, K; Vahanian, A; Karsch, K; Cokkinos, D; Karatasakis, G; Toutouzas, P; Rodas, M; Keltai, M; Chierchia, S; Silva, E; Erikssen, J; Ruzyllo, W; Stepinska, J; Ribeiro, VD; Fernandez-Ortiz, A; Macaya, C; Goy, J; Deckers, J; Skene, A; Wilcox, R; Guerci, A; Harrington, R; Hochman, J; Holmes, D; Kleiman, N; Kopecky, S; Lee, K; Lincoff, A; Ohman, E; Pepine, C; Isea, J				Topol, E; Califf, R; Simoons, M; Diaz, R; Paolasso, E; Klein, W; Boland, J; DeBacker, G; Armstrong, P; Corbalan, R; Isaza, D; Widimsky, P; Urrutia, C; Luomanmaki, K; Vahanian, A; Karsch, K; Cokkinos, D; Karatasakis, G; Toutouzas, P; Rodas, M; Keltai, M; Chierchia, S; Silva, E; Erikssen, J; Ruzyllo, W; Stepinska, J; Ribeiro, VD; Fernandez-Ortiz, A; Macaya, C; Goy, J; Deckers, J; Skene, A; Wilcox, R; Guerci, A; Harrington, R; Hochman, J; Holmes, D; Kleiman, N; Kopecky, S; Lee, K; Lincoff, A; Ohman, E; Pepine, C; Isea, J		PURSUIT Trial Investigators	Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ACUTE MYOCARDIAL-INFARCTION; ATHERECTOMY TRIAL CAVEAT; UNSTABLE ANGINA; ANGIOPLASTY; INTERVENTION; THROMBOLYSIS; MULTICENTER; INTEGRELIN; RECEPTORS; HIRUDIN	Background Aggregation of platelets is the pathophysiologic basis of the acute coronary syndromes. Eptifibatide, a synthetic cyclic heptapeptide, is a selective high-affinity inhibitor of the platelet glycoprotein IIb/IIIa receptor, which is involved in platelet aggregation. We tested the hypothesis that inhibition of platelet aggregation with eptifibatide would have an incremental benefit beyond that of heparin and aspirin in reducing the frequency of adverse outcomes in patients with acute coronary syndromes who did not have persistent ST-segment elevation. Methods Patients who had presented with ischemic chest pain within the previous 24 hours and who had either electrocardiographic changes indicative of ischemia (but not persistent ST-segment elevation) or high serum concentrations of creatine kinase MB isoenzymes were enrolled in the study. They were randomly assigned, in a double-blind manner, to receive a bolus and infusion of either eptifibatide or placebo, in addition to standard therapy, for up to 72 hours (or up to 96 hours, if coronary intervention was performed near the end of the 72-hour period). The primary end point was a composite of death and nonfatal myocardial infarction occurring up to 30 days after the index event. Results A total of 10,948 patients were enrolled between November 1995 and January 1997. As compared with the placebo group, the eptifibatide group had a 1.5 percent absolute reduction in the incidence of the primary end point (14.2 percent, vs. 15.7 percent in the placebo group; P = 0.04). The benefit was apparent by 96 hours and persisted through 30 days. The effect was consistent in most major subgroups except for women (odds ratios for death or nonfatal myocardial infarction, 0.8 [95 percent confidence interval, 0.7 to 0.9] in men, and 1.1 [0.9 to 1.3] in women). Bleeding was more common in the eptifibatide group, although there was no increase in the incidence of hemorrhagic stroke. Conclusions inhibition of platelet aggregation with eptifibatide reduced the incidence of the composite end point of death or nonfatal myocardial infarction in patients with acute coronary syndromes who did not have persistent ST-segment elevation. (N Engl J Med 1998;339:436-43.) (C)1998, Massachusetts Medical Society.	Duke Univ, Clin Res Inst, Durham, NC 27705 USA	Duke University	Harrington, R (corresponding author), Duke Univ, Clin Res Inst, 2024 W Main St, Durham, NC 27705 USA.		Manolis, Antonis/F-5003-2014; Widimsky, Petr/P-8088-2016; Fernandez-Ortiz, Antonio/B-2227-2017; De Backer, Guy/AAI-4607-2021	Manolis, Antonis/0000-0002-0336-4745; Widimsky, Petr/0000-0001-5686-7752; Fernandez-Ortiz, Antonio/0000-0002-3239-1910; 				Abdelmeguid AE, 1996, CIRCULATION, V94, P3369, DOI 10.1161/01.CIR.94.12.3369; Alexander JH, 1998, AM HEART J, V135, P157, DOI 10.1016/S0002-8703(98)70357-6; ANTMAN EM, 1994, CIRCULATION, V90, P1624, DOI 10.1161/01.CIR.90.4.1624; Bazzino O, 1998, NEW ENGL J MED, V338, P1498; Bazzino O, 1998, NEW ENGL J MED, V338, P1488; Berkowitz SD, 1997, CIRCULATION, V95, P809; BITTL JA, 1995, NEW ENGL J MED, V333, P764, DOI 10.1056/NEJM199509213331204; BOEHRER JD, 1994, AM J CARDIOL, V74, P1166, DOI 10.1016/0002-9149(94)90474-X; BRAUNWALD E, 1994, CIRCULATION, V89, P1545; CALIFF RM, 1994, NEW ENGL J MED, V330, P956, DOI 10.1056/nejm199404073301402; Califf RM, 1998, J AM COLL CARDIOL, V31, P241, DOI 10.1016/S0735-1097(97)00506-8; *CAPTURE INV, 1997, LANCET, V350, P744; CHESEBRO JH, 1987, CIRCULATION, V76, P142, DOI 10.1161/01.CIR.76.1.142; CHESEBRO JH, 1992, NEW ENGL J MED, V327, P192, DOI 10.1056/NEJM199207163270310; COLLER BS, 1995, CIRCULATION, V92, P2373, DOI 10.1161/01.CIR.92.9.2373; ELLIOTT JM, 1995, CIRCULATION, V91, P2158, DOI 10.1161/01.CIR.91.8.2158; Hanrath P, 1997, CIRCULATION, V96, P1445; HARRINGTON RA, 1995, AM J CARDIOL, V76, P1222, DOI 10.1016/S0002-9149(99)80345-2; Harrington RA, 1997, AM J CARDIOL, V80, pB34, DOI 10.1016/S0002-9149(97)00575-4; HARRINGTON RA, 1995, J AM COLL CARDIOL, V25, P1693, DOI 10.1016/0735-1097(95)00091-H; Klootwijk P., 1997, Journal of the American College of Cardiology, V29, p367A; LEFKOVITS J, 1995, NEW ENGL J MED, V332, P1553, DOI 10.1056/NEJM199506083322306; Lincoff AM, 1997, J AM COLL CARDIOL, V30, P149, DOI 10.1016/S0735-1097(97)00110-1; Lincoff AM, 1997, AM J CARDIOL, V79, P286, DOI 10.1016/S0002-9149(96)00749-7; Mahaffey K. W., 1997, Journal of the American College of Cardiology, V29, p410A; PAMPALLONA S, 1994, J STAT PLAN INFER, V42, P19, DOI 10.1016/0378-3758(94)90187-2; Phillips DR, 1997, CIRCULATION, V96, P1488, DOI 10.1161/01.CIR.96.5.1488; PHILLIPS DR, 1988, BLOOD, V71, P831; Schulman SP, 1996, CIRCULATION, V94, P2083, DOI 10.1161/01.CIR.94.9.2083; SERRUYS PW, 1995, NEW ENGL J MED, V333, P757, DOI 10.1056/NEJM199509213331203; Simoons ML, 1997, LANCET, V349, P1429; TCHENG JE, 1995, CIRCULATION, V91, P2151, DOI 10.1161/01.CIR.91.8.2151; Tcheng JE, 1997, LANCET, V349, P1422; TOPOL E, 1994, CIRCULATION, V90, P1631; TOPOL E, 1993, NEW ENGL J MED, V329, P673, DOI 10.1056/nejm199309023291001; Topol E, 1998, CIRCULATION, V97, P2386; Topol EJ, 1997, JAMA-J AM MED ASSOC, V278, P479, DOI 10.1001/jama.278.6.479; Topol EJ, 1997, NEW ENGL J MED, V336, P1689; Topol EJ, 1996, NEW ENGL J MED, V335, P775; VANDEWERF F, 1995, JAMA-J AM MED ASSOC, V273, P1586, DOI 10.1001/jama.273.20.1586; WALI AU, 1997, CIRCULATION S1, V96, P597; YUSUF S, 1991, JAMA-J AM MED ASSOC, V266, P93, DOI 10.1001/jama.266.1.93	42	1330	1350	0	46	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 13	1998	339	7					436	443						8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	109UP	9705684				2022-12-28	WOS:000075342500004
J	Jackson, WC				Jackson, WC			In a word	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	2	2	4	14	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 12	1998	280	6					493	494		10.1001/jama.280.6.493	http://dx.doi.org/10.1001/jama.280.6.493			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	108AY	9707125				2022-12-28	WOS:000075244900001
J	Wellems, TE; Wootton, JC; Fujioka, H; Su, XZ; Cooper, R; Baruch, D; Fidock, DA				Wellems, TE; Wootton, JC; Fujioka, H; Su, XZ; Cooper, R; Baruch, D; Fidock, DA			P-falciparum CG2, linked to chloroquine resistance, does not resemble Na+/H+ exchangers	CELL			English	Article									NIAID, NIH, Bethesda, MD 20892 USA; NIH, Natl Ctr Biotechnol Informat, Natl Lib Med, Bethesda, MD 20894 USA; Case Western Reserve Univ, Dept Pathol, Cleveland, OH 44106 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Library of Medicine (NLM); Case Western Reserve University	Wellems, TE (corresponding author), NIAID, NIH, Bethesda, MD 20892 USA.			Su, Xinzhuan/0000-0003-3246-3248; Fidock, David/0000-0001-6753-8938				ALTSCHUL SF, 1994, NAT GENET, V6, P119, DOI 10.1038/ng0294-119; Altschul SF, 1996, METHOD ENZYMOL, V266, P460; FITCH CD, 1969, P NATL ACAD SCI USA, V64, P1181, DOI 10.1073/pnas.64.4.1181; JONES DT, 1994, BIOCHEMISTRY-US, V33, P3038, DOI 10.1021/bi00176a037; KROGSTAD DJ, 1987, SCIENCE, V238, P1283, DOI 10.1126/science.3317830; Ridley RG, 1998, CURR BIOL, V8, pR346, DOI 10.1016/S0960-9822(98)70218-0; Sanchez CP, 1997, J BIOL CHEM, V272, P2652, DOI 10.1074/jbc.272.5.2652; Sanchez CP, 1998, CELL, V92, P601, DOI 10.1016/S0092-8674(00)81127-7; SONNHAMMER ELL, 1998, IN PRESS ISMB; Su XZ, 1997, CELL, V91, P593, DOI 10.1016/S0092-8674(00)80447-X	10	21	21	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	AUG 7	1998	94	3					285	286		10.1016/S0092-8674(00)81471-3	http://dx.doi.org/10.1016/S0092-8674(00)81471-3			2	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	109EN	9708730	Bronze			2022-12-28	WOS:000075308400004
J	Kemp, M				Kemp, M			Shelley's shocks	NATURE			English	Editorial Material									Univ Oxford, Dept Hist Art, Oxford OX1 2PG, England	University of Oxford	Kemp, M (corresponding author), Univ Oxford, Dept Hist Art, 35 Beaumont St, Oxford OX1 2PG, England.								0	0	0	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 6	1998	394	6693					529	529		10.1038/28966	http://dx.doi.org/10.1038/28966			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	107YN	9707110	Bronze			2022-12-28	WOS:000075238700025
J	Mahoney, MS; Kahn, M				Mahoney, MS; Kahn, M			A medical mystery	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Tulane Univ, Sch Med, New Orleans, LA 70112 USA	Tulane University	Mahoney, MS (corresponding author), Tulane Univ, Sch Med, 1430 Tulane Ave, New Orleans, LA 70112 USA.		Kahn, Marc J/G-1682-2011						0	1	1	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 10	1998	339	11					745	745		10.1056/NEJM199809103391106	http://dx.doi.org/10.1056/NEJM199809103391106			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	116RF	9731091	Bronze			2022-12-28	WOS:000075737800006
J	Feldman, WC; Barraclough, BL; Maurice, S; Elphic, RC; Lawrence, DJ; Thomsen, DR; Binder, AB				Feldman, WC; Barraclough, BL; Maurice, S; Elphic, RC; Lawrence, DJ; Thomsen, DR; Binder, AB			Major compositional units of the moon: Lunar prospector thermal and fast neutrons	SCIENCE			English	Article							HYDROGEN CONTENT; SPECTRA	Global maps of thermal and fast neutron fluxes from the moon suggest three end-member compositional units. A high thermal and Low fast neutron flux unit correlates with the Lunar highlands and is consistent with feldspathic rocks. The South Pole-Aitken basin and a strip that surrounds the nearside maria have intermediate thermal and fast neutron flux Levels, consistent with more mafic rocks. There appears to be a smooth transition between the most mafic and feldspathic compositions, which correspond to Low and high surface altitudes, respectively. The maria show Low thermal and high fast neutron fluxes, consistent with basaltic rocks.	Univ Calif Los Alamos Natl Lab, Los Alamos, NM 87545 USA; Observ Midi Pyrenees, F-31400 Toulouse, France; Lunar Res Inst, Gilroy, CA 95020 USA	United States Department of Energy (DOE); Los Alamos National Laboratory; Universite de Toulouse; Universite Toulouse III - Paul Sabatier	Feldman, WC (corresponding author), Univ Calif Los Alamos Natl Lab, MS D-466, Los Alamos, NM 87545 USA.		Lawrence, David J/E-7463-2015	Lawrence, David J/0000-0002-7696-6667				ALCOUFFE RE, 1995, LA7369M LANL; Binder AB, 1998, SCIENCE, V281, P1475, DOI 10.1126/science.281.5382.1475; BYRD RC, 1994, LA12833MS LANL; DRAKE DM, 1988, J GEOPHYS RES-SOLID, V93, P6353, DOI 10.1029/JB093iB06p06353; Elphic RC, 1998, SCIENCE, V281, P1493, DOI 10.1126/science.281.5382.1493; FELDMAN WC, 1989, J GEOPHYS RES-SOLID, V94, P513, DOI 10.1029/JB094iB01p00513; Feldman WC, 1997, J GEOPHYS RES-PLANET, V102, P25565, DOI 10.1029/97JE02353; FELDMAN WC, 1991, GEOPHYS RES LETT, V18, P2157, DOI 10.1029/91GL02618; FELDMAN WC, 1986, NUCL INSTRUM METH A, V245, P182, DOI 10.1016/0168-9002(86)90274-3; Feldman WC, 1998, SCIENCE, V281, P1496, DOI 10.1126/science.281.5382.1496; FELDMAN WC, IN RPESS NUCL INST A; HASKIN L, 1991, LUNAR SOURCEBOOK USE, P357; LINGENFELTER RE, 1972, EARTH PLANET SC LETT, V16, P355, DOI 10.1016/0012-821X(72)90153-7; Lucey PG, 1998, J GEOPHYS RES-PLANET, V103, P3679, DOI 10.1029/97JE03019; LUCEY PG, 1994, SCIENCE, V266, P1855, DOI 10.1126/science.266.5192.1855; Masarik J, 1996, J GEOPHYS RES-PLANET, V101, P18891, DOI 10.1029/96JE01563; REEDY RC, METEOR PLANET SCI S, V33, pA127; Smith DE, 1997, J GEOPHYS RES-PLANET, V102, P1591, DOI 10.1029/96JE02940; Wieczorek MA, 1998, J GEOPHYS RES-PLANET, V103, P1715, DOI 10.1029/97JE03136	19	75	78	1	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 4	1998	281	5382					1489	1493		10.1126/science.281.5382.1489	http://dx.doi.org/10.1126/science.281.5382.1489			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	116RJ	9727971				2022-12-28	WOS:000075738100035
J	Wei, XY; Samarabandu, J; Devdhar, RS; Siegel, AJ; Acharya, R; Berezney, R				Wei, XY; Samarabandu, J; Devdhar, RS; Siegel, AJ; Acharya, R; Berezney, R			Segregation of transcription and replication sites into higher order domains	SCIENCE			English	Article							RNA-POLYMERASE-II; NUCLEAR MATRIX; CELLS NUCLEUS; VISUALIZATION; ORGANIZATION	Microscopy shows that individual sites of DNA replication and transcription of mammalian nuclei segregate into sets of roughly 22 and 16 higher order domains, respectively, Each domain set displayed a distinct network-like appearance, including regions of individual domains and interdigitation of domains between the two networks. These data support a dynamic mosaic model for the higher order arrangement of genomic function inside the cell nuclei.	SUNY Buffalo, Dept Biol Sci, Buffalo, NY 14260 USA; SUNY Buffalo, Dept Elect & Comp Engn, Buffalo, NY 14260 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	Berezney, R (corresponding author), SUNY Buffalo, Dept Biol Sci, Buffalo, NY 14260 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM023922] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 23922] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BASKIN Y, 1995, SCIENCE, V268, P1564, DOI 10.1126/science.7777854; BEREZNEY R, 1995, INT REV CYTOL B, V162; BEREZNEY R, 1984, CHROMOSOMAL NONHISTO, V4, P119; GOLDMAN MA, 1984, SCIENCE, V224, P686, DOI 10.1126/science.6719109; HASSAN AB, 1994, J CELL SCI, V107, P425; HATTON KS, 1988, MOL CELL BIOL, V8, P2149, DOI 10.1128/MCB.8.5.2149; HOFFMAN M, 1993, SCIENCE, V259, P1257, DOI 10.1126/science.8446894; JACKSON DA, 1993, EMBO J, V12, P1059, DOI 10.1002/j.1460-2075.1993.tb05747.x; NAKAYASU H, 1989, J CELL BIOL, V108, P1, DOI 10.1083/jcb.108.1.1; SAMARABANDU J, 1995, P SOC PHOTO-OPT INS, V2434, P370, DOI 10.1117/12.208708; SELIG S, 1992, EMBO J, V11, P1217, DOI 10.1002/j.1460-2075.1992.tb05162.x; SMITH HC, 1986, MOL CELL BIOCHEM, V70, P151; SPADARI S, 1985, ARZNEIMITTEL-FORSCH, V35-2, P1108; SPECTOR DL, 1993, ANNU REV CELL BIOL, V9, P265, DOI 10.1146/annurev.cellbio.9.1.265; STACK SM, 1977, J CELL SCI, V26, P281; WANSINK DG, 1994, J CELL SCI, V107, P1449; WANSINK DG, 1993, J CELL BIOL, V122, P283, DOI 10.1083/jcb.122.2.283; XING YG, 1993, SCIENCE, V259, P1326, DOI 10.1126/science.8446901; Zeng CM, 1998, P NATL ACAD SCI USA, V95, P1585, DOI 10.1073/pnas.95.4.1585; Zeng CM, 1997, P NATL ACAD SCI USA, V94, P6746, DOI 10.1073/pnas.94.13.6746	20	196	196	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 4	1998	281	5382					1502	1505		10.1126/science.281.5382.1502	http://dx.doi.org/10.1126/science.281.5382.1502			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	116RJ	9727975				2022-12-28	WOS:000075738100039
J	Hamlin, C; Sheard, S				Hamlin, C; Sheard, S			Revolutions in public health: 1848, and 1998?	BMJ-BRITISH MEDICAL JOURNAL			English	Article									Univ Notre Dame, Dept Hist, Notre Dame, IN 46556 USA; Univ Liverpool, Dept Publ Hlth, Liverpool L69 3BX, Merseyside, England	University of Notre Dame; University of Liverpool	Hamlin, C (corresponding author), Univ Notre Dame, Dept Hist, 219 Oshaughnessy Hall, Notre Dame, IN 46556 USA.	S.Hamlin.l@nd.edu						Bellamy C., 1988, ADM CENTRAL LOCAL RE; Brundage A, 1988, ENGLANDS PRUSSIAN MI; Bynum W. F., 1994, SCI PRACTICE MED 19; Chadwick Edwin, 1965, REPORT SANITARY COND; Finer SE, 1952, LIFE TIMES E CHADWIC; FRAZER WM, 1947, DUNCAN LIVERPOOL BEI; HAMLIN C, 1995, AM J PUBLIC HEALTH, V85, P856, DOI 10.2105/AJPH.85.6.856; Hamlin C., 1998, PUBLIC HLTH SOCIAL J; *HLTH TOWNS ASS, 1846, REP COMM MEM ASS LIN; Kearns G., 1988, SOC HLTH POPULATION, P213; Kunitz Stephen J., 1994, DIS SOCIAL DIVERSITY; Law C.M., 1967, T I BRIT GEOGR, V41, P125, DOI DOI 10.2307/621331; Lewis J, 1986, WHAT PRICE COMMUNITY; Lewis RA, 1952, E CHADWICK PUBLIC HL; MacDonagh Oliver, 1977, EARLY VICTORIAN GOVT; OLIEN DD, 1983, MORPETH VICTORIAN PU; PATERSON ROBERT G., 1948, BULL HISTORY MED, V22, P373; Pelling Margaret, 1978, CHOLERA FEVER ENGLIS; Petersen A. R., 1996, NEW PUBLIC HLTH DISC; Poovey Mary, 1995, MAKING SOCIAL BODY B; ROSEN G, 1947, Bull Hist Med, V21, P674; Rosen George, 1958, HIST PUBLIC HLTH; Smith F. B., 1979, PEOPLES HLTH 1830 19; Szreter S, 1998, ECON HIST REV, V51, P84, DOI 10.1111/1468-0289.00084; Tesh S.N., 1988, HIDDEN ARGUMENTS POL; TURSHEN M, 1989, POLITICS PUBLIC HLTH; Wohl Anthony, 1983, ENDANGERED LIVES PUB	27	56	56	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 29	1998	317	7158					587	591		10.1136/bmj.317.7158.587	http://dx.doi.org/10.1136/bmj.317.7158.587			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	117EK	9721121	Green Published			2022-12-28	WOS:000075767800023
J	Heneine, W; Tibell, A; Switzer, WM; Sandstrom, P; Rosales, GV; Mathews, A; Korsgren, O; Chapman, LE; Folks, TM; Groth, CG				Heneine, W; Tibell, A; Switzer, WM; Sandstrom, P; Rosales, GV; Mathews, A; Korsgren, O; Chapman, LE; Folks, TM; Groth, CG			No evidence of infection with porcine endogenous retrovirus in recipients of porcine islet-cell xenografts	LANCET			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; REVERSE-TRANSCRIPTASE; DIABETIC-PATIENTS; TRANSPLANTATION; ASSAY; XENOTRANSPLANTATION; SURVIVAL; PLASMA	Background The study of whether porcine xenografts can lead to porcine endogenous retrovirus (PERV) infection of recipients is critical for evaluating the safety of pig-to-man xenotransplantation. PERV is carried in the pig germline, and all recipients of porcine tissues or organs will be exposed to the virus. Methods We studied 10 diabetic patients who had received porcine fetal islets between 1990 and 1993, looking for evidence of PERV infection by using PCR serology, PCR, and reverse transcriptase assays. Prolonged xenograft survival (up to a year) was confirmed in five patients by porcine C-peptide excretion and detection of pig mitochondrial DNA (mtDNA) in serum. Findings Despite the evidence for extended exposure to pig cells and despite concomitant immunosuppressive therapy, we were unable to detect markers of PERV infection in any patient, Screening for two PERV sequences in peripheral blood lymphocytes collected 4-7 years after the xenotransplantation was negative. Markers of PERV expression, including viral RNA and reverse transcriptase, were undetectable in sera from both early (day 3 to day 180) and late (4-7 years) time points. Western blot analysis for antibodies was consistently negative, Interpretation These results suggested the absence of PERV infection in these patients. Also this study establishes a minimum standard for post-transplant surveillance of patients given porcine xenografts.	Ctr Dis Control & Prevent, HIV & Retrovirol Branch, Natl Ctr Infect Dis, Atlanta, GA 30333 USA; Karolinska Inst, Huddinge Hosp, Dept Transplantat Surg, S-10401 Stockholm, Sweden; Univ Uppsala, Acad Hosp, Dept Clin Immunol, S-75105 Uppsala, Sweden	Centers for Disease Control & Prevention - USA; Karolinska Institutet; Uppsala University	Heneine, W (corresponding author), Ctr Dis Control & Prevent, HIV & Retrovirol Branch, Natl Ctr Infect Dis, 1600 Clifton Rd NE,Mail Stop G-19, Atlanta, GA 30333 USA.	WMH2@cdc.gov		Korsgren, Olle/0000-0002-8524-9547				Akiyoshi DE, 1998, J VIROL, V72, P4503, DOI 10.1128/JVI.72.5.4503-4507.1998; Bjoersdorff A., 1995, Xenotransplantation, V2, P26, DOI 10.1111/j.1399-3089.1995.tb00062.x; Busch Michael P., 1997, American Journal of Medicine, V102, P117, DOI 10.1016/S0002-9343(97)00077-6; CHAPMAN LE, 1995, NEW ENGL J MED, V333, P1498, DOI 10.1056/NEJM199511303332211; CHARI RS, 1994, NEW ENGL J MED, V331, P234, DOI 10.1056/NEJM199407283310404; COFFIN J M, 1990, P1437; Deacon T, 1997, NAT MED, V3, P350, DOI 10.1038/nm0397-350; DUNNING JJ, 1994, PATHOL BIOL, V42, P231; GALILI U, 1995, TRANSPLANTATION, V59, P1549, DOI 10.1097/00007890-199506150-00008; GROTH CG, 1994, LANCET, V344, P1402, DOI 10.1016/S0140-6736(94)90570-3; HENEINE W, 1995, J INFECT DIS, V171, P1210, DOI 10.1093/infdis/171.5.1210; KAPLAN JE, 1993, REV MED VIROL, V3, P137, DOI 10.1002/rmv.1980030304; Lerma JGG, 1998, J INFECT DIS, V177, P1221, DOI 10.1086/515272; LeTissier P, 1997, NATURE, V389, P681, DOI 10.1038/39489; LIEBER MM, 1975, VIROLOGY, V66, P616, DOI 10.1016/0042-6822(75)90234-2; LUTZ H, 1983, AM J VET RES, V44, P2054; MULDER J, 1994, J CLIN MICROBIOL, V32, P292, DOI 10.1128/JCM.32.2.292-300.1994; Patience C, 1997, NAT MED, V3, P282, DOI 10.1038/nm0397-282; SAIKI RK, 1986, NATURE, V324, P163, DOI 10.1038/324163a0; Satake Masahiro, 1994, Xenotransplantation, V1, P24, DOI 10.1111/j.1399-3089.1994.tb00047.x; SHERR CJ, 1975, J VIROL, V15, P1440, DOI 10.1128/JVI.15.6.1440-1448.1975; SUZUKA I, 1986, FEBS LETT, V198, P339, DOI 10.1016/0014-5793(86)80432-X; TIBELL A, 1994, TRANSPLANT P, V26, P1121; Watson A, 1997, J VIROL, V71, P284, DOI 10.1128/JVI.71.1.284-290.1997; Wilson CA, 1998, J VIROL, V72, P3082, DOI 10.1128/JVI.72.4.3082-3087.1998; Yamamoto S, 1996, J VIROL METHODS, V61, P135, DOI 10.1016/0166-0934(96)02078-2	26	287	306	1	15	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 29	1998	352	9129					695	699		10.1016/S0140-6736(98)07145-1	http://dx.doi.org/10.1016/S0140-6736(98)07145-1			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	116MT	9728986				2022-12-28	WOS:000075729700014
J	Martin, U; Kiessig, V; Blusch, JH; Haverich, A; von der Helm, K; Herden, T; Steinhoff, G				Martin, U; Kiessig, V; Blusch, JH; Haverich, A; von der Helm, K; Herden, T; Steinhoff, G			Expression of pig endogenous retrovirus by primary porcine endothelial cells and infection of human cells	LANCET			English	Article								Background The risk of interspecies transmission of retroviruses during xenotransplantation is suggested by reports of pig endogenous retrovirus (PERV) released from porcine cell lines productively infecting human cell lines in vitro and of infectious PERV being released from pig peripheral blood mononuclear cells after mitogenic stimulation. Endothelial cells are the main interface between a xenograft and the recipient's leucocytes and tissues. Methods We have analysed pig primary aortic endothelial cells (PAEC) together with other transplantation-relevant porcine cells and tissues for expression of PERV mRNA. Release of virus particles by PAEC was monitored by reverse transcriptase (RT) activity in the medium of cultured PAEC. Infectivity for human cells was tested by co-cultivation of irradiated PAEC with the human embryonal kidney cell line HEK293 and looking for virus release from the human cells. Findings PAECs, hepatocytes, lung, and skin from a variety of pig strains and breeds expressed PERV mRNA, PAEC released infectious particles. Go-cultivation of PAEC and HEK293 led to productive infection of the human cells and expression of PERV types A and B. Interpretation Release of infectious virus from PAEC occurred without mitogenic stimulation, suggesting a serious risk of retrovirus transfer after xenotransplantation.	Hannover Med Sch, Leibniz Res Labs Biotechnol & Artificial Organs, D-30659 Hannover, Germany; Hannover Med Sch, Dept Thorac & Cardiovasc Surg, D-30659 Hannover, Germany; Pettenkofer Inst, Munich, Germany	Hannover Medical School; Hannover Medical School	Martin, U (corresponding author), Hannover Med Sch, Leibniz Res Labs Biotechnol & Artificial Organs, Podbielskistr 380, D-30659 Hannover, Germany.		Martin, Ulrich/F-4888-2017; Haverich, Axel/AAC-7552-2022	Martin, Ulrich/0000-0003-1058-4540; 				Bach FH, 1998, NATURE, V391, P326, DOI 10.1038/34766; Heneine W, 1996, TRANSPLANTATION, V62, P1360, DOI 10.1097/00007890-199611150-00033; Hoopes CW, 1997, TRANSPLANTATION, V64, P347, DOI 10.1097/00007890-199707270-00029; LeTissier P, 1997, NATURE, V389, P681, DOI 10.1038/39489; Patience C, 1997, NAT MED, V3, P282, DOI 10.1038/nm0397-282; SAIFUDDIN M, 1995, J EXP MED, V182, P501, DOI 10.1084/jem.182.2.501; SILVER J, 1993, NUCLEIC ACIDS RES, V21, P3593, DOI 10.1093/nar/21.15.3593; Vogel G, 1998, SCIENCE, V279, P648, DOI 10.1126/science.279.5351.648; Weiss RA, 1998, NATURE, V391, P327, DOI 10.1038/34772; Wilson CA, 1998, J VIROL, V72, P3082, DOI 10.1128/JVI.72.4.3082-3087.1998; 1998, NAT MED, V4, P131; 1998, NATURE, V391, P309	12	270	280	0	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	AUG 29	1998	352	9129					692	694		10.1016/S0140-6736(98)07144-X	http://dx.doi.org/10.1016/S0140-6736(98)07144-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	116MT	9728985				2022-12-28	WOS:000075729700013
J	Patience, C; Patton, GS; Takeuchi, Y; Weiss, RA; McClure, MO; Rydberg, L; Breimer, ME				Patience, C; Patton, GS; Takeuchi, Y; Weiss, RA; McClure, MO; Rydberg, L; Breimer, ME			No evidence of pig DNA or retroviral infection in patients with short-term extracorporeal connection to pig kidneys	LANCET			English	Article							EX-VIVO CONNECTION; HUMANS; CELLS	Background The xenotransplantation of organs and tissues, in particular those from pigs, is viewed as a means to alleviate the shortage of human donor organs and cells available for transplantation and also as a therapy for other diseases. The potential microbiological hazards of xenotransplantation have recently attracted much attention. One concern is over pig endogenous retroviruses (PERV). Until the possible consequences of infection by PERV are better understood it is unlikely that a significant number of porcine xenotransplants will proceed. However, a small number of patients have already been treated with dr exposed to living porcine cells or tissue, and investigation of these patients may provide valuable information. Methods We took serial blood samples from two renal dialysis patients whose circulation had been linked extracorporeally to pig kidneys and tested them for pig DNA and PERV DNA by nested PCR. The patients' plasma was also tested for neutralising antibodies to two anthropotropic PERV strains. Findings Having established that the nested PCRs could detect single molecules of target sequence, we analysed DNA isolated from patients' peripheral blood mononuclear cells. We found no evidence of pig or PERV DNA in either patient, even in samples taken as early as 6 h after the perfusion. Furthermore, we found no evidence of seroconversion for PERV-specific antibodies. Interpretation The absence of porcine cells in the circulation of both patients, even in the samples taken soon after the perfusion experiment, suggests that any porcine cells dislodged from the kidney became rapidly sequestered from the circulation. Since cell-to-cell contact increases the efficency of infection of PERV this removal of porcine cells may increase the risk of transmission of PERV to the xenograft recipient. We did not, however, detect indications of infection by PERV by PCR or neutralisation assay. The genetic and serological methods described here will be useful for detection of possible PERV infection in other patients.	Inst Canc Res, Chester Beatty Labs, Sect Virol, London SW3 6JB, England; Univ London Imperial Coll Sci Technol & Med, St Marys, Sch Med, Dept GU Med & Communicable Dis, London, England; Univ Gothenburg, Sahlgrenska Hosp, Dept Clin Chem, Goteborg, Sweden; Univ Gothenburg, Sahlgrenska Hosp, Dept Transfus Med, Goteborg, Sweden; Univ Gothenburg, Sahlgrenska Hosp, Dept Surg, Goteborg, Sweden	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Imperial College London; Sahlgrenska University Hospital; University of Gothenburg; Sahlgrenska University Hospital; University of Gothenburg; Sahlgrenska University Hospital; University of Gothenburg	Patience, C (corresponding author), Inst Canc Res, Chester Beatty Labs, Sect Virol, 237 Fulham Rd, London SW3 6JB, England.							Breimer ME, 1996, XENOTRANSPLANTATION, V3, P328, DOI 10.1111/j.1399-3089.1996.tb00155.x; Heneine W, 1996, TRANSPLANTATION, V62, P1360, DOI 10.1097/00007890-199611150-00033; Hoopes CW, 1997, TRANSPLANTATION, V64, P347, DOI 10.1097/00007890-199707270-00029; LeTissier P, 1997, NATURE, V389, P681, DOI 10.1038/39489; Patience C, 1997, NAT MED, V3, P282, DOI 10.1038/nm0397-282; Rydberg L, 1996, XENOTRANSPLANTATION, V3, P340, DOI 10.1111/j.1399-3089.1996.tb00156.x; TAKEUCHI Y, IN PRESS J VIROL	7	246	257	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	AUG 29	1998	352	9129					699	701		10.1016/S0140-6736(98)04369-4	http://dx.doi.org/10.1016/S0140-6736(98)04369-4			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	116MT	9728987				2022-12-28	WOS:000075729700015
J	Rakitzis, TP; Kandel, SA; Alexander, AJ; Kim, ZH; Zare, RN				Rakitzis, TP; Kandel, SA; Alexander, AJ; Kim, ZH; Zare, RN			Photofragment helicity caused by matter-wave interference from multiple dissociative states	SCIENCE			English	Article							VECTOR PROPERTIES; PHOTODISSOCIATION; POLARIZATION; ORIENTATION; ALIGNMENT; MOLECULES; FRAGMENTS; LIGHT; ATOMS; ICN	Isolated diatomic molecules of iodine monochloride (ICL) were photodissociated by a beam of Linearly polarized light, and the resulting ground-state CL atom photofragments were detected by a method that is sensitive to the handedness (helicity) of the electronic angular momentum. It was found that this helicity oscillates between "topspin" and "backspin" as a function of the wavelength of the dissociating light. The helicity originates solely from the (de Broglie) matter-wave interference of multiple dissociating pathways of the electronic excited states of ICI. These measurements can be related to the identity and to the detailed shapes of the dissociating pathways, thus demonstrating that it is possible to probe repulsive states by spectroscopic means.	Stanford Univ, Dept Chem, Stanford, CA 94305 USA	Stanford University	Zare, RN (corresponding author), Stanford Univ, Dept Chem, Stanford, CA 94305 USA.		Zare, Richard N./A-8410-2009; Alexander, Andrew J/E-5330-2011; Kim, Zee Hwan/A-9273-2010; Rakitzis, Peter/ABA-1640-2021; Rakitzis, T. Peter/C-5564-2011	Alexander, Andrew J/0000-0002-0897-020X; Rakitzis, T. Peter/0000-0002-0385-3936; Zare, Richard/0000-0001-5266-4253				BLACK JF, 1990, MOL PHYS, V71, P1143, DOI 10.1080/00268979000102381; FLEMMING E, 1995, J CHEM PHYS, V103, P4090, DOI 10.1063/1.469595; GLASSMAUJEAN M, 1987, PHYS REV A, V36, P1170, DOI 10.1103/PhysRevA.36.1170; HACK E, 1991, INT REV PHYS CHEM, V10, P287, DOI 10.1080/01442359109353260; HASSELBRINK E, 1988, CHEM PHYS, V126, P191, DOI 10.1016/0301-0104(88)85032-8; KUPRIYANOV DV, 1993, CHEM PHYS, V171, P25, DOI 10.1016/0301-0104(93)85129-V; KUPRIYANOV DV, 1990, Z PHYS D ATOM MOL CL, V15, P105, DOI 10.1007/BF01437004; KUPRIYANOV DV, 1993, J PHYS B-AT MOL OPT, V26, pL803, DOI 10.1088/0953-4075/26/23/001; ORREWING AJ, 1994, ISR J CHEM, V34, P95; ORREWING AJ, 1994, ANNU REV PHYS CHEM, V45, P315, DOI 10.1146/annurev.physchem.45.1.315; Rakitzis TP, 1998, J CHEM PHYS, V108, P8291, DOI 10.1063/1.476257; Rakitzis TP, 1997, J CHEM PHYS, V107, P9382, DOI 10.1063/1.475235; RAKITZIS TP, UNPUB; Schinke R, 1992, PHOTODISSOCIATION DY; SIEBBELES LDA, 1992, J CHEM SOC FARADAY T, V88, P2565, DOI 10.1039/ft9928802565; SIEBBELES LDA, 1994, J CHEM PHYS, V100, P3610, DOI 10.1063/1.466402; TONOKURA K, 1993, J CHEM PHYS, V99, P3461, DOI 10.1063/1.466169; VASYUTINSKII OS, 1980, OPT SPECTROSC, V51, P124; VASYUTINSKII OS, 1981, ZH EKSP TEOR FIZ, V54, P855	20	90	91	2	57	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 28	1998	281	5381					1346	1349		10.1126/science.281.5381.1346	http://dx.doi.org/10.1126/science.281.5381.1346			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	115LQ	9721098				2022-12-28	WOS:000075666800048
J	Thornberry, NA; Lazebnik, Y				Thornberry, NA; Lazebnik, Y			Caspases: Enemies within	SCIENCE			English	Review							INTERLEUKIN-1-BETA CONVERTING-ENZYME; CELL-DEATH; CYSTEINE PROTEASE; LAMIN-A; APOPTOSIS; INHIBITION; ACTIVATION; SUBSTRATE; CLEAVAGE; EFFECTOR	Apoptosis, an evolutionarily conserved form of cell suicide, requires specialized machinery. The central component of this machinery is a proteolytic system involving a family of proteases called caspases. These enzymes participate in a cascade that is triggered in response to proapoptotic signals and culminates in cleavage of a set of proteins, resulting in disassembly of the cell. Understanding caspase regulation is intimately Linked to the ability to rationally manipulate apoptosis for therapeutic gain.	Merck Res Labs, Dept Biochem, Rahway, NJ 07065 USA; Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA	Merck & Company; Cold Spring Harbor Laboratory	Thornberry, NA (corresponding author), Merck Res Labs, Dept Biochem, R80W-250,POB 2000, Rahway, NJ 07065 USA.							Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; BELTRAMI E, 1995, P NATL ACAD SCI USA, V92, P8744, DOI 10.1073/pnas.92.19.8744; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; BUMP NJ, 1995, SCIENCE, V269, P1885, DOI 10.1126/science.7569933; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; Cryns VL, 1997, J BIOL CHEM, V272, P29449, DOI 10.1074/jbc.272.47.29449; Davidson FF, 1998, NATURE, V391, P587, DOI 10.1038/35385; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; Deveraux QL, 1998, EMBO J, V17, P2215, DOI 10.1093/emboj/17.8.2215; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; GU Y, 1995, EMBO J, V14, P1923, DOI 10.1002/j.1460-2075.1995.tb07184.x; HAKEM R, IN PRESS CELL; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Koseki T, 1998, P NATL ACAD SCI USA, V95, P5156, DOI 10.1073/pnas.95.9.5156; Kothakota S, 1997, SCIENCE, V278, P294, DOI 10.1126/science.278.5336.294; KUIDA K, IN PRESS CELL; LI P, 1997, IN PRESS CELL, V91, P479; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; Muzio M, 1998, J BIOL CHEM, V273, P2926, DOI 10.1074/jbc.273.5.2926; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; Orth K, 1996, J BIOL CHEM, V271, P16443, DOI 10.1074/jbc.271.28.16443; Porter AG, 1997, BIOESSAYS, V19, P501, DOI 10.1002/bies.950190609; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; RAY CA, 1992, CELL, V69, P597, DOI 10.1016/0092-8674(92)90223-Y; Rheaume E, 1997, EMBO J, V16, P6346, DOI 10.1093/emboj/16.21.6346; Rotonda J, 1996, NAT STRUCT BIOL, V3, P619, DOI 10.1038/nsb0796-619; Rudel T, 1997, SCIENCE, V276, P1571, DOI 10.1126/science.276.5318.1571; Seshagiri S, 1997, P NATL ACAD SCI USA, V94, P13606, DOI 10.1073/pnas.94.25.13606; Shu HB, 1997, IMMUNITY, V6, P751, DOI 10.1016/S1074-7613(00)80450-1; Takahashi A, 1996, P NATL ACAD SCI USA, V93, P8395, DOI 10.1073/pnas.93.16.8395; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; Thornberry NA, 1998, CHEM BIOL, V5, pR97, DOI 10.1016/S1074-5521(98)90615-9; Uren AG, 1998, TRENDS BIOCHEM SCI, V23, P159, DOI 10.1016/S0968-0004(98)01198-0; WALKER NPC, 1994, CELL, V78, P343, DOI 10.1016/0092-8674(94)90303-4; Wen LP, 1997, J BIOL CHEM, V272, P26056, DOI 10.1074/jbc.272.41.26056; WILSON KP, 1994, NATURE, V370, P270, DOI 10.1038/370270a0; XUE D, 1995, NATURE, V377, P248, DOI 10.1038/377248a0; Xue D, 1997, NATURE, V390, P305, DOI 10.1038/36889; Yang XL, 1998, MOL CELL, V1, P319, DOI 10.1016/S1097-2765(00)80032-5; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9	48	5893	6220	9	412	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 28	1998	281	5381					1312	1316		10.1126/science.281.5381.1312	http://dx.doi.org/10.1126/science.281.5381.1312			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	115LQ	9721091				2022-12-28	WOS:000075666800040
J	Xu, L; Anwyl, R; Rowan, MJ				Xu, L; Anwyl, R; Rowan, MJ			Spatial exploration induces a persistent reversal of long-term potentiation in rat hippocampus	NATURE			English	Article							SYNAPTIC PLASTICITY; IN-VIVO; BRAIN TEMPERATURE; MOTOR-ACTIVITY; 1-5 HZ; DEPRESSION; DEPOTENTIATION; STIMULATION; MEMORY; ASSOCIATION	Experience-dependent long-lasting increases in excitatory synaptic transmission in the hippocampus are believed to underlie certain types of memory(1-3). Whereas stimulation of hippocampal pathways in freely moving rats can readily elicit a long-term potentiation (LTP) of transmission that may last for weeks, previous studies have failed to detect persistent increases in synaptic efficacy after hippocampus-mediated learning(4-6). As changes in synaptic efficacy are contingent on the history of plasticity at the synapses(7), we have examined the effect of experience-dependent hippocampal activation on transmission after the induction of LTP, We show that exploration of a new, non-stressful environment rapidly induces a complete and persistent reversal of the expression of high-frequency stimulation-induced early-phase LTP in the CA1 area of the hippocampus, without affecting baseline transmission in a control pathway. LTP expression is not affected by exploration of familiar environments. We found that spatial exploration affected LTP within a defined time window because neither the induction of LTP nor the maintenance of long-established LTP was blocked. The discovery of a novelty-induced reversal of LTP expression provides strong evidence that extensive long-lasting decreases in synaptic efficacy may act in tandem with enhancements at selected synapses to allow the detection and storage of new information by the hippocampus.	Trinity Coll, Dept Pharmacol & Therapeut, Dublin 2, Ireland; Trinity Coll, Dept Physiol, Dublin 2, Ireland; Chinese Acad Sci, Kunming Inst Zool, Kunming, Peoples R China	Trinity College Dublin; Trinity College Dublin; Chinese Academy of Sciences; Kunming Institute of Zoology	Rowan, MJ (corresponding author), Trinity Coll, Dept Pharmacol & Therapeut, Dublin 2, Ireland.		Xu, Lin/T-5531-2017	Xu, Lin/0000-0002-2710-3507; Rowan, Michael Joseph/0000-0002-3867-9536	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Abraham WC, 1996, TRENDS NEUROSCI, V19, P126, DOI 10.1016/S0166-2236(96)80018-X; BLAND BH, 1986, PROG NEUROBIOL, V26, P1, DOI 10.1016/0301-0082(86)90019-5; BUZSAKI G, 1989, NEUROSCIENCE, V31, P551, DOI 10.1016/0306-4522(89)90423-5; Doyle C, 1996, J NEUROSCI, V16, P418; Doyle CA, 1997, NEUROSCIENCE, V77, P75, DOI 10.1016/S0306-4522(96)00427-7; Dudai Y, 1996, NEURON, V17, P367, DOI 10.1016/S0896-6273(00)80168-3; Eichenbaum H, 1996, CURR OPIN NEUROBIOL, V6, P187, DOI 10.1016/S0959-4388(96)80072-9; ERICKSONLAMY K, 1993, BASIC ASPECTS GLAUCO, V3, P275; ERRINGTON ML, 1995, J NEUROPHYSIOL, V74, P1793, DOI 10.1152/jn.1995.74.4.1793; Gluck MA, 1997, ANNU REV PSYCHOL, V48, P481, DOI 10.1146/annurev.psych.48.1.481; GREEN JD, 1954, J NEUROPHYSIOL, V17, P553; Grunwald T, 1998, P NATL ACAD SCI USA, V95, P3193, DOI 10.1073/pnas.95.6.3193; HARGREAVES EL, 1990, J NEUROSCI, V10, P1472; Honey RC, 1998, J NEUROSCI, V18, P2226; Huang YY, 1996, LEARN MEMORY, V3, P74, DOI 10.1101/lm.3.2-3.74; HUERTA PT, 1995, NEURON, V15, P1053, DOI 10.1016/0896-6273(95)90094-2; Jeffery KJ, 1997, HIPPOCAMPUS, V7, P95; LEUNG LS, 1980, BRAIN RES, V198, P95; ManahanVaughan D, 1997, J NEUROSCI, V17, P3303; Martinez JL, 1996, ANNU REV PSYCHOL, V47, P173, DOI 10.1146/annurev.psych.47.1.173; Miller KD, 1996, NEURON, V17, P371, DOI 10.1016/S0896-6273(00)80169-5; Morris RGM, 1997, PHILOS T ROY SOC B, V352, P1489, DOI 10.1098/rstb.1997.0136; MOSER E, 1993, SCIENCE, V259, P1324, DOI 10.1126/science.8446900; MOSER EI, 1994, LEARN MEMORY, V1, P55; O'Keefe J, 1978, HIPPOCAMPUS COGNITIV; Parkin AJ, 1997, CURR BIOL, V7, pR768, DOI 10.1016/S0960-9822(06)00400-3; STAUBLI U, 1990, BRAIN RES, V513, P113, DOI 10.1016/0006-8993(90)91096-Y; Staubli U, 1996, J NEUROSCI, V16, P853; Xu L, 1997, NATURE, V387, P497, DOI 10.1038/387497a0	29	222	237	3	32	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 27	1998	394	6696					891	894		10.1038/29783	http://dx.doi.org/10.1038/29783			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	114LW	9732871				2022-12-28	WOS:000075611800048
J	Hiom, K; Melek, M; Gellert, M				Hiom, K; Melek, M; Gellert, M			DNA transposition by the RAG1 and RAG2 proteins: A possible source of oncogenic translocations	CELL			English	Article							POLYNUCLEOTIDYL TRANSFER-REACTIONS; V(D)J RECOMBINATION; CHROMOSOMAL TRANSLOCATION; STRAND TRANSFER; SIGNAL ENDS; TARGET SITE; MECHANISM; CLEAVAGE; INTEGRATION; GENES	The RAG1 and RAG2 proteins are known to initiate V(D)J recombination by making a double-strand break between the recombination signal sequence (RSS) and the neighboring coding DNA. We show that these proteins can also drive the coupled insertion of cleaved recombination signals into new DNA sites in a transpositional reaction. This RAG-mediated DNA transfer provides strong evidence for the evolution of the V(D)J recombination system from an ancient mobile DNA element and suggests that repeated transposition may have promoted the expansion of the antigen receptor loci. The inappropriate diversion of V(D)J rearrangement to a transpositional pathway may also help to explain certain types of DNA translocation associated with lymphatic tumors.	NIDDKD, Mol Biol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Gellert, M (corresponding author), NIDDKD, Mol Biol Lab, NIH, Bethesda, MD 20892 USA.		Hiom, Kevin/B-4374-2009					Agrawal A, 1997, CELL, V89, P43, DOI 10.1016/S0092-8674(00)80181-6; APLAN PD, 1990, SCIENCE, V250, P1426, DOI 10.1126/science.2255914; ATKINSON PW, 1993, P NATL ACAD SCI USA, V90, P9693, DOI 10.1073/pnas.90.20.9693; BAKHSHI A, 1987, P NATL ACAD SCI USA, V84, P2396, DOI 10.1073/pnas.84.8.2396; BEGLEY CG, 1989, P NATL ACAD SCI USA, V86, P2031, DOI 10.1073/pnas.86.6.2031; BOEHM T, 1989, FASEB J, V3, P2344, DOI 10.1096/fasebj.3.12.2676678; Bogue M, 1996, CURR OPIN IMMUNOL, V8, P175, DOI 10.1016/S0952-7915(96)80055-0; Bogue MA, 1997, IMMUNITY, V7, P37, DOI 10.1016/S1074-7613(00)80508-7; CHOW SA, 1992, SCIENCE, V255, P723, DOI 10.1126/science.1738845; COEN ES, 1989, AM SOC MICROBIOLOGY, P413; Colot V, 1998, MOL CELL BIOL, V18, P4337, DOI 10.1128/MCB.18.7.4337; Craig NL, 1997, ANNU REV BIOCHEM, V66, P437, DOI 10.1146/annurev.biochem.66.1.437; Craig NL, 1996, SCIENCE, V271, P1512, DOI 10.1126/science.271.5255.1512; ENGELMAN A, 1991, CELL, V67, P1211, DOI 10.1016/0092-8674(91)90297-C; Gellert M, 1997, ADV IMMUNOL, V64, P39, DOI 10.1016/S0065-2776(08)60886-X; Goossens T, 1998, P NATL ACAD SCI USA, V95, P2463, DOI 10.1073/pnas.95.5.2463; Han JO, 1997, MOL CELL BIOL, V17, P2226, DOI 10.1128/MCB.17.4.2226; Hiom K, 1997, CELL, V88, P65, DOI 10.1016/S0092-8674(00)81859-0; Hiom K, 1998, MOL CELL, V1, P1011, DOI 10.1016/S1097-2765(00)80101-X; KORSMEYER SJ, 1992, ANNU REV IMMUNOL, V10, P785, DOI 10.1146/annurev.immunol.10.1.785; LEWIS SM, 1994, ADV IMMUNOL, V56, P27, DOI 10.1016/S0065-2776(08)60450-2; MCBLANE JF, 1995, CELL, V83, P387, DOI 10.1016/0092-8674(95)90116-7; Melek M, 1998, SCIENCE, V280, P301, DOI 10.1126/science.280.5361.301; MIZUUCHI K, 1991, CELL, V66, P129, DOI 10.1016/0092-8674(91)90145-O; MIZUUCHI K, 1992, J BIOL CHEM, V267, P21273; MIZUUCHI K, 1992, ANNU REV BIOCHEM, V61, P1011; Mizuuchi K, 1997, GENES CELLS, V2, P1, DOI 10.1046/j.1365-2443.1997.970297.x; OETTINGER MA, 1990, SCIENCE, V248, P1517, DOI 10.1126/science.2360047; RABBITTS TH, 1991, ADV IMMUNOL, V50, P119; Ramsden DA, 1997, NATURE, V388, P488, DOI 10.1038/41351; RAMSDEN DA, 1995, GENE DEV, V9, P2409, DOI 10.1101/gad.9.19.2409; SADOFSKY MJ, 1995, GENE DEV, V9, P2193, DOI 10.1101/gad.9.17.2193; SAKANO H, 1979, NATURE, V280, P288, DOI 10.1038/280288a0; Savilahti H, 1996, CELL, V85, P271, DOI 10.1016/S0092-8674(00)81103-4; Steen SB, 1996, GENES CELLS, V1, P543; THOMPSON CB, 1995, IMMUNITY, V3, P531, DOI 10.1016/1074-7613(95)90124-8; TSUJIMOTO Y, 1985, SCIENCE, V229, P1390, DOI 10.1126/science.3929382; TYCKO B, 1990, CANCER CELL-MON REV, V2, P1; vanGent DC, 1996, CELL, V85, P107, DOI 10.1016/S0092-8674(00)81086-7; vanGent DC, 1996, SCIENCE, V271, P1592, DOI 10.1126/science.271.5255.1592	40	407	413	1	13	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 21	1998	94	4					463	470		10.1016/S0092-8674(00)81587-1	http://dx.doi.org/10.1016/S0092-8674(00)81587-1			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	113GB	9727489	Bronze			2022-12-28	WOS:000075541100008
J	Kimelman, D; Griffin, KJP				Kimelman, D; Griffin, KJP			Mesoderm induction: A postmodern view	CELL			English	Review							XENOPUS EMBRYOS; TGF-BETA; MUTATION		Univ Washington, Dept Biochem, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Kimelman, D (corresponding author), Univ Washington, Dept Biochem, Seattle, WA 98195 USA.							Griffin KJP, 1998, DEVELOPMENT, V125, P3379; Harland R, 1997, ANNU REV CELL DEV BI, V13, P611, DOI 10.1146/annurev.cellbio.13.1.611; HEMMATIBRIVANLOU A, 1992, NATURE, V359, P609, DOI 10.1038/359609a0; Henry GL, 1996, DEVELOPMENT, V122, P1007; HO RK, 1990, NATURE, V348, P728, DOI 10.1038/348728a0; Horb ME, 1997, DEVELOPMENT, V124, P1689; JONES EA, 1987, DEVELOPMENT, V101, P557; Joseph EM, 1998, DEVELOPMENT, V125, P2677; KIMMEL CB, 1989, NATURE, V337, P358, DOI 10.1038/337358a0; NIEUWKOOP P D, 1969, Wilhelm Roux' Archiv fuer Entwicklungsmechanik der Organismen, V162, P341, DOI 10.1007/BF00578701; Watabe T, 1995, GENE DEV, V9, P3038, DOI 10.1101/gad.9.24.3038; WEEKS DL, 1987, CELL, V51, P861, DOI 10.1016/0092-8674(87)90109-7; WOLPERT L, 1969, J THEOR BIOL, V25, P1, DOI 10.1016/S0022-5193(69)80016-0; Wylie C, 1996, DEVELOPMENT, V122, P2987; Zhang J, 1998, CELL, V94, P515, DOI 10.1016/S0092-8674(00)81592-5	15	48	49	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	AUG 21	1998	94	4					419	421		10.1016/S0092-8674(00)81582-2	http://dx.doi.org/10.1016/S0092-8674(00)81582-2			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	113GB	9727484	Bronze			2022-12-28	WOS:000075541100003
J	Jegalian, K; Page, DC				Jegalian, K; Page, DC			A proposed path by which genes common to mammalian X and Y chromosomes evolve to become X inactivated	NATURE			English	Article							CPG ISLANDS; ZFY; PROTEIN; METHYLATION; EXPRESSION; EVOLUTION; SELECTION; REGION; ESCAPE; RPS4	Mammalian X and Y chromosomes evolved from an autosomal pair; the X retained and the Y gradually lost most ancestral genes(1,2), In females, one X chromosome is silenced by X inactivation, a process that is often assumed to have evolved on a broadly regional or chromosomal basis(3). Here we propose that genes or clusters common to both the X and Y chromosomes (X-Y genes) evolved independently along a multistep path, eventually acquiring dosage compensation on the X chromosome. Three genes studied here, and other extant genes, appear to be intermediates. ZFX, RPS4X and SMCX were monitored for X inactivation in diverse species by assaying CpG-island methylation, which mirrors X inactivation in many eutherians. ZFX evidently escaped X inactivation in proto-eutherians, which also possessed a very similar Y-linked gene; both characteristics were retained in most extant orders, but not in myomorph rodents. For RPS4X, escape from X inactivation seems unique to primates. SMCX escapes inactivation in primates and myomorphs but not in several other lineages. Thus, X inactivation can evolve independently for each of these genes. We propose that it is an adaptation to the decay of a homologous, Y-linked gene.	MIT, Howard Hughes Med Inst, Whitehead Inst, Cambridge, MA 02142 USA; MIT, Dept Biol, Cambridge, MA 02142 USA	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT)	Page, DC (corresponding author), MIT, Howard Hughes Med Inst, Whitehead Inst, 9 Cambridge Ctr, Cambridge, MA 02142 USA.							ADLER DA, 1991, P NATL ACAD SCI USA, V88, P4592, DOI 10.1073/pnas.88.11.4592; Adler DA, 1997, P NATL ACAD SCI USA, V94, P9244, DOI 10.1073/pnas.94.17.9244; AGUINIK AI, 1994, HUM MOL GENET, V3, P873; AGUINIK AI, 1994, HUM MOL GENET, V3, P879; ASHWORTH A, 1991, NATURE, V351, P406, DOI 10.1038/351406a0; Brown CJ, 1997, AM J HUM GENET, V60, P1333, DOI 10.1086/515488; Charlesworth B, 1996, CURR BIOL, V6, P149, DOI 10.1016/S0960-9822(02)00448-7; CROSS SH, 1995, CURR OPIN GENET DEV, V5, P309, DOI 10.1016/0959-437X(95)80044-1; DEsposito M, 1996, NAT GENET, V13, P227, DOI 10.1038/ng0696-227; Disteche CM, 1997, AM J HUM GENET, V60, P1312, DOI 10.1086/515484; FISHER EMC, 1990, CELL, V63, P1205, DOI 10.1016/0092-8674(90)90416-C; GOLDMAN MA, 1988, BIOESSAYS, V9, P50, DOI 10.1002/bies.950090204; Graves JAM, 1992, CURR OPIN GENET DEV, V2, P890, DOI 10.1016/S0959-437X(05)80112-1; LOVETT M, 1991, P NATL ACAD SCI USA, V88, P9628, DOI 10.1073/pnas.88.21.9628; LUOH SW, 1995, GENOMICS, V29, P353, DOI 10.1006/geno.1995.9994; LYON MF, 1974, NATURE, V250, P651, DOI 10.1038/250651a0; Mahaffey CL, 1997, GENOMICS, V41, P123, DOI 10.1006/geno.1997.4611; MIGEON BR, 1981, P NATL ACAD SCI-BIOL, V78, P5066, DOI 10.1073/pnas.78.8.5066; Muller H.J., 1950, HARVEY LECT, V43, P165; NOVACEK MJ, 1992, NATURE, V356, P121, DOI 10.1038/356121a0; Ohno S., 1967, SEX CHROMOSOMES SEX; Omoe K, 1996, GENOMICS, V31, P44, DOI 10.1006/geno.1996.0007; PAGE DC, 1987, CELL, V51, P1091, DOI 10.1016/0092-8674(87)90595-2; Rice WR, 1996, BIOSCIENCE, V46, P331, DOI 10.2307/1312947; SCHNEIDERGADICKE A, 1989, CELL, V57, P1247, DOI 10.1016/0092-8674(89)90061-5; SINCLAIR AH, 1988, NATURE, V336, P780, DOI 10.1038/336780a0; TRIBIOLI C, 1992, NUCLEIC ACIDS RES, V20, P727, DOI 10.1093/nar/20.4.727; WU JS, 1994, NAT GENET, V7, P491, DOI 10.1038/ng0894-491; WU JS, 1994, HUM MOL GENET, V3, P153, DOI 10.1093/hmg/3.1.153; ZINN AR, 1991, GENOMICS, V11, P1097, DOI 10.1016/0888-7543(91)90037-F	30	165	171	0	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 20	1998	394	6695					776	780		10.1038/29522	http://dx.doi.org/10.1038/29522			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	112PR	9723615				2022-12-28	WOS:000075503600044
J	Hulley, S; Grady, D; Bush, T; Furberg, C; Herrington, D; Riggs, B; Vittinghoff, E				Hulley, S; Grady, D; Bush, T; Furberg, C; Herrington, D; Riggs, B; Vittinghoff, E		HERS	Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HORMONE REPLACEMENT THERAPY; ACUTE MYOCARDIAL-INFARCTION; VENOUS THROMBOEMBOLISM; RISK; USERS; MORTALITY; HYPERCHOLESTEROLEMIA; CHOLESTEROL; ASSOCIATION; PRAVASTATIN	Context. - Observational studies have found lower rates of coronary heart disease (CHD) in postmenopausal women who take estrogen than in women who do not, but this potential benefit has not been confirmed in clinical trials. Objective. - To determine if estrogen plus progestin therapy alters the risk for CHD events in postmenopausal women with established coronary disease. Design. - Randomized, blinded, placebo-controlled secondary prevention trial. Setting. - Outpatient and community settings at 20 US clinical centers. Participants. - A total of 2763 women with coronary disease, younger than 80 years, and postmenopausal with an intact uterus, Mean age was 66.7 years. Intervention. - Either 0.625 mg of conjugated equine estrogens plus 2.5 mg of medroxyprogesterone acetate in I tablet daily (n = 1380) or a placebo of identical appearance (n = 1383), Follow-up averaged 4.1 years; 82% of those assigned to hormone treatment were taking it at the end of 1 year, and 75% at the end of 3 years. Main Outcome Measures. - The primary outcome was the occurrence of nonfatal myocardial infarction (MI) or CHD death. Secondary cardiovascular outcomes included coronary revascularization, unstable angina, congestive heart failure, resuscitated cardiac arrest, stroke or transient ischemic attack, and peripheral arterial disease. All-cause mortality was also considered. Results. - Overall, there were no significant differences between groups in the primary outcome or in any of the secondary cardiovascular outcomes: 172 women in the hormone group and 176 women in the placebo group had MI or CHD death (relative hazard [RH], 0.99; 95% confidence interval [CI], 0.80-1.22), The lack of an overall effect occurred despite a net 11% lower low-density lipoprotein cholesterol level and 10% higher high-density lipoprotein cholesterol level in the hormone group compared with the placebo group (each P < .001). Within the overall null effect, there was a statistically significant time trend, with more CHD events in the hormone group than in the placebo group in year 1 and fewer in years 4 and 5, More women in the hormone group than in the placebo group experienced venous thromboembolic events (34 vs 12; RH, 2.89; 95% CI, 1.50-5.58) and gallbladder disease (84 vs 62; RH, 1.38; 95% CI, 1.00-1.92), There were no significant differences in several other end points for which power was limited, including fracture, cancer, and total mortality (131 vs 123 deaths; RH, 1.08; 95% CI, 0.84-1.38). Conclusions. - During an average follow-up of 4.1 years, treatment with oral conjugated equine estrogen plus medroxyprogesterone acetate did not reduce the overall rate of CHD events in postmenopausal women with established coronary disease. The treatment did increase the rate of thromboembolic events and gallbladder disease. Based on the finding of no overall cardiovascular benefit and a pattern of early increase in risk of CHD events, we do not recommend starting this treatment for the purpose of secondary prevention of CHD. However, given the favorable pattern of CHD events after several years of therapy, it could be appropriate for women already receiving this treatment to continue.	Univ Calif San Francisco, San Francisco, CA 94143 USA; Johns Hopkins Univ, Baltimore, MD USA; Wake Forest Univ, Sch Med, Winston Salem, NC 27109 USA; Wyeth Ayerst Res, Radnor, PA USA	University of California System; University of California San Francisco; Johns Hopkins University; Wake Forest University; Pfizer	Hulley, S (corresponding author), Univ Calif San Francisco, Box 0886, San Francisco, CA 94143 USA.							Adams MR, 1997, ARTERIOSCL THROM VAS, V17, P217, DOI 10.1161/01.ATV.17.1.217; ADAMS MR, 1990, ARTERIOSCLEROSIS, V10, P1051, DOI 10.1161/01.ATV.10.6.1051; Anderson G, 1998, CONTROL CLIN TRIALS, V19, P61; [Anonymous], 1970, JAMA, V214, P1303; Barrett-Connor E, 1998, ANNU REV PUBL HEALTH, V19, P55, DOI 10.1146/annurev.publhealth.19.1.55; BARRETTCONNOR E, 1991, ANN INTERN MED, V115, P455, DOI 10.7326/0003-4819-115-6-455; Beral V, 1997, LANCET, V350, P1047, DOI 10.1016/S0140-6736(97)08233-0; BUCHWALD H, 1990, NEW ENGL J MED, V323, P946, DOI 10.1056/NEJM199010043231404; BUSH TL, 1987, CIRCULATION, V75, P1102, DOI 10.1161/01.CIR.75.6.1102; BUSH TL, 1990, MENOPAUSE BIOL CLIN, P211; CAULEY JA, 1990, AM J OBSTET GYNECOL, V163, P1438, DOI 10.1016/0002-9378(90)90602-4; Daly E, 1996, LANCET, V348, P977, DOI 10.1016/S0140-6736(96)07113-9; Downs JR, 1998, JAMA-J AM MED ASSOC, V279, P1615, DOI 10.1001/jama.279.20.1615; EVERSON GT, 1991, J CLIN INVEST, V87, P237, DOI 10.1172/JCI114977; FALKEBORN M, 1992, BRIT J OBSTET GYNAEC, V99, P821, DOI 10.1111/j.1471-0528.1992.tb14414.x; FRICK MH, 1987, NEW ENGL J MED, V317, P1237, DOI 10.1056/NEJM198711123172001; Grady D, 1997, JAMA-J AM MED ASSOC, V278, P477, DOI 10.1001/jama.1997.03550060053030; GRADY D, 1992, ANN INTERN MED, V117, P1016, DOI 10.7326/0003-4819-117-12-1016; Grady D, 1998, CONTROL CLIN TRIALS, V19, P314, DOI 10.1016/S0197-2456(98)00010-5; Grodstein F, 1996, NEW ENGL J MED, V335, P453, DOI 10.1056/NEJM199608153350701; Grodstein F, 1996, LANCET, V348, P983, DOI 10.1016/S0140-6736(96)07308-4; Guetta V, 1996, CIRCULATION, V93, P1928, DOI 10.1161/01.CIR.93.10.1928; Gutthann SP, 1997, BMJ-BRIT MED J, V314, P796, DOI 10.1136/bmj.314.7083.796; Hemminki E, 1997, BRIT MED J, V315, P149, DOI 10.1136/bmj.315.7101.149; HENDERSON BE, 1991, ARCH INTERN MED, V151, P75, DOI 10.1001/archinte.151.1.75; Herrington DM, 1998, AM HEART J, V136, P115, DOI 10.1016/S0002-8703(98)70191-7; Jick H, 1996, LANCET, V348, P981, DOI 10.1016/S0140-6736(96)07114-0; LAN KKG, 1984, COMMUN STAT-THEOR M, V13, P2339, DOI 10.1080/03610928408828830; MANN RD, 1994, J CLIN EPIDEMIOL, V47, P307, DOI 10.1016/0895-4356(94)90014-0; Matthews KA, 1996, AM J EPIDEMIOL, V143, P971; McCrohon JA, 1996, CLIN ENDOCRINOL, V45, P435, DOI 10.1046/j.1365-2265.1996.8070816.x; MILLER VT, 1995, JAMA-J AM MED ASSOC, V273, P199, DOI 10.1001/jama.1995.03520270033028; Newton KM, 1997, AM J EPIDEMIOL, V145, P269; OBrien JE, 1996, J AM COLL CARDIOL, V28, P1111, DOI 10.1016/S0735-1097(96)00306-3; OKeefe JH, 1997, J AM COLL CARDIOL, V29, P1; PEPI Trial, 1995, JAMA-J AM MED ASSOC, V274, P1676; Petitti Diana B., 1994, Annals of Epidemiology, V4, P115; PSATY BM, 1994, ARCH INTERN MED, V154, P1333, DOI 10.1001/archinte.154.12.1333; RAUTAHARJU PM, 1992, J ELECTROCARDIOL, V24, P179; RIFKIND BM, 1984, JAMA-J AM MED ASSOC, V251, P365; ROSENBERG L, 1993, AM J EPIDEMIOL, V137, P54, DOI 10.1093/oxfordjournals.aje.a116602; Rosenson RS, 1998, JAMA-J AM MED ASSOC, V279, P1643, DOI 10.1001/jama.279.20.1643; Rossouw JE, 1996, CIRCULATION, V94, P2982, DOI 10.1161/01.CIR.94.11.2982; Ryan TJ, 1996, J AM COLL CARDIOL, V28, P1328; Sacks FM, 1996, NEW ENGL J MED, V335, P1001, DOI 10.1056/NEJM199610033351401; SAMAAN SA, 1995, J AM COLL CARDIOL, V26, P1403, DOI 10.1016/0735-1097(95)00360-6; SARREL PM, 1995, MENOPAUSE, V2, P187, DOI 10.1097/00042192-199502040-00001; Schrott HG, 1997, JAMA-J AM MED ASSOC, V277, P1281, DOI 10.1001/jama.277.16.1281; SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001; Sidney S, 1997, ANN INTERN MED, V127, P501, DOI 10.7326/0003-4819-127-7-199710010-00001; STAMPFER MJ, 1991, PREV MED, V20, P47, DOI 10.1016/0091-7435(91)90006-P; SULLIVAN JM, 1990, ARCH INTERN MED, V150, P2557, DOI 10.1001/archinte.150.12.2557; Sullivan JM, 1997, AM J CARDIOL, V79, P847, DOI 10.1016/S0002-9149(97)00001-5; The Coronary Drug Project, 1973, JAMA-J AM MED ASSOC, V226, P652; THOMPSON SG, 1989, J EPIDEMIOL COMMUN H, V43, P173, DOI 10.1136/jech.43.2.173; WILLIAMS JK, 1994, J AM COLL CARDIOL, V24, P1757, DOI 10.1016/0735-1097(94)90184-8	56	4678	4833	1	213	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 19	1998	280	7					605	613		10.1001/jama.280.7.605	http://dx.doi.org/10.1001/jama.280.7.605			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	110ME	9718051	Bronze			2022-12-28	WOS:000075384300028
J	Spiess, AE; Kahrilas, PJ				Spiess, AE; Kahrilas, PJ			Treating achalasia - From whalebone to laparoscope	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							LOWER ESOPHAGEAL SPHINCTER; BOTULINUM TOXIN INJECTION; HELLER-DOR OPERATION; PNEUMATIC DILATION; ANTIREFLUX PROCEDURE; FORCEFUL DILATATION; MOTILITY DISORDERS; VIGOROUS ACHALASIA; ENDOSCOPIC CONTROL; DOUBLE-BLIND	Objective. - To review the pathophysiology and management of achalasia. Data Sources. - Peer-reviewed publications located via MEDLINE using the search term esophageal achalasia (subheadings: complications, drug therapy, epidemiology, etiology, physiopathology, surgery, and therapy) published in English from 1966 to December 1997. Study Selection. - Of 2632 citations identified, 4.5% were selected for inclusion by authors' blinded review of the abstracts. New developments in the understanding of achalasia or reports of therapeutic efficacy in either controlled trials or uncontrolled consecutive series involving 10 patients or more observed for a year or longer were reviewed in detail. Data Extraction. - All 6 controlled therapeutic trials were included, and therapeutic efficacy in uncontrolled series was assessed by the authors extracting the patients with a good-to-excellent response from each study and calculating a pooled estimate of response rate with individual studies weighted proportionally to sample size. Data Synthesis.-Achalasia results from irreversible destruction of esophageal myenteric plexus neurons causing aperistalsis and failed lower sphincter relaxation. The only therapies that adequately compensate for this dysfunction for a sustained time are pneumatic dilation and Heller myotomy. The single controlled trial comparing these treatments found surgery superior to dilation (95% vs 51% nearly complete symptom resolution, P < .01). In uncontrolled trials pneumatic dilation (weighted mean [SD]) is 72% (26%) effective vs 84% (20%) for Heller myotomy. The limitation of dilation is a 3% risk of perforation; thoracotomy morbidity has been the major limitation of myotomy. Surgical morbidity has been sharply reduced by laparoscopic techniques. Conclusions. - Both pneumatic dilation and surgical myotomy are effective therapies for achalasia; laparoscopic Heller myotomy is emerging as the optimal surgical therapy.	Northwestern Univ, Sch Med, Dept Med, Div Gastroenterol & Hepatol, Chicago, IL 60611 USA	Northwestern University	Kahrilas, PJ (corresponding author), Northwestern Univ, Sch Med, Dept Med, Div Gastroenterol & Hepatol, Passavant Pavil,Suite 746,303 E Super St, Chicago, IL 60611 USA.	p-kahrilas@nwu.edu			NIDCD NIH HHS [R01 DC00646] Funding Source: Medline; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC000646] Funding Source: NIH RePORTER	NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		ABID S, 1994, AM J GASTROENTEROL, V89, P979; AGGESTRUP S, 1992, CHEST, V102, P1013, DOI 10.1378/chest.102.4.1013; Annese V, 1996, GASTROENTEROLOGY, V111, P1418, DOI 10.1016/S0016-5085(96)70002-1; [Anonymous], 1674, PHARM RATIONALIS SIV; BARKIN JS, 1990, GASTROINTEST ENDOSC, V36, P123, DOI 10.1016/S0016-5107(90)70964-9; BARNETT JL, 1990, GASTROINTEST ENDOSC, V36, P482, DOI 10.1016/S0016-5107(90)71120-0; BETTARELLO A, 1976, CLIN GASTROENTEROL, V5, P103; BONAVINA L, 1995, ANN CHIR GYNAECOL FE, V84, P165; BORTOLOTTI M, 1981, GASTROENTEROLOGY, V80, P39; CASSELLA RR, 1964, ANN SURG, V160, P474, DOI 10.1097/00000658-196409000-00010; CASTRINI G, 1982, J THORAC CARDIOV SUR, V84, P575; CHUONG JJH, 1984, DIGEST DIS SCI, V29, P1105, DOI 10.1007/BF01317084; COCCIA G, 1991, GUT, V32, P604, DOI 10.1136/gut.32.6.604; COHEN NN, 1975, GASTROINTEST ENDOSC, V22, P29, DOI 10.1016/S0016-5107(75)73678-7; Cosentini E, 1997, ARCH SURG-CHICAGO, V132, P143; COX J, 1986, GUT, V27, P986, DOI 10.1136/gut.27.8.986; CSENDES A, 1985, DIGEST DIS SCI, V30, P941, DOI 10.1007/BF01308293; CSENDES A, 1989, GUT, V30, P299, DOI 10.1136/gut.30.3.299; Cuilliere C, 1997, GUT, V41, P87, DOI 10.1136/gut.41.1.87; CUSHIERI A, 1993, ENDOSC SURG ALLIED T, V1, P280; DIMARINO AJ, 1982, DIGEST DIS SCI, V27, P1063, DOI 10.1007/BF01391441; DiSimone MP, 1996, ANN THORAC SURG, V61, P1106, DOI 10.1016/0003-4975(96)00027-6; DONAHUE PE, 1994, SURGERY, V116, P719; DURANCEAU A, 1982, AM J SURG, V143, P22, DOI 10.1016/0002-9610(82)90124-6; EARLAM RJ, 1969, MAYO CLIN PROC, V44, P478; Eckardt VF, 1997, GASTROINTEST ENDOSC, V45, P349, DOI 10.1016/S0016-5107(97)70142-1; ECKARDT VF, 1992, GASTROENTEROLOGY, V103, P1732, DOI 10.1016/0016-5085(92)91428-7; ELLIS FH, 1993, BRIT J SURG, V80, P882, DOI 10.1002/bjs.1800800727; ELLIS FH, 1992, EUR J CARDIO-THORAC, V6, P86, DOI 10.1016/1010-7940(92)90080-H; Fagge CH, 1872, GUYS HOSP REP, V17, P413; FEKETE F, 1982, INT SURG, V67, P103; FELLOWS IW, 1983, GUT, V24, P1020, DOI 10.1136/gut.24.11.1020; Ferguson MK, 1996, ANN THORAC SURG, V62, P327, DOI 10.1016/0003-4975(96)00176-2; Fishman VM, 1996, AM J GASTROENTEROL, V91, P1724; FOLEY R, 1995, ANN ROY COLL SURG, V77, P60; GALLEZ JF, 1987, ENDOSCOPY, V19, P76, DOI 10.1055/s-2007-1018241; GALLONE L, 1982, SURG GYNECOL OBSTET, V155, P337; GELFOND M, 1981, GUT, V22, P312, DOI 10.1136/gut.22.4.312; GELFOND M, 1982, GASTROENTEROLOGY, V83, P963; GOLDBLUM JR, 1994, AM J SURG PATHOL, V18, P327, DOI 10.1097/00000478-199404000-00001; GOLDENBERG SP, 1991, GASTROENTEROLOGY, V101, P743, DOI 10.1016/0016-5085(91)90534-R; GOODMAN P, 1990, DIGEST DIS SCI, V35, P1549, DOI 10.1007/BF01540574; HEIMLICH HJ, 1978, ANN OTO RHINOL LARYN, V87, P519, DOI 10.1177/000348947808700410; Heller E., 1914, MITT GRENZGEB MED CH, V27, P141; HOLLOWAY RH, 1986, GASTROENTEROLOGY, V90, P924, DOI 10.1016/0016-5085(86)90869-3; HOWARD PJ, 1992, GUT, V33, P1011, DOI 10.1136/gut.33.8.1011; Hunter JG, 1997, ANN SURG, V225, P655, DOI 10.1097/00000658-199706000-00003; JACOBS JB, 1983, ANN OTO RHINOL LARYN, V92, P353, DOI 10.1177/000348948309200409; JANKOVIC J, 1991, NEW ENGL J MED, V324, P1186, DOI 10.1056/nejm199104253241707; JARA FM, 1979, ARCH SURG-CHICAGO, V114, P935; JONES DB, 1983, J CLIN PATHOL, V36, P655, DOI 10.1136/jcp.36.6.655; KADAKIA SC, 1993, AM J GASTROENTEROL, V88, P34; Kahrilas P J, 1987, Am J Med, V82, P439; KATZ PO, 1987, ANN INTERN MED, V106, P593, DOI 10.7326/0003-4819-106-4-593; LAMBROZA A, 1995, AM J GASTROENTEROL, V90, P1226; LEE JD, 1993, GASTROINTEST ENDOSC, V39, P157; Lendrum FC, 1937, ARCH INTERN MED, V59, P474, DOI 10.1001/archinte.1937.00170190109007; LEVINE ML, 1991, AM J GASTROENTEROL, V86, P1581; MALTHANER RA, 1994, ANN THORAC SURG, V58, P1343, DOI 10.1016/0003-4975(94)91910-0; Mattioli S, 1996, HEPATO-GASTROENTEROL, V43, P492; MAYBERRY JF, 1985, Q J MED, V56, P451; MEARIN F, 1993, EUR J CLIN INVEST, V23, P724, DOI 10.1111/j.1365-2362.1993.tb01292.x; MEARIN F, 1994, GUT, V35, P1360, DOI 10.1136/gut.35.10.1360; MEIJSSEN MAC, 1992, GUT, V33, P155, DOI 10.1136/gut.33.2.155; MENZIESGOW N, 1978, BRIT J SURG, V65, P483, DOI 10.1002/bjs.1800650711; MILLER DL, 1995, ANN THORAC SURG, V60, P922, DOI 10.1016/0003-4975(95)00522-M; MITCHELL PC, 1995, CAN J SURG, V38, P445; Morino M, 1995, INT SURG, V80, P332; MURRAY GF, 1984, ANN THORAC SURG, V37, P185, DOI 10.1016/S0003-4975(10)60321-9; MURRAY JA, 1995, GASTROENTEROLOGY, V109, P1241, DOI 10.1016/0016-5085(95)90584-7; OKIKE N, 1979, ANN THORAC SURG, V28, P119, DOI 10.1016/S0003-4975(10)63767-8; OLSEN AM, 1951, J THORAC SURG, V22, P164; ORRINGER MB, 1989, ANN THORAC SURG, V47, P340, DOI 10.1016/0003-4975(89)90369-X; PAI GP, 1984, ANN THORAC SURG, V38, P201, DOI 10.1016/S0003-4975(10)62237-0; PAMPHLETT R, 1989, J NEUROL SCI, V92, P181, DOI 10.1016/0022-510X(89)90135-4; Panaccione R, 1997, GASTROENTEROLOGY, V112, pA250; Pandolfo N, 1996, HEPATO-GASTROENTEROL, V43, P160; PARKMAN HP, 1993, DIGEST DIS SCI, V38, P75, DOI 10.1007/BF01296777; PASRICHA PJ, 1993, GASTROENTEROLOGY, V105, P1045, DOI 10.1016/0016-5085(93)90947-B; Pasricha PJ, 1996, GASTROENTEROLOGY, V110, P1410, DOI 10.1053/gast.1996.v110.pm8613045; PASRICHA PJ, 1995, NEW ENGL J MED, V332, P774, DOI 10.1056/NEJM199503233321203; PERACCHIA A, 1991, HEPATO-GASTROENTEROL, V38, P514; PETERS JH, 1995, ARCH SURG-CHICAGO, V130, P632; PICCIOCCHI A, 1993, SURG TODAY, V23, P855, DOI 10.1007/BF00311361; PINOTTI HW, 1991, HEPATO-GASTROENTEROL, V38, P470; QUALMAN SJ, 1984, GASTROENTEROLOGY, V87, P848; Raiser F, 1996, ARCH SURG-CHICAGO, V131, P593; Richter J E, 1989, Gastroenterology, V97, P1340; ROBERTSON CS, 1988, DIGESTION, V40, P244, DOI 10.1159/000199661; ROBERTSON CS, 1993, GUT, V34, P299, DOI 10.1136/gut.34.3.299; ROBERTSON GSM, 1995, BRIT J SURG, V82, P957, DOI 10.1002/bjs.1800820733; ROSATI R, 1995, AM J SURG, V169, P424, DOI 10.1016/S0002-9610(99)80190-1; SANDLER RS, 1995, JAMA-J AM MED ASSOC, V274, P1359, DOI 10.1001/jama.274.17.1359; SARIYANNIS C, 1975, THORAX, V30, P539, DOI 10.1136/thx.30.5.539; SAUER L, 1989, ARCH SURG-CHICAGO, V124, P929; SCHWARTZ HM, 1993, DIGEST DIS SCI, V38, P1409, DOI 10.1007/BF01308596; SHAH AN, 1994, GASTROENTEROL ENDOSC, V30, P294; SIFRIM D, 1994, GASTROENTEROLOGY, V106, P875, DOI 10.1016/0016-5085(94)90745-5; SMART HL, 1986, J ROY SOC MED, V79, P71, DOI 10.1177/014107688607900204; SMART HL, 1987, GUT, V28, P883, DOI 10.1136/gut.28.7.883; SPECHLER SJ, 1995, GUT, V37, P305, DOI 10.1136/gut.37.3.305; STIPA S, 1990, SURG GYNECOL OBSTET, V170, P212; STREITZ JM, 1995, ANN THORAC SURG, V59, P1604, DOI 10.1016/0003-4975(94)00997-L; TODORCZUK JR, 1991, DIGEST DIS SCI, V36, P274, DOI 10.1007/BF01318195; TRAUBE M, 1989, AM J GASTROENTEROL, V84, P1259; TRAUBE M, 1984, JAMA-J AM MED ASSOC, V252, P1733, DOI 10.1001/jama.252.13.1733; TRIADAFILOPOULOS G, 1991, DIGEST DIS SCI, V36, P260, DOI 10.1007/BF01318193; Vaezi M, 1997, GASTROENTEROLOGY, V112, pA318; VANTRAPPEN G, 1971, GUT, V12, P268, DOI 10.1136/gut.12.4.268; VANTRAPPEN G, 1983, GUT, V24, P1013, DOI 10.1136/gut.24.11.1013; VANTRAPPEN G, 1975, DISEASES OESOPHAGUS, P287; VERVE GN, 1997, DIGEST DIS SCI, V42, P307; WEHRMANN T, 1995, GASTROINTEST ENDOSC, V42, P31, DOI 10.1016/S0016-5107(95)70239-3; WITZEL L, 1981, ENDOSCOPY, V13, P176, DOI 10.1055/s-2007-1021677; WONG RKH, 1989, DIGEST DIS SCI, V34, P349, DOI 10.1007/BF01536254; WONG RKH, 1987, J CLIN GASTROENTEROL, V9, P386, DOI 10.1097/00004836-198708000-00006; WYCHULIS AR, 1971, J AMER MED ASSOC, V215, P1638, DOI 10.1001/jama.215.10.1638; YON J, 1975, ANN SURG, V182, P672, DOI 10.1097/00000658-197512000-00002	118	214	224	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 19	1998	280	7					638	642		10.1001/jama.280.7.638	http://dx.doi.org/10.1001/jama.280.7.638			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	110ME	9718057				2022-12-28	WOS:000075384300034
J	Elsman, J				Elsman, J			Relevance of pregnancy and lactation to osteoporosis?	LANCET			English	Editorial Material							BONE-MINERAL DENSITY; CALCIUM; TURNOVER; WOMEN; METABOLISM; RECOVERY; MARKERS; MASS		Garvan Inst Med Res, Bone & Mineral Res Program, Sydney, NSW 2010, Australia	Garvan Institute of Medical Research	Elsman, J (corresponding author), Garvan Inst Med Res, Bone & Mineral Res Program, Sydney, NSW 2010, Australia.		Eisman, John A/C-2886-2014					Abrams SA, 1998, J CLIN ENDOCR METAB, V83, P1056, DOI 10.1210/jc.83.4.1056; Affinito P, 1996, J CLIN ENDOCR METAB, V81, P2314, DOI 10.1210/jc.81.6.2314; CROSS NA, 1995, J BONE MINER RES, V10, P1312; CROSS NA, 1995, AM J CLIN NUTR, V61, P514, DOI 10.1093/ajcn/61.3.514; Gulson BL, 1997, J LAB CLIN MED, V130, P51, DOI 10.1016/S0022-2143(97)90058-5; KALKWARF HJ, 1995, OBSTET GYNECOL, V86, P26, DOI 10.1016/0029-7844(95)00083-4; KALKWARF KJ, 1997, NEW ENGL J MED, V337, P523; KENT GN, 1990, J BONE MINER RES, V5, P361, DOI 10.1002/jbmr.5650050409; KENT GN, 1991, CALCIFIED TISSUE INT, V48, P293, DOI 10.1007/BF02556384; Krebs NF, 1997, AM J CLIN NUTR, V65, P1738, DOI 10.1093/ajcn/65.6.1738; Laskey MA, 1998, AM J CLIN NUTR, V67, P685, DOI 10.1093/ajcn/67.4.685; LEPRE F, 1993, NEW ENGL J MED, V328, P666, DOI 10.1056/NEJM199303043280917; Liel Y, 1998, SOUTH MED J, V91, P33, DOI 10.1097/00007611-199801000-00006; Lopez JM, 1996, OSTEOPOROSIS INT, V6, P153, DOI 10.1007/BF01623940; PRENTICE A, 1995, AM J CLIN NUTR, V62, P58, DOI 10.1093/ajcn/62.1.58; Prentice A, 1998, J CLIN ENDOCR METAB, V83, P1059, DOI 10.1210/jc.83.4.1059; Ritchie LD, 1998, AM J CLIN NUTR, V67, P693, DOI 10.1093/ajcn/67.4.693; SOWERS M, 1995, OBSTET GYNECOL, V85, P285, DOI 10.1016/0029-7844(94)00351-D; Sowers MF, 1996, JAMA-J AM MED ASSOC, V276, P549, DOI 10.1001/jama.276.7.549; TUPPURAINEN M, 1995, ACTA OBSTET GYN SCAN, V74, P624, DOI 10.3109/00016349509013475; Yamaga A, 1996, J CLIN ENDOCR METAB, V81, P752, DOI 10.1210/jc.81.2.752	21	36	38	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 15	1998	352	9127					504	505		10.1016/S0140-6736(05)79245-X	http://dx.doi.org/10.1016/S0140-6736(05)79245-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	111KC	9716051				2022-12-28	WOS:000075435300005
J	Myers, J; Gullestad, L; Vagelos, R; Do, D; Bellin, D; Ross, H; Fowler, MB				Myers, J; Gullestad, L; Vagelos, R; Do, D; Bellin, D; Ross, H; Fowler, MB			Clinical, hemodynamic, and cardiopulmonary exercise test determinants of survival in patients referred for evaluation of heart failure	ANNALS OF INTERNAL MEDICINE			English	Article						heart failure, congestive; exercise test; hemodynamics; peak Vo(2); outcome and process assessment (health care)	OXYGEN-CONSUMPTION; DILATED CARDIOMYOPATHY; TRANSPLANTATION; CAPACITY; CANDIDATES	Background: Accurate prognosis in chronic heart failure has become increasingly important in assessing the efficacy of treatment and in appropriately allocating scarce resources for transplantation. Previous studies of severe heart failure have been limited by short follow-up periods and few deaths. Objective: To establish clinical, hemodynamic, and cardiopulmonary exercise test determinants of survival in patients with heart failure. Design: Retrospective study. Setting: Hospital-based outpatient heart failure clinic. Participants: 644 patients referred for evaluation of heart failure over 10 years. Measurements: Age, cause of heart failure, body surface area, cardiac index, ejection fraction, pulmonary capillary wedge pressure, left ventricular dimensions, watts achieved during exercise, heart rate, maximum systolic blood pressure, a nd oxygen uptake ((V) over dot O-2) at the ventilatory threshold and at peak exercise were measured at baseline. Univariate and multivariate analyses were done for clinical, hemodynamic, and exercise test predictors of death. A Cox hazards model was developed for time of death. Results: During a mean follow-up period of 4 years, 187 patients (29%) died and 101 underwent transplantation. Actuarial 1-year and 5-year survival rates were 90.5% and 73.4%, respectively. Resting systolic blood pressure, watts achieved, peak (V) over dot O-2, (V) over dot O-2 at the ventilatory threshold, and peak heart rate were greater among survivors than among nonsurvivors. Cause of heart failure (coronary artery disease or cardiomyopathy) was a strong determinant of death (relative risk for coronary artery disease, 1.73; P < 0.01). By multivariate analysis, only peak (V) over dot O-2 was a significant predictor of death. Stratification of peak (V) over dot O-2 above and below 12, 14, and 16 mL/kg per minute demonstrated significant differences in risk for death, but each cut-point predicted risk to a similar degree. Conclusions: Peak (V) over dot O-2 outperforms clinical variables, right-heart catheterization data, exercise time, and other exercise test variables in predicting outcome in severe chronic heart failure. Direct measurement of (V) over dot O-2 should be included when clinical or surgical decisions are being made in patients referred for evaluation of heart failure or those considered for transplantation.	Stanford Univ, Sch Med, Falk Cardiovasc Res Ctr, Med Ctr, Stanford, CA 96305 USA; Palo Vet Affairs Hlth Care Syst, Palo Alto, CA USA	Stanford University	Fowler, MB (corresponding author), Stanford Univ, Sch Med, Falk Cardiovasc Res Ctr, Med Ctr, Stanford, CA 96305 USA.			Vagelos, Randall/0000-0001-6562-7216				AARONSON KD, 1995, J HEART LUNG TRANSPL, V14, P981; Aaronson KD, 1997, CIRCULATION, V95, P2660, DOI 10.1161/01.CIR.95.12.2660; Bart BA, 1997, J AM COLL CARDIOL, V30, P1002, DOI 10.1016/S0735-1097(97)00235-0; CHANG JA, 1994, CURR PROB CARDIOLOGY, V19, P537; Chomsky DB, 1996, CIRCULATION, V94, P3176, DOI 10.1161/01.CIR.94.12.3176; COHN JN, 1991, NEW ENGL J MED, V325, P303, DOI 10.1056/NEJM199108013250502; COHN JN, 1993, CIRCULATION, V87, P5; Connors AF, 1996, JAMA-J AM MED ASSOC, V276, P889, DOI 10.1001/jama.276.11.889; FOLLNSBEE WP, 1993, EXERCISE HEART, P252; MANCINI DM, 1991, CIRCULATION, V83, P778, DOI 10.1161/01.CIR.83.3.778; MINOTTI JR, 1993, J APPL PHYSIOL, V75, P373, DOI 10.1152/jappl.1993.75.1.373; MUDGE GH, 1993, J AM COLL CARDIOL, V22, P21, DOI 10.1016/0735-1097(93)90812-F; Myers J, 1997, CHEST, V111, P787, DOI 10.1378/chest.111.3.787; MYERS J, 1991, ANN INTERN MED, V115, P377, DOI 10.7326/0003-4819-115-5-377; Myers J, 1996, ESSENTIALS CARDIOPUL; Packer M, 1996, NEW ENGL J MED, V334, P1349, DOI 10.1056/NEJM199605233342101; Rickenbacher PR, 1996, J AM COLL CARDIOL, V27, P1192, DOI 10.1016/0735-1097(95)00587-0; ROUL G, 1994, EUR HEART J, V15, P495, DOI 10.1093/oxfordjournals.eurheartj.a060533; SAXON LA, 1993, AM J CARDIOL, V72, P62, DOI 10.1016/0002-9149(93)90220-7; Stelken AM, 1996, J AM COLL CARDIOL, V27, P345, DOI 10.1016/0735-1097(95)00464-5; STEVENSON LW, 1987, AM J MED, V83, P871, DOI 10.1016/0002-9343(87)90644-9; STEVENSON LW, 1995, CIRCULATION, V92, P174, DOI 10.1161/01.CIR.92.9.174; STEVENSON LW, 1995, J AM COLL CARDIOL, V25, P163, DOI 10.1016/0735-1097(94)00357-V; SULLIVAN M, 1984, CHEST, V86, P375, DOI 10.1378/chest.86.3.375; SZLACHCIC J, 1985, AM J CARDIOL, V55, P1037, DOI 10.1016/0002-9149(85)90742-8; Wasserman K., 1994, PRINCIPLES EXERCISE, V2nd edn; YUSUF S, 1991, NEW ENGL J MED, V325, P293, DOI 10.1056/NEJM199108013250501	27	200	204	0	9	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 15	1998	129	4					286	+		10.7326/0003-4819-129-4-199808150-00004	http://dx.doi.org/10.7326/0003-4819-129-4-199808150-00004			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	109NP	9729181				2022-12-28	WOS:000075329100004
J	Topol, EJ				Topol, EJ			What role for catheter laboratories in unstable angina?	LANCET			English	Editorial Material							CORONARY ANGIOPLASTY; HEPARIN		Cleveland Clin Fdn, Dept Cardiol, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Topol, EJ (corresponding author), Cleveland Clin Fdn, Dept Cardiol, Cleveland, OH 44195 USA.			Topol, Eric/0000-0002-1478-4729				BITTL JA, 1995, NEW ENGL J MED, V333, P764, DOI 10.1056/NEJM199509213331204; Boden WE, 1998, NEW ENGL J MED, V338, P1785, DOI 10.1056/NEJM199806183382501; BRAUNWALD E, 1994, CIRCULATION, V89, P1545; Cohen M, 1997, NEW ENGL J MED, V337, P447, DOI 10.1056/NEJM199708143370702; Lange RA, 1998, NEW ENGL J MED, V338, P1838, DOI 10.1056/NEJM199806183382509; LEFKOVITS J, 1995, NEW ENGL J MED, V332, P1553, DOI 10.1056/NEJM199506083322306; Lincoff AM, 1997, J AM COLL CARDIOL, V30, P149, DOI 10.1016/S0735-1097(97)00110-1; SERRUYS PW, 1995, NEW ENGL J MED, V333, P757, DOI 10.1056/NEJM199509213331203; Topol EJ, 1998, CIRCULATION, V97, P211, DOI 10.1161/01.CIR.97.2.211; TOPOL EJ, 1997, JAMA-J AM MED ASSOC, V278, P484	10	11	11	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	AUG 15	1998	352	9127					500	501		10.1016/S0140-6736(98)22033-2	http://dx.doi.org/10.1016/S0140-6736(98)22033-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	111KC	9716048				2022-12-28	WOS:000075435300002
J	Winfree, E; Liu, FR; Wenzler, LA; Seeman, NC				Winfree, E; Liu, FR; Wenzler, LA; Seeman, NC			Design and self-assembly of two-dimensional DNA crystals	NATURE			English	Article							DOUBLE-CROSSOVER MOLECULES; ATOMIC FORCE MICROSCOPE; NUCLEIC-ACID JUNCTIONS; GOLD SPHERES; CONSTRUCTION; NANOCONSTRUCTION; COMPONENTS; SEQUENCES; BIOCHIP; DEVICE	Molecular self-assembly presents a 'bottom-up' approach to the fabrication of objects specified with nanometre precision. DNA molecular structures and intermolecular interactions are particularly amenable to the design and synthesis of complex molecular objects. We report the design and observation of two-dimensional crystalline forms of DNA that self-assemble from synthetic DNA double-crossover molecules. Intermolecular interactions between the structural units are programmed by the design of 'sticky ends' that associate according to Watson-Crick complementarity, enabling us to create specific periodic patterns on the nanometre scale. The patterned crystals have been visualized by atomic force microscopy.	CALTECH, Pasadena, CA 91125 USA; NYU, Dept Chem, New York, NY 10003 USA	California Institute of Technology; New York University	Winfree, E (corresponding author), CALTECH, Pasadena, CA 91125 USA.	winfree@hope.caltech.edu; ned.seeman@nyu.edu	Winfree, Erik/L-4002-2013	Winfree, Erik/0000-0002-5899-7523				ADLEMAN LM, 1994, SCIENCE, V266, P1021, DOI 10.1126/science.7973651; Alivisatos AP, 1996, NATURE, V382, P609, DOI 10.1038/382609a0; BINNIG G, 1986, PHYS REV LETT, V56, P930, DOI 10.1103/PhysRevLett.56.930; Braun E, 1998, NATURE, V391, P775, DOI 10.1038/35826; Breaker R R, 1994, Chem Biol, V1, P223, DOI 10.1016/1074-5521(94)90014-0; Carter ES, 1996, COMPUT APPL BIOSCI, V12, P25; CHEN JH, 1991, NATURE, V350, P631, DOI 10.1038/350631a0; COHEN SN, 1973, P NATL ACAD SCI USA, V70, P3240, DOI 10.1073/pnas.70.11.3240; FU TJ, 1993, BIOCHEMISTRY-US, V32, P3211, DOI 10.1021/bi00064a003; Grunbaum B., 1986, TILINGS PATTERNS; HADDON RC, 1985, P NATL ACAD SCI USA, V82, P1874, DOI 10.1073/pnas.82.7.1874; HANSMA HG, 1992, SCIENCE, V256, P1180, DOI 10.1126/science.256.5060.1180; JOANNOPOLOUS JD, 1995, PHOTONIC CRYSTALS MO; Li XJ, 1996, J AM CHEM SOC, V118, P6131, DOI 10.1021/ja960162o; LIU B, 1994, NANOBIOLOGY, V3, P177; MA RI, 1986, NUCLEIC ACIDS RES, V14, P9745, DOI 10.1093/nar/14.24.9745; Mirkin CA, 1996, NATURE, V382, P607, DOI 10.1038/382607a0; NIEMEYER CM, 1994, NUCLEIC ACIDS RES, V22, P5530, DOI 10.1093/nar/22.25.5530; OUPOROV IV, 1995, BIOPHYS J, V68, P266, DOI 10.1016/S0006-3495(95)80183-9; PETRILLO ML, 1988, BIOPOLYMERS, V27, P1337, DOI 10.1002/bip.360270902; Qiu HX, 1997, J MOL BIOL, V267, P881, DOI 10.1006/jmbi.1997.0918; REIF J, 1997, IN PRESS P 3 DIMACS; RHODES D, 1980, NATURE, V286, P573, DOI 10.1038/286573a0; RIBEIRO FR, 1995, J MOL CATAL A-CHEM, V96, P245; ROBINSON BH, 1987, PROTEIN ENG, V1, P295, DOI 10.1093/protein/1.4.295; SantaLucia J, 1996, BIOCHEMISTRY-US, V35, P3555, DOI 10.1021/bi951907q; SCHWACHA A, 1995, CELL, V83, P783, DOI 10.1016/0092-8674(95)90191-4; SEEMAN NC, 1982, J THEOR BIOL, V99, P237, DOI 10.1016/0022-5193(82)90002-9; SEEMAN NC, 1990, J BIOMOL STRUCT DYN, V8, P573, DOI 10.1080/07391102.1990.10507829; SHAIU WL, 1993, J VAC SCI TECHNOL A, V11, P820, DOI 10.1116/1.578311; SHAIU WL, 1993, NUCLEIC ACIDS RES, V21, P99, DOI 10.1093/nar/21.1.99; SUN S, 1996, PROT ENG, V9, P1205; Vainshtein B. K., 1994, MODERN CRYSTALLOGRAP, V1; Wang H., 1963, P S MATH THEOR AUT, P23; WANG JC, 1979, P NATL ACAD SCI USA, V76, P200, DOI 10.1073/pnas.76.1.200; WHITESIDES GM, 1991, SCIENCE, V254, P1312, DOI 10.1126/science.1962191; Winfree E., 1996, DNA BASED COMPUTERS, P199; WINFREE E, 1996, P 2 DIMACS M DNA BAS; YUE K, 1992, P NATL ACAD SCI USA, V89, P4163, DOI 10.1073/pnas.89.9.4163; ZHANG YW, 1994, J AM CHEM SOC, V116, P1661, DOI 10.1021/ja00084a006	40	2144	2267	27	776	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 6	1998	394	6693					539	544		10.1038/28998	http://dx.doi.org/10.1038/28998			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	107YN	9707114				2022-12-28	WOS:000075238700036
J	Ewart, WR; Winikoff, B				Ewart, WR; Winikoff, B			Toward safe and effective medical abortion	SCIENCE			English	Article									Wellcome Trust, London NW1 2BE, England; Populat Council, New York, NY 10017 USA	University of London; University College London; Population Council	Ewart, WR (corresponding author), Wellcome Trust, 183 Euston Rd, London NW1 2BE, England.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Cameron ST, 1996, BRIT J OBSTET GYNAEC, V103, P1222, DOI 10.1111/j.1471-0528.1996.tb09633.x; GIRAKU L, 1997, ADDRESSING COMPLICAT; *POP INF PROGR J H, 1997, ISSUES WORLD HLTH 1, V25; WHO, 1993, AB TAB AV DAT FREQ M; Winikoff B, 1997, AM J OBSTET GYNECOL, V176, P431, DOI 10.1016/S0002-9378(97)70511-8	5	8	8	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 24	1998	281	5376					520	521		10.1126/science.281.5376.520	http://dx.doi.org/10.1126/science.281.5376.520			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	104KA	9705721				2022-12-28	WOS:000075012300024
J	Cave, H; ten Bosch, JV; Suciu, S; Guidal, C; Waterkeyn, C; Otten, J; Bakkus, M; Thielemans, K; Grandchamp, B; Vilmer, E				Cave, H; ten Bosch, JV; Suciu, S; Guidal, C; Waterkeyn, C; Otten, J; Bakkus, M; Thielemans, K; Grandchamp, B; Vilmer, E		European Org Res Treatment Canc Childhood Leuke	Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							POLYMERASE CHAIN-REACTION; DELTA-T-CELL; INVITRO AMPLIFICATION; GENE REARRANGEMENTS; QUANTITATION; INDUCTION; SEQUENCES; REMISSION; PROBES; END	Background and Methods The implications of the detection of residual disease after treatment of acute lymphoblastic leukemia (ALL) are unclear. We conducted a prospective study at 11 centers to determine the predictive value of the presence or absence of detectable residual disease at several points in time during the first six months after complete remission of childhood ALL had been induced. Junctional sequences of T-cell-receptor or immunoglobulin gene rearrangements were used as clonal markers of leukemic cells. Residual disease was quantitated with a competitive polymerase-chain-reaction (PCR) assay. Of 246 patients enrolled at diagnosis and treated with a uniform chemotherapy protocol, 178 were monitored for residual disease with one clone-specific probe (in 74 percent) or more than one probe tin 26 percent). The median follow-up period was 38 months. Results The presence or absence and level of residual leukemia were significantly correlated with the risk of early relapse at each of the times studied (P<0.001). PCR measurements identified patients at high risk for relapse after the completion of induction therapy (those with greater than or equal to 10(-2) residual blasts per 2x10(5) mononuclear bone marrow cells) or at later time points (those with greater than or equal to 10(-3) residual blasts). Multivariate analysis showed that as compared with immunophenotype, age, risk group (standard or very high risk), and white-cell count at diagnosis, the presence or absence and level of residual disease were the most powerful independent prognostic factors. Conclusions Residual leukemia after induction of a remission is a powerful prognostic factor in childhood ALL. Detection of residual disease by PCR should be used to identify patients at risk for relapse and should be taken into account in considering alternative treatment. (N Engl J Med 1998;339:591-8.) (C) 1998, Massachusetts Medical Society.	Hop Robert Debre, Serv Hematol Immunol, F-75019 Paris, France; Hop Robert Debre, Biochim Genet Lab, F-75019 Paris, France; Free Univ Brussels, Dept Physiol, Brussels, Belgium; European Org Res Treatment Canc, Ctr Data, Brussels, Belgium; Free Univ Brussels, Akad Ziekenhuis, B-1090 Brussels, Belgium	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Robert-Debre - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Robert-Debre - APHP; UDICE-French Research Universities; Universite Paris Cite; Universite Libre de Bruxelles; Vrije Universiteit Brussel; European Organisation for Research & Treatment of Cancer; Universite Libre de Bruxelles; Vrije Universiteit Brussel	Vilmer, E (corresponding author), Hop Robert Debre, Serv Hematol Immunol, 48 Blvd Serurier, F-75019 Paris, France.			Bakkus, Marleen/0000-0002-0863-3369; Cave, Helene/0000-0003-2840-1511	NCI NIH HHS [5U10-CA11488-24, 5U10-CA11488-25, 5U10-CA11488-23] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U10CA011488] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BREIT TM, 1991, LEUKEMIA, V5, P116; Breslow N., 1984, CANCER CLIN TRIALS, P381; BRISCO MJ, 1994, LANCET, V343, P196, DOI 10.1016/S0140-6736(94)90988-1; CAMPANA D, 1995, BLOOD, V85, P1416, DOI 10.1182/blood.V85.6.1416.bloodjournal8561416; CAVE H, 1994, BLOOD, V83, P1892; Coustan-Smith E, 1998, LANCET, V351, P550, DOI 10.1016/S0140-6736(97)10295-1; COX DR, 1972, J R STAT SOC B, V34, P187; DAURIOL L, 1989, LEUKEMIA, V3, P155; HANSENHAGGE TE, 1989, BLOOD, V74, P1762; Henze G, 1987, Haematol Blood Transfus, V30, P147; MACINTYRE EA, 1990, J CLIN INVEST, V86, P2125, DOI 10.1172/JCI114951; NIZET Y, 1993, BLOOD, V82, P1618; OUSPENSKAIA MV, 1995, LEUKEMIA, V9, P321; PETO J, 1984, CANCER CLIN TRIALS, P361; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; POTTER MN, 1993, BRIT J HAEMATOL, V83, P412, DOI 10.1111/j.1365-2141.1993.tb04665.x; REITER A, 1994, BLOOD, V84, P3122, DOI 10.1182/blood.V84.9.3122.3122; Roberts WM, 1997, NEW ENGL J MED, V336, P317, DOI 10.1056/NEJM199701303360501; SHIACH CR, 1993, BRIT J HAEMATOL, V85, P431, DOI 10.1111/j.1365-2141.1993.tb03197.x; TRAINOR KJ, 1991, BLOOD, V78, P192; WASSERMAN R, 1992, J CLIN ONCOL, V10, P1879, DOI 10.1200/JCO.1992.10.12.1879; YAMADA M, 1990, NEW ENGL J MED, V323, P448, DOI 10.1056/NEJM199008163230705; YOKOTA S, 1991, BLOOD, V77, P331	23	572	607	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 27	1998	339	9					591	598		10.1056/NEJM199808273390904	http://dx.doi.org/10.1056/NEJM199808273390904			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	113LR	9718378				2022-12-28	WOS:000075552900004
J	Guo, ZH; Turner, C; Castle, D				Guo, ZH; Turner, C; Castle, D			Relocation of the t-SNARE SNAP-23 from lamellipodia-like cell surface projections regulates compound exocytosis in mast cells	CELL			English	Article							SYNAPTOSOMAL-ASSOCIATED PROTEIN; GUANINE-NUCLEOTIDES; CHROMAFFIN CELLS; ENDOCRINE-CELLS; IDENTIFICATION; FUSION; SECRETION; MEMBRANE; TRANSPORT; GRANULES	For regulated secretion, mast cells and several other cell types utilize compound exocytosis, a combination of granule-plasma membrane and granule-granule fusions. The molecular machinery that controls this massive export process has not been identified. We report that SNAP-23, a t-SNARE related to SNAP-25, relocates in response to stimulation from plasma membrane lamellipodia-like projections to granule membranes in permeabilized mast cells. While relocation is a prerequisite for secretion, it can occur without membrane fusion and will expedite a subsequent secretory response. After relocation, SNAP-23 is required for exocytosis, implying a crucial role in promoting membrane fusion. Thus, relocation of this SNARE regulates compound exocytosis and links granule-plasma membrane and granule-granule fusions.	Univ Virginia, Hlth Sci Ctr, Dept Cell Biol, Charlottesville, VA 22908 USA	University of Virginia	Castle, D (corresponding author), Univ Virginia, Hlth Sci Ctr, Dept Cell Biol, Charlottesville, VA 22908 USA.				NIDCR NIH HHS [DE09655] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE009655] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Abraham SN, 1997, INFECT IMMUN, V65, P3501, DOI 10.1128/IAI.65.9.3501-3508.1997; ANDERSON P, 1973, ACTA PHYSIOL SCAND, V88, P359, DOI 10.1111/j.1748-1716.1973.tb05465.x; Araki S, 1997, BIOCHEM BIOPH RES CO, V234, P257, DOI 10.1006/bbrc.1997.6560; ARIDOR M, 1993, SCIENCE, V262, P1569, DOI 10.1126/science.7504324; Banerjee A, 1996, J BIOL CHEM, V271, P20227, DOI 10.1074/jbc.271.34.20227; BENNETT MK, 1993, CELL, V74, P863, DOI 10.1016/0092-8674(93)90466-4; Bock JB, 1997, NATURE, V387, P133, DOI 10.1038/387133a0; BRAND SH, 1993, EMBO J, V12, P3753, DOI 10.1002/j.1460-2075.1993.tb06053.x; Brown AM, 1998, MOL BIOL CELL, V9, P1053, DOI 10.1091/mbc.9.5.1053; BURRY RW, 1992, J HISTOCHEM CYTOCHEM, V40, P1849, DOI 10.1177/40.12.1453003; Chen FS, 1997, BIOCHEMISTRY-US, V36, P5719, DOI 10.1021/bi962331n; CHOCK SP, 1989, J BIOL CHEM, V264, P2862; DETOLEDO GA, 1990, J GEN PHYSIOL, V95, P397, DOI 10.1085/jgp.95.3.397; FERNANDEZ JM, 1991, BIOPHYS J, V59, P1022, DOI 10.1016/S0006-3495(91)82317-7; FERRONOVICK S, 1994, NATURE, V370, P191, DOI 10.1038/370191a0; FOX JEB, 1988, J CELL BIOL, V106, P1525, DOI 10.1083/jcb.106.5.1525; Gaisano HY, 1997, FEBS LETT, V414, P298, DOI 10.1016/S0014-5793(97)01013-2; Galli T, 1998, MOL BIOL CELL, V9, P1437, DOI 10.1091/mbc.9.6.1437; GOMPERTS BD, 1992, METHOD ENZYMOL, V219, P178; Heidelberger R, 1998, J GEN PHYSIOL, V111, P225, DOI 10.1085/jgp.111.2.225; HESS DT, 1992, J NEUROSCI, V12, P4634; HIDE I, 1993, J CELL BIOL, V123, P585, DOI 10.1083/jcb.123.3.585; HohneZell B, 1996, FEBS LETT, V394, P109, DOI 10.1016/0014-5793(96)00931-3; JACOBSSON G, 1994, P NATL ACAD SCI USA, V91, P12487, DOI 10.1073/pnas.91.26.12487; Kannan R, 1996, FEBS LETT, V385, P159, DOI 10.1016/0014-5793(96)00350-X; KEMBLE GW, 1994, CELL, V76, P383, DOI 10.1016/0092-8674(94)90344-1; KOFFER A, 1993, BIOCHIM BIOPHYS ACTA, V1176, P222, DOI 10.1016/0167-4889(93)90048-T; KOFFER A, 1990, J CELL BIOL, V111, P919, DOI 10.1083/jcb.111.3.919; KOFFER A, 1993, BIOCHIM BIOPHYS ACTA, V1176, P231, DOI 10.1016/0167-4889(93)90049-U; KRUGER PG, 1980, EXP CELL RES, V129, P83, DOI 10.1016/0014-4827(80)90333-X; Mariot P, 1996, EMBO J, V15, P6476, DOI 10.1002/j.1460-2075.1996.tb01038.x; Mehta PP, 1996, P NATL ACAD SCI USA, V93, P10471, DOI 10.1073/pnas.93.19.10471; MILLER SG, 1992, METHOD ENZYMOL, V219, P234; Mollinedo F, 1997, BIOCHEM BIOPH RES CO, V231, P808, DOI 10.1006/bbrc.1997.6196; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Norman JC, 1996, MOL BIOL CELL, V7, P1429, DOI 10.1091/mbc.7.9.1429; Oberhauser AF, 1996, BIOPHYS J, V71, P1131, DOI 10.1016/S0006-3495(96)79315-3; OBERHAUSER AF, 1992, NATURE, V360, P270, DOI 10.1038/360270a0; OSullivan AJ, 1996, MOL BIOL CELL, V7, P397, DOI 10.1091/mbc.7.3.397; Otto H, 1997, P NATL ACAD SCI USA, V94, P6197, DOI 10.1073/pnas.94.12.6197; OYLER GA, 1989, J CELL BIOL, V109, P3039, DOI 10.1083/jcb.109.6.3039; PALADE GE, 1959, SUBCELLULAR PARTICLE, P64; PARSONS TD, 1995, NEURON, V15, P1085, DOI 10.1016/0896-6273(95)90097-7; PRICE LS, 1995, CURR BIOL, V5, P68, DOI 10.1016/S0960-9822(95)00018-2; Ravichandran V, 1996, J BIOL CHEM, V271, P13300, DOI 10.1074/jbc.271.23.13300; Rossi G, 1997, J BIOL CHEM, V272, P16610, DOI 10.1074/jbc.272.26.16610; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; Sadoul K, 1997, J BIOL CHEM, V272, P33023, DOI 10.1074/jbc.272.52.33023; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; Tagaya M, 1996, FEBS LETT, V394, P83, DOI 10.1016/0014-5793(96)00932-5; Ungermann C, 1998, EMBO J, V17, P3269, DOI 10.1093/emboj/17.12.3269; Veit M, 1996, FEBS LETT, V385, P119, DOI 10.1016/0014-5793(96)00362-6; WALCHSOLIMENA C, 1995, J CELL BIOL, V128, P637, DOI 10.1083/jcb.128.4.637; Wang GY, 1997, J CELL SCI, V110, P505; Wong PPC, 1997, BIOCHEM BIOPH RES CO, V230, P64, DOI 10.1006/bbrc.1996.5884; Wu TT, 1997, J CELL SCI, V110, P1533	58	219	221	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	AUG 21	1998	94	4					537	548		10.1016/S0092-8674(00)81594-9	http://dx.doi.org/10.1016/S0092-8674(00)81594-9			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	113GB	9727496	Bronze			2022-12-28	WOS:000075541100015
J	Williams, GC; Deci, EL				Williams, GC; Deci, EL			The importance of supporting autonomy in medical education	ANNALS OF INTERNAL MEDICINE			English	Article							SELF-DETERMINATION THEORY; INTRINSIC MOTIVATION; QUALITATIVE-ANALYSIS; INTERNAL-MEDICINE; STUDENTS; BEHAVIOR; STYLES; PREDICTORS; CARE; NEED	Many thoughtful leaders in medicine have asserted their belief that when physicians are more humanistic in their interactions with patients, their patients have more positive health outcomes. Consequently, many advocates have called for the practice of teaching students and residents to provide more humanistically oriented care. This article reviews research from motivational psychology, guided by self-determination theory, that suggests that when medical educators are more humanistic in their training of students, the students become more humanistic in their care of patients. Being humanistic in medical education can be achieved through support of the autonomy of students. Autonomy support means working from the students' perspectives to promote their active engagement and sense of volition with respect to learning. Research suggests that when educators are more supportive of student autonomy, students not only display a more humanistic orientation toward patients but also show greater conceptual understanding and better psychological adjustment.	Univ Rochester, Dept Clin & Social Sci Psychol, Rochester, NY 14627 USA; Univ Rochester, Sch Med & Dent, Rochester, NY 14627 USA; Genesee Hosp, New Rochelle, NY USA	University of Rochester; University of Rochester	Williams, GC (corresponding author), Univ Rochester, Dept Clin & Social Sci Psychol, 601 Elmwood Ave, Rochester, NY 14627 USA.		Deci, Edward L./Y-4790-2019; Deci, Edward L/T-7048-2017; Williams, Geoffrey/AAN-1143-2021	Deci, Edward L./0000-0001-8246-8536; Deci, Edward L/0000-0001-8246-8536; 	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD019914] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK050807] Funding Source: NIH RePORTER; NICHD NIH HHS [HD 19914] Funding Source: Medline; NIDDK NIH HHS [DK 50807] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		*AM BOARD INT MED, 1996, POL PROC CERT; ASHWORTH CD, 1984, SOC SCI MED, V19, P1235, DOI 10.1016/0277-9536(84)90376-9; Bandura A., 1996, SELF EFFICACY EXERCI; BECKER HS, 1966, BOYS WHITE STUDENT C; BENWARE CA, 1984, AM EDUC RES J, V21, P755, DOI 10.3102/00028312021004755; Cohen-Cole SA, 1991, MED INTERVIEW 3 FUNC; Deci E. L., 1985, INTRINSIC MOTIVATION; Deci EL, 1996, LEARN INDIVID DIFFER, V8, P165, DOI 10.1016/S1041-6080(96)90013-8; DECI EL, 1981, J EDUC PSYCHOL, V73, P642, DOI 10.1037/0022-0663.73.5.642; DECI EL, 1982, J EDUC PSYCHOL, V74, P852, DOI 10.1037/0022-0663.74.6.852; DECI EL, 1994, J PERS, V62, P119, DOI 10.1111/j.1467-6494.1994.tb00797.x; ENDE J, 1995, ACAD MED, V70, P224, DOI 10.1097/00001888-199503000-00014; ENGEL GL, 1977, SCIENCE, V196, P129, DOI 10.1126/science.847460; GROLNICK WS, 1987, J PERS SOC PSYCHOL, V52, P890, DOI 10.1037/0022-3514.52.5.890; KOESTNER R, 1984, J PERS, V52, P233, DOI 10.1111/j.1467-6494.1984.tb00879.x; Laine C, 1996, JAMA-J AM MED ASSOC, V275, P152, DOI 10.1001/jama.275.2.152; Lazare A., 1995, MED INTERVIEW CLIN C, P3; MCMURRAY JE, 1993, ANN INTERN MED, V119, P812, DOI 10.7326/0003-4819-119-8-199310150-00007; PLATT FW, 1979, ANN INTERN MED, V91, P898, DOI 10.7326/0003-4819-91-6-898; Regan-Smith M G, 1994, JAMA, V272, P1380, DOI 10.1001/jama.272.17.1380; Rogers C.R., 1969, FREEDOM LEARN; Rosenthal R., 1991, ESSENTIALS BEHAV RES, V2nd Edn; ROTTER JB, 1966, PSYCHOL MONOGR, V80, P1, DOI 10.1037/h0092976; RYAN RM, 1982, J PERS SOC PSYCHOL, V43, P450, DOI 10.1037/0022-3514.43.3.450; RYAN RM, 1986, J PERS SOC PSYCHOL, V50, P550, DOI 10.1037/0022-3514.50.3.550; TAYLOR CR, 1992, NEW ENGL J MED, V326, P1436, DOI 10.1056/NEJM199205213262118; VALLERAND RJ, 1992, J PERS, V60, P599, DOI 10.1111/j.1467-6494.1992.tb00922.x; Williams G. C., 1996, J GEN INTERN MED S, V1, P138; Williams GC, 1996, J PERS SOC PSYCHOL, V70, P115, DOI 10.1037/0022-3514.70.1.115; Williams GC, 1996, J PERS SOC PSYCHOL, V70, P767, DOI 10.1037/0022-3514.70.4.767; WILLIAMS GC, 1994, J GEN INTERN MED, V9, P327, DOI 10.1007/BF02599180; Williams GC, 1997, SOC SCI MED, V45, P1705, DOI 10.1016/S0277-9536(97)00103-2; Williams GC, 1998, HEALTH PSYCHOL, V17, P269, DOI 10.1037/0278-6133.17.3.269; WILLIAMS GC, IN PRESS DIABETES CA; Williams GC, 1998, PARTNERSHIPS HEALTHC, P67	35	130	133	1	16	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 15	1998	129	4					303	308		10.7326/0003-4819-129-4-199808150-00007	http://dx.doi.org/10.7326/0003-4819-129-4-199808150-00007			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	109NP	9729184				2022-12-28	WOS:000075329100007
J	Ishii, N; Fujii, M; Hartman, PS; Tsuda, M; Yasuda, K; Senoo-Matsuda, N; Yanase, S; Ayusawa, D; Suzuki, K				Ishii, N; Fujii, M; Hartman, PS; Tsuda, M; Yasuda, K; Senoo-Matsuda, N; Yanase, S; Ayusawa, D; Suzuki, K			A mutation in succinate dehydrogenase cytochrome b causes oxidative stress and ageing in nematodes	NATURE			English	Article							MITOCHONDRIAL RESPIRATORY-CHAIN; CAENORHABDITIS-ELEGANS; UBIQUINONE OXIDOREDUCTASE; SENSITIVE MUTANT; COMPLEX-II; DAMAGE; DEFICIENCY	Much attention has focused on the aetiology of oxidative damage in cellular and organismal ageing(1-4). Especially toxic are the reactive oxygen byproducts of respiration and other biological processes(5). A mev-1(kn1) mutant of Caenorhabditis elegans has been found to be hypersensitive to raised oxygen concentrations(6,7), Unlike the wild type, its lifespan decreases dramatically as oxygen concentrations are increased from 1 tee 60% (ref. 7). Strains bearing this mutation accumulate markers of ageing (such as fluorescent materials and protein carbonyls) faster than the wild type(8,9). We show here that mev-1 encodes a subunit of the enzyme succinate dehydrogenase cytochrome b, which is a component of complex II of the mitochondrial electron transport chain. We found that the ability of complex II to catalyse electron transport from succinate to ubiquinone is compromised in mev-l animals. This may cause an indirect increase in superoxide levels, which in turn leads to oxygen hypersensitivity and premature ageing. Our results indicate that mev-1 governs the rate of ageing by modulating the cellular response to oxidative stress.	Tokai Univ, Sch Med, Dept Mol Life Sci, Kanagawa 2591193, Japan; Yokohama City Univ, Kihara Inst Biol Res, Dept Biochem, Kanagawa 2440813, Japan; Texas Christian Univ, Dept Biol, Ft Worth, TX 76129 USA; Kyowa Hakko Kogyo Co Ltd, Tokyo Res Lab, Tokyo 1948533, Japan	Tokai University; Yokohama City University; Texas Christian University; Kyowa Kirin Ltd	Ishii, N (corresponding author), Tokai Univ, Sch Med, Dept Mol Life Sci, Kanagawa 2591193, Japan.		Yasuda, Kayo/ABA-5867-2021	Yasuda, Kayo/0000-0002-6205-9249				Ackrell B A, 1978, Methods Enzymol, V53, P466; Adachi H, 1998, J GERONTOL A-BIOL, V53, pB240, DOI 10.1093/gerona/53A.4.B240; AGARWAL S, 1994, P NATL ACAD SCI USA, V91, P12332, DOI 10.1073/pnas.91.25.12332; BOURGERON T, 1995, NAT GENET, V11, P144, DOI 10.1038/ng1095-144; CADENAS E, 1980, BIOCHEM J, V188, P31, DOI 10.1042/bj1880031; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COCHRAN B, 1994, BBA-BIOENERGETICS, V1188, P162, DOI 10.1016/0005-2728(94)90035-3; FIRE A, 1986, EMBO J, V5, P2673, DOI 10.1002/j.1460-2075.1986.tb04550.x; FRIDEN H, 1990, MOL MICROBIOL, V4, P1045, DOI 10.1111/j.1365-2958.1990.tb00677.x; HARMAN D, 1968, J GERONTOL, V23, P476, DOI 10.1093/geronj/23.4.476; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; HONDA S, 1993, J GERONTOL, V48, pB57, DOI 10.1093/geronj/48.2.B57; HOSOKAWA H, 1994, MECH AGEING DEV, V74, P161, DOI 10.1016/0047-6374(94)90087-6; ISHII N, 1990, MUTAT RES, V237, P165, DOI 10.1016/0921-8734(90)90022-J; LARSEN PL, 1993, P NATL ACAD SCI USA, V90, P8905, DOI 10.1073/pnas.90.19.8905; Martin GM, 1996, NAT GENET, V13, P25, DOI 10.1038/ng0596-25; MARTIN JJ, 1988, J NEUROL SCI, V84, P189, DOI 10.1016/0022-510X(88)90124-4; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; MUNNICH A, 1992, J INHERIT METAB DIS, V15, P448, DOI 10.1007/BF01799603; RIGGS JE, 1984, NEUROLOGY, V34, P48, DOI 10.1212/WNL.34.1.48; Robinson KM, 1995, METHOD ENZYMOL, V260, P34, DOI 10.1016/0076-6879(95)60128-7; Taylor RW, 1996, ANN NEUROL, V39, P224, DOI 10.1002/ana.410390212; TURRENS JF, 1985, ARCH BIOCHEM BIOPHYS, V237, P408, DOI 10.1016/0003-9861(85)90293-0; WALLACE DC, 1992, ANNU REV BIOCHEM, V61, P1175, DOI 10.1146/annurev.bi.61.070192.005523; YU L, 1987, J BIOL CHEM, V262, P1137	25	536	553	7	56	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 13	1998	394	6694					694	697		10.1038/29331	http://dx.doi.org/10.1038/29331			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	110MD	9716135				2022-12-28	WOS:000075384200048
J	Horowitz, TS; Wolfe, JM				Horowitz, TS; Wolfe, JM			Visual search has no memory	NATURE			English	Article							ATTENTION	Humans spend a lot of time searching for things, such as roadside traffic signs(1), soccer balls(2) or tumours in mammograms(3). These tasks involve the deployment of attention from one item in the visual field to the next. Common sense suggests that rejected items should be noted in some fashion so that effort is not expended in re-examining items that have been attended to and rejected. However, common sense is wrong. Here we asked human observers to search for a letter 'T' among letters 'L'. This search demands visual attention and normally proceeds at a rate of 20-30 milliseconds per item(4). In the critical condition, we randomly relocated all letters every 111 milliseconds. This made it impossible for the subjects to keep track of the progress of the search. Nevertheless, the efficiency of the search was unchanged. Theories of visual search all assume that search relies on accumulating information about the identity of objects over time(5-7). Such theories predict that search efficiency will be drastically reduced if the scene is continually shuffled while the observer is trying to search through it. As we show that efficiency is not impaired, the standard theories must be revised.	Brigham & Womens Hosp, Boston, MA 02115 USA; Harvard Univ, Sch Med, Ctr Ophthalm Res, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Horowitz, TS (corresponding author), Brigham & Womens Hosp, 221 Longwood Ave, Boston, MA 02115 USA.		Horowitz, Todd S/J-3376-2013; Wolfe, Jeremy M/C-1621-2012; Wolfe, Jeremy M/A-9248-2016	Wolfe, Jeremy M/0000-0002-6475-1984; Wolfe, Jeremy M/0000-0002-6475-1984; Horowitz, Todd/0000-0001-5571-6266				Chun MM, 1996, COGNITIVE PSYCHOL, V30, P39, DOI 10.1006/cogp.1996.0002; FAIRCLOUGH S, 1993, VISUAL SEARCH, V2, P419; GALE AG, 1993, VISUAL SEARCH, V2, P231; GROSSBERG S, 1994, PSYCHOL REV, V101, P470, DOI 10.1037/0033-295X.101.3.470; HELSEN W, 1993, VISUAL SEARCH, V2, P379; Irwin DE, 1996, CURR DIR PSYCHOL SCI, V5, P94, DOI 10.1111/1467-8721.ep10772833; PALMER J, 1995, CURR DIR PSYCHOL SCI, V4, P118, DOI 10.1111/1467-8721.ep10772534; Rensink RA, 1997, PSYCHOL SCI, V8, P368, DOI 10.1111/j.1467-9280.1997.tb00427.x; Simons DJ, 1997, TRENDS COGN SCI, V1, P261, DOI 10.1016/S1364-6613(97)01080-2; TREISMAN AM, 1980, COGNITIVE PSYCHOL, V12, P97, DOI 10.1016/0010-0285(80)90005-5; WOLFE JM, 1994, PSYCHON B REV, V1, P202, DOI 10.3758/BF03200774; Wolfe JM, 1998, PSYCHOL SCI, V9, P33, DOI 10.1111/1467-9280.00006	12	378	396	4	46	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 6	1998	394	6693					575	577		10.1038/29068	http://dx.doi.org/10.1038/29068			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	107YN	9707117				2022-12-28	WOS:000075238700047
J	Stilling, B; Mehlsen, J; Hamberg, O; Larsen, JJ; Gram, NC; Madsbad, S				Stilling, B; Mehlsen, J; Hamberg, O; Larsen, JJ; Gram, NC; Madsbad, S			Effect of starch-free bread on metabolic control in type 2 diabetes	LANCET			English	Article							FATTY-ACIDS; LIPOPROTEINS		Rigshosp, Nutr Unit, DK-1263 Copenhagen K, Denmark; Frederiksberg Hosp, Dept Clin Physiol, Frederiksberg, Denmark; Amtssygehuset, Dept Med F, Copenhagen, Denmark; Univ Copenhagen, Panum Inst, Dept Med Physiol, DK-2200 Copenhagen, Denmark; Hvidovre Hosp, Dept Endocrinol, Copenhagen, Denmark	Rigshospitalet; University of Copenhagen; University of Copenhagen	Stilling, B (corresponding author), Rigshosp, Nutr Unit, 2111, DK-1263 Copenhagen K, Denmark.		Mehlsen, Jesper/AAA-5848-2022	Madsbad, Sten/0000-0002-5017-1815				[Anonymous], 1987, Diabetes Care, V10, P639; GARG A, 1988, NEW ENGL J MED, V319, P829, DOI 10.1056/NEJM198809293191304; MATTSON FH, 1985, J LIPID RES, V26, P194; MENSINK RP, 1987, LANCET, V1, P122, DOI 10.1016/S0140-6736(87)91965-9; Toeller M, 1997, DIABETOLOGIA, V40, P1219, DOI 10.1007/s001250050810	5	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	AUG 1	1998	352	9125					369	370		10.1016/S0140-6736(05)60468-0	http://dx.doi.org/10.1016/S0140-6736(05)60468-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	106BU	9717929				2022-12-28	WOS:000075110500017
J	Streitberger, K; Kleinhenz, J				Streitberger, K; Kleinhenz, J			Introducing a placebo needle into acupuncture research	LANCET			English	Article							PAIN	Background A problem acupuncture research has to face is the concept of a control group. If, in control groups, non-acupoint needling is done, physiological acupuncture effects are implied. Therefore the effects shown in this group are often close to those shown in the acupuncture group. In other trials, control groups have received obviously different treatments, such as transcutaneous electrical nervous stimulation or TENS-laser treatment; it is not clear if the effects of acupuncture are due only to the psychological effects of the treatment. Methods We developed a placebo acupuncture needle, with which it should be possible to simulate an acupuncture procedure without penetrating the shin. In a cross-over experiment with 60 volunteers we tested whether needling with the placebo needle feels any different from real acupuncture. Findings Of 60 volunteers, 54 felt a penetration with acupuncture (mean visual analogue scale [VAS] 13.4; SD 10.58) and 47 felt it with placebo (VAS 8.86; SD 10.55), 34 felt a dull pain sensation (DEQI) with acupuncture and 13 with placebo. None of the volunteers suspected that the needle may not have penetrated the skin. Interpretation The placebo needle is sufficiently credible to be used in investigations of the effects of acupuncture.	Univ Heidelberg, Anesthesiol Clin, D-69120 Heidelberg, Germany	Ruprecht Karls University Heidelberg	Kleinhenz, J (corresponding author), Univ Heidelberg, Anesthesiol Clin, Neuenheimer Feld 110, D-69120 Heidelberg, Germany.							BING Z, 1990, NEUROSCIENCE, V37, P809, DOI 10.1016/0306-4522(90)90110-P; DESAINTONGE DMC, 1994, LANCET, V344, P995, DOI 10.1016/S0140-6736(94)91647-0; FEINSTEIN AR, 1984, CIRCULATION, V70, P767, DOI 10.1161/01.CIR.70.5.767; GHIA JN, 1976, PAIN, V2, P285, DOI 10.1016/0304-3959(76)90006-3; JENSEN LB, 1979, SCAND J DENT RES, V87, P373; KUBIENA G, 1989, WIEN KLIN WOCHENSCHR, V101, P362; LEBAR SD, 1989, SCI BASES ACUPUNCTUR, P79; LEWIT K, 1979, PAIN, V6, P83, DOI 10.1016/0304-3959(79)90142-8; LEWITH GT, 1983, PAIN, V16, P111, DOI 10.1016/0304-3959(83)90202-6; LIU X, 1986, PAIN, V24, P383, DOI 10.1016/0304-3959(86)90124-7; MELZACK R, 1980, PAIN, V9, P209, DOI 10.1016/0304-3959(80)90008-1; MOORE ME, 1976, ANN INTERN MED, V84, P3812; PINI G, 1984, PAIN, V18, P239; VILLANUEVA L, 1986, PAIN, V26, P233, DOI 10.1016/0304-3959(86)90078-3; VINCENT C, 1995, J ROY SOC MED, V88, P199	15	600	640	2	105	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	AUG 1	1998	352	9125					364	365		10.1016/S0140-6736(97)10471-8	http://dx.doi.org/10.1016/S0140-6736(97)10471-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	106BU	9717924				2022-12-28	WOS:000075110500012
J	Weisinger, JR; Bellorin-Font, E				Weisinger, JR; Bellorin-Font, E			Magnesium and phosphorus	LANCET			English	Article							HOSPITAL POPULATION; HYPOPHOSPHATEMIA; PHOSPHATE; DEFICIENCY; HYPERPARATHYROIDISM; HYPERMAGNESEMIA; HYPOMAGNESEMIA; TRANSPORT; KIDNEY	A summary of new findings regarding alterations of magnesium (Mg2+) and phosphorus (P) metabolism are reviewed for the clinician caring for patients in general wards. Alterations in serum concentrations of Mg2+ and P are frequently observed in acute or very ill patients in emergency rooms or intensive-care areas. A significant proportion of these alterations are iatrogenic. Most of the symptoms related are non-specific, and usually they are associated with changes In concentration of other ions. The need to measure Mg2+ and P routinely and to define better the real abnormal values is stressed. Correction of the abnormalities must be early in the course of the alterations.	Hop Univ Caracas, Serv Nefrol & Trasplante Renal, Div Nephrol & Renal Transplantat, Dept Med, Caracas 1041, Venezuela; Cent Univ Venezuela, Dept Med, Caracas, Venezuela; MSAS, Ctr Nacl Dialisis & Trasplante, Res Ctr, Caracas, Venezuela	University of Central Venezuela	Weisinger, JR (corresponding author), Hop Univ Caracas, Serv Nefrol & Trasplante Renal, Div Nephrol & Renal Transplantat, Dept Med, AP 47365, Caracas 1041, Venezuela.		Hug, Balthasar L./G-1568-2010					ABBOTT LG, 1993, MINER ELECTROL METAB, V19, P314; ALGHAMDI SMG, 1994, AM J KIDNEY DIS, V24, P737, DOI 10.1016/S0272-6386(12)80667-6; ARRAMBIDE K, 1993, SEMIN NEPHROL, V13, P273; BELLORINFONT E, 1990, AM J PHYSIOL, V258, pF1640, DOI 10.1152/ajprenal.1990.258.6.F1640; BELLORINFONT E, 1984, ENDOCRINOLOGY, V115, P544, DOI 10.1210/endo-115-2-544; BELLORINFONT E, 1990, DIURETICS, V2, P427; BETRO MG, 1972, BRIT MED J, V1, P273, DOI 10.1136/bmj.1.5795.273; BRAUTBAR N, 1983, MINER ELECTROL METAB, V9, P45; CAVERZASIO J, 1992, J ENDOCRINOL, V134, P361, DOI 10.1677/joe.0.1340361; CHENG L, 1983, AM J PHYSIOL, V245, pF175, DOI 10.1152/ajprenal.1983.245.2.F175; CLARK BA, 1992, AM J NEPHROL, V12, P336, DOI 10.1159/000168469; CLARKE BL, 1995, CLIN ENDOCRINOL, V43, P479, DOI 10.1111/j.1365-2265.1995.tb02621.x; DREZNER MK, 1982, VITAMIN D CHEM BIOCH, P945; Elisaf M, 1995, J TRACE ELEM MED BIO, V9, P210, DOI 10.1016/S0946-672X(11)80026-X; HEBERT LEE A., 1966, J CLIN INVEST, V45, P1886, DOI 10.1172/JCI105493; HERBERT P, 1997, CRIT CARE MED, V25, P749; KING AL, 1987, SOUTH MED J, V80, P831, DOI 10.1097/00007611-198707000-00008; KNOCHEL J, 1993, KIDNEY, P1086; KNOCHEL JP, 1992, AM J MED, V92, P455, DOI 10.1016/0002-9343(92)90739-X; LOPEZHILKER S, 1990, AM J PHYSIOL, V259, pF432, DOI 10.1152/ajprenal.1990.259.3.F432; MCLEAN RM, 1994, AM J MED, V96, P63, DOI 10.1016/0002-9343(94)90117-1; Mehrotra R, 1997, AM J KIDNEY DIS, V29, P106, DOI 10.1016/S0272-6386(97)90016-0; MURER H, 1994, J EXP BIOL, V196, P167; OCONNOR LR, 1977, NEW ENGL J MED, V297, P901, DOI 10.1056/NEJM197710272971702; QUAMME GA, 1989, AM J PHYSIOL, V256, pF197, DOI 10.1152/ajprenal.1989.256.2.F197; Quamme GA, 1997, KIDNEY INT, V52, P1180, DOI 10.1038/ki.1997.443; Redwood SR, 1996, J AM COLL CARDIOL, V28, P1765, DOI 10.1016/S0735-1097(96)00373-7; Rude RK, 1996, OSTEOPOROSIS INT, V6, P453, DOI 10.1007/BF01629578; RUDE RK, 1993, ENDOCRIN METAB CLIN, V22, P377, DOI 10.1016/S0889-8529(18)30172-5; RYAN MP, 1993, MINER ELECTROL METAB, V19, P290; Slatopolsky E, 1996, J CLIN INVEST, V97, P2534, DOI 10.1172/JCI118701; SLATOPOLSKY E, 1977, CLIN NEPHROL, V7, P138; SLATOPOLSKY E, 1984, J CLIN INVEST, V74, P2136, DOI 10.1172/JCI111639; STEIN JH, 1966, AM J MED SCI, V252, P78, DOI 10.1097/00000441-196607000-00012; WEISINGER JR, 1986, ARCH INTERN MED, V146, P473, DOI 10.1001/archinte.146.3.473; WONG ET, 1983, AM J CLIN PATHOL, V79, P348, DOI 10.1093/ajcp/79.3.348	36	231	237	1	9	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	AUG 1	1998	352	9125					391	396		10.1016/S0140-6736(97)10535-9	http://dx.doi.org/10.1016/S0140-6736(97)10535-9			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	106BU	9717944				2022-12-28	WOS:000075110500043
J	Russon, L; Alison, D				Russon, L; Alison, D			Palliative care does not mean giving up	BRITISH MEDICAL JOURNAL			English	Article									St James Univ Hosp, Palliat Care Team, Leeds LS9 7TF, W Yorkshire, England	Saint James's University Hospital	Russon, L (corresponding author), St James Univ Hosp, Palliat Care Team, Ashley Wing, Leeds LS9 7TF, W Yorkshire, England.							ONEILL J, 1994, AM J HOSPICE PAL NOV, P36; *STAND MED ADV COM, 1992, PRINC PROV PALL CAR; World Health Organization, 1990, CANC PAIN REL PALL C	3	11	11	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 18	1998	317	7152					196	197						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	103FZ	9705638				2022-12-28	WOS:000075047800035
J	Salonen, JT; Tuomainen, TP; Nyyssonen, K; Lakka, HM; Punnonen, K				Salonen, JT; Tuomainen, TP; Nyyssonen, K; Lakka, HM; Punnonen, K			Relation between iron stores and non-insulin dependent diabetes in men: case-control study	BRITISH MEDICAL JOURNAL			English	Article									Univ Kuopio, Res Inst Publ Hlth, FIN-70211 Kuopio, Finland; Univ Kuopio, Dept Publ Hlth & Gen Practice, FIN-70211 Kuopio, Finland; Kuopio Univ Hosp, Dept Clin Chem, FIN-70211 Kuopio, Finland	University of Eastern Finland; University of Eastern Finland; Kuopio University Hospital	Salonen, JT (corresponding author), Univ Kuopio, Res Inst Publ Hlth, POB 1627, FIN-70211 Kuopio, Finland.				NHLBI NIH HHS [HL44199] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		OBERLEY LW, 1988, FREE RADICAL BIO MED, V5, P113, DOI 10.1016/0891-5849(88)90036-6; SALONEN JT, 1995, BRIT MED J, V311, P1124, DOI 10.1136/bmj.311.7013.1124; Tuomainen TP, 1997, DIABETES CARE, V20, P426, DOI 10.2337/diacare.20.3.426; Tuomainen TP, 1998, CIRCULATION, V97, P1461; Witte DL, 1996, CLIN CHIM ACTA, V245, P139, DOI 10.1016/0009-8981(95)06212-2	5	188	198	1	9	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	SEP 12	1998	317	7160					727	727		10.1136/bmj.317.7160.727	http://dx.doi.org/10.1136/bmj.317.7160.727			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	121CT	9732340	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000075995100021
J	Cummings, SR; Browner, WS; Bauer, D; Stone, K; Ensrud, K; Jamal, S; Ettinger, B				Cummings, SR; Browner, WS; Bauer, D; Stone, K; Ensrud, K; Jamal, S; Ettinger, B		Study Osteoporotic Fractures Res Grp	Endogenous hormones and the risk of hip and vertebral fractures among older women	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							FEMORAL-NECK FRACTURE; VITAMIN-D STATUS; POSTMENOPAUSAL WOMEN; ESTROGEN THERAPY; ELDERLY WOMEN; BONE; OSTEOPOROSIS; 1,25-DIHYDROXYVITAMIN-D; 17-BETA-ESTRADIOL; ENDOMETRIUM	Background and Methods. In postmenopausal women, the serum concentrations of endogenous sex hormones and vitamin D might influence the risk of hip and vertebral fractures. In a study of a cohort of women 65 years of age or older, we compared the serum hormone concentrations at base line in 133 women who subsequently had hip fractures and 138 women who subsequently had vertebral fractures with those in randomly selected control women from the same cohort. Women who were taking estrogen were excluded. The results were adjusted for age and weight. Results. The women with undetectable serum estradiol concentrations (<5 pg per milliliter [18 pmol per liter]) had a relative risk of 2.5 for subsequent hip fracture (95 percent confidence interval, 1.4 to 4.6) and subsequent vertebral fracture (95 percent confidence interval, 1.4 to 4.2), as compared with the women with detectable serum estradiol concentrations. Serum concentrations of sex hormone-binding globulin that were 1.0 mu g per deciliter (34.7 nmol per liter) or higher were associated with a relative risk of 2.0 for hip fracture (95 percent confidence interval, 1.1 to 3.9) and 2.3 for vertebral fracture (95 percent confidence interval, 1.2 to 4.4), Women with both undetectable serum estradiol concentrations and serum sex hormone-binding globulin concentrations of 1 mu g per deciliter or more had a relative risk of 6.9 for hip fracture (95 percent confidence interval, 1.5 to 32.0) and 7.9 for vertebral fracture (95 percent confidence interval, 2.2 to 28.0). For those with low serum 1,25-dihydroxyvitamin D concentrations (less than or equal to 23 pg per milliliter [55 pmol per liter]), the risk of hip fracture increased by a factor of 2.1 (95 percent confidence interval, 1.2 to 3.5). Conclusions. Postmenopausal women with undetectable serum estradiol concentrations and high serum concentrations of sex hormone-binding globulin have an increased risk of hip and vertebral fracture. (N Engl J Med 1998;339:733-8.) (C) 1998, Massachusetts Medical Society.	Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA; Vet Affairs Med Ctr, Dept Med, Minneapolis, MN 55417 USA; Univ Minnesota, Sch Publ Hlth, Div Epidemiol, Minneapolis, MN 55455 USA; Kaiser Permanente Med Care Program, Div Res, Oakland, CA 94611 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA); Minneapolis VA Health Care System; University of Minnesota System; University of Minnesota Twin Cities; Kaiser Permanente	Cummings, SR (corresponding author), Suite 600,74 New Montgomery St, San Francisco, CA 94143 USA.			Ensrud, Kristine/0000-0002-9069-3036	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR035582] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR35582] Funding Source: Medline; NIA NIH HHS [AG05407, AG05394] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALOIA JF, 1985, AM J MED, V78, P95, DOI 10.1016/0002-9343(85)90468-1; BLACK DM, 1995, J BONE MINER RES, V10, P890; BROWNER WS, 1986, AM J EPIDEMIOL, V123, P143, DOI 10.1093/oxfordjournals.aje.a114208; COOPER C, 1989, BONE MINER, V5, P193, DOI 10.1016/0169-6009(89)90096-2; CUMMINGS SR, 1987, AM J EPIDEMIOL, V126, P796, DOI 10.1093/oxfordjournals.aje.a114716; CUMMINGS SR, 1995, NEW ENGL J MED, V332, P767, DOI 10.1056/NEJM199503233321202; CUMMINGS SR, 1995, J BONE MINER RES, V10, P1605; DAVIDSON BJ, 1982, J CLIN ENDOCR METAB, V54, P115, DOI 10.1210/jcem-54-1-115; DORGAN JF, 1996, CANCER EPIDEM BIOMAR, V5, P553; DUNSTAN CR, 1990, CALCIFIED TISSUE INT, V47, P270, DOI 10.1007/BF02555908; ETTINGER B, 1992, AM J OBSTET GYNECOL, V166, P479, DOI 10.1016/0002-9378(92)91653-R; Ettinger B, 1997, AM J OBSTET GYNECOL, V176, P112, DOI 10.1016/S0002-9378(97)80022-1; FURUYAMA S, 1970, STEROIDS, V16, P415, DOI 10.1016/S0039-128X(70)80124-6; Garnero P, 1996, J BONE MINER RES, V11, P1531; Genant HK, 1997, ARCH INTERN MED, V157, P2609, DOI 10.1001/archinte.157.22.2609; HESHMATI HM, 1997, J BONE MINER RES  S1, V12, pS121; HORDON LD, 1990, BONE MINER, V11, P247, DOI 10.1016/0169-6009(90)90063-L; KOCHERSBERGER G, 1988, Comprehensive Therapy, V14, P24; LAMBERG-ALLARDT C, 1989, EUR J CLIN NUTR, V43, P355; LANYON LE, 1993, CALCIFIED TISSUE INT, V53, pS102, DOI 10.1007/BF01673415; LAU EMC, 1989, GERONTOLOGY, V35, P198, DOI 10.1159/000213023; LAUFER LR, 1983, AM J OBSTET GYNECOL, V145, P585, DOI 10.1016/0002-9378(83)91201-2; LIPS P, 1982, METAB BONE DIS RELAT, V4, P85, DOI 10.1016/0221-8747(82)90021-2; LONGCOPE C, 1984, MATURITAS, V6, P309, DOI 10.1016/0378-5122(84)90002-1; LUND B, 1982, HORM METAB RES, V14, P271, DOI 10.1055/s-2007-1018990; MAYES D, 1968, J CLIN ENDOCR METAB, V28, P1169, DOI 10.1210/jcem-28-8-1169; Naessen T, 1997, AM J OBSTET GYNECOL, V177, P115, DOI 10.1016/S0002-9378(97)70448-4; PRENTICE RL, 1986, BIOMETRIKA, V73, P1; Riggs BL, 1998, J BONE MINER RES, V13, P763, DOI 10.1359/jbmr.1998.13.5.763; RIGGS BL, 1983, AM J MED, V75, P899, DOI 10.1016/0002-9343(83)90860-4; RIGGS BL, 1973, J CLIN ENDOCR METAB, V36, P1097, DOI 10.1210/jcem-36-6-1097; RUDMAN D, 1989, J AM COLL NUTR, V8, P324; Speroff L, 1996, JAMA-J AM MED ASSOC, V276, P1397, DOI 10.1001/jama.276.17.1397; STEIGER P, 1992, J BONE MINER RES, V7, P625; Tomkinson A, 1997, J CLIN ENDOCR METAB, V82, P3128, DOI 10.1210/jc.82.9.3128; TONIOLO PG, 1995, JNCI-J NATL CANCER I, V87, P190, DOI 10.1093/jnci/87.3.190; VANDEWALLE B, 1989, MOL CELL ENDOCRINOL, V61, P239, DOI 10.1016/0303-7207(89)90135-4; VANHEMERT AM, 1989, CLIN ENDOCRINOL, V31, P499	38	520	528	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 10	1998	339	11					733	738		10.1056/NEJM199809103391104	http://dx.doi.org/10.1056/NEJM199809103391104			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	116RF	9731089	Bronze			2022-12-28	WOS:000075737800004
J	Song, HJ; Ming, GL; He, ZG; Lehmann, M; McKerracher, L; Tessier-Lavigne, M; Poo, MM				Song, HJ; Ming, GL; He, ZG; Lehmann, M; McKerracher, L; Tessier-Lavigne, M; Poo, MM			Conversion of neuronal growth cone responses from repulsion to attraction by cyclic nucleotides	SCIENCE			English	Article							MYELIN-ASSOCIATED GLYCOPROTEIN; DEPENDENT PROTEIN-KINASE; SEMAPHORIN-III; NITRIC-OXIDE; SPINAL-CORD; C-ELEGANS; INTRACELLULAR CALCIUM; AXONAL REGENERATION; GUIDANCE MOLECULES; KINETIC-ANALYSIS	Nerve growth is regulated by attractive and repulsive factors in the nervous system. Microscopic gradients of Collapsin-1/Semaphorin III/D (Sema III) and myelin-associated glycoprotein trigger repulsive turning responses by growth cones of cultured Xenopus spinal neurons; the repulsion can be converted to attraction by pharmacological activation of the guanosine 3',5'-monophosphate (cGMP) and adenosine 3',5'-monophosphate signaling pathways, respectively. Sema ill also causes the collapse of cultured rat sensory growth cones, which can be inhibited by activation of the cGMP pathway. Thus cyclic nucleotides can regulate growth cone behaviors and may be targets for designing treatments to alleviate the inhibition of nerve regeneration by repulsive factors.	Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA; Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA; Univ Calif San Francisco, Howard Hughes Med Inst, Dept Anat, San Francisco, CA 94143 USA; Univ Montreal, Dept Pathol, Montreal, PQ H3C 3J7, Canada; McGill Univ, Montreal, PQ H3C 3J7, Canada	University of California System; University of California San Diego; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco; Universite de Montreal; McGill University	Poo, MM (corresponding author), Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA.		Ming, Guo-li/J-7880-2013	Ming, Guo-li/0000-0002-2517-6075	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS022764] Funding Source: NIH RePORTER; NINDS NIH HHS [NS22764] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BANDTLOW CE, 1993, SCIENCE, V259, P80, DOI 10.1126/science.8418499; Behar O, 1996, NATURE, V383, P525, DOI 10.1038/383525a0; BIXBY JL, 1984, J PHYSIOL-LONDON, V353, P143, DOI 10.1113/jphysiol.1984.sp015328; BUTT E, 1990, FEBS LETT, V263, P47, DOI 10.1016/0014-5793(90)80702-K; Chen H, 1997, NEURON, V19, P547, DOI 10.1016/S0896-6273(00)80371-2; COLAMARINO SA, 1995, CELL, V81, P621, DOI 10.1016/0092-8674(95)90083-7; Cooper J.R., 1996, BIOCH BASIS NEUROPHA, Vseventh; EVERS J, 1989, J NEUROSCI, V9, P1523; FAN JH, 1995, NEURON, V14, P263, DOI 10.1016/0896-6273(95)90284-8; Fong JHJ, 1996, BIOCHEM BIOPH RES CO, V221, P19, DOI 10.1006/bbrc.1996.0537; Gibbs SM, 1998, NEURON, V20, P83, DOI 10.1016/S0896-6273(00)80436-5; HAMELIN M, 1993, NATURE, V364, P327, DOI 10.1038/364327a0; He ZG, 1997, CELL, V90, P739, DOI 10.1016/S0092-8674(00)80534-6; ISHII N, 1992, NEURON, V9, P873, DOI 10.1016/0896-6273(92)90240-E; IVINS JK, 1991, J NEUROSCI, V11, P1597; KATER SB, 1988, TRENDS NEUROSCI, V11, P317; KENNEDY TE, 1994, CELL, V78, P425, DOI 10.1016/0092-8674(94)90421-9; KEYNES R, 1995, CELL, V83, P161, DOI 10.1016/0092-8674(95)90157-4; Kolodkin AL, 1997, CELL, V90, P753, DOI 10.1016/S0092-8674(00)80535-8; KOLODKIN AL, 1993, CELL, V75, P1389, DOI 10.1016/0092-8674(93)90625-Z; LAUFER R, 1987, EMBO J, V6, P901, DOI 10.1002/j.1460-2075.1987.tb04836.x; Li M, 1996, J NEUROSCI RES, V46, P404, DOI 10.1002/(SICI)1097-4547(19961115)46:4<404::AID-JNR2>3.3.CO;2-W; LOHOF AM, 1992, J NEUROSCI, V12, P1253; Loschinger J, 1997, J NEUROBIOL, V33, P825, DOI 10.1002/(SICI)1097-4695(19971120)33:6<825::AID-NEU9>3.0.CO;2-B; LUO YL, 1993, CELL, V75, P217, DOI 10.1016/0092-8674(93)80064-L; MCKERRACHER L, 1994, NEURON, V13, P805, DOI 10.1016/0896-6273(94)90247-X; MESSERSMITH EK, 1995, CELL, V81, P949; Ming GL, 1997, NEURON, V19, P1225, DOI 10.1016/S0896-6273(00)80414-6; MUKHOPADHYAY G, 1994, NEURON, V13, P757, DOI 10.1016/0896-6273(94)90042-6; Puschel AW, 1996, MOL CELL NEUROSCI, V7, P419, DOI 10.1006/mcne.1996.0030; ROSKAMS AJ, 1994, NEURON, V13, P289; ROTHERMEL JD, 1988, BIOCHEM J, V251, P757, DOI 10.1042/bj2510757; SATO S, 1984, ANN NEUROL, V15, P264, DOI 10.1002/ana.410150310; Schafer M, 1996, NEURON, V16, P1107, DOI 10.1016/S0896-6273(00)80137-3; Schwab ME, 1996, PHYSIOL REV, V76, P319, DOI 10.1152/physrev.1996.76.2.319; SCHWARZSCHILD MA, 1991, J NEUROCHEM, V56, P400, DOI 10.1111/j.1471-4159.1991.tb08165.x; SERAFINI T, 1994, CELL, V78, P409, DOI 10.1016/0092-8674(94)90420-0; Shirasaki R, 1998, SCIENCE, V279, P105, DOI 10.1126/science.279.5347.105; Song HJ, 1997, NATURE, V388, P275, DOI 10.1038/40864; SOUTHAM E, 1991, NEUROSCI LETT, V130, P107, DOI 10.1016/0304-3940(91)90239-P; Tang S, 1997, MOL CELL NEUROSCI, V9, P333, DOI 10.1006/mcne.1997.0633; Taniguchi M, 1997, NEURON, V19, P519, DOI 10.1016/S0896-6273(00)80368-2; TESSIERLAVIGNE M, 1988, NATURE, V336, P775, DOI 10.1038/336775a0; WOLIN MS, 1982, J BIOL CHEM, V257, P13312; WU HH, 1994, SCIENCE, V265, P1593, DOI 10.1126/science.7521541	45	675	698	1	25	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 4	1998	281	5382					1515	1518		10.1126/science.281.5382.1515	http://dx.doi.org/10.1126/science.281.5382.1515			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	116RJ	9727979				2022-12-28	WOS:000075738100043
J	Sram, I; Ashton, J				Sram, I; Ashton, J			Millennium report to Sir Edwin Chadwick	BRITISH MEDICAL JOURNAL			English	Article							HEALTH		NHS Execut NW, Warrington WA3 7QN, Cheshire, England		Sram, I (corresponding author), NHS Execut NW, Warrington WA3 7QN, Cheshire, England.							ASHTON J, 1988, P 1 UK HLTH CIT C 19; ASHTON JR, 1995, NEW PUBLIC HLTH; ASHTON JR, 1997, IN PRESS J EPIDEMIOL; BELL S, 1997, ENV LAW; Benzeval M, 1995, TACKLING INEQUALITIE; Blane D., 1996, HLTH SOCIAL ORG HLTH; *CHILD ACC PREV TR, 1989, BAS PRINC CHILD ACC; *COMM SOC JUST, 1994, SOC JUST STRAT NAT R; COX M, 1987, HLTH LIFESTYLE SURVE; Dahlgren G., 1992, POLICIES STRATEGIES; DELAMOTHE T, 1991, BRIT MED J, V303, P1046, DOI 10.1136/bmj.303.6809.1046; DENVER F, 1997, HLTH INEQUALITIES; *DEP ED EMPL, 1998, WORK ETH BOOST NEW D; *DEP ENV, 1993, ENGL HOUS COND SURV; *DEP HLTH, 1997, HLTH LIV CTR; *DEP TRAD IND, 1991, HOM LEIS ACC RES 12; Department of Health, 1998, CHIEF MED OFF PROJ S; EVANS FJ, 1996, FORGING MODERN STATE; Finer SE, 1952, LIFE TIMES E CHADWIC; Freeman H.U.G.H., 1993, UNHEALTHY HOUSING, P168; Gabe J., 1993, UNHEALTHY HOUSING RE, P191; GIBSON T, 1993, MEADOWELL COMMUNITY; Hamlin C, 1998, BMJ-BRIT MED J, V317, P587, DOI 10.1136/bmj.317.7158.587; HAMLIN C, 1995, AM J PUBLIC HEALTH, V85, P856, DOI 10.2105/AJPH.85.6.856; Hamlin C., 1998, PUBLIC HLTH SOCIAL J; HUTTON W, 1995, STATE WE ARE; JACOBSON B, 1991, NATIONS HLTH STRATEG; JOHNSON P, 1993, EC J C PAPERS 1 S417, V103, P42; Jones K., 1994, MAKING SOCIAL POLICY; KAVANAGH D, 1992, THATCHERISM BRIT POL; LEADBEATER C, 1994, DEMOS, P4; MICHIC J, 1992, EC LEGACY 1979 1992; MIDWINTER E, 1995, DEV SOCIAL WELFARE B; MOSSIALOS E, 1998, J HLTH SER RES POLIC, V3, P2; ODONNELL O, 1991, J HEALTH ECON, V10, P1, DOI 10.1016/0167-6296(91)90014-E; Royle Edward, 1997, MODERN BRITAIN SOCIA; SKIDELSKY R, 1993, UNEMPLOYMENT; *STAT OFF, 1998, OUR HLTH NAT CONTR H; Stewart Michael, 1993, KEYNES 1990S RETURN; TIMMINS N, 1995, 5 GIANTS BIOGRAPHY W; WEBB S, 1991, TIME MORTGAGE BENEFI; White A, 1993, HLTH SURVEY ENGLAND; Wilkinson R., 1996, UNHEALTHY SOC AFFLIC; 1982, HALSBURYS LAWS ENGLA, V38; 1997, HALSBURYS LAWS ENGLA	45	10	11	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 29	1998	317	7158					592	596		10.1136/bmj.317.7158.592	http://dx.doi.org/10.1136/bmj.317.7158.592			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	117EK	9721122	Green Published			2022-12-28	WOS:000075767800024
J	Stoye, J				Stoye, J			No clear answers on safety of pigs as tissue donor source	LANCET			English	Editorial Material							XENOTRANSPLANTATION; RETROVIRUS		Natl Inst Med Res, Div Virol, London NW7 1AA, England	MRC National Institute for Medical Research	Stoye, J (corresponding author), Natl Inst Med Res, Div Virol, London NW7 1AA, England.			Stoye, Jonathan/0000-0003-3377-323X				Advisory Council on California Indian Policy, 1997, AN TISS HUM, P1; Akiyoshi DE, 1998, J VIROL, V72, P4503, DOI 10.1128/JVI.72.5.4503-4507.1998; Bach FH, 1998, NAT MED, V4, P141, DOI 10.1038/nm0298-141; Boeke J. D., 1997, P343; CHAPMAN LE, 1995, NEW ENGL J MED, V333, P1498, DOI 10.1056/NEJM199511303332211; Fishman Jay A., 1994, Xenotransplantation, V1, P47, DOI 10.1111/j.1399-3089.1994.tb00049.x; LeTissier P, 1997, NATURE, V389, P681, DOI 10.1038/39489; MICHAELS MG, 1994, TRANSPLANTATION, V57, P1, DOI 10.1097/00007890-199401000-00001; Patience C, 1997, NAT MED, V3, P282, DOI 10.1038/nm0397-282; SMITH DM, 1993, NEW ENGL J MED, V328, P142, DOI 10.1056/NEJM199301143280218; STOYE JP, 1995, NAT MED, V1, P1100, DOI 10.1038/nm1195-1100a; TAKEUCHI Y, IN PRESS J VIROL; Weiss RA, 1998, NATURE, V391, P327, DOI 10.1038/34772; Wilson CA, 1998, J VIROL, V72, P3082, DOI 10.1128/JVI.72.4.3082-3087.1998	14	39	44	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	AUG 29	1998	352	9129					666	667		10.1016/S0140-6736(98)22035-6	http://dx.doi.org/10.1016/S0140-6736(98)22035-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	116MT	9728974				2022-12-28	WOS:000075729700002
J	Schulz, H; Hennecke, H; Thony-Meyer, L				Schulz, H; Hennecke, H; Thony-Meyer, L			Prototype of a heme chaperone essential for cytochrome c maturation	SCIENCE			English	Article							ESCHERICHIA-COLI; BRADYRHIZOBIUM-JAPONICUM; BIOGENESIS; CONSTRUCTION; PERIPLASM; CLEAVAGE; BACTERIA; PATHWAY; SYSTEM; C(550)	Heme, the iron-containing cofactor essential for the activity of many enzymes, is incorporated into its target proteins by unknown mechanisms. Here, an Escherichia coli hemoprotein, CcmE, was shown to bind heme in the bacterial periplasm by way of a single covalent bond to a histidine. The heme was then released and delivered to apocytochrome c. Thus, CcmE can be viewed as a heme chaperone guiding heme to its appropriate biological partner and preventing illegitimate complex formation.	ETH Zurich, Inst Mikrobiol, CH-8092 Zurich, Switzerland	Swiss Federal Institutes of Technology Domain; ETH Zurich	Thony-Meyer, L (corresponding author), ETH Zurich, Inst Mikrobiol, Schmelzbergstr 7, CH-8092 Zurich, Switzerland.	lthoeny@micro.biol.ethz.ch						BASILE G, 1980, J BIOL CHEM, V255, P7181; CHANG ACY, 1978, J BACTERIOL, V134, P1141, DOI 10.1128/JB.134.3.1141-1156.1978; Dailey H. A., 1990, BIOSYNTHESIS HEME CH, P123; Fabianek RA, 1998, J BACTERIOL, V180, P1947, DOI 10.1128/JB.180.7.1947-1950.1998; FUHRHOP JH, 1975, PORPHYRINS METALLOPO, P757; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Goldman BS, 1998, MOL MICROBIOL, V27, P871, DOI 10.1046/j.1365-2958.1998.00708.x; GONZALES DH, 1990, J BIOENERG BIOMEMBR, V22, P753; GRELLET F, 1996, U72502 GENBANK; Grove J, 1996, MOL MICROBIOL, V19, P467, DOI 10.1046/j.1365-2958.1996.383914.x; HAMILTON CM, 1989, J BACTERIOL, V171, P4617, DOI 10.1128/jb.171.9.4617-4622.1989; HOWE G, 1994, PHOTOSYNTH RES, V40, P147, DOI 10.1007/BF00019332; Kranz R, 1998, MOL MICROBIOL, V29, P383, DOI 10.1046/j.1365-2958.1998.00869.x; MANOIL C, 1986, SCIENCE, V233, P1403, DOI 10.1126/science.3529391; MEISSNER PS, 1987, P NATL ACAD SCI USA, V84, P4171, DOI 10.1073/pnas.84.12.4171; Page MD, 1998, TRENDS BIOCHEM SCI, V23, P103, DOI 10.1016/S0968-0004(98)01173-6; Sambongi Y, 1996, MOL MICROBIOL, V19, P1193, DOI 10.1111/j.1365-2958.1996.tb02465.x; THONYMEYER L, 1989, CELL, V57, P683, DOI 10.1016/0092-8674(89)90137-2; THONYMEYER L, 1995, J BACTERIOL, V177, P4321; ThonyMeyer L, 1996, EUR J BIOCHEM, V235, P754, DOI 10.1111/j.1432-1033.1996.00754.x; ThonyMeyer L, 1997, MICROBIOL MOL BIOL R, V61, P337; THONYMEYER L, 1994, MOL MICROBIOL, V12, P1, DOI 10.1111/j.1365-2958.1994.tb00988.x; ThonyMeyer L, 1997, EUR J BIOCHEM, V246, P794, DOI 10.1111/j.1432-1033.1997.t01-1-00794.x; Zufferey R, 1998, J BIOL CHEM, V273, P6452, DOI 10.1074/jbc.273.11.6452	24	161	174	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 21	1998	281	5380					1197	1200		10.1126/science.281.5380.1197	http://dx.doi.org/10.1126/science.281.5380.1197			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	113CE	9712585				2022-12-28	WOS:000075531200055
J	Huhn, RD; Dave, HP				Huhn, RD; Dave, HP			Staphylococcal psoas abscess	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									NHLBI, Bethesda, MD 20892 USA; Vet Affairs Med Ctr, Washington, DC 20422 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); US Department of Veterans Affairs; Veterans Health Administration (VHA)	Huhn, RD (corresponding author), NHLBI, Bldg 10, Bethesda, MD 20892 USA.								0	2	2	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 20	1998	339	8					519	519		10.1056/NEJM199808203390805	http://dx.doi.org/10.1056/NEJM199808203390805			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	111PN	9709045				2022-12-28	WOS:000075447000005
J	Wijnen, JT; Vasen, HFA; Khan, PM; Zwinderman, AH; van der Klift, H; Mulder, A; Tops, C; Moller, P; Fodde, R; Menko, F; Taal, B; Nagengast, F; Brunner, H; Kleibeuker, J; Sijmons, R; Griffioen, G; Brocker-Vriends, A; Bakker, E; van Leeuwen-Cornelisse, I; Meijers-Heijboer, A; Lindhout, D; Breuning, M; Post, J; Schaap, C; Apold, J; Heimdal, K; Bertario, L; Bisgaard, ML; Goetz, P				Wijnen, JT; Vasen, HFA; Khan, PM; Zwinderman, AH; van der Klift, H; Mulder, A; Tops, C; Moller, P; Fodde, R; Menko, F; Taal, B; Nagengast, F; Brunner, H; Kleibeuker, J; Sijmons, R; Griffioen, G; Brocker-Vriends, A; Bakker, E; van Leeuwen-Cornelisse, I; Meijers-Heijboer, A; Lindhout, D; Breuning, M; Post, J; Schaap, C; Apold, J; Heimdal, K; Bertario, L; Bisgaard, ML; Goetz, P			Clinical findings with implications for genetic testing in families with clustering of colorectal cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							GRADIENT-GEL-ELECTROPHORESIS; MICROSATELLITE INSTABILITY; COLON-CANCER; MUTATION ANALYSIS; APC GENE; HNPCC; POLYPOSIS; MAJORITY; RECEPTOR; HOMOLOG	Background Germ-line mutations in DNA mismatch-repair genes (MSH2, MLH1, PIMS1, PMS2, and MSH6) cause susceptibility to hereditary nonpolyposis colorectal cancer. We assessed the prevalence of MSH2 and MLH1 mutations in families suspected of having hereditary nonpolyposis colorectal cancer and evaluated whether clinical findings can predict the outcome of genetic testing. Methods We used denaturing gradient gel electrophoresis to identify MSH2 and MLH1 mutations in 184 kindreds with familiar clustering of colorectal cancer or other cancers associated with hereditary nonpolyposis colorectal cancer. Information on the site of cancer, the age at diagnosis, and the number of affected family members was obtained from all families. Results Mutations of MSH2 or MLH1 were found in 47 of the 184 kindreds (26 percent). Clinical factors associated with these mutations were early age at diagnosis of colorectal cancer, the occurrence in the kindred of endometrial cancer or tumors of the small intestine, a higher number of family members with colorectal or endometrial cancer, the presence of multiple colorectal cancers or both colorectal and endometrial cancers in a single family member, and fulfillment of the Amsterdam criteria for the diagnosis of hereditary nonpolyposis colorectal cancer (at least three family members in two or more successive generations must have colorectal cancer, one of whom is a first-degree relative of the other two; cancer must be diagnosed before the age of 50 in at least one family member; and familial adenomatous polyposis must be ruled out). Multivariate analysis showed that a younger age at diagnosis of colorectal cancer, fulfillment of the Amsterdam criteria, and the presence of endometrial cancer in the kindred were independent predictors of germ-line mutations of MSH2 or MLH1. These results were used to devise a logistic model for estimating the likelihood of a mutation in MSH2 and MLH1. Conclusions Assessment of clinical findings can improve the rate of detection of mutations of DNA mismatch-repair genes in families suspected of having hereditary nonpolyposis colorectal cancer. (N Engl J Med 1998;339:511-8.) (C)1998, Massachusetts Medical Society.	Fdn Detect Hereditary Tumors, NL-2333 AA Leiden, Netherlands; Leiden Univ, Med Ctr, Dept Human Genet, Leiden, Netherlands; Leiden Univ, Med Ctr, Dept Gastroenterol, Leiden, Netherlands; Leiden Univ, Med Ctr, Dept Med Stat, Leiden, Netherlands; Leiden Univ, Med Ctr, Clin Genet Ctr, Leiden, Netherlands; Norwegian Radium Hosp, Unit Med Genet, Oslo, Norway; Vrije Univ Amsterdam, Univ Hosp, Amsterdam, Netherlands; Netherlands Canc Inst, Amsterdam, Netherlands; Univ Nijmegen Hosp, NL-6500 HB Nijmegen, Netherlands; Univ Groningen Hosp, Groningen, Netherlands; Erasmus Univ, Rotterdam, Netherlands; Clin Genet Ctr, NL-3501 CA Utrecht, Netherlands; Clin Genet Ctr, Maastricht, Netherlands; Haukeland Hosp, N-5021 Bergen, Norway; Norwegian Radium Hosp, Oslo, Norway; Ist Nazl Tumori, I-20133 Milan, Italy; Univ Copenhagen, Hvidovre Hosp, Danish Hereditary Nonpolyposis Colorectal Canc Re, DK-2650 Hvidovre, Denmark; Charles Univ Prague, Prague, Czech Republic	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; University of Oslo; Vrije Universiteit Amsterdam; Netherlands Cancer Institute; Radboud University Nijmegen; University of Groningen; Erasmus University Rotterdam; Maastricht University; Maastricht University Medical Centre (MUMC); University of Oslo; Fondazione IRCCS Istituto Nazionale Tumori Milan; University of Copenhagen; Charles University Prague	Vasen, HFA (corresponding author), Fdn Detect Hereditary Tumors, Rijnsburgerweg 10,Poortgebouw Zuid, NL-2333 AA Leiden, Netherlands.		Sijmons, Rolf/E-5829-2012; Lindhout, Dick/AAH-5765-2019; Bakker, Egbert/D-3525-2009; Fodde, Riccardo/AAW-9394-2021; Breuning, Martijn H/E-3429-2010; Brunner, Han/C-9928-2013	Sijmons, Rolf/0000-0001-8446-2779; Bakker, Egbert/0000-0002-2843-7357; Fodde, Riccardo/0000-0001-9839-4324; Vasen, Hans/0000-0003-2682-2603; Lindhout, Dick/0000-0001-9580-624X; Bertario, Lucio/0000-0001-5653-1431				AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; Aaltonen LA, 1998, NEW ENGL J MED, V338, P1481, DOI 10.1056/NEJM199805213382101; Akiyama Y, 1997, CANCER RES, V57, P3920; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; Dunlop MG, 1997, HUM MOL GENET, V6, P105, DOI 10.1093/hmg/6.1.105; FODDE R, 1992, GENOMICS, V13, P1162, DOI 10.1016/0888-7543(92)90032-N; FODDE R, 1994, HUM MUTAT, V3, P83, DOI 10.1002/humu.1380030202; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; Jass JR, 1996, J MOL MED-JMM, V74, P547; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; KOLODNER RD, 1995, CANCER RES, V55, P242; Laken SJ, 1997, NAT GENET, V17, P79, DOI 10.1038/ng0997-79; LAZAR V, 1994, HUM MOL GENET, V3, P2257, DOI 10.1093/hmg/3.12.2257; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; Liu B, 1996, NAT MED, V2, P169, DOI 10.1038/nm0296-169; LIU B, 1995, NAT MED, V1, P348, DOI 10.1038/nm0495-348; LYNCH HT, 1993, GASTROENTEROLOGY, V104, P1535, DOI 10.1016/0016-5085(93)90368-M; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; Miyaki M, 1997, NAT GENET, V17, P271, DOI 10.1038/ng1197-271; Moslein G, 1996, HUM MOL GENET, V5, P1245, DOI 10.1093/hmg/5.9.1245; MYERS RM, 1987, METHOD ENZYMOL, V155, P501; NAN HJ, 1995, HUM MOL GENET, V4, P237, DOI 10.1093/hmg/4.2.237; NICOLAIDES NC, 1994, NATURE, V371, P75, DOI 10.1038/371075a0; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; PARSONS R, 1995, CANCER RES, V55, P5548; Peltomaki P, 1997, GASTROENTEROLOGY, V113, P1146, DOI 10.1053/gast.1997.v113.pm9322509; Pensotti V, 1997, GENE CHROMOSOME CANC, V19, P135; RodriguezBigas MA, 1997, J NATL CANCER I, V89, P1758, DOI 10.1093/jnci/89.23.1758; SPIRIO L, 1993, CELL, V75, P951, DOI 10.1016/0092-8674(93)90538-2; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; VASEN HFA, 1994, GUT, V35, P1262, DOI 10.1136/gut.35.9.1262; Vasen HFA, 1996, GASTROENTEROLOGY, V110, P1020, DOI 10.1053/gast.1996.v110.pm8612988; VASEN HFA, 1991, DIS COLON RECTUM, V34, P424, DOI 10.1007/BF02053699; WATSON P, 1993, CANCER, V71, P677, DOI 10.1002/1097-0142(19930201)71:3<677::AID-CNCR2820710305>3.0.CO;2-#; Weber TK, 1997, CANCER RES, V57, P3798; WIJNEN J, 1995, AM J HUM GENET, V56, P1060; Wijnen J, 1997, AM J HUM GENET, V61, P329, DOI 10.1086/514847; Wijnen J, 1996, AM J HUM GENET, V58, P300	38	293	309	0	11	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 20	1998	339	8					511	518		10.1056/NEJM199808203390804	http://dx.doi.org/10.1056/NEJM199808203390804			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	111PN	9709044				2022-12-28	WOS:000075447000004
J	Gluck, SL				Gluck, SL			Acid-base	LANCET			English	Article							RENAL TUBULAR-ACIDOSIS; COLLECTING DUCT ACIDIFICATION; PRIMARY HYPERALDOSTERONISM; METABOLIC ALKALOSIS; FANCONIS-SYNDROME; PROXIMAL TUBULE; DIAGNOSIS; PATHOPHYSIOLOGY; POTASSIUM; AMMONIUM	Acid-base disorders are common clinical problems resulting from a wide variety of pathophysiological conditions, including newly recognised acquired and genetic causes. The history and physical examination and measurement of blood and urinary indices allow identification of the underlying cause of these disorders in most cases. Treatment directed at correction of electrolyte abnormalities and the underlying cause for the disorder is essential for preventing the acute and long-term metabolic consequences of acid-base derangements.	St Louis Univ, Sch Med, Div Renal, Dept Med, St Louis, MO 63110 USA; St Louis Univ, Sch Med, Div Renal, Dept Cell Biol & Physiol, St Louis, MO 63110 USA	Saint Louis University; Saint Louis University	Gluck, SL (corresponding author), St Louis Univ, Sch Med, Div Renal, Dept Med, 660 S Euclid Ave,Box 8126, St Louis, MO 63110 USA.	sgluck@imgate.wustl.edu			NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR032087] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK045181, R01DK038848] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR32087] Funding Source: Medline; NIDDK NIH HHS [DK38848, DK45181] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABREO K, 1993, ARCH INTERN MED, V153, P1005, DOI 10.1001/archinte.153.8.1005; ALPERN RJ, 1990, PHYSIOL REV, V70, P79, DOI 10.1152/physrev.1990.70.1.79; ALPERN RJ, 1996, BRENNER RECTORS KIDN, P408; Bailey JL, 1996, MINER ELECTROL METAB, V22, P66; BASTANI B, 1993, J AM SOC NEPHROL, V3, P293; Batlle D, 1996, AM J KIDNEY DIS, V27, P896, DOI 10.1016/S0272-6386(96)90530-2; BATLLE DC, N ENGL J MED, V318, P594; BETTICE JA, 1984, AM J PHYSIOL, V247, pF326, DOI 10.1152/ajprenal.1984.247.2.F326; Boron WF, 1997, J EXP BIOL, V200, P263; BREM AS, 1993, MOL CELL ENDOCRINOL, V97, pC1, DOI 10.1016/0303-7207(93)90204-W; BRENES LG, 1993, J AM SOC NEPHROL, V4, P1073; BREYER MD, 1987, AM J NEPHROL, V7, P150, DOI 10.1159/000167453; Bruce LJ, 1997, J CLIN INVEST, V100, P1693, DOI 10.1172/JCI119694; COGAN MG, 1982, AM J MED, V72, P275, DOI 10.1016/0002-9343(82)90820-8; COHEN EP, 1992, J AM SOC NEPHROL, V3, P264; DINUBILE MJ, 1988, LANCET, V2, P951; DRISCOLL DF, 1987, CRIT CARE MED, V15, P905, DOI 10.1097/00003246-198710000-00002; DYCK RF, 1990, AM J NEPHROL, V10, P359, DOI 10.1159/000168150; Elisaf MS, 1996, DIABETES RES CLIN PR, V34, P23, DOI 10.1016/S0168-8227(96)01332-0; FLESSNER MF, 1990, MINER ELECTROL METAB, V16, P299; GOOD DW, 1990, SEMIN NEPHROL, V10, P132; GOOD DW, 1989, AM J KIDNEY DIS, V14, P262, DOI 10.1016/S0272-6386(89)80199-4; GOSALBEZ R, 1993, J UROLOGY, V150, P710, DOI 10.1016/S0022-5347(17)35594-5; Halperin ML, 1992, BIOCH PHYSL AMMONIUM; HAMBLING C, 1993, Q J MED, V86, P383; HAMM LL, 1990, KIDNEY INT, V38, P728, DOI 10.1038/ki.1990.265; HOLMBERG C, 1986, CLIN GASTROENTEROL, V15, P583; Jaber BL, 1997, AM J KIDNEY DIS, V30, P561, DOI 10.1016/S0272-6386(97)90317-6; JACOBSEN D, 1982, ACTA MED SCAND, V212, P17; JACOBSON HR, 1984, J CLIN INVEST, V74, P2107, DOI 10.1172/JCI111635; JONES JW, 1982, KIDNEY INT, V21, P402, DOI 10.1038/ki.1982.36; Kamel KS, 1997, AM J KIDNEY DIS, V29, P136, DOI 10.1016/S0272-6386(97)90021-4; KNEPPER MA, 1991, KIDNEY INT, V40, pS95; Kone BC, 1998, J BIOL CHEM, V273, P2543, DOI 10.1074/jbc.273.5.2543; KURTZ I, 1990, MINER ELECTROL METAB, V16, P331; MANTERO F, 1990, HORM RES, V34, P175, DOI 10.1159/000181820; MCKENNA TJ, 1991, J CLIN ENDOCR METAB, V73, P952, DOI 10.1210/jcem-73-5-952; MCSHERRY E, 1981, KIDNEY INT, V20, P799, DOI 10.1038/ki.1981.213; MELNICK JZ, 1994, AM J KIDNEY DIS, V23, P118, DOI 10.1016/S0272-6386(12)80820-1; NAGAMI GT, 1990, J CLIN INVEST, V86, P32, DOI 10.1172/JCI114702; NICAR MJ, 1983, UROLOGY, V21, P8, DOI 10.1016/0090-4295(83)90113-9; OSTER JR, 1988, SO MED J, V81, P29; OSTHER PJ, 1993, UROL RES, V21, P169, DOI 10.1007/BF00590032; RASTOGI S, 1985, KIDNEY INT, V28, P801, DOI 10.1038/ki.1985.201; ROCCA A, 1995, J IMMUNOL, V155, P3245; SCHEICH A, 1994, CLIN INVEST MED, V17, P448; SCHLUETER W, 1992, J AM SOC NEPHROL, V3, P953; SEBASTIAN A, 1977, NEW ENGL J MED, V297, P576, DOI 10.1056/NEJM197709152971104; Simon D B, 1997, Adv Nephrol Necker Hosp, V27, P343; Simpson D P, 1975, Curr Probl Clin Biochem, V4, P58; SLY WS, 1983, P NATL ACAD SCI-BIOL, V80, P2752, DOI 10.1073/pnas.80.9.2752; Smulders YM, 1996, ARCH INTERN MED, V156, P1629, DOI 10.1001/archinte.156.15.1629; STONE DK, 1983, J CLIN INVEST, V72, P77, DOI 10.1172/JCI110986; ULICK S, 1993, J LAB CLIN MED, V122, P673; WELBOURNE TC, 1990, SEMIN NEPHROL, V10, P339	55	38	41	0	9	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 8	1998	352	9126					474	479		10.1016/S0140-6736(98)03087-6	http://dx.doi.org/10.1016/S0140-6736(98)03087-6			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	108EA	9708770				2022-12-28	WOS:000075252000046
J	Kim, J; Yu, W; Kovalski, K; Ossowski, L				Kim, J; Yu, W; Kovalski, K; Ossowski, L			Requirement for specific proteases in cancer cell intravasation as revealed by a novel semiquantitative PCR-based assay	CELL			English	Article							PLASMINOGEN-ACTIVATOR; CHORIOALLANTOIC MEMBRANE; METASTATIC ABILITY; CHICK-EMBRYO; TUMOR-CELLS; CARCINOMA; INVASION; UROKINASE; EXPRESSION; MODEL	Proteases are crucial for cancer metastasis, but due to lack of assays, their role in intravasation has not yet been tested. We have developed a human Alu sequence PCR-based assay to quantitate intravasated cells in an in vivo model. We demonstrated that metalloproteinases (MMPs), and most likely MMP-9, are required for intravasation by showing that marimastat, an inhibitor of MMPs, reduced intravasation by more than 90%, and that only tumor cell lines expressing MMP-9 intravasated. Cells with low surface urokinase plasminogen activator (uPA) and uPA receptor (uPAR) were also incapable of intravasation, despite the presence of high levels of MMP-9. We concluded that breaching of the vascular wall is a rate-limiting step for intravasation, and consequently for metastasis, and that cooperation between uPA/uPAR and MMP-9 is required to complete this step.	CUNY Mt Sinai Sch Med, Div Neoplast Dis, New York, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Ossowski, L (corresponding author), CUNY Mt Sinai Sch Med, Div Neoplast Dis, New York, NY 10029 USA.				NCI NIH HHS [CA-40758] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA040758] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARMSTRONG PB, 1982, CANCER RES, V42, P1826; AXELROD JH, 1989, MOL CELL BIOL, V9, P2133, DOI 10.1128/MCB.9.5.2133; Chambers AF, 1997, J NATL CANCER I, V89, P1260, DOI 10.1093/jnci/89.17.1260; DAVIES B, 1993, CANCER RES, V53, P2087; Eccles SA, 1996, CANCER RES, V56, P2815; FOLTZ CM, 1982, INTERACTION PLATELET, P353; HEARING VJ, 1988, CANCER RES, V48, P1270; Hua J, 1996, CANCER RES, V56, P5279; Jaffe EA, 1984, BIOL ENDOTHELIAL CEL, P1; KARIYA Y, 1987, GENE, V53, P1, DOI 10.1016/0378-1119(87)90087-4; KOBAYASHI H, 1994, THROMB HAEMOSTASIS, V71, P474; Koop S, 1996, P NATL ACAD SCI USA, V93, P11080, DOI 10.1073/pnas.93.20.11080; LENGYEL E, 1995, CANCER RES, V55, P963; MATSUMOTO K, 1989, J ORAL PATHOL MED, V18, P498, DOI 10.1111/j.1600-0714.1989.tb01350.x; Mazzieri R, 1997, EMBO J, V16, P2319, DOI 10.1093/emboj/16.9.2319; MIGNATTI P, 1993, PHYSIOL REV, V73, P161, DOI 10.1152/physrev.1993.73.1.161; MIRAYLOPEZ R, 1987, CANCER RES, V47, P3558; NoguchiTakino M, 1996, INT J ONCOL, V8, P97; OSSOWSKI L, 1980, CANCER RES, V40, P2300; OSSOWSKI L, 1992, CANCER RES, V52, P6754; OSSOWSKI L, 1988, CELL, V52, P321, DOI 10.1016/S0092-8674(88)80025-4; OSSOWSKI L, 1983, CELL, V33, P323, DOI 10.1016/0092-8674(83)90414-2; OSSOWSKI L, 1988, J CELL BIOL, V107, P2437, DOI 10.1083/jcb.107.6.2437; OSSOWSKI L, 1983, CELL, V35, P611, DOI 10.1016/0092-8674(83)90093-4; POSTE G, 1980, CANCER RES, V40, P1636; RIZZO V, 1993, MICROVASC RES, V46, P320, DOI 10.1006/mvre.1993.1056; Shioda T, 1997, AM J PATHOL, V150, P2099; Sundareshan P, 1997, CANCER LETT, V113, P17, DOI 10.1016/S0304-3835(96)04552-1; YU H, 1990, CANCER RES, V50, P7623; Yu W, 1997, J CELL BIOL, V137, P767, DOI 10.1083/jcb.137.3.767; Zubair AC, 1996, CANCER LETT, V107, P91, DOI 10.1016/0304-3835(96)04347-9	31	386	406	0	15	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	AUG 7	1998	94	3					353	362		10.1016/S0092-8674(00)81478-6	http://dx.doi.org/10.1016/S0092-8674(00)81478-6			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	109EN	9708737	Bronze			2022-12-28	WOS:000075308400011
J	Sorell, T				Sorell, T			Tobacco company sponsorship discredits medical but not all research	BRITISH MEDICAL JOURNAL			English	Article									Univ Essex, Colchester CO4 3SQ, Essex, England	University of Essex	Sorell, T (corresponding author), Univ Essex, Winvenhow Pk, Colchester CO4 3SQ, Essex, England.								0	3	3	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 1	1998	317	7154					334	334						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	110YQ	9729077				2022-12-28	WOS:000075409500031
J	Kramer, MS; Cutler, N; Feighner, J; Shrivastava, R; Carman, J; Sramek, JJ; Reines, SA; Liu, GH; Snavely, D; Wyatt-Knowles, E; Hale, JJ; Mills, SG; MacCoss, M; Swain, CJ; Harrison, T; Hill, RG; Hefti, F; Scolnick, EM; Cascieri, MA; Chicchi, GG; Sadowski, S; Williams, AR; Hewson, L; Smith, D; Carlson, EJ; Hargreaves, RJ; Rupniak, NMJ				Kramer, MS; Cutler, N; Feighner, J; Shrivastava, R; Carman, J; Sramek, JJ; Reines, SA; Liu, GH; Snavely, D; Wyatt-Knowles, E; Hale, JJ; Mills, SG; MacCoss, M; Swain, CJ; Harrison, T; Hill, RG; Hefti, F; Scolnick, EM; Cascieri, MA; Chicchi, GG; Sadowski, S; Williams, AR; Hewson, L; Smith, D; Carlson, EJ; Hargreaves, RJ; Rupniak, NMJ			Distinct mechanism for antidepressant activity by blockade of central substance P receptors	SCIENCE			English	Article							TACHYKININ NK1 RECEPTOR; RAT-BRAIN; SEPARATION DISTRESS; GUINEA-PIGS; NONPEPTIDE ANTAGONIST; PERIAQUEDUCTAL GRAY; ANTIEMETIC ACTIVITY; ISOLATION CALLS; LIMBIC REGIONS; HIGH-AFFINITY	The Localization of substance P in brain regions that coordinate stress responses and receive convergent monoaminergic innervation suggested that: substance P antagonists might have psychotherapeutic properties. Like clinically used antidepressant and anxiolytic drugs, substance P antagonists suppressed isolation-induced vocalizations in guinea pigs. In a placebo-controlled trial in patients with moderate to severe major depression, robust antidepressant effects of the substance P antagonist MK-869 were consistently observed, in preclinical studies, substance P antagonists did not: interact with monoamine systems in the manner seen with established antidepressant drugs. These findings suggest that substance P may play an important role in psychiatric disorders.	Merck Res Labs, W Point, PA 19456 USA; Eastside Med Grp, New York, NY 10021 USA; Thomas Jefferson Univ, Jefferson Med Coll, Dept Psychiat & Human Behav, Philadelphia, PA 19107 USA; Calif Clin Trials, Beverly Hills, CA 90211 USA; Feighner Res Inst, San Diego, CA 92121 USA; Carman Res, Smyrna, GA 30080 USA; Merck Res Labs, Rahway, NJ 07065 USA; Merck Sharp & Dohme Ltd, Neurosci Res Ctr, Harlow CM20 2QR, Essex, England	Merck & Company; Jefferson University; Merck & Company; Merck & Company	Kramer, MS (corresponding author), Merck Res Labs, W Point, PA 19456 USA.	Mark-Kramer@merck.com; Nadia_Rupniak@merck.com		Hewson, Louise/0000-0001-6630-7089				Aguiar MS, 1996, PHYSIOL BEHAV, V60, P1183, DOI 10.1016/0031-9384(96)00156-4; American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th ed., DOI DOI 10.1001/JAMA.1994.03520100096; BANNON MJ, 1986, BRAIN RES, V381, P393, DOI 10.1016/0006-8993(86)90097-1; BARDEN N, 1983, J NEUROCHEM, V41, P834, DOI 10.1111/j.1471-4159.1983.tb04816.x; BERESFORD IJM, 1991, BRIT J PHARMACOL, V104, P292, DOI 10.1111/j.1476-5381.1991.tb12423.x; BERGER P, 1990, EUR J PHARMACOL, V177, P91, DOI 10.1016/0014-2999(90)90554-J; BERRETTINI WH, 1985, BIOL PSYCHIAT, V20, P965, DOI 10.1016/0006-3223(85)90193-3; BOJA JW, 1992, SYNAPSE, V12, P27, DOI 10.1002/syn.890120104; BOURIN M, 1983, ARZNEIMITTELFORSCH, V33-2, P1173; BRENT PJ, 1988, NEUROPHARMACOLOGY, V27, P743, DOI 10.1016/0028-3908(88)90084-6; BRISTOW LJ, 1994, EUR J PHARMACOL, V253, P245, DOI 10.1016/0014-2999(94)90198-8; BRODIN E, 1994, NEUROPEPTIDES, V26, P253, DOI 10.1016/0143-4179(94)90079-5; BRODIN E, 1987, NEUROPHARMACOLOGY, V26, P581, DOI 10.1016/0028-3908(87)90151-1; CASCIERI MA, 1985, J BIOL CHEM, V260, P1501; CASCIERI MA, 1992, MOL PHARMACOL, V42, P458; CESURA AM, 1990, EUR J PHARMACOL, V186, P95, DOI 10.1016/0014-2999(90)94064-5; *DEP HLTH ED WELF, 1976, DHEW PUBL ADM, P583; DIETL MM, 1991, BRAIN RES, V539, P211, DOI 10.1016/0006-8993(91)91623-9; DUBINSKY B, 1971, NEUROPHARMACOLOGY, V10, P537, DOI 10.1016/0028-3908(71)90019-0; ELLIOTT PJ, 1988, EXP BRAIN RES, V73, P345; Gardner CJ, 1996, REGUL PEPTIDES, V65, P45, DOI 10.1016/0167-0115(96)00071-7; Garland AM, 1996, MOL PHARMACOL, V49, P438; GITTER BD, 1991, EUR J PHARMACOL, V197, P237, DOI 10.1016/0014-2999(91)90532-U; GRAHAM EA, 1993, NEUROPEPTIDES, V24, P228; HALE JJ, IN PRESS J MED CHEM; HARRISON T, 1994, BIOORG MED CHEM LETT, V4, P2545, DOI 10.1016/S0960-894X(01)80280-8; HERMAN BH, 1981, SCIENCE, V211, P1060, DOI 10.1126/science.7466377; HERMAN BH, 1978, PHARMACOL BIOCHEM BE, V9, P213, DOI 10.1016/0091-3057(78)90167-3; HOKFELT T, 1987, PSYCHOPHARMACOLOGY 3, P401; HOROVITZ Z. P., 1966, INT J NEUROPHARMACOL, V5, P405; HUTSON PH, 1995, NEUROPHARMACOLOGY, V34, P383, DOI 10.1016/0028-3908(95)00016-Y; INSEL TR, 1986, PHARMACOL BIOCHEM BE, V24, P1263, DOI 10.1016/0091-3057(86)90182-6; JOHNSTON PA, 1991, N-S ARCH PHARMACOL, V343, P283; KALIN NH, 1987, BRAIN RES, V408, P192, DOI 10.1016/0006-8993(87)90371-4; LISOPRAWSKI A, 1981, NEUROSCI LETT, V25, P47, DOI 10.1016/0304-3940(81)90099-9; MANTYH PW, 1984, BRAIN RES, V307, P147, DOI 10.1016/0006-8993(84)90470-0; MANTYH PW, 1995, P NATL ACAD SCI USA, V92, P2622, DOI 10.1073/pnas.92.7.2622; MASON G S, 1992, British Journal of Pharmacology, V105, p251P; MICZEK KA, 1995, PSYCHOPHARMACOLOGY, V121, P38, DOI 10.1007/BF02245590; MIKULINA EM, 1997, SOC NEUR ABSTR, V23, P126; Molewijk HE, 1996, PSYCHOPHARMACOLOGY, V128, P31, DOI 10.1007/s002130050106; NAGAHISA A, 1992, BRIT J PHARMACOL, V107, P273, DOI 10.1111/j.1476-5381.1992.tb12737.x; NEWMAN JD, 1991, BRAIN RES, V538, P24, DOI 10.1016/0006-8993(91)90371-2; PANKSEPP J, 1978, BIOL PSYCHIAT, V13, P607; PEROUTKA SJ, 1981, SCIENCE, V212, P827, DOI 10.1126/science.7221567; Pioro EP, 1990, HUMAN NERVOUS SYSTEM, P1051; PORSOLT RD, 1983, PHARM BIOCH BEHAV, V20, P979; RILEY L A, 1991, Molecular and Cellular Neuroscience, V2, P139, DOI 10.1016/1044-7431(91)90006-A; RIMON R, 1984, BIOL PSYCHIAT, V19, P509; ROSEN A, 1992, ACTA PHYSIOL SCAND, V146, P341, DOI 10.1111/j.1748-1716.1992.tb09428.x; Rupniak NMJ, 1997, EUR J PHARMACOL, V326, P201, DOI 10.1016/S0014-2999(97)85415-5; RUPNIAK NMJ, 1993, BRIT J PHARMACOL, V110, P1607, DOI 10.1111/j.1476-5381.1993.tb14008.x; Rupniak NMJ, 1996, PAIN, V67, P189, DOI 10.1016/0304-3959(96)03109-0; RUPNIAK NMJ, 1994, EUR J PHARMACOL, V265, P179, DOI 10.1016/0014-2999(94)90430-8; RUPNIAK NMJ, 1994, EUR J PHARMACOL, V262, P171, DOI 10.1016/0014-2999(94)90042-6; SADOWSKI S, 1993, NEUROPEPTIDES, V24, P317, DOI 10.1016/0143-4179(93)90001-Q; Scott J. P., 1974, EXCERPTA MED INT C S, V359, P735; SHAIKH MB, 1993, BRAIN RES, V625, P283, DOI 10.1016/0006-8993(93)91070-9; SHI SR, 1991, J HISTOCHEM CYTOCHEM, V39, P741, DOI 10.1177/39.6.1709656; SHIGEMOTO R, 1993, NEUROSCI LETT, V153, P157, DOI 10.1016/0304-3940(93)90311-8; Shirayama Y, 1996, BRAIN RES, V739, P70, DOI 10.1016/S0006-8993(96)00812-8; SIEGEL RA, 1984, NEUROCHEM INT, V6, P783, DOI 10.1016/0197-0186(84)90011-1; SNIDER RM, 1991, SCIENCE, V251, P435, DOI 10.1126/science.1703323; Teixeira RM, 1996, EUR J PHARMACOL, V311, P7, DOI 10.1016/0014-2999(96)00390-1; TEJANIBUTT SM, 1990, EUR J PHARMACOL, V191, P239, DOI 10.1016/0014-2999(90)94155-Q; VASSOUT A, 1994, NEUROPEPTIDES, V26, pS38; 1996, MARTINDALE EXTRA PHA, P299; 1997, PHYSICIANS DESK REFE, P2494; 1996, MIMS ANN; 1995, Patent No. 18124	70	887	937	1	35	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 11	1998	281	5383					1640	1645		10.1126/science.281.5383.1640	http://dx.doi.org/10.1126/science.281.5383.1640			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	118TR	9733503				2022-12-28	WOS:000075856500036
J	Jick, H; Vasilakis, C; Weinrauch, LA; Meier, CR; Jick, SS; Derby, LE				Jick, H; Vasilakis, C; Weinrauch, LA; Meier, CR; Jick, SS; Derby, LE			A population-based study of appetite-suppressant drugs and the risk of cardiac-valve regurgitation	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							FENFLURAMINE-PHENTERMINE	Background. Recent case reports suggest that a combination of the appetite suppressants fenfluramine and phentermine is associated with an increased risk of cardiac-valve regurgitation. There are also reports of valvular disorders in persons taking fenfluramine or dexfenfluramine alone, particularly for more than three months. Methods We conducted a population-based follow-up study and a nested case-control analysis of 6532 subjects who received dexfenfluramine, 2371 who received fenfluramine, and 862 who received phentermine to assess the risk of a subsequent clinical diagnosis of a valvular disorder of uncertain origin. For comparison, we identified a group of 9281 obese subjects who had not taken appetite suppressants who were matched to the treated subjects for age, sex, and weight. All subjects were free of diagnosed cardiovascular disease at the start of followup. The average duration of follow-up for all subjects was about four years. Results. There were 11 cases of newly diagnosed idiopathic valvular disorders, 5 after the use of dexfenfluramine and 6 after the use of fenfluramine. There were six cases of aortic regurgitation, two cases of mitral regurgitation, and three cases of combined aortic and mitral regurgitation. There were no cases of idiopathic cardiac-valve abnormalities among the subjects who had not taken appetite suppressants or among those who took only phentermine. The five-year cumulative incidence of idiopathic cardiac-valve disorders was 0 per 10,000 subjects among those who had not taken appetite suppressants (95 percent confidence interval, 0 to 15.4) and among those who took phentermine alone (95 percent confidence interval, 0 to 76.6), 7.1 per 10,000 subjects among those who took either fenfluramine or dexfenfluramine for less than four months (95 percent confidence interval, 3.6 to 17.8; P = 0.02 for the comparison with subjects who had not taken appetite suppressants), and 35.0 per 10,000 subjects among those who received either of these medications for four or more months (95 percent confidence interval, 16.4 to 76.2; P < 0.001). Conclusions. The use of fenfluramine or dexfenfluramine, particularly for four months or longer, is associated with an increased risk of newly diagnosed cardiac-valve disorders, particularly aortic regurgitation. (N Engl J Med 1998;339:719-24.) (C) 1998, Massachusetts Medical Society.	Boston Univ, Med Ctr, Boston Collaborat Drug Surveillance Program, Lexington, MA 02421 USA; Mt Auburn Hosp, Dept Med, Cambridge, MA USA; Harvard Univ, Sch Med, Boston, MA USA	Boston University; Harvard University; Mount Auburn Hospital; Harvard University; Harvard Medical School	Jick, H (corresponding author), Boston Univ, Med Ctr, Boston Collaborat Drug Surveillance Program, 11 Muzzey St, Lexington, MA 02421 USA.			Jick, Hershel/0000-0003-4270-5992; Weinrauch, Larry/0000-0003-1357-9528; Jick, Susan/0000-0002-2215-1067	FDA HHS [FD-U-001405-01] Funding Source: Medline	FDA HHS		Abenhaim L, 1996, NEW ENGL J MED, V335, P609, DOI 10.1056/NEJM199608293350901; Connolly HM, 1997, NEW ENGL J MED, V337, P581, DOI 10.1056/NEJM199708283370901; Connolly HM, 1997, NEW ENGL J MED, V337, P1783; Graham DJ, 1997, NEW ENGL J MED, V337, P635, DOI 10.1056/NEJM199708283370911; Jick H, 1997, LANCET, V350, P1045, DOI 10.1016/S0140-6736(05)70451-7; JICK H, 1991, BRIT MED J, V302, P766, DOI 10.1136/bmj.302.6779.766; Jick H., 1992, PHARMACOEPIDEM DR S, V1, P347, DOI DOI 10.1002/PDS.2630010607; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KURZ X, 1997, NEW ENGL J MED, V337, P1172; Rasmussen S, 1997, NEW ENGL J MED, V337, P1773; ROTHMAN KJ, 1978, J CHRON DIS, V31, P557, DOI 10.1016/0021-9681(78)90043-7; Rothman KJ, 1979, EPIDEMIOLOGIC ANAL P; *US DEP HHS, 1997, MMWR-MORBID MORTAL W, V46, P1061; Weissman NJ, 1998, NEW ENGL J MED, V339, P725, DOI 10.1056/NEJM199809103391103	14	194	194	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 10	1998	339	11					719	724		10.1056/NEJM199809103391102	http://dx.doi.org/10.1056/NEJM199809103391102			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	116RF	9731087				2022-12-28	WOS:000075737800002
J	Hart, CA; Kariuki, S				Hart, CA; Kariuki, S			Antimicrobial resistance in developing countries	BRITISH MEDICAL JOURNAL			English	Article							STREPTOCOCCUS-PNEUMONIAE; STAPHYLOCOCCUS-AUREUS; GLOBAL BURDEN; PENICILLIN; CHILDREN; DISEASE; AFRICA; PNEUMOCOCCI		Univ Liverpool, Dept Med Microbiol & Genitourinary Med, Liverpool L69 3GA, Merseyside, England; Kenya Med Res Inst, Ctr Microbiol Res, Nairobi, Kenya	University of Liverpool; Kenya Medical Research Institute	Hart, CA (corresponding author), Univ Liverpool, Dept Med Microbiol & Genitourinary Med, Liverpool L69 3GA, Merseyside, England.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		APPELBAUM PC, 1977, LANCET, V2, P995; APPELBAUM PC, 1992, CLIN INFECT DIS, V15, P77, DOI 10.1093/clinids/15.1.77; Ben Hassen A, 1995, Bull Soc Pathol Exot, V88, P257; BOTHA P, 1988, LANCET, V1, P54; COPPO A, 1995, AM J TROP MED HYG, V53, P351, DOI 10.4269/ajtmh.1995.53.351; Gakuu LN, 1997, E AFR MED J, V74, P198; Galimand M, 1997, NEW ENGL J MED, V337, P677, DOI 10.1056/NEJM199709043371004; GREEN SDR, 1993, ANN TROP PAEDIATR, V13, P45, DOI 10.1080/02724936.1993.11747624; HANSMAN D, 1974, MED J AUSTRALIA, V2, P353, DOI 10.5694/j.1326-5377.1974.tb70836.x; Hart CA, 1997, ANN TROP MED PARASIT, V91, P777, DOI 10.1080/00034989760536; Hart CA, 1997, CURR OPIN INFECT DIS, V10, P408, DOI 10.1097/00001432-199710000-00016; HART CA, 1996, MANSONS TROPICAL MED, P873; Hossain MA, 1998, J ANTIMICROB CHEMOTH, V42, P99, DOI 10.1093/jac/42.1.99; Keersmaekers K, 1998, SEXUALLY TRANSMITTED INFECTIONS AND AIDS IN THE TROPICS, P3; KLUGMAN KP, 1990, CLIN MICROBIOL REV, V3, P171, DOI 10.1128/CMR.3.2.171-196.1990; KLUGMAN KP, 1994, J ANTIMICROB CHEMOTH, V34, P191, DOI 10.1093/jac/34.2.191; MAMUN KZ, 1991, THESIS U LIVERPOOL; MASTRO TD, 1993, PEDIATR INFECT DIS J, V12, P824, DOI 10.1097/00006454-199310000-00006; Meheus A, 1998, SEXUALLY TRANSMITTED INFECTIONS AND AIDS IN THE TROPICS, P397; Mirza SH, 1996, J MED MICROBIOL, V44, P317, DOI 10.1099/00222615-44-5-317; MUNOZ R, 1991, J INFECT DIS, V164, P302, DOI 10.1093/infdis/164.2.302; Murdoch DA, 1998, LANCET, V351, P339, DOI 10.1016/S0140-6736(05)78338-0; Murray CJL, 1997, LANCET, V349, P1347, DOI 10.1016/S0140-6736(96)07494-6; Murray CJL, 1997, LANCET, V349, P1269, DOI 10.1016/S0140-6736(96)07493-4; Pablos-Mendez A, 1998, NEW ENGL J MED, V338, P1641, DOI 10.1056/NEJM199806043382301; Ross JDC, 1998, INT J STD AIDS, V9, P318, DOI 10.1258/0956462981922322; THEVANESAM V, 1994, J HOSP INFECT, V26, P123, DOI 10.1016/0195-6701(94)90054-X; Wain J, 1997, CLIN INFECT DIS, V25, P1404, DOI 10.1086/516128; Yomo A, 1997, ANN TROP PAEDIATR, V17, P239, DOI 10.1080/02724936.1997.11747894	29	222	236	0	15	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	SEP 5	1998	317	7159					647	650		10.1136/bmj.317.7159.647	http://dx.doi.org/10.1136/bmj.317.7159.647			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	118GN	9727995	Green Published			2022-12-28	WOS:000075830200025
J	Hawkey, PM				Hawkey, PM			The origins and molecular basis of antibiotic resistance	BRITISH MEDICAL JOURNAL			English	Article							BETA-LACTAMASES; ENTEROCOCCI; GENES		Univ Leeds, Dept Microbiol, Leeds LS2 9JT, W Yorkshire, England; Univ Leeds, Antimicrobial Res Ctr, Leeds LS2 9JT, W Yorkshire, England	University of Leeds; University of Leeds	Hawkey, PM (corresponding author), Univ Leeds, Dept Microbiol, Leeds LS2 9JT, W Yorkshire, England.							BUSH K, 1995, ANTIMICROB AGENTS CH, V39, P1211, DOI 10.1128/AAC.39.6.1211; CHOPRA I, 1992, J ANTIMICROB CHEMOTH, V29, P247; Davies J., 1997, ANTIBIOTIC RESISTANC; Feinman SE, 1998, ASM NEWS, V64, P24; GARCIABUSTOS J, 1990, P NATL ACAD SCI USA, V87, P5415, DOI 10.1073/pnas.87.14.5415; GASCOYNEBINZI DM, 1994, J ANTIMICROB CHEMOTH, V33, P1011, DOI 10.1093/jac/33.5.1011; Grubb WB, 1998, REV MED MICROBIOL, V9, P153; HUGHES VM, 1983, NATURE, V302, P725, DOI 10.1038/302725a0; Leclercq R, 1997, CLIN INFECT DIS, V24, P545, DOI 10.1093/clind/24.4.545; LIVERMORE DM, 1995, CLIN MICROBIOL REV, V8, P557, DOI 10.1128/CMR.8.4.557; Medeiros AA, 1997, CLIN INFECT DIS, V24, pS19, DOI 10.1093/clinids/24.Supplement_1.S19; Michel M, 1997, LANCET, V349, P1901, DOI 10.1016/S0140-6736(96)11192-2; MUSSER JM, 1995, CLIN MICROBIOL REV, V8, P496, DOI 10.1128/CMR.8.4.496; SHAW KJ, 1993, MICROBIOL REV, V57, P138, DOI 10.1128/MMBR.57.1.138-163.1993; Tomasz A, 1995, MICROB DRUG RESIST, V1, P103, DOI 10.1089/mdr.1995.1.103; WEBB V, 1993, ANTIMICROB AGENTS CH, V37, P2379, DOI 10.1128/AAC.37.11.2379	16	94	102	1	48	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	SEP 5	1998	317	7159					657	660		10.1136/bmj.317.7159.657	http://dx.doi.org/10.1136/bmj.317.7159.657			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	118GN	9727999	Green Published			2022-12-28	WOS:000075830200029
J	Johnson, AP; Warner, M; Woodford, N; Speller, DCE; Livermore, DM				Johnson, AP; Warner, M; Woodford, N; Speller, DCE; Livermore, DM			Antibiotic resistance among enterococci causing endocarditis in the UK: analysis of isolates referred to a reference laboratory	BMJ-BRITISH MEDICAL JOURNAL			English	Article							INFECTIVE ENDOCARDITIS		Cent Publ Hlth Lab, Antibiot Reference Unit, London NW9 5HT, England	Public Health England	Johnson, AP (corresponding author), Cent Publ Hlth Lab, Antibiot Reference Unit, London NW9 5HT, England.	ajohnson@phls.co.uk	Woodford, Neil/D-4123-2011; Johnson, Alan P/F-4420-2014	Woodford, Neil/0000-0003-1396-8953; 				[Anonymous], 1991, J Antimicrob Chemother, V27 Suppl D, P1; MURRAY BE, 1990, CLIN MICROBIOL REV, V3, P46, DOI 10.1128/CMR.3.1.46-65.1990; PRASAD A, 1995, BRIT J HOSP MED, V54, P341; Simmons NA, 1998, HEART, V79, P207; WILSON WR, 1995, JAMA-J AM MED ASSOC, V274, P1706, DOI 10.1001/jama.274.21.1706	5	14	15	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 5	1998	317	7159					629	630		10.1136/bmj.317.7159.629	http://dx.doi.org/10.1136/bmj.317.7159.629			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	118GN	9727989	Green Submitted, Bronze			2022-12-28	WOS:000075830200017
J	Kristiansen, BE; Tveten, Y; Jenkins, A				Kristiansen, BE; Tveten, Y; Jenkins, A			Which contacts of patients with meningococcal disease carry the pathogenic strain of Neisseria meningitidis? A population based study	BRITISH MEDICAL JOURNAL			English	Article							HOUSEHOLD CONTACTS; CLOSE CONTACTS; INFECTION; CARRIAGE; FAMILY; SPREAD	Objectives: To determine the prevalence of the pathogenic strain of Neisseria meningitidis in contacts of patients with meningococcal disease, and to determine which contact groups are likely to be carriers and warrant chemoprophylaxis, Design: Population based study. Setting: Norwegian county of Telemark. Subjects: 1535 primary contacts of 48 patients with meningococcal disease, and 78 secondary contacts. Interventions: Carriers of the pathogenic strain were treated with rifampicin. All household members and kissing contacts under 15 years of age were treated with oral penicillin. Contacts were taught to recognise the symptoms of meningococcal disease. Results: In 21 of 48 cases investigated, contacts carrying the pathogenic strain of N meningitidis were found. A total of 42 such contacts were identified. Contacts were stratified into three classes according to the assumed closeness of contact with patients. In class 1 (household members and kissing contacts) the prevalence of the pathogenic strain was 12.4% (95% confidence interval 5.5% to 19.3%). In classes 2 and 3 the prevalence was 1.9% (0.9% to 3.4%) and 1.6% (0.14% to 3.1%). Conclusions: There is a high rate of carriage of the pathogenic strain of N meningitidis in patients' household members and kissing contacts, and this supports the practice of giving chemoprophylaxis to these contacts. The prevalence of carriage among other contacts is 2-3 times that found in the general population (0.7%); the benefits of chemoprophylaxis to these contacts may be marginal.	Univ Tromso, Dept Med Microbiol, N-9037 Tromso, Norway; AS Telelab, Telemark Biomed Ctr, N-3705 Skien, Norway	UiT The Arctic University of Tromso	Kristiansen, BE (corresponding author), Univ Tromso, Dept Med Microbiol, N-9037 Tromso, Norway.			Kristiansen, Bjorn - Erik/0000-0001-8299-4624; Jenkins, Andrew/0000-0003-2588-8483				Achtman M, 1995, MENINGOCOCCAL DIS, P159; ANDERSEN BM, 1978, SCAND J INFECT DIS, V10, P277, DOI 10.3109/inf.1978.10.issue-4.04; [Anonymous], 1995, CONTROL COMMUNICABLE; BOVRE K, 1980, NIPH (National Institute of Public Health) Annals (Oslo), V3, P9; Cartwright K, 1997, BRIT MED J, V315, P757; Cartwright K., 1995, MENINGOCOCCAL DIS, P115; CARTWRIGHT KAV, 1991, EPIDEMIOL INFECT, V106, P133, DOI 10.1017/S0950268800056491; CAUGANT DA, 1994, J CLIN MICROBIOL, V32, P323, DOI 10.1128/JCM.32.2.323-330.1994; CAUGANT DA, 1996, ANN C I PUBL HLTH OS; *CDC, 1996, REC IMM PRACT ADV CO; COOKE RPD, 1989, BRIT MED J, V298, P555, DOI 10.1136/bmj.298.6673.555; DEWALS P, 1981, J INFECTION, V3, P53, DOI 10.1016/S0163-4453(81)80009-6; HOIBY EA, 1986, A VAN LEEUW J MICROB, V52, P255, DOI 10.1007/BF00555251; KRISTIANSEN BE, 1995, J CLIN MICROBIOL, V33, P1174, DOI 10.1128/JCM.33.5.1174-1179.1995; KRISTIANSEN BE, 1992, SCAND J INFECT DIS, V24, P165, DOI 10.3109/00365549209052608; KRISTIANSEN BE, 1988, J CLIN MICROBIOL, V26, P1988, DOI 10.1128/JCM.26.10.1988-1992.1988; *MEN DIS SURV GROU, 1976, JAMA-J AM MED ASSOC, V235, P261; MUNFORD RS, 1974, LANCET, V1, P1275; OLCEN P, 1981, SCAND J INFECT DIS, V13, P105, DOI 10.3109/inf.1981.13.issue-2.05; OLCEN P, 1979, J CLIN PATHOL, V32, P1222, DOI 10.1136/jcp.32.12.1222; Pearson N, 1995, J PUBLIC HEALTH MED, V17, P455; *PUBL HLTH LAB SER, 1995, CONTR MEN DIS GUID C; RELLER LB, 1973, J INFECT DIS, V127, P56, DOI 10.1093/infdis/127.1.56; *WHO, 1996, 105 WHO; Woods CR, 1996, J INFECT DIS, V174, P760, DOI 10.1093/infdis/174.4.760	25	32	32	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	SEP 5	1998	317	7159					621	625		10.1136/bmj.317.7159.621	http://dx.doi.org/10.1136/bmj.317.7159.621			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	118GN	9727987	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000075830200015
J	Ishiura, M; Kutsuna, S; Aoki, S; Iwasaki, H; Andersson, CR; Tanabe, A; Golden, SS; Johnson, CH; Kondo, T				Ishiura, M; Kutsuna, S; Aoki, S; Iwasaki, H; Andersson, CR; Tanabe, A; Golden, SS; Johnson, CH; Kondo, T			Expression of a gene cluster kaiABC as a circadian feedback process in cyanobacteria	SCIENCE			English	Article							DROSOPHILA PERIOD GENE; CLOCK GENE; POSITIONAL CLONING; RHYTHMS; LUCIFERASE; SEQUENCE; FREQUENCY; TIMELESS; PROTEINS; ELEMENT	Cyanobacteria are the simplest organisms known to have a circadian clock. A circadian crock gene cluster kaiABC was cloned from the cyanobacterium Synechococcus. Nineteen clock mutations were mapped to the three kai genes. Promoter activities upstream of the kaiA and kaiB genes showed circadian rhythms of expression, and both kaiA and kaiBC messenger RNAs displayed circadian cycling. inactivation of any single kai gene abolished these rhythms and reduced kaiBC-promoter activity. Continuous kaiC overexpression repressed the kaiBC promoter, whereas kaiA overexpression enhanced it. Temporal kaiC overexpression reset the phase of the rhythms. Thus, a negative feedback control of kaiC expression by KaiC generates a circadian oscillation in cyanobacteria, and KaiA sustains the oscillation by enhancing kaiC expression.	Nagoya Univ, Grad Sch Sci, Div Biol Sci, Chikusa Ku, Nagoya, Aichi 4648602, Japan; Vanderbilt Univ, Dept Biol, Nashville, TN 37235 USA; Texas A&M Univ, Dept Biol, College Stn, TX 77843 USA	Nagoya University; Vanderbilt University; Texas A&M University System; Texas A&M University College Station	Ishiura, M (corresponding author), Nagoya Univ, Grad Sch Sci, Div Biol Sci, Chikusa Ku, Furo Cho, Nagoya, Aichi 4648602, Japan.	ishiura@bio.nagoya-u.ac.jp; kondo@bio.nagoya-u.ac.jp	Johnson, Carl H/I-4655-2014	Iwasaki, Hideo/0000-0002-3754-4955	NIMH NIH HHS [MH01179] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [K02MH001179] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Allada R, 1998, CELL, V93, P791, DOI 10.1016/S0092-8674(00)81440-3; ARONSON BD, 1994, SCIENCE, V263, P1578, DOI 10.1126/science.8128244; BALDWIN TO, 1984, BIOCHEMISTRY-US, V23, P3663, DOI 10.1021/bi00311a014; BARGIELLO TA, 1984, NATURE, V312, P752, DOI 10.1038/312752a0; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; Bunning E, 1973, PHYSL CLOCK; BUSTOS SA, 1991, J BACTERIOL, V173, P7525, DOI 10.1128/jb.173.23.7525-7533.1991; CHANG ACY, 1978, J BACTERIOL, V134, P1141, DOI 10.1128/JB.134.3.1141-1156.1978; CROTHWAITE SK, 1997, SCIENCE, V276, P763; Darlington TK, 1998, SCIENCE, V280, P1599, DOI 10.1126/science.280.5369.1599; Dunlap JC, 1996, ANNU REV GENET, V30, P579, DOI 10.1146/annurev.genet.30.1.579; Gekakis N, 1998, SCIENCE, V280, P1564, DOI 10.1126/science.280.5369.1564; GEKAKIS N, 1995, SCIENCE, V270, P811, DOI 10.1126/science.270.5237.811; Golden SS, 1997, ANNU REV PLANT PHYS, V48, P327, DOI 10.1146/annurev.arplant.48.1.327; ISHIURA M, UNPUB; King DP, 1997, CELL, V89, P641, DOI 10.1016/S0092-8674(00)80245-7; KONDO T, 1993, P NATL ACAD SCI USA, V90, P5672, DOI 10.1073/pnas.90.12.5672; KONDO T, 1994, SCIENCE, V266, P1233, DOI 10.1126/science.7973706; Kondo T, 1997, SCIENCE, V275, P224, DOI 10.1126/science.275.5297.224; KONDO T, UNPUB; Kutsuna S, 1998, J BACTERIOL, V180, P2167, DOI 10.1128/JB.180.8.2167-2174.1998; MCCLUNG CR, 1989, NATURE, V339, P558, DOI 10.1038/339558a0; MILLAR AJ, 1992, PLANT CELL, V4, P1075, DOI 10.1105/tpc.4.9.1075; MOHAMED A, 1989, PLANT MOL BIOL, V13, P693, DOI 10.1007/BF00016024; MYERS MP, 1995, SCIENCE, V270, P805, DOI 10.1126/science.270.5237.805; PITTENDRIGH CS, 1993, ANNU REV PHYSIOL, V55, P16; PRENTKI P, 1984, GENE, V29, P303, DOI 10.1016/0378-1119(84)90059-3; ROSE RE, 1988, NUCLEIC ACIDS RES, V16, P356, DOI 10.1093/nar/16.1.356; Rutila JE, 1998, CELL, V93, P805, DOI 10.1016/S0092-8674(00)81441-5; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; Sun ZS, 1997, CELL, V90, P1003, DOI 10.1016/S0092-8674(00)80366-9; Sweeney BM., 1987, RHYTHMIC PHENOMENA P; Tei H, 1997, NATURE, V389, P512, DOI 10.1038/39086; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; YOSHIDA M, 1995, FEBS LETT, V359, P1, DOI 10.1016/0014-5793(94)01438-7; ZEHRING WA, 1984, CELL, V39, P369, DOI 10.1016/0092-8674(84)90015-1	36	537	581	5	81	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 4	1998	281	5382					1519	1523		10.1126/science.281.5382.1519	http://dx.doi.org/10.1126/science.281.5382.1519			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	116RJ	9727980				2022-12-28	WOS:000075738100044
J	Pearson, SD; Sabin, JE; Emanuel, EJ				Pearson, SD; Sabin, JE; Emanuel, EJ			Ethical guidelines for physician compensation based on capitation	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							MANAGED CARE; RISK; PATIENT; PAYMENT		Harvard Univ, Sch Med, Boston, MA 02115 USA; Harvard Pilgrim Hlth Care, Boston, MA 02215 USA; NIH, Bethesda, MD 20892 USA	Harvard University; Harvard Medical School; Harvard Pilgrim Health Care; National Institutes of Health (NIH) - USA	Pearson, SD (corresponding author), Harvard Univ, Sch Med, Boston, MA 02115 USA.							ABRAMS FR, 1993, NEW ENGL J MED, V328, P975, DOI 10.1056/NEJM199304013281320; *AM SOC INT MED, 1995, ASS APPR PAT CAR CAP; Angell M, 1993, Kennedy Inst Ethics J, V3, P279; Berwick DM, 1996, NEW ENGL J MED, V335, P1227, DOI 10.1056/NEJM199610173351611; BLENDON RJ, 1993, JAMA-J AM MED ASSOC, V269, P2573, DOI 10.1001/jama.269.19.2573; Bodenheimer TS, 1996, JAMA-J AM MED ASSOC, V276, P1025, DOI 10.1001/jama.276.13.1025; CHURCHILL LR, 1989, HASTINGS CENT REP, V19, P28, DOI 10.2307/3562740; CRAWSHAW R, 1995, JAMA-J AM MED ASSOC, V273, P1553, DOI 10.1001/jama.273.19.1553; EMANUEL EJ, IN PRESS J HLTH POLI; Felsenthal E, 1996, WALL STREET J   1126, pB10; FREUDENHEIM M, 1996, NY TIMES         MAY, P1; HILLMAN AL, 1992, MED CARE, V30, P136, DOI 10.1097/00005650-199202000-00005; HILLMAN AL, 1991, HEALTH AFFAIR, V10, P205, DOI 10.1377/hlthaff.10.4.207; Jacobs S E, 1995, Med Econ, V72, P56; KASSIRER JP, 1995, NEW ENGL J MED, V333, P50, DOI 10.1056/NEJM199507063330110; Kuttner R, 1998, NEW ENGL J MED, V338, P1558, DOI 10.1056/NEJM199805213382123; LARSON E, 1996, TIME            0122, P44; Latham SR, 1996, AM J LAW MED, V22, P399; LEVINSKY NG, 1984, NEW ENGL J MED, V311, P1573, DOI 10.1056/NEJM198412133112412; Murray D, 1997, Med Econ, V74, P79; PELLEGRINO ED, 1987, JAMA-J AM MED ASSOC, V258, P1939, DOI 10.1001/jama.258.14.1939; RELMAN AS, 1988, NEW ENGL J MED, V319, P784, DOI 10.1056/NEJM198809223191209; Rodwin M. A., 1993, MED MONEY MORALS PHY; SABIN JE, 1994, BEHAV SCI LAW, V12, P317, DOI 10.1002/bsl.2370120403; Selker HP, 1996, ANN INTERN MED, V124, P449, DOI 10.7326/0003-4819-124-4-199602150-00010; Simon CJ, 1997, HEALTH AFFAIR, V16, P120, DOI 10.1377/hlthaff.16.3.120; TERRY K, 1996, MED ECON, V73, P126; THOMPSON DF, 1993, NEW ENGL J MED, V329, P573, DOI 10.1056/NEJM199308193290812; WOOLHANDLER S, 1995, NEW ENGL J MED, V333, P1706, DOI 10.1056/NEJM199512213332510; 1996, FED REG, V61, P13430	30	46	46	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 3	1998	339	10					689	693		10.1056/NEJM199809033391009	http://dx.doi.org/10.1056/NEJM199809033391009			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	115WA	9725929				2022-12-28	WOS:000075688100009
J	Seinela, L; Ahvenainen, J; Ronneikko, J; Haavisto, M				Seinela, L; Ahvenainen, J; Ronneikko, J; Haavisto, M			Reasons for and outcome of upper gastrointestinal endoscopy in patients aged 85 years or more: retrospective study	BRITISH MEDICAL JOURNAL			English	Article									Tampere City Hosp, Dept Geriatr, FIN-33500 Tampere, Finland		Seinela, L (corresponding author), Tampere City Hosp, Dept Geriatr, Kaupin Sairaala,Parantolankatu 6, FIN-33500 Tampere, Finland.							BRUSSAARD CC, 1988, GASTROINTEST ENDOSC, V34, P118, DOI 10.1016/S0016-5107(88)71275-4; COOPER BT, 1986, AGE AGEING, V15, P343, DOI 10.1093/ageing/15.6.343; GIBBINS F J, 1974, Age and Ageing, V3, P240, DOI 10.1093/ageing/3.4.240; JACOBSOHN WZ, 1977, GERIATRICS, V32, P80; LOCKHART SP, 1985, BRIT MED J, V290, P283, DOI 10.1136/bmj.290.6464.283	5	19	20	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 29	1998	317	7158					575	575		10.1136/bmj.317.7158.575	http://dx.doi.org/10.1136/bmj.317.7158.575			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	117EK	9721114	Bronze, Green Submitted, Green Published			2022-12-28	WOS:000075767800018
J	Towler, B; Irwig, L; Glasziou, P; Kewenter, J; Weller, D; Silagy, C				Towler, B; Irwig, L; Glasziou, P; Kewenter, J; Weller, D; Silagy, C			A systematic review of the effects of screening for colorectal cancer using the faecal occult blood test, Hemoccult	BRITISH MEDICAL JOURNAL			English	Article							CONTROLLED TRIAL; COLON CANCER	Objective: To review effectiveness of screening for colorectal cancer with faecal occult blood test, Hemoccult, and to consider benefits and harms of screening. Design: Systematic review of trials of Hemoccult screening, with meta-analysis of results from the randomised controlled trials. Subjects: Four randomised controlled trials and two non-randomised trials of about 330 000 and 113 000 people respectively aged greater than or equal to 40 years in five countries. Main outcome measures: Meta-analysis of effects of screening on mortality from colorectal cancer. Results: Quality of trial design was generally high, and screening resulted in a favourable shift in the stage distribution of colorectal cancers in the screening groups. Meta-analysis of mortality results from the four randomised controlled trials showed that those allocated to screening had a reduction in mortality from colorectal cancer of 16% (relative risk 0.84 (95% confidence interval 0.77 to 0.93)). When adjusted for attendance for screening, this reduction was 23% (relative risk 0.77 (0.57 to 0.89)) for people actually screened, if a biennial Hemoccult screening programme were offered to 10 000 people and about two thirds attended for at least one Hemoccult test, 8.5 (3.6 to 13.5) deaths from colorectal cancer would be prevented over a period of 10 years. Conclusion: Although benefits of screening are likely to outweigh harms for populations at high risk of colorectal cancer, more information is needed about the harmful effects of screening, the community's responses to screening, and costs of screening for different healthcare systems before widespread screening can be recommended.	Flinders Med Ctr, Australasian Cochrane Ctr, Bedford Pk, SA 5042, Australia; Univ Sydney, Dept Publ Hlth & Community Med, Sydney, NSW 2006, Australia; Univ Queensland, Sch Med, Dept Social & Prevent Med, Herston, Qld 4006, Australia; Sahlgrenska Hosp, Dept Surg & Pathol, Gothenburg, Sweden; Flinders Univ S Australia, Dept Evidence Based Care & Gen Practice, Adelaide, SA 5042, Australia	Flinders Medical Centre; University of Sydney; University of Queensland; Sahlgrenska University Hospital; Flinders University South Australia	Towler, B (corresponding author), 23 4th St, Mackay, Qld 4740, Australia.		Glasziou, Paul/A-7832-2008	Glasziou, Paul/0000-0001-7564-073X				Allison JE, 1996, NEW ENGL J MED, V334, P155, DOI 10.1056/NEJM199601183340304; *AUSTR CANC SOC, 1994, GUID EARL DET SCREEN; BROWN SS, 1997, BRIT MED J, V314, P533; Castiglione G, 1996, BRIT J CANCER, V74, P141, DOI 10.1038/bjc.1996.329; CHURCH TR, 1991, CANC SCREENING, P83; DUNLOP MG, 1992, BRIT J SURG, V79, P488, DOI 10.1002/bjs.1800790606; Faivre J, 1991, Eur J Cancer Prev, V1, P49; GILBERTSEN VA, 1980, J CHRON DIS, V33, P107, DOI 10.1016/0021-9681(80)90034-X; GLASZIOU PP, 1995, BMJ-BRIT MED J, V311, P1356, DOI 10.1136/bmj.311.7016.1356; GLASZIOU PP, 1992, J CLIN EPIDEMIOL, V45, P1251, DOI 10.1016/0895-4356(92)90166-K; HARDCASTLE JD, 1989, LANCET, V1, P1160; JEFFS P, 1996, CANC SERIES, V5; KEWENTER J, 1994, SCAND J GASTROENTERO, V29, P468, DOI 10.3109/00365529409096840; KEWENTER J, 1988, CANCER, V62, P645, DOI 10.1002/1097-0142(19880801)62:3<645::AID-CNCR2820620333>3.0.CO;2-#; Kewenter J, 1996, DIS COLON RECTUM, V39, P676, DOI 10.1007/BF02056949; Kronborg O, 1996, LANCET, V348, P1467, DOI 10.1016/S0140-6736(96)03430-7; KRONBORG O, 1989, SCAND J GASTROENTERO, V24, P599, DOI 10.3109/00365528909093096; LAU J, 1997, META ANAL VERSION 0; LYNCH HT, 1985, CA-CANCER J CLIN, V35, P95, DOI 10.3322/canjclin.35.2.95; MANDEL JS, 1993, NEW ENGL J MED, V328, P1365, DOI 10.1056/NEJM199305133281901; MULROW CD, 1997, COCHRANE LIBRARY; Parkin DM, 1992, CANC INCIDENCE 5 CON, VVI; Petitti D, 1994, METAANALYSIS DECISIO; STJOHN DJB, 1993, ANN INTERN MED, V118, P785, DOI 10.7326/0003-4819-118-10-199305150-00005; WINAWER SJ, 1993, J NATL CANCER I, V85, P1311, DOI 10.1093/jnci/85.16.1311	26	374	379	0	11	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 29	1998	317	7158					559	565		10.1136/bmj.317.7158.559	http://dx.doi.org/10.1136/bmj.317.7158.559			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	117EK	9721111	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000075767800015
J	Zinnecker, H; McCaughrean, MJ; Rayner, JT				Zinnecker, H; McCaughrean, MJ; Rayner, JT			A symmetrically pulsed jet of gas from an invisible protostar in Orion	NATURE			English	Article							SPACE-TELESCOPE OBSERVATIONS; IRAS SOURCES; YOUNG STARS; NUMERICAL SIMULATIONS; MOLECULAR-HYDROGEN; OUTFLOWS; SPECTROGRAPH; MODELS; GALAXY; SHOCKS	Young stars are thought to accumulate most of their mass through an accretion disk, which channels the gas and dust of a collapsing cloud onto the central protostellar object(1). The rotational and magnetic forces in the star-disk system often produce high-velocity jets of outflowing gas(2-6). These jets-an in principle be used to study the accretion and ejection history of the system, which is hidden from direct view by the dust and dense gas of the parent cloud. But the structures of these jets are often too complex to determine which features arise at the source and which are the result of subsequent interactions with, the surrounding gas. Here we present infrared observations of a very young jet driven by an invisible protostar in the vicinity of the Horsehead nebula in Orion. These observations reveal a sequence of geyser-like eruptions occurring at quasi-regular intervals and with near-perfect mirror symmetry either side of the source. This symmetry is strong evidence that such features must be associated with the formation of the jet, probably related to recurrent or even chaotic instabilities in the accretion disk.	Astrophys Inst Potsdam, D-14482 Potsdam, Germany; Univ Hawaii, Inst Astron, Honolulu, HI 96822 USA	University of Hawaii System	Zinnecker, H (corresponding author), Astrophys Inst Potsdam, Sternwarte 16, D-14482 Potsdam, Germany.			Rayner, John/0000-0002-3165-159X; McCaughrean, Mark/0000-0002-1452-5268				Bachiller R, 1996, ANNU REV ASTRON ASTR, V34, P111, DOI 10.1146/annurev.astro.34.1.111; Balbus SA, 1998, REV MOD PHYS, V70, P1, DOI 10.1103/RevModPhys.70.1; Beckwith SVW, 1996, NATURE, V383, P139, DOI 10.1038/383139a0; BELL KR, 1994, ASTROPHYS J, V427, P987, DOI 10.1086/174206; Burrows CJ, 1996, ASTROPHYS J, V473, P437, DOI 10.1086/178156; CAMENZIND M, 1997, P IAU S, V182, P241; Chini R, 1997, ASTRON ASTROPHYS, V325, P542; Claussen M. J., 1997, P IAU S, V182, P515; Fendt C, 1996, ASTRON ASTROPHYS, V313, P591; GREDEL R, 1994, ASTRON ASTROPHYS, V289, pL19; GREENE TP, 1993, P SOC PHOTO-OPT INS, V1946, P313, DOI 10.1117/12.158684; Heathcote S, 1996, ASTRON J, V112, P1141, DOI 10.1086/118085; Herbst TM, 1996, ASTRON J, V111, P2403, DOI 10.1086/117974; HERBST TM, 1993, P SOC PHOTO-OPT INS, V1946, P605, DOI 10.1117/12.158714; HIRTH GA, 1994, ASTROPHYS J, V427, pL99, DOI 10.1086/187374; HODAPP KW, 1994, PUBL ASTRON SOC PAC, V106, P87, DOI 10.1086/133347; MCCAUGHREAN MJ, 1994, ASTROPHYS J, V436, pL189, DOI 10.1086/187664; MCHARDY I, 1987, NATURE, V325, P696, DOI 10.1038/325696a0; MIRABEL IF, 1994, NATURE, V371, P46, DOI 10.1038/371046a0; Ouyed R, 1997, NATURE, V385, P409, DOI 10.1038/385409a0; RAGA AC, 1992, ASTROPHYS J, V386, P222, DOI 10.1086/171008; Ray TP, 1997, NATURE, V385, P415, DOI 10.1038/385415a0; Reipurth B, 1997, ASTRON J, V114, P2708, DOI 10.1086/118681; REIPURTH B, 1989, NATURE, V340, P42, DOI 10.1038/340042a0; REIPURTH B, 1994, GEN CATALOG HERBIG H; Rodriguez LF, 1996, REV MEX ASTRON ASTR, V32, P27; SHU FH, 1997, P IAU S, V182, P225; SMITH MD, 1995, ASTRON ASTROPHYS, V296, P789; SMITH MD, 1990, MON NOT R ASTRON SOC, V245, P108; SMITH MD, 1991, MON NOT R ASTRON SOC, V248, P730, DOI 10.1093/mnras/248.4.730; Smith MD, 1997, ASTRON ASTROPHYS, V327, P1206; STONE JM, 1993, ASTROPHYS J, V413, P210, DOI 10.1086/172989; Suttner G, 1997, ASTRON ASTROPHYS, V318, P595; VANDERKLIS M, 1989, ANNU REV ASTRON ASTR, V27, P517, DOI 10.1146/annurev.astro.27.1.517; WOUTERLOOT JGA, 1986, ASTRON ASTROPHYS, V168, P237; WOUTERLOOT JGA, 1989, ASTRON ASTROPHYS, V215, P131; ZENSUS JA, 1997, ANNU REV ASTRON ASTR, V35, P605; ZINNECKER H, 1992, ASTRON ASTROPHYS, V265, P726; ZINNECKER H, 1989, LOW MASS STAR FORMAT, P447; [No title captured]	40	131	132	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 27	1998	394	6696					862	865		10.1038/29716	http://dx.doi.org/10.1038/29716			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	114LW	9732868				2022-12-28	WOS:000075611800039
J	Nguyen, C				Nguyen, C			The veteran	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 26	1998	280	8					692	692		10.1001/jama.280.8.692	http://dx.doi.org/10.1001/jama.280.8.692			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	111PM	9728626				2022-12-28	WOS:000075446900012
J	Zhang, J; Houston, DW; King, ML; Payne, C; Wylie, C; Heasman, J				Zhang, J; Houston, DW; King, ML; Payne, C; Wylie, C; Heasman, J			The role of maternal VegT in establishing the primary germ layers in Xenopus embryos	CELL			English	Article							BOX TRANSCRIPTION FACTOR; MESODERM INDUCTION; POLE BLASTOMERES; MESSENGER-RNA; LAEVIS; ENDODERM; GENE; EXPRESSION; OOGENESIS; BLASTULA	VegT is a T-box transcription factor whose mRNA is synthesized during oogenesis and localized in the vegetal hemisphere of the egg and early embryo. We show that maternally expressed VegT controls the pattern of primary germ layer specification in Xenopus embryos. Reduction of the maternal store completely alters the fates of different regions of the blastula so that animal cell fate is changed from epidermis and nervous system to epidermis only, equatorial cell fate is changed from mesoderm to ectoderm, and vegetal cell fate is changed from endoderm to mesoderm and ectoderm. Vegetal cells lose their capacity both to form endoderm and to release mesoderm-inducing signals. These results show that a single maternally expressed gene controls the patterning of the Xenopus blastula.	Univ Minnesota, Sch Med, Inst Human Genet, Minneapolis, MN 55455 USA; Univ Minnesota, Sch Med, Dept Paediat, Minneapolis, MN 55455 USA; Univ Minnesota, Sch Med, Dept Cell Biol & Neuroanat, Minneapolis, MN 55455 USA; Univ Miami, Sch Med, Dept Anat & Cell Biol, Miami, FL 33136 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Miami	Heasman, J (corresponding author), Univ Minnesota, Sch Med, Inst Human Genet, Minneapolis, MN 55455 USA.				NICHD NIH HHS [1 HD33002] Funding Source: Medline; NIGMS NIH HHS [GM33932] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD033002] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033932] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEARER EL, 1994, EUR J CELL BIOL, V63, P255; El-Hodiri HM, 1998, DEV BIOL, V198, P174; GURDON JB, 1985, CELL, V41, P913, DOI 10.1016/S0092-8674(85)80072-6; HARLAND RM, 1991, METHOD CELL BIOL, V36, P685; HEASMAN J, 1991, METHOD CELL BIOL, V36, P213; HEASMAN J, 1984, CELL, V37, P185, DOI 10.1016/0092-8674(84)90314-3; HEASMAN J, 1994, CELL, V79, P791, DOI 10.1016/0092-8674(94)90069-8; Heasman J, 1997, DEVELOPMENT, V124, P4179; HEMMATIBRIVANLO.A, 1989, DEVELOPMENT, V106, P611; Henry GL, 1996, DEVELOPMENT, V122, P1007; HOPWOOD ND, 1989, EMBO J, V8, P3409, DOI 10.1002/j.1460-2075.1989.tb08505.x; Horb ME, 1997, DEVELOPMENT, V124, P1689; Hudson C, 1997, CELL, V91, P397, DOI 10.1016/S0092-8674(00)80423-7; JONAS E, 1985, P NATL ACAD SCI USA, V82, P5413, DOI 10.1073/pnas.82.16.5413; KELLER R, 1988, DEVELOPMENT, V103, P193; LAMB TM, 1995, DEVELOPMENT, V121, P3627; LEMAIRE P, 1994, DEVELOPMENT, V120, P1191; Lustig KD, 1996, DEVELOPMENT, V122, P4001; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; NIEUWKOOP P D, 1969, Wilhelm Roux' Archiv fuer Entwicklungsmechanik der Organismen, V162, P341, DOI 10.1007/BF00578701; Papaioannou VE, 1998, BIOESSAYS, V20, P9, DOI 10.1002/(SICI)1521-1878(199801)20:1<9::AID-BIES4>3.0.CO;2-Q; Sasai Y, 1996, EMBO J, V15, P4547, DOI 10.1002/j.1460-2075.1996.tb00832.x; SHI YB, 1994, DEV BIOL, V161, P48, DOI 10.1006/dbio.1994.1006; SIVE HL, 1993, GENE DEV, V7, P1, DOI 10.1101/gad.7.1.1; Smith J, 1997, CURR OPIN GENET DEV, V7, P474, DOI 10.1016/S0959-437X(97)80073-1; SMITH JC, 1989, DEVELOPMENT, V105, P665; SNAPE A, 1987, DEV BIOL, V119, P503, DOI 10.1016/0012-1606(87)90053-4; Stennard F, 1996, DEVELOPMENT, V122, P4179; STIEGLER P, 1993, MECH DEVELOP, V41, P163, DOI 10.1016/0925-4773(93)90046-Z; WHITFIELD T, 1993, DEV BIOL, V155, P361, DOI 10.1006/dbio.1993.1035; WILSON PA, 1994, CURR BIOL, V4, P676, DOI 10.1016/S0960-9822(00)00152-4; WRIGHT CVE, 1989, DEVELOPMENT, V105, P787; Wylie C, 1996, DEVELOPMENT, V122, P2987; WYLIE CC, 1987, DEV BIOL, V119, P496, DOI 10.1016/0012-1606(87)90052-2; Zhang J, 1996, DEVELOPMENT, V122, P4119	35	373	378	0	14	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 21	1998	94	4					515	524		10.1016/S0092-8674(00)81592-5	http://dx.doi.org/10.1016/S0092-8674(00)81592-5			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	113GB	9727494	hybrid			2022-12-28	WOS:000075541100013
J	Levine, RA				Levine, RA			Treating histologically mild chronic hepatitis C: Monotherapy, combination therapy, or tincture of time?	ANNALS OF INTERNAL MEDICINE			English	Editorial Material								The recent National Institutes of Health Consensus Conference on hepatitis C solidified the justification for a selective approach to treatment. Nevertheless, the high profile of chronic hepatitis C has led to a sense of urgency about treating "all-comers" and thus has caused the variable natural history of this disease to be overlooked. The debate about whom to treat has failed to focus attention on the alternative approach of waiting for better emerging therapies for the subset of patients with histologically mild chronic hepatitis C. Practitioners should be more confident about postponing treatment in less symptomatic patients if liver biopsy specimens show no more than grade 1 necroinflammatory activity or stage 1 fibrosis. Patients with these lesions, in the absence of clinical signs of advancing disease, are much less likely than patients with higher grades or stages to progress to cirrhosis. A "cure" for chronic hepatitis C remains elusive. End points of treatment depend on the achievement of sustained clearance of serum hepatitis C virus RNA, which is influenced, in turn, by the patient's viral replication and immune balance. Treatment of histologically mild chronic hepatitis C may ultimately mimic that of HIV infection.	SUNY Hlth Sci Ctr, Syracuse, NY 13210 USA	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center	Levine, RA (corresponding author), Univ Hosp, Dept Med, Div Gastroenterol, 750 E Adams St, Syracuse, NY 13210 USA.							[Anonymous], 1997, HEPATOLOGY, V26, pS2; Bedossa P, 1996, HEPATOLOGY, V24, P289, DOI 10.1002/hep.510240201; Bennett WG, 1997, ANN INTERN MED, V127, P855, DOI 10.7326/0003-4819-127-10-199711150-00001; Berg T., 1997, Hepatology, V26, p423A; Bonkovsky HL, 1997, HEPATOLOGY, V25, P759, DOI 10.1002/hep.510250345; DAVIS GL, 1997, HEPATOLOGY, V26, pA249; Di Bisceglie A. M., 1997, Hepatology, V26, p214A; Gavier B, 1997, GASTROENTEROLOGY, V113, P1647, DOI 10.1053/gast.1997.v113.pm9352868; Heathcote EJL, 1998, HEPATOLOGY, V27, P1136, DOI 10.1002/hep.510270431; Koff RS, 1997, ANN INTERN MED, V127, P918, DOI 10.7326/0003-4819-127-10-199711150-00011; Lai MY, 1996, GASTROENTEROLOGY, V111, P1307, DOI 10.1053/gast.1996.v111.pm8898645; LEVINE RA, 1970, GASTROENTEROLOGY, V58, P371; Major ME, 1997, HEPATOLOGY, V25, P1527, DOI 10.1002/hep.510250637; Marcellin P, 1997, ANN INTERN MED, V127, P875, DOI 10.7326/0003-4819-127-10-199711150-00003; Marcellin P, 1997, HEPATOLOGY, V26, pS133, DOI 10.1002/hep.510260723; Mathurin P, 1998, HEPATOLOGY, V27, P868, DOI 10.1002/hep.510270333; Pardo M, 1997, HEPATOLOGY, V26, P1318; Pawlotsky JM, 1997, AM J GASTROENTEROL, V92, P1775; Poynard T, 1997, LANCET, V349, P825, DOI 10.1016/S0140-6736(96)07642-8; Reichard O, 1998, LANCET, V351, P83, DOI 10.1016/S0140-6736(97)06088-1; Silverman AL, 1997, AM J GASTROENTEROL, V92, P1793; Suzuki H., 1997, Hepatology, V26, p422A; TONG MJ, 1995, NEW ENGL J MED, V332, P1463, DOI 10.1056/NEJM199506013322202; vonWeizsacker F, 1997, HEPATOLOGY, V26, P251, DOI 10.1002/hep.510260237; Wu CH, 1998, GASTROENTEROLOGY, V114, P1304, DOI 10.1016/S0016-5085(98)70437-8; Yano M, 1996, HEPATOLOGY, V23, P1334, DOI 10.1002/hep.510230607	26	18	18	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 15	1998	129	4					323	326		10.7326/0003-4819-129-4-199808150-00010	http://dx.doi.org/10.7326/0003-4819-129-4-199808150-00010			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	109NP	9729187				2022-12-28	WOS:000075329100009
J	Mahanty, NK; Sah, P				Mahanty, NK; Sah, P			Calcium-permeable AMPA receptors mediate long-term potentiation in interneurons in the amygdala	NATURE			English	Article							RAT BASOLATERAL AMYGDALA; NEOCORTICAL NEURONS; CA2+ PERMEABILITY; B SUBUNIT; CHANNELS; LOCALIZATION; TRANSMISSION; HIPPOCAMPUS; EXPRESSION; RECORDINGS	Fear conditioning is a paradigm that has been used as a model for emotional learning in animals'. The cellular correlate of fear conditioning is thought to be associative N-methyl-D-aspartate (NMDA) receptor-dependent synaptic plasticity within the amygdala(1-3). Here we show that glutamatergic synaptic transmission to inhibitory interneurons in the basolateral amygdala is mediated solely by alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors. In contrast to AMPA receptors at inputs to pyramidal neurons, these receptors have an inwardly rectifying current-voltage relationship, indicative of a high permeability to calcium(4 5), Tetanic stimulation of inputs to interneurons caused an immediate and sustained increase in the efficacy of these synapses. This potentiation required a rise in postsynaptic calcium, but was independent of NMDA receptor activation. The potentiation of excitatory inputs to interneurons was reflected as an increase in the amplitude of the GABAA-mediated inhibitory synaptic current in pyramidal neurons. These results demonstrate that excitatory synapses onto interneurons within a fear conditioning circuit show NMDA-receptor independent long-term potentiation. This plasticity might underlie the increased synchronization of activity between neurons in the basolateral amygdala after fear conditioning(6).	Univ Newcastle, Fac Med & Hlth Sci, Neurosci Grp, Newcastle, NSW 2308, Australia; Univ Newcastle, Fac Med & Hlth Sci, Discipline Human Physiol, Newcastle, NSW 2308, Australia	University of Newcastle; University of Newcastle	Sah, P (corresponding author), Univ Newcastle, Fac Med & Hlth Sci, Neurosci Grp, Newcastle, NSW 2308, Australia.		Sah, Pankaj/C-8175-2009	Sah, Pankaj/0000-0001-5063-1589				BLANTON MG, 1989, J NEUROSCI METH, V30, P203, DOI 10.1016/0165-0270(89)90131-3; COBB SR, 1995, NATURE, V378, P75, DOI 10.1038/378075a0; CONNORS BW, 1990, TRENDS NEUROSCI, V13, P99, DOI 10.1016/0166-2236(90)90185-D; FARB CR, 1995, J COMP NEUROL, V362, P86, DOI 10.1002/cne.903620106; Geiger JRP, 1997, NEURON, V18, P1009, DOI 10.1016/S0896-6273(00)80339-6; GEIGER JRP, 1995, NEURON, V15, P193, DOI 10.1016/0896-6273(95)90076-4; Gu JG, 1996, NATURE, V381, P793, DOI 10.1038/381793a0; HESTRIN S, 1993, NEURON, V11, P1083, DOI 10.1016/0896-6273(93)90221-C; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; Isa T, 1996, J PHYSIOL-LONDON, V491, P719, DOI 10.1113/jphysiol.1996.sp021252; Jia ZP, 1996, NEURON, V17, P945, DOI 10.1016/S0896-6273(00)80225-1; JONAS P, 1995, NEURON, V15, P987, DOI 10.1016/0896-6273(95)90087-X; JONAS P, 1994, NEURON, V12, P1281, DOI 10.1016/0896-6273(94)90444-8; LEDOUX JE, 1995, ANNU REV PSYCHOL, V46, P209, DOI 10.1146/annurev.ps.46.020195.001233; MAHANTY NK, 1996, SOC NEUR ABSTR, V22; MALENKA RC, 1989, TRENDS NEUROSCI, V12, P444, DOI 10.1016/0166-2236(89)90094-5; MCBAIN CJ, 1993, J PHYSIOL-LONDON, V462, P373, DOI 10.1113/jphysiol.1993.sp019560; MCCORMICK DA, 1985, J NEUROPHYSIOL, V54, P782, DOI 10.1152/jn.1985.54.4.782; McDonald AJ, 1996, NEUROSCI LETT, V208, P175, DOI 10.1016/0304-3940(96)12585-4; QUIRK GJ, 1995, NEURON, V15, P1029, DOI 10.1016/0896-6273(95)90092-6; Racca C, 1996, EUR J NEUROSCI, V8, P1580, DOI 10.1111/j.1460-9568.1996.tb01303.x; RAINNIE DG, 1991, J NEUROPHYSIOL, V66, P999, DOI 10.1152/jn.1991.66.3.999; RAINNIE DG, 1993, J NEUROPHYSIOL, V69, P1350, DOI 10.1152/jn.1993.69.4.1350; ROGAN MT, 1995, NEURON, V15, P127, DOI 10.1016/0896-6273(95)90070-5; Rogan MT, 1997, NATURE, V390, P604, DOI 10.1038/37601; SAH P, 1990, J PHYSIOL-LONDON, V430, P605, DOI 10.1113/jphysiol.1990.sp018310; Smith BN, 1996, J NEUROPHYSIOL, V76, P1958, DOI 10.1152/jn.1996.76.3.1958; Washburn MS, 1997, J NEUROSCI, V17, P9393; WASHBURN MS, 1992, J NEUROSCI, V12, P4066	29	308	311	0	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 13	1998	394	6694					683	687		10.1038/29312	http://dx.doi.org/10.1038/29312			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	110MD	9716132				2022-12-28	WOS:000075384200045
J	Abraham, J; Lewis, G				Abraham, J; Lewis, G			Secrecy end transparency of medicines licensing in the EU	LANCET			English	Editorial Material									Univ Sussex, Dept Sociol, Brighton BN1 9QN, E Sussex, England; Univ Reading, Dept Sociol, Reading, Berks, England	University of Sussex; University of Reading	Abraham, J (corresponding author), Univ Sussex, Dept Sociol, Arts C Bldg, Brighton BN1 9QN, E Sussex, England.							BROWN P, 1990, SCRIP, V1564, P9; *EUR MED EV AG, 1997, INT REP CONS EX TRAN; *HLTH ACT INT, 1992, SECR CAMP INF PACK, P2; *NAT CONS COUNC, 1994, SECR MED EUR, P14; WARDEN J, 1993, BRIT MED J, V306, P1228; 1994, REGULATORY AFFAIRS J, V5, P481; 1991, SCRIP, V1602, P5	7	17	17	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	AUG 8	1998	352	9126					480	482		10.1016/S0140-6736(97)11282-X	http://dx.doi.org/10.1016/S0140-6736(97)11282-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	108EA	9708771				2022-12-28	WOS:000075252000047
J	Madison, JM; Irwin, RS				Madison, JM; Irwin, RS			Chronic obstructive pulmonary disease	LANCET			English	Article							RANDOMIZED CONTROLLED TRIAL; ACUTE RESPIRATORY-FAILURE; ACUTE EXACERBATIONS; DOUBLE-BLIND; NONINVASIVE VENTILATION; BACTERIAL-INFECTION; CHRONIC-BRONCHITIS; SMOKING CESSATION; LUNG-DISEASE; COPD	Acute exacerbations of underlying COPD are a common cause of respiratory deterioration. Developments have been made in preventive measures, but admission to hospital for acute exacerbations can be expected to remain common. Several expert consensus guidelines have been published to define the appropriate management of COPD patients. These consensus guidelines generally agree, but all acknowledge a lack of large well-controlled clinical studies, especially studies focusing on the management of acute exacerbations. Consequently, many potential controversies exist about the details of managing patients with acute exacerbations. Although studies of many fundamental aspects of management are still needed, the results of controlled clinical trials are sufficient to emphasise the importance of a careful clinical assessment, supplemental oxygen, inhaled bronchodilators to partially improve airway obstruction, corticosteroids to decrease the likelihood of treatment failures and to speed recovery, antibiotics, especially in severe patients, and non-invasive positive-pressure ventilation for treatment of acute ventilatory failure in selected patients.	Univ Massachusetts, Sch Med, Pulm Allergy & Crit Care Med Div, Worcester, MA 01655 USA	University of Massachusetts System; University of Massachusetts Worcester	Madison, JM (corresponding author), Univ Massachusetts, Sch Med, Pulm Allergy & Crit Care Med Div, 55 Lake Ave, Worcester, MA 01655 USA.							AbouShala N, 1996, CRIT CARE MED, V24, P705, DOI 10.1097/00003246-199604000-00025; ALBERT RK, 1980, ANN INTERN MED, V92, P753, DOI 10.7326/0003-4819-92-6-753; Allegra L, 1996, RESPIRATION, V63, P174; [Anonymous], 1980, Ann Intern Med, V93, P391; Anthonisen N., 1997, EUR RESPIR REV, V7, P202; ANTHONISEN NR, 1987, ANN INTERN MED, V106, P196, DOI 10.7326/0003-4819-106-2-196; AUBIER M, 1980, AM REV RESPIR DIS, V122, P747, DOI 10.1164/arrd.1980.122.5.747; BLASI F, 1993, EUR RESPIR J, V6, P19; BOTT J, 1993, LANCET, V341, P1555, DOI 10.1016/0140-6736(93)90696-E; BROCHARD L, 1995, NEW ENGL J MED, V333, P817, DOI 10.1056/NEJM199509283331301; BROWN D G, 1986, Respiratory Care, V31, P1069; Buist AS, 1996, EUR RESPIR REV, V6, P253; *CDC, 1987, ANN INTERN MED, V107, P521; CELLI BR, 1995, AM J RESP CRIT CARE, V152, pS77; CLANCY R, 1995, AM J RESP CRIT CARE, V151, P1682; Collet JP, 1997, AM J RESP CRIT CARE, V156, P1719, DOI 10.1164/ajrccm.156.6.9612096; DAVIS RM, 1989, AM REV RESPIR DIS, V140, pS82, DOI 10.1164/ajrccm/140.3_Pt_2.S82; Dhand R, 1997, AM J RESP CRIT CARE, V156, P3, DOI 10.1164/ajrccm.156.1.9610025; Eller J, 1998, CHEST, V113, P1542, DOI 10.1378/chest.113.6.1542; ELLIOTT MW, 1995, NEW ENGL J MED, V333, P870, DOI 10.1056/NEJM199509283331309; EMERMAN CL, 1991, CHEST, V99, P595, DOI 10.1378/chest.99.3.595; EPSTEIN RL, 1978, RESP CARE, V23, P1151; ERBLAND ML, 1998, INT C AM LUNG ASS AM; FERGUSON GT, 1993, NEW ENGL J MED, V328, P1017; FLETCHER C, 1977, BRIT MED J, V1, P1545; Gaissert HA, 1996, J THORAC CARDIOV SUR, V111, P296, DOI 10.1016/S0022-5223(96)70438-5; GLENNY RW, 1987, CHEST, V91, P289, DOI 10.1378/chest.91.2.289-c; GOLDSTEIN RS, 1994, LANCET, V344, P1394, DOI 10.1016/S0140-6736(94)90568-1; Grossman RF, 1998, CHEST, V113, p249S, DOI 10.1378/chest.113.4_Supplement.249S; Hillberg RE, 1997, NEW ENGL J MED, V337, P1746, DOI 10.1056/NEJM199712113372407; HODGKIN JE, 1990, CLIN CHEST MED, V11, P555; HUDSON LD, 1990, MED CLIN N AM, V74, P661, DOI 10.1016/S0025-7125(16)30544-2; IRWIN RS, 1993, DRUGS, V46, P80, DOI 10.2165/00003495-199346010-00006; IRWIN RS, 1982, J INFECT DIS, V145, P234, DOI 10.1093/infdis/145.2.234; IRWIN RS, 1996, INTENS CARE MED, P773; Jasmer RM, 1997, CHEST, V111, P1672, DOI 10.1378/chest.111.6.1672; JEFFERY PK, 1997, EUR RESPIR REV, V7, P111; JEFFREY AA, 1992, THORAX, V47, P34, DOI 10.1136/thx.47.1.34; KARPEL JP, 1990, CHEST, V98, P835, DOI 10.1378/chest.98.4.835; KIRILOFF LH, 1985, CHEST, V88, P436, DOI 10.1378/chest.88.3.436; MARTINEZ J, 1997, EUR RESPIR REV, V7, P240; McEvoy CE, 1997, CHEST, V111, P732, DOI 10.1378/chest.111.3.732; MENEELY GR, 1962, AM REV RESPIR DIS, V85, P762; MONSO E, 1995, AM J RESP CRIT CARE, V152, P1316, DOI 10.1164/ajrccm.152.4.7551388; Moran JL, 1998, CRIT CARE MED, V26, P71, DOI 10.1097/00003246-199801000-00019; MOSER KM, 1973, NEW ENGL J MED, V288, P427, DOI 10.1056/NEJM197303012880901; MURATA GH, 1992, ARCH INTERN MED, V152, P73, DOI 10.1001/archinte.152.1.73; MURATA GH, 1990, CHEST, V98, P845, DOI 10.1378/chest.98.4.845; MURATA GH, 1989, ANN EMERG MED, V18, P501, DOI 10.1016/S0196-0644(89)80833-9; MURPHY TF, 1992, AM REV RESPIR DIS, V146, P1067, DOI 10.1164/ajrccm/146.4.1067; MUSHLIN AI, 1991, JAMA-J AM MED ASSOC, V266, P80; NEWMAN SL, 1986, CURRENT PULMONOLOGY, V7, P272; Niewoehner DE, 1996, CHEST, V110, P867, DOI 10.1378/chest.110.4.867-a; Paggiaro PL, 1998, LANCET, V351, P773, DOI 10.1016/S0140-6736(97)03471-5; Pare PD, 1996, EUR RESPIR REV, V6, P259; Pearson MG, 1997, THORAX, V52, pS1; POSTMA DS, 1989, AM REV RESPIR DIS, V140, pS100, DOI 10.1164/ajrccm/140.3_Pt_2.S100; RENNARD S, 1997, EUR RESPIR REV, V7, P206; RENNARD SI, 1995, CHEST, V107, pS171, DOI 10.1378/chest.107.5_Supplement.171S; Repine JE, 1997, AM J RESP CRIT CARE, V156, P341, DOI 10.1164/ajrccm.156.2.9611013; RICE KL, 1987, ANN INTERN MED, V107, P305, DOI 10.7326/0003-4819-107-2-305; ROTHBARTH PH, 1995, AM J RESP CRIT CARE, V151, P1682, DOI 10.1164/ajrccm.151.5.7735634; SAETTA M, 1994, AM J RESP CRIT CARE, V150, P1646, DOI 10.1164/ajrccm.150.6.7952628; SAETTA M, 1997, EUR RESPIR REV, V7, P211; SAINT S, 1995, JAMA-J AM MED ASSOC, V273, P957, DOI 10.1001/jama.273.12.957; Sandford AJ, 1997, EUR RESPIR J, V10, P1380, DOI 10.1183/09031936.97.10061380; SaudnyUnterberger H, 1997, AM J RESP CRIT CARE, V156, P794, DOI 10.1164/ajrccm.156.3.9612102; SCHMIDT GA, 1989, JAMA-J AM MED ASSOC, V261, P3444, DOI 10.1001/jama.261.23.3444; SCHWARTZ JL, 1991, CLIN CHEST MED, V12, P737; SENEFF MG, 1995, JAMA-J AM MED ASSOC, V274, P1852, DOI 10.1001/jama.274.23.1852; Senior RM, 1998, AM J RESP CRIT CARE, V157, pS139, DOI 10.1164/ajrccm.157.4.nhlbi-12; SHERRILL DL, 1990, CLIN CHEST MED, V11, P375; SIAFAKAS NM, 1995, EUR RESPIR J, V8, P1398, DOI 10.1183/09031936.95.08081398; SIAFAKAS NM, 1996, EUR RESPIR REV, V6, P270; SILAGY C, 1994, LANCET, V343, P139, DOI 10.1016/S0140-6736(94)90933-4; SMITH CB, 1980, AM REV RESPIR DIS, V121, P225; SMYMIOS NA, 1995, CHEST, V108, P991; SNIDER GL, 1985, AM REV RESPIR DIS, V132, P182; SPEIZER FE, 1989, AM REV RESPIR DIS, V140, pS49, DOI 10.1164/ajrccm/140.3_Pt_2.S49; Spika J S, 1990, Infect Dis Clin North Am, V4, P11; STOCKLEY RA, 1997, EUR RESPIR REV, V7, P128; Thompson WH, 1996, AM J RESP CRIT CARE, V154, P407, DOI 10.1164/ajrccm.154.2.8756814; Turner MO, 1997, ARCH INTERN MED, V157, P1736, DOI 10.1001/archinte.157.15.1736; ULRIK CS, 1995, THORAX, V50, P750, DOI 10.1136/thx.50.7.750; VESTBO J, 1989, RESP MED, V83, P207, DOI 10.1016/S0954-6111(89)80033-2; Wanner A, 1996, AM J RESP CRIT CARE, V154, P1868, DOI 10.1164/ajrccm.154.6.8970383; Wilson R, 1998, CHEST, V113, p242S, DOI 10.1378/chest.113.4_Supplement.242S; WRENN K, 1991, ANN INTERN MED, V115, P241, DOI 10.7326/0003-4819-115-4-241; 1994, CAN MED ASS J, V151, P5	89	80	84	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 8	1998	352	9126					467	473		10.1016/S0140-6736(97)11081-9	http://dx.doi.org/10.1016/S0140-6736(97)11081-9			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	108EA	9708769	Bronze, Green Published			2022-12-28	WOS:000075252000045
J	Dernburg, AF; McDonald, K; Moulder, G; Barstead, R; Dresser, M; Villeneuve, AM				Dernburg, AF; McDonald, K; Moulder, G; Barstead, R; Dresser, M; Villeneuve, AM			Meiotic recombination in C-elegans initiates by a conserved mechanism and is dispensable for homologous chromosome synapsis	CELL			English	Article							DOUBLE-STRAND BREAKS; NEMATODE CAENORHABDITIS-ELEGANS; PACHYTENE KARYOTYPE ANALYSIS; SACCHAROMYCES-CEREVISIAE; WILD-TYPE; SYNAPTONEMAL COMPLEXES; YEAST MEIOSIS; 3 DIMENSIONS; HOT-SPOT; MUTANTS	Chromosome segregation at meiosis I depends on pairing and crossing-over between homologs. In most eukaryotes, pairing culminates with formation of the proteinaceous synaptonemal complex (SC). In budding yeast, recombination initiates through double-strand DNA breaks (DSBs) and is thought to be essential for SC formation. Here, we examine whether this mechanism for initiating meiotic recombination is conserved, and we test the dependence of homologous chromosome synapsis on recombination in C. elegans. We find that a homolog of the yeast DSB-generating enzyme, Spo11p, is required for meiotic exchange in this metazoan, and that radiation-induced breaks partially alleviate this dependence. Thus, initiation of recombination by DSBs is apparently conserved. However, homologous synapsis is independent of recombination in the nematode, since it occurs normally in a C. elegans spo-11 null mutant.	Stanford Univ, Sch Med, Dept Dev Biol, Stanford, CA 94305 USA; Univ Calif Berkeley, Electron Microscopy Lab, Berkeley, CA 94720 USA; Oklahoma Med Res Fdn, Oklahoma City, OK 73104 USA	Stanford University; University of California System; University of California Berkeley; Oklahoma Medical Research Foundation	Villeneuve, AM (corresponding author), Stanford Univ, Sch Med, Dept Dev Biol, Stanford, CA 94305 USA.			Dernburg, Abby/0000-0001-8037-1079	NIGMS NIH HHS [GM53804-01, R01 GM053804] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGARD DA, 1989, METHOD CELL BIOL, V30, P353; ALANI E, 1990, CELL, V61, P419, DOI 10.1016/0092-8674(90)90524-I; BEANAN MJ, 1992, DEVELOPMENT, V116, P755; Bergerat A, 1997, NATURE, V386, P414, DOI 10.1038/386414a0; BRENNER S, 1974, GENETICS, V77, P71; Bullard SA, 1996, P NATL ACAD SCI USA, V93, P13054, DOI 10.1073/pnas.93.23.13054; CAO L, 1990, CELL, V61, P1089, DOI 10.1016/0092-8674(90)90072-M; Chen H, 1996, J STRUCT BIOL, V116, P56, DOI 10.1006/jsbi.1996.0010; DEMASSY B, 1994, P NATL ACAD SCI USA, V91, P11929, DOI 10.1073/pnas.91.25.11929; DEMBURG AF, 1998, METHOD CELL BIOL, V53, P187; DURBIN R, 1991, A C ELEGANS DATABASE; Edgar LG, 1995, METHOD CELL BIOL, V48, P303; GIROUX CN, 1989, GENOME, V31, P88, DOI 10.1139/g89-017; GOLDSTEIN P, 1982, CHROMOSOMA, V84, P585, DOI 10.1007/BF00292857; GOLDSTEIN P, 1982, CHROMOSOMA, V86, P577, DOI 10.1007/BF00330128; GRELL RF, 1970, CHROMOSOMA, V31, P434, DOI 10.1007/BF00285834; Haber JE, 1997, CELL, V89, P163, DOI 10.1016/S0092-8674(00)80194-4; HAWLEY RS, 1980, GENETICS, V94, P625; HAWLEY RS, 1993, CELL, V72, P301, DOI 10.1016/0092-8674(93)90108-3; HODGKIN J, 1979, GENETICS, V91, P67; HOWARD RJ, 1987, EXP MYCOL, V11, P250, DOI 10.1016/0147-5975(87)90014-4; Keeney S, 1997, CELL, V88, P375, DOI 10.1016/S0092-8674(00)81876-0; KIM JS, 1987, GENOME, V29, P457, DOI 10.1139/g87-079; Kiss JZ, 1995, TECHNIQUES MODERN BI, P89; KLAPHOLZ S, 1985, GENETICS, V110, P187; Kleckner N, 1996, P NATL ACAD SCI USA, V93, P8167, DOI 10.1073/pnas.93.16.8167; Lichten M, 1995, ANNU REV GENET, V29, P423, DOI 10.1146/annurev.ge.29.120195.002231; MCDONALD K, 1998, MOL BIOL; MCKIM KS, 1988, GENETICS, V120, P987; McKim KS, 1998, SCIENCE, V279, P876, DOI 10.1126/science.279.5352.876; MCKIM KS, 1993, GENETICS, V134, P749; MOENS PB, 1994, BIOESSAYS, V16, P101, DOI 10.1002/bies.950160206; Moore DP, 1998, CURR TOP DEV BIOL, V37, P263; NAG DK, 1995, GENETICS, V141, P75; Nairz K, 1997, GENE DEV, V11, P2272, DOI 10.1101/gad.11.17.2272; NELSON DW, 1985, GENE, V38, P245, DOI 10.1016/0378-1119(85)90224-0; PADMORE R, 1991, CELL, V66, P1239, DOI 10.1016/0092-8674(91)90046-2; Prinz S, 1997, GENETICS, V146, P781; Riddle D. L, 1997, C ELEGANS, P47; Rocco V, 1996, GENES CELLS, V1, P645, DOI 10.1046/j.1365-2443.1996.00256.x; Roeder GS, 1997, GENE DEV, V11, P2600, DOI 10.1101/gad.11.20.2600; ROSE AM, 1984, MOL GEN GENET, V195, P52, DOI 10.1007/BF00332723; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHEDL T, 1997, DEV GENETICS GERM LI, P241; SCHMEKEL K, 1995, TRENDS CELL BIOL, V5, P239, DOI 10.1016/S0962-8924(00)89017-0; SCHWACHA A, 1995, CELL, V83, P783, DOI 10.1016/0092-8674(95)90191-4; SUN H, 1989, NATURE, V338, P87, DOI 10.1038/338087a0; THORNE LW, 1993, GENETICS, V134, P29; VILLENEUVE AM, 1994, GENETICS, V136, P887; WEINER BM, 1994, CELL, V77, P977, DOI 10.1016/0092-8674(94)90438-3; WOLF KW, 1994, BIOESSAYS, V16, P107, DOI 10.1002/bies.950160207; WOLFE J, 1976, CHROMOSOMA, V55, P289, DOI 10.1007/BF00292827; XU LH, 1995, EMBO J, V14, P5115, DOI 10.1002/j.1460-2075.1995.tb00194.x; ZETKA M, 1995, TRENDS GENET, V11, P27, DOI 10.1016/S0168-9525(00)88983-0	54	562	576	1	21	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 7	1998	94	3					387	398		10.1016/S0092-8674(00)81481-6	http://dx.doi.org/10.1016/S0092-8674(00)81481-6			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	109EN	9708740	Bronze			2022-12-28	WOS:000075308400014
J	Kuida, K; Haydar, TF; Kuan, CY; Gu, Y; Taya, C; Karasuyama, H; Su, MSS; Rakic, P; Flavell, RA				Kuida, K; Haydar, TF; Kuan, CY; Gu, Y; Taya, C; Karasuyama, H; Su, MSS; Rakic, P; Flavell, RA			Reduced apoptosis and cytochrome c-mediated caspase activation in mice lacking Caspase 9	CELL			English	Article							CELL; ENZYME; DEFICIENT; ENCODES; BCL-2	Caspases are essential components of the mammalian cell death machinery. Here we test the hypothesis that Caspase 9 (Casp9) is a critical upstream activator of caspases through gene targeting in mice. The majority of Casp9 knockout mice die perinatally with a markedly enlarged and malformed cerebrum caused by reduced apoptosis during brain development. Casp9 deletion prevents activation of Casp3 in embryonic brains in vivo, and Casp9-deficient thymocytes show resistance to a subset of apoptotic stimuli, including absence of Casp3-like cleavage and delayed DNA fragmentation. Moreover, the cytochrome c-mediated cleavage of Casp3 is absent in the cytosolic extracts of Casp9-deficient cells but is restored after addition of in vitro-translated Casp9. Together, these results indicate that Casp9 is a critical upstream activator of the caspase cascade in vivo.	Vertex Pharmaceut Inc, Cambridge, MA 02139 USA; Yale Univ, Sch Med, Neurobiol Sect, New Haven, CT 06510 USA; Yale Univ, Sch Med, Howard Hughes Med Inst, Immunobiol Sect, New Haven, CT 06510 USA; Tokyo Metropolitan Inst Med Sci, Bunkyo Ku, Tokyo 113, Japan	Vertex Pharmaceuticals; Yale University; Howard Hughes Medical Institute; Yale University; Tokyo Metropolitan Institute of Medical Science	Flavell, RA (corresponding author), Vertex Pharmaceut Inc, Cambridge, MA 02139 USA.		Karasuyama, Hajime/A-7966-2011	Karasuyama, Hajime/0000-0003-0689-0836; Haydar, Tarik/0000-0001-6772-3076				Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; Bergeron L, 1998, GENE DEV, V12, P1304, DOI 10.1101/gad.12.9.1304; Bossy-Wetzel E, 1998, EMBO J, V17, P37, DOI 10.1093/emboj/17.1.37; CAVINESS VS, 1995, TRENDS NEUROSCI, V18, P379, DOI 10.1016/0166-2236(95)93933-O; Clayton LK, 1997, EMBO J, V16, P2282, DOI 10.1093/emboj/16.9.2282; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; GLUCKSMANN A, 1951, BIOL REV, V26, P59, DOI 10.1111/j.1469-185X.1951.tb00774.x; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; Hofmann K, 1997, TRENDS BIOCHEM SCI, V22, P155, DOI 10.1016/S0968-0004(97)01043-8; Huttner WB, 1997, CURR OPIN NEUROBIOL, V7, P29, DOI 10.1016/S0959-4388(97)80117-1; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; KALLEN B, 1955, J ANAT, V89, P153; Kaufman M.H., 1992, ATLAS MOUSE DEV; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; KUIDA K, 1995, SCIENCE, V267, P2000, DOI 10.1126/science.7535475; LI P, 1995, CELL, V80, P401, DOI 10.1016/0092-8674(95)90490-5; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; Muzio M, 1998, J BIOL CHEM, V273, P2926, DOI 10.1074/jbc.273.5.2926; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; NAKAYAMA K, 1993, SCIENCE, V261, P1584, DOI 10.1126/science.8372353; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; OPPENHEIM RW, 1991, ANNU REV NEUROSCI, V14, P453, DOI 10.1146/annurev.ne.14.030191.002321; RAKIC P, 1988, SCIENCE, V241, P170, DOI 10.1126/science.3291116; RAKIC P, 1995, TRENDS NEUROSCI, V18, P383, DOI 10.1016/0166-2236(95)93934-P; Reed JC, 1997, CELL, V91, P559, DOI 10.1016/S0092-8674(00)80442-0; SAH VP, 1995, NAT GENET, V10, P175, DOI 10.1038/ng0695-175; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; WANG S, 1998, CELL, V12, P806; Wang SY, 1998, CELL, V92, P501, DOI 10.1016/S0092-8674(00)80943-5; Wang XD, 1996, EMBO J, V15, P1012, DOI 10.1002/j.1460-2075.1996.tb00438.x; Woo M, 1998, GENE DEV, V12, P806, DOI 10.1101/gad.12.6.806; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Yang XL, 1998, MOL CELL, V1, P319, DOI 10.1016/S1097-2765(00)80032-5; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	42	1390	1416	0	31	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	AUG 7	1998	94	3					325	337		10.1016/S0092-8674(00)81476-2	http://dx.doi.org/10.1016/S0092-8674(00)81476-2			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	109EN	9708735	hybrid			2022-12-28	WOS:000075308400009
J	Haddow, JE				Haddow, JE			Antenatal screening for Down's syndrome: where are we and where next?	LANCET			English	Editorial Material							SERUM ALPHA-FETOPROTEIN; ABNORMALITIES		Fdn Blood Res, Scarborough, ME 04070 USA	Foundation for Blood Research (FBR)	Haddow, JE (corresponding author), Fdn Blood Res, Scarborough, ME 04070 USA.							CUCKLE HS, 1984, LANCET, V1, P926; Haddow JE, 1998, NEW ENGL J MED, V338, P955, DOI 10.1056/NEJM199804023381404; HOOK EB, 1981, OBSTET GYNECOL, V58, P282; MERKATZ IR, 1984, AM J OBSTET GYNECOL, V148, P886, DOI 10.1016/0002-9378(84)90530-1; Palomaki G E, 1996, J Med Screen, V3, P12; TABOR A, 1986, LANCET, V1, P1287; Taipale P, 1998, NEW ENGL J MED, V338, P1229; Verma L, 1998, LANCET, V352, P9, DOI 10.1016/S0140-6736(97)11090-X; WALD N, 1996, PRENAT DIAGN, V16, P153; WALD NJ, 1988, BRIT MED J, V297, P883, DOI 10.1136/bmj.297.6653.883	10	37	37	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 1	1998	352	9125					336	337		10.1016/S0140-6736(98)22031-9	http://dx.doi.org/10.1016/S0140-6736(98)22031-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	106BU	9717914				2022-12-28	WOS:000075110500002
J	Hannum, H				Hannum, H			Condemning the drinks industry rules out potentially useful research	BRITISH MEDICAL JOURNAL			English	Article									Tufts Univ, Fletcher Sch Law & Diplomacy, Medford, MA 02155 USA	Tufts University	Hannum, H (corresponding author), Tufts Univ, Fletcher Sch Law & Diplomacy, Medford, MA 02155 USA.								0	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 1	1998	317	7154					335	336						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	110YQ	9729078				2022-12-28	WOS:000075409500032
J	Thomas, S; Booth, JCL; Levine, T; Regan, L; Summerfield, JA				Thomas, S; Booth, JCL; Levine, T; Regan, L; Summerfield, JA			Fractured rib, pleural effusion, and ascites	LANCET			English	Article							ENDOMETRIOSIS		St Marys Hosp, Imperial Coll Sch Med, Dept Med, London W2 1NY, England; St Marys Hosp, Imperial Coll Sch Med, Dept Obstet & Gynaecol, London W2 1NY, England; St Marys Hosp, Imperial Coll Sch Med, Dept Histopathol, London W2 1NY, England	Imperial College London; Imperial College London; Imperial College London	Summerfield, JA (corresponding author), St Marys Hosp, Imperial Coll Sch Med, Dept Med, Praed St, London W2 1NY, England.							COMITE F, 1989, J CLIN ENDOCR METAB, V69, P837, DOI 10.1210/jcem-69-4-837; ELNEWIHI HM, 1995, AM J GASTROENTEROL, V90, P632; Flanagan KL, 1996, THORAX, V51, P1062, DOI 10.1136/thx.51.10.1062; JENKS JE, 1984, OBSTET GYNECOL, V63, pS75; TAUB WH, 1989, J CLIN GASTROENTEROL, V11, P458, DOI 10.1097/00004836-198908000-00023	5	2	2	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	AUG 1	1998	352	9125					366	366		10.1016/S0140-6736(98)04480-8	http://dx.doi.org/10.1016/S0140-6736(98)04480-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	106BU	9717925				2022-12-28	WOS:000075110500013
J	Turnidge, J				Turnidge, J			What can be done about resistance to antibiotics?	BMJ-BRITISH MEDICAL JOURNAL			English	Article							STAPHYLOCOCCUS-AUREUS		Womens & Childrens Hosp, Adelaide, SA 5006, Australia	Womens & Childrens Hospital Australia	Turnidge, J (corresponding author), Womens & Childrens Hosp, Adelaide, SA 5006, Australia.	TrunidgeJ@wch.sa.gov.au						Acar JF, 1997, CLIN INFECT DIS, V24, pS1, DOI 10.1093/clinids/24.Supplement_1.S1; *AM SOC MICR, 1995, REP ASM TASK FORC AN; [Anonymous], 1995, INFECT CONT HOSP EP, V16, P105; COCKBURN J, 1987, MED J AUSTRALIA, V147, P324, DOI 10.5694/j.1326-5377.1987.tb133510.x; Edmond MB, 1996, ANN INTERN MED, V124, P329, DOI 10.7326/0003-4819-124-3-199602010-00008; Guillemot D, 1998, JAMA-J AM MED ASSOC, V279, P365, DOI 10.1001/jama.279.5.365; KEANE CT, 1991, J HOSP INFECT, V19, P147, DOI 10.1016/0195-6701(91)90218-W; Kozyrskyj AL, 1998, JAMA-J AM MED ASSOC, V279, P1736, DOI 10.1001/jama.279.21.1736; LEVY SB, 1993, JAMA-J AM MED ASSOC, V269, P1840, DOI 10.1001/jama.269.14.1840; LEVY SB, 1987, REV INFECT DIS, V9, pS231; Little P, 1997, BMJ-BRIT MED J, V314, P722, DOI 10.1136/bmj.314.7082.722; McIsaac WJ, 1998, CAN MED ASSOC J, V158, P75; McManus P, 1997, MED J AUSTRALIA, V167, P124, DOI 10.5694/j.1326-5377.1997.tb138809.x; MURRAY BE, 1994, NEW ENGL J MED, V330, P1229, DOI 10.1056/NEJM199404283301710; NOWAK R, 1994, SCIENCE, V264, P364, DOI 10.1126/science.8153619; PANLILIO AL, 1992, INFECT CONT HOSP EP, V13, P582; Pichichero ME, 1997, PEDIATR INFECT DIS J, V16, P680, DOI 10.1097/00006454-199707000-00011; Seppala H, 1997, NEW ENGL J MED, V337, P441, DOI 10.1056/NEJM199708143370701; STINGEMORE N, 1989, MED J AUSTRALIA, V150, P626, DOI 10.5694/j.1326-5377.1989.tb136725.x; *THER GUID, 1998, THER GUID ANT; Turnidge JD, 1996, MED J AUSTRALIA, V164, P68, DOI 10.5694/j.1326-5377.1996.tb101350.x; WHO, 1997, WHO M BERL GERM 13 1; Witte W, 1998, SCIENCE, V279, P996, DOI 10.1126/science.279.5353.996	23	25	27	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 5	1998	317	7159					645	647		10.1136/bmj.317.7159.645	http://dx.doi.org/10.1136/bmj.317.7159.645			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	118GN	9727994	Green Published			2022-12-28	WOS:000075830200024
J	Calman, K				Calman, K			Personal paper - The 1848 Public Health Act and its relevance to improving public health in England now	BRITISH MEDICAL JOURNAL			English	Article									Dept Hlth, London SW1A 2NS, England		Calman, K (corresponding author), Dept Hlth, Richmond House, London SW1A 2NS, England.		Calman, Kenneth C/C-9855-2010					CALMAN KC, 1998, POTENTIAL HLTH; Secretary of State for Health, 1998, CM3852; The Expert Advisory Group on Cancer to the Chief Medical Officers of England and Wales, 1995, POL FRAM COMM CANC S; *WORK GROUP SPEC M, 1993, HOSP DOCT TRAIN FUT	4	15	15	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 29	1998	317	7158					596	598		10.1136/bmj.317.7158.596	http://dx.doi.org/10.1136/bmj.317.7158.596			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	117EK	9721123	Green Published			2022-12-28	WOS:000075767800025
J	Lord, GM; Matarese, G; Howard, LK; Baker, RJ; Bloom, SR; Lechler, RI				Lord, GM; Matarese, G; Howard, LK; Baker, RJ; Bloom, SR; Lechler, RI			Leptin modulates the T-cell immune response and reverses starvation-induced immunosuppression	NATURE			English	Article							ANOREXIA-NERVOSA; SERUM LEPTIN; MEDIATED-IMMUNITY; INTERFERON-GAMMA; DIABETIC MICE; OBESE GENE; RECEPTOR; MOUSE; WEIGHT; HUMANS	Nutritional deprivation suppresses immune function(1-3). The cloning of the obese gene and identification of its protein product leptin(4) has provided fundamental insight into the hypothalamic regulation of body weight(5,6). Circulating levels of this adipocyte-derived hormone are proportional to fat mass(6,7) but maybe lowered rapidly by fasting(8,9) or increased by inflammatory mediators(10,11). The impaired T-cell immunity of mice(12,13) now known to be defective in leptin (ob/ob)(4) or its receptor (db/db)(14,13), has never been explained. Impaired cell-mediated immunity(1-3) and reduced levels of leptin(7) are both features of low body weight in humans. Indeed, malnutrition predisposes to death from infectious diseases(16). We report here that leptin has a specific effect on T-lymphocyte responses, differentially regulating the proliferation of naive and memory T cells. Leptin increased Th1 and suppressed Th2 cytokine production. Administration of leptin to mice reversed the immunosuppressive effects of acute starvation. Our findings suggest a new role for leptin in linking nutritional status to cognate cellular immune function, and provide a molecular mechanism to account for the immune dysfunction observed in starvation.	Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, Sch Med, Dept Immunol, London W12 0NN, England; Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, Sch Med, Dept Endocrinol, London W12 0NN, England	Imperial College London; Imperial College London	Lechler, RI (corresponding author), Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, Sch Med, Dept Immunol, Du Cane Rd, London W12 0NN, England.		Matarese, Giuseppe/AAO-4077-2021; Abraham, Sabu/E-1144-2019; Lord, Graham M/B-3797-2011	Matarese, Giuseppe/0000-0001-9429-0616; Abraham, Sabu/0000-0002-0916-5827; Lord, Graham/0000-0003-2069-4743; Howard, Jane/0000-0003-2754-8300				Abbas AK, 1996, NATURE, V383, P787, DOI 10.1038/383787a0; Ahima RS, 1996, NATURE, V382, P250, DOI 10.1038/382250a0; Beak SA, 1996, ENDOCRINOLOGY, V137, P4130, DOI 10.1210/en.137.10.4130; Besedovsky HO, 1996, ENDOCR REV, V17, P64, DOI 10.1210/er.17.1.64; Boden G, 1996, J CLIN ENDOCR METAB, V81, P3419, DOI 10.1210/jc.81.9.3419; Boehm U, 1997, ANNU REV IMMUNOL, V15, P749, DOI 10.1146/annurev.immunol.15.1.749; CASON J, 1986, CLIN EXP IMMUNOL, V64, P370; CHANDRA RK, 1980, PEDIATR RES, V14, P544, DOI 10.1093/ajcn/33.1.13; CHANDRA RK, 1991, AM J CLIN NUTR, V53, P1087, DOI 10.1093/ajcn/53.5.1087; Considine RV, 1996, NEW ENGL J MED, V334, P292, DOI 10.1056/NEJM199602013340503; FERNANDES G, 1978, J CLIN INVEST, V61, P243, DOI 10.1172/JCI108933; Friedman J M, 1998, Nutr Rev, V56, ps38; Ghilardi N, 1996, P NATL ACAD SCI USA, V93, P6231, DOI 10.1073/pnas.93.13.6231; Gotoda T, 1997, HUM MOL GENET, V6, P869, DOI 10.1093/hmg/6.6.869; Grinspoon S, 1996, J CLIN ENDOCR METAB, V81, P3861, DOI 10.1210/jc.81.11.3861; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; Janik JE, 1997, J CLIN ENDOCR METAB, V82, P3084, DOI 10.1210/jc.82.9.3084; Laufer TM, 1996, NATURE, V383, P81, DOI 10.1038/383081a0; Lee GH, 1996, NATURE, V379, P632, DOI 10.1038/379632a0; LOMBARDI G, 1990, INT IMMUNOL, V2, P9, DOI 10.1093/intimm/2.1.9; POLACK E, 1993, J CLIN IMMUNOL, V13, P445, DOI 10.1007/BF00920020; Sarraf P, 1997, J EXP MED, V185, P171, DOI 10.1084/jem.185.1.171; SEMNANI RT, 1994, J EXP MED, V180, P2125, DOI 10.1084/jem.180.6.2125; SHEARS P, 1991, EPIDEMIOL INFECT, V107, P241, DOI 10.1017/S0950268800048895; Staite ND, 1996, BLOOD, V88, P2973, DOI 10.1182/blood.V88.8.2973.bloodjournal8882973; Young JL, 1997, EUR J IMMUNOL, V27, P2383, DOI 10.1002/eji.1830270937; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	27	1694	1795	1	98	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 27	1998	394	6696					897	901		10.1038/29795	http://dx.doi.org/10.1038/29795			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	114LW	9732873				2022-12-28	WOS:000075611800050
J	Endow, SA; Waligora, KW				Endow, SA; Waligora, KW			Determinants of kinesin motor polarity	SCIENCE			English	Article							PROTEIN; NCD; DROSOPHILA; DOMAIN; MICROTUBULES; POLYMERASE; MOVEMENT	The kinesin motor protein family members move along microtubules with characteristic polarity. Chimeric motors containing the stalk and neck of the minus-end-directed motor, Ncd, fused to the motor domain of plus-end-directed kinesin were analyzed. The Ncd stalk and neck reversed kinesin motor polarity, but mutation of the Ncd neck reverted the chimeric motor to plus-end movement. Thus, residues or regions contributing to motor polarity must be present in both the Ncd neck and the kinesin motor core. The neck-motor junction was critical for Ncd minus-end movement; attachment of the neck to the stalk may also play a role.	Duke Univ, Med Ctr, Dept Microbiol, Durham, NC 27710 USA	Duke University	Endow, SA (corresponding author), Duke Univ, Med Ctr, Dept Microbiol, Durham, NC 27710 USA.			Endow, Sharyn A./0000-0002-0907-8889	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046225] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM046225] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLOOM GS, 1995, PROTEIN PROFILE, V2, P1109; Case RB, 1997, CELL, V90, P959, DOI 10.1016/S0092-8674(00)80360-8; CHANDRA R, 1993, J BIOL CHEM, V268, P9005; Crevel IMTC, 1997, J MOL BIOL, V273, P160, DOI 10.1006/jmbi.1997.1319; Endow SA, 1998, BIOESSAYS, V20, P108, DOI 10.1002/(SICI)1521-1878(199802)20:2<108::AID-BIES2>3.0.CO;2-P; ENDOW SA, 1990, NATURE, V345, P81, DOI 10.1038/345081a0; HATSUMI M, 1992, J CELL SCI, V103, P1013; Henningsen U, 1997, NATURE, V389, P93, DOI 10.1038/38022; Hirokawa N, 1998, SCIENCE, V279, P519, DOI 10.1126/science.279.5350.519; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Kozielski F, 1997, CELL, V91, P985, DOI 10.1016/S0092-8674(00)80489-4; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Romberg L, 1998, J CELL BIOL, V140, P1407, DOI 10.1083/jcb.140.6.1407; Sablin EP, 1996, NATURE, V380, P555, DOI 10.1038/380555a0; SAWIN KE, 1992, J CELL SCI, V101, P303; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Song H, 1996, BIOCHEMISTRY-US, V35, P11203, DOI 10.1021/bi960997b; Song H, 1997, P NATL ACAD SCI USA, V94, P322, DOI 10.1073/pnas.94.1.322; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; Uyeda TQP, 1996, P NATL ACAD SCI USA, V93, P4459, DOI 10.1073/pnas.93.9.4459; Vale RD, 1996, J CELL BIOL, V135, P291, DOI 10.1083/jcb.135.2.291; Vale RD, 1997, ANNU REV CELL DEV BI, V13, P745, DOI 10.1146/annurev.cellbio.13.1.745; WALKER RA, 1988, J CELL BIOL, V107, P1437, DOI 10.1083/jcb.107.4.1437; YANG JT, 1989, CELL, V56, P879, DOI 10.1016/0092-8674(89)90692-2	24	130	131	1	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 21	1998	281	5380					1200	1202		10.1126/science.281.5380.1200	http://dx.doi.org/10.1126/science.281.5380.1200			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	113CE	9712586				2022-12-28	WOS:000075531200056
J	Martin, PY; Gines, P; Schrier, RW				Martin, PY; Gines, P; Schrier, RW			Mechanisms of disease - Nitric oxide as a mediator of hemodynamic abnormalities and sodium and water retention in cirrhosis	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							PORTAL-HYPERTENSIVE RATS; ATRIAL-NATRIURETIC-FACTOR; CENTRAL BLOOD-VOLUME; HYPERDYNAMIC CIRCULATION; VASCULAR HYPORESPONSIVENESS; ARTERIAL VASODILATION; LIVER-CIRRHOSIS; RENAL SODIUM; PREASCITIC CIRRHOSIS; ALCOHOLIC CIRRHOSIS		Univ Colorado, Hlth Sci Ctr, Dept Med, Denver, CO 80262 USA; Hosp Clin Barcelona, Inst Inves Biomed August Pi Sunyer, Liver Unit, Barcelona, Spain	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS	Schrier, RW (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Med, 4200 E 9th Ave, Denver, CO 80262 USA.		Ginès, Pere/C-7730-2014	Ginès, Pere/0000-0003-4657-4504				ALBILLOS A, 1995, AM J PHYSIOL-GASTR L, V268, pG459, DOI 10.1152/ajpgi.1995.268.3.G459; ARNAL JF, 1993, EUR J PHARMACOL, V237, P265, DOI 10.1016/0014-2999(93)90278-P; Atucha NM, 1996, GASTROENTEROLOGY, V111, P1627, DOI 10.1016/S0016-5085(96)70026-4; ATUCHA NM, 1994, AM J PHYSIOL-REG I, V267, pR1454, DOI 10.1152/ajpregu.1994.267.6.R1454; Battista S, 1997, J HEPATOL, V26, P75, DOI 10.1016/S0168-8278(97)80012-8; Bech JN, 1996, AM J PHYSIOL-RENAL, V270, pF845, DOI 10.1152/ajprenal.1996.270.5.F845; Bernardi M, 1997, J HEPATOL, V27, P588, DOI 10.1016/S0168-8278(97)80367-4; BERNARDI M, 1993, GASTROENTEROLOGY, V105, P188, DOI 10.1016/0016-5085(93)90025-8; BERNARDI M, 1992, HEPATOLOGY, V16, P341, DOI 10.1002/hep.1840160210; BERNARDI M, 1995, J HEPATOL, V22, P309, DOI 10.1016/0168-8278(95)80284-3; BICHET D, 1982, ANN INTERN MED, V96, P413, DOI 10.7326/0003-4819-96-4-413; BICHET DG, 1982, NEW ENGL J MED, V307, P1552, DOI 10.1056/NEJM198212163072504; BOSCH J, 1988, KIDNEY LIVER DISEASE, P286; CAHILL PA, 1995, HEPATOLOGY, V22, P598, DOI 10.1016/0270-9139(95)90585-5; Cahill PA, 1996, J HEPATOL, V25, P370, DOI 10.1016/S0168-8278(96)80124-3; CAMPILLO B, 1995, HEPATOLOGY, V22, P1423, DOI 10.1016/0270-9139(95)90147-7; CASTRO A, 1993, HEPATOLOGY, V18, P367, DOI 10.1016/0270-9139(93)90020-N; CLARIA J, 1994, HEPATOLOGY, V20, P1615, DOI 10.1002/hep.1840200635; CLARIA J, 1992, HEPATOLOGY, V15, P343, DOI 10.1002/hep.1840150227; CLARIA J, 1991, GASTROENTEROLOGY, V100, P494, DOI 10.1016/0016-5085(91)90222-7; Colombato LA, 1996, GASTROENTEROLOGY, V110, P193, DOI 10.1053/gast.1996.v110.pm8536856; CRIADOJIMENEZ M, 1995, J MOL MED, V73, P31, DOI 10.1007/BF00203616; ESLER M, 1992, ANN INTERN MED, V116, P446, DOI 10.7326/0003-4819-116-6-446; FERNANDEZSEARA J, 1989, GASTROENTEROLOGY, V97, P1304, DOI 10.1016/0016-5085(89)91704-6; FORREST EH, 1995, J HEPATOL, V23, P254, DOI 10.1016/0168-8278(95)80468-4; GARCIAESTAN JQ, 1994, AM J PHYSIOL, V267, pR549, DOI 10.1152/ajpregu.1994.267.2.R549; Gines P, 1997, SEMIN LIVER DIS, V17, P175, DOI 10.1055/s-2007-1007196; GINES P, 1988, HEPATOLOGY, V8, P636, DOI 10.1002/hep.1840080333; Gines P, 1997, KIDNEY INT, pS77; GINES P, 1997, DIS KIDNEY, V3, P2099; GROSZMANN RJ, 1994, HEPATOLOGY, V20, P1359, DOI 10.1016/0270-9139(94)90780-3; GUARNER C, 1993, HEPATOLOGY, V18, P1139; Guevara M, 1998, HEPATOLOGY, V27, P35, DOI 10.1002/hep.510270107; HARTLEB M, 1994, GASTROENTEROLOGY, V107, P1085, DOI 10.1016/0016-5085(94)90233-X; Henriksen J. H., 1996, KIDNEY LIVER DIS, P241; Iwao T, 1997, J HEPATOL, V27, P484, DOI 10.1016/S0168-8278(97)80352-2; Kone BC, 1997, AM J PHYSIOL-RENAL, V272, pF561, DOI 10.1152/ajprenal.1997.272.5.F561; Laffi G, 1995, HEPATOLOGY, V22, P1666, DOI 10.1016/0270-9139(95)90189-2; LAVILLA G, 1992, GASTROENTEROLOGY, V102, P2114, DOI 10.1016/0016-5085(92)90340-5; LEE FY, 1993, GASTROENTEROLOGY, V105, P1464, DOI 10.1016/0016-5085(93)90152-3; LEE FY, 1992, HEPATOLOGY, V16, P1043, DOI 10.1002/hep.1840160430; MACGILCHRIST AJ, 1991, HEPATOLOGY, V13, P689, DOI 10.1016/0270-9139(91)92565-P; MAROTO A, 1993, HEPATOLOGY, V17, P788, DOI 10.1016/0270-9139(93)90153-E; Martin PY, 1996, AM J PHYSIOL-RENAL, V270, pF494, DOI 10.1152/ajprenal.1996.270.3.F494; Martin PY, 1998, J CLIN INVEST, V101, P235, DOI 10.1172/JCI626; MATSUMOTO A, 1995, ANN INTERN MED, V123, P110, DOI 10.7326/0003-4819-123-2-199507150-00005; MITTAL MK, 1994, AM J PHYSIOL, V267, pG416, DOI 10.1152/ajpgi.1994.267.3.G416; Moller S, 1997, J HEPATOL, V27, P284, DOI 10.1016/S0168-8278(97)80173-0; MoralesRuiz M, 1996, HEPATOLOGY, V24, P1481, DOI 10.1002/hep.510240630; MOSCA P, 1992, AM J PHYSIOL, V263, pG544, DOI 10.1152/ajpgi.1992.263.4.G544; NIEDERBERGER M, 1995, GASTROENTEROLOGY, V109, P1624, DOI 10.1016/0016-5085(95)90652-5; Niederberger M, 1996, HEPATOLOGY, V24, P947; NIEDERBERGER M, 1995, HEPATOLOGY, V21, P1625, DOI 10.1016/0270-9139(95)90468-9; PALMER RMJ, 1988, NATURE, V333, P664, DOI 10.1038/333664a0; Pilette C, 1996, EUR J PHARMACOL, V312, P63, DOI 10.1016/0014-2999(96)00448-7; PIZCUETA P, 1992, GASTROENTEROLOGY, V103, P1909, DOI 10.1016/0016-5085(92)91451-9; POULOS JE, 1995, GASTROENTEROLOGY, V108, P1496, DOI 10.1016/0016-5085(95)90699-1; RAIJ L, 1995, KIDNEY INT, V48, P20, DOI 10.1038/ki.1995.262; Rockey DC, 1998, GASTROENTEROLOGY, V114, P344, DOI 10.1016/S0016-5085(98)70487-1; ROS J, 1995, HEPATOLOGY, V22, P915, DOI 10.1016/0270-9139(95)90315-1; ROS J, 1995, HEPATOLOGY, V21, P554, DOI 10.1002/hep.1840210241; SATO S, 1987, RADIOLOGY, V164, P347, DOI 10.1148/radiology.164.2.2955448; SCHRIER RW, 1988, HEPATOLOGY, V8, P1151, DOI 10.1002/hep.1840080532; SCHROEDER ET, 1976, KIDNEY INT, V9, P511, DOI 10.1038/ki.1976.65; Shah V, 1997, J CLIN INVEST, V100, P2923, DOI 10.1172/JCI119842; SHAPIRO MD, 1985, KIDNEY INT, V28, P206, DOI 10.1038/ki.1985.142; SIEBER CC, 1993, GASTROENTEROLOGY, V104, P1750, DOI 10.1016/0016-5085(93)90655-V; SOGNI P, 1995, J HEPATOL, V23, P471, DOI 10.1016/0168-8278(95)80207-X; VALLANCE P, 1991, LANCET, V337, P776, DOI 10.1016/0140-6736(91)91384-7; VOROBIOFF J, 1984, GASTROENTEROLOGY, V87, P1120; Weigert AL, 1995, HEPATOLOGY, V22, P1856, DOI 10.1002/hep.1840220635; WONG F, 1994, HEPATOLOGY, V19, P312; WOOD LJ, 1988, HEPATOLOGY, V8, P831, DOI 10.1002/hep.1840080422	73	283	292	0	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 20	1998	339	8					533	541		10.1056/NEJM199808203390807	http://dx.doi.org/10.1056/NEJM199808203390807			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	111PN	9709047				2022-12-28	WOS:000075447000007
J	Bruner, AB; Fishman, M				Bruner, AB; Fishman, M			Adolescents and illicit drug use	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									Johns Hopkins Univ, Sch Med, Dept Pediat, Baltimore, MD 21287 USA; Johns Hopkins Univ, Sch Med, Dept Psychiat & Behav Sci, Baltimore, MD 21287 USA; Mt Manor Treatment Ctr, Baltimore, MD USA	Johns Hopkins University; Johns Hopkins University	Bruner, AB (corresponding author), Johns Hopkins Univ, Sch Med, Dept Pediat, 600 N Wolfe St,Pk 307, Baltimore, MD 21287 USA.	abruner@welclink.welch.jhu.edu						Brown SA, 1994, APPLIED PREVENTIVE P, V3, P61, DOI [10.1016/S0962-1849(05)80139-8, DOI 10.1016/S0962-1849(05)80139-8]; DAVIS P, 1997, WASHINGTON POST 1214; Elster AB., AMA GUIDELINES ADOLE; Fishman MJ, 1998, J ADDICT DIS, V17, P145; GILLMAN TJ, 1998, DALLAS MORNING 0527; Hicks, 1993, Adolesc Med, V4, P453; Kokotailo P, 1995, NIDA Res Monogr, V156, P112; *NAT CTR ADD SUBST, NAT SURV AM ATT SUBS, V2; *NAT CTR ADD SUBST, AD COMM REP AD ALC T; *NAT CTR ADD SUBST, 1997 BACK SCH SURV; *NEWS INF SERV U M, MON FUT STUD; *OFF NAT DRUG CONT, PULS CHECK SUMM 1998; *OFF NAT DRUG CONT, 1997, NAT DRUG CONTR STRAT; *OFF NAT DRUG CONT, 1998, NAT DRUG CONTR STRAT; Pope HG, 1996, JAMA-J AM MED ASSOC, V275, P521, DOI 10.1001/jama.275.7.521; Robins L N, 1985, NIDA Res Monogr, V56, P178; *SUBST AB MENT HLT, PREL RES 1996 NAT HO	17	24	24	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 19	1998	280	7					597	598		10.1001/jama.280.7.597	http://dx.doi.org/10.1001/jama.280.7.597			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	110ME	9718040				2022-12-28	WOS:000075384300011
J	Altman, DG; Bland, JM				Altman, DG; Bland, JM			Statistics notes - Time to event (survival) data	BRITISH MEDICAL JOURNAL			English	Article							HANDEDNESS; MORTALITY		Inst Hlth Sci, Ctr Stat Med, ICRF, Med Stat Grp, Oxford OX3 7LF, England; St George Hosp, Sch Med, Dept Publ Hlth Sci, London SW17 0RE, England	University of Oxford; St Georges University London	Altman, DG (corresponding author), Inst Hlth Sci, Ctr Stat Med, ICRF, Med Stat Grp, Oxford OX3 7LF, England.							ABRAHAMSSON PA, 1996, J UROLOGY, V155, P296; AGGLETON JP, 1994, BRIT MED J, V309, P1681, DOI 10.1136/bmj.309.6970.1681; AUS G, 1995, J UROLOGY, V154, P460, DOI 10.1016/S0022-5347(01)67074-5; CERHAN JR, 1994, AM J EPIDEMIOL, V140, P368, DOI 10.1093/oxfordjournals.aje.a117259; HALPERN DF, 1991, NEW ENGL J MED, V324, P998; KIRK AP, 1980, GUT, V21, P78, DOI 10.1136/gut.21.1.78; MACMANUS I, 1997, BRIT MED J, V314, P1132	7	108	110	1	16	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 15	1998	317	7156					468	469						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	112JF	9703534				2022-12-28	WOS:000075490200029
J	Grattan, LM; Oldach, D; Perl, TM; Lowitt, MH; Matuszak, DL; Dickson, C; Parrott, C; Shoemaker, RC; Kauffman, CL; Wasserman, MP; Hebel, JR; Charache, P; Morris, JG				Grattan, LM; Oldach, D; Perl, TM; Lowitt, MH; Matuszak, DL; Dickson, C; Parrott, C; Shoemaker, RC; Kauffman, CL; Wasserman, MP; Hebel, JR; Charache, P; Morris, JG			Learning and memory difficulties after environmental exposure to waterways containing toxin-producing Pfiesteria or Pfiesteria-like dinoflagellates	LANCET			English	Article							DOMOIC ACID INTOXICATION; ATTENTION; MUSSELS	Background At the beginning of autumn, 1996, fish with "punched-out" skin lesions and erratic behaviour associated with exposure to toxins produced by Pfiesteria piscicida or Pfiesteria-like dinoflagellate species were seen in the Pocomoke River and adjacent waterways on the eastern shore of the Chesapeake Bay in Maryland, USA. In August, 1997, fish kills associated with Pfiesteria occurred in these same areas. People who had had contact with affected waterways reported symptoms, including memory difficulties, which raises questions ia about the human-health impact of environmental exposure to Pfiesteria toxins. Methods We assessed 24 people who had been exposed. We collected data on exposure history and symptoms, did a complete medical and laboratory assessment (13 people), and carried out a neuropsychological screening battery. Performance on neuropsychological measures was compared with a matched control group. Results People with high exposure were significantly more likely than occupationally matched controls to complain of neuropsychological symptoms (including new or increased forgetfulness); headache; and skin lesions or a burning sensation of shin on contact with water. No consistent physical or laboratory abnormalities were found. However, exposed people had significantly reduced scores on the Rey Auditory Verbal Learning and Stroop Color-Word tests (indicative of difficulties with learning and higher cognitive function), and the Grooved Pegboard task. There was a dose-response effect with the lowest scores among people with the highest exposure. By 3-6 months after cessation of exposure, all those assessed had test scores that had returned to within normal ranges. Interpretation People with environmental exposure to waterways in which Pfiesteria toxins are present are at risk of developing a reversible clinical syndrome characterised by difficulties with learning and higher cognitive functions. Risk of illness is directly related to degree of exposure, with the most prominent symptoms and signs occurring among people with chronic daily exposure to affected waterways.	Univ Maryland, Sch Med, Dept Med, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Dept Neurol, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Dept Dermatol, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Dept Pathol, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Dept Epidemiol & Prevent Med, Baltimore, MD 21201 USA; Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA; Johns Hopkins Sch Hyg, Baltimore, MD USA; Maryland Dept Hlth & Mental Hyg, Baltimore, MD USA; Somerset Cty Hlth Dept, Westover, MD USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; Johns Hopkins University; Johns Hopkins University; Maryland Department of Health & Mental Hygiene	Morris, JG (corresponding author), Univ Maryland, Sch Med, Dept Med, Rm 934,10 S Pine St, Baltimore, MD 21201 USA.	jmorris@umppal.ab.umd.edu						BARONA A, 1984, J CONSULT CLIN PSYCH, V52, P885, DOI 10.1037/0022-006X.52.5.885; BURKHOLDER JM, 1992, NATURE, V358, P407, DOI 10.1038/358407a0; CENDES F, 1995, ANN NEUROL, V37, P123, DOI 10.1002/ana.410370125; Craik FIM, 1996, J EXP PSYCHOL GEN, V125, P159, DOI 10.1037/0096-3445.125.2.159; DAVIES ADM, 1968, J CLIN PSYCHOL, V24, P98; GLASGOW HB, 1995, J TOXICOL ENV HEALTH, V46, P501, DOI 10.1080/15287399509532051; Golden C.J., 1978, STROOP COLOR WORD TE; Greenberg D R, 1998, Md Med J, V47, P133; Heaton RK, 1986, NEUROPSYCHOLOGICAL A; LEITER R, 1972, LEITER ADULT INTELLI; LEVIN ED, 1997, ENV HLTH PERSPEC, V105, P2; Lezak M.D., 2012, NEUROPSYCHOLOGICAL A; Lowitt M H, 1998, Md Med J, V47, P124; MORRIS JG, 1995, INFECT GASTROINTESTI, P251; MORROW LA, 1992, NEUROPSYCHOLOGIA, V30, P911, DOI 10.1016/0028-3932(92)90035-K; NOGA EJ, 1993, VET REC, V133, P96, DOI 10.1136/vr.133.4.96; PERL TM, 1990, NEW ENGL J MED, V322, P1775, DOI 10.1056/NEJM199006213222504; REITAN R, 1992, MAKING TEST MANUAL A; Rey A, 1964, LEXAMEN CLINIQUE PSY; Rogers R., 1997, CLIN ASSESSMENT MALI; SAKOMOTO Y, 1987, SO MED J, V80, P866; Schmidt M., 1996, W PSYCHOL SERVICES; SELNES OA, 1991, PERCEPT MOTOR SKILL, V73, P539, DOI 10.2466/PMS.73.5.539-550; STOLLERY B, 1988, FLINDT J WORK ENV HL, V14, P45; TEITELBAUM JS, 1990, NEW ENGL J MED, V322, P1781, DOI 10.1056/NEJM199006213222505; War Department, 1944, ARM IND TEST BATT MA	26	119	122	0	10	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 15	1998	352	9127					532	539		10.1016/S0140-6736(98)02132-1	http://dx.doi.org/10.1016/S0140-6736(98)02132-1			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	111KC	9716058	hybrid			2022-12-28	WOS:000075435300012
J	Nadelman, RB; Wormser, GP				Nadelman, RB; Wormser, GP			Lyme borreliosis	LANCET			English	Article							ERYTHEMA CHRONICUM MIGRANS; CLINICAL MANIFESTATIONS; CONTROLLED TRIAL; DISEASE; BURGDORFERI; NEUROBORRELIOSIS; ARTHRITIS; SERODIAGNOSIS; FAILURE; COMPLICATIONS	Lyme borreliosis (Lyme disease) is often said to be associated with "protean" manifestations, a reference to the ancient god Proteus, who could assume many forms and thus elude his pursuers. This legendary quality has clouded out understanding of Lyme borreliosis by giving Borrelia burgdorferi Infection a mythical aura of its own. This review shows that this illness, while incompletely understood, is far more palpable than Proteus and is (in most cases) much more readily subdued. The clinical presentations of Lyme borreliosis do differ in North America and Eurasia, possibly due to the differing pathogenicity of distinct genospecies of Borrelia burgdorferi The most common manifestation, however, in both continents is erythema migrans. Diagnosis should rest on a careful history and objective clinical findings, supported by appropriately chosen laboratory tests. Reports of coinfection with other tickborne diseases should prompt a fresh look at Lyme borrellosis. Assertions about "protean manifestations" of B burgdorferi Infection should be reappraised. Advances in laboratory techniques are welcome but culture remains the gold standard for the diagnosis-and no laboratory test result should substitute for careful clinical observation and critical analysis.	New York Med Coll, Dept Med, Div Infect Dis, Valhalla, NY 10595 USA; Westchester Cty Med Ctr, Div Infect Dis, Lyme Dis Diagnost Ctr, Valhalla, NY 10595 USA	New York Medical College; Westchester Medical Center	Nadelman, RB (corresponding author), Westchester Cty Med Ctr, Div Infect Dis, Lyme Dis Diagnost Ctr, Macy Pavil 209SE, Valhalla, NY 10595 USA.				NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR043135] Funding Source: NIH RePORTER; NIAMS NIH HHS [R01-AR43135] Funding Source: Medline; PHS HHS [U50/CCU 210286, U50/CCU 210280] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AGUEROROSENFELD ME, 1993, J CLIN MICROBIOL, V31, P3090, DOI 10.1128/JCM.31.12.3090-3095.1993; AI CX, 1990, INT J EPIDEMIOL, V19, P1061, DOI 10.1093/ije/19.4.1061; ASBRINK E, 1986, ZBL BAKT-INT J MED M, V263, P229; BALMELLI T, 1995, RES MICROBIOL, V146, P329, DOI 10.1016/0923-2508(96)81056-4; BARANTON G, 1992, INT J SYST BACTERIOL, V42, P378, DOI 10.1099/00207713-42-3-378; BARBOUR AG, 1993, SCIENCE, V260, P1610, DOI 10.1126/science.8503006; BENACH JL, 1983, NEW ENGL J MED, V308, P740, DOI 10.1056/NEJM198303313081302; BERGER BW, 1989, REV INFECT DIS, V11, pS1475; BERGER BW, 1992, J AM ACAD DERMATOL, V27, P34, DOI 10.1016/0190-9622(92)70152-6; BERGLUND J, 1995, NEW ENGL J MED, V333, P1319, DOI 10.1056/NEJM199511163332004; CLARK JR, 1985, LARYNGOSCOPE, V95, P1341; Dattwyler RJ, 1997, NEW ENGL J MED, V337, P289, DOI 10.1056/NEJM199707313370501; DATTWYLER RJ, 1996, P 7 INT C LYM BORR S, P662; DENNIS DT, 1995, DERMATOL CLIN, V13, P537, DOI 10.1016/S0733-8635(18)30060-3; deSilva AM, 1997, J CLIN INVEST, V99, P377, DOI 10.1172/JCI119169; ENGSTROM SM, 1995, J CLIN MICROBIOL, V33, P419, DOI 10.1128/JCM.33.2.419-427.1995; ETTESTAD PJ, 1995, J INFECT DIS, V171, P356, DOI 10.1093/infdis/171.2.356; FEDER HM, 1992, CLIN INFECT DIS, V15, P788, DOI 10.1093/clind/15.5.788; FISH D, 1995, AM J MED, V98, pS2, DOI 10.1016/S0002-9343(99)80038-2; Fraser CM, 1997, NATURE, V390, P580, DOI 10.1038/37551; GARCIAMONCO JC, 1995, ANN NEUROL, V37, P691, DOI 10.1002/ana.410370602; GARCIAMONCO JC, 1993, LYME DIS, P219; Gerber MA, 1996, NEW ENGL J MED, V335, P1270, DOI 10.1056/NEJM199610243351703; Gern L., 1993, P59; GOLDBLATT D, 1997, SEMIN NEUROL, V17, P1; Gross DM, 1998, SCIENCE, V281, P703, DOI 10.1126/science.281.5377.703; HALPERIN J, 1990, BRAIN, V113, P1207, DOI 10.1093/brain/113.4.1207; HALPERIN JJ, 1991, NEUROLOGY, V41, P1571, DOI 10.1212/WNL.41.10.1571; Halperin JJ, 1996, NEUROLOGY, V46, P619, DOI 10.1212/WNL.46.3.619; HANSEN K, 1992, BRAIN, V115, P399, DOI 10.1093/brain/115.2.399; HOVMARK A, 1986, ZBL BAKT-INT J MED M, V263, P275; KARLSSON M, 1994, NEUROLOGY, V44, P1203, DOI 10.1212/WNL.44.7.1203; Kirkland KB, 1997, ARCH INTERN MED, V157, P2635, DOI 10.1001/archinte.157.22.2635; KORENBERG EI, 1993, EUR J EPIDEMIOL, V9, P86, DOI 10.1007/BF00463095; Krause PJ, 1996, JAMA-J AM MED ASSOC, V275, P1657, DOI 10.1001/jama.275.21.1657; KRUGER H, 1990, ACTA NEUROL SCAND, V82, P59; Kurtenbach K, 1998, INFECT IMMUN, V66, P1248, DOI 10.1128/IAI.66.3.1248-1251.1998; Linde M. R. van der, 1993, Aspects of Lyme borreliosis., P131; LOGIGIAN EL, 1990, NEW ENGL J MED, V323, P1438, DOI 10.1056/NEJM199011223232102; Luft BJ, 1996, ANN INTERN MED, V124, P785, DOI 10.7326/0003-4819-124-9-199605010-00002; Maraspin V, 1996, CLIN INFECT DIS, V22, P788, DOI 10.1093/clinids/22.5.788; MASSAROTTI EM, 1992, AM J MED, V92, P396, DOI 10.1016/0002-9343(92)90270-L; MATUSCHKA FR, 1992, PARASITOL RES, V78, P695, DOI 10.1007/BF00931523; MIRALLES D, 1992, AM J MED, V93, P352, DOI 10.1016/0002-9343(92)90248-A; Nadelman RB, 1997, MT SINAI J MED, V64, P409; Nadelman RB, 1997, NEW ENGL J MED, V337, P27, DOI 10.1056/NEJM199707033370105; NADELMAN RB, 1993, AM J MED, V94, P583, DOI 10.1016/0002-9343(93)90208-7; Nadelman RB, 1996, AM J MED, V100, P502, DOI 10.1016/S0002-9343(95)99915-9; NADELMAN RB, 1992, ANN INTERN MED, V117, P273, DOI 10.7326/0003-4819-117-4-273; NOCTON JJ, 1994, NEW ENGL J MED, V330, P229, DOI 10.1056/NEJM199401273300401; Ohlenbush A, 1996, J INFECT DIS, V174, P421, DOI 10.1093/infdis/174.2.421; Picken RN, 1997, J INVEST DERMATOL, V108, P92, DOI 10.1111/1523-1747.ep12285646; PLORER A, 1993, J INVEST DERMATOL, V100, P103, DOI 10.1111/1523-1747.ep12462773; PREACMURSIC V, 1989, INFECTION, V17, P355, DOI 10.1007/BF01645543; RAHN DW, 1998, LYME DIS; Ras NM, 1997, INT J SYST BACTERIOL, V47, P1112, DOI 10.1099/00207713-47-4-1112; Reik L, 1991, LYME DIS NERVOUS SYS; RUBIN DA, 1992, PACE, V15, P252, DOI 10.1111/j.1540-8159.1992.tb06492.x; Sangha O, 1998, ANN INTERN MED, V128, P346, DOI 10.7326/0003-4819-128-5-199803010-00002; SCHWAN TG, 1995, P NATL ACAD SCI USA, V92, P2909, DOI 10.1073/pnas.92.7.2909; Seltzer Elyse G., 1997, Clinical Infectious Diseases, V25, P361; SHAPIRO ED, 1992, NEW ENGL J MED, V327, P1769, DOI 10.1056/NEJM199212173272501; Sigal LH, 1998, NEW ENGL J MED, V339, P216, DOI 10.1056/NEJM199807233390402; SIGAL LH, 1990, AM J MED, V88, P577, DOI 10.1016/0002-9343(90)90520-N; SIGAL LH, 1995, AM J MED, V98, pS1, DOI 10.1016/S0002-9343(99)80037-0; Silver HM, 1997, INFECT DIS CLIN N AM, V11, P93, DOI 10.1016/S0891-5520(05)70343-3; SONNESYN SW, 1995, AM J CARDIOL, V76, P97, DOI 10.1016/S0002-9149(99)80814-5; Stanek G, 1996, WIEN KLIN WOCHENSCHR, V108, P741; STANEK G, 1990, NEW ENGL J MED, V322, P249, DOI 10.1056/NEJM199001253220407; *STAT CONN DEP PUB, 1993, CONN EPIDEMIOL, V13, P9; STEERE AC, 1990, NEW ENGL J MED, V323, P219, DOI 10.1056/NEJM199007263230402; STEERE AC, 1990, J INFECT DIS, V161, P1203, DOI 10.1093/infdis/161.6.1203; STEERE AC, 1993, JAMA-J AM MED ASSOC, V269, P1812, DOI 10.1001/jama.269.14.1812; STEERE AC, 1989, NEW ENGL J MED, V321, P586, DOI 10.1056/NEJM198908313210906; STEERE AC, 1977, ANN INTERN MED, V86, P685, DOI 10.7326/0003-4819-86-6-685; Steere AC, 1998, NEW ENGL J MED, V339, P209, DOI 10.1056/NEJM199807233390401; STEERE AC, 1994, ARTHRITIS RHEUM-US, V37, P878, DOI 10.1002/art.1780370616; STEERE AC, 1987, ANN INTERN MED, V107, P725, DOI 10.7326/0003-4819-107-5-725; STEERE AC, 1983, ANN INTERN MED, V99, P66; STEERE AC, 1980, ANN INTERN MED, V110, P339; Strle F, 1996, INFECTION, V24, P80, DOI 10.1007/BF01780665; Strle F, 1996, CLIN INFECT DIS, V23, P61, DOI 10.1093/clinids/23.1.61; STRLE F, UNPUB COMP CULTURE C; Telford SR, 1997, EMERG INFECT DIS, V3, P165, DOI 10.3201/eid0302.970209; Tugwell P, 1997, ANN INTERN MED, V127, P1109, DOI 10.7326/0003-4819-127-12-199712150-00011; VANDAM AP, 1993, CLIN INFECT DIS, V17, P708, DOI 10.1093/clinids/17.4.708; Warshafsky S, 1996, J GEN INTERN MED, V11, P329, DOI 10.1007/BF02600042; WEBER K, 1990, INFECTION, V18, P91, DOI 10.1007/BF01641422; Weber K, 1993, ASPECTS LYME BORRELI; Weber R, 1998, CLIN INFECT DIS, V26, P253, DOI 10.1086/517052; WILSKE B, 1986, J INFECT DIS, V153, P304, DOI 10.1093/infdis/153.2.304; WILSKE B, 1993, MED MICROBIOL IMMUN, V182, P255, DOI 10.1007/BF00579624; Wormser GP, 1998, J CLIN MICROBIOL, V36, P296, DOI 10.1128/JCM.36.1.296-298.1998; WORMSER GP, 1995, CLIN INFECT DIS, V21, P1267, DOI 10.1093/clinids/21.5.1267; Wormser GP, 1996, LANCET, V347, P981, DOI 10.1016/S0140-6736(96)91475-0; Wormser GP, 1997, SEMIN NEUROL, V17, P45, DOI 10.1055/s-2008-1040912; 1995, MMWR, V44, P590; 1997, MMWR S, V46, P20	98	262	271	0	17	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 15	1998	352	9127					557	565		10.1016/S0140-6736(98)01146-5	http://dx.doi.org/10.1016/S0140-6736(98)01146-5			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	111KC	9716075				2022-12-28	WOS:000075435300043
J	Polanczyk, CA; Goldman, L; Marcantonio, ER; Orav, EJ; Lee, TH				Polanczyk, CA; Goldman, L; Marcantonio, ER; Orav, EJ; Lee, TH			Supraventricular arrhythmia in patients having noncardiac surgery: Clinical correlates and effect on length of stay	ANNALS OF INTERNAL MEDICINE			English	Article						tachycardia, supraventricular; arrhythmia; length of stay; surgical procedures, operative; risk factors	CORONARY-ARTERY BYPASS; ATRIAL-FIBRILLATION; CARDIAC-ARRHYTHMIAS; RISK-FACTORS; COMPLICATIONS; PNEUMONECTOMY; THORACOTOMY	Background: Few recent data are available on risk factors for perioperative supraventricular arrhythmia (SVA) after noncardiac surgery or on the effect of SVA on clinical outcomes. Objective: To determine the incidence, clinical correlates, and effect on length of stay of perioperative SVA in patients having major noncardiac surgery. Design: Prospective cohort study. Setting: Urban tertiary care teaching hospital. Participants: 4181 patients 50 years of age or older who had major, nonemergency, noncardiac procedures and were in sinus rhythm at the preoperative evaluation. Measurements: Preoperative clinical data, postoperative enzyme data, serial electrocardiograms, and clinical outcomes were collected prospectively. Outcomes were 1) SVA that persisted or led to treatment and 2) increase in length of stay attributable to SVA. Results: Perioperative SVA occurred in 317 patients (7.6%); it occurred in 83 patients (2.0%) during surgery and in 256 (6.1 %) after surgery. Independent preoperative correlates of SVA were male sex (odds ratio [OR], 1.3 [95% CI, 1.0 to 1.7]), age 70 years or older (OR, 1.3 [CI, 1.0 to 1.7]), significant valvular disease (OR, 2.1 [CI, 1.2 to 3.6]), history of SVA (OR, 3.4 [CI, 2.4 to 4.8]) or asthma (OR, 2.0 [CI, 1.3 to 3.1]), congestive heart failure (OR, 1.7 [CI, 1.1 to 2.7]), premature atrial complexes on preoperative electrocardiography (OR, 2.1 [CI, 1.3 to 3.4]), American Society of Anesthesiologists class III or IV (OR, 1.4 [CI, 1.1 to 1.9]), and type of procedure: abdominal aortic aneurysm (OR, 3.9 [CI, 2.4 to 6.3]) or abdominal (OR, 2.5 [CI, 1.7 to 3.6]), vascular (OR, 1.6 [CI, 1.1 to 2.4]), and intrathoracic (OR, 9.2 [CI, 6.7 to 13]) procedures. Among patients who had intrathoracic surgery, those receiving digoxin were at lower risk (OR, 0.2 [CI, 0.04 to 0.8]) for SVA than those not receiving digoxin. Patients with perioperative acute cardiac and noncardiac events had high relative risks for SVA. Supraventricular arrhythmia was associated with a 33% increase in length of stay after adjustment for other clinical data (P < 0.001). Conclusions: In this cohort, SVA was common after noncardiac surgery and was associated with prolonged length of stay.	Brigham & Womens Hosp, Boston, MA 02115 USA; Univ Calif San Francisco, Sch Med, San Francisco, CA 94143 USA; Harvard Univ, Sch Med, Boston, MA USA	Harvard University; Brigham & Women's Hospital; University of California System; University of California San Francisco; Harvard University; Harvard Medical School	Lee, TH (corresponding author), Partners Community HealthCare Inc, Prudential Tower Suite 1159,800 Boylston St, Boston, MA 02199 USA.		Marcantonio, Edward R/U-3929-2017; Polanczyk, Carisi CAP/D-6208-2013	Marcantonio, Edward R/0000-0002-2911-4250; 	AHRQ HHS [R01-HS06573] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		CROSBY LH, 1990, AM J CARDIOL, V66, P1520, DOI 10.1016/0002-9149(90)90550-K; FROST L, 1992, INT J CARDIOL, V36, P253, DOI 10.1016/0167-5273(92)90293-C; FURBERG CD, 1994, AM J CARDIOL, V74, P236, DOI 10.1016/0002-9149(94)90363-8; GERSON MC, 1990, AM J MED, V88, P101, DOI 10.1016/0002-9343(90)90456-N; GOLD RL, 1985, J AM COLL CARDIOL, V6, P119, DOI 10.1016/S0735-1097(85)80262-X; GOLDMAN L, 1978, CHEST, V73, P450, DOI 10.1378/chest.73.4.450; GOLDMAN L, 1983, ANN INTERN MED, V98, P504, DOI 10.7326/0003-4819-98-4-504; HASHIMOTO K, 1991, J THORAC CARDIOV SUR, V101, P56; HILLIS LD, 1978, ARCH INTERN MED, V138, P972, DOI 10.1001/archinte.138.6.972; INCALZI RA, 1990, CHEST, V97, P1092, DOI 10.1378/chest.97.5.1092; Jakobsen CJ, 1997, J CARDIOTHOR VASC AN, V11, P746, DOI 10.1016/S1053-0770(97)90169-5; KROWKA MJ, 1987, CHEST, V91, P490, DOI 10.1378/chest.91.4.490; MICHELSON EL, 1979, AM HEART J, V97, P442, DOI 10.1016/0002-8703(79)90390-9; SHIELDS TW, 1968, SURG GYNECOL OBSTETR, V126, P743; SORENSEN O, 1986, ACTA ANAESTH SCAND, V30, P630, DOI 10.1111/j.1399-6576.1986.tb02489.x; Thomas EJ, 1997, AM J MED, V102, P277, DOI 10.1016/S0002-9343(96)00451-2; VONKNORRING J, 1992, ANN THORAC SURG, V53, P642, DOI 10.1016/0003-4975(92)90325-X; WAHI R, 1989, ANN THORAC SURG, V48, P33, DOI 10.1016/0003-4975(89)90172-0; WOHLGELERNTER D, 1984, CARDIOVASC MED, V9, P763; YOUSIF H, 1990, INT J CARDIOL, V26, P313, DOI 10.1016/0167-5273(90)90087-L	20	176	184	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 15	1998	129	4					279	+		10.7326/0003-4819-129-4-199808150-00003	http://dx.doi.org/10.7326/0003-4819-129-4-199808150-00003			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	109NP	9729180				2022-12-28	WOS:000075329100003
J	Wallace, MB; Kemp, JA; Trnka, YM; Donovan, JM; Farraye, FA				Wallace, MB; Kemp, JA; Trnka, YM; Donovan, JM; Farraye, FA			Is colonoscopy indicated for small adenomas found by screening flexible sigmoidoscopy?	ANNALS OF INTERNAL MEDICINE			English	Article						colonoscopy; adenomas; sigmoidoscopy; polyps; colorectal neoplasms	COLORECTAL-CANCER; RECTOSIGMOID ADENOMAS; COLON-CANCER; POLYPS; RISK; NEOPLASMS; DISTAL; MORTALITY; HISTORY; SIZE	Background: There is controversy over whether patients who have a small tubular adenoma on screening flexible sigmoidoscopy should undergo colonoscopic examination of the proximal colon. Objective: To prospectively determine the prevalence of advanced polyps in the proximal colon among patients who have small adenomas on screening sigmoidoscopy. Design: Prospective cohort study. Setting: A health maintenance organization and a Veterans Affairs medical center. Patients: Asymptomatic patients older than 50 years of age who had no risk factors for colon cancer and underwent sigmoidoscopy. Intervention: At the time of sigmoidoscopy, all polyps were biopsied and characterized. All patients with distal adenomas were offered colonoscopy. Measurements: The size and histology of polyps identified by sigmoidoscopy and colonoscopy were noted. Polyps were considered advanced if they were larger than 10 mm or were tubulovillous, villous, or malignant. The prevalence of advanced proximal polyps was determined, and patients were stratified by the size and number of distal polyps found by sigmoidoscopy. Results: Among 4490 patients who underwent sigmoidoscopy, a neoplastic lesion was detected in 401 (8.9%) and colonoscopy was done in 301 (75%). Of 90 patients with a single tubular adenoma 1 to 5 mm in diameter in the distal colon, 0% (95% CI, 0.0% to 4.0%) had an advanced proximal polyp compared with 5.4% (CI, 2.4% to 10.4%) of those who had multiple distal polyps 1 to 5 mm or 6 to 10 mm in diameter and 7.9% (CI, 2.6% to 17.6%) of those who had advanced distal polyps (P = 0.013 for trend). The low-risk group with a single tubular adenoma 1 to 5 mm in diameter represented 44% of all patients with distal adenomas or cancers found at flexible sigmoidoscopy. Conclusions: Among patients undergoing screening sigmoidoscopy, those with single tubular adenomas of 5 mm or less had a low prevalence of advanced proximal polyps. These patients may not benefit from colonoscopy.	Med Univ S Carolina, MPH, Div Gastroenterol, Charleston, SC 29425 USA; Brigham & Womens Hosp, Boston, MA 02115 USA; Harvard Pilgrim Hlth Care, Boston, MA USA; Brockton W Roxbury Vet Affairs Med Ctr, Boston, MA 02132 USA	Medical University of South Carolina; Harvard University; Brigham & Women's Hospital; Harvard Pilgrim Health Care; Harvard University	Wallace, MB (corresponding author), Med Univ S Carolina, MPH, Div Gastroenterol, 171 Ashley Ave, Charleston, SC 29425 USA.			Farraye, Francis/0000-0001-6371-2441				ATKIN WS, 1992, NEW ENGL J MED, V326, P658, DOI 10.1056/NEJM199203053261002; BOND JH, 1993, GASTROINTEST ENDOSC, V39, P592, DOI 10.1016/S0016-5107(93)70184-4; BOND JH, 1993, ANN INTERN MED, V119, P836, DOI 10.7326/0003-4819-119-8-199310150-00010; Byers T, 1997, CA-CANCER J CLIN, V47, P154, DOI 10.3322/canjclin.47.3.154; Casella G., 2021, STAT INFERENCE; DINNING JP, 1994, ARCH INTERN MED, V154, P853, DOI 10.1001/archinte.154.8.853; GROSSMAN S, 1989, GASTROENTEROLOGY, V96, P299, DOI 10.1016/0016-5085(89)91551-5; Hofstad B, 1996, GUT, V39, P449, DOI 10.1136/gut.39.3.449; Lemmel GT, 1996, GASTROINTEST ENDOSC, V44, P109, DOI 10.1016/S0016-5107(96)70125-6; MANDEL JS, 1993, NEW ENGL J MED, V328, P1365, DOI 10.1056/NEJM199305133281901; Morales TG, 1996, GASTROINTEST ENDOSC, V43, P25; Papatheodoridis GV, 1996, AM J GASTROENTEROL, V91, P1809; Read TE, 1997, NEW ENGL J MED, V336, P8, DOI 10.1056/NEJM199701023360102; REX DK, 1992, GASTROENTEROLOGY, V102, P317, DOI 10.1016/0016-5085(92)91817-N; SCHWARTZ E, 1995, GASTROINTEST ENDOSC, V42, P292, DOI 10.1016/S0016-5107(95)70124-9; SELBY JV, 1992, NEW ENGL J MED, V326, P653, DOI 10.1056/NEJM199203053261001; SPENCER RJ, 1984, MAYO CLIN PROC, V59, P305, DOI 10.1016/S0025-6196(12)61425-6; STRYKER SJ, 1987, GASTROENTEROLOGY, V93, P1009, DOI 10.1016/0016-5085(87)90563-4; TRIPP MR, 1987, CANCER, V60, P1599, DOI 10.1002/1097-0142(19871001)60:7<1599::AID-CNCR2820600730>3.0.CO;2-I; US Preventive Services Task Force, 1996, GUID CLIN PREV SERV, P18; WAYE JD, 1988, AM J GASTROENTEROL, V83, P120; Winawer SJ, 1997, GASTROENTEROLOGY, V112, P594, DOI 10.1053/gast.1997.v112.agast970594; WINAWER SJ, 1993, NEW ENGL J MED, V329, P1977, DOI 10.1056/NEJM199312303292701; ZARCHY TM, 1994, GASTROENTEROLOGY, V106, P1501, DOI 10.1016/0016-5085(94)90403-0	24	71	73	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 15	1998	129	4					273	+		10.7326/0003-4819-129-4-199808150-00002	http://dx.doi.org/10.7326/0003-4819-129-4-199808150-00002			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	109NP	9729179				2022-12-28	WOS:000075329100002
J	Choo, V				Choo, V			The line between research and audit	LANCET			English	Editorial Material									Lancet, London WC1B 3SL, England		Choo, V (corresponding author), Lancet, London WC1B 3SL, England.							Amdur RJ, 1997, JAMA-J AM MED ASSOC, V277, P909, DOI 10.1001/jama.277.11.909; Cuckle H, 1997, LANCET, V350, P1629, DOI 10.1016/S0140-6736(05)64047-0; Grudzinskas JG, 1997, LANCET, V350, P1630, DOI 10.1016/S0140-6736(05)64048-2; GRUDZINSKAS JG, 1997, SCREENING DOWN SYNDR; Neilson JP, 1997, LANCET, V350, P754, DOI 10.1016/S0140-6736(05)62562-7; Neilson JP, 1997, LANCET, V350, P1631, DOI 10.1016/S0140-6736(05)64051-2; Rennie D, 1997, JAMA-J AM MED ASSOC, V277, P922, DOI 10.1001/jama.277.11.922; Soothill P, 1997, LANCET, V350, P1629, DOI 10.1016/S0140-6736(05)64046-9; Venn-Treloar J, 1998, BRIT MED J, V316, P1027; Wald NJ, 1997, LANCET, V350, P1632, DOI 10.1016/S0140-6736(05)64052-4; *WORLD MED ASS DEC, 1997, JAMA-J AM MED ASSOC, V277, P925, DOI DOI 10.1001/JAMA.1997.03540350075038	11	16	16	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 1	1998	352	9125					337	338		10.1016/S0140-6736(05)60461-8	http://dx.doi.org/10.1016/S0140-6736(05)60461-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	106BU	9717915				2022-12-28	WOS:000075110500003
J	Tarnow-Mordi, WO				Tarnow-Mordi, WO			Room air or oxygen for asphyxiated babies?	LANCET			English	Editorial Material							RANDOMIZATION; TRIALS		Univ Dundee, Ninewells Hosp & Med Sch, Dept Child Hlth, Int Neonatal Network, Dundee DD1 9SY, Scotland	University of Dundee	Tarnow-Mordi, WO (corresponding author), Univ Dundee, Ninewells Hosp & Med Sch, Dept Child Hlth, Int Neonatal Network, Dundee DD1 9SY, Scotland.							ALEXANDER F, 1989, J EPIDEMIOL COMMUN H, V43, P29, DOI 10.1136/jech.43.1.29; American Heart Association Emergency Cardiac Care Committee and Subcommittees, 1992, J AMER MED ASSOC, V268, P2276, DOI [10.1001/jama.268.16.2276, DOI 10.1001/JAMA.268.16.2276]; Donner A, 1996, J CLIN EPIDEMIOL, V49, P435, DOI 10.1016/0895-4356(95)00511-0; GRANT A, 1989, LANCET, V2, P345; RAMJI S, 1993, PEDIATR RES, V34, P809, DOI 10.1203/00006450-199312000-00023; SAUGSTAD OD, 1990, ACTA PAEDIATR SCAND, V79, P881, DOI 10.1111/j.1651-2227.1990.tb11348.x; SAUGSTAD OD, 1975, PEDIATR RES, V9, P158, DOI 10.1203/00006450-197504000-00002; SAUGSTAD OD, 1996, PRENAT NEONAT MED, V1, P26; SAUGSTAD OD, 1998, PEDIATRICS, V102; SCHULZ KF, 1994, JAMA-J AM MED ASSOC, V272, P125, DOI 10.1001/jama.272.2.125; TarnowMordi W, 1997, BRIT J OBSTET GYNAEC, V104, P763, DOI 10.1111/j.1471-0528.1997.tb12015.x	11	8	8	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	AUG 1	1998	352	9125					341	342		10.1016/S0140-6736(05)60464-3	http://dx.doi.org/10.1016/S0140-6736(05)60464-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	106BU	9717918				2022-12-28	WOS:000075110500006
J	Farmer, P; Kim, JY				Farmer, P; Kim, JY			Community based approaches to the control of multidrug resistant tuberculosis: introducing "DOTS-plus"	BRITISH MEDICAL JOURNAL			English	Article							NEW-YORK-CITY; MYCOBACTERIUM-TUBERCULOSIS; PULMONARY TUBERCULOSIS; TRANSMISSION; HOMELESS		Harvard Univ, Sch Med, Dept Social Med, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Farmer, P (corresponding author), Harvard Univ, Sch Med, Dept Social Med, 641 Huntington House, Boston, MA 02115 USA.	pefarmer@bics.bwh.harvard.edu						ABDERRAHIM K, 1976, Bulletin of the International Union Against Tuberculosis, V51, P359; Barnes PF, 1996, JAMA-J AM MED ASSOC, V275, P305, DOI 10.1001/jama.275.4.305; BECKSAGUE C, 1992, JAMA-J AM MED ASSOC, V268, P1280, DOI 10.1001/jama.268.10.1280; Bifani PJ, 1996, JAMA-J AM MED ASSOC, V275, P452, DOI 10.1001/jama.275.6.452; Blower SM, 1996, SCIENCE, V273, P497, DOI 10.1126/science.273.5274.497; Crofton J., 1997, GUIDELINES MANAGEMEN; Farmer P, 1991, SEMIN RESP INFECT, V6, P373; FARMER PE, IN PRESS INT J TUBER; FARMER PE, 1997, C GLOB LUNG HLTH 199; FRIEDEN TR, 1995, NEW ENGL J MED, V333, P229, DOI 10.1056/NEJM199507273330406; Garrett Laurie, 1998, NEWSDAY         0325, pA21; GOBLE M, 1993, NEW ENGL J MED, V328, P527, DOI 10.1056/NEJM199302253280802; Kim SJ, 1997, INT J TUBERC LUNG D, V1, P302; KOCHI A, 1993, RES MICROBIOL, V144, P104, DOI 10.1016/0923-2508(93)90023-U; Kritski AL, 1996, AM J RESP CRIT CARE, V153, P331, DOI 10.1164/ajrccm.153.1.8542139; NARDELL E, 1986, NEW ENGL J MED, V315, P1570, DOI 10.1056/NEJM198612183152502; PABLOSMENDEZ A, 1990, NEW YORK STATE J MED, V90, P351; Rullan JV, 1996, EMERG INFECT DIS, V2, P125, DOI 10.3201/eid0202.960208; TAYLER E, 1994, LANCET, V343, P968, DOI 10.1016/S0140-6736(94)90082-5; TURETT GS, 1995, CLIN INFECT DIS, V21, P1238, DOI 10.1093/clinids/21.5.1238; *US CDCP, 1998, MMWR-MORBID MORTAL W, V47, P371; VALWAY SE, 1994, J INFECT DIS, V170, P151, DOI 10.1093/infdis/170.1.151; *WHO, 1997, WHO REP TUB EP; *WHO, 1997, ANT DRUG RES WORLD W; ZHANG LX, 1995, TUBERCLE LUNG DIS, V76, P100, DOI 10.1016/0962-8479(95)90549-9	25	193	204	0	13	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	SEP 5	1998	317	7159					671	674		10.1136/bmj.317.7159.671	http://dx.doi.org/10.1136/bmj.317.7159.671			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	118GN	9728004	Green Published			2022-12-28	WOS:000075830200034
J	Cooper, RA; Laud, P; Dietrich, CL				Cooper, RA; Laud, P; Dietrich, CL			Current and projected workforce of nonphysician clinicians	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PHYSICIAN WORKFORCE; NURSE PRACTITIONERS; ASSISTANTS; REFORM; REQUIREMENTS; EDUCATION; RESIDENTS	Nonphysician clinicians (NPCs) are becoming increasingly prominent as health care providers. This study examines 10 such disciplines: nurse practitioners (NPs), physician assistants (PAs), nurse-midwives, chiropractors, acupuncturists, naturopaths, optometrists, podiatrists, nurse anesthetists, and clinical nurse specialists. The aggregate number of NPCs graduating annually in these 10 disciplines doubled between 1992 and 1997, and a further increment of 20% is projected for 2001. Assuming that enrollments remain at the levels attained in 2001, NPC supply will grow from 228 000 in 1995 to 384 000 in 2005, and it will continue to expand at a similar rate thereafter. The greatest growth is projected among those NPCs who provide primary care services. Moreover, the greatest concentrations of both practicing NPCs and NPC training programs are in those states that already have the greatest abundance of physicians. On a per capita basis, the projected growth in NPC supply between 1995 and 2005 will be double that of physicians. Because of the existing training pipeline, it is probable that most of the growth projected for 2005 will occur. The further expansion of both NPC and physician supply thereafter warrants careful reconsideration.	Med Coll Wisconsin, Hlth Policy Inst, Milwaukee, WI 53226 USA	Medical College of Wisconsin	Cooper, RA (corresponding author), Med Coll Wisconsin, Hlth Policy Inst, 8701 Watertown Plank Rd, Milwaukee, WI 53226 USA.	rcooper@mcw.edu						AIKEN LH, 1994, INQUIRY-J HEALTH CAR, V31, P318; *ALL STAT LIC DIV, 1997, STAT NAT LIC SUMM; *AM AC PHYS ASS, 1997, 1996 1997 AAPA PHYS; *AM AC PHYS ASS, 1997, INF UPD PROJ NUMB PH; *AM ASS AC OR MED, 1995, FACT SHEET 1; *AM ASS COLL NURS, 1995, ROL DIFF NURS PRACT; *AM ASS COLL POD M, 1996, SUMM POD MED ENR GRA; *AM ASS NURS AN, 1996, 1996 MEMB SURV STAT; *AM CHIR ASS, 1994, CHIR STAT ART; *AM CHIR ASS, 1994, 1994 ANN PHYS SURV S; *AM NURS CRED CTR, 1996, PRACT AR CERT NURS S; *AM POD MED ASS, 1997, POD MED; *ASS SCH COLL OPT, 1996, 1989 1996 ANN SURV O; BERLIN LE, 1998, ENROLLMENT GRADUATIO; BRENNAN T, 1996, REGULATION MARKETS Q; Buppert C K, 1995, Nurse Pract, V20, P43; *BUR HLTH PROF DIV, 1994, SURV CERT NURS PRACT; *BUR LAB STAT, 1998, 1998 1999 OCC OUTL H; CAWLEY JF, 1997, J AM ACAD PHYS ASSIS, V10, P80; CAWLEY JF, 1993, GENERAL INTERNIST WH, P117; COHEN JJ, 1994, JAMA-J AM MED ASSOC, V272, P712, DOI 10.1001/jama.272.9.712; COOPER RA, 1994, JAMA-J AM MED ASSOC, V272, P680, DOI 10.1001/jama.272.9.680; Cooper RA, 1996, HEALTH AFFAIR, V15, P226, DOI 10.1377/hlthaff.15.3.226; COOPER RA, 1995, JAMA-J AM MED ASSOC, V274, P1534, DOI 10.1001/jama.274.19.1534; Cooper RA, 1998, JAMA-J AM MED ASSOC, V280, P795, DOI 10.1001/jama.280.9.795; *COUNC GRAD MED ED, 1994, REC IMPR ACC HLTH CA; *COUNC STAT GOV, 1994, BOOK STAT 1994 1995, V30; DIAL TH, 1995, HEALTH AFFAIR, V14, P168, DOI 10.1377/hlthaff.14.2.168; Ellis GL, 1997, AM J EMERG MED, V15, P229, DOI 10.1016/S0735-6757(97)90002-4; ERGIL KV, 1997, NIH CONS DEV C AC BE, P31; *FED CHIR LIC BOAR, 1997, OFF DIR CHIR LIC PRA; GONZALEZ ML, 1997, PHYSICIAN MARKETPLAC; GREEN BA, 1995, HEALTH AFFAIR, V14, P192, DOI 10.1377/hlthaff.14.2.192; HOOKER RS, 1997, J AM ACAD PHYS ASSIS, V10, P81; HOOKER RS, 1997, PHYSICIAN ASSISTANTS; JONES PE, 1994, JAMA-J AM MED ASSOC, V271, P1266, DOI 10.1001/jama.271.16.1266; Lohr KN, 1996, JAMA-J AM MED ASSOC, V275, P748; LOMAS J, 1985, CAN J PUBLIC HEALTH, V76, P119; Mason DJ, 1997, NURS ECON, V15, P306; MEZIBOV D, 1997, SCH PRODUCE PRIMARY; MITCHELL B, 1994, STATE ACUPUNCTURE LA; MITCHELL BB, 1997, ACUPUNCTURE ORIENTAL; MOSES EB, 1997, REG NURS POP FIND NA; MOSES EB, 1992, REG NURS POP FIND NA; *NAT ADV COUNC NUR, 1994, REP SECR HLTH HUM SE; *NAT COUNC STAT BO, 1996, 1995 1996 SUMM STAT; *NAT LEAG NURS, 1997, NURS DAT SOURC 1994, V2; *NAT ORG NURS PRAC, 1996, WORKF POL PROJ TECHN; OLIVER DR, 1993, 9 ASS PHYS ASS PROGR; OSTERWEIS M, 1996, US HLTH WORKFORCE PO; OSTERWEIS M, 1993, ROLES PHYSICIAN ASSI; Pan S, 1997, Nurse Pract, V22, P16; *PEW HLTH PROF COM, 1995, STAT HLTH PERS HDB D; RIPORTELLAMULLER R, 1995, HEALTH AFFAIR, V14, P181, DOI 10.1377/hlthaff.14.2.181; SAFRIET BJ, 1994, INQUIRY-J HEALTH CAR, V31, P310; SEKSCENSKI ES, 1994, NEW ENGL J MED, V331, P1266, DOI 10.1056/NEJM199411103311905; SIMON AF, 1996, 12 ASS PHYS ASS; SMITHPETERS L, 1994, DIRECTORY PROFESSION; Starr P, 1982, SOCIAL TRANSFORMATIO; *US DEP HHS, 1991, 8 US DEP HLTH HUM HU; WEINER JP, 1994, JAMA-J AM MED ASSOC, V272, P222; Wennberg J. E., 1996, DARTMOUTH ATLAS HLTH; 1997, GRADUATE PROGRAMS BU	63	148	148	0	8	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 2	1998	280	9					788	794		10.1001/jama.280.9.788	http://dx.doi.org/10.1001/jama.280.9.788			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	114LA	9729990				2022-12-28	WOS:000075609900007
J	Muscholl, MW; Hense, HW; Brockel, U; Doring, A; Riegger, GAJ; Schunkert, H				Muscholl, MW; Hense, HW; Brockel, U; Doring, A; Riegger, GAJ; Schunkert, H			Changes in left ventricular structure and function in patients with white coat hypertension: cross sectional survey	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ESTABLISHED HYPERTENSION; BLOOD-PRESSURE; DIASTOLIC FUNCTION; HYPERTROPHY; HEART; MASS; ECHOCARDIOGRAPHY	Objectives: To assess the relation between white coat hypertension and alterations of left ventricular structure and function. Design: Cross sectional survey. Setting: Augsburg, Germany. Subjects: 1677 subjects, aged 25 to 74 years, who participated in an echocardiographic substudy of the monitoring of trends and determinants in cardiovascular disease Augsburg study during 1994-5. Outcome measures: Blood pressure measurements and M mode, two dimensional, and Doppler echocardiography. After at least 30 minutes' rest blood pressure was measured three times by a technician, and once by a physician after echocardiography. Subjects were classified as normotensive (technician <140/90 min Hg, physician <160/95 mm Hg; n = 849), white coat hypertensive (technician < 140/90 mm Hg, physician greater than or equal to 160/95 mm Hg;, n = 160), mildly hypertensive (technician greater than or equal to 140/90 mm Hg, physician <160/95 mm Hg; n = 129), and sustained hypertensive (taking antihypertensive drugs or blood pressure measured by a technican greater than or equal to 140/90 mm Hg, and physician greater than or equal to 160/95 mm Hg; n = 538). Results: White coat hypertension was more common in men than women (10.9% versus 8.2%, respectively) and positively related to age and body mass index. After adjustment for these variables, white coat hypertension was associated with an increase in left ventricular mass and an increased prevalence of left ventricular hypertrophy (odds ratio 1.9, 95% confidence interval 1.2 to 3.2; P = 0.009) compared with normotensive patients. The increase in left ventricular mass was secondary to significantly increased septal and posterior wall thicknesses whereas end diastolic diameters were similar in both groups with white coat hypertension or normotension. Additionally, the systolic white coat effect (difference between blood pressures recorded by a technician and physician) was associated with increased left ventricular mass and increased prevalence of left ventricular hypertrophy (P < 0.05 each). Values for systolic left ventricular function (M mode fractional shortening) were above normal in subjects with white coat hypertension whereas diastolic filling and left atrial size Were similar to those in normotension. Conclusion: About 10% of the general population show exaggerated inotropic and blood pressure responses when mildly stressed. This is associated with an increased risk of left ventricular hypertrophy.	Univ Regensburg, Klin & Poliklin Innere Med 2, D-93042 Regensburg, Germany; Univ Munster, Inst Epidemiol & Sozial Med, D-4400 Munster, Germany; GSF Forschungszentrum Umwelt & Gesundheit, Inst Epidemiol, Munich, Germany	University of Regensburg; University of Munster; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health	Schunkert, H (corresponding author), Univ Regensburg, Klin & Poliklin Innere Med 2, D-93042 Regensburg, Germany.	heribert.schunkert@klinik.uni-regensburg.de						Bidlingmeyer I, 1996, J HYPERTENS, V14, P327, DOI 10.1097/00004872-199603000-00009; CARDILLO C, 1993, HYPERTENSION, V21, P836, DOI 10.1161/01.HYP.21.6.836; CAVALLINI MC, 1995, HYPERTENSION, V26, P413, DOI 10.1161/01.HYP.26.3.413; Cuspidi C, 1995, J HYPERTENS, V13, P1707; DEVEREUX RB, 1977, CIRCULATION, V55, P613, DOI 10.1161/01.CIR.55.4.613; Glen SK, 1996, LANCET, V348, P654, DOI 10.1016/S0140-6736(96)02303-3; GOSSE P, 1993, HYPERTENSION, V22, P766, DOI 10.1161/01.HYP.22.5.766; HAMMOND IW, 1988, J AM COLL CARDIOL, V12, P996, DOI 10.1016/0735-1097(88)90467-6; Hense HW, 1995, J HUM HYPERTENS, V9, P935; HIRAISHI S, 1983, AM J CARDIOL, V52, P1249, DOI 10.1016/0002-9149(83)90582-9; HOEGHOLM A, 1993, AM J HYPERTENS, V6, P282, DOI 10.1093/ajh/6.4.282; HOEGHOLM A, 1994, HYPERTENSION, V24, P101, DOI 10.1161/01.HYP.24.1.101; JULIUS S, 1990, HYPERTENSION, V16, P617, DOI 10.1161/01.HYP.16.6.617; KEIL U, 1988, ACTA MED SCAND, P119; KINGWELL BA, 1994, CLIN EXP PHARMACOL P, V21, P31, DOI 10.1111/j.1440-1681.1994.tb02433.x; KUWAJIMA I, 1993, HYPERTENSION, V22, P826, DOI 10.1161/01.HYP.22.6.826; LEVY D, 1987, AM J CARDIOL, V59, P956, DOI 10.1016/0002-9149(87)91133-7; LEVY D, 1990, NEW ENGL J MED, V323, P1706; LEVY D, 1988, ANN INTERN MED, V108, P7, DOI 10.7326/0003-4819-108-1-7; MANCIA G, 1987, HYPERTENSION, V9, P209, DOI 10.1161/01.HYP.9.2.209; Mancia G, 1996, J HYPERTENS, V14, P1049, DOI 10.1097/00004872-199609000-00001; MUSCHOLL M, 1990, HERZ, V15, P377; PERLOFF D, 1983, JAMA-J AM MED ASSOC, V229, P2892; SCHUNKERT H, 1994, NEW ENGL J MED, V330, P1634, DOI 10.1056/NEJM199406093302302; SCHUNKERT H, 1995, CIRC RES, V76, P489, DOI 10.1161/01.RES.76.3.489; SIEGEL WC, 1990, HYPERTENSION, V16, P140, DOI 10.1161/01.HYP.16.2.140; Soma J, 1996, J AM COLL CARDIOL, V28, P190, DOI 10.1016/0735-1097(96)00129-5; WALLERSON DC, 1990, EUR HEART J, V11, P67, DOI 10.1093/eurheartj/11.suppl_I.67; *WHO, 1983, PRIM PREV ESS HYP RE, P686; *WHO MONICA PROJ, 1989, INT J EPIDEMIOL, V18, pS29	30	74	76	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 29	1998	317	7158					565	570		10.1136/bmj.317.7158.565	http://dx.doi.org/10.1136/bmj.317.7158.565			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	117EK	9721112	Bronze, Green Published, Green Submitted			2022-12-28	WOS:000075767800016
J	Perrett, DI; Lee, KJ; Penton-Voak, I; Rowland, D; Yoshikawa, S; Burt, DM; Henzi, SP; Castles, DL; Akamatsu, S				Perrett, DI; Lee, KJ; Penton-Voak, I; Rowland, D; Yoshikawa, S; Burt, DM; Henzi, SP; Castles, DL; Akamatsu, S			Effects of sexual dimorphism on facial attractiveness	NATURE			English	Article							PHYSICAL ATTRACTIVENESS; EVOLUTIONARY PSYCHOLOGY; PERCEPTION; SELECTION; BEAUTY; SHAPE	Testosterone-dependent secondary sexual characteristics in males may signal immunological competence(1) and are sexually selected for in several species(2,3). In humans, oestrogen-dependent characteristics of the female body correlate with health and reproductive fitness and are found attractive(4-6). Enhancing the sexual dimorphism of human faces should raise am-activeness by enhancing sex-hormone-related cues to youth and fertility in females(5,7-11), and to dominance and immunocompetence in males(5,12,13). Here we report the results of asking subjects to choose the most attractive faces from continua that enhanced or diminished differences between the average shape of female and male faces. As predicted, subjects preferred feminized ta, average shapes of a female face. This preference applied across UK and Japanese populations but was stronger for within-population judgements, which indicates that attractiveness cues are learned. Subjects preferred feminized to average or masculinized shapes of a male face. Enhancing masculine facial characteristics increased both perceived dominance and negative attributions (for example, coldness or dishonesty) relevant to relationships and paternal investment. These results indicate a selection pressure that limits sexual dimorphism and encourages neoteny in humans.	Univ St Andrews, Sch Psychol, St Andrews KY16 9JU, Fife, Scotland; Kyoto Univ, Grad Sch Educ, Dept Cognit Psychol Educ, Kyoto 6068501, Japan; ATR, Human Informat Proc Res Labs, Kyoto 61902, Japan; Univ Natal, Dept Psychol, ZA-4001 Durban, South Africa	University of St Andrews; Kyoto University; University of Kwazulu Natal	Perrett, DI (corresponding author), Univ St Andrews, Sch Psychol, St Andrews KY16 9JU, Fife, Scotland.	dp@st-andrews.ac.uk	Burt, Michael/D-6684-2013	Burt, Michael/0000-0001-5627-6012; Penton-Voak, Ian/0000-0003-4232-0953; Perrett, David/0000-0002-6025-0939				ANDERSSON M, 1982, NATURE, V299, P818, DOI 10.1038/299818a0; Barber N, 1995, ETHOL SOCIOBIOL, V16, P395, DOI 10.1016/0162-3095(95)00068-2; BERRY DS, 1993, J PERS, V61, P497, DOI 10.1111/j.1467-6494.1993.tb00780.x; BOOTH A, 1993, SOC FORCES, V72, P463, DOI 10.2307/2579857; BUSSE W W, 1989, Drugs, V37, P1; CUNNINGHAM MR, 1990, J PERS SOC PSYCHOL, V59, P61, DOI 10.1037/0022-3514.59.1.61; CUNNINGHAM MR, 1995, J PERS SOC PSYCHOL, V68, P261, DOI 10.1037/0022-3514.68.2.261; CUNNINGHAM MR, 1986, J PERS SOC PSYCHOL, V50, P925, DOI 10.1037/0022-3514.50.5.925; DEUTSCH FM, 1986, J APPL SOC PSYCHOL, V16, P771; Gangestad SW, 1997, EVOL HUM BEHAV, V18, P69, DOI 10.1016/S1090-5138(97)00003-2; GRAMMER K, 1994, J COMP PSYCHOL, V108, P233, DOI 10.1037/0735-7036.108.3.233; JACKSON LA, 1992, PHYSICAL APPEARANCE; JOHNSTON VS, 1993, ETHOL SOCIOBIOL, V14, P183, DOI 10.1016/0162-3095(93)90005-3; JONES D, 1995, CURR ANTHROPOL, V36, P723, DOI 10.1086/204427; KIRKPATRICK M, 1991, NATURE, V350, P33, DOI 10.1038/350033a0; LANGLOIS JH, 1990, PSYCHOL SCI, V1, P115, DOI 10.1111/j.1467-9280.1990.tb00079.x; MANNING JT, 1997, EVOL HUM BEHAV, V18, P2223; MARTIN RD, 1990, NATURE, V293, P7; MOLLER AP, 1992, NATURE, V357, P238, DOI 10.1038/357238a0; PERRETT DI, 1994, NATURE, V368, P239, DOI 10.1038/368239a0; ROWLAND DA, 1995, IEEE COMPUT GRAPH, V15, P70, DOI 10.1109/38.403830; SINGH D, 1993, HUM NATURE-INT BIOS, V4, P297, DOI 10.1007/BF02692203; Symons D, 1979, EVOLUTION HUMAN SEXU; Thornhill Randy, 1996, Trends in Ecology and Evolution, V11, P98, DOI 10.1016/0169-5347(96)81051-2	24	881	893	6	391	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 27	1998	394	6696					884	887		10.1038/29772	http://dx.doi.org/10.1038/29772			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	114LW	9732869				2022-12-28	WOS:000075611800046
J	Kapur, N; Borrill, C; Stride, C				Kapur, N; Borrill, C; Stride, C			Psychological morbidity and job satisfaction in hospital consultants and junior house officers: multicentre, cross sectional survey	BRITISH MEDICAL JOURNAL			English	Article							DISTRESS		Manchester Royal Infirm, Dept Psychiat & Behav Sci, Manchester M13 9WL, Lancs, England; Univ Sheffield, Inst Work Psychol, Sheffield S10 2TN, S Yorkshire, England	University of Manchester; University of Sheffield	Kapur, N (corresponding author), Manchester Royal Infirm, Dept Psychiat & Behav Sci, Rawnsley Bldg, Manchester M13 9WL, Lancs, England.			Stride, Christopher/0000-0001-9960-2869				Borrill C., 1996, MENTAL HLTH WORKFORC; FIRTHCOZENS J, 1987, BRIT MED J, V295, P533, DOI 10.1136/bmj.295.6597.533; Goldberg D.P, 1972, DETECTION PSYCHIAT I; HSU K, 1987, AM J PSYCHIAT, V144, P1561; Ramirez AJ, 1996, LANCET, V347, P724, DOI 10.1016/S0140-6736(96)90077-X	5	42	43	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 22	1998	317	7157					511	512						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	115AM	9712596				2022-12-28	WOS:000075641400019
J	Brewer, JB; Zhao, Z; Desmond, JE; Glover, GH; Gabrieli, JDE				Brewer, JB; Zhao, Z; Desmond, JE; Glover, GH; Gabrieli, JDE			Making memories: Brain activity that predicts how well visual experience will be remembered	SCIENCE			English	Article							POSITRON EMISSION TOMOGRAPHY; HIPPOCAMPAL-FORMATION; ACTIVATION; ANATOMY; LOBE	Experiences are remembered or forgotten, but the neural determinants for the mnemonic fate of experience are unknown. Event-related functional magnetic resonance imaging was used to identify specific brain activations that differentiated between visual experiences that were later remembered well, remembered less well, or forgotten. During scanning of medial temporal lobe and frontal lobe regions, subjects viewed complex, color photographs. Subjects later received a test of memory for the photographs. The magnitudes of focal activations in right prefrontal cortex and in bilateral parahippocampal cortex predicted which photographs were later remembered well, remembered less well, or forgotten.	Stanford Univ, Neurosci Program, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Stanford, CA 94305 USA; Stanford Univ, Dept Psychol, Stanford, CA 94305 USA; Stanford Univ, Dept Radiol, Stanford, CA 94305 USA	Stanford University; Stanford University; Stanford University; Stanford University	Brewer, JB (corresponding author), Stanford Univ, Neurosci Program, Bldg 420,Jordan Hall, Stanford, CA 94305 USA.		Gabrieli, John/AAJ-2869-2020		NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [P41EB015891] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB))		Aguirre GK, 1996, CEREB CORTEX, V6, P823, DOI 10.1093/cercor/6.6.823; Buckner RL, 1998, NEURON, V20, P285, DOI 10.1016/S0896-6273(00)80456-0; Buckner RL, 1996, P NATL ACAD SCI USA, V93, P14878, DOI 10.1073/pnas.93.25.14878; D'Esposito M, 1998, COGNITIVE BRAIN RES, V7, P1, DOI 10.1016/S0926-6410(98)00004-4; Dolan RJ, 1997, NATURE, V388, P582, DOI 10.1038/41561; Epstein R, 1998, NATURE, V392, P598, DOI 10.1038/33402; Gabrieli JDE, 1996, PSYCHOL SCI, V7, P278, DOI 10.1111/j.1467-9280.1996.tb00374.x; Gabrieli JDE, 1997, SCIENCE, V276, P264, DOI 10.1126/science.276.5310.264; Glover GH, 1998, MAGN RESON MED, V39, P361, DOI 10.1002/mrm.1910390305; GOLDMANRAKIC PS, 1984, NEUROSCIENCE, V12, P719, DOI 10.1016/0306-4522(84)90166-0; Haxby JV, 1996, P NATL ACAD SCI USA, V93, P922, DOI 10.1073/pnas.93.2.922; HAYES C, 1996, P 4 ANN M ISMRM NEW; JANOWSKY JS, 1989, BEHAV NEUROSCI, V103, P548, DOI 10.1037/0735-7044.103.3.548; Kelley WM, 1998, NEURON, V20, P927, DOI 10.1016/S0896-6273(00)80474-2; Maguire EA, 1998, SCIENCE, V280, P921, DOI 10.1126/science.280.5365.921; Malonek D, 1996, SCIENCE, V272, P551, DOI 10.1126/science.272.5261.551; Martin A, 1997, HIPPOCAMPUS, V7, P587, DOI 10.1002/(SICI)1098-1063(1997)7:6<587::AID-HIPO1>3.0.CO;2-C; MILNER B, 1971, BRIT MED BULL, V27, P272, DOI 10.1093/oxfordjournals.bmb.a070866; PALLER KA, 1987, ELECTROEN CLIN NEURO, V67, P360, DOI 10.1016/0013-4694(87)90124-6; PETERSEN SE, 1988, NATURE, V331, P585, DOI 10.1038/331585a0; RAICHLE ME, 1994, CEREB CORTEX, V4, P8, DOI 10.1093/cercor/4.1.8; Rombouts SARB, 1997, HIPPOCAMPUS, V7, P594, DOI 10.1002/(SICI)1098-1063(1997)7:6<594::AID-HIPO2>3.3.CO;2-I; RUGG MC, 1995, ELECTROPHYSIOLOGY MI; SAINTCYR JA, 1988, BRAIN, V111, P941, DOI 10.1093/brain/111.4.941; SANQUIST TF, 1984, PSYCHOPHYSIOLOGY, V23, P298; Schacter DL, 1996, P NATL ACAD SCI USA, V93, P321, DOI 10.1073/pnas.93.1.321; SCOVILLE WB, 1957, J NEUROL NEUROSUR PS, V20, P11, DOI 10.1136/jnnp.20.1.11; SQUIRE LR, 1992, P NATL ACAD SCI USA, V89, P1837, DOI 10.1073/pnas.89.5.1837; Stern CE, 1996, P NATL ACAD SCI USA, V93, P8660, DOI 10.1073/pnas.93.16.8660; Talairach J., 1988, COPLANAR STEREOTAXIC; TULVING E, 1994, NEUROREPORT, V5, P2525, DOI 10.1097/00001756-199412000-00030; Wagner AD, 1998, SCIENCE, V281, P1188, DOI 10.1126/science.281.5380.1188; WOODS RP, 1992, J COMPUT ASSIST TOMO, V16, P620, DOI 10.1097/00004728-199207000-00024; Xiong JH, 1995, HUM BRAIN MAPP, V3, P287, DOI 10.1002/hbm.460030404	34	836	851	4	64	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 21	1998	281	5380					1185	1187		10.1126/science.281.5380.1185	http://dx.doi.org/10.1126/science.281.5380.1185			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	113CE	9712581				2022-12-28	WOS:000075531200051
J	Lenzen, CU; Steinmann, D; Whiteheart, SW; Weis, WI				Lenzen, CU; Steinmann, D; Whiteheart, SW; Weis, WI			Crystal structure of the hexamerization domain of N-ethylmaleimide-sensitive fusion protein	CELL			English	Article							GTP HYDROLYSIS; ALPHA-SNAP; VESICULAR TRANSPORT; MEMBRANE-FUSION; ATPASE ACTIVITY; YEAST VACUOLES; NSF; MECHANISM; BINDING; EXOCYTOSIS	N-ethylmaleimide-sensitive fusion protein (NSF) is a cytosolic ATPase required for many intracellular vesicle fusion reactions. NSF consists of an amino-terminal region that interacts with other components of the vesicle trafficking machinery, followed by two homologous ATP-binding cassettes, designated D1 and D2, that possess essential ATPase and hexamerization activities, respectively. The crystal structure of D2 bound to Mg2+-AMPPNP has been determined at 1.75 Angstrom resolution. The structure consists of a nucleotide-binding and a helical domain, and it is unexpectedly similar to the first two domains of the clamp-loading subunit delta' of E. coli DNA polymerase III. The structure suggests several regions responsible for coupling of ATP hydrolysis to structural changes in full-length NSF.	Stanford Univ, Sch Law, Dept Biol Struct, Stanford, CA 94305 USA; Univ Kentucky, Albert B Chandler Med Ctr, Coll Med, Dept Biochem, Lexington, KY 40536 USA	Stanford University; University of Kentucky	Weis, WI (corresponding author), Stanford Univ, Sch Law, Dept Biol Struct, Stanford, CA 94305 USA.		Weis, William I/G-1437-2011	Weis, William I/0000-0002-5583-6150; Whiteheart, Sidney/0000-0001-5577-0473				ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Banerjee A, 1996, J BIOL CHEM, V271, P20223, DOI 10.1074/jbc.271.34.20223; Barnard RJO, 1996, MOL BIOL CELL, V7, P693, DOI 10.1091/mbc.7.5.693; Barnard RJO, 1997, J CELL BIOL, V139, P875, DOI 10.1083/jcb.139.4.875; BENNETT MK, 1994, ANNU REV BIOCHEM, V63, P63, DOI 10.1146/annurev.bi.63.070194.000431; Beyer A, 1997, PROTEIN SCI, V6, P2043; Bird LE, 1998, CURR OPIN STRUC BIOL, V8, P14, DOI 10.1016/S0959-440X(98)80004-3; BLOCK MR, 1988, P NATL ACAD SCI USA, V85, P7852, DOI 10.1073/pnas.85.21.7852; Boyer PD, 1997, ANNU REV BIOCHEM, V66, P717, DOI 10.1146/annurev.biochem.66.1.717; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1998, IN PRESS ACTA CRYS D; Burgoyne RD, 1998, BIOESSAYS, V20, P328, DOI 10.1002/(SICI)1521-1878(199804)20:4<328::AID-BIES9>3.0.CO;2-L; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; Cowtan KD, 1996, ACTA CRYSTALLOGR D, V52, P43, DOI 10.1107/S090744499500761X; EAKLE KA, 1988, MOL CELL BIOL, V8, P4098, DOI 10.1128/MCB.8.10.4098; Egelman EH, 1996, STRUCTURE, V4, P759, DOI 10.1016/S0969-2126(96)00081-0; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Fleming KG, 1998, J BIOL CHEM, V273, P15675, DOI 10.1074/jbc.273.25.15675; GERSTEIN M, 1993, J MOL BIOL, V229, P494, DOI 10.1006/jmbi.1993.1048; GRAHAM TR, 1991, J CELL BIOL, V114, P207, DOI 10.1083/jcb.114.2.207; Guenther B, 1997, CELL, V91, P335, DOI 10.1016/S0092-8674(00)80417-1; Hanson PI, 1997, CELL, V90, P523, DOI 10.1016/S0092-8674(00)80512-7; JIANG JS, 1994, J MOL BIOL, V243, P100, DOI 10.1006/jmbi.1994.1633; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KOONIN EV, 1993, NUCLEIC ACIDS RES, V21, P2541, DOI 10.1093/nar/21.11.2541; Korolev S, 1997, CELL, V90, P635, DOI 10.1016/S0092-8674(00)80525-5; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAMBRIGHT DG, 1994, NATURE, V369, P621, DOI 10.1038/369621a0; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LINDER P, 1989, NATURE, V337, P121, DOI 10.1038/337121a0; Maegley KA, 1996, P NATL ACAD SCI USA, V93, P8160, DOI 10.1073/pnas.93.16.8160; Matveeva EA, 1997, J BIOL CHEM, V272, P26413, DOI 10.1074/jbc.272.42.26413; Mayer A, 1997, J CELL BIOL, V136, P307, DOI 10.1083/jcb.136.2.307; Mayer A, 1996, CELL, V85, P83, DOI 10.1016/S0092-8674(00)81084-3; MIXON MB, 1995, SCIENCE, V270, P954, DOI 10.1126/science.270.5238.954; MORGAN A, 1994, J BIOL CHEM, V269, P29347; MORGAN A, 1995, TRENDS CELL BIOL, V5, P335, DOI 10.1016/S0962-8924(00)89059-5; NAGIEC EE, 1995, J BIOL CHEM, V270, P29182, DOI 10.1074/jbc.270.49.29182; Nichols BJ, 1997, NATURE, V387, P199, DOI 10.1038/387199a0; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; Otwinowski Z., 1993, P CCP4 STUD WEEK DAT, P56; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; Pannu NS, 1996, ACTA CRYSTALLOGR A, V52, P659, DOI 10.1107/S0108767396004370; Patel S, 1998, TRENDS CELL BIOL, V8, P65, DOI 10.1016/S0962-8924(97)01212-9; PETERS JM, 1992, J MOL BIOL, V223, P557, DOI 10.1016/0022-2836(92)90670-F; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; SCHWEINS T, 1995, NAT STRUCT BIOL, V2, P36, DOI 10.1038/nsb0195-36; SHERIFF S, 1987, ACTA CRYSTALLOGR A, V43, P118, DOI 10.1107/S010876738709977X; Smith CA, 1996, BIOPHYS J, V70, P1590, DOI 10.1016/S0006-3495(96)79745-X; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; SONDEK J, 1994, NATURE, V372, P276, DOI 10.1038/372276a0; STORY RM, 1992, NATURE, V355, P318, DOI 10.1038/355318a0; Subramanya HS, 1996, NATURE, V384, P379, DOI 10.1038/384379a0; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; TAGAYA M, 1993, J BIOL CHEM, V268, P2662; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; WHITEHEART SW, 1994, J CELL BIOL, V126, P945, DOI 10.1083/jcb.126.4.945; WHITEHEART SW, 1995, TRENDS CELL BIOL, V5, P64, DOI 10.1016/S0962-8924(00)88948-5; WILSON DW, 1992, J CELL BIOL, V117, P531, DOI 10.1083/jcb.117.3.531; WILSON DW, 1989, NATURE, V339, P355, DOI 10.1038/339355a0; WOODMAN PG, 1997, BIOCHIM BIOPHYS ACTA, V1357, P156	64	284	286	0	6	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 21	1998	94	4					525	536		10.1016/S0092-8674(00)81593-7	http://dx.doi.org/10.1016/S0092-8674(00)81593-7			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	113GB	9727495	Bronze			2022-12-28	WOS:000075541100014
J	Miller, AI				Miller, AI			Biotic transitions - Biotic transitions in global marine diversity	SCIENCE			English	Review							PHANEROZOIC TAXONOMIC DIVERSITY; COORDINATED STASIS; MASS EXTINCTIONS; FOSSIL RECORD; KINETIC-MODEL; ORDOVICIAN RADIATION; PATTERNS; STABILITY; BRACHIOPODS; COMMUNITIES	Long-term transitions in the composition of Earth's marine biota during the Phanerozoic have historically been explained in two different ways. One view is that they were mediated through biotic interactions among organisms played out over geologic time. The other is that mass extinctions transcended any such interactions and governed diversity over the long term by resetting the relative diversities of higher taxa. However, a growing body of evidence suggests that macroevolutionary processes effecting biotic transitions during background times were not fundamentally different from those operating during mass extinctions. Physical perturbations at many geographic scales combined to produce the long-term trajectory of Phanerozoic diversity.	Univ Cincinnati, Dept Geol, Cincinnati, OH 45221 USA	University System of Ohio; University of Cincinnati	Miller, AI (corresponding author), Univ Cincinnati, Dept Geol, POB 210013, Cincinnati, OH 45221 USA.	arnold.miller@uc.edu						Adrain JM, 1998, SCIENCE, V280, P1922, DOI 10.1126/science.280.5371.1922; Benton, 1993, FOSS REC; BENTON MJ, 1995, SCIENCE, V268, P52, DOI 10.1126/science.7701342; Brett Carlton E., 1995, P285; Brett CE, 1996, PALAEOGEOGR PALAEOCL, V127, P1, DOI 10.1016/S0031-0182(96)00085-5; Briggs JC, 1998, BIOSCIENCE, V48, P389, DOI 10.2307/1313378; Courtillot V, 1996, NATURE, V381, P146, DOI 10.1038/381146a0; Droser ML, 1996, AM SCI, V84, P122; Erwin DH, 1998, SCIENCE, V279, P1324, DOI 10.1126/science.279.5355.1324; GILINSKY NL, 1994, PALEOBIOLOGY, V20, P445, DOI 10.1017/S0094837300012926; GOULD SJ, 1985, PALEOBIOLOGY, V11, P2, DOI 10.1017/S0094837300011350; GOULD SJ, 1980, PALEOBIOLOGY, V6, P383, DOI 10.1017/S0094837300003572; Holland SM, 1996, PALAEOGEOGR PALAEOCL, V127, P147, DOI 10.1016/S0031-0182(96)00092-2; JABLONSKI D, 1986, SCIENCE, V231, P129, DOI 10.1126/science.231.4734.129; JABLONSKI D, 1983, SCIENCE, V222, P1123, DOI 10.1126/science.222.4628.1123; Jablonski D, 1998, SCIENCE, V279, P1327, DOI 10.1126/science.279.5355.1327; JABLONSKI D, 1990, EVOLUTIONARY INNOVATIONS, P253; JABLONSKI D, 1991, SCIENCE, V252, P1831, DOI 10.1126/science.252.5014.1831; JABLONSKI D, 1983, BIOTIC INTERACTIONS, P747; Jacobs DK, 1998, P NATL ACAD SCI USA, V95, P9396, DOI 10.1073/pnas.95.16.9396; Kerr RA, 1997, SCIENCE, V278, P576, DOI 10.1126/science.278.5338.576; Miller AI, 1996, PALEOBIOLOGY, V22, P304, DOI 10.1017/S0094837300016237; Miller AI, 1997, PALEOBIOLOGY, V23, P155, DOI 10.1017/S0094837300016754; Miller AI, 1997, ANNU REV ECOL SYST, V28, P85, DOI 10.1146/annurev.ecolsys.28.1.85; Miller Arnold I., 1997, Geobios Memoire Special (Villeurbanne), V20, P397; Morris SC, 1998, PHILOS T R SOC B, V353, P327, DOI 10.1098/rstb.1998.0213; Patzkowsky ME, 1997, PALEOBIOLOGY, V23, P420, DOI 10.1017/S0094837300019825; PATZKOWSKY ME, 1993, GEOLOGY, V21, P19; RAUP D M, 1976, Paleobiology, V2, P289; RAUP DM, 1991, PALEOBIOLOGY, V17, P37, DOI 10.1017/S0094837300010332; RHOADS D C, 1970, Journal of Marine Research, V28, P150; Sepkoski J. J., 1982, MILWAUKEE PUBLIC MUS, V51, P1; SEPKOSKI JJ, 1993, PALEOBIOLOGY, V19, P43, DOI 10.1017/S0094837300012306; SEPKOSKI JJ, 1993, PALEOBIOLOGY, V19, P168, DOI 10.1017/S0094837300015852; SEPKOSKI JJ, 1978, PALEOBIOLOGY, V4, P223, DOI 10.1017/S0094837300005972; Sepkoski JJ, 1998, PHILOS T R SOC B, V353, P315, DOI 10.1098/rstb.1998.0212; SEPKOSKI JJ, 1981, NATURE, V293, P435, DOI 10.1038/293435a0; SEPKOSKI JJ, 1984, PALEOBIOLOGY, V10, P246, DOI 10.1017/S0094837300008186; SEPKOSKI JJ, 1991, PALEOBIOLOGY, V17, P58, DOI 10.1017/S0094837300010356; SEPKOSKI JJ, 1979, PALEOBIOLOGY, V5, P222, DOI 10.1017/S0094837300006539; SEPKOSKI JJ, 1981, PALEOBIOLOGY, V7, P36, DOI 10.1017/S0094837300003778; SEPKOSKI JJ, 1997, J PALEONTOL, V71, P5397; Sepkoski Jr J.J., 1992, MILWAUKEE PUBLIC MUS, V83, P1; Stanley S. M., 1979, MACROEVOLUTION PATTE; TEVESZ MJS, 1990, CAUSES EVOLUTION PAL, P21; THAYER CW, 1979, SCIENCE, V203, P458, DOI 10.1126/science.203.4379.458; THAYER CW, 1983, RECENT FOSSIL BENTHI, P479; VALENTINE JW, 1989, GLOBAL PLANET CHANGE, V75, P137, DOI 10.1016/0921-8181(89)90020-9; VERMEIJ G J, 1977, Paleobiology, V3, P245	49	80	82	1	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 21	1998	281	5380					1157	1160		10.1126/science.281.5380.1157	http://dx.doi.org/10.1126/science.281.5380.1157			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	113CE	9716540	Green Submitted			2022-12-28	WOS:000075531200039
J	Sorum, PC				Sorum, PC			Striking against managed care - The last gasp of la medicine liberale?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HEALTH SYSTEM; UNITED-STATES; FRANCE; REFORM; GUIDELINES; LESSONS; AUDIT		Albany Med Primary Care Network, Latham, NY 12110 USA; Albany Med Coll, Dept Pediat, Albany, NY 12208 USA; Albany Med Coll, Dept Med, Albany, NY 12208 USA	Albany Medical College; Albany Medical College	Sorum, PC (corresponding author), Albany Med Primary Care Network, 724 Watervliet-Shaker Rd, Latham, NY 12110 USA.							AMOURETTI M, 1992, BRIT MED J, V304, P428, DOI 10.1136/bmj.304.6824.428; BEZAT JM, 1997, MONDE           0323, P1; BEZAT JM, 1997, MONDE           0329, P8; BEZAT JM, 1997, MONDE           0612, P7; CHABOT JM, 1997, LEA REV PRATICIEN PA, V47, P997; CHARROIS O, 1997, MONDE           0408, P18; Colin C, 1997, LANCET, V349, P791, DOI 10.1016/S0140-6736(97)01388-3; *CTR RECH ET DOC E, 1997, ECO SANT 97 DAT CD R; del Torso S, 1997, Pediatrics, V99, pE8, DOI 10.1542/peds.99.1.e8; DEPOUVOURVILLE G, 1989, SOC SCI MED, V29, P341, DOI 10.1016/0277-9536(89)90282-7; DurandZaleski I, 1997, BRIT MED J, V315, P943; Duriez M, 1996, SYSTEME SANTE FRANCE; FIELDING JE, 1993, JAMA-J AM MED ASSOC, V270, P748, DOI 10.1001/jama.270.6.748; FLYNN G, 1995, REMAKING HEXAGON NEW; GILSON M, 1997, NOUVEL OBSERVAT 0403, P30; GIRAUD A, 1992, BRIT MED J, V304, P426, DOI 10.1136/bmj.304.6824.426; GODT PJ, 1987, J HEALTH POLIT POLIC, V12, P459, DOI 10.1215/03616878-12-3-459; GONZALEZ ML, 1997, SOCIOECONOMIC CHARAC; HASSENTEUFEL P, 1997, MED FACE ETAT UNE CO; *HAUT COM SANT PUB, 1996, SANT FRANC 96, P198; HOFFMANN S, 1997, NY REV BOOKS    0717, P45; HUNTER B, 1996, STATESMEN YB 1996 97, P496; Jackson JL, 1997, ARCH INTERN MED, V157, P155, DOI 10.1001/archinte.157.2.155; Lalardrie S., 1996, Archives de Pediatrie, V3, p261S, DOI 10.1016/0929-693X(96)86061-1; Lassey M. L., 1997, HLTH CARE SYSTEMS WO; LEFAOU AL, 1997, EC SANTE QUESTIONS; LEFAOU AL, 1992, MED AP HP CARRIERES; LEVY D, 1996, MED MAITRISE MED; Maisonneuve H, 1996, BRIT MED J, V313, P818; RANDOLPH L, 1997, PHYSICIAN CHARACTERI; RODWIN VG, 1993, HEALTH AFFAIR, V12, P111, DOI 10.1377/hlthaff.12.3.111; Schwarzinger M, 1997, Rev Prat, V47, P1233; *SERV TECHN CAISS, 1997, 1997 CONV NAT MED GE; WILSFORD D, 1987, J HEALTH POLIT POLIC, V12, P481, DOI 10.1215/03616878-12-3-481; WOLSTENHOLME RJ, 1988, POSTGRAD MED J, V64, P407, DOI 10.1136/pgmj.64.751.407; 1997, ADRENALINE       APR	36	11	11	1	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 19	1998	280	7					659	664		10.1001/jama.280.7.659	http://dx.doi.org/10.1001/jama.280.7.659			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	110ME	9718064				2022-12-28	WOS:000075384300041
J	Huberman, JA				Huberman, JA			DNA replication - Choosing a place to begin	SCIENCE			English	Editorial Material							BETA-GLOBIN LOCUS; HUMAN-CELLS; REGION		Roswell Pk Canc Inst, Dept Canc Genet, Buffalo, NY 14263 USA	Roswell Park Cancer Institute	Huberman, JA (corresponding author), Roswell Pk Canc Inst, Dept Canc Genet, Buffalo, NY 14263 USA.							Aladjem MI, 1998, SCIENCE, V281, P1005, DOI 10.1126/science.281.5379.1005; ALADJEM MI, 1995, SCIENCE, V270, P815, DOI 10.1126/science.270.5237.815; Bielinsky AK, 1998, SCIENCE, V279, P95, DOI 10.1126/science.279.5347.95; COVERLEY D, 1994, ANNU REV BIOCHEM, V63, P745, DOI 10.1146/annurev.bi.63.070194.003525; DEPAMPHILIS ML, 1993, ANNU REV BIOCHEM, V62, P29; Dutta A, 1997, ANNU REV CELL DEV BI, V13, P293, DOI 10.1146/annurev.cellbio.13.1.293; FORRESTER WC, 1990, GENE DEV, V4, P1637, DOI 10.1101/gad.4.10.1637; HEINZEL SS, 1991, MOL CELL BIOL, V11, P2263, DOI 10.1128/MCB.11.4.2263; KITSBERG D, 1993, NATURE, V366, P588, DOI 10.1038/366588a0; KRYSAN PJ, 1991, MOL CELL BIOL, V11, P1464, DOI 10.1128/MCB.11.3.1464; Newlon C. S., 1996, DNA REPLICATION EUKA, P873; Wu JR, 1998, EMBO J, V17, P1810, DOI 10.1093/emboj/17.6.1810	12	9	9	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 14	1998	281	5379					929	930		10.1126/science.281.5379.929	http://dx.doi.org/10.1126/science.281.5379.929			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	110ZK	9722466				2022-12-28	WOS:000075412700027
J	Grimes, D; von Hertzen, H; Piaggio, G; Van Look, PFA; Peregoudov, S; Vucurevic, M; Roberts, HE; Wu, SC; Bagshaw, SN; Otubu, JA; Ogedengbe, OK; Pretnar-Darovec, A; Kirkman, RJ; Ding, JH; Mittal, S; Leavesley, G; Austin, KL; Creinin, M; Adetoro, OO; Guilbert, E; Chen, JK; Bygdeman, M; Bartfai, G; Khomassuridze, A; Cheng, WY; Oyunbileg, A; Sparrow, M				Grimes, D; von Hertzen, H; Piaggio, G; Van Look, PFA; Peregoudov, S; Vucurevic, M; Roberts, HE; Wu, SC; Bagshaw, SN; Otubu, JA; Ogedengbe, OK; Pretnar-Darovec, A; Kirkman, RJ; Ding, JH; Mittal, S; Leavesley, G; Austin, KL; Creinin, M; Adetoro, OO; Guilbert, E; Chen, JK; Bygdeman, M; Bartfai, G; Khomassuridze, A; Cheng, WY; Oyunbileg, A; Sparrow, M		Task Force Postovulatory Methods Fertility Reg	Randomised controlled trial of levonorgestrel versus the Yuzpe regimen of combined oral contraceptives for emergency contraception	LANCET			English	Article							POST-COITAL CONTRACEPTION; POSTCOITAL CONTRACEPTION; LONG	Background A previous randomised study suggested that the progestagen, levonorgestrel, given alone in two separate doses each of 0.75 mg caused nausea and vomiting in fewer women and might be more effective than the Yuzpe regimen of combined oral contraceptives for emergency contraception, although the difference was not significant. We compared these two regimens when started within 72 h of unprotected coitus. Methods We enrolled in the double-blind, randomised trial 1998 women at 21 centres worldwide. Women with regular menses, not using hormonal contraception, and requesting emergency contraception after one unprotected coitus, received levonorgestrel (0.75 mg, repeated 12 h later) or the Yuzpe regimen (ethinyloestradiol 100 mu g plus levonorgestrel 0.5 mg, repeated 12 h later). Findings Outcome was unknown for 43 women (25 assigned levonorgestrel, 18 assigned Yuzpe regimen). Among the remaining 1955 women, the crude pregnancy rate was 1.1% (11/976) in the levonorgestrel group compared with 3.2% (31/979) in the Yuzpe regimen group. The crude relative risk of pregnancy for levonorgestrel compared with the Yuzpe regimen was 0.36 (95% CI 0.18-0.70). The proportion of pregnancies prevented (compared with the expected number without treatment) was 85% (74-93) with the levonorgestrel regimen and 57% (39-71) with the Yuzpe regimen. Nausea (23.1 vs 50.5%) and vomiting (5.6 vs 18.8%) were significantly less frequent with the levonorgestrel regimen than with the Yuzpe regimen (p<0.01). The efficacy of both treatments declined with increasing time since unprotected coitus (p=0.01). Interpretation The levonorgestrel regimen was better tolerated and more effective than the current standard in hormonal emergency contraception. With either regimen, the earlier the treatment is given, the more effective it seems to be.	New Zealand Family Planning Assoc, Auckland, New Zealand; Natl Res Inst Family Planning, Beijing, Peoples R China; New Zealand Family Planning Assoc, Christchurch, New Zealand; Univ Jos, Jos, Nigeria; Univ Lagos, Lagos, Nigeria; Univ Ljubljana, Dept Obstet & Gynaecol, Ljubljana, Slovenia; Univ Manchester, Manchester M13 9PL, Lancs, England; Jiangsu Family Planning Inst, Nanjing, Peoples R China; All India Inst Med Sci, New Delhi, India; Family Planning Assoc Western Australia, Northbridge, Australia; Ctr Res Human Reprod, Panama City, Panama; Univ Pittsburgh, Sch Med, Pittsburgh, PA 15260 USA; Ogun State Univ Teaching Hosp, Shagamu, Nigeria; Univ Laval, Le Ctr Hosp, Ste Foy, PQ G1K 7P4, Canada; Shanghai Inst Planned Parenthood Res, Shanghai, Peoples R China; Karolinska Hosp, Stockholm, Sweden; Albert Szent Gyorgyi Med Univ, H-6701 Szeged, Hungary; Zhordania Inst Human Reprod, Tbilisi, Georgia; Tianjin Municipal Res Inst Family Planning, Tianjin, Peoples R China; State Res Ctr MCH Human Reprod, Ulaanbaatar, Mongolia; New Zealand Family Planning Assoc, Wellington, New Zealand	National Research Institute for Family Planning - China; University of Jos; University of Lagos; University of Ljubljana; University of Manchester; All India Institute of Medical Sciences (AIIMS) New Delhi; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Laval University; Karolinska Institutet; Karolinska University Hospital; Szeged University	von Hertzen, H (corresponding author), WHO, Special Programme Res Dev & Res Training Huma, CH-1211 Geneva 27, Switzerland.		Creinin, Mitchell/AAH-3488-2020	Creinin, Mitchell/0000-0001-5967-8180				FASOLI M, 1989, CONTRACEPTION, V39, P459, DOI 10.1016/0010-7824(89)90123-6; FASOLI M, 1989, CONTRACEPTION, V39, P699; GLASIER A, 1992, NEW ENGL J MED, V327, P1041, DOI 10.1056/NEJM199210083271501; GROU F, 1994, AM J OBSTET GYNECOL, V171, P1529, DOI 10.1016/0002-9378(94)90396-4; HO PC, 1993, HUM REPROD, V8, P389, DOI 10.1093/oxfordjournals.humrep.a138057; KANE LA, 1989, NEW ZEAL MED J, V102, P151; Machin D, 1997, SAMPLE SIZE TABLES C; MAKUCH R, 1978, CANCER TREAT REP, V62, P1037; Trussell J, 1998, CONTRACEPTION, V57, P363, DOI 10.1016/S0010-7824(98)00042-0; Trussell J, 1996, FAM PLANN PERSPECT, V28, P58, DOI 10.2307/2136125; Trussell J, 1996, OBSTET GYNECOL, V88, P150, DOI 10.1016/0029-7844(96)00036-1; WEBB AMC, 1992, BMJ-BRIT MED J, V305, P927, DOI 10.1136/bmj.305.6859.927; WILCOX AJ, 1995, NEW ENGL J MED, V333, P1517, DOI 10.1056/NEJM199512073332301; YUZPE AA, 1982, FERTIL STERIL, V37, P508	14	547	562	1	26	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 8	1998	352	9126					428	433						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	108EA	9708750				2022-12-28	WOS:000075252000009
J	Clement, S; Sikorski, J; Wilson, J; Candy, B				Clement, S; Sikorski, J; Wilson, J; Candy, B			Incorporating patient preferences into clinical trials - Merits of alternative strategies for incorporating patient preferences into clinical trials must be considered carefully	BRITISH MEDICAL JOURNAL			English	Letter									United Med & Dent Sch Guys & St Thomas Hosp, Dept Gen Practice, London SE11 6SP, England	University of London; King's College London	Clement, S (corresponding author), United Med & Dent Sch Guys & St Thomas Hosp, Dept Gen Practice, London SE11 6SP, England.		Clement, Sarah/E-9601-2010					Sikorski J, 1996, BRIT MED J, V312, P546, DOI 10.1136/bmj.312.7030.546; Torgerson DJ, 1998, BRIT MED J, V316, P360, DOI 10.1136/bmj.316.7128.360	2	5	5	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 4	1998	317	7150					78	78						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	105PD	9705635				2022-12-28	WOS:000075081600046
J	Owen, L; McNeill, A; Callum, C				Owen, L; McNeill, A; Callum, C			Trends in smoking during pregnancy in England, 1992-7: quota sampling surveys	BRITISH MEDICAL JOURNAL			English	Article									Hlth Educ Author, London SW1P 2HW, England		Owen, L (corresponding author), Hlth Educ Author, Trevelyan House, London SW1P 2HW, England.			McNeill, Ann/0000-0002-6223-4000				CAMPION P, 1994, ADDICTION, V89, P1245, DOI 10.1111/j.1360-0443.1994.tb03303.x; CAMPION P, 1994, HLTH ED J, V53, P163; Department of Health, 1992, HLTH NAT STRAT HLTH; Foster K, 1997, INFANT FEEDING 1995; Royal College of Physicians, 1992, SMOK YOUNG	5	71	73	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	SEP 12	1998	317	7160					728	728		10.1136/bmj.317.7160.728	http://dx.doi.org/10.1136/bmj.317.7160.728			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	121CT	9732341	Green Submitted, Bronze, Green Published			2022-12-28	WOS:000075995100022
J	Cantor, JC; Bergeisen, L; Baker, LC				Cantor, JC; Bergeisen, L; Baker, LC			Effect of an intensive educational program for minority college students and recent graduates on the probability of acceptance to medical school	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CARE	Context.-Increasing the number of minority physicians is a long-standing goal of professional associations and government. Objective.-To determine the effectiveness of an intensive summer educational program for minority college students and recent graduates on the probability of acceptance to medical school. Design.-Nonconcurrent prospective cohort study based on data from medical school applications, Medical College Admission Tests, and the Association of American Medical Colleges Student and Applicant information Management System. Setting.-Eight US medical schools or consortia of medical schools. Participants.-Underrepresented minority (black, Mexican American, mainland Puerto Rican, and American Indian) applicants to US allopathic medical schools in 1997 (N=3830), 1996 (N=4654), and 1992 (N=3447). Intervention.-The Minority Medical Education Program (MMEP), a 6-week, residential summer educational program focused on training in the sciences and improvement of writing, verbal reasoning, studying, test taking, and presentation skills. Main Outcome Measure.-Probability of acceptance to at least 1 medical school. Results.-In the 1997 medical school application cohort, 223 (49.3%) of 452 MMEP participants were accepted compared with 1406 (41.6%) of 3378 minority nonparticipants (P=.002). Positive and significant program effects were also found in the 1996 (P=.01) and 1992 (P=.005) cohorts and in multivariate analysis after adjusting for nonprogrammatic factors likely to influence acceptance (P<.001). Program effects were also observed in students who participated in the MMEP early in college as well as those who participated later and among those with relatively high as well as low grades and test scores. Conclusions.-The MMEP enhanced the probability of medical school acceptance among its participants. Intensive summer education is a strategy that may help improve diversity in the physician workforce.	United Hosp Fund, New York, NY 10118 USA; Assoc Amer Med Coll, Washington, DC USA; Stanford Univ, Sch Med, Stanford, CA 94305 USA	Association of American Medical Colleges; Stanford University	Cantor, JC (corresponding author), United Hosp Fund, 350 5th Ave,23rd Floor, New York, NY 10118 USA.			Baker, Laurence/0000-0001-5032-794X				*ASS AM MED COLL, 1998, QUEST ANSW AFF ACT M; *ASS AM MED COLL, STUD APPL INF MAN SY; *ASS AM MED COLL, 1996, MIN STUD MED ED FACT; Cantor JC, 1996, INQUIRY-J HEALTH CAR, V33, P167; Helms LB, 1998, ACAD MED, V73, P231, DOI 10.1097/00001888-199803000-00010; Komaromy M, 1996, NEW ENGL J MED, V334, P1305, DOI 10.1056/NEJM199605163342006; LIBBY DL, 1997, HLTH AFF MILLWOOD, V16, P215; MOY E, 1995, JAMA-J AM MED ASSOC, V273, P1515, DOI 10.1001/jama.273.19.1515; NICKENS HW, 1994, NEW ENGL J MED, V331, P472, DOI 10.1056/NEJM199408183310712; READY T, 1994, MORE MINORITIES HLTH, P29; Rivo ML, 1996, NEW ENGL J MED, V334, P892, DOI 10.1056/NEJM199604043341405	11	35	35	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 2	1998	280	9					772	776		10.1001/jama.280.9.772	http://dx.doi.org/10.1001/jama.280.9.772			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	114LA	9729987				2022-12-28	WOS:000075609900004
J	Weiland, O				Weiland, O			Can HCV infection be cleared?	LANCET			English	Editorial Material							HEPATITIS-C; INDIVIDUALS; RNA		Huddinge Hosp, Karolinska Inst, Div Infect Dis, S-14186 Huddinge, Sweden	Karolinska Institutet	Weiland, O (corresponding author), Huddinge Hosp, Karolinska Inst, Div Infect Dis, S-14186 Huddinge, Sweden.			Weiland, Ola/0000-0002-6934-9724				ALBERTI A, 1992, LANCET, V340, P697, DOI 10.1016/0140-6736(92)92234-7; Hawkins A, 1997, J CLIN MICROBIOL, V35, P187, DOI 10.1128/JCM.35.1.187-192.1997; Haydon GH, 1998, GUT, V42, P570, DOI 10.1136/gut.42.4.570; Lindsay KL, 1997, HEPATOLOGY, V26, pS71, DOI 10.1002/hep.510260713; Marcellin P, 1997, ANN INTERN MED, V127, P875, DOI 10.7326/0003-4819-127-10-199711150-00003; Mason AL, 1998, HEPATOLOGY, V27, P1736, DOI 10.1002/hep.510270638; REICHARD O, IN PRESS J MED VIROL	7	7	7	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 29	1998	352	9129					669	670		10.1016/S0140-6736(05)60815-X	http://dx.doi.org/10.1016/S0140-6736(05)60815-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	116MT	9728977				2022-12-28	WOS:000075729700005
J	Herman, ST; Pedley, TA				Herman, ST; Pedley, TA			New options for the treatment of epilepsy	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							NEWLY-DIAGNOSED EPILEPSY; PHARMACOKINETICS; CARBAMAZEPINE; LAMOTRIGINE; VIGABATRIN; SAFETY		Columbia Presbyterian Med Ctr, Inst Neurol, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Neurol, New York, NY 10032 USA	Columbia University; NewYork-Presbyterian Hospital; Columbia University	Pedley, TA (corresponding author), Columbia Presbyterian Med Ctr, Inst Neurol, 710 W 168th St, New York, NY 10032 USA.			Herman, Susan/0000-0002-6556-083X				Bergey GK, 1997, NEUROLOGY, V49, P739, DOI 10.1212/WNL.49.3.739; Biton V, 1997, EPILEPSIA, V38, pS42, DOI 10.1111/j.1528-1157.1997.tb04518.x; Blum D E, 1998, Adv Neurol, V76, P57; BRODIE MJ, 1995, LANCET, V345, P476, DOI 10.1016/S0140-6736(95)90581-2; Chadwick DW, 1997, EPILEPSIA, V38, pS59, DOI 10.1111/j.1528-1157.1997.tb04522.x; DEVINSKY O, 1995, ANN NEUROL, V38, P670, DOI 10.1002/ana.410380418; Dooley J, 1996, NEUROLOGY, V46, P240, DOI 10.1212/WNL.46.1.240; Dreifus FE, 1998, NEW ENGL J MED, V338, P1869, DOI 10.1056/NEJM199806253382602; FEUCHT M, 1994, EPILEPSIA, V35, P993, DOI 10.1111/j.1528-1157.1994.tb02544.x; KALVIAINEN R, 1995, ARCH NEUROL-CHICAGO, V52, P989, DOI 10.1001/archneur.1995.00540340081016; Krauss GL, 1998, NEUROLOGY, V50, P614, DOI 10.1212/WNL.50.3.614; LEPPIK IE, 1990, NEUROLOGY, V40, P456, DOI 10.1212/WNL.40.3_Part_1.456; Macdonald RL, 1997, CURR OPIN NEUROL, V10, P121, DOI 10.1097/00019052-199704000-00009; MOTTE J, 1997, NEW ENGL J MED, V337, P1801; Pellock JM, 1997, EPILEPSIA, V38, P1261, DOI 10.1111/j.1528-1157.1997.tb00061.x; RITTER FJ, 1993, NEW ENGL J MED, V328, P29; Sachdeo RC, 1997, EPILEPSIA, V38, P294, DOI 10.1111/j.1528-1157.1997.tb01120.x; Schachter SC, 1998, EPILEPSIA, V39, P677, DOI 10.1111/j.1528-1157.1998.tb01151.x; Shorvon S, 1997, EPILEPSIA, V38, pS45, DOI 10.1111/j.1528-1157.1997.tb04519.x; Vigevano F, 1997, EPILEPSIA, V38, P1270; WALKER MC, 1995, PHARMACOL THERAPEUT, V67, P351, DOI 10.1016/0163-7258(95)00021-6	21	8	8	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 26	1998	280	8					693	694		10.1001/jama.280.8.693	http://dx.doi.org/10.1001/jama.280.8.693			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	111PM	9728627				2022-12-28	WOS:000075446900013
J	Nazerali, H; Hogerzeil, HV				Nazerali, H; Hogerzeil, HV			The quality and stability of essential drugs in rural Zimbabwe: controlled longitudinal study	BRITISH MEDICAL JOURNAL			English	Article									WHO, Act Programme Essential Drugs, CH-1211 Geneva, Switzerland; Zimbabwe Essential Drugs Act Programme, Harare, Zimbabwe	World Health Organization	Hogerzeil, HV (corresponding author), WHO, Act Programme Essential Drugs, CH-1211 Geneva, Switzerland.							HOGERZEIL HV, 1992, BRIT MED J, V304, P210, DOI 10.1136/bmj.304.6821.210; Hogerzeil HV, 1996, EUR J OBSTET GYN R B, V69, P25, DOI 10.1016/0301-2115(95)02530-8; HOGERZEIL HV, 1991, LANCET, V338, P754, DOI 10.1016/0140-6736(91)91470-F; NAZERALI H, 1996, WHODAP9416; WALKER GJA, 1988, LANCET, V2, P393	5	32	34	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 22	1998	317	7157					512	513						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	115AM	9712597				2022-12-28	WOS:000075641400020
J	Zou, JY; Guo, YL; Guettouche, T; Smith, DF; Voellmy, R				Zou, JY; Guo, YL; Guettouche, T; Smith, DF; Voellmy, R			Repression of heat shock transcription factor HSF1 activation by HSP90 (HSP90 complex) that forms a stress-sensitive complex with HSF1	CELL			English	Article							PROGESTERONE-RECEPTOR COMPLEXES; DNA-BINDING ACTIVITY; AMINO-ACID-ANALOGS; STEROID-RECEPTORS; GLUCOCORTICOID RECEPTOR; IN-VIVO; RETICULOCYTE LYSATE; MOLECULAR-CLONING; PROTEIN-SYNTHESIS; GENE-EXPRESSION	Heat shock and other proteotoxic stresses cause accumulation of nonnative proteins that trigger activation of heat shock protein (Hsp) genes. A chaperone/Hsp functioning as repressor of heat shock transcription factor (HSF) could make activation of hsp genes dependent on protein unfolding. In a novel in vitro system, in which human HSF1 can be activated by nonnative protein, heat, and geldanamycin, addition of Hsp90 inhibits activation. Reduction of the level of Hsp90 but not of Hsp/c70, Hop, Hip, p23, CyP40, or Hsp40 dramatically activates HSF1. In vivo, geldanamycin activates HSF1 under conditions in which it is an Hsp90-specific reagent. Hsp90-containing HSF1 complex is present in the unstressed cell and dissociates during stress. We conclude that Hsp90, by itself and/or associated with multichaperone complexes, is a major repressor of HSF1.	Univ Miami, Sch Med, Dept Biochem & Mol Biol, Miami, FL 33101 USA; Univ Nebraska, Med Ctr, Dept Pharmacol, Omaha, NE 68198 USA	University of Miami; University of Nebraska System; University of Nebraska Medical Center	Voellmy, R (corresponding author), Univ Miami, Sch Med, Dept Biochem & Mol Biol, Miami, FL 33101 USA.				NIGMS NIH HHS [GM31125] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAVAYA K, 1991, GENE DEV, V5, P2117, DOI 10.1101/gad.5.11.2117; ABRAVAYA K, 1992, GENE DEV, V6, P1153, DOI 10.1101/gad.6.7.1153; ANANTHAN J, 1986, SCIENCE, V232, P522, DOI 10.1126/science.3083508; Baler R, 1996, CELL STRESS CHAPERON, V1, P33, DOI 10.1379/1466-1268(1996)001<0033:EFAROH>2.3.CO;2; BALER R, 1992, J CELL BIOL, V117, P1151, DOI 10.1083/jcb.117.6.1151; BALER R, 1993, MOL CELL BIOL, V13, P2486, DOI 10.1128/MCB.13.4.2486; Bose S, 1996, SCIENCE, V274, P1715, DOI 10.1126/science.274.5293.1715; CATELLI MG, 1985, EMBO J, V4, P3131, DOI 10.1002/j.1460-2075.1985.tb04055.x; CRAIG EA, 1991, TRENDS BIOCHEM SCI, V16, P1472; DIDOMENICO BJ, 1982, CELL, V31, P593, DOI 10.1016/0092-8674(82)90315-4; Freeman BC, 1996, SCIENCE, V274, P1718, DOI 10.1126/science.274.5293.1718; Frydman J, 1997, TRENDS BIOCHEM SCI, V22, P87, DOI 10.1016/S0968-0004(97)01005-0; HATTORI H, 1993, J CELL SCI, V104, P629; Hedge Ramanujan S., 1995, Journal of Cellular Physiology, V165, P186; HIGHTOWER LE, 1980, J CELL PHYSIOL, V102, P407, DOI 10.1002/jcp.1041020315; HUANG LE, 1994, J BIOL CHEM, V269, P30718; HUTCHISON KA, 1995, J BIOL CHEM, V270, P18841, DOI 10.1074/jbc.270.32.18841; JAKOB U, 1994, TRENDS BIOCHEM SCI, V19, P205, DOI 10.1016/0968-0004(94)90023-X; JOHNSON JL, 1994, MOL CELL BIOL, V14, P1956, DOI 10.1128/MCB.14.3.1956; KELLEY PM, 1978, CELL, V15, P1277, DOI 10.1016/0092-8674(78)90053-3; LAI BT, 1984, MOL CELL BIOL, V4, P2802, DOI 10.1128/MCB.4.12.2802; LARSON JS, 1988, NATURE, V335, P372, DOI 10.1038/335372a0; LEPOCK JR, 1993, J CELL BIOL, V122, P1267, DOI 10.1083/jcb.122.6.1267; LINDQUIST S, 1980, DEV BIOL, V77, P463, DOI 10.1016/0012-1606(80)90488-1; Morimoto R I, 1996, EXS, V77, P139; MOSSER DD, 1993, MOL CELL BIOL, V13, P5427, DOI 10.1128/MCB.13.9.5427; NADEAU K, 1993, J BIOL CHEM, V268, P1479; Nair SC, 1996, CELL STRESS CHAPERON, V1, P237, DOI 10.1379/1466-1268(1996)001<0237:APOMCI>2.3.CO;2; Nakai A, 1997, MOL CELL BIOL, V17, P469, DOI 10.1128/MCB.17.1.469; NATHAN DF, 1995, MOL CELL BIOL, V15, P3917; NUNES SL, 1995, BIOCHEM BIOPH RES CO, V213, P1, DOI 10.1006/bbrc.1995.2090; OReilly D.R., 1992, BACULOVIRUS EXPRESSI; PICARD D, 1990, NATURE, V348, P166, DOI 10.1038/348166a0; Prapapanich V, 1996, MOL ENDOCRINOL, V10, P420, DOI 10.1210/me.10.4.420; PRATT WB, 1993, J BIOL CHEM, V268, P21455; RABINDRAN SK, 1991, P NATL ACAD SCI USA, V88, P6906, DOI 10.1073/pnas.88.16.6906; RABINDRAN SK, 1994, MOL CELL BIOL, V14, P6552, DOI 10.1128/MCB.14.10.6552; RIEHL RM, 1985, BIOCHEMISTRY-US, V24, P6586, DOI 10.1021/bi00344a042; SANCHEZ ER, 1985, J BIOL CHEM, V260, P2398; SANCHEZ ER, 1990, J BIOL CHEM, V265, P20123; SCHERRER LC, 1992, BIOCHEMISTRY-US, V31, P7325, DOI 10.1021/bi00147a017; SCHUH S, 1985, J BIOL CHEM, V260, P4292; SMITH DF, 1993, MOL ENDOCRINOL, V7, P1418, DOI 10.1210/me.7.11.1418; SMITH DF, 1993, MOL ENDOCRINOL, V7, P4, DOI 10.1210/me.7.1.4; SMITH DF, 1995, MOL CELL BIOL, V15, P6804; SMITH DF, 1993, MOL CELL BIOL, V13, P869, DOI 10.1128/MCB.13.2.869; Voellmy R, 1996, EXS, V77, P121; Whitesell L, 1997, ONCOGENE, V14, P2809, DOI 10.1038/sj.onc.1201120; WHITESELL L, 1994, P NATL ACAD SCI USA, V91, P8324, DOI 10.1073/pnas.91.18.8324; Whitesell L, 1996, MOL ENDOCRINOL, V10, P705, DOI 10.1210/me.10.6.705; Xiao NQ, 1997, MOL ENDOCRINOL, V11, P1365, DOI 10.1210/me.11.9.1365; ZIMARINO V, 1987, NATURE, V327, P727, DOI 10.1038/327727a0; ZOU J, 1998, IN PRESS CELL STRESS; ZUO JR, 1994, MOL CELL BIOL, V14, P7557, DOI 10.1128/MCB.14.11.7557	54	908	952	2	71	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	AUG 21	1998	94	4					471	480		10.1016/S0092-8674(00)81588-3	http://dx.doi.org/10.1016/S0092-8674(00)81588-3			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	113GB	9727490	Bronze			2022-12-28	WOS:000075541100009
J	Greenhalgh, T				Greenhalgh, T			Meta-analysis is a blunt and potentially misleading instrument for analysing models of service delivery - Commentary	BRITISH MEDICAL JOURNAL			English	Editorial Material							DIABETIC-PATIENTS; GENERAL-PRACTICE; CARE		UCL, Sch Med, Royal Free Hosp, Whittington Hosp, London N19 5NF, England	University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School	Greenhalgh, T (corresponding author), UCL, Sch Med, Royal Free Hosp, Whittington Hosp, London N19 5NF, England.		Greenhalgh, Trisha/B-1825-2015	Greenhalgh, Trisha/0000-0003-2369-8088				BRADSHAW C, 1995, DIABETIC MED, V12, P628, DOI 10.1111/j.1464-5491.1995.tb00554.x; BUTLER C, 1997, EUR J GEN PRACT, V3, P23; *GEN MED SERV COMM, 1997, DEF CAR SERV; GREENHALGH PM, 1994, 67 ROYAL COLL GEN PR; GREENHALGH PM, 1997, READ PAPER BASICS EV, P41; HAYES TM, 1984, BRIT MED J, V289, P728, DOI 10.1136/bmj.289.6447.728; HOSKINS PL, 1993, DIABETIC MED, V10, P81, DOI 10.1111/j.1464-5491.1993.tb02001.x; HURWITZ B, 1993, BRIT MED J, V306, P624, DOI 10.1136/bmj.306.6878.624; Jacobson LD, 1997, BRIT J GEN PRACT, V47, P449; *MIN HLTH, 1996, PRIM CAR FUT LIST PR; MULROW CD, 1995, SYSTEMATIC REV, P1; NAJI S, 1994, BRIT MED J, V308, P1208; Thompson SG, 1995, SYSTEMATIC REV, P48	13	11	11	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	AUG 8	1998	317	7155					395	396						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	110YR	9729094				2022-12-28	WOS:000075409600029
J	Quigley, JP; Armstrong, PB				Quigley, JP; Armstrong, PB			Tumor cell intravasation Alu-cidated: The chick embryo opens the window	CELL			English	Review							EXPRESSION; INHIBITION		SUNY Stony Brook, Dept Pathol, Stony Brook, NY 11794 USA; Univ Calif Davis, Dept Mol & Cellular Biol, Davis, CA 95616 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; University of California System; University of California Davis	Quigley, JP (corresponding author), SUNY Stony Brook, Dept Pathol, Stony Brook, NY 11794 USA.			Armstrong, Peter/0000-0001-5197-1999				ARMSTRONG PB, 1982, CANCER RES, V42, P1826; ARMSTRONG PB, 1984, INVASION, P126; BERNHARD EJ, 1994, P NATL ACAD SCI USA, V91, P4293, DOI 10.1073/pnas.91.10.4293; Chambers AF, 1997, J NATL CANCER I, V89, P1260, DOI 10.1093/jnci/89.17.1260; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; HOLMGREN L, 1995, NAT MED, V1, P149, DOI 10.1038/nm0295-149; Hua J, 1996, CANCER RES, V56, P5279; Kim J, 1998, CELL, V94, P353, DOI 10.1016/S0092-8674(00)81478-6; KOOK YH, 1994, EMBO J, V13, P3983, DOI 10.1002/j.1460-2075.1994.tb06714.x; Koop S, 1996, P NATL ACAD SCI USA, V93, P11080, DOI 10.1073/pnas.93.20.11080; Mazzieri R, 1997, EMBO J, V16, P2319, DOI 10.1093/emboj/16.9.2319; OSSOWSKI L, 1988, CELL, V52, P321, DOI 10.1016/S0092-8674(88)80025-4; RAMOSDESIMONE N, 1998, IN RPESS J BIOL CHEM; Vu TH, 1998, CELL, V93, P411, DOI 10.1016/S0092-8674(00)81169-1; Zetter BR, 1998, ANNU REV MED, V49, P407, DOI 10.1146/annurev.med.49.1.407	15	70	72	0	3	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	AUG 7	1998	94	3					281	284		10.1016/S0092-8674(00)81470-1	http://dx.doi.org/10.1016/S0092-8674(00)81470-1			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	109EN	9708729	Bronze			2022-12-28	WOS:000075308400003
J	Nicoll, RA; Malenka, RC				Nicoll, RA; Malenka, RC			Neuroscience - A tale of two transmitters	SCIENCE			English	Editorial Material							GLYCINE; GABA; INHIBITION; TERMINALS		Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Physiol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Nicoll, RA (corresponding author), Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, San Francisco, CA 94143 USA.							BOWERS CW, 1994, TRENDS NEUROSCI, V17, P315, DOI 10.1016/0166-2236(94)90168-6; BURGER PM, 1991, NEURON, V7, P287, DOI 10.1016/0896-6273(91)90267-4; CHAUDHRY FA, IN PRESS J NEUROSCI; CULLHEIM S, 1981, J PHYSIOL-LONDON, V312, P209, DOI 10.1113/jphysiol.1981.sp013624; DALE HENRY, 1935, PROC ROY SOC MED, V28, P319; ECCLES JC, 1954, J PHYSIOL-LONDON, V126, P524, DOI 10.1113/jphysiol.1954.sp005226; EDWARDS RG, COMMUNICATION; HAMILL OP, 1983, NATURE, V305, P805, DOI 10.1038/305805a0; HOKFELT T, 1991, NEURON, V7, P867, DOI 10.1016/0896-6273(91)90333-U; Jonas P, 1998, SCIENCE, V281, P419, DOI 10.1126/science.281.5375.419; Kirsch J, 1998, NATURE, V392, P717, DOI 10.1038/33694; McIntire SL, 1997, NATURE, V389, P870, DOI 10.1038/39908; Nicoll R A, 1979, Int Rev Neurobiol, V21, P217; NICOLL RA, 1980, ANNU REV NEUROSCI, V3, P227, DOI 10.1146/annurev.ne.03.030180.001303; Ornung G, 1996, J COMP NEUROL, V365, P413; Ottersen O.P., 1990, GLYCINE NEUROTRANS, P303; Sagne C, 1997, FEBS LETT, V417, P177, DOI 10.1016/S0014-5793(97)01279-9; TRILLER A, 1987, J CELL BIOL, V104, P947, DOI 10.1083/jcb.104.4.947; ZAFRA F, 1995, J NEUROSCI, V15, P3952	19	31	32	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 17	1998	281	5375					360	361		10.1126/science.281.5375.360	http://dx.doi.org/10.1126/science.281.5375.360			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	102HR	9705712				2022-12-28	WOS:000074918800034
J	Wetzel, MS; Eisenberg, DM; Kaptchuk, TJ				Wetzel, MS; Eisenberg, DM; Kaptchuk, TJ			Courses involving complementary and alternative medicine at US medical schools	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CARE	Context.-With the public's increasing use of complementary and alternative medicine, medical schools must consider the challenge of educating physicians about these therapies. Objectives.-To document the prevalence, scope, and diversity of medical school education in complementary and alternative therapy topics and to obtain information about the organizational and academic features of these courses. Design.-Mail survey and follow-up letter and telephone survey conducted in 1997-1998. Participants.-Academic or curriculum deans and faculty at each of the 125 US medical schools. Main Outcome Measures.-Courses taught at US medical schools and administrative and educational characteristics of these courses. Results.-Replies were received from 117 (94%) of the 125 US medical schools. Of schools that replied, 75 (64%) reported offering elective courses in complementary or alternative medicine or including these topics in required courses. Of the 123 courses reported, 84 (68%) were stand-alone electives, 38 (31%) were part of required courses, and one (1%) was part of an elective. Thirty-eight courses (31%) were offered by departments of family practice and 14 (11%) by departments of medicine or internal medicine. Educational formats included lectures, practitioner lecture and/or demonstration, and patient presentations. Common topics included chiropractic, acupuncture, homeopathy, herbal therapies, and mind-body techniques. Conclusions.-There is tremendous heterogeneity and diversity in content, format, and requirements among courses in complementary and alternative medicine at US medical schools.	Beth Israel Deaconess Med Ctr, Dept Med, Ctr Alternat Med Res, Boston, MA 02215 USA; Harvard Univ, Sch Med, Off Educ Dev, Boston, MA USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Wetzel, MS (corresponding author), Beth Israel Deaconess Med Ctr, Dept Med, Ctr Alternat Med Res, 330 Brookline Ave, Boston, MA 02215 USA.	mwetzel@warren.med.harvard.edu			NIAMS NIH HHS [U24 AR43441] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [U24AR043441] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		*AM MED ASS COUNC, 1997, ENC MED STUD ED COMP; *ASS AM MED COLL, 1997, DIR AM MED ED; Association of American Medical Colleges, 1998, 1 ASS AM MED SCH, P7; Astin JA, 1998, JAMA-J AM MED ASSOC, V279, P1548, DOI 10.1001/jama.279.19.1548; Berman B M, 1995, J Am Board Fam Pract, V8, P361; BERMAN BM, 1994, ALTERNATIVE MED EXPA; Blumberg D L, 1995, Altern Ther Health Med, V1, P31; Breedlove C, 1997, JAMA-J AM MED ASSOC, V278, P1702, DOI 10.1001/jama.1997.03550200078038; Carlston M, 1997, Fam Med, V29, P559; Eisenberg DM, 1997, ANN INTERN MED, V127, P61, DOI 10.7326/0003-4819-127-1-199707010-00010; EISENBERG DM, 1993, NEW ENGL J MED, V328, P246, DOI 10.1056/NEJM199301283280406; *FED STAT MED BOAR, 1997, REP HLTH CAR FRAUD S; Fox E, 1997, JAMA-J AM MED ASSOC, V278, P761; GUYATT G, 1992, JAMA-J AM MED ASSOC, V268, P2420, DOI 10.1001/jama.1992.03490170092032; MARTIN JB, 1997, CAB PRIM CAR SER HAR; MUEHSAM PA, 1997, GEA CORRES       SPR, P10; MUEHSAM PA, 1998, GEA CORRES       SPR, P24; MURRAY RH, 1992, NEW ENGL J MED, V326, P61, DOI 10.1056/NEJM199201023260113	18	274	281	0	16	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 2	1998	280	9					784	787		10.1001/jama.280.9.784	http://dx.doi.org/10.1001/jama.280.9.784			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	114LA	9729989	Bronze			2022-12-28	WOS:000075609900006
J	Harper, JT; Humphrey, HF; Pfeffer, WT				Harper, JT; Humphrey, HF; Pfeffer, WT			Three-dimensional deformation measured in an Alaskan glacier	SCIENCE			English	Article							SURFACE VELOCITY; STORGLACIAREN; SWEDEN	Measurements of movement along 28 boreholes reveal the three-dimensional flow field in a 6 million cubic meter reach of Worthington Glacier, a temperate valley glacier Located in Alaska. Sliding at the bed accounted for 60 to 70 percent of the glacier's surface motion. Strain rates in the ice were low from the surface to a depth of about 120 meters, but then increased rapidly toward the bed. Ice deformation was not affected by temporal changes in the sliding rate. The three-dimensional pattern of motion indicates that plane strain, which is often assumed by models, is a poor approximation of this viscous flow.	Univ Wyoming, Dept Geol & Geophys, Laramie, WY 82071 USA; Univ Colorado, Inst Arctic & Alpine Res, Boulder, CO 80309 USA	University of Wyoming; University of Colorado System; University of Colorado Boulder	Harper, JT (corresponding author), Univ Wyoming, Dept Geol & Geophys, Laramie, WY 82071 USA.			Harper, Joel/0000-0002-2151-8509; humphrey, neil/0000-0002-5175-2080				BLAKE EW, 1992, J GLACIOL, V38, P113, DOI 10.3189/S0022143000009655; BRIGGS JC, 1974, GEOPHYSICS, P39; Harbor J, 1997, GEOLOGY, V25, P739, DOI 10.1130/0091-7613(1997)025<0739:IOSDCO>2.3.CO;2; HARPER JT, 1995, GEOLOGY, V23, P901, DOI 10.1130/0091-7613(1995)023<0901:BVAOAT>2.3.CO;2; HARPER JT, 1996, US ARMY COLD REG RES, V9627, P41; HARPER JT, 1997, THESIS U WYOMING; Hodge S.M., 1974, J GLACIOL, V13, P349, DOI [10.1017/s0022143000023157, DOI 10.1017/S0022143000023157]; HOOKE RL, 1989, J GLACIOL, V35, P235, DOI 10.3189/S0022143000004561; HOOKE RL, 1987, J GLACIOL, V33, P72, DOI 10.3189/S0022143000005372; HUZURBAZAR SV, UNPUB; IKEN A, 1986, J GLACIOL, V32, P101, DOI 10.3189/S0022143000006936; KAMB B, 1994, J GEOPHYS RES-SOL EA, V99, P15231, DOI 10.1029/94JB00467; MEIER MF, 1960, 351 US GEOL SURV; NYE JF, 1953, PROC R SOC LON SER-A, V219, P477, DOI 10.1098/rspa.1953.0161; PATERSON WS, 1963, J GEOPHYS RES, V68, P4537, DOI 10.1029/JZ068i015p04537; Raymond C. F., 1971, J GLACIOL, V10, P39; Raymond C.F., 1971, J GLACIOL, V10, P55; WELCH BC, IN PRESS J GLACIOL	18	19	20	3	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 28	1998	281	5381					1340	1342		10.1126/science.281.5381.1340	http://dx.doi.org/10.1126/science.281.5381.1340			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	115LQ	9721096				2022-12-28	WOS:000075666800046
J	Wu, WS; Holmans, P; Wavrant-Devrieze, F; Shears, S; Kehoe, P; Crook, R; Booth, J; Williams, N; Perez-Tur, J; Roehl, K; Fenton, L; Chartier-Harlin, MC; Lovestone, S; Williams, J; Hutton, M; Hardy, J; Owen, MJ; Goate, A				Wu, WS; Holmans, P; Wavrant-Devrieze, F; Shears, S; Kehoe, P; Crook, R; Booth, J; Williams, N; Perez-Tur, J; Roehl, K; Fenton, L; Chartier-Harlin, MC; Lovestone, S; Williams, J; Hutton, M; Hardy, J; Owen, MJ; Goate, A			Genetic studies on chromosome 12 in late-onset Alzheimer disease	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							APOLIPOPROTEIN-E; ALLELE; TRAITS; RISK	Context. - The only genetic locus universally accepted to be important as a risk factor for late-onset Alzheimer disease (AD) is the apolipoprotein E (APOE) locus on chromosome 19. However, this locus does not account for all the risk in late-onset disease, and a recent report has suggested a second locus on chromosome 12p11-12. Objective. - To look for evidence of linkage on chromosome 12 and to test for the presence of the new locus in an independent sample of familial late-onset AD cases. Design. - Retrospective cohort study. As part of a 20-centimorgan genome screen (approximately equal to 200 markers), we tested a series of 18 genetic markers on chromosome 12 and carried out multipoint, nonparametric lod score and exclusion analyses. Setting. - Clinic populations in the continental United States selected from the National Institute of Mental Health AD Genetics Consortium. Patients. - We selected samples for DNA analysis from affected sibling pairs, 497 subjects from 230 families with 2 or more affected individuals with probable or definite AD with onset ages older than 60 years (mean +/- SD, 75 +/- 6 years). Within the families, we used the 2 probable or definitely affected individuals. In families with more than 2 such cases available, we used all of them; in families with only 2 such cases in which unaffected individuals were available, we also sampled the oldest unaffected individual and used genotype data from this unaffected individual to check for nonpaternity and genotyping errors. Main Outcome Measure. - Presence of linkage or locus on chromosome 12. Results. - Although linkage analyses confirmed the presence of a genetic susceptibility factor at the APOE locus in these families with late-onset AD, we were unable to confirm the presence of a locus close to the marker D12S1042. A moderate lod score (1.91) was found near D12S98 close to the alpha(2)-macroglobulin locus in the affected pairs in which both members did not possess an APOE epsilon 4 allele. Conclusions. - APOE remains the only locus established to be a risk factor for late-onset AD. We were unable to confirm that a locus on chromosome 12p11-12 has a major effect on risk for late-onset AD, although an effect smaller than that for APOE cannot be excluded.	Mayo Clin Jacksonville, Neurogenet Lab, Jacksonville, FL 32224 USA; Washington Univ, Sch Med, Dept Psychiat, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Genet, St Louis, MO 63110 USA; Univ Wales, Coll Med, Neuropsychiat Genet Unit, Cardiff CF1 3NS, S Glam, Wales; Inst Pasteur, INSERM, F-59019 Lille, France; Inst Psychiat, Old Age Psychiat Sect, London SE5 8AF, England	Mayo Clinic; Washington University (WUSTL); Washington University (WUSTL); Cardiff University; Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; University of London; King's College London	Hardy, J (corresponding author), Mayo Clin Jacksonville, Neurogenet Lab, 4500 San Pablo Rd,Bridsall Bldg, Jacksonville, FL 32224 USA.	hardy.john@mayo.edu	Hardy, John/C-2451-2009; Lovestone, Simon/E-8725-2010; Chartier-Harlin, Marie-Christine/L-4527-2018; Holmans, Peter/F-4518-2015; Perez-Tur, Jordi/A-2143-2010; Kehoe, Patrick/P-8760-2018	Hardy, John/0000-0002-3122-0423; Chartier-Harlin, Marie-Christine/0000-0001-6416-6526; Holmans, Peter/0000-0003-0870-9412; Perez-Tur, Jordi/0000-0002-9111-1712; Williams, Julie/0000-0002-4069-0259; Lovestone, Simon/0000-0003-0473-4565; Goate, Alison/0000-0002-0576-2472; Kehoe, Patrick/0000-0002-7542-1139; Newton-Bishop, Julia/0000-0001-9147-6802	NIA NIH HHS [AG14616, AG00634] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG014616] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Blacker D, 1997, NEUROLOGY, V48, P139, DOI 10.1212/WNL.48.1.139; CHARTIERHARLIN MC, 1994, HUM MOL GENET, V3, P569, DOI 10.1093/hmg/3.4.569; CORDER EH, 1994, NAT GENET, V7, P180, DOI 10.1038/ng0694-180; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; Kang DE, 1997, NEUROLOGY, V49, P56, DOI 10.1212/WNL.49.1.56; Kruglyak L, 1996, NAT GENET, V14, P132, DOI 10.1038/ng1096-132; KRUGLYAK L, 1995, AM J HUM GENET, V57, P439; Lendon CL, 1997, NEUROSCI LETT, V222, P187, DOI 10.1016/S0304-3940(97)13381-X; Martin ES, 1997, ALZ DIS ASSOC DIS, V11, P163, DOI 10.1097/00002093-199709000-00009; PERICAKVANCE MA, 1995, TRENDS GENET, V11, P504, DOI 10.1016/S0168-9525(00)89161-1; PericakVance MA, 1997, JAMA-J AM MED ASSOC, V278, P1237, DOI 10.1001/jama.278.15.1237; PericakVance MA, 1996, ANN NEUROL, V39, P700, DOI 10.1002/ana.410390605; RISCH N, 1990, AM J HUM GENET, V46, P222; STRITTMATTER WJ, 1992, P NATL ACAD SCI USA, V90, P1971; TALBOT C, 1994, LANCET, V343, P1432, DOI 10.1016/S0140-6736(94)92557-7; WavrantDeVrieze F, 1997, NEUROSCI LETT, V227, P68, DOI 10.1016/S0304-3940(97)00304-2	16	90	91	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 19	1998	280	7					619	622		10.1001/jama.280.7.619	http://dx.doi.org/10.1001/jama.280.7.619			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	110ME	9718053	Bronze			2022-12-28	WOS:000075384300030
J	Perry, FS				Perry, FS			A memorable family - See first ...	BRITISH MEDICAL JOURNAL			English	Article																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 15	1998	317	7156					481	481						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	112JF	9703554				2022-12-28	WOS:000075490200062
J	Henry, JA; Hoffman, JR				Henry, JA; Hoffman, JR			Continuing controversy on gut decontamination	LANCET			English	Editorial Material							OVERDOSE		St Marys Hosp, Imperial Coll Sch Med, Dept Accid & Emergency Med, London W2 1NY, England; Univ Calif Los Angeles, Sch Med, Dept Med & Emergency Med, Los Angeles, CA 90024 USA	Imperial College London; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Henry, JA (corresponding author), St Marys Hosp, Imperial Coll Sch Med, Dept Accid & Emergency Med, Praed St, London W2 1NY, England.							*AM AC CLIN TOX EU, 1997, CLIN TOXICOL, V35, P699; CURTIS RA, 1984, ARCH INTERN MED, V144, P48, DOI 10.1001/archinte.144.1.48; KULIG K, 1985, ANN EMERG MED, V14, P562, DOI 10.1016/S0196-0644(85)80780-0; MERIGIAN KS, 1990, AM J EMERG MED, V8, P479, DOI 10.1016/0735-6757(90)90146-Q; POND SM, 1995, MED J AUSTRALIA, V163, P345, DOI 10.5694/j.1326-5377.1995.tb124625.x; WRIGHT N, 1980, J ROY COLL PHYS LOND, V14, P114	6	25	26	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	AUG 8	1998	352	9126					420	421		10.1016/S0140-6736(05)79183-2	http://dx.doi.org/10.1016/S0140-6736(05)79183-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	108EA	9708747				2022-12-28	WOS:000075252000006
J	Bers, DM; Fill, M				Bers, DM; Fill, M			Muscle contraction - Coordinated feet and the dance of ryanodine receptors	SCIENCE			English	Editorial Material							SKELETAL-MUSCLE; CALCIUM-RELEASE; SARCOPLASMIC-RETICULUM; FK506-BINDING PROTEIN; ELEMENTARY EVENTS		Loyola Univ, Stritch Sch Med, Dept Physiol, Maywood, IL 60153 USA	Loyola University Chicago	Bers, DM (corresponding author), Loyola Univ, Stritch Sch Med, Dept Physiol, Maywood, IL 60153 USA.		Bers, Donald M/C-4507-2012	Bers, Donald/0000-0002-2237-9483	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM111397] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERS DM, 1993, AM J PHYSIOL, V264, pC1587, DOI 10.1152/ajpcell.1993.264.6.C1587; BLOCK BA, 1988, J CELL BIOL, V107, P2587, DOI 10.1083/jcb.107.6.2587; BRILLANTES AMB, 1994, CELL, V77, P513, DOI 10.1016/0092-8674(94)90214-3; CHENG H, 1993, SCIENCE, V262, P740, DOI 10.1126/science.8235594; FABIATO A, 1985, J GEN PHYSIOL, V85, P247, DOI 10.1085/jgp.85.2.247; FERRIER GR, 1995, J PHYSIOL-LONDON, V484, P107, DOI 10.1113/jphysiol.1995.sp020651; Marx SO, 1998, SCIENCE, V281, P818, DOI 10.1126/science.281.5378.818; Rios E, 1997, ANNU REV BIOPH BIOM, V26, P47, DOI 10.1146/annurev.biophys.26.1.47; Shou WN, 1998, NATURE, V391, P489, DOI 10.1038/35146; TSUGORKA A, 1995, SCIENCE, V269, P1723, DOI 10.1126/science.7569901; Wagenknecht T, 1996, BIOPHYS J, V70, P1709, DOI 10.1016/S0006-3495(96)79733-3	11	26	26	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 7	1998	281	5378					790	791		10.1126/science.281.5378.790	http://dx.doi.org/10.1126/science.281.5378.790			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	108ZD	9714684				2022-12-28	WOS:000075295600036
J	Hakem, R; Hakem, A; Duncan, GS; Henderson, JT; Woo, M; Soengas, MS; Elia, A; de la Pompa, JL; Kagi, D; Khoo, W; Potter, J; Yoshida, R; Kaufman, SA; Lowe, SW; Penninger, JM; Mak, TW				Hakem, R; Hakem, A; Duncan, GS; Henderson, JT; Woo, M; Soengas, MS; Elia, A; de la Pompa, JL; Kagi, D; Khoo, W; Potter, J; Yoshida, R; Kaufman, SA; Lowe, SW; Penninger, JM; Mak, TW			Differential requirement for Caspase 9 in apoptotic pathways in vivo	CELL			English	Article							PROGRAMMED CELL-DEATH; CONVERTING-ENZYME; DEFICIENT MICE; MOUSE; THYMOCYTES; FAMILY; GENES; BCL-2; BAX	Mutation of Caspase 9 (Casp9) results in embryonic lethality and defective brain development associated with decreased apoptosis. Casp9 (-/-) embryonic stem cells and embryonic fibroblasts are resistant to several apoptotic stimuli, including UV and gamma irradiation. Casp9(-/-) thymocytes are also resistant to dexamethasone- and gamma irradiation-induced apoptosis, but are surprisingly sensitive to apoptosis induced by UV irradiation or anti-CD95. Resistance to apoptosis is accompanied by retention of the mitochondrial membrane potential in mutant cells. In addition, cytochrome c is translocated to the cytosol of Casp9(-/-) ES cells upon UV stimulation, suggesting that Casp9 acts downstream of cytochrome c. Caspase processing is inhibited in Casp9(-/-) ES cells but not in thymocytes or splenocytes. Comparison of the requirement for Casp9 and Casp3 in different apoptotic settings indicates the existence of at least four different apoptotic pathways in mammalian cells.	Amgen Inst, Toronto, ON M5G 2C1, Canada; Univ Toronto, Dept Med Biophys, Ontario Canc Inst, Toronto, ON M5G 2C1, Canada; Univ Toronto, Dept Immunol, Toronto, ON M5G 2C1, Canada; Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Program Mol Biol & Canc, Toronto, ON M5G 1X5, Canada; Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA; Amgen Inc, Thousand Oaks, CA 91320 USA	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; Cold Spring Harbor Laboratory; Amgen	Mak, TW (corresponding author), Amgen Inst, Toronto, ON M5G 2C1, Canada.		Penninger, Josef M/I-6860-2013; Duncan, Gordon/AIE-7011-2022; De La Pompa, José Luis/F-9719-2014; Soengas, Maria S/H-6455-2015	Penninger, Josef M/0000-0002-8194-3777; De La Pompa, José Luis/0000-0001-6761-7265; Soengas, Maria S/0000-0003-0612-6299; Hakem, Razqallah/0000-0001-5948-7931	NATIONAL CANCER INSTITUTE [P01CA013106] Funding Source: NIH RePORTER; NCI NIH HHS [CA13106] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAKHSHI A, 1985, CELL, V41, P899, DOI 10.1016/S0092-8674(85)80070-2; Bergeron L, 1998, GENE DEV, V12, P1304, DOI 10.1101/gad.12.9.1304; Bossy-Wetzel E, 1998, EMBO J, V17, P37, DOI 10.1093/emboj/17.1.37; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; Clem RJ, 1998, P NATL ACAD SCI USA, V95, P554, DOI 10.1073/pnas.95.2.554; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Deckwerth TL, 1996, NEURON, V17, P401, DOI 10.1016/S0896-6273(00)80173-7; Deveraux QL, 1998, EMBO J, V17, P2215, DOI 10.1093/emboj/17.8.2215; Donehower LA, 1996, SEMIN CANCER BIOL, V7, P269, DOI 10.1006/scbi.1996.0035; Duan HJ, 1996, J BIOL CHEM, V271, P16720, DOI 10.1074/jbc.271.28.16720; GREEN DR, 1995, CURR OPIN IMMUNOL, V7, P694, DOI 10.1016/0952-7915(95)80079-4; Hakem R, 1996, CELL, V85, P1009, DOI 10.1016/S0092-8674(00)81302-1; Hengartner MO, 1996, CURR OPIN GENET DEV, V6, P34, DOI 10.1016/S0959-437X(96)90007-6; Hu YM, 1998, P NATL ACAD SCI USA, V95, P4386, DOI 10.1073/pnas.95.8.4386; Kharbanda S, 1997, P NATL ACAD SCI USA, V94, P6939, DOI 10.1073/pnas.94.13.6939; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; KUIDA K, 1995, SCIENCE, V267, P2000, DOI 10.1126/science.7535475; Li F, 1997, J BIOL CHEM, V272, P30299, DOI 10.1074/jbc.272.48.30299; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liston P, 1996, NATURE, V379, P349, DOI 10.1038/379349a0; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; Mignotte B, 1998, EUR J BIOCHEM, V252, P1, DOI 10.1046/j.1432-1327.1998.2520001.x; Mishina Y, 1995, GENE DEV, V9, P3027, DOI 10.1101/gad.9.24.3027; MOTOYAMA N, 1995, SCIENCE, V267, P1506, DOI 10.1126/science.7878471; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Pan GH, 1998, J BIOL CHEM, V273, P5841, DOI 10.1074/jbc.273.10.5841; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; Roy N, 1997, EMBO J, V16, P6914, DOI 10.1093/emboj/16.23.6914; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; Srinivasula SM, 1996, J BIOL CHEM, V271, P27099, DOI 10.1074/jbc.271.43.27099; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; TSUJIMOTO Y, 1985, SCIENCE, V229, P1390, DOI 10.1126/science.3929382; Wang SY, 1998, CELL, V92, P501, DOI 10.1016/S0092-8674(00)80943-5; WHITE E, 1993, GENE DEV, V7, P2277, DOI 10.1101/gad.7.12a.2277; Woo M, 1998, GENE DEV, V12, P806, DOI 10.1101/gad.12.6.806; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Zhivotovsky B, 1998, NATURE, V391, P449, DOI 10.1038/35060; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	42	1122	1143	0	37	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 7	1998	94	3					339	352		10.1016/S0092-8674(00)81477-4	http://dx.doi.org/10.1016/S0092-8674(00)81477-4			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	109EN	9708736	Bronze			2022-12-28	WOS:000075308400010
J	McMahon, SB; Van Buskirk, HA; Dugan, KA; Copeland, TD; Cole, MD				McMahon, SB; Van Buskirk, HA; Dugan, KA; Copeland, TD; Cole, MD			The novel ATM-related protein TRRAP is an essential cofactor for the c-Myc and E2F oncoproteins	CELL			English	Article							NEOPLASTIC TRANSFORMATION; ATAXIA-TELANGIECTASIA; ONCOGENIC ACTIVITY; REPRESSOR SIN3; GENE-PRODUCT; LINEAR-SPACE; KINASE; TRANSCRIPTION; APOPTOSIS; BINDING	The c-Myc and E2F transcription factors are among the most potent regulators of cell cycle progression in higher eukaryotes. This report describes the isolation of a novel, highly conserved 434 kDa protein, designated TRRAP, which interacts specifically with the c-Myc N terminus and has homology to the ATM/PI3- kinase family. TRRAP also interacts specifically with the E2F-1 transactivation domain. Expression of transdominant mutants of the TRRAP protein or antisense RNA blocks c-Myc- and E1A-mediated oncogenic transformation. These data suggest that TRRAP is an essential cofactor for both the c-Myc and E1A/E2F oncogenic transcription factor pathways.	Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA; NCI, ABL Basic Res Program, Frederick Canc Res & Dev Ctr, Frederick, MD 21702 USA	Princeton University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Cole, MD (corresponding author), Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA.			McMahon, Steven/0000-0002-3405-1768				ALITALO K, 1983, P NATL ACAD SCI-BIOL, V80, P1707, DOI 10.1073/pnas.80.6.1707; AMATI B, 1993, CELL, V72, P233, DOI 10.1016/0092-8674(93)90663-B; ASKEW DS, 1991, ONCOGENE, V6, P1915; AYER DE, 1995, CELL, V80, P767, DOI 10.1016/0092-8674(95)90355-0; Baskaran R, 1997, NATURE, V387, P516, DOI 10.1038/387516a0; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; BERRY R, 1995, NAT GENET, V10, P415, DOI 10.1038/ng0895-415; BROCKMANN D, 1995, CURR TOP MICROBIOL, V199, P81; BROUGH DE, 1995, MOL CELL BIOL, V15, P1536; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; Danska JS, 1996, MOL CELL BIOL, V16, P5507; Desbarats L, 1996, GENE DEV, V10, P447, DOI 10.1101/gad.10.4.447; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DYNLACHT BD, 1994, P NATL ACAD SCI USA, V91, P6359, DOI 10.1073/pnas.91.14.6359; ENOCH T, 1995, TRENDS BIOCHEM SCI, V20, P426, DOI 10.1016/S0968-0004(00)89093-3; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FREYTAG SO, 1992, SCIENCE, V256, P379, DOI 10.1126/science.256.5055.379; FREYTAG SO, 1990, CELL GROWTH DIFFER, V1, P339; Gallant P, 1996, SCIENCE, V274, P1523, DOI 10.1126/science.274.5292.1523; HARLOW E, 1986, MOL CELL BIOL, V6, P1579, DOI 10.1128/MCB.6.5.1579; HARTLEY KO, 1995, CELL, V82, P849, DOI 10.1016/0092-8674(95)90482-4; HATEBOER G, 1993, P NATL ACAD SCI USA, V90, P8489, DOI 10.1073/pnas.90.18.8489; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; HELIN K, 1993, MOL CELL BIOL, V13, P6501, DOI 10.1128/MCB.13.10.6501; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; HOPP TP, 1988, BIO-TECHNOL, V6, P1204, DOI 10.1038/nbt1088-1204; HUANG XQ, 1991, ADV APPL MATH, V12, P337, DOI 10.1016/0196-8858(91)90017-D; HUNTER T, 1995, CELL, V83, P1, DOI 10.1016/0092-8674(95)90225-2; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; Lavin MF, 1996, CURR OPIN IMMUNOL, V8, P459, DOI 10.1016/S0952-7915(96)80030-6; LI LH, 1994, EMBO J, V13, P4070, DOI 10.1002/j.1460-2075.1994.tb06724.x; MacGregor D, 1996, J CELL PHYSIOL, V167, P95, DOI 10.1002/(SICI)1097-4652(199604)167:1<95::AID-JCP11>3.3.CO;2-Q; Mateyak MK, 1997, CELL GROWTH DIFFER, V8, P1039; Morgan SE, 1997, MOL CELL BIOL, V17, P2020, DOI 10.1128/MCB.17.4.2020; MYERS EW, 1988, COMPUT APPL BIOSCI, V4, P11, DOI 10.1093/bioinformatics/4.1.11; Nevins JR, 1997, J CELL PHYSIOL, V173, P233, DOI 10.1002/(SICI)1097-4652(199711)173:2<233::AID-JCP27>3.0.CO;2-F; OHTANI K, 1994, MOL CELL BIOL, V14, P1603, DOI 10.1128/MCB.14.3.1603; PENN LJZ, 1990, EMBO J, V9, P1113, DOI 10.1002/j.1460-2075.1990.tb08217.x; PENN LJZ, 1990, MOL CELL BIOL, V10, P4961, DOI 10.1128/MCB.10.9.4961; RESAR LMS, 1993, MOL CELL BIOL, V13, P1130, DOI 10.1128/MCB.13.2.1130; Sakamuro D, 1996, NAT GENET, V14, P69, DOI 10.1038/ng0996-69; SchreiberAgus N, 1997, P NATL ACAD SCI USA, V94, P1235, DOI 10.1073/pnas.94.4.1235; SCHREIBERAGUS N, 1995, CELL, V80, P777, DOI 10.1016/0092-8674(95)90356-9; Shan B, 1996, P NATL ACAD SCI USA, V93, P679, DOI 10.1073/pnas.93.2.679; SIKORSKI RS, 1990, CELL, V60, P307, DOI 10.1016/0092-8674(90)90745-Z; Sommer A, 1998, J BIOL CHEM, V273, P6632, DOI 10.1074/jbc.273.12.6632; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; TAYLOR SS, 1995, FASEB J, V9, P1255, DOI 10.1096/fasebj.9.13.7557015; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; ZAKIAN VA, 1995, CELL, V82, P685, DOI 10.1016/0092-8674(95)90463-8; ZHENG XF, 1995, CELL, V82, P121, DOI 10.1016/0092-8674(95)90058-6	52	518	533	0	24	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	AUG 7	1998	94	3					363	374		10.1016/S0092-8674(00)81479-8	http://dx.doi.org/10.1016/S0092-8674(00)81479-8			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	109EN	9708738	Bronze			2022-12-28	WOS:000075308400012
J	Masood, E				Masood, E			Xenotransplant experts face good and bad news	NATURE			English	News Item																		1998, NATURE MED, V4, P876	1	2	3	1	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 6	1998	394	6693					513	513		10.1038/28920	http://dx.doi.org/10.1038/28920			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	107YN	9707103	Bronze			2022-12-28	WOS:000075238700008
J	Cuzick, J; Holland, R; Barth, V; Davies, R; Faupel, M; Fentiman, I; Frischbier, HJ; LaMarque, JL; Merson, M; Sacchini, V; Vanel, D; Veronesi, U				Cuzick, J; Holland, R; Barth, V; Davies, R; Faupel, M; Fentiman, I; Frischbier, HJ; LaMarque, JL; Merson, M; Sacchini, V; Vanel, D; Veronesi, U			Electropotential measurements as a new diagnostic modality for breast cancer	LANCET			English	Article							RADIOLOGISTS; VARIABILITY; MAMMOGRAPHY; LESIONS; BIOPSY	Background Proliferative changes in breast epithelium are an intrinsic aspect in the development of breast cancer, and result in regions of epithelial electrical depolarisation within the breast parenchyma, which can extend to the shin surface. Diagnostic information might be obtained from a non-imaging and non-invasive test based on shin-surface elect ro potentials. Methods In 661 women, scheduled for open biopsy at eight European centres, we studied whether measurements of breast electrical activity with surface sensors could distinguish benign from malignant breast disease. A depolarisation index was developed. Results We found a highly significant trend of progressive electrical changes according to the proliferative characteristics of the biopsied tissue. Discriminatory information was obtained in both premenopausal and postmenopausal women, and the index was not related to age. The best test performances were for women with palpable lesions. The median index was 0.398 for nonproliferative benign lesions, 0.531 for proliferative benign lesions, and 0.644 for cancer (ductal carcinoma-in-situ and invasive). A specificity of 55% was obtained at 90% sensitivity for women with palpable lesions when a discriminant based on age and the depolarisation index was used. Interpretation This new modality may have diagnostic value, especially in reducing the number of unnecessary diagnostic tests among women with inconclusive findings on physical examination. Understanding and control of the biological variability of these electrical phenomena will be important in the improvement of this test. Studies in populations with a lower cancer prevalence are needed to assess further the diagnostic value of this approach.	Imperial Canc Res Fund, Dept Math Stat & Epidemiol, London WC2A 3PX, England; Natl Expert & Training Ctr Breast Canc Screening, Nijmegen, Netherlands; Esslingen Hosp, Esslingen, Germany; Hackensack Univ, Med Ctr, Hackensack, NJ USA; Univ Med & Dent New Jersey, New Jersey Med Sch, Newark, NJ USA; SpectRx Inc, Norcross, GA USA; Guys Hosp, London SE1 9RT, England; Univ Hamburg, Hamburg, Germany; Inst Montpellier Imagerie Medicobiol & Mastol, Montpellier, France; Ist Nazl Tumori, I-20133 Milan, Italy; Ist Europeo Oncol, Milan, Italy; Inst Gustave Roussy, Villejuif, France	Cancer Research UK; Hackensack University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; Guy's & St Thomas' NHS Foundation Trust; University of Hamburg; Fondazione IRCCS Istituto Nazionale Tumori Milan; IRCCS European Institute of Oncology (IEO); UNICANCER; Gustave Roussy	Cuzick, J (corresponding author), Imperial Canc Res Fund, Dept Math Stat & Epidemiol, POB 123,61 Lincolns Inn Fields, London WC2A 3PX, England.	j.cuzick@icrf.icnet.uk	Fentiman, Ian S/I-7644-2019; Fentiman, Ian/AAB-9886-2020					Beam CA, 1996, ARCH INTERN MED, V156, P209, DOI 10.1001/archinte.156.2.209; BINGGELI R, 1986, J THEOR BIOL, V123, P377, DOI 10.1016/S0022-5193(86)80209-0; BRAND IR, 1993, BRIT J RADIOL, V66, P394, DOI 10.1259/0007-1285-66-785-394; Capko D., 1996, Breast Cancer Research and Treatment, V41, P230; COLE P, 1978, AM J EPIDEMIOL, V108, P112, DOI 10.1093/oxfordjournals.aje.a112594; CUZICK J, 1985, STAT MED, V4, P87, DOI 10.1002/sim.4780040112; DAVIES RJ, 1987, CANCER RES, V47, P4646; DICKHAUT M, 1996, EUR SCH ONC, P63; Egglin TKP, 1996, JAMA-J AM MED ASSOC, V276, P1752, DOI 10.1001/jama.276.21.1752; ELMORE JG, 1994, NEW ENGL J MED, V331, P1493, DOI 10.1056/NEJM199412013312206; FAUPEL ML, 1996, EUR SCH ONC, P37; GALLAGER HS, 1969, CANCER, V24, P1170, DOI 10.1002/1097-0142(196912)24:6<1170::AID-CNCR2820240615>3.0.CO;2-6; GOLLER DA, 1986, ARCH SURG-CHICAGO, V121, P345; GORDENNE W, 1981, J BELG RADIOL, V64, P339; GREEN B, 1995, BRIT J SURG, V82, P1509, DOI 10.1002/bjs.1800821119; Hardy J R, 1990, Clin Oncol (R Coll Radiol), V2, P148, DOI 10.1016/S0936-6555(05)80148-7; HASSELGREN PO, 1993, SURGERY, V114, P836; HERMANSEN C, 1987, CANCER, V60, P1866, DOI 10.1002/1097-0142(19871015)60:8<1866::AID-CNCR2820600832>3.0.CO;2-Z; LAYFIELD LJ, 1993, CANCER-AM CANCER SOC, V72, P1642, DOI 10.1002/1097-0142(19930901)72:5<1642::AID-CNCR2820720525>3.0.CO;2-8; MARINO AA, 1994, TUMOR BIOL, V15, P82, DOI 10.1159/000217878; Peer PGM, 1996, BREAST CANCER RES TR, V38, P153, DOI 10.1007/BF01806669; SIBBERING DM, 1995, BREAST, V4, P127, DOI 10.1016/0960-9776(95)90008-X; SLAUGHTER DP, 1953, CANCER, V6, P963, DOI 10.1002/1097-0142(195309)6:5<963::AID-CNCR2820060515>3.0.CO;2-Q; STANDERTSKJOLDNORDENSTAM CG, 1980, ANN CHIR GYNAECOL, V69, P48; STERNS EE, 1992, CAN J SURG, V35, P41; URBANHORTH JS, 1994, COMPUTER INTENSIVE S; Weiss B., 1994, BREAST DIS, V7, P91	27	81	98	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	AUG 1	1998	352	9125					359	363		10.1016/S0140-6736(97)10002-2	http://dx.doi.org/10.1016/S0140-6736(97)10002-2			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	106BU	9717923				2022-12-28	WOS:000075110500011
